PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HULSKAMP, M; MISERA, S; JURGENS, G				HULSKAMP, M; MISERA, S; JURGENS, G			GENETIC DISSECTION OF TRICHOME CELL-DEVELOPMENT IN ARABIDOPSIS	CELL			English	Article							SIGNAL TRANSDUCTION; C-ELEGANS; DROSOPHILA; THALIANA; FATE; MAP	Trichomes are specialized epidermal cells that are regularly distributed on the leaves of Arabidopsis plants. During leaf development, each trichome undergoes cell morphogenesis, resulting in a very precise architecture. We have isolated and characterized more than 70 trichome mutants that represent 21 different genes. By analyzing their cellular phenotypes, it has been possible to define specific steps in trichome development. Although these steps normally occur in a temporal sequence, genetic dissection indicates that the morphology of the mature cell is largely assembled in independent events. The results suggest a model of how a specialized cell type originates from a uniform cell layer.	UNIV MUNICH, INST GENET & MIKROBIOL, LEHRSTUHL GENET, D-80638 MUNICH, GERMANY	University of Munich				Hulskamp, Martin/0000-0003-4165-6754				APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; FEENSTRA WJ, 1978, INFORM SERV, V15, P35; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLSTEIN TW, 1990, DEV BIOL, V142, P392, DOI 10.1016/0012-1606(90)90360-U; IRISH VF, 1992, DEVELOPMENT, V115, P745; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; KOORNNEEF M, 1982, MUTAT RES, V93, P109, DOI 10.1016/0027-5107(82)90129-4; Koornneef M., 1987, ARABID INF SERV, V1987, P46; Koornneef M., 1981, ARABID INF SERV, V18, P45; KOORNNEEF M, 1983, ARABID INF SERV, V20, P89; Kramer Helmut, 1993, Trends in Cell Biology, V3, P103, DOI 10.1016/0962-8924(93)90165-W; LEECHEN S, 1967, CAN J GENET CYTOL, V9, P381, DOI 10.1139/g67-039; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; Marks M D, 1991, Symp Soc Exp Biol, V45, P77; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MAYER U, 1993, DEVELOPMENT, V117, P149; MEDFORD JI, 1992, PLANT CELL, V4, P1029, DOI 10.1105/tpc.4.9.1029; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; POETHIG S, 1989, TRENDS GENET, V5, P273, DOI 10.1016/0168-9525(89)90101-7; Poodry C.A., 1980, Genetics and Biology of Drosophila, V2d, P443; REDEI GP, 1962, Z VEREBUNGSL, V93, P164; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SMITH LG, 1992, PLANT CELL, V4, P1017, DOI 10.1105/tpc.4.9.1017; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; Uphof J.C.T., 1962, ENCYCL PLANT ANAT, V5, P1; WOODS DF, 1992, ANNU REV GENET, V26, P305	32	501	540	6	128	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					555	566		10.1016/0092-8674(94)90118-X	http://dx.doi.org/10.1016/0092-8674(94)90118-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313475				2022-12-28	WOS:A1994MX20700015
J	SGARBOSSA, EB; PINSKI, SL; MALONEY, JD				SGARBOSSA, EB; PINSKI, SL; MALONEY, JD			THE ROLE OF PACING MODALITY IN DETERMINING LONG-TERM SURVIVAL IN THE SICK SINUS SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						SICK SINUS SYNDROME; CARDIAC PACING, ARTIFICIAL; PACEMAKER, ARTIFICIAL; HEART ATRIUM; HEART VENTRICLE	PACEMAKER SYNDROME; SINGLE-CHAMBER; FOLLOW-UP; ATRIAL-FIBRILLATION; NODE DISEASE; IMPLANTATION; MODE; CONDUCTION; MORBIDITY; MORTALITY	Objective: To determine whether the atrial-based pacing modalities (''physiologic pacing'') improve survival when compared with single-chamber ventricular pacing in patients with the sick sinus syndrome. Design: Retrospective, nonrandomized study. Setting: A tertiary care teaching hospital. Patients: A total of 507 patients with a mean age of 66 years who received an initial pacemaker for the sick sinus syndrome between January 1980 and December 1989. Pacing modes were ventricular (22%), atrial (4%), and dual-chamber (74%). Measurements: Total and cardiovascular mortality rates. Mean follow-up was 66 months. Results: Independent predictors of total mortality by the Cox proportional hazards model were 1) New York Heart Association functional class (hazard ratio = 1.67/class; 95% CI, 1.31 to 2.11); 2) age (hazard ratio = 1.62/12-year increment; CI, 1.28 to 2.05); 3) peripheral vascular disease (hazard ratio = 2.21; CI, 1.42 to 3.42); 4) bundle branch block (hazard ratio = 2.04; CI, 1.33 to 3.13); 5) coronary artery disease (hazard ratio = 1.66; CI, 1.15 to 2.39); and 6) valvular heart disease (hazard ratio = 1.71; CI, 1.08 to 2.69). The same variables were independent predictors of cardiovascular mortality, with cerebrovascular disease reaching borderline statistical significance (hazard ratio = 1.69; CI, 1.00 to 2.86). Using univariate analysis, single-chamber ventricular pacing had more than 40% increased risk for both total and cardiovascular death, but the difference was of borderline statistical significance (total mortality: P = 0.053; hazard ratio = 1.43; CI, 0.99 to 2.07; cardiovascular mortality: P = 0.15; hazard ratio = 1.41; CI = 0.87 to 2.29). Conclusions: Because the role of the ventricular pacing mode as a long-term predictor of total and cardiovascular mortality remains inconclusive, a large, randomized study is necessary to confirm whether physiologic pacing provides a substantial reduction in mortality when compared with ventricular pacing.			SGARBOSSA, EB (corresponding author), CLEVELAND CLIN FDN, DEPT CARDIOL, DESK F15, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							ALEXANDER LA, 1992, PACE, V15, P508; ALT E, 1985, PACE, V8, P849, DOI 10.1111/j.1540-8159.1985.tb05904.x; AUSUBEL K, 1985, ANN INTERN MED, V103, P420, DOI 10.7326/0003-4819-103-3-420; BAIG MW, 1991, PROG CARDIOVASC DIS, V33, P283, DOI 10.1016/0033-0620(91)90021-D; BERNSTEIN AD, 1992, AM J CARDIOL, V69, P331, DOI 10.1016/0002-9149(92)90229-R; BERNSTEIN AD, 1987, PACE, V10, P794, DOI 10.1111/j.1540-8159.1987.tb06035.x; BREIVIK K, 1979, ACTA MED SCAND, V206, P153; CAMM AJ, 1990, PACE, V13, P695, DOI 10.1111/j.1540-8159.1990.tb02091.x; DEYO RA, 1991, ANN INTERN MED, V114, P695, DOI 10.7326/0003-4819-114-8-695; EAGLE KA, 1986, ANN INTERN MED, V105, P264, DOI 10.7326/0003-4819-105-2-264; FEUER JM, 1989, AM J CARDIOL, V64, P1376, DOI 10.1016/0002-9149(89)90586-9; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; FRYE R L, 1984, Journal of the American College of Cardiology, V4, P434; GOLDSCHLAGER N, 1988, POSTGRAD MED, V83, P156, DOI 10.1080/00325481.1988.11700191; GRIFFIN JC, 1991, CLIN CARDIOL, V14, P257; HAYES DL, 1984, AM HEART J, V107, P644, DOI 10.1016/0002-8703(84)90309-0; HELDMAN D, 1990, PACE, V13, P1742, DOI 10.1111/j.1540-8159.1990.tb06883.x; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; JELIC V, 1992, PACE, V15, P141, DOI 10.1111/j.1540-8159.1992.tb03057.x; Kulbertus H E, 1983, Cardiovasc Clin, V14, P189; LEE J, 1992, COMPUT APPL BIOSCI, V8, P23; LEVINE PA, 1983, PACE, V6, P279, DOI 10.1111/j.1540-8159.1983.tb04358.x; MABO P, 1991, PACE, V14, P2133, DOI 10.1111/j.1540-8159.1991.tb06484.x; MITSUOKA T, 1988, BRIT HEART J, V60, P338; PASSAMANI E, 1991, NEW ENGL J MED, V324, P1589, DOI 10.1056/NEJM199105303242209; RASMUSSEN K, 1971, AM HEART J, V81, P38, DOI 10.1016/0002-8703(71)90052-4; REDIKER DE, 1988, AM J CARDIOL, V61, P323, DOI 10.1016/0002-9149(88)90938-1; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; ROSENQVIST M, 1990, CLIN CARDIOL, V13, P43, DOI 10.1002/clc.4960130108; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; Rosenqvist Marten, 1992, Cardiology Clinics, V10, P691; RUBENSTEIN JJ, 1972, CIRCULATION, V46, P5, DOI 10.1161/01.CIR.46.1.5; SANTINI M, 1990, AM J CARDIOL, V65, P729, DOI 10.1016/0002-9149(90)91379-K; SASAKI Y, 1988, PACE, V11, P1575, DOI 10.1111/j.1540-8159.1988.tb06277.x; SHAW DB, 1980, BMJ-BRIT MED J, V280, P139, DOI 10.1136/bmj.280.6208.139; SKAGEN K, 1976, ACTA MED SCAND, V199, P13; SMULYAN H, 1992, J CLIN EPIDEMIOL, V45, P53, DOI 10.1016/0895-4356(92)90188-S; STANGL K, 1990, PACE, V13, P2080, DOI 10.1111/j.1540-8159.1990.tb06946.x; STONE JM, 1982, AM HEART J, V104, P1319, DOI 10.1016/0002-8703(82)90162-4; SUTTON R, 1986, PACE, V9, P1110, DOI 10.1111/j.1540-8159.1986.tb06678.x; SUTTON R, 1990, PACE, V13, P1823, DOI 10.1111/j.1540-8159.1990.tb06897.x; TORRESANI J, 1984, PACE, V7, P1148, DOI 10.1111/j.1540-8159.1984.tb05675.x; VANHEMEL NM, 1981, PACE, V4, P8; VOGT P, 1988, PACE, V11, P1896, DOI 10.1111/j.1540-8159.1988.tb06326.x; WELLS CK, 1990, J CLIN EPIDEMIOL, V43, P361, DOI 10.1016/0895-4356(90)90122-6; YUSUF S, 1991, AM J CARDIOL, V68, P954, DOI 10.1016/0002-9149(91)90416-I; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; ZANINI R, 1989, PACE, V12, P1065, DOI 10.1111/j.1540-8159.1989.tb01927.x; ZANINI R, 1990, PACE, V13, P2076, DOI 10.1111/j.1540-8159.1990.tb06945.x; 1989, CURRENT POPULATI P25, V1018, P1; 1990, EGRET REFERENCE MANU	51	41	42	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					359	365		10.7326/0003-4819-119-5-199309010-00002	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338288				2022-12-28	WOS:A1993LZ47600002
J	NELSON, KE; CELENTANO, DD; SUPRASERT, S; WRIGHT, N; EIUMTRAKUL, S; TULVATANA, S; MATANASARAWOOT, A; AKARASEWI, P; KUNTOLBUTRA, S; ROMYEN, S; SIRISOPANA, N; THEETRANONT, C				NELSON, KE; CELENTANO, DD; SUPRASERT, S; WRIGHT, N; EIUMTRAKUL, S; TULVATANA, S; MATANASARAWOOT, A; AKARASEWI, P; KUNTOLBUTRA, S; ROMYEN, S; SIRISOPANA, N; THEETRANONT, C			RISK-FACTORS FOR HIV-INFECTION AMONG YOUNG-ADULT MEN IN NORTHERN THAILAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; TRANSMISSION; WOMEN	Objective.-To determine the sociodemographic and behavioral risk factors associated with human immunodeficiency virus (HIV) infection in two cohorts of young men selected for military service in northern Thailand. Design.-Military conscripts were studied cross-sectionally after conscription in May 1991 and November 1991. Risk factors were assessed by interview with trained nonmilitary interviewers. Setting.-Two military training bases in Chiang Mai, Thailand. Participants.-A total of 2417 young men aged 19 to 23 years (mean age, 21 years) conscripted by lottery into military service in the Royal Thai Army or Royal Thai Air Force from six provinces in northern Thailand. Main Outcome Measures.-Human immunodeficiency virus seroprevalence by enzyme-linked immunosorbent assay confirmed by Western blot and univariate and multivariate analyses of sociodemographic and behavioral risk factors associated with HIV seroprevalence. Results.-Overall, 289 (12.0%) of 2417 men were HIV-seropositive at baseline. The strongest associations with being HIV positive were heterosexual activities. History of sex with a female commercial sex worker (CSW) was frequent (96.5% of men who were HIV-positive and 79.0% of men who were HIV-negative) and strongly associated with HIV infection on univariate and multivariate analyses (adjusted odds ratio, 1.60 to 2.07, depending on the frequency of CSW contact). Also, sexually transmitted diseases were common and associated with HIV infection in both univariate and multivariate analyses (adjusted odds ratio, 3.36). Sex with other males and injection drug use were uncommon and not associated with HIV infection. Condom use was reported in 61.5% of men at last sex with a CSW but was not shown to be protective of prevalent HIV infection. Conclusion.-The epidemic of HIV infection has spread widely among young men in northern Thailand, despite reported frequent and recent use of condoms during sex with female CSWs. Control of HIV infection in this population will probably require more regular and effective use of condoms, prevention and treatment of sexually transmitted diseases, and reduction in the frequency of CSW contact.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; CHIANG MAI UNIV,DEPT FAMILY MED,CHIANG MAI,THAILAND; CHIANG MAI UNIV,DEPT PATHOL,CHIANG MAI,THAILAND; MINIST PUBL HLTH,CHIANG MAI,THAILAND; ROYAL THAI ARMY,CHIANG MAI,THAILAND; ROYAL THAI AF,CHIANG MAI,THAILAND; ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ; ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND	Johns Hopkins University; Chiang Mai University; Chiang Mai University; Ministry of Public Health - Thailand; Rutgers State University New Brunswick; Rutgers State University Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	NELSON, KE (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY,BALTIMORE,MD 21205, USA.							ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; BAGASRA O, 1993, J INFECT DIS, V167, P789, DOI 10.1093/infdis/167.4.789; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; FORD N, 1991, SOC SCI MED, V33, P405, DOI 10.1016/0277-9536(91)90321-3; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; HALSEY NA, 1992, JAMA-J AM MED ASSOC, V267, P2062, DOI 10.1001/jama.267.15.2062; JOHNSON AM, 1988, AIDS, V2, pS49, DOI 10.1097/00002030-198800001-00008; MUECKE MA, 1992, SOC SCI MED, V35, P891, DOI 10.1016/0277-9536(92)90103-W; PADIAN NS, 1987, REV INFECT DIS, V9, P947; Phongpaichit Pasuk, 1982, PEASANT GIRLS BANGKO, P71; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; SIRISOPANA N, 1992, 8 INT C AIDS AMST; TAWEESAK N, 1992, 8TH INT C AIDS AMST; THONGCHAROEN P, 1989, HUMAN IMMUNODEFICIEN; UNGACHASAK K, 1990, 6TH INT C AIDS SAN F; UNGCHUSAK K, 1991, 7 INT C AIDS FLOR; WANGROONGSARB Y, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P517; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	20	132	134	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					955	960		10.1001/jama.270.8.955	http://dx.doi.org/10.1001/jama.270.8.955			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8345647				2022-12-28	WOS:A1993LT56700026
J	NOVELLO, AC				NOVELLO, AC			UNITED-STATES PUBLIC-HEALTH-SERVICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									OFF SURGEON GEN,WASHINGTON,DC 20201										0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					806	806		10.1001/jama.270.7.806	http://dx.doi.org/10.1001/jama.270.7.806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR612	8340968				2022-12-28	WOS:A1993LR61200006
J	UJHELYI, MR; ROBERT, S; CUMMINGS, DM; COLUCCI, RD; GREEN, PJ; SAILSTAD, J; VLASSES, PH; ZAROWITZ, BJ				UJHELYI, MR; ROBERT, S; CUMMINGS, DM; COLUCCI, RD; GREEN, PJ; SAILSTAD, J; VLASSES, PH; ZAROWITZ, BJ			INFLUENCE OF DIGOXIN IMMUNE FAB THERAPY AND RENAL DYSFUNCTION ON THE DISPOSITION OF TOTAL AND FREE DIGOXIN	ANNALS OF INTERNAL MEDICINE			English	Article						DIGOXIN; IMMUNOGLOBULINS, FAB; KIDNEY FAILURE, CHRONIC; DRUG TOXICITY; KIDNEY DISEASES	DIGITALIS INTOXICATION; ANTIBODY FRAGMENTS; TOXIC PATIENTS; SERUM; KINETICS; PHARMACOKINETICS; FAILURE	Objective: To characterize the disposition of total and free serum digoxin following the administration of digoxin Fab antibody in patients with varying degrees of renal function. Design: Observational study of pharmacokinetics and pharmacodynamics. Setting: Critical care and telemetry units of two university-affiliated teaching institutions, Hartford Hospital and Henry Ford Hospital. Patients: Fourteen digoxin-intoxicated patients (baseline total digoxin > 3.2 nmol/mL) with mean (+/- SD) serum creatinine of 380.1 +/- 212.2 mumol/L who received digoxin Fab antibody therapy. Measurements: Serum was drawn every 12 to 24 hours for 80 to 327 hours after Fab administration. Total and free digoxin were assayed in serum by fluorescence polarization immunoassay or modified immunofluorometric assay. Results: Before Fab was administered, total digoxin ranged from 3.5 to 10,5 nmol/mL. After treatment with Fab, total digoxin increased rapidly to a mean (+/- SD) maximum of 51.8 +/- 22.7 nmol/mL and decreased to 7.2 +/- 4.7 nmol/mL at the last measurement. Total digoxin was eliminated in a two-phase fashion. The half-life of the initial phase of total digoxin decline was 11.6 +/- 4.1 hours, and the half-life of the second or terminal elimination phase was 118 +/- 57 hours. Free digoxin levels decreased rapidly following Fab therapy, to a mean nadir of 0.6 +/- 1.1 nmol/mL, but rebounded to a mean maximum free digoxin concentration of 1.7 +/- 1.3 nmol/mL in 77 +/- 46 hours. The time to maximum free digoxin rebound occurred later in patients with end-stage renal disease (n = 4) compared with other patients (127 +/- 40 hours compared with 55 +/- 28 hours). Conclusion: Elimination of digoxin following Fab therapy is prolonged in digoxin-toxic patients with renal dysfunction. In addition, rebound of free digoxin is delayed in anephric patients. Monitoring free digoxin following the administration of Fab may be of value in selected patients to guide additional Fab dosing, confirm possible rebound toxicity, or guide the reinitiation of digoxin therapy.	HARTFORD HOSP, HARTFORD, CT 06115 USA; UNIV CONNECTICUT, HARTFORD, CT 06112 USA; UNIV CONNECTICUT, STORRS, CT 06268 USA; HENRY FORD HOSP, COLL PHARM, DETROIT, MI 48202 USA; WAYNE STATE UNIV, DETROIT, MI 48202 USA; E CAROLINA UNIV, SCH MED, GREENVILLE, NC 27834 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA; UNIV HOSP CONSORTIUM, OAK BROOK, IL USA; WELLCOME RES LABS, RES TRIANGLE PK, NC 27709 USA	Hartford Hospital; University of Connecticut; University of Connecticut; Henry Ford Health System; Henry Ford Hospital; Wayne State University; University of North Carolina; East Carolina University; Jefferson University; Wellcome Research Laboratories			Ujhelyi, Michael/AAL-1844-2020	CUMMINGS, DOYLE/0000-0002-8237-7885				ALLEN NM, 1991, DICP ANN PHARMAC, V25, P1315, DOI 10.1177/106002809102501205; ALLEN NM, 1990, DICP ANN PHARMAC, V24, P991, DOI 10.1177/106002809002401015; ANTMAN EM, 1990, CIRCULATION, V81, P1744, DOI 10.1161/01.CIR.81.6.1744; BUTLER VP, 1977, J CLIN INVEST, V59, P345, DOI 10.1172/JCI108647; COLE PL, 1986, DRUG INTEL CLIN PHAR, V20, P267, DOI 10.1177/106002808602000403; COLUCCI R D, 1989, Pharmacotherapy, V9, P175; ERDMANN E, 1989, KLIN WOCHENSCHR, V67, P16, DOI 10.1007/BF01736529; HURSTING MJ, 1987, CLIN CHEM, V33, P1652; KOUP JR, 1975, CLIN PHARMACOL THER, V18, P9; MAHDYOON H, 1990, AM HEART J, V120, P1189, DOI 10.1016/0002-8703(90)90135-K; NUWAYHID NF, 1989, THER DRUG MONIT, V11, P680, DOI 10.1097/00007691-198911000-00012; OHNHAUS EE, 1972, EUR J CLIN PHARMACOL, V5, P34, DOI 10.1007/BF00560893; RABETOY GM, 1990, AM J NEPHROL, V10, P518, DOI 10.1159/000168179; REUNING RH, 1973, J CLIN PHARMACOL, V13, P127, DOI 10.1002/j.1552-4604.1973.tb00074.x; SCHAUMANN W, 1986, EUR J CLIN PHARMACOL, V30, P527, DOI 10.1007/BF00542410; SINCLAIR AJ, 1989, BRIT J CLIN PHARMACO, V28, P352, DOI 10.1111/j.1365-2125.1989.tb05437.x; SMITH TW, 1976, NEW ENGL J MED, V294, P797, DOI 10.1056/NEJM197604082941501; SMOLARZ A, 1985, J TOXICOL-CLIN TOXIC, V23, P327, DOI 10.3109/15563658508990641; Ujhelyi M, 1990, Conn Med, V54, P63; UJHELYI MR, 1988, DRUG INTEL CLIN PHAR, V22, P345, DOI 10.1177/106002808802200421; UJHELYI MR, 1990, THER DRUG MONIT, V12, P288, DOI 10.1097/00007691-199005000-00014; UJHELYI MR, 1991, DICP ANN PHARMAC, V25, P1047, DOI 10.1177/106002809102501002; UJHELYI MR, 1992, THER DRUG MONIT, V14, P147, DOI 10.1097/00007691-199204000-00013; WENGER TL, 1985, J AM COLL CARDIOL, V5, pA118, DOI 10.1016/S0735-1097(85)80471-X; WENGER TL, 1988, PRIMARY CARDIOL, V1, P19; 1988, DIGIBIND PRODUCT INF	26	24	24	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					273	277		10.7326/0003-4819-119-4-199308150-00004	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328735				2022-12-28	WOS:A1993LV52500004
J	FRIES, JF; KOOP, CE; BEADLE, CE; COOPER, PP; ENGLAND, MJ; GREAVES, RF; SOKOLOV, JJ; WRIGHT, D				FRIES, JF; KOOP, CE; BEADLE, CE; COOPER, PP; ENGLAND, MJ; GREAVES, RF; SOKOLOV, JJ; WRIGHT, D			REDUCING HEALTH-CARE COSTS BY REDUCING THE NEED AND DEMAND FOR MEDICAL-SERVICES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORPORATE FITNESS PROGRAM; ADVANCE DIRECTIVES; PROMOTION PROGRAM; EDUCATION-PROGRAM; NEW-HAVEN; ABSENTEEISM; POPULATION; WORK; EXPENDITURES; ILLNESS		C EVERETT KOOP INST, HANOVER, NH USA; WASHINGTON BUSINESS GRP HLTH, WASHINGTON, DC USA; STANFORD UNIV, STANFORD, CA 94305 USA; HLTH NET, LOS ANGELES, CA USA; WILLIAM M MERCER, NEW YORK, NY USA; SOKOLOV ALLIANCE, LOS ANGELES, CA USA; TAU GRP, NEW YORK, NY USA	Stanford University			Fries, James F/F-6271-2011					BAUN WB, 1986, J OCCUP ENVIRON MED, V28, P18, DOI 10.1097/00043764-198601000-00007; BERTERA RL, 1990, AM J PUBLIC HEALTH, V80, P1101, DOI 10.2105/AJPH.80.9.1101; BLAIR SN, 1986, PREV MED, V15, P166, DOI 10.1016/0091-7435(86)90086-1; BLY JL, 1986, JAMA-J AM MED ASSOC, V256, P3235, DOI 10.1001/jama.256.23.3235; BOWNE DW, 1984, J OCCUP ENVIRON MED, V26, P809, DOI 10.1097/00043764-198411000-00010; BRESLOW L, 1993, PREV MED, V22, P86, DOI 10.1006/pmed.1993.1006; BROWN ER, 1992, JAMA-J AM MED ASSOC, V267, P552; BURTON WN, 1991, J OCCUP ENVIRON MED, V33, P311; CLINTON B, 1992, NEW ENGL J MED, V327, P804, DOI 10.1056/NEJM199209103271112; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRIES JF, 1993, AM J MED, V94, P455, DOI 10.1016/0002-9343(93)90078-4; Fries JF, 1981, VITALITY AGING; FUCHS VR, 1984, MILBANK FUND Q, V62, P143; GIBBS JO, 1985, J OCCUP ENVIRON MED, V27, P826, DOI 10.1097/00043764-198511000-00016; GINZBERG E, 1992, NEW ENGL J MED, V327, P1310, DOI 10.1056/NEJM199210293271812; GOLASZEWSKI T, 1992, J OCCUP ENVIRON MED, V34, P1164; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; Harvey M R, 1993, Am J Health Promot, V7, P296; Henritze J, 1989, Am J Health Promot, V4, P25, DOI 10.4278/0890-1171-4.1.25; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; JONES RC, 1990, J OCCUP ENVIRON MED, V32, P95; LEAF A, 1993, JAMA-J AM MED ASSOC, V269, P616, DOI 10.1001/jama.269.5.616; LEIGH JP, 1992, ARCH INTERN MED, V152, P1201, DOI 10.1001/archinte.152.6.1201; LEIGH JP, 1992, INQUIRY-J HEALTH CAR, V29, P44; LORIG K, 1985, MED CARE, V23, P1044, DOI 10.1097/00005650-198509000-00003; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; LYNCH WD, 1990, J OCCUP ENVIRON MED, V32, P9, DOI 10.1097/00043764-199001000-00006; MANNING W, 1991, COSTS POOR HLTH HABI, P223; MCGINNIS JM, 1992, EMERGING ISSUES BIOM, V1, P13; Morrison E M, 1990, Health Care Financ Rev, V12, P81; Patrick D. L., 1993, HLTH STATUS HLTH POL; Pelletier K R, 1988, Am J Health Promot, V2, P75; Pelletier K R, 1991, Am J Health Promot, V5, P311; PELLETIER KR, 1992, PURSUIT WELLNESS, V7; PODRID PJ, 1989, ANN INTERN MED, V111, P193, DOI 10.7326/0003-4819-111-3-193; REINHARDT UE, 1992, NEW ENGL J MED, V327, P809, DOI 10.1056/NEJM199209103271114; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROOS NP, 1989, MILBANK Q, V67, P347, DOI 10.2307/3350220; Russell LB., 1986, IS PREVENTION BETTER; SCHNEIDER EL, 1983, NEW ENGL J MED, V309, P854, DOI 10.1056/NEJM198310063091411; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SCHROEDER SA, 1991, NEW ENGL J MED, V325, P1099, DOI 10.1056/NEJM199110103251510; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SHEPHARD RJ, 1982, CAN J PUBLIC HEALTH, V73, P259; SIMMONS HE, 1992, NEW ENGL J MED, V327, P1525, DOI 10.1056/NEJM199211193272113; SOKOLOV JJ, 1992, COMPENS BENEFITS SPR, P1; SOKOLOV JJ, 1992, HEALTHCARE FORUM SPR, P36; SOMERS AR, 1984, NEW ENGL J MED, V311, P853, DOI 10.1056/NEJM198409273111312; STEFFY BD, 1986, AM J HLTH PROMOT, V2, P25; SULLIVAN LW, 1992, NEW ENGL J MED, V327, P801, DOI 10.1056/NEJM199209103271111; TEMKINGREENER H, 1992, MILBANK Q, V70, P679, DOI 10.2307/3350216; TSAI SP, 1988, PREV MED, V17, P475, DOI 10.1016/0091-7435(88)90046-1; TSAI SP, 1990, J OCCUP ENVIRON MED, V32, P245, DOI 10.1097/00043764-199003000-00012; VERBRUGGE LM, 1984, MILBANK FUND Q, V62, P475, DOI 10.2307/3349861; VICKERY DM, 1988, MED CARE, V26, P580, DOI 10.1097/00005650-198806000-00006; VICKERY DM, 1983, JAMA-J AM MED ASSOC, V250, P2952, DOI 10.1001/jama.250.21.2952; VICKERY DM, 1993, TAKE CARE YOURSELF; WARNER KE, 1988, J OCCUP ENVIRON MED, V30, P106; WEISBROD BA, 1991, J ECON LIT, V29, P523; WELCH HG, 1991, ANN INTERN MED, V115, P223, DOI 10.7326/0003-4819-115-3-223; WENNBERG JE, 1987, MED CARE, V25, P354, DOI 10.1097/00005650-198704000-00008; WENNBERG JE, 1988, JAMA-J AM MED ASSOC, V259, P3027, DOI 10.1001/jama.259.20.3027; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WETZLER HP, 1985, AM J PUBLIC HEALTH, V75, P1329, DOI 10.2105/AJPH.75.11.1329; Yen L T, 1991, Am J Health Promot, V6, P46; [No title captured]; 1991, PHS9150213 DHHS PUBL; 1990, PREVENTION 89 90 FED; 1991, PHS921232 DHHS PUBL	76	277	280	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					321	325		10.1056/NEJM199307293290506	http://dx.doi.org/10.1056/NEJM199307293290506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8321260	Bronze			2022-12-28	WOS:A1993LN62100006
J	EDDY, DM				EDDY, DM			3 BATTLES TO WATCH IN THE 1990S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									DUKE UNIV, DURHAM, NC 27706 USA	Duke University								AKIYAMA T, 1991, AM J CARDIOL, V68, P1551, DOI 10.1016/0002-9149(91)90308-8; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; Eddy David M., 1990, JAMA-J AM MED ASSOC, V263, P3081; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P2575, DOI 10.1001/jama.268.18.2575; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P3077, DOI 10.1001/jama.263.22.3077; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P287, DOI 10.1001/jama.263.2.287; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1839, DOI 10.1001/jama.263.13.1839; EDDY DM, 1990, SEP P CORN HLTH CAR; Eddy DM., 1990, JAMA-J AM MED ASSOC, V263, P3084; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V269, P2554, DOI 10.1001/jama.269.19.2554; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; METTLIN C, 1991, CANCER, V67, P2949, DOI 10.1002/1097-0142(19910615)67:12<2949::AID-CNCR2820671202>3.0.CO;2-X; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SOX HC, 1993, JAMA-J AM MED ASSOC, V269, P2678, DOI 10.1001/jama.269.20.2678; WINAWER SJ, 1993, NEW ENGL J MED, V328, P1416, DOI 10.1056/NEJM199305133281909; 1991, HLTH CARE RESOURCE B; 1978, REPORT ASSESSING EFF; 1985, ASSESSING MED TECHNO	24	97	97	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					520	526						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320794				2022-12-28	WOS:A1993LN42600038
J	WEISS, RB; VOGELZANG, NJ; PETERSON, BA; PANASCI, LC; CARPENTER, JT; GAVIGAN, M; SARTELL, K; FREI, E; MCINTYRE, OR				WEISS, RB; VOGELZANG, NJ; PETERSON, BA; PANASCI, LC; CARPENTER, JT; GAVIGAN, M; SARTELL, K; FREI, E; MCINTYRE, OR			A SUCCESSFUL SYSTEM OF SCIENTIFIC-DATA AUDITS FOR CLINICAL-TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MISCONDUCT; PROGRAM	Objective.-To report on data collected during on-site audits of source documents in the Cancer and Leukemia Group B (CALGB). Design.-A retrospective review of audit reports in four audit cycles. Setting.-A cooperative group of institutions conducting clinical trials in cancer treatment. Participants.-Patients taking part in clinical trials at collaborating CALGB institutions, members of the CALGB Data Audit Committee, and group chairmen of CALGB. Main Outcome Measure.-The results of 691 institutional audits conducted by the CALGB in 1982 through 1992 with comparisons of main CALGB institutions vs affiliates. Results.-In four full reviews of all participating institutions in the CALGB, 3787 patients have had their on-site medical records compared with data submitted to the CALGB Data Management Center. Compliance with federal regulations for oversight by an institutional review board improved from a deficiency rate of 28.0% among the main institutions and 49.6% of the affiliate institutions in the first audit cycle to respective figures of 13.3% and 28.2% in the fourth cycle. Consent form deficiencies also dropped overall from 18.5% in the first cycle to 3.9% in the fourth. Patient eligibility was verified by auditors in 94.5%, and assessment of tumor changes in response to treatment was verified in 96.4% in the fourth cycle; both figures were only slightly lower in the first cycle. Two instances of scientific impropriety were discovered for a rate of only 0.28% of all audits. Both occurred prior to 1984, and none have occurred since. Major protocol deviations in drug dosing have held steady at about 11% over four audit cycles. Over the 11-year period of audits, three main institutions and 96 affiliate institutions have discontinued CALGB membership due solely, or at least partly, to unfavorable audit results. Conclusion.-Scientific improprieties have occurred very rarely in clinical trials conducted by the CALGB. Protocol compliance in assessing patient eligibility and tumor responses has been high. Attention to administrative matters of consent forms, institutional review board approval, and ancillary data submission has measurably improved in the CALGB, which is at least partly due to the pressure from this on-site peer review of investigator performance.	MCGILL CANC CTR,DEPT MED,MONTREAL,PQ,CANADA; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; CANC & LEUKEMIA GRP B,CENT OFF,LEBANON,NH; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27514; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,BOSTON,MA 02115; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756	McGill University; Uniformed Services University of the Health Sciences - USA; University of Chicago; University of Minnesota System; University of Minnesota Twin Cities; University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Dartmouth College	WEISS, RB (corresponding author), WALTER REED ARMY MED CTR,DEPT MED,MED ONCOL SECT,WASHINGTON,DC 20307, USA.				NCI NIH HHS [CA 16450, CA 26806, CA 41287] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA041287, U10CA016450, U10CA026806] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROAD WJ, 1983, SCIENCE, V121, P137; CHEUNG NKV, 1992, J CLIN ONCOL, V10, P671, DOI 10.1200/JCO.1992.10.4.671; CULLITON BJ, 1986, SCIENCE, V234, P1069, DOI 10.1126/science.3535072; GREENBERG DS, 1991, J NATL I HLTH RES, V3, P32; HOLDEN C, 1986, SCIENCE, V124, P1488; Knox R, 1983, JAMA, V249, P1797, DOI 10.1001/jama.249.14.1797; KOSHLAND DE, 1987, SCIENCE, V235, P141, DOI 10.1126/science.3798097; KOSHLAND DE, 1991, SCIENCE, V3, P32; MAUER JK, 1985, CANCER TREAT REP, V69, P1177; RENNIE D, 1989, JAMA-J AM MED ASSOC, V261, P2543, DOI 10.1001/jama.261.17.2543; SHAPIRO MF, 1989, JAMA-J AM MED ASSOC, V261, P2505, DOI 10.1001/jama.261.17.2505; SHAPIRO MF, 1985, NEW ENGL J MED, V312, P731, DOI 10.1056/NEJM198503143121128; SUNDERLAND M, 1990, P AN M AM SOC CLIN, V9, P60; SYLVESTER RJ, 1981, NEW ENGL J MED, V305, P852, DOI 10.1056/NEJM198110083051503; WEISS GR, 1987, P AM SOC CLIN ONCOL, V6, P227; WEISS RB, 1992, ACCOUNTABIL RES POL, V2, P13; 1982, NEW ENGL J MED, V306, P1076	17	56	57	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					459	464		10.1001/jama.270.4.459	http://dx.doi.org/10.1001/jama.270.4.459			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320783				2022-12-28	WOS:A1993LN42600024
J	MASSRY, SG				MASSRY, SG			NEPHROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOLYTIC-UREMIC SYNDROME; SURVIVAL; DISEASE				MASSRY, SG (corresponding author), UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033, USA.							AVRAM MM, 1992, AM J KIDNEY DIS, V20, P324, DOI 10.1016/S0272-6386(12)70294-9; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BITZAN M, 1991, J PEDIATR-US, V119, P380, DOI 10.1016/S0022-3476(05)82049-9; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; BRUNNER FP, 1992, KIDNEY INT, V42, pS4; FADDA GZ, 1993, KIDNEY INT, V43, P554, DOI 10.1038/ki.1993.82; HELD PJ, 1990, AM J KIDNEY DIS, V15, P451, DOI 10.1016/S0272-6386(12)70363-3; HELD PJ, 1992, KIDNEY INT, V42, pS16; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P455; MASSRY SG, 1993, AM J KIDNEY DIS, V21, P81, DOI 10.1016/S0272-6386(12)80727-X; MOOSA A, 1990, BRIT J HAEMATOL, V74, P300, DOI 10.1111/j.1365-2141.1990.tb02587.x; PARFREY PS, 1991, J AM SOC NEPHROL, V2, P2; ROCH GA, 1991, NEW ENGL J MED, V325, P353; ROSTAND SG, 1991, J AM SOC NEPHROL, V2, P1053; SIEGLER RL, 1991, J PEDIATR-US, V118, P195, DOI 10.1016/S0022-3476(05)80482-2; STOJCEVATANEVA O, IN PRESS AM J NEPHRO	17	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					227	228		10.1001/jama.270.2.227	http://dx.doi.org/10.1001/jama.270.2.227			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315741				2022-12-28	WOS:A1993LL36800027
J	PELLEGRINO, ED				PELLEGRINO, ED			ETHICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESUSCITATION; WANGLIE,HELGA; FUTILITY				PELLEGRINO, ED (corresponding author), GEORGETOWN UNIV, WASHINGTON, DC USA.							ACKERMAN F, 1991, HASTINGS CENT REP, V21, P27, DOI 10.2307/3562998; ANGELL M, 1991, NEW ENGL J MED, V325, P511, DOI 10.1056/NEJM199108153250712; CAPRON AM, 1991, HASTINGS CENT REP, V21, P26, DOI 10.2307/3562887; FABERLANGENDOEN K, 1991, ARCH INTERN MED, V151, P235, DOI 10.1001/archinte.151.2.235; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; Jecker N S, 1993, Camb Q Healthc Ethics, V2, P151; KNAUS W, 1993, CAMB Q HLTH CARE ETH, V2, P147; LANTOS J D, 1989, American Journal of Medicine, V87, P81, DOI 10.1016/S0002-9343(89)80487-5; Paris J J, 1993, Camb Q Healthc Ethics, V2, P147; Stell Lance K, 1992, St Louis Univ Public Law Rev, V11, P481; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1983, DECIDING FOREGO LIFE, P241	14	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					202	203		10.1001/jama.270.2.202	http://dx.doi.org/10.1001/jama.270.2.202			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL368	8315731				2022-12-28	WOS:A1993LL36800017
J	SCHMIDT, GA; WOOD, LDH				SCHMIDT, GA; WOOD, LDH			CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; END-EXPIRATORY PRESSURE; AIRWAY PRESSURE; TIDAL VOLUME; VENTILATION; PEEP				SCHMIDT, GA (corresponding author), UNIV CHICAGO,CHICAGO,IL 60637, USA.			Schmidt, Gregory/0000-0002-5013-6323				CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; CURTIS SE, 1992, AM REV RESPIR DIS, V145, P348, DOI 10.1164/ajrccm/145.2_Pt_1.348; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; GUTIERREZ G, 1992, CRIT CARE MED, V20, P451, DOI 10.1097/00003246-199204000-00004; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HALL JB, 1992, PRINCIPLES CRITICAL, P1617; HALUSZKA J, 1990, AM REV RESPIR DIS, V141, P1194, DOI 10.1164/ajrccm/141.5_Pt_1.1194; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; KIISKI R, 1992, AM REV RESPIR DIS, V146, P1131, DOI 10.1164/ajrccm/146.5_Pt_1.1131; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; MARINI JJ, 1992, AM REV RESPIR DIS, V146, P2, DOI 10.1164/ajrccm/146.1.2; MIRO AM, 1993, CHEST, V103, P266, DOI 10.1378/chest.103.1.266; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; PETROF BJ, 1990, AM REV RESPIR DIS, V141, P281, DOI 10.1164/ajrccm/141.2.281; RONCO JJ, 1992, AM REV RESPIR DIS, V141, P25; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; WALLEY KR, 1990, CRIT CARE MED, V18, P336, DOI 10.1097/00003246-199003000-00019; YOUNES M, 1992, AM REV RESPIR DIS, V145, P121, DOI 10.1164/ajrccm/145.1.121; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	20	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					194	196		10.1001/jama.270.2.194	http://dx.doi.org/10.1001/jama.270.2.194			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315727				2022-12-28	WOS:A1993LL36800013
J	BEATTY, OL; HARPER, R; SHERIDAN, B; ATKINSON, AB; BELL, PM				BEATTY, OL; HARPER, R; SHERIDAN, B; ATKINSON, AB; BELL, PM			INSULIN-RESISTANCE IN OFFSPRING OF HYPERTENSIVE PARENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; PIMA-INDIANS; GLUCOSE-INTOLERANCE; FAMILY HISTORY; BLOOD-PRESSURE; METABOLISM; SENSITIVITY; RECEPTOR; OBESITY; GENE	Objective-To determine if insulin resistance is present in normotensive adults at increased risk of developing hypertension. Design-Normotensive subjects with at least one hypertensive parent were paired with offspring of normotensive parents (controls), being matched for age, sex, social class, and physical activity. Setting-Outpatient clinic. Subjects-30 paired subjects (16 men and 14 women) with and without a family history of hypertension, aged 18-32, with a body mass index <25 kg/m2, with blood pressure < 130/85 mm Hg, and not taking drugs. Interventions-Euglycaemic glucose clamp (two hour infusion of insulin 1 mU/kg/min) and intravenous glucose tolerance test (injection of 100 ml 20% glucose). Main outcome measures-Insulin mediated glucose disposal and insulin secretion. Results-The offspring of hypertensive parents had slightly higher blood pressure than did the controls (mean 117 (SD 6) v 108 (5) mm Hg systolic, p=0.013; 76 (7) v 67 (6) mm Hg diastolic, p=0.017). Their insulin mediated glucose disposal was lower than that of controls (29.5 (6.5) v 40.1 (8.6) mumol/kg/min, p=0.002), but, after adjustment for blood pressure, the difference was not significant (difference 6.9 (95% confidence interval -1.5 to 15.3), p=0.10). Insulin secretion in the first hour after injection of glucose was slightly but not significantly higher in the offspring of hypertensive patients (9320 (5484) v 6723 (3751) pmol.min/l). The two groups had similar concentrations of plasma glucose (5.2 (0.3) v 5.1 (0.4) mmol/l), serum cholesterol (4.4 (0.8) v 4.6 (0.8) mmol/l), serum triglyceride (0.89 (0.52) v 0.68 (0.27) mmol/l), and serum low density lipoprotein cholesterol (2.81 (0.65) v 2.79 (0.61) mmol/l). The offspring of hypertensive parents, however, had lower serum concentrations of high density lipoprotein cholesterol (1.24 (0.31) v 1.56 (0.35) mmol/l, p=0.002) and higher serum concentrations of non-esterified fatty acids (0.7 (0.4) v 0.4 (0.4) mmol/l, p=0.039). Conclusions-Young normotensive subjects who are at increased risk of developing hypertension are insulin resistant.	ROYAL VICTORIA HOSP, SIR GEORGE E CLARK METAB UNIT, BELFAST BT12 6BA, NORTH IRELAND; ROYAL VICTORIA HOSP, REG ENDOCRINE LAB, BELFAST BT12 6BA, NORTH IRELAND									BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; DEFRONZO RA, 1982, INT J OBESITY, V6, P73; DEFRONZO RA, 1981, DIABETOLOGIA, V21, P165, DOI 10.1007/BF00252649; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRARI P, 1991, AM J MED, V91, P589, DOI 10.1016/0002-9343(91)90211-F; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; JARRETT RJ, 1992, LANCET, V340, P469, DOI 10.1016/0140-6736(92)91781-3; JULIUS S, 1991, J HYPERTENS, V9, P983, DOI 10.1097/00004872-199111000-00001; KOLTERMAN OG, 1980, J CLIN INVEST, V65, P1272, DOI 10.1172/JCI109790; KUSARI J, 1991, J CLIN INVEST, V88, P1323, DOI 10.1172/JCI115437; LAAKSO M, 1990, J CLIN INVEST, V85, P1844, DOI 10.1172/JCI114644; LAAKSO M, 1991, DIABETES S1, V40, pA100; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; MOORE RD, 1983, BIOCHIM BIOPHYS ACTA, V737, P1, DOI 10.1016/0304-4157(83)90013-8; MUNGER RG, 1988, J HYPERTENS, V6, P647, DOI 10.1097/00004872-198808000-00008; NATALI A, 1991, HYPERTENSION, V17, P170, DOI 10.1161/01.HYP.17.2.170; OELBAUM RS, 1991, DIABETOLOGIA, V34, P260, DOI 10.1007/BF00405085; POLLARE T, 1989, BRIT MED J, V298, P1152, DOI 10.1136/bmj.298.6681.1152; POLLARE T, 1988, DIABETOLOGIA, V31, P415, DOI 10.1007/BF00271585; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; RABEN N, 1991, DIABETES, V40, P118, DOI 10.2337/diabetes.40.1.118; RANDLE PJ, 1963, LANCET, V1, P785; REAVEN G, 1968, DIABETES, V17, P560, DOI 10.2337/diab.17.9.560; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RIZZA RA, 1981, DIABETES, V30, P990, DOI 10.2337/diabetes.30.12.990; ROONEY DP, 1991, EUR J CLIN INVEST, V21, P430, DOI 10.1111/j.1365-2362.1991.tb01391.x; ROONEY DP, 1992, METABOLISM, V41, P317, DOI 10.1016/0026-0495(92)90278-I; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SALTIN B, 1968, CIRCULATION, V38, P1104, DOI 10.1161/01.CIR.38.6.1104; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; STAMLER R, 1979, JAMA-J AM MED ASSOC, V241, P43, DOI 10.1001/jama.241.1.43; SWISLOCKI ALM, 1989, AM J HYPERTENS, V2, P419, DOI 10.1093/ajh/2.6.419; VALDES CT, 1991, J CLIN ENDOCR METAB, V72, P642, DOI 10.1210/jcem-72-3-642; WATT G, 1986, J HYPERTENS, V4, P1, DOI 10.1097/00004872-198602000-00001; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; WILLIAMS RR, 1989, J HYPERTENS       S6, V7, P8; 1990, CHALLENGE 90S CHANGE	41	102	105	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1993	307	6896					92	96		10.1136/bmj.307.6896.92	http://dx.doi.org/10.1136/bmj.307.6896.92			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343735	Green Published, Bronze			2022-12-28	WOS:A1993LM58500022
J	BORCHJOHNSEN, K; WENZEL, H; VIBERTI, GC; MOGENSEN, CE				BORCHJOHNSEN, K; WENZEL, H; VIBERTI, GC; MOGENSEN, CE			IS SCREENING AND INTERVENTION FOR MICROALBUMINURIA WORTHWHILE IN PATIENTS WITH INSULIN-DEPENDENT DIABETES	BRITISH MEDICAL JOURNAL			English	Article							ALBUMIN EXCRETION; KIDNEY-FUNCTION; NEPHROPATHY; PREDICTOR; MELLITUS; RISK; PROTEINURIA; MORTALITY	Objective-To analyse the cost-benefit of screening for and antihypertensive treatment of early renal disease indicated by microalbuminuria in patients with insulin dependent diabetes mellitus. Design-Previously published data were used to estimate transition probabilities for each step from normoalbuminuria until death. The effect of intervention on urinary albumin excretion rate by antihypertensive treatment was arbitrarily set at three different levels. All direct costs (screening, antihypertensive treatment, treatment of end stage renal failure) were included in the cost-benefit analysis by using real discount rates of 2.5% and 6%. Setting-Computer simulation. Subjects-Simulated cohort of 8000 patients. Main outcome measures-Mortality, incidence of diabetic nephropathy, incidence of end stage renal failure, and costs versus savings. Results-Assuming treatment effects of 33% and 67% median life expectancy increased by four to 14 years, respectively, and the need for dialysis or transplantation decreased by 21% to 63%. Costs and savings would balance if the annual rate of increase of albuminuria was decreased from 20% to 18% a year. Conclusions-Screening and intervention programmes are likely to have life saving effects and lead to considerable economic savings.	UNIV BIELEFELD,SCH PUBL HLTH,W-4800 BIELEFELD,GERMANY; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,METAB MED UNIT,LONDON,ENGLAND; UNIV HOSP ARHUS,ARHUS KOMMUNEHOSP,MED DEPT M,DK-8000 AARHUS,DENMARK	University of Bielefeld; University of London; King's College London; Aarhus University	BORCHJOHNSEN, K (corresponding author), KOMMUNE HOSP COPENHAGEN,INST PREVENT MED,DK-1399 COPENHAGEN K,DENMARK.							BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; BORCHJOHNSEN K, 1989, DAN MED BULL, V36, P336; Christensen C K, 1987, J Diabet Complications, V1, P45, DOI 10.1016/S0891-6632(87)80079-X; CHRISTENSEN CK, 1991, DAN MED BULL, V38, P145; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; Deckerf T., 1987, SCAND ACTUAR J, V1, P19; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Feldt-Rasmussen B, 1984, DIABETIC NEPHROPATHY, V3, P101; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; HALLAB M, 1993, BRIT MED J, V306, P175, DOI 10.1136/bmj.306.6871.175; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; Kofoed-Enevoldsen A, 1987, J Diabet Complications, V1, P96, DOI 10.1016/S0891-6632(87)80064-8; KOFOEDENEVOLDSEN A, 1987, DIABETES, V36, P205, DOI 10.2337/diabetes.36.2.205; KRANS HMJ, 1992, GIORN ITAL DIABET S2, V12, P1; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MARSHALL SM, 1989, Q J MED, V70, P61; MATHIESEN ER, 1989, DIABETOLOGIA, V32, P884, DOI 10.1007/BF00297455; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1992, DIABETES CARE, V15, P1192, DOI 10.2337/diacare.15.9.1192; MOGENSEN CE, 1992, J HYPERTENS, V10, pS43, DOI 10.1097/00004872-199204001-00009; MOGENSEN CE, 1992, J AM SOC NEPHROL, V3, pA336; MOGENSEN CE, 1986, UREMIA INVEST, V9, P85; PARVING HH, 1983, LANCET, V1, P1175; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P550, DOI 10.1530/acta.0.1000550; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, P3111; VIBERTI GC, 1982, LANCET, V1, P1430; 1991, BMJ, V302, P210; 1990, STATISTISCHES JB 199	35	133	133	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1722	1723		10.1136/bmj.306.6894.1722	http://dx.doi.org/10.1136/bmj.306.6894.1722			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343628	Green Published, Bronze			2022-12-28	WOS:A1993LK36700019
J	OMAHONY, B				OMAHONY, B			INTERACTIONS BETWEEN A GENERAL-PRACTITIONER AND REPRESENTATIVES OF DRUG COMPANIES	BRITISH MEDICAL JOURNAL			English	Article							DOCTORS				OMAHONY, B (corresponding author), SURG,LISMORE,WATERFORD,IRELAND.							AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; LEXCHIN J, 1989, INT J HEALTH SERV, V19, P663, DOI 10.2190/HUFK-5Y54-QX1E-AD62; SMITH R, 1986, BRIT MED J, V293, P905, DOI 10.1136/bmj.293.6552.905; 1991, DATA SHEET COMPENDIU, pR5	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1649	1649		10.1136/bmj.306.6893.1649	http://dx.doi.org/10.1136/bmj.306.6893.1649			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LJ337	8324433	Bronze, Green Published			2022-12-28	WOS:A1993LJ33700020
J	TURPIE, AGG; GENT, M; LAUPACIS, A; LATOUR, Y; GUNSTENSEN, J; BASILE, F; KLIMEK, M; HIRSH, J				TURPIE, AGG; GENT, M; LAUPACIS, A; LATOUR, Y; GUNSTENSEN, J; BASILE, F; KLIMEK, M; HIRSH, J			A COMPARISON OF ASPIRIN WITH PLACEBO IN PATIENTS TREATED WITH WARFARIN AFTER HEART-VALVE REPLACEMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL ANTICOAGULANT-THERAPY; THROMBOEMBOLIC COMPLICATIONS; DIFFERENT INTENSITIES; ACETYLSALICYLIC-ACID; PREVENTION; TRIAL	Background. Despite the use of warfarin, major systemic embolism remains an important complication in patients with heart-valve replacement. Although the addition of antiplatelet agents has the potential to reduce this complication, their efficacy and safety when given in combination with warfarin are uncertain. Methods. In a randomized, double-blind, placebo-controlled trial, we assessed the efficacy and safety of adding aspirin (100 mg per day) to warfarin treatment (target international normalized ratio, 3.0 to 4.5) in 370 patients with mechanical heart valves or with tissue valves plus atrial fibrillation or a history of thromboembolism. Results. A total of 186 patients were randomly assigned to aspirin and 184 to placebo, and they were followed for up to 4 years (average, 2.5). Major systemic embolism or death from vascular causes occurred in 6 aspirin-treated patients (1.9 percent per year) and 24 placebo-treated patients (8.5 percent per year) (risk reduction with aspirin, 77 percent; 95 percent confidence interval, 44 to 91 percent; P<0.001). Major systemic embolism, nonfatal intracranial hemorrhage, or death from hemorrhage or vascular causes occurred in 12 patients assigned to aspirin (3.9 percent per year) and 28 patients assigned to placebo (9.9 percent per year) (risk reduction, 61 per cent; 95 percent confidence interval, 24 to 80 percent; P = 0.005); major systemic embolism or death from any cause occurred in 13 patients (4.2 percent) and 33 patients (11.7 percent), respectively (risk reduction, 65 percent; 95 percent confidence interval, 33 to 82 percent; P<0.001); and death from all causes occurred in 9 patients (2.8 percent) and 22 patients (7.4 percent), respectively (risk reduction, 63 percent; 95 percent confidence interval, 19 to 83 percent; P = 0.01). Bleeding occurred in 71 patients in the aspirin group (35.0 percent), as compared with 49 patients in the placebo group (22.0 percent) (increase in risk, 55 percent; 95 percent confidence interval, 8 to 124 percent; P = 0.02); major bleeding occurred in 24 and 19 patients, respectively (increase in risk, 27 percent; 95 percent confidence interval, -30 to 132 percent; P = 0.43). Conclusions. In patients with mechanical heart valves and high-risk patients with prosthetic tissue valves, the addition of aspirin to warfarin therapy reduced mortality, particularly mortality from vascular causes, together with major systemic embolism. Although there was some increase in bleeding, the risk of the combined treatment was more than offset by the considerable benefit.	MCMASTER UNIV, DEPT MED, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, DEPT SURG, HAMILTON L8S 4L8, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT MED, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, UNIV HOSP, LONDON N6A 5A5, ONTARIO, CANADA; HOP HOTEL DIEU, DEPT MED, MONTREAL, PQ, CANADA; HOP HOTEL DIEU, DEPT SURG, MONTREAL, PQ, CANADA	McMaster University; McMaster University; McMaster University; Western University (University of Western Ontario); Western University (University of Western Ontario); Universite de Montreal; Universite de Montreal	TURPIE, AGG (corresponding author), HAMILTON CIV HOSP, RES CTR, HGH MCMASTER CLIN, GEN DIV, 237 BARTON ST E, HAMILTON L8L 2X2, ON, CANADA.							ALTMAN R, 1976, J THORAC CARDIOV SUR, V72, P127; ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427; BLOOMFIELD P, 1991, NEW ENGL J MED, V324, P573, DOI 10.1056/NEJM199102283240901; CHESEBRO JH, 1983, AM J CARDIOL, V51, P1537, DOI 10.1016/0002-9149(83)90673-2; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; COLVIN BT, 1990, J CLIN PATHOL, V43, P177; COX DR, 1972, J R STAT SOC B, V34, P187; DALE J, 1977, AM HEART J, V94, P101, DOI 10.1016/S0002-8703(77)80351-7; FUSTER V, 1988, SEMIN THROMB HEMOST, V14, P50, DOI 10.1055/s-2007-1002755; HAWTHORNE AB, 1991, BRIT J CLIN PHARMACO, V32, P77, DOI 10.1111/j.1365-2125.1991.tb05616.x; HERD CM, 1987, AUST NZ J MED, V17, P195, DOI 10.1111/j.1445-5994.1987.tb00040.x; HIRSH J, 1989, CHEST, V95, pS12; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; RAJAH SM, 1980, ACTA THERAPEUTIC S93, V6, P54; ROBERTS MS, 1984, EUR J CLIN PHARMACOL, V27, P67, DOI 10.1007/BF02395209; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SIEBERT DJ, 1983, CLIN PHARMACOL THER, V33, P367, DOI 10.1038/clpt.1983.47; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; STEIN PD, 1989, CHEST, V95, pS107, DOI 10.1378/chest.95.2_Supplement.107S; SULLIVAN JM, 1971, NEW ENGL J MED, V284, P1391, DOI 10.1056/NEJM197106242842501; TURPIE AGG, 1988, LANCET, V1, P1242; 1978, COEUR, V9, P915	24	442	451	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					524	529		10.1056/NEJM199308193290802	http://dx.doi.org/10.1056/NEJM199308193290802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8336751				2022-12-28	WOS:A1993LR89200002
J	QUICK, RE; HERWALDT, BL; THOMFORD, JW; GARNETT, ME; EBERHARD, ML; WILSON, M; SPACH, DH; DICKERSON, JW; TELFORD, SR; STEINGART, KR; POLLOCK, R; PERSING, DH; KOBAYASHI, JM; JURANEK, DD; CONRAD, PA				QUICK, RE; HERWALDT, BL; THOMFORD, JW; GARNETT, ME; EBERHARD, ML; WILSON, M; SPACH, DH; DICKERSON, JW; TELFORD, SR; STEINGART, KR; POLLOCK, R; PERSING, DH; KOBAYASHI, JM; JURANEK, DD; CONRAD, PA			BABESIOSIS IN WASHINGTON-STATE - A NEW SPECIES OF BABESIA	ANNALS OF INTERNAL MEDICINE			English	Article						BABESIOSIS; WASHINGTON; TICK-BORNE DISEASES; FLUORESCENT ANTIBODY; TECHNIQUE; ZOONOSES	BORRELIA-BURGDORFERI; MICROTI INFECTION; ANTIBODY; SURFACE; BLOOD; IDENTIFICATION; MEROZOITES; WISCONSIN; DISEASE; RODENTS	Objective; To,characterize the etiologic agent (WA1) of the first reported case of babesiosis acquired in Washington State. Design: Case report, and serologic, molecular, and epizootiologic studies. Setting: South-central Washington State. Patient: A 41-year-old immunocompetent man with an intact spleen who developed a moderately severe case of babesiosis. Measurements: Serum specimens from the patient were assayed by indirect immunofluorescent antibody (IFA) testing for reactivity with seven Babesia species and with WA1, which was propagated in hamsters inoculated with his blood. A Babesia-specific, ribosomal-DNA (rDNA) probe was hybridized to Southern blots of restriction-endonuclease-digested preparations of DNA from WA1, Babesia microti, and Babesia gibsoni. Serum specimens from 83 family members and neighbors were assayed for IFA reactivity with WA1 and B. microti. Small mammals and ticks were examined for Babesia infection. Results: The patient's serum had very strong IFA reactivity with WA1, strong reactivity with B. gibsoni (which infects dogs), but only weak reactivity with B. microti. DNA hybridization patterns with the rDNA probe clearly differentiated WA1 from B. gibsoni and B. microti. Four of the patient's neighbors had IFA titers to WA1 of 256. The tick vector and animal reservoir of WA1 have not yet been identified, despite trapping 83 mammals and collecting 235 ticks. Conclusions: WA1 is morphologically indistinguishable but antigenically and genotypically distinct from B. microti. Some patients elsewhere who were assumed to have been infected with B. microti may have been infected with WA1. Improved serodiagnostic and molecular techniques are needed for characterizing Babesia species and elucidating the epidemiology of babesiosis, an emergent zoonosis.	CTR DIS CONTROL & PREVENT, PARASIT DIS BRANCH, EPIDEMIOL PROGRAM OFF, 4700 BUFORD HIGHWAY NE, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, ATLANTA, GA 30341 USA; UNIV CALIF DAVIS, DAVIS, CA 95616 USA; FAMILY PRACTICE CLIN, GOLDENDALE, WA USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; SW WASHINGTON HLTH DIST, VANCOUVER, WA USA; WASHINGTON STATE UNIV, PULLMAN, WA 99164 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; DEPT HLTH, SEATTLE, WA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of California System; University of California Davis; University of Washington; University of Washington Seattle; Harvard University; Harvard T.H. Chan School of Public Health; Washington State University; Mayo Clinic					PHS HHS [R01-41497, R01-30548, R01-32403] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON JF, 1991, J CLIN MICROBIOL, V29, P2779, DOI 10.1128/JCM.29.12.2779-2783.1991; ARTHUR DR, 1968, PARASITOLOGY, V58, P893, DOI 10.1017/S0031182000069663; BRANDT F, 1977, J PARASITOL, V63, P934, DOI 10.2307/3279918; BREDT AB, 1981, JAMA-J AM MED ASSOC, V245, P1938, DOI 10.1001/jama.245.19.1938; BURGDORFER W, 1985, AM J TROP MED HYG, V34, P925, DOI 10.4269/ajtmh.1985.34.925; CHISHOLM ES, 1978, AM J TROP MED HYG, V27, P14, DOI 10.4269/ajtmh.1978.27.14; CONRAD PA, 1992, J CLIN MICROBIOL, V30, P1210, DOI 10.1128/JCM.30.5.1210-1215.1992; CONRAD PA, 1987, MOL BIOCHEM PARASIT, V25, P213, DOI 10.1016/0166-6851(87)90085-5; CULLEN JM, 1987, LAB ANIM SCI, V37, P640; ETKIND P, 1980, J PARASITOL, V66, P107, DOI 10.2307/3280599; FAY FH, 1969, J PARASITOL, V55, P1258, DOI 10.2307/3277271; GARNHAM PCC, 1980, T ROY SOC TROP MED H, V74, P153, DOI 10.1016/0035-9203(80)90232-1; GLEASON NN, 1970, J PARASITOL, V56, P1256, DOI 10.2307/3277582; GOFF WL, 1988, INFECT IMMUN, V56, P2363, DOI 10.1128/IAI.56.9.2363-2368.1988; GOLIGHTLY LM, 1989, REV INFECT DIS, V11, P629; GOMBERT ME, 1982, JAMA-J AM MED ASSOC, V248, P3005, DOI 10.1001/jama.248.22.3005; GORENFLOT A, 1990, INFECT IMMUN, V58, P4076, DOI 10.1128/IAI.58.12.4076-4082.1990; GRAY JS, 1991, J WILDLIFE DIS, V27, P86, DOI 10.7589/0090-3558-27.1.86; Healy G., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P35, DOI 10.1016/0035-9203(89)90601-9; HEALY GR, 1980, AM J CLIN PATHOL, V73, P107; HOARE CA, 1980, T ROY SOC TROP MED H, V74, P143, DOI 10.1016/0035-9203(80)90230-8; HOLBROOK AA, 1970, 2ND P C EQ INF DIS P, P249; IACOPINO V, 1990, ARCH INTERN MED, V150, P1527, DOI 10.1001/archinte.150.7.1527; KNOWLES DP, 1991, INFECT IMMUN, V59, P2412, DOI 10.1128/IAI.59.7.2412-2417.1991; LANE RS, 1986, ZBL BAKT-INT J MED M, V263, P55; LEVINE ND, 1971, T AM MICROSC SOC, V90, P2, DOI 10.2307/3224894; LYKINS JD, 1975, EXP PARASITOL, V37, P388, DOI 10.1016/0014-4894(75)90008-9; MCELWAIN TF, 1987, J IMMUNOL, V138, P2298; MELDRUM SC, 1992, CLIN INFECT DIS, V15, P1019, DOI 10.1093/clind/15.6.1019; ONG KR, 1990, LANCET, V336, P112, DOI 10.1016/0140-6736(90)91624-J; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; PIESMAN J, 1986, INT J PARASITOL, V16, P381, DOI 10.1016/0020-7519(86)90118-9; POPOVSKY MA, 1988, TRANSFUSION, V28, P59, DOI 10.1046/j.1537-2995.1988.28188127955.x; ROSNER F, 1984, AM J MED, V76, P696, DOI 10.1016/0002-9343(84)90298-5; ROWIN KS, 1982, ANN INTERN MED, V97, P556, DOI 10.7326/0003-4819-97-4-556; RUEBUSH TK, 1980, ANTIMICROB AGENTS CH, V18, P289, DOI 10.1128/AAC.18.2.289; RUEBUSH TK, 1980, T ROY SOC TROP MED H, V74, P149, DOI 10.1016/0035-9203(80)90231-X; SCHOLTENS RG, 1968, AM J TROP MED HYG, V17, P810, DOI 10.4269/ajtmh.1968.17.810; Skrabalo Z., 1957, Documenta de Medicina Geographica et Tropica, V9, P11; STEKETEE RW, 1985, JAMA-J AM MED ASSOC, V253, P2675, DOI 10.1001/jama.253.18.2675; Telford S. R. III, 1993, PARASIT PROTOZOA, V5, P1; THOMFORD JW, 1993, J PARASITOL, V79, P77, DOI 10.2307/3283281; YAMANE I, IN PRESS AM J VET RE; 1992, MED LETT DRUGS THER, V34, P17; 1992, CALIFORNIA MORBIDITY, V3, P1	45	156	164	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					284	290		10.7326/0003-4819-119-4-199308150-00006	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328736				2022-12-28	WOS:A1993LV52500006
J	CHALK, R				CHALK, R			HUMAN-RIGHTS AND CHILD HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CHALK, R (corresponding author), INST MED,COMM HLTH & HUMAN RIGHTS,2101 CONSTITUTION AVE NW,WASHINGTON,DC 20418, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					565	565						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331746				2022-12-28	WOS:A1993LP43600005
J	WARDEN, CH; HEDRICK, CC; QIAO, JH; CASTELLANI, LW; LUSIS, AJ				WARDEN, CH; HEDRICK, CC; QIAO, JH; CASTELLANI, LW; LUSIS, AJ			ATHEROSCLEROSIS IN TRANSGENIC MICE OVEREXPRESSING APOLIPOPROTEIN-A-II	SCIENCE			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; CELL-DERIVED CHOLESTEROL; ESTER TRANSFER PROTEIN; PLASMA-LIPOPROTEINS; HEART-DISEASE; ADIPOSE-CELLS; PARTICLES; SUBCLASSES; SUSCEPTIBILITY	Concentrations of plasma high density lipoprotein (HDL) are inversely correlated with atherosclerotic coronary artery disease. The two most abundant protein constituents of HDL are apolipoproteins A-I and A-II (apoA-I and apoA-II). ApoA-I is required for assembly of HDL and, when overexpressed in transgenic mice, confers resistance to early atherosclerosis. The present studies reveal that transgenic mice that overexpress mouse apoA-II had elevated HDL-cholesterol concentrations but, nevertheless, exhibited increased atherosclerotic lesion development as compared to normal mice. The HDL in the transgenic mice was larger and had an increased ratio of apoA-II to apoA-I. Thus, both the composition and amount of HDL appear to be important determinants of atherosclerosis.	UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Hedrick, Catherine/D-1106-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481, R01HL042488, R37HL042488] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28481, HL-07386, HL-42488] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BRESLOW JL, 1989, METABOLIC BASIS INHE, P1251; BURSTEIN M, 1970, J LIPID RES, V11, P583; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1986, J LIPID RES, V27, P1135; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; FIELDING PE, 1980, P NATL ACAD SCI-BIOL, V77, P3327, DOI 10.1073/pnas.77.6.3327; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Haberland ME, 1992, MOL GENETICS CORONAR, P35; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; HUGHES TA, 1992, J LAB CLIN MED, V119, P57; JIAO S, 1990, J LIPID RES, V31, P467; Karathanasis S. K., 1992, MONOGRAPHS HUMAN GEN, P140; KHOO JC, 1990, J LIPID RES, V31, P645; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; MEHRABIAN M, 1991, ARTERIOSCLER THROMB, V11, P947, DOI 10.1161/01.ATV.11.4.947; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1982, HIGH DENSITY LIPOPRO, P191; MOWRI H, 1990, CIRCULATION, V82, P558; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; NOWICKA G, 1990, J LIPID RES, V31, P1947; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PATSCH JR, 1987, PLASMA LIPOPROTEINS, P211; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; SLOOP CH, 1987, J LIPID RES, V28, P225; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; WALSH A, 1989, J BIOL CHEM, V264, P6488; YAMAZAKI S, 1983, J BIOL CHEM, V258, P5847	35	323	327	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1993	261	5120					469	472		10.1126/science.8332912	http://dx.doi.org/10.1126/science.8332912			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332912				2022-12-28	WOS:A1993LN62300035
J	HANSKI, I; TURCHIN, P; KORPIMAKI, E; HENTTONEN, H				HANSKI, I; TURCHIN, P; KORPIMAKI, E; HENTTONEN, H			POPULATION OSCILLATIONS OF BOREAL RODENTS - REGULATION BY MUSTELID PREDATORS LEADS TO CHAOS	NATURE			English	Article							MICROTINE CYCLES; PREY ABUNDANCE; LEAST WEASELS; NIVALIS; DYNAMICS; HYPOTHESIS; NUMBERS; SIZE	THE four-year cycle of microtine rodents in boreal and arctic regions was first described in 1924 (ref. 1). Competing hypotheses on the mechanisms underlying the small mammal cycle have been extensively tested2-5, but so far the sustained rodent oscillations are unexplained. Here we use two mutually supportive approaches to investigate this question. First, building on studies of the interaction between rodents and their mustelid predators6-9, we construct a predator-prey model with seasonality. Second, we use a new technique of nonlinear analysis10,11 to examine empirical time-series data, and compare them with the model dynamics. The model parameterized with field data predicts dynamics that closely resemble the observed dynamics of boreal rodent populations. Both the predicted and observed dynamics are chaotic, albeit with a statistically significant periodic component. Our results suggest that the multiannual oscillations of rodent populations in Fennoscandia are due to delayed density dependence imposed by mustelid predators, and are chaotic.	SO FOREST EXPT STN,PINEVILLE,LA 71360; UNIV TURKU,DEPT BIOL,ECOL ZOOL LAB,SF-20500 TURKU 50,FINLAND; FINNISH FOREST RES UNIT,DEPT FOREST ECOL,SF-01301 VANTAA,FINLAND	United States Department of Agriculture (USDA); United States Forest Service; University of Turku; Natural Resources Institute Finland (Luke)	HANSKI, I (corresponding author), UNIV HELSINKI,DEPT ZOOL,DIV ECOL,POB 17,P RAUTATIEKATU 13,SF-00014 HELSINKI,FINLAND.							BATZLI GO, 1992, WILDLIFE 2001 : POPULATIONS, P831; CHRISTIAN CJ, 1978, PYMATUNING LAB ECOL, V5, P143; Elton C., 1942, VOLES MICE LEMMINGS; ERLINGE S, 1974, OIKOS, V25, P308, DOI 10.2307/3543948; ERLINGE S, 1983, OIKOS, V40, P36, DOI 10.2307/3544197; ERLINGE S, 1975, OIKOS, V26, P378, DOI 10.2307/3543510; GILLINGHAM BJ, 1984, J MAMMAL, V65, P517, DOI 10.2307/1381110; HANSKI I, 1991, J ANIM ECOL, V60, P353, DOI 10.2307/5465; HANSKI I, 1991, TRENDS ECOL EVOL, V6, P141, DOI 10.1016/0169-5347(91)90052-Y; HANSSON L, 1988, TRENDS ECOL EVOL, V3, P195, DOI 10.1016/0169-5347(88)90006-7; HANSSON L, 1985, ANN ZOOL FENN, V22, P277; HANSSON L, 1984, SPEC PUBL CARNEGIE M, V10, P225; HENTTONEN H, 1987, OIKOS, V50, P353, DOI 10.2307/3565496; HENTTONEN H, 1987, OIKOS, V50, P366, DOI 10.2307/3565497; JEDRZEJEWSKA B, 1989, ACTA THERIOL, V34, P347; KAIKUSALO A, 1984, CARNEGIE MUS NAT HIS, V10, P243; KORPIMAKI E, 1989, OIKOS, V55, P205, DOI 10.2307/3565424; KORPIMAKI E, 1991, OECOLOGIA, V88, P552, DOI 10.1007/BF00317719; Krebs C.J., 1974, ADV ECOL RES, V8, P267, DOI DOI 10.1016/S0065-2504(08)60280-9; LAINE K, 1983, OIKOS, V40, P407, DOI 10.2307/3544313; LAINE KM, 1987, OIKOS, V50, P389, DOI 10.2307/3565500; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MAY RM, 1973, COMPLEXITY STABILITY; OKSANEN L, 1992, ECOGRAPHY, V15, P226, DOI 10.1111/j.1600-0587.1992.tb00029.x; TAPPER S, 1979, J ANIM ECOL, V48, P603, DOI 10.2307/4182; TAPPER SC, 1976, J ZOOL, V179, P219; TURCHIN P, IN PRESS OIKOS; TURCHIN P, 1993, ECODYN RSM RESPONSE; WOLF A, 1985, PHYSICA D, V16, P285, DOI 10.1016/0167-2789(85)90011-9	30	370	381	0	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					232	235		10.1038/364232a0	http://dx.doi.org/10.1038/364232a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321318				2022-12-28	WOS:A1993LM68300055
J	JOHNS, ME; NIPARKO, JK				JOHNS, ME; NIPARKO, JK			OTOLARYNGOLOGY - HEAD AND NECK-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											JOHNS, ME (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.							BRACKMANN DE, IN PRESS OTOLARYNGOL; CABLE J, 1992, HEARING RES, V64, P6, DOI 10.1016/0378-5955(92)90164-I; CHANG KW, 1993, ARCH OTOLARYNGOL, V119, P276; COHEN NL, 1993, NEW ENGL J MED, V328, P233, DOI 10.1056/NEJM199301283280403; CORWIN JT, 1991, ANNU REV NEUROSCI, V14, P301, DOI 10.1146/annurev.neuro.14.1.301; DOLCETTI R, 1991, EUR ARCH OTO-RHINO-L, V248, P279; MAESTRO R, 1992, ONCOGENE, V7, P1159; MARION RW, 1991, ANN NY ACAD SCI, V680, P32; MIYAMOTO RT, 1992, AM J OTOL, V13, P215; OGDEN GR, 1992, J PATHOL, V166, P389, DOI 10.1002/path.1711660411; QUITTNER A, 1992, 1ST P EUR S PED COCH, V1, P86; RUBEL EW, 1992, NOISE INDUCED HEARIN, P204; SOMERS KD, 1992, CANCER RES, V52, P5997; TORIUMI DM, 1991, ARCH OTOLARYNGOL, V117, P1101; TRUELSON JM, 1992, CANCER, V70, P56, DOI 10.1002/1097-0142(19920701)70:1<56::AID-CNCR2820700110>3.0.CO;2-Q; WOLF GT, 1992, LARYNGOSCOPE, V102, P934, DOI 10.1288/00005537-199208000-00015; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					243	245		10.1001/jama.270.2.243	http://dx.doi.org/10.1001/jama.270.2.243			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315748				2022-12-28	WOS:A1993LL36800035
J	RAYMENT, I; HOLDEN, HM; WHITTAKER, M; YOHN, CB; LORENZ, M; HOLMES, KC; MILLIGAN, RA				RAYMENT, I; HOLDEN, HM; WHITTAKER, M; YOHN, CB; LORENZ, M; HOLMES, KC; MILLIGAN, RA			STRUCTURE OF THE ACTIN-MYOSIN COMPLEX AND ITS IMPLICATIONS FOR MUSCLE-CONTRACTION	SCIENCE			English	Article							DEPENDENT ADENOSINE-TRIPHOSPHATASE; HEAVY-CHAIN; BINDING-SITES; SUBFRAGMENT-1; DISSOCIATION; MECHANISM; ASSOCIATION; SKELETAL; MEROMYOSIN; LOCATION	Muscle contraction consists of a cyclical interaction between myosin and actin driven by the concomitant hydrolysis of adenosine triphosphate (ATP). A model for the rigor complex of F actin and the myosin head was obtained by combining the molecular structures of the individual proteins with the low-resolution electron density maps of the complex derived by cryo-electron microscopy and image analysis. The spatial relation between the ATP binding pocket on myosin and the major contact area on actin suggests a working hypothesis for the crossbridge cycle that is consistent with previous independent structural and biochemical studies.	UNIV WISCONSIN, INST ENZYME RES, MADISON, WI 53705 USA; MAX PLANCK INST MED RES, DEPT BIOPHYS, W-6900 HEIDELBERG 1, GERMANY; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	University of Wisconsin System; University of Wisconsin Madison; Max Planck Society; Scripps Research Institute	RAYMENT, I (corresponding author), UNIV WISCONSIN, DEPT BIOCHEM, 1710 UNIV AVE, MADISON, WI 53705 USA.		Lorenz, Michael/HII-5763-2022; rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835; Holmes, Kenneth/0000-0001-8894-9453; Yohn, Christopher/0000-0002-5937-8070				BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; BETRAND R, 1992, BIOCHEMISTRY-US, V31, P12219; BOTTS J, 1989, P NATL ACAD SCI USA, V86, P2204, DOI 10.1073/pnas.86.7.2204; BRENNER B, 1986, BIOPHYS J, V50, P1101, DOI 10.1016/S0006-3495(86)83554-8; BRENNER B, 1982, P NATL ACAD SCI-BIOL, V79, P7288, DOI 10.1073/pnas.79.23.7288; CHEN T, 1991, BIOCHEMISTRY-US, V30, P4546, DOI 10.1021/bi00232a026; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; Cooke R, 1990, CURR OPIN CELL BIOL, V2, P62, DOI 10.1016/S0955-0674(05)80032-8; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; CURMI PMG, 1988, J MOL BIOL, V203, P781, DOI 10.1016/0022-2836(88)90209-4; DASGUPTA G, 1990, BIOCHEMISTRY-US, V29, P8503, DOI 10.1021/bi00488a043; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; GEEVES MA, 1991, BIOCHEM J, V274, P1; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOODY RS, 1983, BIOCHIM BIOPHYS ACTA, V726, P13, DOI 10.1016/0304-4173(83)90009-5; GREENE LE, 1980, J BIOL CHEM, V255, P543; Hill T.L., 1974, Progress Biophys Molec Biol, V28, P267, DOI 10.1016/0079-6107(74)90020-0; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; JOHARA M, 1993, P NATL ACAD SCI USA, V90, P2127, DOI 10.1073/pnas.90.6.2127; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LORENZ M, UNPUB; LYMM RW, 1971, BIOCHEMISTRY-US, V10, P4617; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MILLER L, 1988, J BIOL CHEM, V263, P1996; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; MORNET D, 1981, NATURE, V292, P801; ONISHI H, 1990, J BIOL CHEM, V265, P19362; PEPIN TM, 1985, BIOCHEMISTRY-US, V24, P3024; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SUTOH K, 1989, J MOL BIOL, V206, P357, DOI 10.1016/0022-2836(89)90485-3; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P4800, DOI 10.1021/bi00262a043; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; SZILAGYI L, 1979, BIOCHEM BIOPH RES CO, V87, P936, DOI 10.1016/0006-291X(79)92047-3; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TOKUNAGA M, 1986, J ELECTRON MICROSC S, V35, P3107; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; VANDEKERCKHOVE J, 1978, EUR J BIOCHEM, V90, P451, DOI 10.1111/j.1432-1033.1978.tb12624.x; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; Wakabayashi T, 1988, Adv Exp Med Biol, V226, P39; WHITTAKER M, UNPUB; 1988, 11 P YAM C EN TRANSD	57	1475	1498	2	211	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					58	65		10.1126/science.8316858	http://dx.doi.org/10.1126/science.8316858			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316858				2022-12-28	WOS:A1993LK43400029
J	MEDVINSKY, AL; SAMOYLINA, NL; MULLER, AM; DZIERZAK, EA				MEDVINSKY, AL; SAMOYLINA, NL; MULLER, AM; DZIERZAK, EA			AN EARLY PRE-LIVER INTRA-EMBRYONIC SOURCE OF CFU-S IN THE DEVELOPING MOUSE	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; COLONY-FORMING CELLS; YOLK-SAC; GROWTH-FACTOR; C-KIT; ONTOGENY; ORIGIN; LIGAND; PRECURSORS; EXPRESSION	IT is widely accepted that during murine embryogenesis, totipotent haematopoietic stem cells first originate in the yolk sac, then migrate to the fetal liver and finally colonize the bone marrow shortly before birth1,2. This view is based on in vitro studies showing that yolk sac cells can differentiate into various haematopoietic lineages1,3-7 and in vivo studies showing that yolk sac contains spleen colony-forming units (CFU-S) beginning at day 8 of gestation1. However, some investigators have failed to find statistically significant numbers of CFU-S arising from day 9 yolk sac3,8-11 and, although one group reported that yolk sac could repopulate the haematopoietic system of W mutant mice2, others have failed to confirm yolk sac-derived repopulation of adults3,12. In the avian and amphibian systems, the yolk sac gives rise only to early, transitory haematopoiesis whereas the definitive adult haematopoietic stem cells in these vertebrates are derived from the mesodermal region containing the dorsal aorta13-17. Because this analogous area of the mouse embryo has not been previously examined for haematopoietic activity, we directly compared the CFU-S activity of the aorta, gonad, mesonephros (AGM) region with the yolk sac and fetal liver during embryogenesis. Here we report that this intra-embryonic AGM region contains CFU-S activity at a higher frequency than that in embryonic yolk sac and that such activity appears in the AGM region before the fetal liver.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	MEDVINSKY, AL (corresponding author), NATL RES CTR HEMATOL,PHYSIOL HEMATOPOIESIS LAB,NOVOZYKOVSKY PR 4A,MOSCOW 125167,RUSSIA.							BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BODINE DM, 1992, BLOOD, V79, P913; BOLSHEV LN, 1965, TABLES MATH STATISTI, V464; CORMIER F, 1988, DEVELOPMENT, V102, P279; DEVRIES P, 1991, J EXP MED, V173, P1205, DOI 10.1084/jem.173.5.1205; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DIETERLENLIEVRE F, 1981, DEV BIOL, V88, P180, DOI 10.1016/0012-1606(81)90228-1; EREN R, 1987, IMMUNOL RES, V6, P279, DOI 10.1007/BF02935522; GIGUERE V, 1983, EMBO J, V8, P2017; HARRISON DE, 1979, BLOOD, V54, P1152; HOUSSAINT E, 1981, CELL DIFFER DEV, V10, P243, DOI 10.1016/0045-6039(81)90007-5; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; JOHNSON GR, 1973, J EMBRYOL EXP MORPH, V30, P83; JONES RJ, 1990, NATURE, V347, P188, DOI 10.1038/347188a0; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; LIU CP, 1991, DEVELOPMENT, V113, P1315; MAENO M, 1985, DEV BIOL, V110, P503, DOI 10.1016/0012-1606(85)90108-3; MAGLI MC, 1982, NATURE, V295, P527, DOI 10.1038/295527a0; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; PERAH G, 1977, J CELL PHYSIOL, V91, P193, DOI 10.1002/jcp.1040910205; PLOEMACHER RE, 1988, EXP HEMATOL, V16, P21; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAMOYLINA NL, 1992, HAEMATOLOGY BLOOD TR, V35, P106; SAMOYLINA NL, 1990, SOV J DEVEL BIOL, V21, P127; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; SYMANN M, 1978, EXP HEMATOL, V6, P749; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; TURPEN JB, 1981, DEV BIOL, V85, P99, DOI 10.1016/0012-1606(81)90239-6; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLF NS, 1986, EXP HEMATOL, V14, P676; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	33	393	401	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					64	67		10.1038/364064a0	http://dx.doi.org/10.1038/364064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316298				2022-12-28	WOS:A1993LK81800058
J	GIBBINS, RL; RILEY, M; BRIMBLE, P				GIBBINS, RL; RILEY, M; BRIMBLE, P			EFFECTIVENESS OF PROGRAM FOR REDUCING CARDIOVASCULAR RISK FOR MEN IN ONE GENERAL-PRACTICE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD LIPID CONCENTRATIONS	Objectives-To assess the effectiveness of a programme for reducing cardiovascular risk in men in terms of clinical measurements and perceptions of patients. Design-Collection of paired data on men attending well person clinics over three to five years. Questionnaire to determine changes in risk related habits. Setting-Well person clinics in rural general practice with five partners in mid-Wales. Subjects-The first 687 men seen in the clinic: analysable data obtained on 520. Initial age range 28-60 years. Main outcome measures-Analysis of serum cholesterol concentration (mmol/l) and blood pressure (mm Hg). Changes in diet, exercise, smoking, and drinking. Results-Mean (SD) cholesterol concentration for all subjects increased from 5.8 (1.0) to 6.0 (1.0), p < 0.001. Overall percentage of ideal weight and mean systolic blood pressure also increased. Mean diastolic blood pressure was unchanged at 84 mm Hg. Professed dietary change, age, and number of visits atl had significant effects on final cholesterol concentration. Those seen more often showed a significant decrease in cholesterol concentrations (in those seen more than twice mean (SD) initial value 6.7 (0.9) mmol/l v final value 6.5 (1.0) mmol/l, p < 0.001). Those over 45 years at start of study showed a significant decrease in diastolic blood pressure (mean (SD) initial value 89 (9) mm Hg v final value 86 (7) mm Hg, p < 0.001). Conclusions-These clinics are not effective in achieving a reduction in mean cholesterol concentration or blood pressure, despite evidence that the message of reduction in risk had been successfully transmitted. Success was achieved in older patients and those in whom a definite problem was identified. Identification of high risk groups and clinical case finding with appropriate long term follow up may be more cost effective in reducing cardiovascular risk than non-specific screening of the whole population.			GIBBINS, RL (corresponding author), THE SURGERY, GLANDWR PARC, POWYS LD2 3DZ, ENGLAND.							BURSTEIN M, 1970, LIPID RES, V19, P583; HOLMEN J, 1991, BRIT MED J, V302, P219, DOI 10.1136/bmj.302.6770.219; KWITEROVICH P, 1989, J HOPKINS COMPLETE G, P293; LENTHER C, 1970, GEIGY TABLES, P553; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MANT D, 1991, BRIT MED J, V302, P1057, DOI 10.1136/bmj.302.6784.1057; Parish R, 1987, Health Trends, V19, P23; RICHMOND W, 1973, CLIN CHEM, V19, P1350; SHEPHERD J, 1987, BRIT MED J, V295, P1245, DOI 10.1136/bmj.295.6608.1245; 1986, 4 WELSH HEART PROGR; 1989, TERMS SERVICE DOCTOR; 1986, HEART WALES; 1959, STATISTICAL B METROP, V40	13	27	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	1993	306	6893					1652	1656		10.1136/bmj.306.6893.1652	http://dx.doi.org/10.1136/bmj.306.6893.1652			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324436	Green Published, Bronze			2022-12-28	WOS:A1993LJ33700023
J	GILLETT, R; HARROW, J				GILLETT, R; HARROW, J			PRESCRIPTIONS FOR MEDICAL-RESEARCH .2. IS MEDICAL-RESEARCH WELL-SERVED BY PEER-REVIEW	BRITISH MEDICAL JOURNAL			English	Article									S BANK UNIV,SCH MANAGEMENT,LONDON SE1 0AA,ENGLAND	London South Bank University	GILLETT, R (corresponding author), DENT RES UNIT LONDON HOSP,COLL MED,MRC,LONDON E1 2AA,ENGLAND.							BARKER J, 1988, DISCOVERING FUTURE B; BRABEN D, 1991, LABORATORY NEWS 1007, P1; COLE S, 1981, SCIENCE, V214, P881, DOI 10.1126/science.7302566; CRADDOCK V, 1993, BIOCHEMIST       APR, P28; DUDLEY H, 1986, BMJ, V292, P199; GILLETT R, 1993, BRIT MED J, V306, P1668, DOI 10.1136/bmj.306.6893.1668; GILLETT R, 1993, MANAGEMENT SMALL MED; GIROLAMI P, 1992, COMMUNICATION   0921; GOWANS JL, 1986, BRIT MED J, V292, P200, DOI 10.1136/bmj.292.6514.200-a; Gutting G, 1980, PARADIGMS REVOLUTION; IRVING M, 1986, BRIT MED J, V292, P134, DOI 10.1136/bmj.292.6513.134; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; LOCK S, 1988, BRIT MED J, V296, P376, DOI 10.1136/bmj.296.6619.376; Lock S., 1985, DIFFICULT BALANCE ED; MADDOX J, 1992, NATURE, V360, P205, DOI 10.1038/360205a0; MADDOX J, 1992, NATURE, V359, P173; NORDIN BEC, 1986, BRIT MED J, V292, P621, DOI 10.1136/bmj.292.6520.621; PEGG D, NEW SCI         0809; PETERS DP, 1982, BEHAV BRAIN SCI, V5, P187, DOI 10.1017/S0140525X00011183; ROY R, 1982, B SCI TECHNOL SOC, V2, P405; SHARPE D, 1980, PARADIGMS REVOLUTION; SMITH R, 1988, BRIT MED J, V296, P484, DOI 10.1136/bmj.296.6620.484; SMITH R, 1988, BRIT MED J, V296, P774, DOI 10.1136/bmj.296.6624.774; SMITH R, 1988, BRIT MED J, V296, P556, DOI 10.1136/bmj.296.6621.556; Szilard L., 1961, VOICE DOLPHINS OTHER; TURNEY J, 1988, TIMES HIGHER ED S, V8, P6; WILSON DH, 1986, BRIT MED J, V292, P621, DOI 10.1136/bmj.292.6520.621-a	27	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1672	1675		10.1136/bmj.306.6893.1672	http://dx.doi.org/10.1136/bmj.306.6893.1672			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LJ337	8324442	Green Published, Bronze			2022-12-28	WOS:A1993LJ33700032
J	POPE, C; MAYS, N				POPE, C; MAYS, N			OPENING THE BLACK-BOX - AN ENCOUNTER IN THE CORRIDORS OF HEALTH-SERVICES RESEARCH	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Health services research has become more prominent as a result of the NHS reforms. Both providers and purchasers want to know exactly where the money is spent and how it could be used more effectively. How best to obtain information about health services is the subject of some debate within and between disciplines engaged in such research. Because of their training doctors are often sceptical of anything other than formal clinical trials and research which produces statistical data. Some sociologists argue that another way to find out what is actually happening in the NHS is to observe people at work and talk to them. This article debates these differing views of research methods. For effective research both quantitative and qualitative approaches need to be used.	QUEENS UNIV BELFAST,INST CLIN SCI,HLTH & HLTH CARE RES UNIT,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND	Queens University Belfast; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London				Pope, Catherine/0000-0002-8935-6702				Bhaskar Roy, 1979, POSSIBILITY NATURALI, P45, DOI DOI 10.4324/9781315756332; BLOOR M, 1976, SOCIOLOGY, V10, P43, DOI 10.1177/003803857601000103; Chalmers I, 1989, EFFECTIVE CARE PREGN; CLARKE M, 1992, BRIT MED J, V304, P1675, DOI 10.1136/bmj.304.6843.1675; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; FOWKES FGR, 1991, BMJ, V45, P102; Hammersley M., 1983, ETHNOGRAPHY PRINCIPL; HILL JD, 1978, LANCET, V1, P837; HUNTER D, 1990, READINGS MED SOCIOLO, P213; MATHER HG, 1976, BRIT MED J, V1, P925, DOI 10.1136/bmj.1.6015.925; MATHER HG, 1971, BMJ-BRIT MED J, V3, P334, DOI 10.1136/bmj.3.5770.334; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; PEATFIELD AC, 1992, MED SOCIOLOGY NEWS, V17, P15; POPE C, 1991, SOCIOL HEALTH ILL, V13, P193, DOI 10.1111/1467-9566.ep11340798; WARE JE, 1986, LANCET, V1, P1017; WELCH BL, 1987, MED CARE, V25, P148, DOI 10.1097/00005650-198702000-00008; WENNBERG JE, 1982, SCI AM, V246, P100; 1989, CORPORATE STRATEGY, P48	18	35	37	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					315	318		10.1136/bmj.306.6873.315	http://dx.doi.org/10.1136/bmj.306.6873.315			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KK718	8338521	Green Published, Bronze			2022-12-28	WOS:A1993KK71800025
J	RESH, MD				RESH, MD			MYRISTYLATION AND PALMITYLATION OF SRC FAMILY MEMBERS - THE FATS OF THE MATTER	CELL			English	Review							PLASMA-MEMBRANE; MOTIF				RESH, MD (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.			Resh, Marilyn/0000-0001-6118-9466				CAMP LA, 1993, J BIOL CHEM, V268, P22566; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MUMBY SM, 1994, IN PRESS P NATL ACAD; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SILVERMAN L, 1993, CELL GROWTH DIFFER, V4, P475; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; ZHOU W, 1994, IN PRESS J VIROL	17	627	636	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					411	413		10.1016/0092-8674(94)90104-X	http://dx.doi.org/10.1016/0092-8674(94)90104-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313462				2022-12-28	WOS:A1994MX20700001
J	ADISESHIAH, M				ADISESHIAH, M			AVOIDABLE FACTORS IN STROKE - CONSIDER CAROTID ENDARTERECTOMY	BRITISH MEDICAL JOURNAL			English	Letter											ADISESHIAH, M (corresponding author), UNIV COLL HOSP LONDON,LONDON WC1E 6AU,ENGLAND.							BRIDGEWATER BJM, 1993, BRIT J SURG, V80, P722, DOI 10.1002/bjs.1800800615; PAYNE JN, 1993, BRIT MED J, V307, P1027, DOI 10.1136/bmj.307.6911.1027	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					201	201		10.1136/bmj.308.6922.201c	http://dx.doi.org/10.1136/bmj.308.6922.201c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312783	Green Published			2022-12-28	WOS:A1994MR97400053
J	BARGMANN, CI; HARTWIEG, E; HORVITZ, HR				BARGMANN, CI; HARTWIEG, E; HORVITZ, HR			ODORANT-SELECTIVE GENES AND NEURONS MEDIATE OLFACTION IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; UDP-GLUCURONOSYL TRANSFERASE; CHEMOSENSORY NEURONS; DEFECTIVE-MUTANTS; NERVOUS-SYSTEM; DROSOPHILA; CELL; CHEMOTAXIS; IDENTIFICATION; TRANSDUCTION	Olfaction is a versatile and sensitive mechanism for detecting volatile odorants. We show that the nematode C. elegans detects many volatile chemicals, which can be attractants, repellents, or attractants at low concentrations and repellents at high concentrations. Through laser ablation, we have identified chemosensory neurons that detect volatile odorants. Chemotaxis to volatile odorants requires different sensory neurons from chemotaxis to water-soluble attractants, indicating that C. elegans might have senses that correspond to smell and taste, respectively. Single neurons have complex sensory properties, since six distinguishable volatile odorants are sensed by only two types of sensory neurons. Chemotaxis to subsets of volatile odorants is disrupted by mutations in the odr genes, which might be involved in odorant sensation or signal transduction.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	BARGMANN, CI (corresponding author), MIT, DEPT BIOL, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.			Bargmann, Cornelia/0000-0002-8484-0618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024663, R37GM024663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001393] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01393] Funding Source: Medline; NIGMS NIH HHS [GM24663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ache B.W., 1987, NEUROBIOLOGY TASTE S, P39; ALBERT PS, 1981, J COMP NEUROL, V198, P435, DOI 10.1002/cne.901980305; ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AMOORE JE, 1977, CHEM SENS FLAV, V2, P267, DOI 10.1093/chemse/2.3.267; ANDREW PA, 1976, NEMATOLOGICA, V22, P451, DOI 10.1163/187529276X00454; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1990, COLD SPRING HARB SYM, V55, P529; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRENNER S, 1974, GENETICS, V77, P71; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; CULOTTI JG, 1978, GENETICS, V90, P243; DAINTY RH, 1985, J APPL BACTERIOL, V59, P303, DOI 10.1111/j.1365-2672.1985.tb03324.x; DAMBLYCHAUDIERE C, 1992, CELL, V69, P159, DOI 10.1016/0092-8674(92)90127-X; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DUSENBER.DB, 1974, J EXP ZOOL, V188, P41, DOI 10.1002/jez.1401880105; DUSENBERY DB, 1975, GENETICS, V80, P297; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GYORGYI TK, 1988, P NATL ACAD SCI USA, V85, P9851, DOI 10.1073/pnas.85.24.9851; HELFAND SL, 1989, P NATL ACAD SCI USA, V86, P2908, DOI 10.1073/pnas.86.8.2908; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HODGKIN J, 1988, NEMATODE CAENORHABDI, P491; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; LAZARD D, 1991, NATURE, V349, P790, DOI 10.1038/349790a0; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; LILLY M, 1990, GENETICS, V124, P293; MCKENNA M, 1989, P NATL ACAD SCI USA, V86, P8118, DOI 10.1073/pnas.86.20.8118; NOTTEBOHM E, 1992, NATURE, V359, P829, DOI 10.1038/359829a0; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; PEVSNER J, 1985, P NATL ACAD SCI USA, V82, P3050, DOI 10.1073/pnas.82.9.3050; REED RR, 1990, CELL, V60, P1, DOI 10.1016/0092-8674(90)90706-K; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; ROYER SM, 1991, J COMP NEUROL, V306, P49, DOI 10.1002/cne.903060105; SICARD G, 1984, BRAIN RES, V292, P283, DOI 10.1016/0006-8993(84)90764-9; SIDDIQI O, 1987, TRENDS GENET, V3, P137, DOI 10.1016/0168-9525(87)90204-6; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STOCKER RF, 1988, DEV BIOL, V127, P12, DOI 10.1016/0012-1606(88)90184-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Wood WB, 1988, NEMATODE CAENORHABDI; WOODARD C, 1992, J NEUROGENET, V8, P17, DOI 10.3109/01677069209167269; WOODARD C, 1989, GENETICS, V123, P315; ZECHMAN JM, 1985, CAN J MICROBIOL, V31, P232, DOI 10.1139/m85-045; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K	55	826	869	5	260	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 13	1993	74	3					515	527		10.1016/0092-8674(93)80053-H	http://dx.doi.org/10.1016/0092-8674(93)80053-H			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348618				2022-12-28	WOS:A1993LT73900013
J	ELMOREMEEGAN, M; ORIORDEN, T				ELMOREMEEGAN, M; ORIORDEN, T			AFRICA ON THE PRECIPICE - AN OMINOUS BUT NOT YET HOPELESS FUTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH		SUNY,DEPT MED,DIV PULM CRIT CARE MED,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College	ELMOREMEEGAN, M (corresponding author), INT COMMUNITY RELIEF STARVAT & SUFFERING,OFF RURAL HLTH PROGRAMS,POB 15619,MBAGATHI,KENYA.							AYITTEY GBN, 1991, WALL STREET J   1018, pA14; CALDWELL JC, 1986, POPUL DEV REV, V12, P171, DOI 10.2307/1973108; DUNCAN DE, 1990, ATLANTIC MONTHLY, V266, P20; FINE JC, 1988, HUNGER ROAD; FLANAGIN A, 1992, JAMA-J AM MED ASSOC, V268, P1985; HANCOCK G, 1989, LORDS POVERTY FREE W; KENNEDY P, 1993, PREPARING 21ST CENTU, P211; MORROW L, 1992, TIME            0907, V140, P40; REICH RB, 1990, OWRK NATIONS PREPARI; RIFKIN S, 1988, SOC SCI MED, V26, P877; ROEMER MI, 1990, AM J PUBLIC HEALTH, V80, P1188, DOI 10.2105/AJPH.80.10.1188; SULLIVAN LW, 1991, ACAD MED, V66, P266, DOI 10.1097/00001888-199105000-00005; WISNER B, 1992, 21ST CENTURY AFRICA; 1991, REPORT KENYA STATIST; 1991, WHO56 REP, P2; 1991, SUBSAHARAN AFRICA; 1991, ECONOMIST, V318, P15; 1991, REPORT UN SECRETARY, P8; 1990, FOOD AGR ORG UN YB; 1989, WORLD POPULATION PRO, P166; 1989, SUBSAHARAN AFRICA CR; 1992, STATE WORLDS CHILDRE	22	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					629	631		10.1001/jama.270.5.629	http://dx.doi.org/10.1001/jama.270.5.629			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331766				2022-12-28	WOS:A1993LP43600032
J	GEIGER, HJ; COOKDEEGAN, RM				GEIGER, HJ; COOKDEEGAN, RM			THE ROLE OF PHYSICIANS IN CONFLICTS AND HUMANITARIAN CRISES - CASE-STUDIES FROM THE FIELD MISSIONS OF PHYSICIANS-FOR-HUMAN-RIGHTS, 1988 TO 1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IRAQ	Violations of human rights in wars, civil conflicts, and brutal repression mounted by governments against their own citizens often have profound consequences to individual and public health and may, in turn, produce humanitarian crises. The skills of physicians, medical and forensic scientists, and other health workers are uniquely valuable in human rights investigations and documentation, producing evidence of abuse more credible and less vulnerable to challenge than traditional methods of case reporting. Only in recent decades, however, have physicians organized specifically to meet this responsibility. This article presents case studies from the field missions of Physicians for Human Rights to illustrate the investigation and documentation of violations of medical neutrality, refugee health crises, the use of indiscriminate weapons, torture, deliberate injury and rape, and mass executions. Participation of health workers in the defense of human rights now includes investigation and documentation of health effects in threatened populations as well as individual victims.	CUNY CITY COLL,SCH MED,DEPT COMMUNITY HLTH & SOCIAL MED,NEW YORK,NY 10031; NATL ACAD SCI,INST MED,WASHINGTON,DC 20418	City University of New York (CUNY) System; City College of New York (CUNY); National Academies of Sciences, Engineering & Medicine				Cook-Deegan, Robert/0000-0002-8251-4237				ANDERSON K, 1993, ANFAL CAMPAIGN IRAQI; [Anonymous], WINDS DEATH IRAQS US; [Anonymous], BLOODY SUNDAY TRAUMA; ASCHERIO A, 1992, NEW ENGL J MED, V327, P931, DOI 10.1056/NEJM199209243271306; Bloche M.G., 1987, URUGUAYS MILITARY PH; BRENNAN TA, 1992, ANN INTERN MED, V117, P78, DOI 10.7326/0003-4819-117-1-78; CARTER J, 1985, JAMA-J AM MED ASSOC, V255, P2798; CASSON J, 1986, TORTURE BRAZIL REPOR; DEWAAL A, 1992, NO MERCY MOGADISHU H; EISENBERG C, 1990, SALVADOR HLTH CARE S; FINE J, 1992, HIDDEN ENEMIES LAND; FINE J, 1987, USE TEAR GAS REPUBLI; FINE J, 1988, SOWING FEAR USES TOR; FULLER A, 1992, RETURN DARKEST DAYS, P5; GEIGER HJ, 1993, FRAMEWORK SURVIVAL H; GEIGER HJ, 1988, CASUALTIES COFLICT M; GEIGER J, 1989, NEW ENGL J MED, V321, P1136, DOI 10.1056/NEJM198910193211629; GINBAR Y, 1993, DEATH M BARAKAT INTE; HOFFMAN LM, 1989, POLITICS KNOWLEDGE A, P70; HU H, 1989, JAMA-J AM MED ASSOC, V262, P640, DOI 10.1001/jama.262.5.640; HU H, 1989, JAMA-J AM MED ASSOC, V262, P660; HU H, 1991, HLTH HUMAN RIGHTS BU; IACOPINO V, 1992, BLOODY MAY EXCESSIVE; IACOPINO V, 1992, CRACKDOWN KASHMIR TO; KIRSCHNER R, 1989, KENYA MEDICOLEGAL AS; MCADAM D, 1988, FREEDOM SUMMER, P155; MIGUEL A, 1991, GUATEMALA GETTING AW; NAIER PA, 1991, HIDDEN VIEW HUMAN RI; NIGHTINGALE EO, 1986, JAMA-J AM MED ASSOC, V255, P2794, DOI 10.1001/jama.255.20.2794; NIGHTINGALE EO, 1990, APARTHEID MED HLTH H, P101; PIERCE C, 1993, HUMAN RIGHTS HOLD RE; RASMUSSEN OV, 1990, DAN MED BULL, V37, P1; SANDLER RH, 1991, JAMA-J AM MED ASSOC, V266, P638, DOI 10.1001/jama.266.5.638; SANDLER RH, 1991, WASHINGTON POST 0415, pA9; SHALLER J, 1988, PANAMA 1987 HLTH CON; SHANSKY R, 1990, HLTH CARE DETENTION; SIRKIN S, 1991, IRAQ OCCUPIED KUWAIT; STOVER E, 1985, BREAKING BODIES MIND, P101; Stover E, 1992, UNQUIET GRAVES SEARC; STOVER E, 1991, SEARCH BRAZILS DISAP; STOVER E, 1991, LAND MINES CAMBODIA; Stover Eric, 1987, OPEN SECRET TORTURE; SWISS S, 1993, JAMA-J AM MED ASSOC, V270, P612, DOI 10.1001/jama.270.5.612; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; TRAVER J, 1993, CRUEL INHUMAN TREATM; YOUNG QD, 1990, JAMA-J AM MED ASSOC, V264, P3127; 1992, PHYSICIANS HUM RIGHT, V5, P9; 1970, HLTH ASPECTS CHEM BI; 1992, NEW ENGL J MED, V325, P977; 1985, HDB INVESTIGATION AL; 1991, MOL GENET MED, V1, P117; 1993, ECN4199350 UN HUM RI; 1993, NEW SCI         0501, V138, P4; 1993, S25274 UN SEC COUNC; 1992, MED BETRAYED PARTICI	55	33	33	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					616	620						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331762				2022-12-28	WOS:A1993LP43600028
J	ALFONSO, A; GRUNDAHL, K; DUERR, JS; HAN, HP; RAND, JB				ALFONSO, A; GRUNDAHL, K; DUERR, JS; HAN, HP; RAND, JB			THE CAENORHABDITIS-ELEGANS UNC-17 GENE - A PUTATIVE VESICULAR ACETYLCHOLINE TRANSPORTER	SCIENCE			English	Article							C-ELEGANS; CHOLINE-ACETYLTRANSFERASE; MESSENGER-RNA; NEMATODE; RESISTANCE; SEQUENCES; ENCODES; CELLS	Mutations in the unc-17 gene of the nematode Caenorhabditis elegans produce deficits in neuromuscular function. This gene was cloned and complementary DNAs were sequenced. On the basis of sequence similarity to mammalian vesicular transporters of biogenic amines and of localization to synaptic vesicles of cholinergic neurons in C. elegans, unc-17 likely encodes the vesicular transporter of acetylcholine. Mutations that eliminated all unc-17 gene function were lethal, suggesting that the acetylcholine transporter is essential. Molecular analysis of unc-17 mutations will allow the correlation of specific parts of the gene (and the protein) with observed functional defects. The mutants will also be useful for the isolation of extragenic suppressors, which could identify genes encoding proteins that interact with UNC-17.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038679] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ALFONSO A, UNPUB; ALFONSO A, IN PRESS J NEUROSCI; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Bektesh S., 1988, GENE DEV, V2, P527; BITTNER M, 1980, ANAL BIOCHEM, V102, P459, DOI 10.1016/0003-2697(80)90182-7; BRENNER S, 1974, GENETICS, V77, P71; Chalfie M., 1988, NEMATODE CAENORHABDI, P337; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSON EL, 1985, GENETICS, V110, P17; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HOSONO R, 1989, ZOOL SCI, V6, P697; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; Nguyen M. A., UNPUB; NONET ML, IN PRESS CELL; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PALATNIK CM, 1979, J MOL BIOL, V128, P371, DOI 10.1016/0022-2836(79)90093-7; RAND JB, 1985, J NEUROCHEM, V44, P189, DOI 10.1111/j.1471-4159.1985.tb07130.x; RAND JB, 1984, GENETICS, V106, P227; RAND JB, 1989, GENETICS, V122, P73; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS JH, 1990, GENETICS, V124, P855; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	32	318	332	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					617	619		10.1126/science.8342028	http://dx.doi.org/10.1126/science.8342028			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342028				2022-12-28	WOS:A1993LP72800042
J	CREWS, CM; ERIKSON, RL				CREWS, CM; ERIKSON, RL			EXTRACELLULAR SIGNALS AND REVERSIBLE PROTEIN-PHOSPHORYLATION - WHAT TO MEK OF IT ALL	CELL			English	Review							MAP KINASE; ACTIVATION; CELLS; RAF				CREWS, CM (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138, USA.		Crews, Craig M./ABH-9346-2020	Crews, Craig M./0000-0002-8456-2005				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; GARDNER AM, 1993, IN PRESS J BIOL CHEM; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG W, 1993, IN PRESS P NATL ACAD; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JOHNSON GL, 1993, IN PRESS J CELL BIOC; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, IN PRESS J BIOL CHEM; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; ZHANG XF, 1993, IN PRESS NATURE; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	22	414	430	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					215	217		10.1016/0092-8674(93)90411-I	http://dx.doi.org/10.1016/0092-8674(93)90411-I			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343948				2022-12-28	WOS:A1993LP72600001
J	SAUER, F; JACKLE, H				SAUER, F; JACKLE, H			DIMERIZATION AND THE CONTROL OF TRANSCRIPTION BY KRUPPEL	NATURE			English	Article							ALCOHOL-DEHYDROGENASE GENE; CULTURED DROSOPHILA CELLS; ACTIVATION; PROTEIN; REPRESSION; BINDING; PRODUCT; EMBRYO; STRIPE; YEAST	KRUPPEL (KR), a Drosophila zinc finger-type1 transcription factor2-4, can both activate and repress gene expression through interaction with a single DNA-binding site4. The opposite regulatory effects of KR are concentration-dependent, and they require distinct portions of KR such as the N-terminal region for activation and the C-terminal region for repression4. Here we show that KR is able to form homodimers through sequences located within the C terminus. When these sequences were fused to separated functional parts of the yeast transcription factor GAL4(5), they reconstituted a functional transcriptional activator on dimerization in vivo. Our results suggest that the KR monomer is a transcriptional activator. At higher concentration KR forms a homodimer and becomes a repressor that functions through the same target sequences as the activator.			SAUER, F (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,POSTFACH 2841,D-37018 GOTTINGEN,GERMANY.							BENSON M, 1987, EMBO J, V6, P1387, DOI 10.1002/j.1460-2075.1987.tb02379.x; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MANIATIS T, 1990, MOL CLONING; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1993, DEV DROSOPHILIA MELA; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	24	96	102	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					454	457		10.1038/364454a0	http://dx.doi.org/10.1038/364454a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332216				2022-12-28	WOS:A1993LP64000058
J	VOGT, MT; CAULEY, JA; NEWMAN, AB; KULLER, LH; HULLEY, SB				VOGT, MT; CAULEY, JA; NEWMAN, AB; KULLER, LH; HULLEY, SB			DECREASED ANKLE ARM BLOOD-PRESSURE INDEX AND MORTALITY IN ELDERLY WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate the relationship of the ankle/arm blood pressure index to short-term mortality in women 65 years of age or older. Design.-Prospective cohort study with average follow-up of 4.3 years. Setting.-Rural community near Pittsburgh, Pa. Participants.-A total of 1492 white women 65 years of age or older, living in the community and ambulatory without the help of another person. Outcome Measures.-All-cause and cause-specific mortality. Results.-The ankle/arm index (the systolic pressure in the posterior tibial artery divided by that in the brachial artery) was measured in 1986 through 1988 and found to be 0.9 or less in 82 (5.5%) of the women, 67 of whom reported no symptoms of claudication. Comparing women with an index of 0.9 or less with those with an index greater than 0.9, the relative risk for all-cause mortality 4 years later (after adjustment for age, smoking, and other risk factors) was 3.1 (95% confidence interval [CI], 1.7 to 5.5); for heart disease, 3.7 (95% CI, 1.2 to 11.6); for cardiovascular diseases, 4.0 (95% CI, 1.3 to 8.5); for cancer, 3.3 (95% CI, 1.3 to 8.5); and for all other causes, 1.1 (95% CI, 0.1 to 9.2). Similar levels of risk were found after excluding women with symptoms of claudication and/or a history of cardiovascular disease at baseline. Conclusions.-Healthy, older women with an ankle/arm index of 0.9 or less are at high risk of death and therefore may be considered for aggressive therapy to modify cardiovascular risk factors.	MED COLL PENN, DEPT MED, PITTSBURGH, PA USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, DIV CLIN EPIDEMIOL, SAN FRANCISCO, CA 94143 USA	Drexel University; University of California System; University of California San Francisco	VOGT, MT (corresponding author), UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, 130 DESOTO ST, PITTSBURGH, PA 15261 USA.		Cauley, Jane A/N-4836-2015; Newman, Anne B./C-6408-2013	Cauley, Jane A/0000-0003-0752-4408; Newman, Anne B./0000-0002-0106-1150	NHLBI NIH HHS [HL 40489, 5T32 HL 07011] Funding Source: Medline; NIAMS NIH HHS [AR 35582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040489, T32HL007011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERNSTEIN EF, 1982, SURG CLIN N AM, V62, P473; BRESLOW NE, 1987, IARC SCI PUBL, V82, pCH2; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1985, CIRCULATION, V71, P516, DOI 10.1161/01.CIR.71.3.516; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; CUTLER SJ, 1958, J CHRON DIS, V8, P699; FOWKES FGR, 1989, BRIT MED J, V298, P405, DOI 10.1136/bmj.298.6671.405; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FOWKES FGR, 1988, INT J EPIDEMIOL, V17, P248, DOI 10.1093/ije/17.2.248; GOFIN R, 1987, ISRAEL J MED SCI, V23, P157; HIATT WR, 1990, J CLIN EPIDEMIOL, V43, P597, DOI 10.1016/0895-4356(90)90164-K; JELNES R, 1986, BRIT MED J, V293, P1137, DOI 10.1136/bmj.293.6555.1137; JONASON T, 1987, ACTA MED SCAND, V221, P253; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KALLERO KS, 1981, J CHRON DIS, V34, P455, DOI 10.1016/0021-9681(81)90005-9; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; KAPANTAIS GH, 1989, PHS891250 US DEP HLT; MALONE JM, 1977, SURGERY, V81, P551; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCKENNA M, 1991, ATHEROSCLEROSIS, V87, P119, DOI 10.1016/0021-9150(91)90014-T; NEWMAN AB, 1991, J CLIN EPIDEMIOL, V44, P15, DOI 10.1016/0895-4356(91)90196-G; Prineas RJ, 1982, CIRCULATION, V65, p1561A; REUNANEN A, 1982, ACTA MED SCAND, V211, P249; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X; SILBERT S, 1958, JAMA-J AM MED ASSOC, V166, P1816, DOI 10.1001/jama.1958.02990150012002; STRANDNESS DE, 1991, PERIPHERAL VASCULAR, P39; VOGT MT, 1993, AM J EPIDEMIOL, V137, P559, DOI 10.1093/oxfordjournals.aje.a116709; 1990, PHS901232 US DEP HLT; 1989, PHS891260 US DEP HLT	31	301	312	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					465	469		10.1001/jama.270.4.465	http://dx.doi.org/10.1001/jama.270.4.465			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320785				2022-12-28	WOS:A1993LN42600025
J	FISHER, M; BOGOUSSLAVSKY, J				FISHER, M; BOGOUSSLAVSKY, J			EVOLVING TOWARD EFFECTIVE THERAPY FOR ACUTE ISCHEMIC STROKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CEREBRAL-ISCHEMIA; ANTAGONISTS; THRESHOLDS; INFARCTION; DIAGNOSIS; TRIALS	Acute ischemic stroke is a common, devastating disorder without beneficial therapy. Recent advances concerning the pathophysiology of ischemic brain injury have led to the development of rational pharmacological interventions. Thrombolytic and cytoprotective therapies may be useful and are being evaluated in clinical trials. The design of adequate clinical trials to evaluate these promising therapies has also evolved based on experience. Potential therapy for acute ischemic stroke must be assessed in a large number of patients who are given the intervention within hours of onset using a neurological scoring scale and a disability scale. Several new magnetic resonance imaging technologies are emerging that should allow the clinician to rapidly and accurately identify ischemic brain lesions and to evaluate cerebral perfusion. The availability of potentially efficacious therapies for ischemic stroke evaluated in well-designed clinical trials with magnetic resonance imaging technology, which can also assess therapeutic effects in vivo, should lead to the emergence of therapy to improve the outcome of patients with ischemic stroke in the near future.	UNIV MASSACHUSETTS,SCH MED,WORCESTER,MA 01605; CHU VAUDOIS,DEPT NEUROL,CH-1011 LAUSANNE,SWITZERLAND	University of Massachusetts System; University of Massachusetts Worcester; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	FISHER, M (corresponding author), MED CTR CENT MASSACHUSETTS,DEPT NEUROL,119 BELMONT ST,WORCESTER,MA 01605, USA.							ALBERS GW, 1991, ANN NEUROL, V30, P511, DOI 10.1002/ana.410300402; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BARSAN W, 1992, STROKE, V23, P149; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; BRYAN RN, 1991, AM J ROENTGENOL, V157, P585; BUCHAN AM, 1991, NEUROREPORT, V2, P473, DOI 10.1097/00001756-199108000-00016; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; GELMERS HJ, 1988, NEW ENGL J MED, V318, P203, DOI 10.1056/NEJM198801283180402; GRANGER CV, 1989, ARCH PHYS MED REHAB, V70, P100; GROTTA JC, 1991, CLIN NEUROPHARMACOL, V14, P373, DOI 10.1097/00002826-199110000-00001; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KUSOMOTO K, 1992, BRAIN RES, V576, P147; Le Bihan D, 1991, Magn Reson Q, V7, P1; LEVINE SR, 1989, ARCH INTERN MED, V149, P90, DOI 10.1001/archinte.149.1.90; LOSCALZO J, 1988, NEW ENGL J MED, V319, P925; LYDEN PD, 1991, STROKE, V22, P1345, DOI 10.1161/01.STR.22.11.1345; MEMZAWA H, 1992, STROKE, V23, P552; MINEMATSU K, 1993, NEUROLOGY, V43, P397, DOI 10.1212/WNL.43.2.397; MINEMATSU K, 1992, STROKE, V23, P1304, DOI 10.1161/01.STR.23.9.1304; MINEMATSU K, 1992, NEUROLOGY, V42, P235, DOI 10.1212/WNL.42.1.235; MINEMATSU K, 1992, J STROKE CEREBROV S1, V2, P138; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; ORGOGOZO JM, 1991, CEREBROVASC DIS, V1, P100, DOI 10.1159/000108904; OVERGAARD K, 1992, STROKE, V23, P1167, DOI 10.1161/01.STR.23.8.1167; PULSINELLI W, 1992, LANCET, V339, P533, DOI 10.1016/0140-6736(92)90347-6; RINGELSTEIN EB, 1992, NEUROLOGY, V42, P289, DOI 10.1212/WNL.42.2.289; ROCCA WA, 1992, STROKE, V23, P519, DOI 10.1161/01.STR.23.4.519; SACKETT DL, 1983, STROKE, V17, P1325; SCATTON B, 1991, CEREBROVASC DIS, V1, P121, DOI 10.1159/000108829; SLOAN MA, 1992, AM J CARDIOL, V69, pA21, DOI 10.1016/0002-9149(92)91169-5; SMITH SE, 1992, STROKE, V23, P861, DOI 10.1161/01.STR.23.6.861; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; VANGIJN J, 1992, CEREBROVASC DIS, V2, P244; VONKUMMER R, 1992, STROKE, V23, P646, DOI 10.1161/01.STR.23.5.646; WARACH S, 1992, NEUROLOGY, V42, P1717, DOI 10.1212/WNL.42.9.1717; WARACH S, 1992, RADIOLOGY, V182, P41, DOI 10.1148/radiology.182.1.1727307; WENDLAND MF, 1991, JMRI-J MAGN RESON IM, V1, P285, DOI 10.1002/jmri.1880010305; Whisnant J P, 1992, J Stroke Cerebrovasc Dis, V2, P42, DOI 10.1016/S1052-3057(10)80034-5; XUE D, 1992, STROKE, V23, P894, DOI 10.1161/01.STR.23.6.894; 1992, STROKE, V23, P148; 1992, STROKE, V23, P3; 1991, NEW ENGL J MED, V325, P445	47	51	55	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					360	364		10.1001/jama.270.3.360	http://dx.doi.org/10.1001/jama.270.3.360			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8315781				2022-12-28	WOS:A1993LM43500032
J	CLOS, J; RABINDRAN, S; WISNIEWSKI, J; WU, C				CLOS, J; RABINDRAN, S; WISNIEWSKI, J; WU, C			INDUCTION TEMPERATURE OF HUMAN HEAT-SHOCK FACTOR IS REPROGRAMMED IN A DROSOPHILA CELL ENVIRONMENT	NATURE			English	Article							BINDING	HEAT shock factor (HSF)1,2, the transcriptional activator of eukaryotic heat shock genes, is induced to bind DNA by a monomer to trimer transition involving leucine zipper interactions3,4. Although this mode of regulation is shared among many eukaryotic species, there is variation in the temperature at which HSF binding activity is induced. We investigated the basis of this variation by analysing the response of a human HSF expressed in Drosophila cells and Drosophila HSF expressed in human cells. We report here that the temperature that induces DNA binding and trimerization of human HSF in Drosophila was decreased by approximately 10-degrees-C to the induction temperature for the host cell, whereas Drosophila HSF expressed in human cells was constitutively active. The results indicate that the activity of HSF in vivo is not a simple function of the absolute environmental temperature.	NCI,BIOCHEM LAB,BLDG 37,RM 4C-09,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; LIS JT, 1992, TRANSCRIPTIONAL REGU, V2, P907; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; TREUTER E, IN PRESS MOL GEN GEN; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	16	75	75	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					252	255		10.1038/364252a0	http://dx.doi.org/10.1038/364252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321322				2022-12-28	WOS:A1993LM68300062
J	DOVER, JS; ARNDT, KA				DOVER, JS; ARNDT, KA			DERMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	DOVER, JS (corresponding author), NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA.							CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; DEMARCHI S, 1992, NEW ENGL J MED, V326, P969; GELLER A C, 1992, Morbidity and Mortality Weekly Report, V41, P20; KOH HK, 1992, J AM ACAD DERMATOL, V26, P914, DOI 10.1016/0190-9622(92)70132-Y; MCHENRY PM, 1992, BRIT MED J, V304, P746, DOI 10.1136/bmj.304.6829.746; OLERUD JE, 1992, ARCH DERMATOL, V128, P501, DOI 10.1001/archderm.128.4.501; PETZELBAUER P, 1992, BRIT J DERMATOL, V126, P542; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; SPRUANCE SL, 1991, J INFECT DIS, V163, P728, DOI 10.1093/infdis/163.4.728	10	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					197	198		10.1001/jama.270.2.197	http://dx.doi.org/10.1001/jama.270.2.197			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL368	8315728				2022-12-28	WOS:A1993LL36800014
J	EISENBERG, JM				EISENBERG, JM			ECONOMICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											EISENBERG, JM (corresponding author), GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA.							DOCKERY JL, 1993, JAMA-J AM MED ASSOC, V269, P1386, DOI 10.1001/jama.1993.03500110054030; GINZBERG E, 1992, JAMA-J AM MED ASSOC, V268, P3115, DOI 10.1001/jama.268.21.3115; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; JOLLY P, 1992, AAMC DATA BOOK STATI; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; PETERSDORF RG, 1993, AM J PUBLIC HEALTH, V83, P328, DOI 10.2105/AJPH.83.3.328; ROSENBLATT RA, 1993, AM J PUBLIC HEALTH, V83, P322, DOI 10.2105/AJPH.83.3.322; SCHROEDER SA, 1993, ACAD MED, V68, P118, DOI 10.1097/00001888-199302000-00002; STIMMEL B, 1992, JAMA-J AM MED ASSOC, V268, P2060, DOI 10.1001/jama.268.15.2060; 1993, 1993 PHYS PAYM REV C, P55; 1990, CURRENT POPULATI P25, V1058, P6; 1992, IMPROVING ACCESS HLT, P7; 1992, 1992 PHYS PAYM REV C, P283	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					198	200		10.1001/jama.270.2.198	http://dx.doi.org/10.1001/jama.270.2.198			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL368	8315729				2022-12-28	WOS:A1993LL36800015
J	KARP, JE; BRODER, S				KARP, JE; BRODER, S			ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; DISOMY				KARP, JE (corresponding author), NCI,BETHESDA,MD 20892, USA.							BROWN KW, 1992, CANCER GENET CYTOGEN, V58, P66, DOI 10.1016/0165-4608(92)90136-V; CATTANACH BM, 1992, NAT GENET, V2, P270, DOI 10.1038/ng1292-270; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; FERGUSONSMITH AC, 1990, CANCER SURV, V9, P487; HAAS OA, 1992, NATURE, V359, P414, DOI 10.1038/359414a0; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; MASCARI MJ, 1992, NEW ENGL J MED, V326, P1599, DOI 10.1056/NEJM199206113262404; MAW MA, 1992, CANCER RES, V52, P3094; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; PING AJ, 1989, AM J HUM GENET, V44, P720; REIK W, 1989, TRENDS GENET, V5, P331, DOI 10.1016/0168-9525(89)90138-8; REIK W, 1992, NATURE, V359, P362, DOI 10.1038/359362a0; VILJOEN D, 1992, J MED GENET, V29, P221, DOI 10.1136/jmg.29.4.221	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					237	239		10.1001/jama.270.2.237	http://dx.doi.org/10.1001/jama.270.2.237			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315746				2022-12-28	WOS:A1993LL36800032
J	RUSSELL, RM				RUSSELL, RM			NUTRITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											RUSSELL, RM (corresponding author), TUFTS UNIV,BOSTON,MA 02111, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DONGWANG X, 1991, ARCH BIOCHEM BIOPHYS, V285, P8; GAZIANO JM, 1992, ANN NY ACAD SCI, V669, P249; GERSTER H, 1991, INT J VITAM NUTR RES, V61, P277; JANERO DR, 1991, FREE RADICAL BIO MED, V11, P129, DOI 10.1016/0891-5849(91)90193-7; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; PALOZZA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P184, DOI 10.1016/0003-9861(92)90658-J; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RUSSELL RM, IN PRESS AM J CLIN N; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; SUTER PM, 1992, NEW ENGL J MED, V326, P983, DOI 10.1056/NEJM199204093261503; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; 1991, LANCET, V336, P131; 1992, NUTR REV, V50, P340	18	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					233	234		10.1001/jama.270.2.233	http://dx.doi.org/10.1001/jama.270.2.233			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315744				2022-12-28	WOS:A1993LL36800030
J	HANSEN, RS; CANFIELD, TK; LAMB, MM; GARTLER, SM; LAIRD, CD				HANSEN, RS; CANFIELD, TK; LAMB, MM; GARTLER, SM; LAIRD, CD			ASSOCIATION OF FRAGILE-X SYNDROME WITH DELAYED REPLICATION OF THE FMR1 GENE	CELL			English	Article							MAMMALIAN-CELLS; CPG ISLAND; DNA-REPLICATION; REGION; EXPRESSION; METHYLATION; SEQUENCES; LOCUS; DEMETHYLATION; INSTABILITY	The fragile X syndrome is commonly associated with mutant alleles of the FMR1 gene that are hypermethylated and have large expansions of CGG repeats. We present data here on the replication timing of FMR1 that confirm predictions of delayed replication of alleles from affected males. The normal FMR1 allele replicates late in S phase, while alleles from affected males replicate later, the major peak of replication occurring in the flow cytometry fraction usually referred to as G2/M. The delayed timing of replication is not the direct result of a single replication fork stalling at the expanded CGG repeat, because delayed replication was observed for regions on both sides of the repeat. The domain of altered replication timing includes sites at least 150 kb 5' and 34 kb 3' of the repeat, indicating that genes in addition to FMR1 may be affected.	UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,PROGRAM MOLEC MED,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	HANSEN, RS (corresponding author), UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195, USA.				NICHD NIH HHS [HD16659] Funding Source: Medline; NIGMS NIH HHS [GM19179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016659, R01HD016659] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATKINS L, 1962, J CELL BIOL, V15, P390, DOI 10.1083/jcb.15.2.390; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN EH, 1987, MOL CELL BIOL, V7, P450, DOI 10.1128/MCB.7.1.450; CLARKE A, 1992, AM J MED GENET, V43, P299, DOI 10.1002/ajmg.1320430146; COLLINS M, 1987, J MOL BIOL, V198, P737, DOI 10.1016/0022-2836(87)90214-2; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; ERSTER SH, 1992, HUM GENET, V90, P55; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; FURST A, 1981, P NATL ACAD SCI-BIOL, V78, P1023, DOI 10.1073/pnas.78.2.1023; GALE JM, 1992, J MOL BIOL, V224, P343, DOI 10.1016/0022-2836(92)90999-Z; Gartler S M, 1992, Mol Genet Med, V2, P121; GILBERT DM, 1987, CELL, V50, P59, DOI 10.1016/0092-8674(87)90662-3; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GOLDMAN MA, 1988, BIOESSAYS, V9, P50, DOI 10.1002/bies.950090204; HANSEN RS, 1990, P NATL ACAD SCI USA, V87, P4174, DOI 10.1073/pnas.87.11.4174; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HATTON KS, 1990, MOL CELL BIOL, V10, P4314, DOI 10.1128/MCB.10.8.4314; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HEITZ D, 1992, J MED GENET, V29, P794, DOI 10.1136/jmg.29.11.794; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LAIRD CD, 1987, GENETICS, V117, P587; LIMADEFARIA A, 1961, CANCER GENET CYTOGEN, V3, P171; LOESCH DZ, 1992, AM J MED GENET, V44, P543, DOI 10.1002/ajmg.1320440502; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OPSTELTEN RJG, 1989, CHROMOSOMA, V98, P422, DOI 10.1007/BF00292787; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; REIK W, 1990, DEVELOPMENT S, V90, P99; RIGGINS GJ, 1992, AM J MED GENET, V43, P237, DOI 10.1002/ajmg.1320430138; ROSENSTRAUS M, 1975, P NATL ACAD SCI USA, V72, P493, DOI 10.1073/pnas.72.2.493; SASAKI H, 1991, DEVELOPMENT, V111, P573; SCHMIDT M, 1990, P NATL ACAD SCI USA, V87, P3685, DOI 10.1073/pnas.87.10.3685; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SPACK EG, 1992, MOL CELL BIOL, V12, P5174, DOI 10.1128/MCB.12.11.5174; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; VASSILEV LT, 1990, MOL CELL BIOL, V10, P4685, DOI 10.1128/MCB.10.9.4685; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; WEBB T, 1992, AM J MED GENET, V43, P1057, DOI 10.1002/ajmg.1320430633; YU S, 1992, AM J HUM GENET, V50, P968; YU WD, 1990, HUM GENET, V85, P590	52	214	218	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1403	1409		10.1016/0092-8674(93)90365-W	http://dx.doi.org/10.1016/0092-8674(93)90365-W			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324827	Bronze			2022-12-28	WOS:A1993LL20900014
J	GILLETT, R; HARROW, J				GILLETT, R; HARROW, J			PRESCRIPTIONS FOR MEDICAL-RESEARCH .1. MANAGEMENT WITHIN THE MEDICAL-RESEARCH-COUNCIL	BRITISH MEDICAL JOURNAL			English	Article								In their submission to the government in advance of the white paper on science policy in the United Kingdom the Medical Research Council commends the MRC's own approach to managing directly funded research. But a series of semi-structured interviews with the directors of some of the MRC's units suggests a gap between the MRC's model of managed research and the reality. Although such units are theoretically managed from MRC head office (and units are charged an overhead for this), in practice each unit runs its own affairs. Between major reviews average contact time with the head office contact person is seven hours a year. The first paper argues that a purchaser-provider split would recognise the benefits of decentralisation and allow units to bid for research funds from several sources, the successful ones guaranteeing their survival through a rolling series of research programmes. The second paper criticises the MRC's cumbersome peer review system. Reliance on outside experts atrophies the scientific skills of head office staff and builds delays into decision making. A purchaser-provider model would allow the head office scientific staff to act like commercial research and development managers, commissioning research, and using the outcome, rather than peer review, as a criterion for continued funding.	S BANK UNIV,SCH MANAGEMENT,LONDON SE1 0AA,ENGLAND	London South Bank University	GILLETT, R (corresponding author), DENT RES UNIT LONDON HOSP,COLL MED,MRC,LONDON E1 2AA,ENGLAND.							BARKER J, 1988, DISCOVERING FUTURE B; BRABEN D, 1991, LABORATORY NEWS 1001, P7; COLE S, 1981, SCIENCE, V214, P881, DOI 10.1126/science.7302566; CRADDOCK V, 1993, BIOCHEMIST       APR, P28; DUDLEY H, 1986, BMJ, V292, P199; GILLETT R, 1993, BRIT MED J, V306, P1668, DOI 10.1136/bmj.306.6893.1668; GILLETT R, 1993, MANAGEMENT MED RES C; GIROLAMI P, 1992, BBC2 J BULL BUS; GOWANS JL, 1986, BRIT MED J, V292, P200, DOI 10.1136/bmj.292.6514.200-a; Gutting G, 1980, PARADIGMS REVOLUTION; IRVING M, 1986, BRIT MED J, V292, P134, DOI 10.1136/bmj.292.6513.134; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; LOCK S, 1988, BRIT MED J, V296, P376, DOI 10.1136/bmj.296.6619.376; Lock S., 1985, DIFFICULT BALANCE ED; MADDOX J, 1992, NATURE, V360, P205, DOI 10.1038/360205a0; MADDOX J, 1992, NATURE, V359, P173; NORDIN BEC, 1986, BRIT MED J, V292, P621, DOI 10.1136/bmj.292.6520.621; PEGG D, NEW SCI         0809, P29; PETERS DP, 1982, BEHAV BRAIN SCI, V5, P187, DOI 10.1017/S0140525X00011183; ROY R, 1982, B SCI TECHNOL SOC, V2, P405; Shapere D., 1964, PARADIGMS REVOLUTION; SMITH R, 1988, BRIT MED J, V296, P484, DOI 10.1136/bmj.296.6620.484; SMITH R, 1988, BRIT MED J, V296, P774, DOI 10.1136/bmj.296.6624.774; SMITH R, 1988, BRIT MED J, V296, P556, DOI 10.1136/bmj.296.6621.556; Szilard L., 1961, VOICE DOLPHINS OTHER; TURNEY J, 1988, TIMES HIGHER ED 0108, P8; WILSON DH, 1986, BRIT MED J, V292, P621, DOI 10.1136/bmj.292.6520.621-a	27	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1668	1672		10.1136/bmj.306.6893.1668	http://dx.doi.org/10.1136/bmj.306.6893.1668			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324441	Green Published, Bronze			2022-12-28	WOS:A1993LJ33700031
J	SILAGY, C; MUIR, J; COULTER, A; THOROGOOD, M; ROE, L				SILAGY, C; MUIR, J; COULTER, A; THOROGOOD, M; ROE, L			CARDIOVASCULAR RISK AND ATTITUDES TO LIFE-STYLE - WHAT DO PATIENTS THINK	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the relation between subjects' level of cardiovascular risk and their beliefs about the harmfulness of their smoking habit, current diet, and level of exercise, together with their stated desire to modify such behaviour. Design-Self administered postal health and life-style questionnaire followed by a structured health check conducted by a nurse. Setting-Five general practices in Luton and Dunstable, Bedfordshire. Subjects-5803 people aged 35-64 years enrolled in the OXCHECK trial who attended for a health check before 1 March 1992. Main outcome measures-Perceived risk to health of lifestyle behaviours, desire to modify behaviour, and a reported serious attempt to modify behaviour in the preceding year. Results-A high proportion of smokers and those who were physically inactive perceived their behaviour to be harmful (1020; (76%; 95% confidence interval 74% to 79%) and 350 (74%; 70% to 78%) respectively) and wished to modify it (1212 (79%; 77% to 81%) and 375 (74%; 71% to 78%) respectively). In contrast, only 289 (45%; 41% to 48%) of obese people and 188 (14%; 12% to 16%) of people with a high dietary fat intake perceived their current diet to be harmful. The more cardiovascular risk factors present, the more likely subjects were to perceive a health risk attached to their diet and lack of exercise (p < 0.01 in both cases) and to want to improve their diet. Conclusion-Awareness of the health risk from smoking and motivation to stop is high. Further efforts are required, however, to educate the public about the risks associated with a high dietary fat intake. Although the health risks of inactivity were widely recognised, motivation to take more exercise needs to be increased.	RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH PROMOT SCI UNIT,LONDON WC1E 7HT,ENGLAND	Radcliffe Infirmary; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	SILAGY, C (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				Anderson K, 1990, AM HEART J, V121, P293; [Anonymous], 1980, CLASSIFICATION OCCUP; ARMITAGE P, 1987, STATISTICAL METHODS, P372; COULTER A, 1987, J ROY COLL GEN PRACT, V37, P533; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; KANNEL WB, 1987, AM HEART J, V114, P213, DOI 10.1016/0002-8703(87)90964-1; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; Prochaska J. O., 1986, TREATING ADDICTIVE B, P3, DOI DOI 10.1007/978-1-4613-2191-0_; SILAGY C, 1992, BRIT MED J, V305, P871, DOI 10.1136/bmj.305.6858.871; THOROGOOD M, 1992, WOMENS HLTH MATTERS; TUCKETT D, 1985, M EXPERTS APPROACH S, P173; 1993, NEW HLTH PROMOTION P; [No title captured]; 1991, BMJ, V302, P1057; 1991, 41 COMM MED ASP FOOD	16	48	49	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1657	1660		10.1136/bmj.306.6893.1657	http://dx.doi.org/10.1136/bmj.306.6893.1657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324437	Bronze, Green Published			2022-12-28	WOS:A1993LJ33700025
J	BECKER, LB; HAN, BH; MEYER, PM; WRIGHT, FA; RHODES, KV; SMITH, DW; BARRETT, J				BECKER, LB; HAN, BH; MEYER, PM; WRIGHT, FA; RHODES, KV; SMITH, DW; BARRETT, J			RACIAL-DIFFERENCES IN THE INCIDENCE OF CARDIAC-ARREST AND SUBSEQUENT SURVIVAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY RESUSCITATION; MYOCARDIAL-INFARCTION; HEALTH-PROFESSIONALS; PREVALENCE; STATEMENT; DISEASE; DEATH	Background. Differences between blacks and whites have been reported in the incidence of several forms of cardiovascular disease, including hypertension and stroke. We examined racial differences in the incidence of cardiac arrest in a large urban population and in subsequent survival. Methods. We collected data on all nontraumatic, out-of-hospital cardiac arrests in Chicago from January 1, 1987, through December 31, 1988, and compared the incidence and survival rates for blacks and whites. We examined the association between survival and race and seven other known risk factors by logistic-regression analysis. We computed incidence rates by coupling our data with U.S. Census population data. Results. Our study population comprised 6451 patients: 3207 whites, 2910 blacks, and 334 persons of other races. The incidence of cardiac arrest was significantly higher tor blacks than for whites in every age group. The survival rate after cardiac arrest was 2.6 percent in whites as compared with 0.8 percent in blacks (P<0.001). Blacks were significantly less likely to have a witnessed cardiac arrest, bystander-initiated cardiopulmonary resuscitation, or a ''favorable'' initial rhythm or to be admitted to the hospital. When they were admitted, blacks were half as likely to survive. The association between race and survival persisted even when other recognized risk factors were taken into account. We did not find important differences between blacks and whites in the response times of the emergency medical services. Conclusions. The black community in our study was at higher risk for cardiac arrest and subsequent death than the white community, even after we controlled for other variables.	UNIV CHICAGO,DEPT MED,EMERGENCY MED SECT,CHICAGO,IL 60637; RESURRECT HOSP,DEPT EMERGENCY,CHICAGO,IL; CHICAGO FIRE DEPT,BUR EMERGENCY MED SERV,CHICAGO,IL; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PREVENT MED,CHICAGO,IL 60612; UNIV CHICAGO,DEPT STAT,CHICAGO,IL 60637; UNIV OKLAHOMA HLTH SCI CTR,DEPT EPIDEMIOL & ST,OKLAHOMA CITY,OK	University of Chicago; Rush University; University of Chicago; University of Oklahoma System; University of Oklahoma Health Sciences Center								[Anonymous], GEN LINEAR MODELS; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BECKER LB, 1993, ANN EMERG MED, V22, P86, DOI 10.1016/S0196-0644(05)80257-4; BRESLOW NE, 1987, IARC SCI PUBL, V32, P135; CASTANER A, 1988, ANN INTERN MED, V109, P33, DOI 10.7326/0003-4819-109-1-33; COBB LA, 1980, ANNU REV MED, V31, P453, DOI 10.1146/annurev.me.31.020180.002321; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; GILLUM RF, 1985, J NATL MED ASSOC, V77, P281; HAGSTROM RM, 1971, CIRCULATION, V44, P884, DOI 10.1161/01.CIR.44.5.884; HALLSTROM A, 1993, AM J PUBLIC HEALTH, V83, P245, DOI 10.2105/AJPH.83.2.245; KEIL JE, 1985, AM HEART J, V109, P776, DOI 10.1016/0002-8703(85)90638-6; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; OALMANN MC, 1971, AM J EPIDEMIOL, V94, P546, DOI 10.1093/oxfordjournals.aje.a121353; SPRAFKA JM, 1988, AM J PUBLIC HEALTH, V78, P1546, DOI 10.2105/AJPH.78.12.1546; WILCOXGOK VL, 1991, MED CARE, V29, P104, DOI 10.1097/00005650-199102000-00003; 1991, CIRCULATION, V83, P1462; 1992, 1990 CENSUS POPULATI; 1980, 180 CENSUS POPULA 15, V1, pCHB; 1986, JAMA-J AM MED ASSOC, V255, P2905	23	312	317	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					600	606		10.1056/NEJM199308263290902	http://dx.doi.org/10.1056/NEJM199308263290902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341333				2022-12-28	WOS:A1993LU21700002
J	CAVANAH, DK; BALLAS, ZK				CAVANAH, DK; BALLAS, ZK			PSEUDOEPHEDRINE REACTION PRESENTING AS RECURRENT TOXIC SHOCK SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Note							DRUG		UNIV IOWA, COLL MED, IOWA CITY, IA 52242 USA	University of Iowa				Ballas, Zuhair/0000-0001-5569-1230; Knaack, Aaron/0000-0001-7712-1415				BALLAS ZK, 1982, ARCH INTERN MED, V142, P165, DOI 10.1001/archinte.142.1.165; CAMISA C, 1988, CUTIS, V41, P339; HUGHES DTD, 1983, J CLIN HOSP PHARM, V8, P315, DOI 10.1111/j.1365-2710.1983.tb01053.x; SHELLEY WB, 1987, J AM ACAD DERMATOL, V17, P403, DOI 10.1016/S0190-9622(87)70220-5; TALIERCIO CP, 1985, MAYO CLIN PROC, V60, P463, DOI 10.1016/S0025-6196(12)60870-2; TAYLOR BJ, 1988, BRIT J DERMATOL, V118, P827, DOI 10.1111/j.1365-2133.1988.tb02602.x; VANARSDEL PP, 1986, ANN ALLERGY, V57, P305	7	12	12	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					302	303		10.7326/0003-4819-119-4-199308150-00009	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328739				2022-12-28	WOS:A1993LV52500009
J	SIMON, HB				SIMON, HB			HYPERTHERMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NEUROLEPTIC MALIGNANT SYNDROME; RECURRENT FEBRILE SEIZURES; WHOLE-BODY HYPERTHERMIA; EXERTIONAL HEATSTROKE; FEVER; HEAT; TEMPERATURE		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	SIMON, HB (corresponding author), MASSACHUSETTS GEN HOSP, DEPT MED, INFECT DIS UNIT, FRUIT ST, BOSTON, MA 02114 USA.							ALLEN J, 1989, Q J MED, V70, P103; ANDERSON RL, 1990, MED J AUSTRALIA, V152, P310, DOI 10.5694/j.1326-5377.1990.tb120955.x; [Anonymous], 1987, Med Sci Sports Exerc, V19, P529; ARMSTRONG LE, 1990, MED SCI SPORT EXER, V22, P36; BERG AT, 1990, J PEDIATR-US, V116, P329, DOI 10.1016/S0022-3476(05)82816-1; BERG AT, 1992, NEW ENGL J MED, V327, P1122, DOI 10.1056/NEJM199210153271603; BULL JM, 1979, ANN INTERN MED, V90, P317, DOI 10.7326/0003-4819-90-3-317; CAROFF SN, 1993, MED CLIN N AM, V77, P185, DOI 10.1016/S0025-7125(16)30278-4; COSTRINI A, 1990, MED SCI SPORT EXER, V22, P15; COSTRINI AM, 1979, AM J MED, V66, P296, DOI 10.1016/0002-9343(79)90548-5; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; DINARELLO CA, 1988, REV INFECT DIS, V10, P168; EPSTEIN Y, 1990, MED SCI SPORT EXER, V22, P29; Falconer J, 1990, Arthritis Care Res, V3, P85, DOI 10.1002/art.1790030206; FARWELL JR, 1990, NEW ENGL J MED, V322, P364, DOI 10.1056/NEJM199002083220604; FREY MAB, 1979, AVIAT SPACE ENVIR MD, V50, P387; GABRIELE P, 1990, CANCER, V66, P2191, DOI 10.1002/1097-0142(19901115)66:10<2191::AID-CNCR2820661025>3.0.CO;2-8; GAVIN LA, 1991, MED CLIN N AM, V75, P179, DOI 10.1016/S0025-7125(16)30478-3; GISOLFI CV, 1974, MED SCI SPORT EXER, V6, P108; GUZE BH, 1985, NEW ENGL J MED, V313, P163, DOI 10.1056/NEJM198507183130306; KARJALAINEN J, 1986, ARCH INTERN MED, V146, P1169, DOI 10.1001/archinte.146.6.1169; KEATINGE WR, 1986, AM J MED, V81, P795, DOI 10.1016/0002-9343(86)90348-7; KLIP A, 1987, LANCET, V1, P463; KNOCHEL JP, 1989, DM-DIS MON, V35, P306; LARACH MG, 1992, ANESTHESIOLOGY, V76, P16, DOI 10.1097/00000542-199201000-00003; LEIBSCHUTZ DC, 1974, SURG GYNECOL OBSTET, V139, P403; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; McLaren J R, 1990, Adv Exp Med Biol, V267, P21; MUSHER DM, 1979, ARCH INTERN MED, V139, P1225, DOI 10.1001/archinte.139.11.1225; NOAKES TD, 1991, MED SCI SPORT EXER, V23, P443; PAYEN JF, 1992, MED SCI SPORT EXER, V24, P420; RICCI J, 1984, CAN MED ASSOC J, V131, P459; ROBERTS NJ, 1991, REV INFECT DIS, V13, P462; ROBINS HI, 1989, RADIOL CLIN N AM, V27, P603; SAKKAS P, 1991, PSYCHIAT ANN, V21, P157, DOI 10.3928/0048-5713-19910301-08; SCHMIDT KD, 1992, MAYO CLIN PROC, V67, P469, DOI 10.1016/S0025-6196(12)60394-2; SEGAR WE, 1958, NEW ENGL J MED, V259, P1191, DOI 10.1056/NEJM195812182592501; SHAPIRO Y, 1990, MED SCI SPORT EXER, V22, P6; SIMON HB, 1979, AM J MED, V66, P257, DOI 10.1016/0002-9343(79)90542-4; SIMON HB, 1976, JAMA-J AM MED ASSOC, V236, P2419, DOI 10.1001/jama.236.21.2419; SIMON HB, 1992, SCI AM MED; SOULIERE CR, 1986, ARCH OTOLARYNGOL, V112, P564; STYRT B, 1990, ARCH INTERN MED, V150, P1589, DOI 10.1001/archinte.150.8.1589; SUTTON JR, 1979, MED J AUSTRALIA, V2, P463, DOI 10.5694/j.1326-5377.1979.tb125756.x; TYRRELL D, 1989, BRIT MED J, V298, P1280, DOI 10.1136/bmj.298.6683.1280; TYRRELL D, 1989, BRIT MED J, V299, P600; WOLFF SM, 1964, AM J MED, V36, P956, DOI 10.1016/0002-9343(64)90123-8; 1981, MMWR MORB MORTAL WKL, V30, P277	48	184	196	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					483	487						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	8332154				2022-12-28	WOS:A1993LR44300008
J	RAVICHANDRAN, KG; BODDUPALLI, SS; HASEMANN, CA; PETERSON, JA; DEISENHOFER, J				RAVICHANDRAN, KG; BODDUPALLI, SS; HASEMANN, CA; PETERSON, JA; DEISENHOFER, J			CRYSTAL-STRUCTURE OF HEMOPROTEIN DOMAIN OF P450BM-3, A PROTOTYPE FOR MICROSOMAL P450S	SCIENCE			English	Article							2 FUNCTIONAL DOMAINS; ELECTRON-TRANSFER; BACILLUS-MEGATERIUM; BINDING-PROTEIN; CYTOCHROME-P-450; RESOLUTION; REFINEMENT; ENZYMES; COMPLEX; ERRORS	Cytochrome P450BM-3, a bacterial fatty acid monooxygenase, resembles the eukaryotic microsomal P450's and their flavoprotein reductase in primary structure and function. The three-dimensional structure of the hemoprotein domain of P450BM-3 was determined by x-ray diffraction and refined to an R factor of 16.9 percent at 2.0 angstrom resolution. The structure consists of an alpha and a beta domain. The active site heme is accessible through a long hydrophobic channel formed primarily by the beta domain and the B' and F helices of the alpha domain. The two molecules in the asymmetric unit differ in conformation around the substrate binding pocket. Substantial differences between P450BM-3 and P450cam, the only other P450 structure available, are observed around the substrate binding pocket and the regions important for redox partner binding. A general mechanism for proton transfer in P450's is also proposed.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM43479] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043479] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; BODDUPALLI SS, 1992, P NATL ACAD SCI USA, V89, P5567, DOI 10.1073/pnas.89.12.5567; BODDUPALLI SS, UNPUB; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; DEMONTELANO PRO, 1986, CYTOCHROME, V450, P217; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUNSALUS IC, 1974, MOL MECHANISMS OXYGE; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LI HY, 1991, J BIOL CHEM, V266, P11909; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OSTER T, 1991, J BIOL CHEM, V266, P22718; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PETERSON JA, 1992, CYTOCHROME P, V450, P708; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; POULOS TL, 1991, METHOD ENZYMOL, V206, P11; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUETTINGER RT, 1989, TRENDS BIOCHEM SCI, V264, P10987; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SONO M, 1982, J BIOL CHEM, V257, P8308; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STEIGEMANN W, 1992, JUL AM CRYST ASS ANN	39	916	936	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1993	261	5122					731	736		10.1126/science.8342039	http://dx.doi.org/10.1126/science.8342039			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8342039				2022-12-28	WOS:A1993LQ73000030
J	TOOLE, MJ; WALDMAN, RJ				TOOLE, MJ; WALDMAN, RJ			REFUGEES AND DISPLACED PERSONS - WAR, HUNGER, AND PUBLIC-HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The number of refugees and internally displaced persons in need of protection and assistance has increased from 30 million in 1990 to more than 43 million today. War and civil strife have been largely responsible for this epidemic of mass migration that has affected almost every region of the world, including Europe. Since 1990, crude death rates (CDRs) during the early influx of refugees who crossed international borders have been somewhat lower than CDRs reported earlier among Cambodian and Ethiopian refugees. Nevertheless, CDRs among refugees arriving in Ethiopia, Kenya, Nepal, Malawi, and Zimbabwe since 1990 ranged from five to 12 times the baseline CDRs in the countries of origin. Among internally displaced populations in northern Iraq, Somalia, and Sudan, CDRs were extremely high, ranging from 12 to 25 times the baseline CDRs for the nondisplaced. Among both refugees and internally displaced persons, death rates among children less than 5 years of age were far higher than among older children and adults. In Bangladesh, the death rate in female Rohingya refugees was several times higher than in males. Preventable conditions such as diarrheal disease, measles, and acute respiratory infections, exacerbated often by malnutrition, caused most deaths. Although relief programs for refugees have improved since 1990, the situation among the internally displaced may have worsened. The international community should intervene earlier in the evolution of complex disasters involving civil war, human rights abuses, food shortages, and mass displacement. Relief programs need to be based on sound health and nutrition information and should focus on the provision of adequate shelter, food, water, sanitation, and public health programs that prevent mortality from diarrhea, measles, and other communicable diseases, especially among young children and women.	WHO,DIV DIARRHOEAL & ACUTE RESP DISEASE CONTROL,CH-1211 GENEVA 27,SWITZERLAND	World Health Organization	TOOLE, MJ (corresponding author), CTR DIS CONTROL & PREVENT,INT HLTH PROGRAM OFF,MAILSTOP FO3,ATLANTA,GA 30333, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; HILDEBRAND K, 1991, JOINT NUTRITION MORT; ISAACSON M, 1993, LANCET, V341, P961, DOI 10.1016/0140-6736(93)91253-I; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; SUDETIC C, 1993, NY TIMES        0524, pA7; TOOLE MJ, 1992, LANCET, V339, P1214, DOI 10.1016/0140-6736(92)91143-V; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, LANCET, V341, P935; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1968, HCRINF29 UN HIGH COM; 1982, HDB EMERGENCIES; 1992, NO MERCY MOGADISHU, P3; 1991, MMWR MORB MORTAL WKL, V40, P443; 1993, UNHCR IMPLEMENTATION; 1993, MMWR MORB MORTAL WKL, V42, P69; 1993, ECN4199350 PUBL; 1992, RESPONDING NUTRITION; 1992, REFUGES, V91, P4; 1993, MMWR MORB MORTAL WKL, V42, P304; 1992, INTERNALLY DISPLACED, P5; 1993, MMWR MORB MORTAL WKL, V42, P14; 1992, STATE WORLDS CHILDRE; 1993, MMWR MORB MORTAL WKL, V42, P468	24	147	149	1	113	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					600	605		10.1001/jama.270.5.600	http://dx.doi.org/10.1001/jama.270.5.600			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331759				2022-12-28	WOS:A1993LP43600025
J	SIEGEL, M				SIEGEL, M			INVOLUNTARY SMOKING IN THE RESTAURANT WORKPLACE - A REVIEW OF EMPLOYEE EXPOSURE AND HEALTH-EFFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ENVIRONMENTAL TOBACCO-SMOKE; LUNG-CANCER RISK; PASSIVE SMOKING; OCCUPATIONAL MORTALITY; DEATH CERTIFICATE; NEW-JERSEY; CARCINOGENS; MALES; WOMEN	Objective.-To determine the relative exposure to environmental tobacco smoke for bar and restaurant employees compared with office employees and with nonsmokers exposed in the home (part 1) and to determine whether this exposure is contributing to an elevated lung cancer risk in these employees (part 2). Data Sources.-MEDLINE and bibliographies from identified publications. Study Selection.-In part 1, published studies of indoor air quality were included if they reported a mean concentration of carbon monoxide, nicotine, or particulate matter from measurements taken in one or more bars, restaurants, offices, or residences with at least one smoker. In part 2, published epidemiologic studies that reported a risk estimate for lung cancer incidence or mortality in food-service workers were included if they controlled, directly or indirectly, for active smoking. Data Extraction.-In part 1, a weighted average of the mean concentration of carbon monoxide, nicotine, and respirable suspended particulates reported in studies was calculated for bars, restaurants, offices, and residences. In part 2, the relative lung cancer risk for food-service workers compared with that for the general population was examined in the six identified studies. Data Synthesis.-Levels of environmental tobacco smoke in restaurants were approximately 1.6 to 2.0 times higher than in office workplaces of other businesses and 1.5 times higher than in residences with at least one smoker. Levels in bars were 3.9 to 6.1 times higher than in off ices and 4.4 to 4.5 times higher than in residences. The epidemiologic evidence suggested that there may be a 50% increase in lung cancer risk among food-service workers that is in part attributable to tobacco smoke exposure in the workplace. Conclusions.-Environmental tobacco smoke is a significant occupational health hazard for food-service workers. To protect these workers, smoking in bars and restaurants should be prohibited.	UNIV CALIF BERKELEY,PREVENT MED RESIDENCY PROGRAM,BERKELEY,CA 94720; UNIV CALIF SAN FRANCISCO,PREVENT MED RESIDENCY PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California Berkeley; University of California System; University of California San Francisco								ANDERSEN AA, 1989, BRIT J CANCER, V60, P112, DOI 10.1038/bjc.1989.232; [Anonymous], 1986, ENV TOBACCO SMOKE ME; BEAUMONT JJ, 1992, AM J IND MED, V21, P491, DOI 10.1002/ajim.4700210405; BULBULYAN M, 1992, CANCER CAUSE CONTROL, V3, P299, DOI 10.1007/BF00146882; CHOI WS, 1991, MMWR MORB MORTAL WKL, V40, P1; COGGON D, 1984, J NATL CANCER I, V72, P61, DOI 10.1093/jnci/72.1.61; DECOUFLE P, 1977, DHEW NIOSH77178 PUBL; DIMICHWARD H, 1988, CAN J PUBLIC HEALTH, V79, P194; DOEBBERT G, 1988, WESTERN J MED, V149, P734; DUBROW R, 1984, AM J IND MED, V6, P207, DOI 10.1002/ajim.4700060305; DUNN JE, 1960, AM J PUBLIC HEALTH N, V50, P1475, DOI 10.2105/AJPH.50.10.1475; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Guerin M.R., 1992, CHEM ENV TOBACCO SMO; GURALNICK L, 1963, VITAL STAT SPECIAL R, V53, P95; HOWE GR, 1983, JNCI-J NATL CANCER I, V70, P37; HUSGAFVELPURSIAINEN K, 1987, INT ARCH OCC ENV HEA, V59, P337, DOI 10.1007/BF00405277; KELLER JE, 1993, ENVIRON RES, V60, P1, DOI 10.1006/enrs.1993.1001; LERCHEN ML, 1987, J NATL CANCER I, V79, P639; LYNGE E, 1982, PREVENTION OCCUPATIO, P557; MACLURE M, 1989, AM J PUBLIC HEALTH, V79, P1381, DOI 10.2105/AJPH.79.10.1381; MENCK HR, 1976, J OCCUP ENVIRON MED, V18, P797, DOI 10.1097/00043764-197612000-00005; Milham S.J, 1976, OCCUPATIONAL MORTALI, VVolume 1; MILNE KL, 1983, AM J IND MED, V4, P565, DOI 10.1002/ajim.4700040410; PERTSCHUK M, 1989, MAJOR LOCAL SMOKING; REPACE JL, 1985, ENVIRON INT, V11, P3, DOI 10.1016/0160-4120(85)90098-4; REPACE JL, 1987, ENV CARCINOGENS METH, V9, P141; SCHOENBERG JB, 1987, J NATL CANCER I, V79, P13; SINGLETON J, 1989, COMS 2 CALIFORNIA OC; STERLING TD, 1982, JAPCA J AIR WASTE MA, V32, P250, DOI 10.1080/00022470.1982.10465397; STERLING TD, 1976, J OCCUP ENVIRON MED, V18, P743, DOI 10.1097/00043764-197611000-00011; TESCHKE K, 1989, ENVIRON RES, V50, P296, DOI 10.1016/S0013-9351(89)80011-8; TURNER S, 1992, ENVIRON INT, V18, P19, DOI 10.1016/0160-4120(92)90207-K; WALD NJ, 1986, BMJ-BRIT MED J, V293, P1217, DOI 10.1136/bmj.293.6556.1217; WILLIAMS RR, 1977, J NATL CANCER I, V59, P1147, DOI 10.1093/jnci/59.4.1147; ZAHM SH, 1989, AM J IND MED, V15, P565, DOI 10.1002/ajim.4700150509; ZIEGLER RG, 1986, AM J EPIDEMIOL, V123, P1080, DOI 10.1093/oxfordjournals.aje.a114336; 1986, AM C GOVT IND HYGIEN; 1987, CALIFORNIA OCCUPATIO; 1992, EPA600690006F PUBL; 1986, HLTH CONSEQUENCES IN; 1991, DHHS NIOSH91108 NAT; 1978, OCCUPATIONAL MORTALI	42	180	184	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					490	493		10.1001/jama.270.4.490	http://dx.doi.org/10.1001/jama.270.4.490			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN426	8320789				2022-12-28	WOS:A1993LN42600030
J	FRASER, I; HUGHES, D; GORDON, S				FRASER, I; HUGHES, D; GORDON, S			DIVALENT CATION-INDEPENDENT MACROPHAGE ADHESION INHIBITED BY MONOCLONAL-ANTIBODY TO MURINE SCAVENGER RECEPTOR	NATURE			English	Article							TYPE-3 COMPLEMENT RECEPTOR; RAT HYBRID MYELOMAS; MYELOMONOCYTIC CELLS; HUMAN MONOCYTE; PROTEINS; FAMILY; LIPOPROTEINS; RECRUITMENT; INTEGRINS; INVITRO	MACROPHAGES interact with other cells and components of the extracellular environment by means of adhesion receptors1,2. Adhesion to artificial substrata in vitro facilitates isolation of macrophages3, and has been used to generate antibodies that inhibit their migration in vivo4,5. Unlike other cell types, macrophages attach to tissue culture plastic in the absence of divalent cations. Here we use an adhesion assay exploiting this property to isolate a rat monoclonal antibody, 2F8, which totally inhibits divalent cation-independent adhesion of murine macrophages to tissue culture plastic in the presence of fetal calf serum. Immunoprecipitation from macrophages and stably transfected Chinese hamster ovary cells revealed that the antigen recognized by monoclonal 2F8 is identical to murine macrophage scavenger receptor6,7. We propose a novel function for this molecule, previously described as an endocytic receptor, thus providing a mechanism for mononuclear phagocyte recruitment to and retention in ligand-rich tissues such as in atherosclerotic lesions.			FRASER, I (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.		Hughes, Derralynn/J-8012-2013	Hughes, Derralynn/0000-0003-4531-9173				ASHKENAS J, 1993, J LIPID RES, V34, P983; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GALFRE G, 1979, NATURE, V277, P131, DOI 10.1038/277131a0; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GODING JW, 1986, HDB EXPT IMMUNOLOGY; HALE G, 1987, J IMMUNOL METHODS, V103, P59, DOI 10.1016/0022-1759(87)90242-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON WD, 1977, J EXP MED, V146, P1613, DOI 10.1084/jem.146.6.1613; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEENEN PJM, 1986, DIFFERENTIATION, V32, P157, DOI 10.1111/j.1432-0436.1986.tb00568.x; PEARLSTEIN E, 1978, J CELL BIOL, V79, P263, DOI 10.1083/jcb.79.1.263; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RABINOVITCH M, 1976, J EXP MED, V143, P290, DOI 10.1084/jem.143.2.290; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; ROSEN H, 1987, J EXP MED, V166, P1685, DOI 10.1084/jem.166.6.1685; ROSEN H, 1989, J EXP MED, V170, P27, DOI 10.1084/jem.170.1.27; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1986, CIBA F SYMP, V118, P102, DOI 10.1002/9780470720998.ch8	23	315	327	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					343	345		10.1038/364343a0	http://dx.doi.org/10.1038/364343a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332192				2022-12-28	WOS:A1993LN57000059
J	HAINSWORTH, JD; GRECO, FA				HAINSWORTH, JD; GRECO, FA			DRUG-THERAPY - TREATMENT OF PATIENTS WITH CANCER OF AN UNKNOWN PRIMARY SITE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COMBINATION-CHEMOTHERAPY REGIMENS; POORLY DIFFERENTIATED CARCINOMA; PAPILLARY SEROUS CARCINOMA; PROSTATE-SPECIFIC ANTIGEN; SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASIS; PRIMARY ORIGIN; ADENOCARCINOMA; NECK; CISPLATIN				HAINSWORTH, JD (corresponding author), SARAH CANNON CANC CTR,250 25TH AVE N,NASHVILLE,TN 37203, USA.							ALLHOFF EP, 1983, J UROLOGY, V129, P315, DOI 10.1016/S0022-5347(17)52074-1; ANDERSON H, 1983, EUR J CANCER CLIN ON, V19, P49, DOI 10.1016/0277-5379(83)90397-8; ARNOLD A, 1983, NEW ENGL J MED, V309, P159; ASHIKARI R, 1976, ANN SURG, V183, P415, DOI 10.1097/00000658-197604000-00015; AUGUST CZ, 1985, INT J GYNECOL PATHOL, V4, P11, DOI 10.1097/00004347-198501000-00002; AZAR HA, 1982, HUM PATHOL, V13, P323, DOI 10.1016/S0046-8177(82)80222-0; BARRIE JR, 1970, AM J SURG, V120, P466, DOI 10.1016/S0002-9610(70)80008-3; BATAINI JP, 1987, LARYNGOSCOPE, V97, P1080; BHATIA SK, 1987, CANCER, V59, P1170, DOI 10.1002/1097-0142(19870315)59:6<1170::AID-CNCR2820590623>3.0.CO;2-2; Bosl GJ, 1989, P AN M AM SOC CLIN, V8, P131; CARLSON LS, 1986, INT J RADIAT ONCOL, V12, P2101, DOI 10.1016/0360-3016(86)90008-8; CHEN KTK, 1986, CANCER, V58, P1371, DOI 10.1002/1097-0142(19860915)58:6<1371::AID-CNCR2820580632>3.0.CO;2-L; COKER DD, 1977, AM J SURG, V134, P517, DOI 10.1016/0002-9610(77)90390-7; DALRYMPLE JC, 1989, CANCER, V64, P110, DOI 10.1002/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5; DEBRAUD F, 1989, CANCER, V64, P510, DOI 10.1002/1097-0142(19890715)64:2<510::AID-CNCR2820640225>3.0.CO;2-2; DEVITA VT, 1987, CANCER RES, V47, P5810; EAGAN RT, 1987, AM J CLIN ONCOL-CANC, V10, P82, DOI 10.1097/00000421-198702000-00018; FERMONT AC, 1980, CLIN RADIOL, V31, P355; FIORE JJ, 1985, CANCER TREAT REP, V69, P591; FOX RM, 1979, LANCET, V1, P1316; GATTER KC, 1985, LANCET, V1, P1302; GENTILE PS, 1988, CANCER, V62, P711, DOI 10.1002/1097-0142(19880815)62:4<711::AID-CNCR2820620411>3.0.CO;2-6; GOLDBERG RM, 1986, J CLIN ONCOL, V4, P395, DOI 10.1200/JCO.1986.4.3.395; GOONERATNE S, 1982, INT J GYNECOL PATHOL, V1, P258, DOI 10.1097/00004347-198203000-00003; GRECO FA, 1986, ANN INTERN MED, V104, P547, DOI 10.7326/0003-4819-104-4-547; GUARISCHI A, 1987, CANCER-AM CANCER SOC, V59, P572, DOI 10.1002/1097-0142(19870201)59:3<572::AID-CNCR2820590336>3.0.CO;2-3; HAINSWORTH JD, 1991, J CLIN ONCOL, V9, P1931, DOI 10.1200/JCO.1991.9.11.1931; HAINSWORTH JD, 1992, J CLIN ONCOL, V10, P912, DOI 10.1200/JCO.1992.10.6.912; HAINSWORTH JD, 1988, ANN INTERN MED, V109, P364, DOI 10.7326/0003-4819-109-5-364; Hales S A, 1989, Leuk Lymphoma, V1, P59, DOI 10.3109/10428198909042460; HOCHSTER H, 1984, CANCER TREAT REP, V68, P931; HORNING SJ, 1989, J CLIN ONCOL, V7, P1281, DOI 10.1200/JCO.1989.7.9.1281; JESSE RH, 1973, CANCER, V31, P854, DOI 10.1002/1097-0142(197304)31:4<854::AID-CNCR2820310414>3.0.CO;2-D; JOHNSON RO, 1964, CANCER CHEMOTH REP, V38, P63; JOSE B, 1979, ACTA RADIOL ONCOL, V18, P161, DOI 10.3109/02841867909128203; KAMBHU S, 1986, P AM ASSOC CANC RES, V27, P185; LEIPZIG B, 1981, LARYNGOSCOPE, V91, P593, DOI 10.1288/00005537-198104000-00012; LENZI R, 1991, P AN M AM SOC CLIN, V10, P301; MCCUNNIFF AJ, 1986, INT J RADIAT ONCOL, V12, P1849, DOI 10.1016/0360-3016(86)90329-9; MCKEEN E, 1980, P AM ASSOC CANC RES, V21, P358; MCMILLAN JH, 1982, RADIOLOGY, V143, P143, DOI 10.1148/radiology.143.1.7063718; MILLIKEN ST, 1987, EUR J CANCER CLIN ON, V23, P1645, DOI 10.1016/0277-5379(87)90443-3; MOERTEL CG, 1972, CANCER-AM CANCER SOC, V30, P1469, DOI 10.1002/1097-0142(197212)30:6<1469::AID-CNCR2820300609>3.0.CO;2-T; MOERTEL CG, 1991, CANCER, V68, P227, DOI 10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I; MOHITTABATABAI MA, 1986, AM SURGEON, V52, P152; MOTZER RJ, 1991, J NATL CANCER I, V83, P341, DOI 10.1093/jnci/83.5.341; NORDSTROM DG, 1979, INT J RADIAT ONCOL, V5, P73, DOI 10.1016/0360-3016(79)90041-5; NYSTROM JS, 1977, SEMIN ONCOL, V4, P53; PACINI P, 1981, ACTA RADIOL ONCOL, V20, P311, DOI 10.3109/02841868109130213; PASTERZ R, 1986, J CLIN ONCOL, V4, P1652, DOI 10.1200/JCO.1986.4.11.1652; PATEL J, 1981, CANCER, V47, P2923, DOI 10.1002/1097-0142(19810615)47:12<2923::AID-CNCR2820471231>3.0.CO;2-N; RABER MN, 1991, ANN ONCOL, V2, P519, DOI 10.1093/oxfordjournals.annonc.a058007; RANSOM DT, 1990, CANCER, V66, P1091, DOI 10.1002/1097-0142(19900915)66:6<1091::AID-CNCR2820660602>3.0.CO;2-F; RICHARDSON RL, 1981, ANN INTERN MED, V94, P181, DOI 10.7326/0003-4819-94-2-181; ROSEN PP, 1980, CANCER, V46, P1298, DOI 10.1002/1097-0142(19800901)46:5<1298::AID-CNCR2820460535>3.0.CO;2-2; SHILDT RA, 1983, CANCER TREAT REP, V67, P77; SPIRO RH, 1983, AM J SURG, V146, P441, DOI 10.1016/0002-9610(83)90227-1; STRNAD CM, 1989, ANN INTERN MED, V111, P213, DOI 10.7326/0003-4819-111-3-213; TELL DT, 1985, JAMA-J AM MED ASSOC, V253, P3574, DOI 10.1001/jama.253.24.3574; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; VANDERGAAST A, 1990, ANN ONCOL, V1, P119; WARNKE RA, 1983, NEW ENGL J MED, V309, P1275, DOI 10.1056/NEJM198311243092102; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302; WOODS RL, 1980, NEW ENGL J MED, V303, P87, DOI 10.1056/NEJM198007103030205; YANG ZY, 1983, ACTA RADIOL ONCOL, V22, P17, DOI 10.3109/02841868309134334	66	182	187	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					257	263						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM682	8316270				2022-12-28	WOS:A1993LM68200007
J	MCINTIRE, SL; JORGENSEN, E; KAPLAN, J; HORVITZ, HR				MCINTIRE, SL; JORGENSEN, E; KAPLAN, J; HORVITZ, HR			THE GABAERGIC NERVOUS-SYSTEM OF CAENORHABDITIS-ELEGANS	NATURE			English	Article							NEMATODE ASCARIS; C-ELEGANS; INHIBITORY MOTONEURONS; GABA; NEURONS	Gamma-AMINOBUTYRIC acid (GABA) is the most abundant inhibitory neurotransmitter in vertebrates and invertebrates1. GABA receptors are the target of anxiolytic, antiepileptic and antispasmodic drugs2, as well as of commonly used insecticides3. How does a specific neurotransmitter such as GABA control animal behaviour? To answer this question, we identified all neurons that react with antisera raised against the neurotransmitter GABA in the nervous system of the nematode Caenorhabditis elegans. We determined the in vivo functions of 25 of the 26 GABAergic neurons by killing these cells with a laser microbeam in living animals and by characterizing a mutant defective in GABA expression. On the basis of the ultrastructurally defined connectivity of the C. elegans nervous system, we deduced how these GABAergic neurons act to control the body and enteric muscles necessary for different behaviours. Our findings provide evidence that GABA functions as an excitatory as well as an inhibitory neurotransmitter.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School								AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BOWERY NG, 1991, SEMINARS NEUROSCI, V3, P241; BOWERY NG, 1989, GABA BASIC RES CLIN, P1; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; Cooper J. R., 1991, BIOCH BASIS NEUROPHA, P133; GUASTELLA J, 1991, J COMP NEUROL, V307, P584, DOI 10.1002/cne.903070406; HALL DH, 1991, J NEUROSCI, V11, P1; HOSKINS SG, 1986, CELL TISSUE RES, V244, P243; JOHNSON CD, 1985, J NEUROSCI, V5, P1984; JOHNSON CD, 1987, J NEUROSCI, V7, P223; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; Olsen RW, 1991, SEMIN NEUROSCI, V3, P175, DOI [10.1016/1044-5765(91)90014-F, DOI 10.1016/1044-5765(91)90014-F]; SATTELLE DB, 1991, NEUROCHEM RES, V16, P363, DOI 10.1007/BF00966100; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS JH, 1990, GENETICS, V124, P855; WALROND JP, 1985, J NEUROSCI, V5, P9; WALROND JP, 1985, J NEUROSCI, V5, P1; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Wood WB, 1988, NEMATODE CAENORHABDI	25	337	343	2	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					337	341		10.1038/364337a0	http://dx.doi.org/10.1038/364337a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332191				2022-12-28	WOS:A1993LN57000057
J	MAROTTI, KR; CASTLE, CK; BOYLE, TP; LIN, AH; MURRAY, RW; MELCHIOR, GW				MAROTTI, KR; CASTLE, CK; BOYLE, TP; LIN, AH; MURRAY, RW; MELCHIOR, GW			SEVERE ATHEROSCLEROSIS IN TRANSGENIC MICE EXPRESSING SIMIAN CHOLESTERYL ESTER TRANSFER PROTEIN	NATURE			English	Article							DENSITY-LIPOPROTEIN LEVELS; PLASMA; SUSCEPTIBILITY; STRAINS; LESIONS; FAT	CHOLESTERYL ester transfer protein (CETP) is a plasma protein that mediates the exchange of neutral lipids among the lipoproteins1-3. Because the principal core lipid of very-low-density lipoprotein (VLDL) is triglyceride and that of high-density lipoprotein (HDL) is cholesterol ester, CETP mediates a 'heteroexchange' of cholesterol ester for triglyceride between those lipoproteins. As a result, animals that express CETP tend to have higher VLDL and low-density lipoprotein (LDL) cholesterol levels, whereas those with no CETP activity tend to have high HDL cholesterol levels2. Because VLDL and LDL are associated with the progression of atherosclerosis, and HDL are considered anti-atherogenic, CETP could be an 'atherogenic' protein, that is, given the other conditions required for atherosclerosis to develop, expression of CETP would accelerate the rate at which the arterial lesions progress. We report here that transgenic mice expressing CETP had much worse atherosclerosis than did non-expressing controls, and we suggest that the increase in lesion severity was due largely to CETP-induced alterations in the lipoprotein profile.			MAROTTI, KR (corresponding author), UPJOHN CO LABS,MOLEC BIOL RES & METAB DIS RES,7242-209-7,KALAMAZOO,MI 49001, USA.							CASTLE CK, 1993, ARTERIOSCLER THROMB, V13, P302, DOI 10.1161/01.ATV.13.2.302; MAHLEY RW, 1982, MED CLIN N AM, V66, P375, DOI 10.1016/S0025-7125(16)31426-2; MAROTTI KR, 1992, ARTERIOSCLER THROMB, V12, P736, DOI 10.1161/01.ATV.12.6.736; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1987, ATHEROSCLEROSIS, V64, P215, DOI 10.1016/0021-9150(87)90249-8; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; RYE KA, 1992, STRUCTURE FUNCTION A, P401; TALL AR, 1992, J INTERN MED, V231, P661, DOI 10.1111/j.1365-2796.1992.tb01255.x; ZILVERSMIT DB, 1975, BIOCHIM BIOPHYS ACTA, V409, P393, DOI 10.1016/0005-2760(75)90036-3	12	411	417	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					73	75		10.1038/364073a0	http://dx.doi.org/10.1038/364073a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316302				2022-12-28	WOS:A1993LK81800061
J	SNADDEN, D				SNADDEN, D			HOW TO DO IT - LEAVE PRACTICE	BRITISH MEDICAL JOURNAL			English	Article											SNADDEN, D (corresponding author), UNIV DUNDEE,WESTGATE HLTH CTR,DEPT GEN PRACTICE,DUNDEE DD2 4AD,SCOTLAND.		Snadden, David/ABF-1586-2020	Snadden, David/0000-0002-4818-1184				HANDY C, 1985, UNDERSTANDING ORG; Macaulay A C, 1992, Fam Med, V24, P64; PRINGLE M, 1992, BRIT MED J, V304, P1357, DOI 10.1136/bmj.304.6838.1357; SNOWISE NG, 1992, BRIT MED J, V305, P398, DOI 10.1136/bmj.305.6850.398	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1740	1742		10.1136/bmj.306.6894.1740	http://dx.doi.org/10.1136/bmj.306.6894.1740			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343633	Bronze, Green Published			2022-12-28	WOS:A1993LK36700029
J	PITT, WR; THOMAS, S; NIXON, J; CLARK, R; BATTISTUTTA, D; ACTON, C				PITT, WR; THOMAS, S; NIXON, J; CLARK, R; BATTISTUTTA, D; ACTON, C			TRENDS IN HEAD-INJURIES AMONG CHILD BICYCLISTS	BRITISH MEDICAL JOURNAL			English	Article									QUEENSLAND INST MED RES,DEPT EPIDEMIOL,HERSTON,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT CHILD HLTH,HERSTON,QLD 4029,AUSTRALIA; ROYAL CHILDRENS HOSP,HERSTON,QLD 4029,AUSTRALIA; QUEENSLAND RADIUM INST,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Queensland; Royal Children's Hospital Brisbane	PITT, WR (corresponding author), MATER CHILDRENS HOSP,BRISBANE,QLD 4101,AUSTRALIA.							ARMSON CJ, 1986, MED J AUSTRALIA, V44, P144; DIX W, 1992, 6 MONTHS REV COMPULS; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; VULCAN AP, 1992, WORLD J SURG, V16, P389, DOI 10.1007/BF02104437	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					177	177		10.1136/bmj.308.6922.177	http://dx.doi.org/10.1136/bmj.308.6922.177			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312769	Green Published			2022-12-28	WOS:A1994MR97400021
J	FREUDENTHAL, AR; JOSEPH, PR				FREUDENTHAL, AR; JOSEPH, PR			SEABATHERS ERUPTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Seabather's eruption is an annoying pruritic dermatitis that appears on the areas covered by the bathing suit as an erythematous macular or papular dermatitis, with or without urticaria. It occurs sporadically in Florida, the Caribbean, and as far north as Bermuda. The cause is not known. Methods. We collected information in Nassau County, Long Island, New York, about cases of all types of water-related dermatitis reported by beach personnel, health providers, and affected swimmers from 1970 through 1991. Concurrently, we surveyed all Nassau County swimming waters, especially during the summer season (June through September), for the presence of organisms capable of causing dermatitis. In 1980 a sudden epidemic of a severe, unfamiliar dermatitis in ocean bathers prompted increased surveillance of cases and waters. Planula larvae of the phylum Cnidaria were collected from the ocean and beaches and inside bathing suits. They were examined, photographed, tested on healthy subjects, and observed in the laboratory for metamorphosis. Results. Three outbreaks of seabather's eruption have occurred on Long Island since 1975. The first, in August 1975, affected a small number of swimmers on the eastern end of Long Island. In 1980 there were thousands of cases along the entire south shore of the island, and in 1990 there were hundreds in the same area. In nonepidemic years, five or fewer cases have been reported yearly. Surveillance for larvae revealed them to be present during the swimming season in epidemic years, but in nonepidemic years they did not appear until autumn, after the swimming season. Applying larvae to the skin of healthy subjects produced a dermatitis indistinguishable from seabather's eruption. All larvae metamorphosed in the laboratory to the adult sea anemone Edwardsiella lineata. Conclusions. Seabather's eruption, previously reported only as sporadic cases in southern climates, has occurred sporadically and in outbreaks 1000 miles north of most previously described cases. These Long Island episodes were probably caused by the planula larvae of E. lineata.	NASSAU CTY DEPT HLTH,OFF MARINE ECOL,MINEOLA,NY; WINTHROP UNIV HOSP,DEPT PEDIAT,MINEOLA,NY	Winthrop University Hospital								FREUDENTHAL AR, 1982, HAZARDS BEACH, V4; GRAUER FH, 1961, ARCH DERMATOL, V84, P720, DOI 10.1001/archderm.1961.01580170014003; HALSTEAD BW, 1965, POISONOUS VENOMOUS M, V1, P344; Mayer A. G, 1912, CARNEGIE I WASHINGTO, V162; SAMS WM, 1949, ARCH DERMATOL SYPH, V60, P227, DOI 10.1001/archderm.1949.01530020095013; TOMCHIK RS, 1993, JAMA-J AM MED ASSOC, V269, P1669, DOI 10.1001/jama.269.13.1669; VERILL AE, 1898, AM J SCI, V6, P493; WAISMAN M, 1989, CLIN DERMATOL, V4, P1	8	50	50	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					542	544		10.1056/NEJM199308193290805	http://dx.doi.org/10.1056/NEJM199308193290805			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8336754				2022-12-28	WOS:A1993LR89200005
J	LLOYD, T; ANDON, MB; ROLLINGS, N; MARTEL, JK; LANDIS, JR; DEMERS, LM; EGGLI, DF; KIESELHORST, K; KULIN, HE				LLOYD, T; ANDON, MB; ROLLINGS, N; MARTEL, JK; LANDIS, JR; DEMERS, LM; EGGLI, DF; KIESELHORST, K; KULIN, HE			CALCIUM SUPPLEMENTATION AND BONE-MINERAL DENSITY IN ADOLESCENT GIRLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY ABSORPTIOMETRY; LUMBAR SPINE; MASS ACCUMULATION; FEMORAL-NECK; YOUNG-WOMEN; FEMALES; AGE; OSTEOPOROSIS; CHILDREN; GROWTH	Objective.-To evaluate the effect of calcium supplementation on bone acquisition in adolescent white girls. Design.-A randomized, double-blind, placebo-controlled trial of the effect of 18 months of calcium supplementation on bone density and bone mass. Subjects.-Ninety-four girls with a mean age of 11.9+0.5 years at study entry. Setting.-University hospital in a small town. Interventions.-Calcium supplementation, 500 mg/d calcium as calcium citrate malate; controls received placebo pills. Main Outcome Measures.-Bone mineral density and bone mineral content of the lumbar spine and total body were measured by dual-energy x-ray absorptiometry and calcium excretion from 24-hour urine specimens. Results.-Calcium intake from dietary sources averaged 960 mg/d for the entire study group. The supplemented group received, on average, an additional 354 mg/d of calcium. The supplemented group compared with the placebo group had greater increases of lumbar spine bone density (18.7% vs 15.8%; P=.03), lumbar spine bone mineral content (39.4% vs 34.7%; P=.06), total body bone mineral density (9.6% vs 8.3%; P=.05), and 24-hour urinary calcium excretion (90.4 vs 72.9 mg/d; P=.02), respectively. Conclusions.-Increasing daily calcium intake from 80% of the recommended daily allowance to 110% via supplementation with calcium citrate malate resulted in significant increases in total body and spinal bone density in adolescent girls. The increase of 24 g of bone gain per year among the supplemented group translates to an additional 1.3% skeletal mass per year during adolescent growth, which may provide protection against future osteoporotic fracture.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PATHOL,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CLIN NUTR,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,CTR BIOSTAT & EPIDEMIOL,HERSHEY,PA 17033; PROCTER & GAMBLE CO,MIAMI VALLEY LABS,CINCINNATI,OH 45247	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Procter & Gamble	LLOYD, T (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT OBSTET & GYNECOL,HERSHEY,PA 17033, USA.		Landis, J. Richard/A-9330-2010	Landis, J Richard/0000-0001-8099-0988	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025973] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 25973] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; CHI EM, 1989, J AM STAT ASSOC, V84, P452, DOI 10.2307/2289929; Christensen C., 1991, AM J MED B, V5, p1S; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DHUPER S, 1990, J CLIN ENDOCR METAB, V71, P1083, DOI 10.1210/jcem-71-5-1083; GALLAGHER JC, 1987, J BONE MINER RES, V2, P491; GILSANZ V, 1988, CALCIFIED TISSUE INT, V43, P260, DOI 10.1007/BF02555144; GLASTRE C, 1990, J CLIN ENDOCR METAB, V70, P1330, DOI 10.1210/jcem-70-5-1330; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HEYSE SP, 1990, CALCIFIED TISSUE INT, V46, P289, DOI 10.1007/BF02563817; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; KATZMAN DK, 1991, J CLIN ENDOCR METAB, V73, P1332, DOI 10.1210/jcem-73-6-1332; KELLY PJ, 1990, J BONE MINER RES, V5, P1169; LLOYD T, 1992, J CLIN ENDOCR METAB, V75, P383, DOI 10.1210/jc.75.2.383; LLOYD T, 1992, J NUCL MED, V33, P1143; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; MATKOVIC V, 1992, AM J CLIN NUTR, V55, P992, DOI 10.1093/ajcn/55.5.992; MAZESS RB, 1990, BONE MINER, V11, P347, DOI 10.1016/0169-6009(90)90030-J; MAZESS RB, 1987, BONE MINER, V2, P211; MILLER JZ, 1988, AM J CLIN NUTR, V48, P1291, DOI 10.1093/ajcn/48.5.1291; NILSSON R, 1991, INT J EPIDEMIOL, V20, P1018, DOI 10.1093/ije/20.4.1018; OBRANT KJ, 1989, CALCIFIED TISSUE INT, V44, P157, DOI 10.1007/BF02556558; OTT SM, 1990, J CLIN ENDOCR METAB, V71, pA1082; PACIFICI R, 1990, J CLIN ENDOCR METAB, V70, P705, DOI 10.1210/jcem-70-3-705; PONDER SW, 1990, AM J DIS CHILD, V144, P1346, DOI 10.1001/archpedi.1990.02150360072023; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; RENCKEN ML, 1991, CALCIFIED TISSUE INT, V48, P245, DOI 10.1007/BF02556375; SANTNER SJ, 1981, CLIN CHEM, V27, P1892; SCHAADT O, 1988, CALCIFIED TISSUE INT, V42, P71, DOI 10.1007/BF02556337; SMITH KT, 1987, CALCIFIED TISSUE INT, V41, P351, DOI 10.1007/BF02556676; Sowers Maryfran, 1991, Annals of Epidemiology, V1, P245; THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060; TURNER JG, 1992, NEW ZEAL MED J, V105, P95; WHITE CM, 1992, AM J DIS CHILD, V146, P31, DOI 10.1001/archpedi.1992.02160130033016; 1988, SAS STAT USERS GUIDE, P1028; NUTRIONIST 3 VERSION; 1990, S PLUS REFERENCE MAN	40	376	387	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					841	844		10.1001/jama.270.7.841	http://dx.doi.org/10.1001/jama.270.7.841			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340983				2022-12-28	WOS:A1993LR61200029
J	WILIMAS, JA; FLYNN, PM; HARRIS, S; DAY, SW; SMITH, R; CHESNEY, PJ; RODMAN, JH; EGUIGUREN, JM; FAIRCLOUGH, DL; WANG, WC				WILIMAS, JA; FLYNN, PM; HARRIS, S; DAY, SW; SMITH, R; CHESNEY, PJ; RODMAN, JH; EGUIGUREN, JM; FAIRCLOUGH, DL; WANG, WC			A RANDOMIZED STUDY OF OUTPATIENT TREATMENT WITH CEFTRIAXONE FOR SELECTED FEBRILE CHILDREN WITH SICKLE-CELL DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YOUNG-CHILDREN; MORTALITY; ILLNESS; INFANTS	Background. Because of their susceptibility to pneumococcal sepsis, children with sickle cell disease and fever are usually hospitalized for antibiotic therapy. Outpatient treatment may be a safe and less expensive alternative for selected patients. Methods. After evaluation in the emergency room, children ranging from 6 months to 12 years of age who had sickle hemoglobinopathies and temperatures exceeding 38.5-degrees-C were randomly assigned to treatment as either inpatients or outpatients. We excluded from randomization children at higher risk of sepsis (as defined by specific criteria, including temperature above 40-degrees-C, white-cell count below 5000 per cubic millimeter or above 30,000 per cubic millimeter, and the presence of pulmonary infiltrates) or with complications of sickle cell disease (such as a hemoglobin level below 5 g per deciliter, dehydration, or severe pain); these children were treated as inpatients. All patients received an initial intravenous dose of ceftriaxone (50 mg per kilogram of body weight). Those treated as outpatients returned 24 hours later for a second dose of ceftriaxone, whereas the inpatients were treated as directed by their physicians. Results. None of the 86 patients (with a total of 98 febrile episodes) in the randomized groups had sepsis, as compared with 6 of the 70 patients (7 of 86 episodes) excluded because of higher risk (P = 0.004). Among the 44 children (50 episodes) assigned to outpatient treatment, there were 11 hospitalizations (22 percent of episodes) within two weeks after treatment (95 percent confidence interval, 12 to 36 percent), whereas after inpatient care only a single patient (2 percent of episodes) was rehospitalized. When the randomized groups were compared, outpatient treatment saved a mean of $1,195 per febrile episode. The median hospital stay was 3 days (range, 1 to 6) for the children randomly assigned to inpatient care and 4 days (range, 1 to 18) for the higher-risk children treated as inpatients (P<0.001). Conclusions. With the use of conservative eligibility criteria, at least half the febrile episodes in children with sickle cell disease can be treated safely on an outpatient basis, with substantial reductions in cost.	LEBONHEUR CHILDRENS HOSP & MED CTR, MEMPHIS, TN USA; ST JUDE CHILDRENS RES HOSP, DEPT INFECT DIS, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT SCI, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT ORAL SURG, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	WILIMAS, JA (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA.		Flynn, Patricia M/N-8146-2018		NATIONAL CANCER INSTITUTE [R25CA023944, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765, CA 23944] Funding Source: Medline; NCRR NIH HHS [RR 00211] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLON M, 1990, ARCH INTERN MED, V150, P501, DOI 10.1001/archinte.150.3.501; Bakshi S S, 1991, J Assoc Acad Minor Phys, V2, P80; BAUER TW, 1980, AM J MED, V69, P833, DOI 10.1016/S0002-9343(80)80008-8; BENNETT JV, 1966, APPL MICROBIOL, V14, P170, DOI 10.1128/AEM.14.2.170-177.1966; CHADWICK EG, 1983, J PEDIATR-US, V103, P141, DOI 10.1016/S0022-3476(83)80802-6; Day S, 1992, J Pediatr Nurs, V7, P52; JOSHPE G, 1973, AM J MED, V55, P720, DOI 10.1016/0002-9343(73)90197-6; KAPLAN SL, 1989, J INFECT DIS, V159, P923, DOI 10.1093/infdis/159.5.923; LEIKIN SL, 1989, PEDIATRICS, V84, P500; MCCARTHY PL, 1982, PEDIATRICS, V70, P802; ROGERS ZR, 1990, J PEDIATR-US, V117, P736, DOI 10.1016/S0022-3476(05)83330-X; SCHAAD UB, 1982, ANTIMICROB AGENTS CH, V21, P248, DOI 10.1128/AAC.21.2.248; VICHINSKY EP, 1991, SEMIN HEMATOL, V28, P220; ZARKOWSKY HS, 1986, J PEDIATR-US, V109, P579, DOI 10.1016/S0022-3476(86)80216-5	14	61	61	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					472	476		10.1056/NEJM199308123290705	http://dx.doi.org/10.1056/NEJM199308123290705			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	8332152	Bronze			2022-12-28	WOS:A1993LR44300005
J	BARSAGI, D; ROTIN, D; BATZER, A; MANDIYAN, V; SCHLESSINGER, J				BARSAGI, D; ROTIN, D; BATZER, A; MANDIYAN, V; SCHLESSINGER, J			SH3 DOMAINS DIRECT CELLULAR-LOCALIZATION OF SIGNALING MOLECULES	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; RECEPTOR TYROSINE KINASES; ACTIN-BINDING PROTEIN; EGF RECEPTOR; ESCHERICHIA-COLI; POINT MUTATION; PHOSPHORYLATION; SITE; GAP; TRANSDUCTION	In this study we describe the cellular distribution of the SH2 and SH3 domains of phospholipase C-gamma (PLC-gamma) and of the adaptor protein GRB2 following their microinjection into living rat embryo fibroblasts. Using immunofluorescence microscopy, we show that a truncated protein composed of the SH2 and SH3 domains of PLC-gamma was localized to the actin cytoskeleton. A similar localization pattern was observed when only the SH3 domain of PLC-gamma was microinjected. In contrast, a truncated protein composed of only the SH2 domains of PLC-gamma exhibited diffuse cytoplasmic distribution. Microinjected GRB2 protein was localized primarily to membrane ruffles, as was GRB2 protein containing SH2 loss-of-function point mutations. Hence, the localization of GRB2 to membrane ruffles does not require interaction with tyrosine-phosphorylated moieties. However, GRB2 proteins with SH3 loss-of-function point mutations exhibited diffuse cytoplasmic distribution. These results indicate that SH3 domains are responsible for the targeting of signaling molecules to specific subcellular locations.	NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	BARSAGI, D (corresponding author), COLD SPRING HARBOR LAB,1 BUNGTOWN RD,COLD SPRING HARBOR,NY 11724, USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [R01CA055360, R37CA055360, P01CA046370] Funding Source: NIH RePORTER; NCI NIH HHS [CA46370, CA55360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HIRAI J, 1990, MOL CELL BIOL, V10, P1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WANG K, 1982, METHOD ENZYMOL, V85, P514	41	336	346	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					83	91		10.1016/0092-8674(93)90296-3	http://dx.doi.org/10.1016/0092-8674(93)90296-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334708				2022-12-28	WOS:A1993LN62500009
J	RAWLINGS, DJ; SAFFRAN, DC; TSUKADA, S; LARGAESPADA, DA; GRIMALDI, JC; COHEN, L; MOHR, RN; BAZAN, JF; HOWARD, M; COPELAND, NG; JENKINS, NA; WITTE, ON				RAWLINGS, DJ; SAFFRAN, DC; TSUKADA, S; LARGAESPADA, DA; GRIMALDI, JC; COHEN, L; MOHR, RN; BAZAN, JF; HOWARD, M; COPELAND, NG; JENKINS, NA; WITTE, ON			MUTATION OF UNIQUE REGION OF BRUTONS TYROSINE KINASE IN IMMUNODEFICIENT XID MICE	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; B-CELLS; LYMPHOCYTES-B; BONE-MARROW; CHROMOSOME; EXPRESSION; GENE	The cytoplasmic tyrosine kinase, Bruton's tyrosine kinase (Btk, formerly bpk or atk), is crucial for B cell development. Loss of kinase activity results in the human immunodeficiency, X-linked agammaglobulinemia, characterized by a failure to produce B cells. In the murine X-linked immunodeficiency (XID), B cells are present but respond abnormally to activating signals. The Btk gene, btk, was mapped to the xid region of the mouse X chromosome by interspecific backcross analysis. A single conserved residue within the amino terminal unique region of Btk was mutated in XID mice. This change in xid probably interferes with normal B cell signaling mediated by Btk protein interactions.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; DNAX RES INST MOLEC & CELLULAR BIOL INC,MOLEC & CELLULAR BIOL RES INST,PALO ALTO,CA 94304	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Largaespada, David/C-9832-2014; Jones, Jeffrey A/E-9827-2013; Bazan, J. Fernando/B-4562-2010		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036834] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIAMS NIH HHS [AR36834] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENNER SA, 1992, CURR OPIN STRUC BIOL, V2, P402; BROWN SDM, 1992, MAMM GENOME, V3, pS274, DOI 10.1007/BF00648438; CHUNG HY, 1992, J IMMUNOL, V149, P3456; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; CONLEY ME, 1985, J IMMUNOL, V134, P3070; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEFRANCO AL, 1992, EUR J BIOCHEM, V210, P381, DOI 10.1111/j.1432-1033.1992.tb17432.x; FORRESTER LM, 1987, J EXP MED, V165, P949, DOI 10.1084/jem.165.4.949; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; Green EL, 1981, GENETICS PROBABILITY, P77; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; Hardy R R, 1990, Semin Immunol, V2, P197; HARDY RR, 1983, NATURE, V306, P270, DOI 10.1038/306270a0; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HILLYARD AL, 1992, MOUSE GENOME, V90, P8; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KITOSHI Y, IN PRESS INT IMMKUNO; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MOSIER DE, 1985, J MOL CELL IMMUNOL, V2, P70; NAHM MH, 1983, J EXP MED, V158, P920, DOI 10.1084/jem.158.3.920; RAWLINGS DE, UNPUB; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROST B, 1992, NATURE, V360, P540, DOI 10.1038/360540b0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; TAKEMORI T, 1987, EMBO J, V6, P951, DOI 10.1002/j.1460-2075.1987.tb04844.x; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WEISS R, 1984, RNA TUMOR VIRUSES MO; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WICKER LS, 1986, CURR TOP MICROBIOL, V124, P87; [No title captured]; 1990, HDB GENETICALLY STAN, P9	40	782	801	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					358	361		10.1126/science.8332901	http://dx.doi.org/10.1126/science.8332901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332901				2022-12-28	WOS:A1993LM67800038
J	BOWMAN, MA; SCHWENK, TL				BOWMAN, MA; SCHWENK, TL			FAMILY MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV MICHIGAN,SCH MED,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan	BOWMAN, MA (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27103, USA.		bowman, marjorie a/F-7235-2013	bowman, marjorie a/0000-0002-1945-9212				[Anonymous], 1992, PEDIATRICS, V89, P1120; BROWN BG, 1992, EUR HEART J, V13, P17, DOI 10.1093/eurheartj/13.suppl_B.17; FLITCRAFT AH, 1992, ARCH FAM MED, V1, P39; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FRIEDMAN LS, 1992, ARCH INTERN MED, V152, P1186, DOI 10.1001/archinte.152.6.1186; HALL CB, 1992, PEDIATRICS, V90, P274; KEMPER KJ, 1992, AM J DIS CHILD, V146, P343, DOI 10.1001/archpedi.1992.02160150083027; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROST K, 1992, ARCH INTERN MED, V152, P381, DOI 10.1001/archinte.152.2.381; SAYRE JW, 1992, AM J DIS CHILD, V146, P1275, DOI 10.1001/archpedi.1992.02160230033010; SCHOEN EJ, 1992, AM FAM PHYSICIAN, V45, P2179; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; Shi L, 1992, J Health Care Poor Underserved, V3, P321; STERN MP, 1992, DIABETES CARE, V15, P638, DOI 10.2337/diacare.15.5.638; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; 1991, NEW ENGL J MED, V325, P293	20	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					205	206		10.1001/jama.270.2.205	http://dx.doi.org/10.1001/jama.270.2.205			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315732				2022-12-28	WOS:A1993LL36800018
J	FOEGE, WH				FOEGE, WH			PREVENTIVE MEDICINE AND PUBLIC-HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FOEGE, WH (corresponding author), EMORY UNIV,CARTER CTR,ATLANTA,GA 30322, USA.							[Anonymous], 1992, AIDS WORLD; CHU SY, 1992, AM J PUBLIC HEALTH, V82, P220, DOI 10.2105/AJPH.82.2.220; FOEGE WH, 1993, 3RD ANN PUBL HLTH FO; JONES NE, 1992, AM J PUBLIC HEALTH, V82, P112, DOI 10.2105/AJPH.82.1.112; LUJAN CC, 1992, JAMA-J AM MED ASSOC, V267, P1384, DOI 10.1001/jama.267.10.1384; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V267, P1649, DOI 10.1001/jama.267.12.1649; IN PRESS 1993 WORLD; IN PRESS ATLANTA PRO; 1993, STATE WORLDS CHILDRE	10	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					251	252		10.1001/jama.270.2.251	http://dx.doi.org/10.1001/jama.270.2.251			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315752				2022-12-28	WOS:A1993LL36800039
J	KLEIN, JD; MCANARNEY, ER				KLEIN, JD; MCANARNEY, ER			ADOLESCENT MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											KLEIN, JD (corresponding author), UNIV ROCHESTER,SCH MED,ROCHESTER,NY 14627, USA.			Klein, Jonathan/0000-0003-4185-1998				BENNET D, 1992, 8TH INT C AIDS AMST; FRANCIS DP, 1992, JAMA-J AM MED ASSOC, V268, P1444, DOI 10.1001/jama.268.11.1444; Howard, 1992, Adolesc Med, V3, P181; JEMMOTT JB, 1992, J ADOLESCENT HEALTH, V13, P512, DOI 10.1016/1054-139X(92)90016-5; MICHAUD PA, 1992, 8TH INT C AIDS AMST; MILLSTEIN SG, 1992, ADOLESCENT HLTH PROM; RICHMOND JB, 1992, B NEW YORK ACAD MED, V68, P32; WEINSTEIN E, 1991, ADOLESCENCE, V26, P331; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; 1992, GUIDELINES ADOLESCEN; 1992, BRIGHT FUTURES; 1991, 1990 US DEPT HLTH HU; 1992, MMWR MORB MORTAL WKL, V41, P945; 1991, ADOLESCENT HLTH, V1	14	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					186	188		10.1001/jama.270.2.186	http://dx.doi.org/10.1001/jama.270.2.186			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315723				2022-12-28	WOS:A1993LL36800009
J	PETER, L				PETER, L			ABC OF ONE TO 7 - SERVICES FOR CHILDREN - PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					117	120		10.1136/bmj.307.6896.117	http://dx.doi.org/10.1136/bmj.307.6896.117			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343709	Green Published, Bronze			2022-12-28	WOS:A1993LM58500035
J	STEINE, S				STEINE, S			WILL IT HURT, DOCTOR - FACTORS PREDICTING PATIENTS EXPERIENCE OF PAIN DURING DOUBLE-CONTRAST EXAMINATION OF THE COLON	BRITISH MEDICAL JOURNAL			English	Article											STEINE, S (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO 2,NORWAY.							FORK FT, 1982, DIAGNOSTIC VALUE LAR; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; MORIARTY KJ, 1992, BRIT MED J, V304, P1166, DOI 10.1136/bmj.304.6835.1166; STEINE S, 1992, Scandinavian Journal of Primary Health Care, V10, P134, DOI 10.3109/02813439209014050; 1990, INCIDENCE CANCER NOR	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					100	100		10.1136/bmj.307.6896.100	http://dx.doi.org/10.1136/bmj.307.6896.100			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343703	Green Published, Bronze			2022-12-28	WOS:A1993LM58500025
J	HE, SY; HUANG, HC; COLLMER, A				HE, SY; HUANG, HC; COLLMER, A			PSEUDOMONAS-SYRINGAE PV SYRINGAE HARPIN (PSS) - A PROTEIN THAT IS SECRETED VIA THE HRP PATHWAY AND ELICITS THE HYPERSENSITIVE RESPONSE IN PLANTS	CELL			English	Article							AVIRULENCE GENE; ERWINIA-RUBRIFACIENS; CULTIVAR SPECIFICITY; YOP PROTEINS; CLUSTER; TOBACCO; PATHOGENICITY; MEMBRANE; CLONING; CELLS	The ability of P. syringae to elicit the hypersensitive response in nonhost plants or pathogenesis in hosts is controlled by hrp genes. The P. syringae pv. syringae 61 hrpZ gene encodes harpin(Pss), a 34.7 kd extracellular protein that elicits hypersensitive necrosis in tobacco and other plants. Harpin(Pss) is heat stable, glycine rich, dissimilar in amino acid sequence to any known protein, produced only in apoplastic fluid-mimicking minimal media, and secreted in a HrpH-dependent manner. The carboxy-terminal 148 amino acid portion of harpin(Pss) contains two directly repeated sequences of GGGLGTP and QTGT and is sufficient and necessary for elicitor activity. The necrosis elicited by harpin(Pss) is an active response of the plant, which can be inhibited by alpha-amanitin, cycloheximide, lanthanum chloride, or sodium vanadate.	CORNELL UNIV,DEPT PLANT PATHOL,ITHACA,NY 14853; NATL CHUNGHSING UNIV,AGR BIOTECHNOL LABS,TAICHUNG 40227,TAIWAN	Cornell University; National Chung Hsing University				He, Sheng Yang/0000-0003-1308-498X				ALLAOUI A, 1993, MOL MICROBIOL, V7, P59, DOI 10.1111/j.1365-2958.1993.tb01097.x; ALLEN C, 1991, MOL PLANT MICROBE IN, V4, P147, DOI 10.1094/MPMI-4-147; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARLAT M, 1991, MOL PLANT MICROBE IN, V4, P593, DOI 10.1094/MPMI-4-593; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AZAD HR, 1984, PHYTOPATHOLOGY, V74, P61, DOI 10.1094/Phyto-74-61; BEER SV, 1993, ADV MOL GENETICS PLA, V2, P281; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; COLLMER A, 1993, IN PRESS BIOTECHNOLO; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; GALAN JE, 1992, J BACTERIOL, V174, P4338; GARDNER JM, 1976, J BACTERIOL, V127, P451, DOI 10.1128/JB.127.1.451-460.1976; GENIN S, 1993, MOL GENETICS PLANT M, V2, P259; GOUGH CL, 1992, MOL PLANT MICROBE IN, V5, P384, DOI 10.1094/MPMI-5-384; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HE SY, 1991, J BACTERIOL, V173, P4310, DOI 10.1128/JB.173.14.4310-4317.1991; HIRANO SS, 1990, ANNU REV PHYTOPATHOL, V28, P155, DOI 10.1146/annurev.py.28.090190.001103; HUANG HC, 1991, MOL PLANT MICROBE IN, V4, P469, DOI 10.1094/MPMI-4-469; HUANG HC, 1988, J BACTERIOL, V170, P4748, DOI 10.1128/jb.170.10.4748-4756.1988; HUANG HC, 1992, J BACTERIOL, V174, P6878, DOI 10.1128/JB.174.21.6878-6885.1992; HUANG HC, 1993, IN PRESS MOL PLANT M; HUANG Y, 1989, Molecular Plant-Microbe Interactions, V2, P132, DOI 10.1094/MPMI-2-132; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KEEN NT, 1990, MOL PLANT MICROBE IN, V3, P112, DOI 10.1094/MPMI-3-112; KEEN NT, 1981, PHYSIOL PLANT PATHOL, V18, P325; KING EO, 1954, J LAB CLIN MED, V44, P301; KLEMENT Z, 1963, NATURE, V199, P299, DOI 10.1038/199299b0; KLEMENT Z, 1964, PHYTOPATHOLOGY, V54, P474; Klement Z., 1982, PHYTOPATHOGENIC PROK, V2, P149; KNOOP V, 1991, J BACTERIOL, V173, P7142, DOI 10.1128/jb.173.22.7142-7150.1991; KOBAYASHI DY, 1989, P NATL ACAD SCI USA, V86, P157, DOI 10.1073/pnas.86.1.157; LABY RJ, 1992, MOL PLANT MICROBE IN, V5, P412, DOI 10.1094/MPMI-5-412; LINDGREN PB, 1988, MOL GEN GENET, V211, P499, DOI 10.1007/BF00425707; LINDGREN PB, 1986, J BACTERIOL, V168, P512, DOI 10.1128/jb.168.2.512-522.1986; LINDOW SE, 1993, IN PRESS BIOTECHNOLO; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; NIEPOLD F, 1985, P NATL ACAD SCI USA, V82, P406, DOI 10.1073/pnas.82.2.406; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAHME LG, 1992, J BACTERIOL, V174, P3499, DOI 10.1128/JB.174.11.3499-3507.1992; Sambrook J, 1989, MOL CLONING LABORATO; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHOTTENSTOMA IMJ, 1988, PHYSIOL MOL PLANT P, V33, P59, DOI 10.1016/0885-5765(88)90043-4; SEQUEIRA L, 1976, SPECIFICITY PLANT DI, P289; SEQUEIRA L, 1979, USDA TECH B, V1586, P111; Silhavy T. J., 1984, EXPT GENE FUSIONS; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; TARTOF KD, 1987, FOCUS, V9, P12; TURNER JG, 1974, PHYTOPATHOLOGY, V64, P885, DOI 10.1094/Phyto-64-885; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; WEI ZM, 1991, ADV MOL GENETICS PLA, P53; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WILLIS DK, 1991, MOL PLANT MICROBE IN, V4, P132, DOI 10.1094/MPMI-4-132; XIAO YX, 1992, J BACTERIOL, V174, P1734, DOI 10.1128/jb.174.6.1734-1741.1992; YUCEL I, 1989, APPL ENVIRON MICROB, V55, P1724, DOI 10.1128/AEM.55.7.1724-1729.1989; [No title captured]	62	397	462	2	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1255	1266		10.1016/0092-8674(93)90354-S	http://dx.doi.org/10.1016/0092-8674(93)90354-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324821	Bronze			2022-12-28	WOS:A1993LL20900003
J	GODIN, IE; GARCIAPORRERO, JA; COUTINHO, A; DIETERLENLIEVRE, F; MARCOS, MAR				GODIN, IE; GARCIAPORRERO, JA; COUTINHO, A; DIETERLENLIEVRE, F; MARCOS, MAR			PARAAORTIC SPLANCHNOPLEURA FROM EARLY MOUSE EMBRYOS CONTAINS B1A CELL PROGENITORS	NATURE			English	Article							YOLK-SAC; B-CELLS; MONOCLONAL-ANTIBODY; STEM-CELLS; ORIGIN; LYMPHOPOIESIS; ONTOGENY; SYSTEM; MICE	DEFINITIVE erythropoiesis in birds originates from stem cells that emerge in the splanchnopleural mesoderm near the embryonic aorta1-4. The yolk sac is still generally held to be the unique provider of haematopoietic stem cells during mammalian ontogeny5, although there may be an alternative intraembryonic source of stem cells in the mouse fetus6,7. Here we search for a possible non-yolk-sac source of stem cells by grafting intraembryonic splanchnopleura from 10- to 18-somite mouse embryos into adult immunodeficient SCID mice. We find significant amounts of donor-derived serum IgM, normal numbers of IgM-secreting plasma cells, and the B1a (IgM(bright)(a)B220(dull)CD5+) cell subset to be fully reconstituted by donor progenitors 3 to 6 months after engraftment. The haematogenic capacity revealed in our experiments is present in a previously unrecognized site, the earliest described in the embryo, 12 hours before fetal liver colonization.	COLL FRANCE, F-94130 NOGENT SUR MARNE, FRANCE; UNIV CANTABRIA, DEPT ANAT & CELL BIOL, E-39011 SANTANDER, SPAIN; INST PASTEUR, CNRS, UNITE IMMUNOBIOL 357, F-75724 PARIS 15, FRANCE; UNIV SALAMANCA, DEPT MED, E-37007 SALAMANCA, SPAIN	UDICE-French Research Universities; PSL Research University Paris; College de France; Universidad de Cantabria; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Salamanca	GODIN, IE (corresponding author), CNRS, INST EMBRYOL CELLULAIRE, F-94130 NOGENT SUR MARNE, FRANCE.		GODIN, Isabelle/K-5769-2013	GODIN, Isabelle/0000-0001-8577-8388; Coutinho, Antonio/0000-0002-0857-9227				COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; CORMIER F, 1988, DEVELOPMENT, V102, P279; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DIETERLENLIEVRE F, 1984, DEV COMP IMMUNOL S, V3, P75; FOSTER I, 1987, EUR J IMMUNOL, V17, P521; GRANDIEN A, 1992, INT IMMUNOL, V4, P1153, DOI 10.1093/intimm/4.10.1153; HARDY RR, 1991, P NATL ACAD SCI USA, V88, P11550, DOI 10.1073/pnas.88.24.11550; HAYAKAWA K, 1988, ANNU REV IMMUNOL, V6, P197, DOI 10.1146/annurev.iy.06.040188.001213; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; KANTOR AB, 1992, P NATL ACAD SCI USA, V89, P3320, DOI 10.1073/pnas.89.8.3320; Kroese FGM, 1989, INT IMMUNOL, V1, P75, DOI 10.1093/intimm/1.1.75; LASSILA O, 1978, NATURE, V272, P353, DOI 10.1038/272353a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MARCOS MAR, 1992, ANN NY ACAD SCI, V651, P433; MARCOS MAR, 1991, SCAND J IMMUNOL, V34, P129, DOI 10.1111/j.1365-3083.1991.tb01529.x; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; PAIGE CJ, 1979, J EXP MED, V150, P548, DOI 10.1084/jem.150.3.548; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1; SOLVASON N, 1991, INT IMMUNOL, V3, P543, DOI 10.1093/intimm/3.6.543	22	309	314	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	1993	364	6432					67	70		10.1038/364067a0	http://dx.doi.org/10.1038/364067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316299				2022-12-28	WOS:A1993LK81800059
J	GUNDERSON, SI; BEYER, K; MARTIN, G; KELLER, W; BOELENS, WC; MATTAJ, IW				GUNDERSON, SI; BEYER, K; MARTIN, G; KELLER, W; BOELENS, WC; MATTAJ, IW			THE HUMAN U1A SNRNP PROTEIN REGULATES POLYADENYLATION VIA A DIRECT INTERACTION WITH POLY(A) POLYMERASE	CELL			English	Article							PRE-MESSENGER-RNA; SPLICE-SITE SELECTION; SACCHAROMYCES-CEREVISIAE; SPECIFICITY FACTOR; BINDING DOMAIN; A-PROTEIN; CLEAVAGE; INVITRO; AAUAAA; RIBONUCLEOPROTEIN	The human U1 snRNP-specific U1A protein autoregulates its production by binding its own pre-mRNA and inhibiting polyadenylation. The mechanism of this regulation has been elucidated by in vitro studies. U1A protein is shown not to prevent either binding of cleavage and polyadenylation specificity factor (CPSF) to its recognition sequence (AUUAAA) or to prevent cleavage of U1A pre-mRNA. Instead, U1A protein bound to U1A pre-mRNA inhibits both specific and nonspecific polyadenylation by mammalian, but not by yeast, poly(A) polymerase (PAP). Domains are identified in both proteins whose removal uncouples the polyadenylation activity of mammalian PAP from its inhibition via RNA-bound U1A protein. Finally, U1A protein is shown to specifically interact with mammalian PAP in vitro. The possibility that this interaction may reflect a broader role of the U1A protein in polyadenylation is discussed.	UNIV BASEL,BIOZENTRUM,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND	University of Basel	GUNDERSON, SI (corresponding author), EUROPEAN MOLEC BIOL LAB,GENE EXPRESS PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Boelens, Wilbert/D-8877-2012	Mattaj, Iain/0000-0002-5537-8284				BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P846, DOI 10.1128/MCB.10.2.846; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GIESELMANN V, 1989, P NATL ACAD SCI USA, V86, P9436, DOI 10.1073/pnas.86.23.9436; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GORLACH M, 1993, MOL BIOL REP, V18, P73, DOI 10.1007/BF00986759; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HASHIMOTO C, 1986, CELL, V45, P581, DOI 10.1016/0092-8674(86)90290-4; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HSIEH SY, 1991, J VIROL, V65, P6438, DOI 10.1128/JVI.65.12.6438-6446.1991; HUMPHREY T, 1987, EMBO J, V6, P4159, DOI 10.1002/j.1460-2075.1987.tb02762.x; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LIAO XLC, 1993, GENE DEV, V7, P419, DOI 10.1101/gad.7.3.419; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MOORE CL, 1986, EMBO J, V5, P1929, DOI 10.1002/j.1460-2075.1986.tb04446.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NEILSSEN RLH, 1991, GENE, V102, P189; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; RAJU VS, 1988, J BIOL CHEM, V263, P11067; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZARKOWER D, 1986, MOL CELL BIOL, V6, P2317, DOI 10.1128/MCB.6.7.2317	54	185	187	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					531	541		10.1016/0092-8674(94)90116-3	http://dx.doi.org/10.1016/0092-8674(94)90116-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313473				2022-12-28	WOS:A1994MX20700013
J	RABB, H; RAMIREZ, G				RABB, H; RAMIREZ, G			METASTATIC CALCIFICATION OF THE SHOULDER IN CHRONIC-RENAL-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											RABB, H (corresponding author), JAMES A HALEY VET AFFAIRS HOSP,TAMPA,FL 33612, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					695	695						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8345855				2022-12-28	WOS:A1993LU58300004
J	BUNIN, GR; KUIJTEN, RR; BUCKLEY, JD; RORKE, LB; MEADOWS, AT				BUNIN, GR; KUIJTEN, RR; BUCKLEY, JD; RORKE, LB; MEADOWS, AT			RELATION BETWEEN MATERNAL DIET AND SUBSEQUENT PRIMITIVE NEUROECTODERMAL BRAIN-TUMORS IN YOUNG-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURAL-TUBE DEFECTS; EXPLORATORY CASE-CONTROL; UNITED-STATES; RISK-FACTORS; CANCER; MEDULLOBLASTOMA; QUESTIONNAIRE; POPULATION; FOLATE	Background. It has been hypothesized that a high dietary intake of nitrosamines and their precursors, nitrites and nitrates, is a risk factor for brain tumors. Vitamins C and E inhibit the formation of nitrosamines and thus may be protective. Methods. We conducted a case-control study of maternal diet and the risk of primitive neuroectodermal tumors of the brain in children. The case patients were under the age of six years at diagnosis in 1986 to 1989. The controls were selected by random-digit telephone dialing and were matched for age and race to 166 case patients. Telephone interviews with the mothers included questions on the frequency of consumption of alcohol, vitamin and mineral supplements, and 53 foods during pregnancy. Results. Significant protective trends were observed for vegetables (odds ratio for the highest quartile group for intake relative to the lowest, 0.37; P for trend = 0.005), fruits and fruit juices (odds ratio, 0.28; P = 0.003), vitamin A (odds ratio, 0.59; P = 0.03), vitamin C (odds ratio, 0.42; P = 0.009), nitrate (odds ratio, 0.44; P = 0.002), and folate (odds ratio, 0.38; P = 0.005). A nonsignificant trend of increasing risk was observed for nitrosamine (odds ratio, 1.65; P = 0.15). The use of iron (odds ratio, 0.43; P = 0.004), calcium (odds ratio, 0.42; P = 0.05), and vitamin C (odds ratio, 0.35; P = 0.04) supplements at any time during the pregnancy and the use of multivitamins during the first six weeks (odds ratio, 0.56; P = 0.02) were associated with decreased risk. In multivariate analyses, folate, early multivitamin use, and iron supplements generally remained protective. Conclusions. These results do not support the hypothesis that nitrosamines have a role in the development of primitive neuroectodermal tumors in young children, but they do suggest that certain other aspects of maternal diet can influence the risk.	CHILDRENS HOSP PHILADELPHIA,DIV ONCOL,PHILADELPHIA,PA; UNIV PENN,SCH MED,PHILADELPHIA,PA 19104; UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Southern California					NCI NIH HHS [CA 29275, CA 13539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA013539, R01CA029275] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BURCH JD, 1987, J NATL CANCER I, V78, P601; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; HAMMAR N, 1991, INT J EPIDEMIOL, V20, P621, DOI 10.1093/ije/20.3.621; HOWE GR, 1986, AM J EPIDEMIOL, V124, P595, DOI 10.1093/oxfordjournals.aje.a114432; HOWE GR, 1989, CANCER RES, V49, P4349; HUNTER DJ, 1988, AM J EPIDEMIOL, V127, P1240, DOI 10.1093/oxfordjournals.aje.a114916; KUIJTEN RR, 1990, CANCER RES, V50, P2608; Lindsted K D, 1990, Epidemiology, V1, P392, DOI 10.1097/00001648-199009000-00010; Magee P. N., 1976, ACS MONOGR SER, V173, P491; MEALEY J, 1977, J NEUROSURG, V46, P56, DOI 10.3171/jns.1977.46.1.0056; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; OLSON SH, 1992, AM J EPIDEMIOL, V135, P210, DOI 10.1093/oxfordjournals.aje.a116273; PRESTONMARTIN S, 1989, CANCER RES, V49, P6137; PRESTONMARTIN S, 1982, CANCER RES, V42, P5240; ROMIEU I, 1990, AM J EPIDEMIOL, V131, P864, DOI 10.1093/oxfordjournals.aje.a115577; RORKE LB, 1983, J NEUROPATH EXP NEUR, V42, P1, DOI 10.1097/00005072-198301000-00001; Sadler TW, 1985, LANGMANS MED EMBRYOL, P334; SCHOENBERG BS, 1976, AM J EPIDEMIOL, V104, P499, DOI 10.1093/oxfordjournals.aje.a112322; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; Tannenbaum S R, 1980, Ann N Y Acad Sci, V355, P267, DOI 10.1111/j.1749-6632.1980.tb21345.x; WARD EM, 1984, AM J EPIDEMIOL, V120, P582, DOI 10.1093/oxfordjournals.aje.a113920; WATTENBERG LW, 1983, CANCER RES, V43, P2448; WILKENS LR, 1992, AM J EPIDEMIOL, V136, P825, DOI 10.1093/aje/136.7.825; Willett W, 1990, NUTR EPIDEMIOLOGY, P92; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; 1991, LANCET, V338, P131; 1976, AGR HDB, V8; 1985, PHYSICIANS DESK REFE; 1981, HLTH EFFECTS NITRA 1	32	167	169	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					536	541		10.1056/NEJM199308193290804	http://dx.doi.org/10.1056/NEJM199308193290804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8336753	Bronze			2022-12-28	WOS:A1993LR89200004
J	MARUSIC, M				MARUSIC, M			DO ANGELS CRY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					548	548						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331742				2022-12-28	WOS:A1993LP43600001
J	MOLLICA, RF; DONELAN, K; TOR, S; LAVELLE, J; ELIAS, C; FRANKEL, M; BLENDON, RJ				MOLLICA, RF; DONELAN, K; TOR, S; LAVELLE, J; ELIAS, C; FRANKEL, M; BLENDON, RJ			THE EFFECT OF TRAUMA AND CONFINEMENT ON FUNCTIONAL HEALTH AND MENTAL-HEALTH STATUS OF CAMBODIANS LIVING IN THAILAND-CAMBODIA BORDER CAMPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SOUTHEAST-ASIAN REFUGEES; CULTURAL BEREAVEMENT; TORTURE; CARE; WAR; INSTRUMENT; DISABILITY; DEPRESSION; SITUATION	Objective.-To assess the long-term impact of trauma and confinement on the functional health and mental health status of Cambodian displaced persons living on the Thailand-Cambodia border. Design.-Household survey of 993 adults randomly selected from household rosters. Household sample selection by multistage area probability sample. Setting.-Site 2, the largest Cambodian displaced-persons camp on the Thailand-Cambodia border. Participants.-Adults 18 years of age and older selected at random within households; 98% of eligible persons selected agreed to participate. Results.-From 1975 through 1979 (Khmer Rouge regime), more than 85% reported lack of food, water, shelter, and medical care, brainwashing, and forced labor; 54% reported murder of a family member or friend; 36% reported torture; 18% reported head injury; and 17% reported rape or sexual abuse. During the refugee period between 1980 and 1990, 56% reported lack of food or water, 44% reported lack of shelter, 28% reported lack of medical care, 24% reported brainwashing, and 8% reported torture. Since 1980, reports of murder of a family member, head injury, and rape/sexual abuse have decreased to 5%. Reports of experiencing combat situations and shelling attacks have remained consistent between the two time periods, approximately 44% and 30%, respectively. From 1989 to 1990, 25% reported experiencing lack of food or water, and 5% to 10% reported serious injury, combat, and shelling conditions. More than 80% said they were in fair or poor health, felt depressed, and had a number of somatic complaints despite good access to medical services. Fifty-five percent and 15% had symptom scores that correlate with Western criteria for depression and posttraumatic stress disorder, respectively. Fifteen percent to 20% reported health impairments limiting activity, and moderate or severe bodily pain. Despite reported high levels of trauma and symptoms, social and work functioning were well preserved in the majority of respondents. Conclusions.-Reports of extensive trauma, poor health status, and depressive symptoms of this population are of concern in predicting future morbidity and mortality. The health and mental health needs of Cambodian displaced persons and their impact on social and economic behavior should be addressed now that the Cambodians have been repatriated.	HARVARD UNIV,SCH PUBL HLTH,HARVARD PROGRAM REFUGEE TRAUMA,BOSTON,MA 02115; POPULAT COUNCIL,NEW YORK,NY; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; CUNY BERNARD M BARUCH COLL,NEW YORK,NY 10010	Harvard University; Harvard T.H. Chan School of Public Health; Population Council; Harvard University; Harvard T.H. Chan School of Public Health; City University of New York (CUNY) System; Baruch College (CUNY)	MOLLICA, RF (corresponding author), ST ELIZABETH HOSP,INDOCHINESE PSYCHIAT CLIN,77 WARREN ST,BRIGHTON,MA 02135, USA.		Donelan, Karen/R-6162-2019					AGAKHAN S, 1986, REFUGEES DYNAMICS DI; BLENDON RJ, 1991, HEALTH AFFAIR, V10, P216, DOI 10.1377/hlthaff.10.3.216; DIEKSTRA RFW, 1988, PSYCHOSOCIAL MENTAL; DOHRENWEND BP, 1990, PSYCHOL MED, V20, P195, DOI 10.1017/S0033291700013374; EISENBRUCH M, 1992, J NERV MENT DIS, V180, P8, DOI 10.1097/00005053-199201000-00004; EISENBRUCH M, 1991, SOC SCI MED, V33, P673, DOI 10.1016/0277-9536(91)90021-4; Eitinger L., 1964, CONCENTRATION CAMP S; FLAHERTY JA, 1988, J NERV MENT DIS, V176, P257; GLASS RI, 1990, LANCET, V335, P868; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; HANNUM H, 1989, HUM RIGHTS QUART, V11, P82, DOI 10.2307/761936; HEARST N, 1986, NEW ENGL J MED, V314, P620, DOI 10.1056/NEJM198603063141005; IDLER EL, 1991, J GERONTOL SOC SCI, V2, P55; KHASIANI SA, 1990, INT MIGR, V28, P369, DOI 10.1111/j.1468-2435.1990.tb00482.x; Kiljunen K., 1984, KAMPUCHEA DECADE GEN; KILJUNEN K, 1985, B CONCERNED ASIAN SC, P1749; KINZIE JD, 1990, AM J PSYCHIAT, V147, P913; Kish L, 1965, SURVEY SAMPLING; KLAUS K, 1992, AM J PSYCHIAT, V149, P337; KLERMAN GL, 1989, ARCH GEN PSYCHIAT, V46, P856; KROLL J, 1989, AM J PSYCHIAT, V146, P1592; LYNCH JF, 1989, BORDER KHMER DEMOGRA; MECHANIC D, 1986, PSYCHOL MED, V16, P1, DOI 10.1017/S0033291700002476; MOLLICA R, 1991, PSYCHOL ASSESSMENT, V3, P1; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P497; MOLLICA RF, 1989, PSYCHIAT CLIN N AM, V12, P363; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P1567; MOLLICA RF, 1989, COMMUNITY CONFINEMEN; MOLLICA RF, 1989, TURNING POINT KHMER; MUSCAT RJ, 1989, CAMBODIA POST SETTLE; NGOR H, 1987, CAMBODIAN ODYSSEY; Reynell J., 1989, POLITICAL PAWNS REFU; ROGGE JR, 1992, REPATRIATIOON CONFLI; SANDLER RH, 1987, MED CARE REFUGEES; SEGAL J, 1976, INT SOC SCI J, V28, P593; STEIN BN, 1986, INT MIGR REV, V20, P264, DOI 10.2307/2546035; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; SZYMUSIAK M, 1986, STONES CRY OUT CAMBO; TAYLOR DC, 1979, LANCET, V2, P1008; THORN L, 1988, RICE TRUCK PADDY FIE; THYGESEN P, 1970, DAN MED BULL, V17, P65; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; URSANO RJ, 1990, MIL MED, V155, P176, DOI 10.1093/milmed/155.4.176; VERNEZ G, 1991, AM PSYCHOL, V46, P627, DOI 10.1037/0003-066X.46.6.627; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; 1991, AMNESTY INT REPORT, P224; 1987, DIAGNOSTIC STATISTIC; 1992, S23613 UN SEC COUNC; 1986, THAILAND TORTURE 3 K, P1; 1990, ECN619912 UN EC SOC; 1985, MONTHLY PROTECTION R; 1987, SEEKING SHELTER CAMB; 1990, ECN619914 UN EC SOC	55	239	240	0	35	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					581	586		10.1001/jama.270.5.581	http://dx.doi.org/10.1001/jama.270.5.581			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331755				2022-12-28	WOS:A1993LP43600021
J	LEVINSON, W; KAUFMAN, K; BICKEL, J				LEVINSON, W; KAUFMAN, K; BICKEL, J			PART-TIME FACULTY IN ACADEMIC MEDICINE - PRESENT STATUS AND FUTURE CHALLENGES	ANNALS OF INTERNAL MEDICINE			English	Article							WOMEN; PHYSICIANS; SCHOOLS; CAREER	Objective: To determine the number, personal and professional characteristics, and attitudes of part-time medicine faculty Participants: Part-time faculty in departments of medicine were identified by the chairs of medicine and faculty roster representatives of the Association of American Medical Colleges for each U.S. medical school and by a survey of faculty. Measurements: A 79-item questionnaire including questions about working conditions, attitudes toward professional and personal issues. and institutional policies. Results: A total of 245 eligible questionnaires were returned (69% of the estimated number of eligible part-time faculty). Sixty-three percent were men and 27% were women. Women faculty worked an average of 35 h/wk, combining their careers with childrearing, whereas men worked 51 h/wk, divided between their faculty position and private practice. Respondents' work time was devoted to teaching and patient care, with no time dedicated for research. Most faculty (86%) were in nontenured track positions; approximately one half (47%) developed the position themselves. Only 8% reported that existing institutional policies allowed part-time faculty more time to reach promotion and tenure standards. A high degree of career satisfaction existed (mean score, 8.6 on a 10-point scale) even though faculty believe that part-time status makes promotion more difficult and negatively influences colleagues' perceptions of them. Conclusion: We estimate that more than 400 faculty work part time in departments of medicine in U.S. medical schools. The majority are men who combine academic careers with private practice. Most part-time faculty work as clinician/teachers in nontenure track positions and are satisfied with their careers.	OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA; CLAREMONT GRAD SCH, CLAREMONT, CA 91711 USA; ASSOC AMER MED COLL, WASHINGTON, DC 20036 USA	Oregon Health & Science University; Claremont Colleges; Claremont Graduate School; Association of American Medical Colleges								ANGELL M, 1981, NEW ENGL J MED, V304, P1161, DOI 10.1056/NEJM198105073041908; Baucom-Copeland S, 1983, J Am Med Womens Assoc (1972), V38, P103; BICKEL J, 1991, ACAD MED, V66, P249, DOI 10.1097/00001888-199105000-00002; BICKEL J, 1988, NEW ENGL J MED, V319, P1579, DOI 10.1056/NEJM198812153192405; BICKEL J, 1991, WOMEN MED STATISTICS; Bonar J W, 1982, J Am Med Womens Assoc (1972), V37, P300; BONAR JW, 1982, J AM MED WOMEN ASSOC, V37, P308; BOWMAN MA, 1985, STRESS WOMEN PHYSICI; Cartwright L K, 1987, J Am Med Womens Assoc (1972), V42, P142; CARTWRIGHT LK, 1987, J AM MED WOMEN ASSOC, V42, P147; DIMOND EG, 1983, JAMA-J AM MED ASSOC, V249, P207, DOI 10.1001/jama.249.2.207; EISENBERG C, 1989, NEW ENGL J MED, V321, P1542, DOI 10.1056/NEJM198911303212210; FEIN OT, 1991, ACAD MED, V66, P694, DOI 10.1097/00001888-199111000-00014; Fletcher S W, 1982, Pharos Alpha Omega Alpha Honor Med Soc, V45, P2; GRISSO JA, 1991, ANN INTERN MED, V114, P43, DOI 10.7326/0003-4819-114-1-43; HEINS M, 1983, JAMA-J AM MED ASSOC, V249, P209, DOI 10.1001/jama.249.2.209; JONES RF, 1987, J MED EDUC, V62, P444; KLASS P, 1988, NY TIMES MAGAZI 0410, P32; KLETKE PR, 1990, AM J PUBLIC HEALTH, V80, P300, DOI 10.2105/AJPH.80.3.300; KRAMER JP, 1986, INTERNIST BERLIN, V27, P13; LEVINSON W, 1989, NEW ENGL J MED, V321, P1511, DOI 10.1056/NEJM198911303212205; MARDEN WD, 1988, PHYSICIAN SUPPLY UTI; MASON NA, 1991, AM J HOSP PHARM, V48, P85, DOI 10.1093/ajhp/48.1.85; MOM, 1987, JAMA-J AM MED ASSOC, V257, P2594; NADELSON CC, 1979, J AM MED WOMEN ASSOC, V34, P400; ORDWAY JE, 1980, J AM MED WOMEN ASSOC, V35, P240; Potter R L, 1983, J Am Med Womens Assoc (1972), V38, P98; SINAL S, 1988, J MED EDUC, V63, P531; Wheeler R, 1990, J Am Med Womens Assoc (1972), V45, P47; WILSON MP, 1987, YALE J BIOL MED, V60, P273; 1991, ANN INTERN MED, P63; 1980, POLICY DOCUMENTS REP, P52; 1986, WOMEN PHYSICIANS LEA	33	53	53	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					220	225		10.7326/0003-4819-119-3-199308010-00008	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8323091				2022-12-28	WOS:A1993LU90300008
J	WARNER, EA				WARNER, EA			COCAINE ABUSE	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; CRACK COCAINE; PULMONARY-EDEMA; SEXUAL-BEHAVIOR; INTRAVENOUS COCAINE; ALKALOIDAL COCAINE; ANTERIOR-PITUITARY; INDUCED SEIZURES; DRUG-ABUSE	Purpose: To discuss the forms of cocaine that are available and their methods Data Sources: Pertinent articles were identified through a MEDLINE search of the English-language literature from 1986 to 1992 and through a manual search of bibliographies of all identified articles. Study Selection: All articles describing complications of cocaine use were either case reports, review articles, or small series. No controlled studies on the subject were available. Data Synthesis: A qualitative description of reported complications without the use of quantitative methods. Results: Multiple complications of cocaine use have been described and are often related to the method of administration of cocaine. Since the introduction of freebase and ''crack'' cocaine, new complications have been noted, and nearly all organ systems have been affected. Indirect complications, related to violent behavior and infectious diseases, are also important consequences of cocaine use. Conclusions: Adverse reactions to cocaine use should be considered in the differential diagnosis of various disorders, particularly ischemic events in young adults. The actual frequency of each complication is unknown.			WARNER, EA (corresponding author), UNIV S FLORIDA, DEPT INTERNAL MED, 12901 BRUCE B DOWNS BLVD, TAMPA, FL 33612 USA.							ABRAMSON DL, 1989, JAMA-J AM MED ASSOC, V262, P617; ADROUNY A, 1985, NEW ENGL J MED, V313, P48; ALLEN LV, 1981, CLIN TOXICOL, V18, P1043, DOI 10.3109/15563658108990335; ALLRED RJ, 1981, ANN EMERG MED, V10, P441; AMIN M, 1990, AM J CARDIOL, V66, P1434, DOI 10.1016/0002-9149(90)90529-A; [Anonymous], 1991, MMWR-MORBID MORTAL W, V40, P485; [Anonymous], 1987, JAMA-J AM MED ASSOC, V257, P3110; BARTH CW, 1986, AM J CARDIOL, V57, P496, DOI 10.1016/0002-9149(86)90787-3; BASELT RC, 1987, CLIN CHEM, V33, P747; BECKER GD, 1988, ARCH OTOLARYNGOL, V114, P90; BENCHIMOL A, 1978, ANN INTERN MED, V88, P519, DOI 10.7326/0003-4819-88-4-519; CALLAHAN CM, 1992, J PEDIATR-US, V120, P763, DOI 10.1016/S0022-3476(05)80245-8; CARLSON RG, 1991, J PSYCHOACTIVE DRUGS, V23, P11, DOI 10.1080/02791072.1991.10472570; CARUANA DS, 1984, ANN INTERN MED, V100, P73, DOI 10.7326/0003-4819-100-1-73; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHOKSHI SK, 1989, ANN INTERN MED, V111, P1039, DOI 10.7326/0003-4819-111-12-1039; COLEMAN DL, 1982, WESTERN J MED, V136, P444; Cook C E, 1990, NIDA Res Monogr, V99, P97; CREGLER LL, 1985, AM J CARDIOL, V56, P794, DOI 10.1016/0002-9149(85)91140-3; CUCCO RA, 1987, AM REV RESPIR DIS, V136, P179, DOI 10.1164/ajrccm/136.1.179; DACKIS CA, 1985, AM J PSYCHIAT, V142, P1097; DERLET RW, 1989, ANN EMERG MED, V18, P182, DOI 10.1016/S0196-0644(89)80111-8; DHOPESH VP, 1991, AM J DRUG ALCOHOL AB, V17, P423, DOI 10.3109/00952999109001601; DHUNA A, 1991, J NEUROL NEUROSUR PS, V54, P803, DOI 10.1136/jnnp.54.9.803; DRESSLER FA, 1990, AM J CARDIOL, V65, P303, DOI 10.1016/0002-9149(90)90292-9; Espinosa Manuel M., 1875, COCA EXOTICA ILLUSTR; ETTINGER NA, 1989, AM J MED, V87, P664, DOI 10.1016/S0002-9343(89)80401-2; FIORELLI RL, 1990, J UROLOGY, V143, P584, DOI 10.1016/S0022-5347(17)40028-0; FISHEL R, 1985, DIS COLON RECTUM, V28, P264, DOI 10.1007/BF02554049; FLORES ED, 1990, J AM COLL CARDIOL, V16, P74, DOI 10.1016/0735-1097(90)90459-3; FOLTIN RW, 1992, J PHARMACOL EXP THER, V261, P841; FORRESTER JM, 1990, AM REV RESPIR DIS, V142, P462, DOI 10.1164/ajrccm/142.2.462; FREDERICKS RK, 1991, STROKE, V22, P1437, DOI 10.1161/01.STR.22.11.1437; FREUDENBERGER RS, 1990, ANN INTERN MED, V113, P715, DOI 10.7326/0003-4819-113-9-715; FRINGS CS, 1987, CLIN CHEM, V33, P1683; GAWIN FH, 1989, ARCH GEN PSYCHIAT, V46, P117; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GITTER MJ, 1991, ANN INTERN MED, V115, P277, DOI 10.7326/0003-4819-115-4-277; GODWIN JE, 1989, ANN INTERN MED, V110, P843, DOI 10.7326/0003-4819-110-10-843_1; GORDON AS, 1990, ARCH OTOLARYNGOL, V116, P1415; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V265, P760, DOI 10.1001/jama.265.6.760; HARRUFF RC, 1988, J FORENSIC SCI, V33, P1231; HERZLICH BC, 1988, ANN INTERN MED, V109, P335, DOI 10.7326/0003-4819-109-4-335; HOFFMAN CK, 1989, RADIOLOGY, V172, P463, DOI 10.1148/radiology.172.2.2748827; HOFFMAN RS, 1992, ANN EMERG MED, V21, P247, DOI 10.1016/S0196-0644(05)80883-2; HOYT DW, 1987, JAMA-J AM MED ASSOC, V258, P504, DOI 10.1001/jama.1987.03400040102031; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; ITKONEN J, 1984, ARCH INTERN MED, V144, P2195, DOI 10.1001/archinte.144.11.2195; JATLOW P, 1988, YALE J BIOL MED, V61, P105; JATLOW PI, 1987, CLIN CHEM, V33, pB66; JEKEL JF, 1986, LANCET, V1, P459; JOHNSON BD, 1990, ADM901663 DHHS US DE; Jones R T, 1990, NIDA Res Monogr, V99, P30; KANEL GC, 1990, HEPATOLOGY, V11, P646, DOI 10.1002/hep.1840110418; KARCH SB, 1991, AM J FOREN MED PATH, V12, P126, DOI 10.1097/00000433-199106000-00008; KARCH SB, 1991, AM J FOREN MED PATH, V12, P1, DOI 10.1097/00000433-199103000-00001; KAYE BR, 1987, JAMA-J AM MED ASSOC, V258, P2104, DOI 10.1001/jama.258.15.2104; KISSNER DG, 1987, AM REV RESPIR DIS, V136, P1250, DOI 10.1164/ajrccm/136.5.1250; KLONER RA, 1992, CIRCULATION, V85, P407, DOI 10.1161/01.CIR.85.2.407; KLOSS MW, 1984, BIOCHEM PHARMACOL, V33, P169, DOI 10.1016/0006-2952(84)90471-4; KOREN G, 1992, J CLIN PHARMACOL, V32, P671, DOI 10.1002/j.1552-4604.1992.tb05780.x; KOSSOWSKY WA, 1989, CHEST, V96, P617, DOI 10.1378/chest.96.3.617; KRENDEL DA, 1990, NEUROLOGY, V40, P1092, DOI 10.1212/WNL.40.7.1092; KRUTCHKOFF DJ, 1990, NEW ENGL J MED, V322, P408; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LATHERS CM, 1988, J CLIN PHARMACOL, V28, P584, DOI 10.1002/j.1552-4604.1988.tb03181.x; LEE HS, 1990, ANN SURG, V211, P15, DOI 10.1097/00000658-199001000-00003; LEVINE SR, 1990, NEW ENGL J MED, V323, P699, DOI 10.1056/NEJM199009133231102; LEVINE SR, 1991, NEUROLOGY, V41, P1173, DOI 10.1212/WNL.41.8.1173; LEVINE SR, 1987, NEUROLOGY, V37, P1849, DOI 10.1212/WNL.37.12.1849; LIBBY DM, 1992, ANN INTERN MED, V116, P567, DOI 10.7326/0003-4819-116-7-567; LICHTENFELD PJ, 1984, ARCH NEUROL-CHICAGO, V41, P223, DOI 10.1001/archneur.1984.04050140125041; LOWENSTEIN DH, 1987, AM J MED, V83, P841, DOI 10.1016/0002-9343(87)90640-1; MACDONALD PT, 1988, J DRUG ISSUES, V18, P437, DOI 10.1177/002204268801800309; MAHLER JC, 1988, JAMA-J AM MED ASSOC, V259, P3126, DOI 10.1001/jama.1988.03720210016009; MARX R, 1991, SEX TRANSM DIS, V18, P92, DOI 10.1097/00007435-199118020-00008; MARZUK PM, 1992, AM J PSYCHIAT, V149, P371; MCHENRY JG, 1989, AM J OPHTHALMOL, V108, P732, DOI 10.1016/0002-9394(89)90871-4; MENDELSON JH, 1989, J CLIN ENDOCR METAB, V69, P1256, DOI 10.1210/jcem-69-6-1256; MENDELSON JH, 1988, AM J PSYCHIAT, V145, P1094; MERIGIAN KS, 1987, J TOXICOL-CLIN TOXIC, V25, P135, DOI 10.3109/15563658708992619; MESTON CM, 1992, J PSYCHOACTIVE DRUGS, V24, P1; MIECZKOWSKI T, 1991, J PSYCHOACTIVE DRUGS, V23, P241, DOI 10.1080/02791072.1991.10471585; MIKKELSEN SL, 1988, CLIN CHEM, V34, P2333; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; MITTLEMAN RE, 1984, JAMA-J AM MED ASSOC, V252, P1889, DOI 10.1001/jama.252.14.1889; MIZRAHI S, 1988, ARCH SURG-CHICAGO, V123, P394; MODY CK, 1988, NEUROLOGY, V38, P1189, DOI 10.1212/WNL.38.8.1189; MURRAY RJ, 1988, CHEST, V93, P427, DOI 10.1378/chest.93.2.427; NADEMANEE K, 1989, ANN INTERN MED, V111, P876, DOI 10.7326/0003-4819-111-11-876; NALBANDIAN H, 1985, SURGERY, V97, P374; NANJI AA, 1984, CHEST, V85, P132, DOI 10.1378/chest.85.1.132; NEWMAN NM, 1988, JAMA-J AM MED ASSOC, V259, P72, DOI 10.1001/jama.259.1.72; OM A, 1992, AM J CARDIOL, V69, P1549, DOI 10.1016/0002-9149(92)90701-Y; OMALLEY S, 1992, AM J DRUG ALCOHOL AB, V18, P131, DOI 10.3109/00952999208992826; PASCUALLEONE A, 1991, NEUROLOGY, V41, P34, DOI 10.1212/WNL.41.1.34; PASCUALLEONE A, 1990, NEUROLOGY, V40, P404, DOI 10.1212/WNL.40.3_Part_1.404; PASTERNACK PF, 1985, AM J CARDIOL, V55, P847, DOI 10.1016/0002-9149(85)90172-9; PATEL RC, 1987, ANN INTERN MED, V107, P186, DOI 10.7326/0003-4819-107-2-186; PENG SK, 1989, ARCH PATHOL LAB MED, V113, P842; PERINO LE, 1987, GASTROENTEROLOGY, V93, P176, DOI 10.1016/0016-5085(87)90331-3; QUART AM, 1991, J AM DENT ASSOC, V122, P85; Rawson R A, 1991, J Subst Abuse, V3, P457; REBHUN J, 1988, ANN ALLERGY, V60, P339; ROD JL, 1987, AM J CARDIOL, V59, P161, DOI 10.1016/S0002-9149(87)80091-7; RODRIGUEZBLAZQUEZ HM, 1990, J UROLOGY, V143, P358, DOI 10.1016/S0022-5347(17)39962-7; ROLFS RT, 1990, AM J PUBLIC HEALTH, V80, P853, DOI 10.2105/AJPH.80.7.853; ROTH D, 1988, NEW ENGL J MED, V319, P673, DOI 10.1056/NEJM198809153191103; RUBIN RB, 1992, J TOXICOL-CLIN TOXIC, V30, P1; RUBIN RB, 1990, AM J MED, V88, P438, DOI 10.1016/0002-9343(90)90506-9; SATEL SL, 1989, JAMA-J AM MED ASSOC, V261, P2995, DOI 10.1001/jama.261.20.2995; SAXON AJ, 1988, WESTERN J MED, V149, P296; SCHOBER S, 1991, DHHS911787 PUBL, P110; SCHROEDER EP, 1990, PROBLEMS DRUG DEPEND, V95, P218; SHESSER R, 1981, ANN EMERG MED, V10, P213, DOI 10.1016/S0196-0644(81)80166-7; SIMPSON RW, 1986, ARCH PATHOL LAB MED, V110, P479; SLUTSKER L, 1992, OBSTET GYNECOL, V79, P778; SMART RG, 1991, AM J DRUG ALCOHOL AB, V17, P13, DOI 10.3109/00952999108992806; SMITH HWB, 1987, ANN INTERN MED, V107, P13, DOI 10.7326/0003-4819-107-1-13; SOLDIN S J, 1991, Clinical Chemistry, V37, P993; STROMINGER MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1672, DOI 10.1001/archopht.1990.01070140026012; SUHL J, 1988, American Review of Respiratory Disease, V137, P488; TASHKIN DP, 1987, CHEST, V92, P638, DOI 10.1378/chest.92.4.638; VEREBEY K, 1987, COCAINE CLIN HDB, P214; VIRMANI R, 1988, AM HEART J, V115, P1068, DOI 10.1016/0002-8703(88)90078-6; VOLPE JJ, 1992, NEW ENGL J MED, V327, P399, DOI 10.1056/NEJM199208063270607; WALLACE BC, 1992, J PSYCHOACTIVE DRUGS, V24, P213, DOI 10.1080/02791072.1992.10471641; WANLESS IR, 1990, GASTROENTEROLOGY, V98, P497, DOI 10.1016/0016-5085(90)90845-R; WASHTON AM, 1991, INT J ADDICT, V25, P1421; WASHTON AM, 1989, MED ASPECTS HUM SEX, V23, P32; WEINSTEIN SP, 1992, AM J DRUG ALCOHOL AB, V18, P157, DOI 10.3109/00952999208992828; WEISS RD, 1988, AM J MED, V85, P879; WELCH RD, 1991, ANN EMERG MED, V20, P154, DOI 10.1016/S0196-0644(05)81215-6; WESSON DR, 1982, J PSYCHOACTIVE DRUGS, V14, P75, DOI 10.1080/02791072.1982.10471913; WETLI CV, 1979, JAMA-J AM MED ASSOC, V241, P2519, DOI 10.1001/jama.241.23.2519; WIENER RS, 1986, AM J MED, V81, P699, DOI 10.1016/0002-9343(86)90559-0; YANG RD, 1991, DIGEST DIS SCI, V36, P238, DOI 10.1007/BF01300764; ZIMMERMAN FH, 1987, J AM COLL CARDIOL, V9, P964, DOI 10.1016/S0735-1097(87)80256-5; 1991, MMWR, V40, P77; 1991, DHHS ADM911788 US DE; 1987, DIAGNOSTIC STATISTIC; 1991, ADM911732 DHHS US DE	144	138	141	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					226	235		10.7326/0003-4819-119-3-199308010-00009	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8323092				2022-12-28	WOS:A1993LU90300009
J	KIM, SG; ASHE, J; HENDRICH, K; ELLERMANN, JM; MERKLE, H; UGURBIL, K; GEORGOPOULOS, AP				KIM, SG; ASHE, J; HENDRICH, K; ELLERMANN, JM; MERKLE, H; UGURBIL, K; GEORGOPOULOS, AP			FUNCTIONAL MAGNETIC-RESONANCE-IMAGING OF MOTOR CORTEX - HEMISPHERIC-ASYMMETRY AND HANDEDNESS	SCIENCE			English	Article							CEREBRAL BLOOD-FLOW; MOVEMENTS; DAMAGE; STROKE	A hemispheric asymmetry in the functional activation of the human motor cortex during contralateral (C) and ipsilateral (I) finger movements, especially in right-handed subjects, was documented with nuclear magnetic resonance imaging at high field strength (4 tesla). Whereas the right motor cortex was activated mostly during contralateral finger movements in both right-handed (C/I mean area of activation = 36.8) and left-handed (C/I = 29.9) subjects, the left motor cortex was activated substantially during ipsilateral movements in left-handed subjects (C/I = 5.4) and even more so in right-handed subjects (C/I = 1.3).	UNIV MINNESOTA, SCH MED, DEPT RADIOL, MINNEAPOLIS, MN 55455 USA; DEPT VET AFFAIRS MED CTR, CTR BRAIN SCI, MINNEAPOLIS, MN 55417 USA; UNIV MINNESOTA, SCH MED, DEPT NEUROL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT PHYSIOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	KIM, SG (corresponding author), UNIV MINNESOTA, SCH MED, CTR MAGNET RESONANCE RES, MINNEAPOLIS, MN 55455 USA.		Ugurbil, Kamil/AAD-6058-2022	Ellermann, Jutta/0000-0002-7109-9656	NCRR NIH HHS [RR08079] Funding Source: Medline; NHLBI NIH HHS [HL33600, HL32427] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033600, P01HL032427] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; De Renzi E., 1982, DISORDERS SPACE EXPL; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; Geschwind N, 1984, CEREBRAL DOMINANCE B; HAALAND KY, 1981, NEUROPSYCHOLOGIA, V19, P17; HAALAND KY, 1989, NEUROPSYCHOLOGIA, V27, P961, DOI 10.1016/0028-3932(89)90071-7; HAALAND KY, 1987, NEUROPSYCHOLOGIA, V25, P783, DOI 10.1016/0028-3932(87)90116-3; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HASLEY JH, 1979, NEUROLOGY, V29, P21; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KIMURA D, 1977, BRAIN, V100, P527, DOI 10.1093/brain/100.3.527; NYBERGHANSEN R, 1963, ACTA NEUROL SCAND, V39, P1, DOI 10.1111/j.1600-0404.1963.tb05384.x; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; ROLAND PE, 1982, J NEUROPHYSIOL, V48, P467, DOI 10.1152/jn.1982.48.2.467; Springer S., 1981, LEFT BRAIN RIGHT BRA; WYKE M, 1966, ARCH NEUROL-CHICAGO, V15, P329, DOI 10.1001/archneur.1966.00470150107016; WYKE M, 1968, NEUROPSYCHOLOGIA, V6, P125, DOI 10.1016/0028-3932(68)90054-7; WYKE M, 1967, NEUROLOGY, V17, P1113, DOI 10.1212/WNL.17.11.1113	19	814	829	3	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1993	261	5121					615	617		10.1126/science.8342027	http://dx.doi.org/10.1126/science.8342027			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342027				2022-12-28	WOS:A1993LP72800041
J	GABOW, PA				GABOW, PA			AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FLUID ANTIBIOTIC CONCENTRATIONS; CHRONIC-RENAL-FAILURE; CYST-DERIVED CELLS; BASEMENT-MEMBRANE; COMPUTED-TOMOGRAPHY; EPITHELIAL-CELLS; LIVER-DISEASE; TRIMETHOPRIM-SULFAMETHOXAZOLE; DIVERTICULAR-DISEASE; TUBEROUS SCLEROSIS				GABOW, PA (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT MED, BOX C-283, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NCRR NIH HHS [RR-69] Funding Source: Medline; NIDDK NIH HHS [5 P01 DK34039] Funding Source: Medline; ORS NIH HHS [MORR-00051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK034039] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); ORS NIH HHS; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE R, 1985, KIDNEY DIALYSIS, V9, P389; AHMED S, 1972, British Journal of Urology, V44, P71; ALMY TP, 1980, NEW ENGL J MED, V302, P324, DOI 10.1056/NEJM198002073020605; ANDERSON ET, 1969, J AMER MED ASSOC, V208, P2472; ASKUPMARK E, 1950, ACTA MED SCAND, V138, P15; AVNER E D, 1992, Journal of the American Society of Nephrology, V3, P292; AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; AVNER ED, 1989, KIDNEY INT, V36, P960, DOI 10.1038/ki.1989.288; BAERT L, 1978, KIDNEY INT, V13, P519, DOI 10.1038/ki.1978.75; BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BELL PE, 1988, KIDNEY INT, V34, P683, DOI 10.1038/ki.1988.233; BENNETT WM, 1977, J LAB CLIN MED, V90, P389; BENNETT WM, 1987, J UROLOGY, V137, P620, DOI 10.1016/S0022-5347(17)44156-5; BENNETT WM, 1985, AM J KIDNEY DIS, V6, P400, DOI 10.1016/S0272-6386(85)80102-5; BENNETT WM, 1976, JAMA-J AM MED ASSOC, V236, P946, DOI 10.1001/jama.236.8.946; BENNETT WM, 1989, KIDNEY INT, V35, P738; BENNETT WM, 1990, CYSTIC KIDNEY, P247; BERNSTEIN J, 1986, SEMIN DIAGN PATHOL, V3, P97; BESARAB A, 1987, KIDNEY INT, V32, P526, DOI 10.1038/ki.1987.241; BIGELOW NH, 1953, AM J MED SCI, V225, P485, DOI 10.1097/00000441-195305000-00004; BRANDT PWT, 1963, BRIT MED J, P468, DOI 10.1136/bmj.2.5355.468; BROWN R A P, 1951, Glasgow Med J, V32, P333; CARONE FA, 1989, KIDNEY INT, V35, P1351, DOI 10.1038/ki.1989.134; CARONE FA, 1992, J AM SOC NEPHROL, V3, P244; CHANDRA M, 1985, NEPHRON, V39, P26, DOI 10.1159/000183332; CHAPMAN A, 1991, Journal of the American Society of Nephrology, V2, P251; CHAPMAN AB, 1990, NEW ENGL J MED, V323, P1091, DOI 10.1056/NEJM199010183231602; CHAPMAN AB, 1992, NEW ENGL J MED, V327, P916, DOI 10.1056/NEJM199209243271303; CHRISTOFERSON L, 1961, JAMA-J AM MED ASSOC, V178, P280, DOI 10.1001/jama.1961.03040420020005; CHURCHILL DN, 1984, KIDNEY INT, V26, P190, DOI 10.1038/ki.1984.154; CORNELL SH, 1970, J UROLOGY, V103, P24, DOI 10.1016/S0022-5347(17)61883-4; CUPPAGE FE, 1980, KIDNEY INT, V17, P372, DOI 10.1038/ki.1980.43; DALGAARD O Z, 1957, Acta Med Scand Suppl, V328, P1; DITLEFSEN EML, 1960, ACTA MED SCAND, V168, P51; Dunger R, 1904, BEITR PATHOL ANAT AL, V35, P445; EBIHARA I, 1988, LAB INVEST, V58, P262; ECKARDT KU, 1989, J CLIN INVEST, V84, P1160, DOI 10.1172/JCI114280; ELZINGA LW, 1992, J AM SOC NEPHROL, V2, P1219; ELZINGA LW, 1987, KIDNEY INT, V32, P884, DOI 10.1038/ki.1987.290; ELZINGA LW, 1988, ANTIMICROB AGENTS CH, V32, P844, DOI 10.1128/AAC.32.6.844; ELZINGA LW, 1993, 5TH P INT WORKSH POL, P134; ETTINGER A, 1969, J UROLOGY, V102, P156, DOI 10.1016/S0022-5347(17)62101-3; EVAN AP, 1979, KIDNEY INT, V16, P743, DOI 10.1038/ki.1979.191; EVERSON GT, 1988, HEPATOLOGY, V8, P1627, DOI 10.1002/hep.1840080626; EVERSON GT, 1990, HEPATOLOGY, V11, P557, DOI 10.1002/hep.1840110406; FICK G, 1992, Journal of the American Society of Nephrology, V3, P295; FICK GM, 1993, J AM SOC NEPHROL, V3, P1863; FORSSELL J, 1958, ACTA MED SCAND, V161, P169; GABOW PA, 1992, AM J KIDNEY DIS, V20, P140, DOI 10.1016/S0272-6386(12)80541-5; GABOW PA, 1989, KIDNEY INT, V35, P675, DOI 10.1038/ki.1989.38; GABOW PA, 1984, ANN INTERN MED, V101, P238, DOI 10.7326/0003-4819-101-2-238; GABOW PA, 1990, KIDNEY INT, V38, P1177, DOI 10.1038/ki.1990.330; GABOW PA, 1990, AM J KIDNEY DIS, V16, P403, DOI 10.1016/S0272-6386(12)80051-5; GABOW PA, 1992, KIDNEY INT, V41, P1311, DOI 10.1038/ki.1992.195; GABOW PA, 1990, HEPATOLOGY, V11, P1033, DOI 10.1002/hep.1840110619; GABOW PA, 1991, SEMIN NEPHROL, V11, P643; GABOW PA, 1991, INT YB NEPHROLOGY 19, P199; GARDNER KD, 1991, KIDNEY INT, V39, P718, DOI 10.1038/ki.1991.87; GARDNER KD, 1969, NEW ENGL J MED, V281, P985, DOI 10.1056/NEJM196910302811804; GATTONE VH, 1991, SEMIN NEPHROL, V11, P617; GO KG, 1986, J NEUROSURG, V65, P642, DOI 10.3171/jns.1986.65.5.0642; GORDON RL, 1979, RADIOLOGY, V131, P357, DOI 10.1148/131.2.357; GRAHAM PC, 1988, KIDNEY INT, V33, P1084, DOI 10.1038/ki.1988.115; GRANOT Y, 1990, KIDNEY INT, V37, P1301, DOI 10.1038/ki.1990.115; GRANTHAM JJ, 1992, J AM SOC NEPHROL, V2, P1161; GRANTHAM JJ, 1987, KIDNEY INT, V31, P1145, DOI 10.1038/ki.1987.121; GREGOIRE JR, 1987, AM J KIDNEY DIS, V9, P27, DOI 10.1016/S0272-6386(87)80158-0; GRETZ N, 1989, AM J KIDNEY DIS, V14, P178, DOI 10.1016/S0272-6386(89)80068-X; Grunfeld J P, 1985, Adv Nephrol Necker Hosp, V14, P1; HABTE B, 1983, ETHIOPIAN MED J, V21, P193; HANNIG VL, 1991, AM J MED GENET, V40, P425, DOI 10.1002/ajmg.1320400409; HARRAP SB, 1991, KIDNEY INT, V40, P501, DOI 10.1038/ki.1991.238; HEGG O, 1966, J PATHOL BACTERIOL, V91, P311, DOI 10.1002/path.1700910204; HOSSACK KF, 1988, NEW ENGL J MED, V319, P907, DOI 10.1056/NEJM198810063191404; HUSEMAN R, 1980, KIDNEY INT, V18, P375, DOI 10.1038/ki.1980.148; HUSTON J, 1993, J AM SOC NEPHROL, V3, P1871; IGLESIAS CG, 1983, AM J KIDNEY DIS, V2, P630; ISHIKAWA I, 1991, SEMIN NEPHROL, V11, P671; KAEHNY WD, 1990, AM J MED, V89, P49, DOI 10.1016/0002-9343(90)90097-W; KAEHNY WD, 1991, SEMIN NEPHROL, V11, P661; KANWAR YS, 1984, KIDNEY INT, V26, P35, DOI 10.1038/ki.1984.131; KELLEY KA, 1991, J AM SOC NEPHROL, V2, P84; KIMBERLING WJ, 1991, SEMIN NEPHROL, V11, P596; KIMBERLING WJ, 1988, NEW ENGL J MED, V319, P913, DOI 10.1056/NEJM198810063191405; KLINGEL R, 1992, AM J KIDNEY DIS, V19, P22, DOI 10.1016/S0272-6386(12)70198-1; KOHLHEPP S, 1990, J AM SOC NEPHROL, V1, P300; KRAMER SA, 1982, J UROLOGY, V128, P1259, DOI 10.1016/S0022-5347(17)53453-9; LEIER CV, 1984, ANN INTERN MED, V100, P683, DOI 10.7326/0003-4819-100-5-683; LEVINE E, 1981, AM J KIDNEY DIS, V1, P99, DOI 10.1016/S0272-6386(81)80036-4; LEVINE E, 1985, RADIOLOGY, V154, P477, DOI 10.1148/radiology.154.2.3966136; LIU ZZ, 1992, AM J PHYSIOL, V263, pF697, DOI 10.1152/ajprenal.1992.263.4.F697; LOUGHLIN KR, 1986, J UROLOGY, V136, P789, DOI 10.1016/S0022-5347(17)45080-4; MACKAY K, 1987, KIDNEY INT, V32, P827, DOI 10.1038/ki.1987.283; MAGGIORE Q, 1967, P EUR DIAL TRANSPLAN, V4, P264; MALEK RS, 1987, AM J MED, V82, P236, DOI 10.1016/0002-9343(87)90062-3; MANGOOKARIM R, 1989, P NATL ACAD SCI USA, V86, P6007, DOI 10.1073/pnas.86.15.6007; MANGOOKARIM R, 1989, FASEB J, V3, P2629, DOI 10.1096/fasebj.3.14.2480260; MCDONALD RA, 1991, SEMIN NEPHROL, V11, P632; MILUTINOVIC J, 1992, AM J KIDNEY DIS, V19, P465, DOI 10.1016/S0272-6386(12)80956-5; MILUTINOVIC J, 1980, AM J CLIN PATHOL, V73, P740; MILUTINOVIC J, 1983, OBSTET GYNECOL, V61, P566; MILUTINOVIC J, 1980, AM J MED, V68, P741, DOI 10.1016/0002-9343(80)90266-1; MILUTINOVIC J, 1989, AM J KIDNEY DIS, V13, P340, DOI 10.1016/S0272-6386(89)80043-5; MILUTINOVIC J, 1984, Q J MED, V53, P511; MIR S, 1983, NEPHRON, V33, P189, DOI 10.1159/000182941; MURPHY G, 1990, AM J NEPHROL, V10, P69, DOI 10.1159/000168057; MUTHER RS, 1981, KIDNEY INT, V20, P519, DOI 10.1038/ki.1981.170; NASH DA, 1977, ARCH INTERN MED, V137, P1571, DOI 10.1001/archinte.137.11.1571; NEUFELD TK, 1992, KIDNEY INT, V41, P1222, DOI 10.1038/ki.1992.184; NEWMAN KD, 1990, ANN SURG, V212, P30, DOI 10.1097/00000658-199007000-00005; OJEDA JL, 1990, KIDNEY INT, V37, P1270, DOI 10.1038/ki.1990.111; OSATHANONDH V, 1964, ARCH PATHOL, V77, P459; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PATTERSON M, 1982, HEPATOLOGY, V2, P475; PAVLOVICKENTERA V, 1987, EXP HEMATOL, V15, P785; PIEKE S A, 1989, American Journal of Human Genetics, V45, pA58; PRETORIUS DH, 1987, J ULTRAS MED, V6, P249; RAMOS A, 1990, ARCH PATHOL LAB MED, V114, P180; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; REEDERS ST, 1986, LANCET, V2, P6; ROMEO G, 1988, LANCET, V2, P8; SCHEFF RT, 1980, ANN INTERN MED, V92, P202, DOI 10.7326/0003-4819-92-2-202; SCHWAB S, 1983, AM J KIDNEY DIS, V3, P63, DOI 10.1016/S0272-6386(83)80012-2; SCHWAB SJ, 1985, AM J KIDNEY DIS, V5, P258, DOI 10.1016/S0272-6386(85)80118-9; SCHWAB SJ, 1987, AM J MED, V82, P714, DOI 10.1016/0002-9343(87)90005-2; SEDMAN A, 1987, KIDNEY INT, V31, P1000, DOI 10.1038/ki.1987.98; SHIKATA K, 1991, CLIN NEPHROL, V36, P223; STAPLETON FB, 1980, J PEDIATR-US, V97, P574, DOI 10.1016/S0022-3476(80)80011-4; SUJANSKY E, 1990, AM J MED GENET, V35, P510, DOI 10.1002/ajmg.1320350413; TABONE J, 1949, CR HEBD ACAD SCI, V229, P471; TANNER GA, 1992, J AM SOC NEPHROL, V2, P1208; TAUB M, 1990, KIDNEY INT, V37, P1090, DOI 10.1038/ki.1990.90; TELENTI A, 1990, MAYO CLIN PROC, V65, P933, DOI 10.1016/S0025-6196(12)65154-4; TORRES VE, 1990, NEW ENGL J MED, V322, P345, DOI 10.1056/NEJM199002083220601; TORRES VE, 1988, AM J KIDNEY DIS, V11, P318, DOI 10.1016/S0272-6386(88)80137-9; TORRES VE, 1988, KIDNEY INT, V33, P1130, DOI 10.1038/ki.1988.121; TORRES VE, 1990, J AM SOC NEPHROL, V1, P84; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; VALVO E, 1985, AM J NEPHROL, V5, P176, DOI 10.1159/000166929; VILLAR MTA, 1992, NEPHRON, V62, P226, DOI 10.1159/000187038; WAKABAYASHI T, 1983, J NEUROSURG, V58, P488, DOI 10.3171/jns.1983.58.4.0488; WATSON ML, 1992, KIDNEY INT, V41, P206, DOI 10.1038/ki.1992.28; WENDELL F, 1963, AM J MED, V34, P76, DOI 10.1016/0002-9343(63)90040-8; WILSON PD, 1991, AM J KIDNEY DIS, V17, P634, DOI 10.1016/S0272-6386(12)80338-6; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WILSON PD, 1991, KIDNEY INT, V39, P450, DOI 10.1038/ki.1991.56; WILSON PD, 1992, J CELL PHYSIOL, V150, P360, DOI 10.1002/jcp.1041500220; YE M, 1993, NEW ENGL J MED, V329, P310, DOI 10.1056/NEJM199307293290503; YE M, 1992, J AM SOC NEPHROL, V3, P984; YIUM J J, 1992, Journal of the American Society of Nephrology, V3, P305; ZEIER M, 1993, J AM SOC NEPHROL, V3, P1451; ZEIER M, 1988, NEPHRON, V49, P177, DOI 10.1159/000185052; 1989, AM J KIDNEY DIS, V13, P85; 1990, USRDS1990 NIH NAT I, P17	154	799	824	1	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					332	342		10.1056/NEJM199307293290508	http://dx.doi.org/10.1056/NEJM199307293290508			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8321262				2022-12-28	WOS:A1993LN62100008
J	YE, M; GRANTHAM, JJ				YE, M; GRANTHAM, JJ			THE SECRETION OF FLUID BY RENAL CYSTS FROM PATIENTS WITH AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVITRO; EPITHELIUM; GROWTH	Background. The mechanism by which fluid accumulates in renal cysts of adults with autosomal dominant polycystic kidney disease is not known. This study was designed to determine whether transepithelial secretion of fluid may account for this accumulation. Methods. We studied in vitro intact cysts that were excised from kidneys removed from three patients with end-stage autosomal dominant polycystic kidney disease. The cysts were loaded with natural cyst fluid or with a combination of Dulbecco's modified Eagle's medium and Ham's F12 medium (DME-F12) and incubated in DME-F12 for 24 hours. Fluid secretion, determined by the change in the weight of the cysts, was expressed as the rate of fluid secretion per square centimeter of surface area per 24 hours, to correct for the wide variation in the sizes of the cysts. To test for endogenous secretagogues, cyst fluid was added to confluent monolayer cultures of canine- and human-kidney cells. Results. During the first 24 hours of incubation, the mean (+/-SE) rate of fluid secretion in nine cysts containing natural cyst fluid was 20.8+/-5.6 mul per square centimeter of surface area per 24 hours, as compared with 2.3+/-3.6 mul per square centimeter per 24 hours in nine cysts containing incubation medium. Each group of cysts was then incubated with forskolin, a nonspecific stimulator of adenylate cyclase activity, for an additional 24 hours. During this period the fluid-secretion rate of cysts containing natural cyst fluid did not change; however, the secretion rate of those containing incubation medium increased to 9.1+/-4.4 mul per square centimeter per 24 hours (mean change, 6.8+/-1.1; P<0.001). Cyst fluid stimulated fluid secretion by polarized monolayers of canine- and human-kidney cells. Conclusions. Renal cysts from patients with autosomal dominant polycystic kidney disease can secrete fluid, and net fluid secretion can be increased by unidentified secretagogues in the cyst fluid. These results suggest that the process of cyst enlargement may be susceptible to pharmacologic intervention.	UNIV KANSAS,MED CTR,SCH MED,DEPT MED,DIV NEPHROL,39TH & RAINBOW BLVD,KANSAS CITY,KS 66103	University of Kansas; University of Kansas Medical Center					NIDDK NIH HHS [DK 45614] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045614] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CUPPAGE FE, 1980, KIDNEY INT, V17, P372, DOI 10.1038/ki.1980.43; EVERSON GT, 1990, HEPATOLOGY, V11, P557, DOI 10.1002/hep.1840110406; GARDNER KD, 1969, NEW ENGL J MED, V281, P985, DOI 10.1056/NEJM196910302811804; GRANTHAM JJ, 1987, KIDNEY INT, V31, P1145, DOI 10.1038/ki.1987.121; GRANTHAM JJ, 1976, PHYSIOL REV, V56, P248, DOI 10.1152/physrev.1976.56.1.248; GRANTHAM JJ, 1983, AM J PHYSIOL, V244, pF3, DOI 10.1152/ajprenal.1983.244.1.F3; HUSEMAN R, 1980, KIDNEY INT, V18, P375, DOI 10.1038/ki.1980.148; MANGOOKARIM R, 1989, P NATL ACAD SCI USA, V86, P6007, DOI 10.1073/pnas.86.15.6007; MANGOOKARIM R, 1989, FASEB J, V3, P2629, DOI 10.1096/fasebj.3.14.2480260; Neufeld TK, 1991, J TISS CULT METHODS, V13, P229; PERRONE RD, 1985, J CLIN INVEST, V76, P1688, DOI 10.1172/JCI112155; YE M, 1992, J AM SOC NEPHROL, V3, P984; YE M, 1986, CHINESE J SURG, V24, P73	13	98	101	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					310	313		10.1056/NEJM199307293290503	http://dx.doi.org/10.1056/NEJM199307293290503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8321258	Bronze			2022-12-28	WOS:A1993LN62100003
J	MASUD, T; LANGLEY, S; WILTSHIRE, P; DOYLE, DV; SPECTOR, TD				MASUD, T; LANGLEY, S; WILTSHIRE, P; DOYLE, DV; SPECTOR, TD			EFFECT OF SPINAL OSTEOPHYTOSIS ON BONE-MINERAL DENSITY-MEASUREMENTS IN VERTEBRAL OSTEOPOROSIS	BRITISH MEDICAL JOURNAL			English	Article									WHIPPS CROSS HOSP & CHEST CLIN,DEPT RHEUMATOL,LONDON E11 1NR,ENGLAND	University of London; Queen Mary University London	MASUD, T (corresponding author), ST THOMAS HOSP,DEPT RHEUMATOL,LONDON SE1 7EH,ENGLAND.		Langley-Evans, Simon C/F-3564-2012; Spector, Tim D/F-6533-2012	Langley-Evans, Simon C/0000-0002-1969-8416; 	Arthritis Research UK [17489] Funding Source: Medline	Arthritis Research UK(Versus Arthritis)		DAWSONHUGHES B, 1990, CALCIFIED TISSUE INT, V46, P280, DOI 10.1007/BF02555008; DEQUEKER J, 1985, CLIN RHEUM DIS, V11, P271; LAWRENCE JS, 1969, ANN RHEUM DIS, V28, P6121; ORWOLL ES, 1990, J CLIN ENDOCR METAB, V70, P1202, DOI 10.1210/jcem-70-4-1202; REID IR, 1991, J CLIN ENDOCR METAB, V72, P1372, DOI 10.1210/jcem-72-6-1372	5	164	171	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					172	173		10.1136/bmj.307.6897.172	http://dx.doi.org/10.1136/bmj.307.6897.172			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343746	Green Published, Bronze			2022-12-28	WOS:A1993LN18400021
J	FULGINITI, VA; LEWY, JE				FULGINITI, VA; LEWY, JE			PEDIATRICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CYSTIC-FIBROSIS GENE		TULANE UNIV,SCH MED,NEW ORLEANS,LA 70112	Tulane University	FULGINITI, VA (corresponding author), UNIV COLORADO,MED CTR,BOULDER,CO 80309, USA.							Adamson J W, 1991, Biotechnology, V19, P351; ALEXANDER SR, 1991, AM J KIDNEY DIS, V18, P42; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; DALTON ME, 1993, NEW ENGL J MED, V328, P114; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FINE RN, 1991, J AM SOC NEPHROL, V1, P1136; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; MEHLS O, 1992, MINER ELECTROL METAB, V18, P320; MEHLS O, 1992, J AM SOC NEPHROL, V2, P5284; PLATT LD, 1992, NEW ENGL J MED, V327, P636, DOI 10.1056/NEJM199208273270910; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; THOMPSON L, 1992, SCIENCE, V258, P744, DOI 10.1126/science.1472258	16	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					246	248		10.1001/jama.270.2.246	http://dx.doi.org/10.1001/jama.270.2.246			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315750				2022-12-28	WOS:A1993LL36800037
J	LAFFEL, GL; BERWICK, DM				LAFFEL, GL; BERWICK, DM			QUALITY HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									INST HEALTHCARE IMPROVEMENT,BOSTON,MA	Institute for Healthcare Improvement	LAFFEL, GL (corresponding author), BRIGHAM & WOMENS HOSP,BOSTON,MA 02115, USA.							Berwick D M, 1992, Qual Manag Health Care, V1, P1; Chopra P S, 1992, Qual Manag Health Care, V1, P21; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; EISENBERG L, 1992, NEW ENGL J MED, V327, P248; GOLDMAN RL, 1992, JAMA-J AM MED ASSOC, V267, P958, DOI 10.1001/jama.267.7.958; GRABOYS TB, 1992, JAMA-J AM MED ASSOC, V268, P2537, DOI 10.1001/jama.268.18.2537; LAFFEL GL, 1992, NEW ENGL J MED, V327, P1220, DOI 10.1056/NEJM199210223271707; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LISTERNICK R, 1992, JAMA-J AM MED ASSOC, V267, P1095, DOI 10.1001/jama.267.8.1095; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; Nelson E C, 1992, QRB Qual Rev Bull, V18, P284; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; Shortell S M, 1992, QRB Qual Rev Bull, V18, P150; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; 1988, J AM COLL CARDIOL  S, V12, pA3; 1992, AHCPR920032 US DEP H; 1992, AHCPR920038 US DEP H; 1988, NEW ENGL J MED, V319, P385	20	12	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					254	255		10.1001/jama.270.2.254	http://dx.doi.org/10.1001/jama.270.2.254			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315754				2022-12-28	WOS:A1993LL36800041
J	WINOGRAD, CH; GERETY, MB				WINOGRAD, CH; GERETY, MB			GERIATRIC-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIP FRACTURE; FALLS; RISK		VET AFFAIRS MED CTR,PALO ALTO,CA; AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio	WINOGRAD, CH (corresponding author), STANFORD UNIV,MED CTR,SCH MED,STANFORD,CA 94305, USA.							AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; BAKER D, 1992, GERONTOLOGIST, V32, P126; DUBEAU TE, 1991, ADV INTERNAL MED, V37, P55; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; GERETY MB, IN PRESS J AM GERIAT; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LEPOR H, 1992, J UROLOGY, V148, P1467, DOI 10.1016/S0022-5347(17)36941-0; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; TINETTI ME, 1990, J GERONTOL, V45, pP239, DOI 10.1093/geronj/45.6.P239; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					213	216		10.1001/jama.270.2.213	http://dx.doi.org/10.1001/jama.270.2.213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315736				2022-12-28	WOS:A1993LL36800022
J	SCHNUCHEL, A; WILTSCHECK, R; CZISCH, M; HERRLER, M; WILLIMSKY, G; GRAUMANN, P; MARAHIEL, MA; HOLAK, TA				SCHNUCHEL, A; WILTSCHECK, R; CZISCH, M; HERRLER, M; WILLIMSKY, G; GRAUMANN, P; MARAHIEL, MA; HOLAK, TA			STRUCTURE IN SOLUTION OF THE MAJOR COLD-SHOCK PROTEIN FROM BACILLUS-SUBTILIS	NATURE			English	Article							NUCLEAR MAGNETIC-RESONANCE; SPIN COUPLING-CONSTANTS; RNA-BINDING DOMAIN; DISTANCE GEOMETRY; TRYPSIN-INHIBITOR; ESCHERICHIA-COLI; IDENTIFICATION; CONFORMATIONS; SPECTROSCOPY; COSY	THE cold-shock domain (CSD) is found in many eukaryotic transcriptional factors and is responsible for the specific binding to DNA of a cis-element called the Y-box1-3. The same domain exists in the sequence of the Xenopus RNA-binding proteins FRG Y1 and FRG Y2 (refs 1, 3). The major cold-shock proteins of Escherichia coli (CS7.4)4-7 and B. subtilis (CspB)8 have sequences that are more than 40 per cent identical to the cold-shock domain. We present here the three-dimensional structure of CspB determined by nuclear magnetic resonance spectroscopy. The 67-residue protein consists of an antiparallel five-stranded beta-barrel with strands connected by turns and loops. The structure resembles that of staphylococcal nuclease and the gene-5 single-stranded-DNA-binding protein9-11. A three-stranded beta-sheet, which contains the conserved RNA-binding motif RNP1 as well as a motif similar to RNP2 in two neighbouring antiparallel beta-strands12-14, has basic and aromatic residues at its surface which could serve as a binding site for single-stranded DNA. CspB binds to single-stranded DNA in gel retardation experiments.	UNIV MARBURG,DEPT BIOCHEM,W-3550 MARBURG,GERMANY	Philipps University Marburg	SCHNUCHEL, A (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.		Willimsky, Gerald/AAA-2445-2021	Willimsky, Gerald/0000-0002-9693-948X; Graumann, Peter/0000-0002-8033-5171				ARUTYUNYAN E G, 1981, Doklady Biochemistry, V258, P189; BRAYER GD, 1983, J MOL BIOL, V169, P565, DOI 10.1016/S0022-2836(83)80065-5; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; HAVEL TF, 1985, J MOL BIOL, V182, P281, DOI 10.1016/0022-2836(85)90346-8; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOLAK TA, 1989, J MOL BIOL, V210, P635, DOI 10.1016/0022-2836(89)90137-X; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; KLINE A, 1988, J MOL BIOL, V204, P657; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCPHERSON A, 1985, BIOL MACROMOL, V2, P323; MURZIN AG, 1992, CURR OPIN STRUC BIOL, V2, P895; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WILLIMSKY G, 1992, J BACTERIOL, V174, P6326, DOI 10.1128/JB.174.20.6326-6335.1992; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WOLFFE AP, 1992, NEW BIOL, V4, P290; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	28	202	205	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					169	171		10.1038/364169a0	http://dx.doi.org/10.1038/364169a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321289				2022-12-28	WOS:A1993LL36700056
J	PINI, A				PINI, A			CHEMOREPULSION OF AXONS IN THE DEVELOPING MAMMALIAN CENTRAL-NERVOUS-SYSTEM	SCIENCE			English	Article							NEURONAL PROJECTIONS; GROWTH CONES; GUIDANCE; COLLAPSE; BRAIN	During development of the nervous system, distinct populations of nerve cells extend specialized processes, axons and dendrites, over considerable distances to locate their targets. There is strong evidence for two general mechanisms by which these connections are made. The first involves attractive and repulsive interactions, both between cells and between them and their extracellular matrix. The second depends on the release of diffusible chemoattractants by target structures. Evidence is now provided for a mechanism of axon guidance in which diffusible chemorepulsive factors create exclusion zones for developing axons, causing them to turn away from inappropriate territory.	MRC,MAMMALIAN DEV UNIT,LONDON NW1 2HE,ENGLAND				Pini, Adrian PJ/C-5342-2009					BAYER SA, 1983, EXP BRAIN RES, V50, P329; BOLZ J, 1990, NATURE, V346, P359, DOI 10.1038/346359a0; CAJAL SRY, 1909, HISTOLOGIE SYSTEME N, V1, P657; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; LUMSDEN AGS, 1986, NATURE, V323, P538, DOI 10.1038/323538a0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; SCHONFELD TA, 1989, J NEUROSCI, V98, P1712; SCHWOB JE, 1984, J COMP NEUROL, V223, P117; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; YAMAMOTO M, 1986, J NEUROSCI, V6, P3576	15	151	154	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					95	98		10.1126/science.8316861	http://dx.doi.org/10.1126/science.8316861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316861				2022-12-28	WOS:A1993LK43400040
J	FORSYTH, JS; OGSTON, SA; CLARK, A; FLOREY, CD; HOWIE, PW				FORSYTH, JS; OGSTON, SA; CLARK, A; FLOREY, CD; HOWIE, PW			RELATION BETWEEN EARLY INTRODUCTION OF SOLID FOOD TO INFANTS AND THEIR WEIGHT AND ILLNESSES DURING THE 1ST 2 YEARS OF LIFE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST; OVERNUTRITION; INFECTION; ECZEMA; ASTHMA; DIET	Objective-To assess the relations between early introduction of solid food and infant weight, gastrointestinal illness, and allergic illnesses during the first two years of life. Design-Prospective observational study of infants followed up for 24 months after birth. Setting-Community setting in Dundee. Patients-671 newborn infants, of whom 455 were still available for study at 2 years of age. Main outcome measures-Infants' diet, weight, and incidence of gastrointestinal illness, respiratory illness, napkin dermatitis, and eczema at 2 weeks and 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 months of age. Results-The infants given solid food at an early age (at < 8 weeks or 8-12 weeks) were heavier than those introduced to solids later (after 12 weeks) at 4, 8, 13, and 26 weeks of age (p < 0.01) but not at 52 and 104 weeks. At their first solid feed those given solids early were heavier than infants of similar age who had not yet received solids. The incidence of gastrointestinal illness, wheeze, and nappy dermatitis was not related to early introduction of solids. There was a significant but less than twofold increase in respiratory illness at 14-26 weeks of age and persistent cough at 14-26 and 27-39 weeks of age among the infants given solids early. The incidence of eczema was increased in the infants who received solids at 8-12 weeks of age. Conclusion-Early introduction of solid food to infants is less harmful than was previously reported. Longer follow up is needed, but, meanwhile, a more relaxed approach to early feeding with solids should be considered.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT EPIDEMIOL & PUBL HLTH, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT OBSTET & GYNAECOL, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee	FORSYTH, JS (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CHILD HLTH, DUNDEE DD1 9SY, SCOTLAND.							ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; AGRAS WS, 1990, J PEDIATR-US, V116, P805, DOI 10.1016/S0022-3476(05)82677-0; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BAKER RJ, 1978, GLIM SYSTEM; CHANDRA RK, 1979, ACTA PAEDIATR SCAND, V68, P691, DOI 10.1111/j.1651-2227.1979.tb18439.x; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; FERGUSSON DM, 1981, CLIN ALLERGY, V11, P325; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; JARRETT EEE, 1984, LANCET, V2, P797; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; MARTIN J, 1988, INFANT FEEDING 1985; MILLA PJ, 1986, ACTA PAEDIATR SCAND, P5; POPKIN BM, 1990, PEDIATRICS, V86, P874; SHUKLA A, 1972, BMJ-BRIT MED J, V4, P507, DOI 10.1136/bmj.4.5839.507; STUFF JE, 1989, J PEDIATR-US, V115, P959, DOI 10.1016/S0022-3476(89)80750-4; TAITZ LS, 1971, BRIT MED J, V1, P315, DOI 10.1136/bmj.1.5744.315; TAYLOR B, 1973, LANCET, V2, P111; Thorogood M, 1979, J R Coll Gen Pract, V29, P427; WILKINSON PW, 1978, BRIT MED J, V1, P1682, DOI 10.1136/bmj.1.6128.1682; 1988, PRESENT DAY PRACTICE; 1980, PRESENT DAY PRACTICE; 1980, PEDIATRICS, V65, P1178; 1982, ACTA PAEDIATR SC   S, V302, P1; 1974, PRESENT DAY PRACTICE	26	103	103	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	1993	306	6892					1572	1576		10.1136/bmj.306.6892.1572	http://dx.doi.org/10.1136/bmj.306.6892.1572			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329916	Green Published, Bronze			2022-12-28	WOS:A1993LH12800016
J	HANDYSIDES, S				HANDYSIDES, S			ENRICHING CAREERS IN GENERAL-PRACTICE .3. BUILDING AN EFFICIENT AND HEALTHY PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							JOB-SATISFACTION; MANAGING CHANGE; MENTAL-HEALTH; PRACTITIONERS; STRESS; APPOINTMENT; MOBILITY											ALBUTT TC, 1912, TIMES           0103; BERWICK DM, 1992, BRIT MED J, V304, P304, DOI 10.1136/bmj.304.6822.304; BLACKBURN JR, 1993, UPDATE          0501, P802; BRADLEY CP, 1992, FAMILTY PRACTITIONER, V9, P90; BRANTHWAITE A, 1988, FAM PRACT, V5, P83, DOI 10.1093/fampra/5.2.83; CHAMBERS R, 1993, BRIT J GEN PRACT, V43, P442; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; DALE MH, 1982, BRIT MED J, V284, P1845, DOI 10.1136/bmj.284.6332.1845; ELLIS N, 1994, MAKING SENSE PARTNER; Fisher R., 1982, GETTING YES NEGOTIAT; HANDY CB, 1981, UNDERSTANDING ORG; Hart, 1988, NEW KIND DOCTOR; HEAD S, 1993, MEDECONOMICS     OCT, P39; HOBBS FDR, 1992, BRIT MED J, V304, P1616, DOI 10.1136/bmj.304.6842.1616; HOWIE JGR, 1992, BRIT J GEN PRACT, V42, P181; IRVINE D, 1993, BRIT J GEN PRACT, V43, P121; IRVINE S, 1992, BALANCING DREAMS DIS; KEY I, 1985, BMJ, V91, P451; KING J, 1990, BRIT MED J, V301, P1258, DOI 10.1136/bmj.301.6763.1258; LAWS C, 1993, MEDECONOMICS     DEC, P52; LESTER JP, 1982, BRIT MED J, V285, P548, DOI 10.1136/bmj.285.6341.548; MACLEOD JAJ, 1987, BRIT MED J, V295, P54, DOI 10.1136/bmj.295.6589.54-a; MAKIN PJ, 1988, J ROY COLL GEN PRACT, V38, P303; MARINKER M, 1984, NEW NHS ACT 1996; MARSH GN, 1991, EFFICIENT CARE GENER; METCALFE D, 1982, BRIT MED J, V284, P90, DOI 10.1136/bmj.284.6309.90; ODOWD TC, 1987, J ROY COLL GEN PRACT, V37, P290; PRINGLE M, 1991, MANAGING CHANGE PRIM; SIDE CD, 1987, BRIT MED J, V294, P1265, DOI 10.1136/bmj.294.6582.1265; SMITH R, 1990, BRIT MED J, V301, P679, DOI 10.1136/bmj.301.6754.679; SPIEGAL N, 1992, BRIT MED J, V304, P231, DOI 10.1136/bmj.304.6821.231; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; TOLSTOI LN, 1954, ANNA KARENINA; 1972, FUTURE GENERAL PRACT; 1993, GENERAL PRACTIT 1112, P70	35	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					179	182		10.1136/bmj.308.6922.179	http://dx.doi.org/10.1136/bmj.308.6922.179			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312771	Green Published			2022-12-28	WOS:A1994MR97400023
J	QUILL, TE				QUILL, TE			DOCTOR, I WANT TO DIE - WILL YOU HELP ME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOPELESSLY ILL PATIENTS; ASSISTED SUICIDE; PHYSICIANS RESPONSIBILITY; RATIONAL SUICIDE; EUTHANASIA; CARE; DEATH; PAIN		UNIV ROCHESTER, SCH MED, PROGRAM BIOPSYCHOSOC STUDIES, ROCHESTER, NY 14627 USA	University of Rochester	QUILL, TE (corresponding author), GENESEE HOSP, DEPT MED, ROCHESTER, NY 14607 USA.							ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ARIES P, 1982, HOUR OF OUR DEATH; BREITBART W, 1989, ONCOLOGY, P49; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Fisher R., 2011, GETTING YES NEGOTIAT; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GARFIELD C, 1978, PSYCHOSOCIAL CARE DY; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; Gomez Carlos F., 1991, REGULATING DEATH EUT; JECKER NS, 1991, J AM GERIATR SOC, V39, P831, DOI 10.1111/j.1532-5415.1991.tb02708.x; KANE RL, 1985, JAMA-J AM MED ASSOC, V253, P2683, DOI 10.1001/jama.253.18.2683; KERR IG, 1988, ANN INTERN MED, V108, P554, DOI 10.7326/0003-4819-108-4-554; Kubler-Ross E., 1969, DEATH DYING; MACKENZIE TB, 1987, INT J PSYCHIAT MED, V17, P3; MEIER DE, 1983, J AM GERIATR SOC, V31, P294, DOI 10.1111/j.1532-5415.1983.tb04874.x; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1993, DEATH DIGNITY MAKING; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; RICHMAN J, 1992, SUICIDE LIFE-THREAT, V22, P130; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; TWYEROSS RG, 1984, SYMPTOM CONTROL FAR; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; ZIMMERMAN JM, 1981, HOSPICE COMPLETE CAR; 1987, HASTINGS CTR REPORT; 1992, JAMA-J AM MED ASSOC, V267, P2229	37	96	96	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					870	873		10.1001/jama.270.7.870	http://dx.doi.org/10.1001/jama.270.7.870			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340988				2022-12-28	WOS:A1993LR61200035
J	NEATON, JD; GRIMM, RH; PRINEAS, RJ; STAMLER, J; GRANDITS, GA; ELMER, PJ; CUTLER, JA; FLACK, JM; SCHOENBERGER, JA; MCDONALD, R; LEWIS, CE; LIEBSON, PR				NEATON, JD; GRIMM, RH; PRINEAS, RJ; STAMLER, J; GRANDITS, GA; ELMER, PJ; CUTLER, JA; FLACK, JM; SCHOENBERGER, JA; MCDONALD, R; LEWIS, CE; LIEBSON, PR			TREATMENT OF MILD HYPERTENSION STUDY - FINAL RESULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR MASS; CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; ST-SEGMENT DEPRESSION; HIGH BLOOD-PRESSURE; DRUG-THERAPY; MYOCARDIAL-ISCHEMIA; PRIMARY PREVENTION; SERUM-CHOLESTEROL; NORMAL MEN	Objective.-To compare six antihypertensive interventions for the treatment of mild hypertension. Design.-Randomized, double-blind, placebo-controlled clinical trial. Setting.-Four hypertension screening and treatment centers in the United States. Participants.-Hypertensive men and women, aged 45 to 69 years, with diastolic blood pressure less than 100 mm Hg. Intervention.-Sustained nutritional-hygienic advice to all participants to reduce weight, dietary sodium intake, and alcohol intake, and increase physical activity. Participants were randomly allocated to take (1) placebo (n=234); (2) chlorthalidone (n=136); (3) acebutolol (n=132); (4) doxazosin mesylate (n=134); (5) amlodipine maleate (n=131); or (6) enalapril maleate (n=135). Main Outcome Measures.-Blood pressure, quality of life, side effects, blood lipid levels and analysis of other serum components, echocardiographic and electrocardiographic changes, and incidence of cardiovascular events over an average of 4.4 years of follow-up. Results.-Blood pressure reductions were sizable in all six groups, and were significantly greater for participants assigned to drug treatment than placebo (-15.9 vs -9.1 mm Hg for systolic blood pressure and -12.3 vs -8.6 mm Hg for diastolic blood pressure; P<.0001). After 4 years, 59% of participants assigned to placebo and 72% of participants given drug treatment continued on their initial medication as mono-therapy. A smaller percentage of participants assigned to the drug-treatment groups died or experienced a major nonfatal cardiovascular event than those assigned to the placebo group (5.1 % vs 7.3%; P=.21). After including other clinical events, the percentage of participants affected was 11.1 % for those in the drug-treatment groups and 16.2% for those in the placebo group (P=.03). Incidence rates of most resting electrocardiographic abnormalities were lower and quality of life was improved more for those assigned to drug-treatment groups rather than the placebo group. Differences among the five drug treatments did not consistently favor one group in terms of regression of left ventricular mass, blood lipid levels, and other outcome measures. Conclusions.-As an initial regimen, drug treatment in combination with nutritional-hygienic intervention was more effective in preventing cardiovascular and other clinical events than was nutritional-hygienic treatment alone. Drug-treatment group differences were minimal. Pending results from large-scale clinical trials to evaluate drug treatments for their effect on cardiovascular clinical events, these findings support the recommendations of the new fifth Joint National Committee report regarding treatment choices for people with stage 1 (''mild'') hypertension.	UNIV ALABAMA, DIV GEN & PREVENT MED, BIRMINGHAM, AL 35294 USA; UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA 15261 USA; UNIV MINNESOTA, SCH MED,DIV GEN MED, MINNEAPOLIS, MN 55455 USA; NORTHWESTERN UNIV, DEPT COMMUNITY HLTH & PREVENT MED, CHICAGO, IL 60611 USA; NHLBI, PREVENT & DEMONSTRAT RES BRANCH, BETHESDA, MD 20892 USA; UNIV MINNESOTA, SCH PUBL HLTH,DIV EPIDEMIOL, MINNEAPOLIS, MN 55414 USA; UNIV MINNESOTA, SCH MED,DIV CARDIOVASC DIS, MINNEAPOLIS, MN 55455 USA; UNIV MIAMI, DEPT EPIDEMIOL & PUBL HLTH, CORAL GABLES, FL 33124 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CARDIOL SECT, CHICAGO, IL 60612 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT PREVENT MED, CHICAGO, IL 60612 USA	University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Minnesota System; University of Minnesota Twin Cities; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Miami; Rush University; Rush University	NEATON, JD (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, 2221 UNIV AVE SE, ROOM 200, MINNEAPOLIS, MN 55414 USA.				NHLBI NIH HHS [R01-HL34767] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034767] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1985, J Hypertens, V3, P379; [Anonymous], 1991, Arch Intern Med, V151, P1413; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1990, Circulation, V82, P1616; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1979, JAMA, V242, P2562; [Anonymous], 1993, ARCH INTERN MED, V153, P154, DOI DOI 10.1001/archinte.1993.00410020010002; ARMSTRONG WF, 1982, AM J CARDIOL, V49, P1638, DOI 10.1016/0002-9149(82)90240-5; BARTEL A, 1971, ARCH INTERN MED, V128, P929, DOI 10.1001/archinte.128.6.929; BLAKE J, 1990, AM J MED, V88, P477, DOI 10.1016/0002-9343(90)90426-E; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; CASALE PN, 1985, J AM COLL CARDIOL, V6, P572, DOI 10.1016/S0735-1097(85)80115-7; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; Cochran W.G., 1967, STAT METHODS; COHEN JD, 1987, AM J CARDIOL, V60, P548, DOI 10.1016/0002-9149(87)90303-1; COX DR, 1972, J R STAT SOC B, V34, P187; CRAWFORD MH, 1978, ANN INTERN MED, V89, P1, DOI 10.7326/0003-4819-89-1-1; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DEANFIELD JE, 1984, AM J CARDIOL, V54, P1195, DOI 10.1016/S0002-9149(84)80066-1; DEANFIELD JE, 1985, AM J MED, V79, P18, DOI 10.1016/0002-9343(85)90489-9; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DYER AR, 1975, J CHRON DIS, V28, P571, DOI 10.1016/0021-9681(75)90070-3; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FERRARA LA, 1984, HYPERTENSION, V6, P755, DOI 10.1161/01.HYP.6.5.755; GLASSER SP, 1989, J CLIN PHARMACOL, V29, P791, DOI 10.1002/j.1552-4604.1989.tb03421.x; GOTTDIENER J, 1992, Journal of the American College of Cardiology, V19, p85A; GRANDITS GA, 1987, CIRCULATION, V76, P393; Grimm R. H., 1989, HYPERTENSION S, V13, P1131; HEDBLAD B, 1989, EUR HEART J, V10, P149, DOI 10.1093/oxfordjournals.eurheartj.a059455; HEGELAND A, 1980, AM J MED, V0069, P00725; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1987, CIRCULATION, V75, P25; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LAIRD NM, 1984, BIOMETRICS, V31, P511; LEHTONEN A, 1984, ACTA MED SCAND, V216, P57; LEVY D, 1990, NEW ENGL J MED, V0322; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LIEBSON PR, 1993, CIRCULATION, V87, P476, DOI 10.1161/01.CIR.87.2.476; MACMAHON S, 1989, AM J CARDIOL, V63, P202, DOI 10.1016/0002-9149(89)90286-5; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASCIOLI SR, 1990, AM J CARDIOL, V66, pC32, DOI 10.1016/0002-9149(90)90760-X; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MIALL WE, 1983, BMJ-BRIT MED J, V287, P1249; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; O'Brien PC, 1984, BIOMETRICS, V31, P511; OFILI EO, 1991, CIRCULATION, V84, P137; PAULY MV, 1986, AM J MED, V81, P3, DOI 10.1016/0002-9343(86)90521-8; PRINEAS RJ, 1982, MINNESOTA CODE MANUA, P1; QUYYUMI AA, 1983, BRIT HEART J, V50, P460; RAUTAHARJU PM, 1987, CLIN INVEST MED, V10, P606; RAUTAHARJU PM, 1990, METHOD INFORM MED, V29, P362; REID DD, 1976, LANCET, V2, P979; ROBSON DJ, 1986, EUR HEART J, V7, P223, DOI 10.1093/oxfordjournals.eurheartj.a062055; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; SMITH WM, 1977, CIRC RES, V40, P98; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; Stamler J, 1989, Hypertension, V13, pI2; STAMLER J, 1987, AM J CARDIOL, V59, pG51, DOI 10.1016/0002-9149(87)90158-5; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STERN S, 1974, BRIT HEART J, V36, P481; WASSERTHEILSMOLLER S, 1992, ARCH INTERN MED, V152, P131, DOI 10.1001/archinte.152.1.131; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; WOLF H, 1986, 13TH P INT C EL 27TH, P1; WOLLAM GL, 1983, AM J MED, V75, P100, DOI 10.1016/0002-9343(83)90126-2; 1988, ARCH INTERN MED, V148, P1028; 1985, HYPERTENSION, V7, P105; 1985, BMJ, V29, P197; 1974, US DHEW75628 PUBL, V1	83	865	887	1	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1993	270	6					713	724		10.1001/jama.270.6.713	http://dx.doi.org/10.1001/jama.270.6.713			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ338	8336373				2022-12-28	WOS:A1993LQ33800026
J	SWISS, S; GILLER, JE				SWISS, S; GILLER, JE			RAPE AS A CRIME OF WAR - A MEDICAL PERSPECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VICTIMS	Although widespread, rape of women has been an underreported aspect of military conflict until recently. The current war in the former Yugoslavia has focused attention on the use of rape as a deliberate strategy to undermine community bonds and weaken resistance to aggression. In addition to providing treatment for individual survivors, the medical community has an important role to play in investigating and documenting incidents of rape. Such documentation can help to establish the magnitude of rape in war and hold perpetrators accountable. Since rape in war affects not only the individual but also the family and community to which the survivor belongs, the restoration of social and community bonds is central to the process of healing and must be addressed within the specific cultural setting.	MED FDN, KAMPALA, UGANDA		SWISS, S (corresponding author), PHYSICIANS HUMAN RIGHTS, WOMENS PROGRAM, 100 BOYLSTON ST, SUITE 702, BOSTON, MA 02116 USA.							BECKER JV, 1984, WOMEN HEALTH, V9, P5, DOI 10.1300/J013v09n04_02; BECKER JV, 1982, J SEX MARITAL THER, V8, P65, DOI 10.1080/00926238208405813; Bracken P J, 1992, Med War, V8, P155, DOI 10.1080/07488009208409041; Brownmiller, 1975, AGAINST OUR WILL; BURGESS AW, 1974, AM J PSYCHIAT, V131, P981; CATES W, 1984, SEXUALLY TRANSMITTED, P119; CLAY J, 1988, 25 CULT SURV INC CUL; ELLIS EM, 1980, WOMEN HEALTH, V5, P39; ELLIS EM, 1981, J ABNORM PSYCHOL, V90, P263, DOI 10.1037/0021-843X.90.3.263; GILLER JE, 1992, THESIS U LONDON; GILLER JE, 1991, LANCET, V337, P604; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; GOLDFELD AE, 1990, END MISSION REPORT S; Herman Judith, 2001, TRAUMA RECOVERY; Hough M., 1983, HOME OFFICE RES STUD, V76; King M C, 1991, Mol Genet Med, V1, P117; LABER J, 1993, NY REV BOOKS    0325, P3; LYKES MB, IN PRESS PSYCHOL WOM; MARCUSSEN H, 1991, EXAMINING TORTURE SU; PESAVENTO BH, 1993, JUN HARV MED SCH C C; Pritchard R. J., 1981, TOKYO WAR CRIMES TRI, V20, P49; SANTIAGO JM, 1985, AM J PSYCHIAT, V142, P1338; SIVARD R., 1991, WORLD MILITARY SOCIA; SWISS S, 1992, LIBERIA ANGUISH DIVI; SWISS S, 1991, LIBERAI WOMEN CHILDR; TIETZE C, 1960, FERTIL STERIL, V11, P485; 1947, TRIAL MAJOR WAR CRIM, V6, P393; 1991, LIBERIANS OUR FORGOT; 1993, ECN4199350 UN DOC; 1983, HUMAN RIGHTS DOCUMEN; 1993, ECN41993L21 UN DOC; 1947, TRIAL MAJOR WAR CRIM, V7, P456; 1993, RAPE KASHMIR CRIME W; 1992, BURMA RAPE FORCED LA; 1986, SERVICES VIETNAMESE, P8	35	92	92	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					612	615		10.1001/jama.270.5.612	http://dx.doi.org/10.1001/jama.270.5.612			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331761				2022-12-28	WOS:A1993LP43600027
J	WITTHUHN, BA; QUELLE, FW; SILVENNOINEN, O; YI, TL; TANG, B; MIURA, O; IHLE, JN				WITTHUHN, BA; QUELLE, FW; SILVENNOINEN, O; YI, TL; TANG, B; MIURA, O; IHLE, JN			JAK2 ASSOCIATES WITH THE ERYTHROPOIETIN RECEPTOR AND IS TYROSINE-PHOSPHORYLATED AND ACTIVATED FOLLOWING STIMULATION WITH ERYTHROPOIETIN	CELL			English	Article							SIGNAL TRANSDUCTION; CYTOPLASMIC REGION; PROTEIN-KINASE; DNA-BINDING; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; IL-2 RECEPTOR; BETA-CHAIN; FAMILY; GROWTH	Erythropoietin (EPO) regulates the proliferation and differentiation of erythroid cells through interaction with its receptor (EPOR). Although EPOR is a member of the cytokine receptor superfamily and lacks a kinase domain, EPO induces tyrosine phosphorylation, which is correlated with gene transcription and mitogenesis. Here we demonstrate that EPO induces tyrosine phosphorylation of JAK2 kinase and activates its in vitro autophosphorylation. Using EPOR mutants, phosphorylation and activation of kinase activity correlate with the induction of mitogenesis. Furthermore, JAK2 physically associates with a membrane-proximal region of the EPOR cytoplasmic domain that is required for biological activity. The results support the hypothesis that JAK2 is the kinase that couples EPO binding to tyrosine phosphorylation and mitogenesis.	NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; TOKYO MED & DENT UNIV, DEPT MED 1, TOKYO 113, JAPAN	New York University; Tokyo Medical & Dental University (TMDU)	WITTHUHN, BA (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA.		witthuhn, bruce/GSE-3193-2022	Miura, Osamu/0000-0002-0981-3054; Quelle, Frederick/0000-0002-1184-6170	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAMEN J, 1992, BLOOD, V80, P1923; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; FERRARI S, 1990, CELL GROWTH DIFFER, V1, P543; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPUR AG, 1992, ONCOGENE, V7, P1347; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IHLE JN, 1993, IN PRESS SEM IMMUNOL; ISFORT R, 1988, J BIOL CHEM, V263, P19203; KRANTZ SB, 1991, BLOOD, V77, P419; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MANO H, 1993, ONCOGENE, V8, P417; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; QUELLE FW, 1991, J BIOL CHEM, V266, P609; QUELLE FW, 1992, J BIOL CHEM, V267, P17055; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TORIGOE T, 1992, BLOOD, V80, P617; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	53	1092	1129	3	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 30	1993	74	2					227	236		10.1016/0092-8674(93)90414-L	http://dx.doi.org/10.1016/0092-8674(93)90414-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343951				2022-12-28	WOS:A1993LP72600004
J	KITSBERG, D; SELIG, S; BRANDEIS, M; SIMON, I; KESHET, I; DRISCOLL, DJ; NICHOLLS, RD; CEDAR, H				KITSBERG, D; SELIG, S; BRANDEIS, M; SIMON, I; KESHET, I; DRISCOLL, DJ; NICHOLLS, RD; CEDAR, H			ALLELE-SPECIFIC REPLICATION TIMING OF IMPRINTED GENE REGIONS	NATURE			English	Article							GROWTH FACTOR-II; HUMAN H19 GENE; PRADER-WILLI; INSITU HYBRIDIZATION; DNA METHYLATION; X-CHROMOSOME; TME LOCUS; MOUSE; EXPRESSION; ANGELMAN	SEVERAL lines of evidence suggest that the paternal and maternal genomes may have different expression patterns in the developing organism1 and this has been confirmed by the identification of endogenous genes that are parentally imprinted in the mouse2-5. little is known about the precise mechanisms involved in the process, but structural differences between the two alleles must somehow provide cis-acting signals for directing parental-specific transcription. Cell-cycle replication time is one parameter that has been shown to be associated with both tissue-specific gene expression6,7 and the allele-specific transcription patterns of the X chromosomes in female cells8. For this reason we have examined the replication timing patterns for the chromosomal regions containing the imprinted genes Igf2, Igf2r, Hl9 and Snrpn in the mouse. At all of these sites, and their corresponding positions in the human genome, the two homologous alleles replicate asynchronously and it is always the paternal allele that is early-replicating. Thus imprinted genes appear to be embedded in large DNA domains with differential replication patterns, which may provide a structural imprint for parental identity.	UNIV FLORIDA,COLL MED,DIV GENET,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT NEUROSCI,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	KITSBERG, D (corresponding author), HEBREW UNIV JERUSALEM,SCH MED,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL.			Simon, Itamar/0000-0002-8517-1903				BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BELL G, 1982, P NATL ACAD SCI USA, V82, P6450; CHEN TR, 1981, AM J MED GENET, V9, P61, DOI 10.1002/ajmg.1320090111; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DITTRICH B, 1992, HUM GENET, V90, P313; DRISCOLL DJ, 1992, GENOMICS, V13, P917, DOI 10.1016/0888-7543(92)90001-9; DRISCOLL MC, 1989, P NATL ACAD SCI USA, V86, P7470, DOI 10.1073/pnas.86.19.7470; DROUIN R, 1990, CHROMOSOMA, V99, P272; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; HAAS OA, 1992, NATURE, V359, P414, DOI 10.1038/359414a0; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; IZUMIKAWA Y, 1991, HUM GENET, V87, P1, DOI 10.1007/BF01213082; JOHNSON DR, 1974, GENETICS, V76, P795; JUNIEN C, 1991, CYTOGENET CELL GENET, V58, P459, DOI 10.1159/000133171; Kuwano Akira, 1992, Human Molecular Genetics, V1, P417, DOI 10.1093/hmg/1.6.417; LEFF SE, 1992, NAT GENET, V2, P1; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; NICHOLLS RD, 1993, P NATL ACAD SCI USA, V90, P2050, DOI 10.1073/pnas.90.5.2050; NICHOLLS RD, 1992, SEMINARS DEV BIOL, V3, P139; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OZCELIK T, 1992, NAT GENET, V2, P2; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RANIER S, 1993, NATURE, V362, P747; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; RINCHIK EM, 1993, NATURE, V361, P72, DOI 10.1038/361072a0; RINCHIK EM, 1992, MAMM GENOME, V3, pS104, DOI 10.1007/BF00648425; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SAUNDERS AM, 1990, GENOMICS, V8, P525, DOI 10.1016/0888-7543(90)90040-2; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHOELSON S, 1983, NATURE, V302, P540, DOI 10.1038/302540a0; SOLTER D, 1988, ANNU REV GENET, V22, P127; SUGAWARA O, 1985, CYTOGENET CELL GENET, V39, P210, DOI 10.1159/000132137; TAKAGI N, 1973, EXP CELL RES, V78, P127, DOI 10.1016/0014-4827(73)90046-3; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	39	342	346	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					459	463		10.1038/364459a0	http://dx.doi.org/10.1038/364459a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332218				2022-12-28	WOS:A1993LP64000060
J	ADELMAN, AG; COHEN, EA; KIMBALL, BP; BONAN, R; RICCI, DR; WEBB, JG; LARAMEE, L; BARBEAU, G; TRABOULSI, M; CORBETT, BN; SCHWARTZ, L; LOGAN, AG				ADELMAN, AG; COHEN, EA; KIMBALL, BP; BONAN, R; RICCI, DR; WEBB, JG; LARAMEE, L; BARBEAU, G; TRABOULSI, M; CORBETT, BN; SCHWARTZ, L; LOGAN, AG			A COMPARISON OF DIRECTIONAL ATHERECTOMY WITH BALLOON ANGIOPLASTY FOR LESIONS OF THE LEFT ANTERIOR DESCENDING CORONARY-ARTERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESTENOSIS	Background. Restenosis is a major limitation of coronary angioplasty. Directional coronary atherectomy was developed with the expectation that it would provide better results than angioplasty, including a lower rate of restenosis. We undertook a randomized, multicenter trial to compare the rates of restenosis for atherectomy and angioplasty when used to treat lesions of the proximal left anterior descending coronary artery. Methods. Of 274 patients referred for first-time, non-surgical revascularization of lesions of the proximal left anterior descending coronary artery, 138 were randomly assigned to undergo atherectomy and 136 to undergo angioplasty; 257 of 265 eligible patients (97 percent) underwent follow-up angiography at a median of 5.9 months. Computer-assisted quantitative measurements of luminal dimensions were determined from the angiograms obtained before and immediately after the procedure and at follow-up. The primary end point of restenosis was defined as stenosis of more than 50 percent of the vessel's diameter at follow-up. Results. Quantitative analysis showed that the procedural success rate was higher in patients who underwent atherectomy than in those who had angioplasty (94 percent vs. 88 percent, P = 0.061); there was no significant difference in the frequency of major in-hospital complications (5 percent vs. 6 percent). At follow-up, the rate of restenosis was 46 percent after atherectomy and 43 percent after angioplasty (P = 0.71). Despite a larger initial gain in the minimal luminal diameter with atherectomy (mean [+/-SD], 1.45+/-0.47 vs. 1.16+/-0.44 mm; P<0.001), there was a larger late loss (0.79+/-0.61 vs. 0.47+/-0.64 mm, P<0.001), resulting in a similar minimal luminal diameter in the two groups at follow-up (1.55+/-0.60 vs. 1.61+/-0.68, P = 0.44). The clinical outcomes at six months were not significantly different between the two groups. Conclusions. The role of atherectomy in percutaneous coronary revascularization remains to be fully defined. However, as compared with angioplasty, atherectomy did not result in better late angiographic or clinical outcomes in patients with lesions of the proximal left anterior descending coronary artery.	SUNNYBROOK HLTH SCI CTR, TORONTO, ON, CANADA; TORONTO HOSP, TORONTO, ON, CANADA; INST CARDIOL MONTREAL, MONTREAL H1T 1C8, QUEBEC, CANADA; VANCOUVER GEN HOSP, VANCOUVER V5Z 1M9, BC, CANADA; ST PAULS HOSP, VANCOUVER V6Z 1Y6, BC, CANADA; OTTAWA HEART INST, OTTAWA, ON, CANADA; HOP LAVAL, INST CARDIOL, QUEBEC CITY, PQ, CANADA; FOOTHILLS PROV GEN HOSP, CALGARY, AB, CANADA; NEW BRUNSWICK HEART CTR, ST JOHN, NB, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Universite de Montreal; Institut de Cardiologie de Montreal; University of British Columbia; St. Paul's Hospital; University of Saskatchewan; University of Ottawa; University of Ottawa Heart Institute; Laval University; University of Calgary	ADELMAN, AG (corresponding author), MT SINAI HOSP, CARDIOVASC CLIN RES LAB, 1609-600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Logan, Alexander G/E-4626-2013					ADELMAN AG, 1992, CAN J CARDIOL, V8, P702; BEATT KJ, 1992, J AM COLL CARDIOL, V19, P258, DOI 10.1016/0735-1097(92)90475-3; BEATT KJ, 1990, J AM COLL CARDIOL, V15, P491, DOI 10.1016/S0735-1097(10)80081-6; BOURASSA MG, 1991, J AM COLL CARDIOL, V18, P368, DOI 10.1016/0735-1097(91)90588-Z; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; ELLIS SG, 1991, CIRCULATION, V84, P644, DOI 10.1161/01.CIR.84.2.644; FISHMAN RF, 1992, J AM COLL CARDIOL, V20, P1101, DOI 10.1016/0735-1097(92)90365-T; FRIERSON JH, 1992, J AM COLL CARDIOL, V19, P745, DOI 10.1016/0735-1097(92)90512-L; HINOHARA T, 1992, J AM COLL CARDIOL, V20, P623, DOI 10.1016/0735-1097(92)90017-H; HINOHARA T, 1990, CIRCULATION, V81, P79; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; KIMBALL BP, 1992, AM HEART J, V124, P1459, DOI 10.1016/0002-8703(92)90057-3; KIMBALL BP, 1992, CHEST, V102, P1676, DOI 10.1378/chest.102.6.1676; KUNTZ RE, 1992, CIRCULATION, V86, P1394, DOI 10.1161/01.CIR.86.5.1394; KUNTZ RE, 1992, CIRCULATION, V86, P1827, DOI 10.1161/01.CIR.86.6.1827; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; POPMA JJ, 1991, CIRCULATION, V84, P1426, DOI 10.1161/01.CIR.84.3.1426; POPMA JJ, 1991, J AM COLL CARDIOL, V18, P1183, DOI 10.1016/0735-1097(91)90534-G; POPMA JJ, 1992, J AM COLL CARDIOL, V19, P1372, DOI 10.1016/0735-1097(92)90590-J; RENSING BJ, 1992, J AM COLL CARDIOL, V19, P939, DOI 10.1016/0735-1097(92)90274-Q; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V19, P267, DOI 10.1016/0735-1097(92)90476-4; SERRUYS PW, 1992, BRIT HEART J, V68, P417; SERRUYS PW, 1991, BRIT HEART J, V66, P122; SIMPSON JB, 1990, CIRCULATION, V82, P313; UMANS VA, 1991, AM J CARDIOL, V68, P534, DOI 10.1016/0002-9149(91)90793-K	26	258	260	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					228	233		10.1056/NEJM199307223290402	http://dx.doi.org/10.1056/NEJM199307223290402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM682	8316267				2022-12-28	WOS:A1993LM68200002
J	KIRSCHNER, KL; BETTS, HB				KIRSCHNER, KL; BETTS, HB			PHYSICAL MEDICINE AND REHABILITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											KIRSCHNER, KL (corresponding author), REHABIL INST CHICAGO,CHICAGO,IL 60611, USA.							DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; DEYO RA, 1990, ANN INTERN MED, V112, P598, DOI 10.7326/0003-4819-112-8-598; DIETZEN CJ, 1992, ARCH PHYS MED REHAB, V73, P652; HERRING SA, 1991, PHYSICAL MED REHABIL, V2, P1; LEHMANN JF, 1978, ARCH PHYS MED REHAB, V59, P410; LEVINSON SF, 1991, ARCH PHYS MED REHAB, V72, P690; LINSENMEYER TA, 1991, ARCH PHYS MED REHAB, V72, P747; POPE AM, 1991, DISABILITY AM NATION; ROGERS J, 1991, MOTHER TO BE GUIDE P; Saal J A, 1990, Orthop Rev, V19, P691; SAAL JA, 1990, PHYSICAL MED REHABIL, V4, P175; SLIWA JA, 1991, ARCH PHYS MED REHAB, V72, P759; TURNER JA, 1992, JAMA-J AM MED ASSOC, V268, P907, DOI 10.1001/jama.268.7.907; WANG YH, 1992, AM J PHYS MED REHAB, V71, P328, DOI 10.1097/00002060-199212000-00004; WHITE MJ, 1992, AM J PHYS MED REHAB, V71, P225, DOI 10.1097/00002060-199208000-00005; YARKONY GM, 1990, AM J PHYS MED REHAB, V69, P81, DOI 10.1097/00002060-199004000-00007; YARKONY GM, 1992, NEUROLOGICAL DISORDE, P203; 1990, VITAL HLTH STAT, V10	19	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					248	250		10.1001/jama.270.2.248	http://dx.doi.org/10.1001/jama.270.2.248			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315751				2022-12-28	WOS:A1993LL36800038
J	EKELUND, H; FINNSTROM, O; GUNNARSKOG, J; KALLEN, B; LARSSON, Y				EKELUND, H; FINNSTROM, O; GUNNARSKOG, J; KALLEN, B; LARSSON, Y			ADMINISTRATION OF VITAMIN-K TO NEWBORN-INFANTS AND CHILDHOOD-CANCER	BRITISH MEDICAL JOURNAL			English	Article							REGISTRY	Objectives-To investigate whether childhood cancer is associated with intramuscular administration of vitamin K to newborn infants. Design-Routines for administration of vitamin K to infants born after normal deliveries during 1973-89 were obtained from maternity hospitals. Occurrence of cancer up to the end of 1991 was identified by comparing these records with the national cancer registry. Adherence to the routine method of administering vitamin K was checked with the medical records of a sample of 396 infants (196 who had developed childhood cancer and 200 controls). Setting-All maternity hospitals in Sweden. Subjects-1 384 424 full term infants born after non-instrumental deliveries, 1 085 654 of whom were born in units where vitamin K was routinely given by intramuscular injection and 272 080 of whom were born where it was given orally. Main outcome measures-Odds ratios for cancer after intramuscular administration of vitamin K versus oral administration after stratification for year of birth. Results-Adherence to routine method of administering vitamin K was 92% in the 235 cases where individual information could be found. The risk of cancer after intramuscular administration of vitamim K was not elevated compared with that after oral administration: odds ratios of 1.01 (95% confidence interval 0.88 to 1.17) for all childhood cancers and 0.90 (0.70 to 1.16) for childhood leukaemia. Conclusions-The alleged association between intramuscular vitamin K prophylaxis to newborn infants and childhood cancer could not be verified in the present study of full term infants born after non-instrumental delivery.	LUND UNIV,DEPT EMBRYOL,BISKOPSGATAN 7,S-22362 LUND,SWEDEN; NATL BOARD HLTH,DEPT PUBL HLTH & EPIDEMIOL,S-10601 STOCKHOLM,SWEDEN; LINKOPING UNIV HOSP,DEPT PAEDIAT,S-58185 LINKOPING,SWEDEN	Lund University; National Board of Health & Welfare; Linkoping University								CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; Ericson A, 1991, Acta Obstet Gynecol Scand, V70, P111, DOI 10.3109/00016349109006191; FORSBERG JG, 1990, APMIS, V98, P37, DOI 10.1111/j.1699-0463.1990.tb00999.x; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HULL D, 1992, BRIT MED J, V305, P326, DOI 10.1136/bmj.305.6849.326; HULL D, 1992, BMJ, V305, P709; PERSHAGEN G, 1992, INT J EPIDEMIOL, V21, P1, DOI 10.1093/ije/21.1.1; ZACK M, 1991, CANCER RES, V51, P3696; 1989, CANCER REGISTRY CANC	10	82	83	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					89	91		10.1136/bmj.307.6896.89	http://dx.doi.org/10.1136/bmj.307.6896.89			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343734	Bronze, Green Published			2022-12-28	WOS:A1993LM58500020
J	JACKSON, R; BARHAM, P; BILLS, J; BIRCH, T; MCLENNAN, L; MACMAHON, S; MALING, T				JACKSON, R; BARHAM, P; BILLS, J; BIRCH, T; MCLENNAN, L; MACMAHON, S; MALING, T			MANAGEMENT OF RAISED BLOOD-PRESSURE IN NEW-ZEALAND - A DISCUSSION DOCUMENT	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; STROKE	A report to the National Advisory Committee on Core Health and Disability Support Services, New Zealand, on the management of raised blood pressure recommends that decisions to treat raised blood pressure should be based primarily on the estimated absolute risk of cardiovascular disease rather than on blood pressure alone. In general, patients with a blood pressure of 150-170 mm Hg systolic or 90-100 mm Hg diastolic, or both, should be given treatment to lower blood pressure if the risk of a major cardiovascular disease event in 10 years is more than about 20%. The results of clinical trials indicate that, at this level of absolute risk, 150 people would require treatment to reduce the annual number of cardiovascular events by about one. Implementation of these recommendations may result in a smaller proportion of people aged under 60, particularly women, receiving treatment but an increased proportion of older people treated. In the absence of specific contraindications, low dose diuretics and low dose beta blockers should be considered for first line treatment, since for only these drug groups is there direct evidence of reduced risk of stroke and coronary disease in people with raised blood pressure.	UNIV AUCKLAND,DEPT GEN PRACTICE,GOODFELLOW UNIT,AUCKLAND,NEW ZEALAND; ROTHERHAM MED CTR,CANTERBURY,NEW ZEALAND; HOKIANGA HLTH SERV,RAWENE,NEW ZEALAND; WAITANGIRUA HLTH CTR,WELLINGTON,NEW ZEALAND; UNIV AUCKLAND,DEPT MED,CLIN TRIALS RES UNIT,AUCKLAND,NEW ZEALAND; UNIV OTAGO,WELLINGTON SCH MED,DEPT MED,DUNEDIN,NEW ZEALAND	University of Auckland; University of Auckland; University of Otago	JACKSON, R (corresponding author), UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934; Maling, Tim/0000-0002-5994-479X				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; CARLSEN JE, 1990, BRIT MED J, V300, P975, DOI 10.1136/bmj.300.6730.975; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CRUICKSHANK JM, 1987, LANCET, V1, P581; KAWACHI I, 1990, SOC SCI MED, V31, P1239, DOI 10.1016/0277-9536(90)90130-K; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RUSSEL D, 1991, LIFE NZ SURVEY COMMI; 1988, EUR HEART J, V9, P8; 1989, BMJ, V298, P694; 1988, ARCH INTERN MED, V148, P1023; 1989, J HYPERTENS, V7, P689	12	230	233	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					107	110		10.1136/bmj.307.6896.107	http://dx.doi.org/10.1136/bmj.307.6896.107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343706	Green Published, Bronze			2022-12-28	WOS:A1993LM58500029
J	SCHRODER, RR; MANSTEIN, DJ; JAHN, W; HOLDEN, H; RAYMENT, I; HOLMES, KC; SPUDICH, JA				SCHRODER, RR; MANSTEIN, DJ; JAHN, W; HOLDEN, H; RAYMENT, I; HOLMES, KC; SPUDICH, JA			3-DIMENSIONAL ATOMIC MODEL OF F-ACTIN DECORATED WITH DICTYOSTELIUM MYOSIN-S1	NATURE			English	Article							HEAVY-CHAIN; MUSCLE; FILAMENTS	ELUCIDATION of the molecular contacts between actin and myosin is central to understanding the force-generating process in muscle and other cells. Actin, a highly conserved globular protein found in all eukaryotes, polymerizes into filaments (F-actin) for most of its biological functions. Myosins, which are more diverse in sequence, share a conserved globular head of about 900 amino acids in length (subfragment-1 or S1) at the N-terminal end of the molecule. S1 contains all the elements necessary for mechanochemical force transduction in vitro1,2. Here we report an atomic model for the actomyosin complex produced by combining the atomic X-ray structure of F-actin3,4 and chicken myosin S1(5) with a three-dimensional reconstruction from electron micrographs of frozen-hydrated F-actin decorated with recombinant Dictyostelium myosin S1. The accuracy of the reconstruction shows the position of actin and myosin molecules unambiguously.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53705; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53705; STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305	MRC National Institute for Medical Research; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Stanford University	SCHRODER, RR (corresponding author), MAX PLANCK INST MED RES,DEPT BIOPHYS,JAHNSTR 29,W-6900 HEIDELBERG,GERMANY.		Manstein, Dietmar J. J/M-1034-2013; Manstein, Dietmar J./AAG-2640-2019; rayment, ivan/A-2720-2008; Schröder, Rasmus R/S-6220-2016	Manstein, Dietmar J. J/0000-0003-0763-0147; Manstein, Dietmar J./0000-0003-0763-0147; rayment, ivan/0000-0001-9279-7835; Holmes, Kenneth/0000-0001-8894-9453				BRENNER B, 1982, P NATL ACAD SCI-BIOL, V79, P7288, DOI 10.1073/pnas.79.23.7288; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; GEEVES MA, 1992, PHILOS T ROY SOC B, V336, P63, DOI 10.1098/rstb.1992.0045; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LORENZ M, IN PRESS J MOL BIOL; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MANSTEIN DJ, 1989, SCIENCE, V246, P656, DOI 10.1126/science.2530629; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOORE PB, 1970, J MOL BIOL, V50, P279, DOI 10.1016/0022-2836(70)90192-0; ONISHI H, 1990, J BIOL CHEM, V265, P19362; RAYMENT I, IN PRESS SCIENCE; RITCHIE MD, IN PRESS P NATN ACAD; SCHRODER RR, 1990, J STRUCT BIOL, V105, P28, DOI 10.1016/1047-8477(90)90095-T; SCHRODER RR, IN PRESS 51ST P MSA; SMITH MF, 1992, J MOL BIOL, V226, P763, DOI 10.1016/0022-2836(92)90631-S; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TROUNG T, 1992, J BIOL CHEM, V267, P9767	22	289	290	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					171	174		10.1038/364171a0	http://dx.doi.org/10.1038/364171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321290				2022-12-28	WOS:A1993LL36700057
J	TALBOT, WS; SWYRYD, EA; HOGNESS, DS				TALBOT, WS; SWYRYD, EA; HOGNESS, DS			DROSOPHILA TISSUES WITH DIFFERENT METAMORPHIC RESPONSES TO ECDYSONE EXPRESS DIFFERENT ECDYSONE RECEPTOR ISOFORMS	CELL			English	Article							IMAGINAL DISKS; INDUCIBLE GENE; ESTROGEN-RECEPTOR; RETINOIC ACID; DNA-BINDING; EARLY PUFF; ENCODES 2; C-JUN; MELANOGASTER; PROTEIN	In D. melanogaster a pulse of the steroid hormone ecdysone triggers the larval-to-adult metamorphosis, a complex process in which this hormone induces imaginal tissues to generate adult structures and larval tissues to degenerate. We show that the EcR gene encodes three ecdysone receptor isoforms (EcR-A, EcR-B1, and EcR-B2) that have common DNA- and hormone-binding domains but different N-terminal regions. We have used isoform-specific monoclonal antibodies to show that at the onset of metamorphosis different ecdysone target tissues express different isoform combinations in a manner consistent with the proposition that the different metamorphic responses of these tissues require different combinations of the EcR isoforms. We have also determined temporal developmental profiles of the EcR isoforms and their mRNAs in whole animals, showing that different isoforms predominate at different developmental stages that are marked by a pulse of ecdysone.	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA	Stanford University; Stanford University								ASHBURNER M, 1973, COLD SPRING HARB SYM, V38, P655; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BATE M, 1991, DEVELOPMENT, V112, P755; Bodenstein D., 1950, BIOL DROSOPHILA, P275; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; BURTIS KC, 1985, THESIS STANFORD U ST; CHERBAS L, 1986, J MOL BIOL, V189, P617, DOI 10.1016/0022-2836(86)90492-4; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; CONDIC ML, 1991, DEVELOPMENT, V111, P23; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DEUTSCH J, 1989, DEV GENET, V10, P220, DOI 10.1002/dvg.1020100311; DIBELLO PR, 1991, GENETICS, V129, P385; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FRISTROM JW, 1977, AM ZOOL, V17, P671; FRISTROM JW, 1973, DEV BIOL, V33, P441, DOI 10.1016/0012-1606(73)90149-8; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GUAY PS, 1991, GENETICS, V129, P169; JOHNSON FB, 1990, GENE DEV, V4, P1044, DOI 10.1101/gad.4.6.1044; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; KOELLE MR, 1992, THESIS STANFORD U ST; KOELLE MR, 1993, IN PRESS P NATL ACAD, V90; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ORO AE, 1992, DEVELOPMENT, V115, P449; PAINESAUNDERS S, 1990, DEV BIOL, V140, P337, DOI 10.1016/0012-1606(90)90084-V; PONTA H, 1990, CELL, V62, P1189; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; RICHARDS G, 1982, ROUX ARCH DEV BIOL, V191, P103, DOI 10.1007/BF00848447; RIDDIFORD LM, 1993, IN PRESS DEV DROSOPH; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; ROSELAND CR, 1979, ROUX ARCH DEV BIOL, V186, P235, DOI 10.1007/BF00848591; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAKURAI S, 1989, GEN COMP ENDOCR, V75, P204, DOI 10.1016/0016-6480(89)90072-5; Sakurai S., 1990, P83; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SEGRAVES WA, 1988, THESIS STANFORD U ST; TALBOT WS, 1993, THESIS STANFORD U ST; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	59	493	510	1	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1323	1337		10.1016/0092-8674(93)90359-X	http://dx.doi.org/10.1016/0092-8674(93)90359-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324824	Bronze			2022-12-28	WOS:A1993LL20900008
J	KOHL, NE; MOSSER, SD; DESOLMS, SJ; GIULIANI, EA; POMPLIANO, DL; GRAHAM, SL; SMITH, RL; SCOLNICK, EM; OLIFF, A; GIBBS, JB				KOHL, NE; MOSSER, SD; DESOLMS, SJ; GIULIANI, EA; POMPLIANO, DL; GRAHAM, SL; SMITH, RL; SCOLNICK, EM; OLIFF, A; GIBBS, JB			SELECTIVE-INHIBITION OF RAS-DEPENDENT TRANSFORMATION BY A FARNESYLTRANSFERASE INHIBITOR	SCIENCE			English	Article							MURINE SARCOMA-VIRUS; PROTEIN FARNESYLTRANSFERASE; GERANYLGERANYLTRANSFERASE; TRANSFERASE; SEQUENCE; HARVEY; ISOPRENYLATION; IDENTIFICATION; REQUIREMENT; CEREVISIAE	To acquire transforming potential, the precursor of the Ras oncoprotein must undergo farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide. Inhibitors of the enzyme that catalyzes this modification, farnesyl protein transferase (FPTase), have therefore been suggested as anticancer agents for tumors in which Ras contributes to transformation. The tetrapeptide analog L-731,735 is a potent and selective inhibitor of FPTase in vitro. A prodrug of this compound, L-731,734, inhibited Ras processing in cells transformed with v-ras. L-731,734 decreased the ability of v-ras-transformed cells to form colonies in soft agar but had no effect on the efficiency of colony formation of cells transformed by either the v-raf or v-mos oncogenes. The results demonstrate selective inhibition of ras-dependent cell transformation with a synthetic organic inhibitor of FPTase.	MERCK RES LABS,DEPT CANC RES,W POINT,PA 19486; MERCK RES LABS,DEPT MED CHEM,W POINT,PA 19486	Merck & Company; Merck & Company								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DECLUE JE, 1991, CANCER RES, V51, P712; DHAR R, 1984, NUCLEIC ACIDS RES, V12, P3611, DOI 10.1093/nar/12.8.3611; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P2674, DOI 10.1073/pnas.81.9.2674; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEIMBROOK D, UNPUB; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JOLY A, 1991, J BIOL CHEM, V266, P13495; KARKAS JD, UNPUB; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOHL NE, UNPUB; KOHN N, UNPUB; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MOSSER SD, UNPUB; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; PRENDERGAST GC, UNPUB; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, ONCOGENE, V6, P2297; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILSO FR, UNPUB; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M	47	619	732	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1934	1937		10.1126/science.8316833	http://dx.doi.org/10.1126/science.8316833			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8316833				2022-12-28	WOS:A1993LJ34900041
J	DENG, XW				DENG, XW			FRESH VIEW OF LIGHT SIGNAL-TRANSDUCTION IN PLANTS	CELL			English	Review							ARABIDOPSIS-THALIANA; GENE-EXPRESSION; PHYTOCHROME; PROTEIN				DENG, XW (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511, USA.		Deng, Xing Wang/ABF-4107-2020					AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ALGARRA P, 1993, FEBS LETT, V315, P69, DOI 10.1016/0014-5793(93)81135-M; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1992, DEVELOPMENT, V115, P337; CLARK GB, 1993, PLANT J, V4, P399, DOI 10.1046/j.1365-313X.1993.04020399.x; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; HOU YM, 1993, PLANT CELL, V5, P329, DOI 10.1105/tpc.5.3.329; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; LAM E, 1989, MOL CELL BIOL, V9, P4819, DOI 10.1128/MCB.9.11.4819; LISCUM E, 1993, PLANT PHYSIOL, V103, P15, DOI 10.1104/pp.103.1.15; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; NAGATANI A, 1993, PLANT PHYSIOL, V102, P269, DOI 10.1104/pp.102.1.269; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; PARKS BM, 1993, PLANT CELL, V5, P39, DOI 10.1105/tpc.5.1.39; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; REYMOND P, 1992, P NATL ACAD SCI USA, V89, P4718, DOI 10.1073/pnas.89.10.4718; ROMERO LC, 1993, P NATL ACAD SCI USA, V90, P1465, DOI 10.1073/pnas.90.4.1465; ROMERO LC, 1991, FEBS LETT, V282, P341, DOI 10.1016/0014-5793(91)80509-2; SCHNEIDERPOETSCH HAW, 1992, PHOTOCHEM PHOTOBIOL, V56, P839, DOI 10.1111/j.1751-1097.1992.tb02241.x; SHINOMURA T, 1994, IN PRESS PLANT PHYSL; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; VONARNIM AG, 1993, J BIOL CHEM, V268, P19626; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; YOSHIDA K, 1993, P NATL ACAD SCI USA, V90, P6636, DOI 10.1073/pnas.90.14.6636	29	135	142	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					423	426		10.1016/0092-8674(94)90107-4	http://dx.doi.org/10.1016/0092-8674(94)90107-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313465				2022-12-28	WOS:A1994MX20700004
J	LANG, RA; BISHOP, JM				LANG, RA; BISHOP, JM			MACROPHAGES ARE REQUIRED FOR CELL-DEATH AND TISSUE REMODELING IN THE DEVELOPING MOUSE EYE	CELL			English	Article							COLONY-STIMULATING FACTOR; SIGNAL RECOGNITION PARTICLE; CSF TRANSGENIC MICE; GENETIC ABLATION; DIPHTHERIA-TOXIN; IMMUNOHISTOCHEMICAL LOCALIZATION; EXPRESSION; DNA; DIFFERENTIATION; ANTIGEN	To identify and characterize tissue remodeling processes mediated by macrophages, we have generated transgenic mice in which diphtheria toxin is expressed from a macrophage-specific transgene. Expression of the transgene disrupts subsets of mature macrophages in both the eye and the peritoneal cavity and results in the persistence of two normally transient ocular tissues, the hyaloid vasculature and the pupillary membrane. Furthermore, the cells comprising the pupillary membrane appear alive up to 14 days after the structure is normally remodeled, suggesting that the macrophage actively elicits target cell death. Thus, these transgenic mice provide direct evidence for the active involvement of macrophages in developmentally programed tissue remodeling and identify the hyaloid vessels and the pupillary membrane in the eye as targets of macrophage-mediated remodeling.	UNIV CALIF SAN FRANCISCO,GW HOOPER FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Lang, Richard/E-5578-2011	Lang, Richard/0000-0002-5212-254X				AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BALAZS EA, 1980, A GRAEF ARCH KLIN EX, V213, P71, DOI 10.1007/BF00413534; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BLEIER R, 1982, J NEUROPATH EXP NEUR, V41, P315, DOI 10.1097/00005072-198205000-00006; BLOOM GUNNAR D., 1965, EXP EYE RES, V4, P249, DOI 10.1016/S0014-4835(65)80038-0; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; CASSADY JR, 1957, ARCH OPHTHALMOL-CHIC, V58, P438; COHN P, 1982, J NEUROPATH EXP NEUR, V41, P330, DOI 10.1097/00005072-198205000-00007; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; CUTHBERTSON RA, 1990, EXP EYE RES, V51, P335, DOI 10.1016/0014-4835(90)90030-X; CUTHBERTSON RA, 1989, DEV BIOL, V134, P119, DOI 10.1016/0012-1606(89)90083-3; DANNA KJ, 1982, J VIROL METHODS, V5, P335, DOI 10.1016/0166-0934(82)90025-8; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVANS GA, 1989, GENE DEV, V3, P259, DOI 10.1101/gad.3.3.259; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRER I, 1990, NEUROSCIENCE, V39, P451, DOI 10.1016/0306-4522(90)90281-8; FUHRMAN LA, 1981, P NATL ACAD SCI USA, V78, P3418; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; HOGAN B, 1986, MANIPULATING MOUSE E; HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253; HUME DA, 1983, J EXP MED, V157, P1704, DOI 10.1084/jem.157.5.1704; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOLLY DJ, 1983, NUCLEIC ACIDS RES, V11, P1855, DOI 10.1093/nar/11.6.1855; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LANG RA, 1991, IN VIVO, V5, P501; LANG RA, 1991, GROWTH FACTORS, V6, P131; LATKER CH, 1981, OPHTHALMOL VIS SCI, V21, P689; MANN I, 1928, DEV ABNORMALITIES; MARAUD R, 1979, BIOL CELL, V35, pA2; MATSUO N, 1971, INVEST OPHTH VISUAL, V10, P108; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; METCALF D, 1992, J EXP MED, V175, P877, DOI 10.1084/jem.175.4.877; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; REESE AB, 1949, ARCH OPHTHALMOL-CHIC, V41, P527; REESE AB, 1955, AM J OPHTHALMOL, V40, P317, DOI 10.1016/0002-9394(55)91866-3; RITCHINSKAYA EB, 1965, ARKH ANAT GISTOL EMB, V48, P91; SALU P, 1985, OPHTHALMIC RES, V17, P125, DOI 10.1159/000265363; Saunders J.W., 1967, MAJOR PROBLEMS DEV B, P289; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; SZIRMAI JA, 1958, ARCH OPHTHALMOL-CHIC, V59, P34, DOI 10.1001/archopht.1958.00940020058006; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; Torrey TW, 1965, ORGANOGENESIS, P559; UCHIDA T, 1982, MOL ACTION TOXINS VI, P1; UCKER DS, 1991, NEW BIOL, V3, P103; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEBER R, 1964, J CELL BIOL, V22, P481, DOI 10.1083/jcb.22.2.481; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307	60	292	299	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					453	462		10.1016/0092-8674(93)80047-I	http://dx.doi.org/10.1016/0092-8674(93)80047-I			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348612				2022-12-28	WOS:A1993LT73900007
J	PEPPELENBOSCH, MP; TERTOOLEN, LGJ; HAGE, WJ; DELAAT, SW				PEPPELENBOSCH, MP; TERTOOLEN, LGJ; HAGE, WJ; DELAAT, SW			EPIDERMAL GROWTH FACTOR-INDUCED ACTIN REMODELING IS REGULATED BY 5-LIPOXYGENASE AND CYCLOOXYGENASE PRODUCTS	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; ARACHIDONIC-ACID; SIGNAL TRANSDUCTION; MORPHOLOGICAL-CHANGES; A431 CELLS; CARCINOMA-CELLS; TYROSINE KINASE; EGF-RECEPTOR; 3T3 CELLS; BINDING	In a number of cell types, epidermal growth factor (EGF) evokes dramatic morphological changes, cortical actin polymerization, and stress fiber breakdown. The molecular processes by which increased EGF receptor tyrosine kinase activity results in actin reorganization and morphological changes are unresolved. Recently, we demonstrated that arachidonic acid metabolites function in EGF signal transduction. We now report that in A431 cells, HeLa cells, and rat-1 fibroblasts, the EGF-induced cortical actin polymerization is produced by lipoxygenase metabolism, whereas in these cells stress fiber breakdown is mediated by cyclooxygenase metabolites. Also, the EGF-provoked rounding up in A431 cells is dependent on arachidonic acid metabolism. We conclude that leukotrienes and prostaglandins act in concert, as second messengers, to produce morphological effects and actin reorganization, providing a novel mechanism for directing growth factor-induced cytoskeletal changes.			PEPPELENBOSCH, MP (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.			Peppelenbosch, Maikel/0000-0001-9112-6028				BERK BC, 1990, J BIOL CHEM, V265, P17334; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DOWNEY GP, 1990, J CELL BIOL, V110, P1975, DOI 10.1083/jcb.110.6.1975; FAULSTICH H, 1977, HOPPESEYLERS Z PHYSL, V385, P181; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; KAWADA N, 1992, BIOCHEM J, V285, P367, DOI 10.1042/bj2850367; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MOLLENAAR WH, 1986, J BIOL CHEM, V251, P279; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PACE J, 1991, J BIOL CHEM, V266, P19938; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Rainsford KD, 1988, PROSTAGLANDINS BIOL, P52; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIJKEN PJ, 1991, J CELL SCI, V100, P491; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1981, EXP CELL RES, V134, P273, DOI 10.1016/0014-4827(81)90426-2; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	46	227	230	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					565	575		10.1016/0092-8674(93)80057-L	http://dx.doi.org/10.1016/0092-8674(93)80057-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348619				2022-12-28	WOS:A1993LT73900017
J	NEEFJES, JJ; MOMBURG, F; HAMMERLING, GJ				NEEFJES, JJ; MOMBURG, F; HAMMERLING, GJ			SELECTIVE AND ATP-DEPENDENT TRANSLOCATION OF PEPTIDES BY THE MHC-ENCODED TRANSPORTER	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; ANTIGEN PRESENTATION	Major histocompatibility complex (MHC) class I molecules present peptides derived from nuclear and cytosolic proteins to CD8+ T cells. These peptides are translocated into the lumen of the endoplasmic reticulum (ER) to associate with class I molecules. Two MHC-encoded putative transporter proteins, TAP1 and TAP2, are required for efficient assembly of class I molecules and presentation of endogenous peptides. Expression of TAP1 and TAP2 in a mutant cell line resulted in the delivery of an 11-amino acid oligomer model peptide to the ER. Peptide translocation depended on the sequence of the peptide, was adenosine triphosphate (ATP)-dependent, required ATP hydrolysis, and was inhibited in a concentration-dependent manner.	GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY; NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS	Helmholtz Association; German Cancer Research Center (DKFZ); Netherlands Cancer Institute			Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211				ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOPPELMAN B, 1992, P NATL ACAD SCI USA, V89, P3908, DOI 10.1073/pnas.89.9.3908; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEVY F, 1991, CELL, V67, P25; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NEEFJES JJ, UNPUB; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0	14	517	523	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					769	771		10.1126/science.8342042	http://dx.doi.org/10.1126/science.8342042			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8342042				2022-12-28	WOS:A1993LQ73000042
J	COLLINS, S				COLLINS, S			THE NEED FOR ADULT THERAPEUTIC CARE IN EMERGENCY FEEDING PROGRAMS - LESSONS FROM SOMALIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHRONIC ENERGY DEFICIENCY				COLLINS, S (corresponding author), CONCERN WORLDWIDE, 248-250 LAVENDER HILL, LONDON SW11 1LJ, ENGLAND.							DRUMMOND J, 1945, LANCET, V1, P282; FERROLUZZI A, 1992, EUR J CLIN NUTR, V46, P173; GOLDEN B, IN PRESS PRIMARY PRO; GOLDEN MHN, 1991, ACTA PAEDIATR SCAND, P95; GOPALAN C, 1975, Progress in Food and Nutrition Science, V1, P207; JAMES WPT, 1988, EUR J CLIN NUTR, V42, P969; Keys A, 1950, BIOL HUMAN STARVATIO, V2, DOI DOI 10.1017/S1352465801003010; LIPSCOMB FM, 1945, LANCET, V249, P313; MCCANCE R, 1951, MED RES COUNCIL SPEC, V275; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; SHETTY P, IN PRESS BODY MASS I; 1992, MMWR MORB MORTAL WKL, V41, P913	13	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					637	638						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331768				2022-12-28	WOS:A1993LP43600034
J	MCINTIRE, SL; JORGENSEN, E; HORVITZ, HR				MCINTIRE, SL; JORGENSEN, E; HORVITZ, HR			GENES REQUIRED FOR GABA FUNCTION IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							NERVOUS-SYSTEM; C-ELEGANS; ACID; ASCARIS	Gamma-AMINOBUTYRIC acid (GABA) neurotransmission is widespread in vertebrate and invertebrate nervous systems1. Here we use a genetic approach to identify molecules specific to GABA function. On the basis of the known in vivo roles of GABAergic neurons in controlling behaviour of the nematode Caenorhabditis elegans2, we identified mutants defective in GABA-mediated behaviours. Five genes are necessary either for GABAergic neuronal differentiation or for pre- or postsynaptic GABAergic function. The gene unc-30 is required for the differentiation of a specific type of GABAergic neuron, the type-D inhibitory motor neuron. The gene unc-25 is necessary for GABA expression and probably encodes the GABA biosynthetic enzyme glutamic acid decarboxylase. The genes unc-46 and unc-47 seem to be required for normal GABA release. Finally, the gene unc-49 is apparently necessary postsynaptically for the inhibitory effect of GABA on the body muscles and might encode a protein needed for the function of a GABA(A)-like receptor. Some of these genes are likely to encode previously unidentified proteins required for GABA function.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School								AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BRENNER S, 1974, GENETICS, V77, P71; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; COOPER JR, 1991, BIOCH BASIS NEUROPHA, V1, P133; ERLANDER MG, 1991, NEUROCHEM RES, V16, P215, DOI 10.1007/BF00966084; FERGUSON EL, 1985, GENETICS, V110, P17; FFRENCHCONSTANT RH, 1991, P NATL ACAD SCI USA, V88, P7209, DOI 10.1073/pnas.88.16.7209; GUASTELLA J, 1991, J COMP NEUROL, V307, P598, DOI 10.1002/cne.903070407; Hedgecock E, 1976, GABA METABOLISM CAEN; HODGKIN J, 1983, GENETICS, V103, P43; KASS IS, 1984, MOL BIOCHEM PARASIT, V13, P213, DOI 10.1016/0166-6851(84)90114-2; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MEIR E, 1991, NEUROCHEM INT, V19, P1; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS JH, 1990, GENETICS, V124, P855; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wood WB, 1988, NEMATODE CAENORHABDI	18	235	246	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					334	337		10.1038/364334a0	http://dx.doi.org/10.1038/364334a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332190				2022-12-28	WOS:A1993LN57000056
J	FEUSSNER, JR; SIMEL, DL				FEUSSNER, JR; SIMEL, DL			GENERAL INTERNAL-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									VET AFFAIRS MED CTR,DURHAM,NC	US Department of Veterans Affairs; Veterans Health Administration (VHA)	FEUSSNER, JR (corresponding author), DUKE UNIV,DURHAM,NC 27706, USA.							BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CARR P, 1992, J GEN INTERN MED, V7, P418, DOI 10.1007/BF02599159; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HSIAO WC, 1992, MED CARE, V30, pN561; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V226, P3289; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; PETERSDORF RG, 1992, NEW ENGL J MED, V326, P408, DOI 10.1056/NEJM199202063260610; ROTER D, 1991, MED CARE, V29, P1083; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; STIMMEL B, 1992, JAMA-J AM MED ASSOC, V268, P2060, DOI 10.1001/jama.268.15.2060; TARAGIN MI, 1992, AM J MED, V93, P537, DOI 10.1016/0002-9343(92)90582-V; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; 1991, LANCET, V337, P1235; 1991, NEW ENGL J MED, V325, P445	19	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					209	211		10.1001/jama.270.2.209	http://dx.doi.org/10.1001/jama.270.2.209			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315734				2022-12-28	WOS:A1993LL36800020
J	ACHESON, D				ACHESON, D			HEALTH, HUMANITARIAN RELIEF, AND SURVIVAL IN FORMER YUGOSLAVIA	BRITISH MEDICAL JOURNAL			English	Article								Since the World Health Organisation's effort in former Yugoslavia started in July 1992 it has been concerned with the public health policies of survival. It has provided advice to the United Nations High Commission for refugees, helped the voluntary agencies coordinate their work, assessed health needs, and provided practical help in the field to all parties to the conflict. Three features of the Bosnia war have particularly deplorable effects on health: ethnic cleansing, deliberate attacks on hospitals, and systematic rape. The WHO's response has included initiatives in nutrition, winter survival, and medical supplies. This experience shows that the WHO can have a useful role complementary to that of other agencies in situations where the basic elements for survival of the population are seriously compromised by war.			ACHESON, D (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND.							TOOLE MJ, 1992, LANCET, V339, P1214, DOI 10.1016/0140-6736(92)91143-V	1	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					44	48		10.1136/bmj.307.6895.44	http://dx.doi.org/10.1136/bmj.307.6895.44			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343673	Bronze, Green Published			2022-12-28	WOS:A1993LL36900030
J	GILLON, R				GILLON, R			PATIENTS IN THE PERSISTENT VEGETATIVE STATE - A RESPONSE	BRITISH MEDICAL JOURNAL			English	Article											GILLON, R (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCI TECHNOL & MED,SCH MED,LONDON SW7 2AZ,ENGLAND.							ANDREWS K, 1993, BRIT MED J, V306, P1600, DOI 10.1136/bmj.306.6892.1600; ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; GILLON R, 1993, ST MARYS GAZETTE, V99, P17; Gillon Ranan., 1985, PHILOS MED ETHICS; 1993, TIMES           0205, P8; 1992, DISCUSSION PAPER TRE	7	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1602	1603		10.1136/bmj.306.6892.1602	http://dx.doi.org/10.1136/bmj.306.6892.1602			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329928	Bronze, Green Published			2022-12-28	WOS:A1993LH12800029
J	RITTER, FJ; LEPPIK, IE; DREIFUSS, FE; RAK, I; SANTILLI, N; HOMZIE, R; DODSON, WE; GLAUSER, TA; SACKELLARES, JC; OLSON, L; GARAFOLO, EA; SHIELDS, WD; FRENCH, J; SPERLING, M; KRAMER, LD; KAMIN, M; ROSENBERG, A; SHUMAKER, R; PERHACH, JL; DIX, R				RITTER, FJ; LEPPIK, IE; DREIFUSS, FE; RAK, I; SANTILLI, N; HOMZIE, R; DODSON, WE; GLAUSER, TA; SACKELLARES, JC; OLSON, L; GARAFOLO, EA; SHIELDS, WD; FRENCH, J; SPERLING, M; KRAMER, LD; KAMIN, M; ROSENBERG, A; SHUMAKER, R; PERHACH, JL; DIX, R			EFFICACY OF FELBAMATE IN CHILDHOOD EPILEPTIC ENCEPHALOPATHY (LENNOX-GASTAUT SYNDROME)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARTIAL SEIZURES; CLINICAL-TRIAL	Background. The Lennox-Gastaut syndrome is a childhood disorder characterized by multiple types of seizures, mental retardation, characteristic electroencephalographic abnormalities, and resistance to standard antiepileptic drugs. Felbamate is an investigational antiepileptic drug with a preclinical profile that suggests it would be effective in patients with multiple types of seizures. In controlled clinical trials, felbamate was superior to placebo in reducing the frequency of refractory partial-onset seizures. Methods. We studied the efficacy of felbamate in 73 patients ranging in age from 4 to 36 years who had the Lennox-Gastaut syndrome. During a 28-day base-line phase, the patients received their usual antiepileptic therapies. At the end of this phase, felbamate or placebo was administered for 70 days in addition to the current antiepileptic medications. The dosage of felbamate was titrated during the first 14 days of the treatment phase to a maximum of 45 mg per kilogram of body weight per day or 3600 mg per day, whichever was less. The primary efficacy variables were the total number of seizures counted during a four-hour period of video recording, parents' or guardians' global evaluations of the patients' quality of life, and the total number of atonic seizures, as reported by parents or guardians. Results. The patients treated with felbamate had a 34 percent decrease in the frequency of atonic seizures, as compared with a 9 percent decrease in the patients who received placebo (P = 0.01). The felbamate-treated patients had a 19 percent decrease in the total frequency of seizures, as compared with a 4 percent increase in the placebo group (P = 0.002). The global-evaluation scores were significantly higher in the felbamate group than in the placebo group from day 49 to the end of the study. There were no significant differences in the frequency of seizures occurring during video monitoring, but there was a significant reduction (P = 0.017) in the number of tonic-clonic seizures during the maintenance period in the felbamate group. The types and frequency of side effects were similar in the two treatment groups. Conclusions. Felbamate is beneficial in patients with the Lennox-Gastaut syndrome.	UNIV MINNESOTA, ST PAUL, MN 55108 USA; UNIV VIRGINIA, HLTH SCI CTR, CHARLOTTESVILLE, VA 22903 USA; WASHINGTON UNIV, ST LOUIS, MO 63130 USA; UNIV MICHIGAN HOSP, ANN ARBOR, MI 48109 USA; UNIV CALIF LOS ANGELES, MED CTR, LOS ANGELES, CA USA; GRAD HOSP PHILADELPHIA, PHILADELPHIA, PA 19146 USA; WALLACE LABS, CRANBURY, NJ 08512 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Virginia; Washington University (WUSTL); University of Michigan System; University of Michigan; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Pennsylvania; Pennsylvania Medicine			Mathern, Gary W./J-2483-2016; French, Jacqueline/G-6795-2013	French, Jacqueline/0000-0003-2242-8027				[Anonymous], 1981, EPILEPSIA, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389; FARRELL K, 1986, EPILEPSIA, V27, pS45, DOI 10.1111/j.1528-1157.1986.tb05733.x; HAUSER WA, 1990, EPILEPSY FREQUENCY C, P327; HOLMES GL, 1987, MAJOR PROBLEMS CLIN, V30, P187; JEAVONS PM, 1977, DEV MED CHILD NEUROL, V19, P9; KELLAWAY P, 1980, ANN NEUROL, V8, P491, DOI 10.1002/ana.410080506; LEPPIK IE, 1991, NEUROLOGY, V41, P1785, DOI 10.1212/WNL.41.11.1785; LOCKMAN LA, 1981, EPILEPSIA, V22, P241; SAKAMOTO K, 1988, CURR THER RES CLIN E, V43, P378; SUTULA TP, 1981, NEUROLOGY, V31, P243, DOI 10.1212/WNL.31.3.243; SWINYARD EA, 1986, EPILEPSIA, V27, P27, DOI 10.1111/j.1528-1157.1986.tb03497.x; THEODORE WH, 1991, EPILEPSIA, V32, P392, DOI 10.1111/j.1528-1157.1991.tb04668.x; WAGNER M L, 1991, Epilepsia, V32, P15; 1989, EPILEPSIA, V30, P422	15	299	301	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1993	328	1					29	33						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF507	8347179				2022-12-28	WOS:A1993KF50700005
J	HEEMSKERK, J; DINARDO, S				HEEMSKERK, J; DINARDO, S			DROSOPHILA HEDGEHOG ACTS AS A MORPHOGEN IN CELLULAR PATTERNING	CELL			English	Article							SEGMENT-POLARITY GENE; DORSAL-VENTRAL PATTERN; WINGLESS GENE; SPATIAL-DISTRIBUTION; LARVAL EPIDERMIS; ENGRAILED LOCUS; BICOID PROTEIN; PATCHED GENE; BETA FAMILY; FLOOR PLATE	The patterning of cell types in embryogenesis is specified by signals emanating from specialized organizer regions. We demonstrate that engrailed-expressing cells in the Drosophila epidermis have organizer properties. These cells influence the pattern of cell type differentiation across the segment. We show that this function is mediated by the hedgehog (hh) gene. The results of modulating the levels of hh in the embryo suggest that hh acts as a morphogen, specifying distinct cell fates by a concentration-dependent mechanism. We present a model that integrates the role of hh with that of the wingless signal in establishing the segmental array of cell type diversity.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; COLUMBIA UNIV, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Rockefeller University; Columbia University				DiNardo, Stephen/0000-0003-4131-5511	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045747] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45747] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CARROLL SB, 1988, GENE DEV, V2, P883, DOI 10.1101/gad.2.7.883; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAWRENCE PA, 1966, J EXP BIOL, V44, P607; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1973, DEV SYSTEMS INSECTS, P157; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LOCKE M, 1960, J EXP BIOL, V37, P398; LOCKE M, 1959, J EXP BIOL, V36, P459; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARTINEZARIAS A, 1959, TRENDS GENET, V5, P262; MEER SVD, 1977, DROS INF SERV, V52, P160; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; Nubler-Jung Katharina, 1979, Wilehm Roux Arch Dev Biol, V186, P211, DOI 10.1007/BF00848590; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORENIC T, 1987, DEV BIOL, V124, P50, DOI 10.1016/0012-1606(87)90458-1; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; Spemann H., 1938, EMBRYONIC DEV INDUCT; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STUMPF HF, 1968, J EXP BIOL, V49, P49; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; Wieschaus E., 1986, P199; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	78	206	221	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					449	460		10.1016/0092-8674(94)90110-4	http://dx.doi.org/10.1016/0092-8674(94)90110-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313468				2022-12-28	WOS:A1994MX20700007
J	GARFIELD, R; LOW, N; CALDERA, J				GARFIELD, R; LOW, N; CALDERA, J			DESOCIALIZING HEALTH-CARE IN A DEVELOPING-COUNTRY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NICARAGUA; SERVICES		COLUMBIA UNIV,SCH PUBL HLTH EPIDEMIOL,NEW YORK,NY 10032; ROYAL SUSSEX CTY HOSP,BRIGHTON BN2 5BE,E SUSSEX,ENGLAND; PAN AMER HLTH ORG,MANAGUA,NICARAGUA	Columbia University; University of Brighton; Pan American Health Organization	GARFIELD, R (corresponding author), COLUMBIA UNIV,SCH NURSING,630 W 168TH ST,NEW YORK,NY 10032, USA.							[Anonymous], 1990, WORLD DEV REPORT; Cornia A., 1987, ADJUSTMENT HUMAN FAC; EPSTEIN PR, 1991, LANCET, V337, P1467; ESPINOSA J, 1993, GASTO NACIONAL SALUD; Garfield Richard, 1992, HLTH CARE NICARAGUA; GARFIELD RM, 1984, AM J PUBLIC HEALTH, V74, P1138, DOI 10.2105/AJPH.74.10.1138; GARFIELD RM, 1987, AM J PUBLIC HEALTH, V77, P15; HALPERIN DC, 1982, NEW ENGL J MED, V307, P388, DOI 10.1056/NEJM198208053070634; LOMBA M, 1990, BARRICADA       0704, P1; LOW N, 1990, LANCET, V336, P1593, DOI 10.1016/0140-6736(90)93382-Y; MCKEE M, 1991, J EPIDEMIOL COMMUN H, V45, P260, DOI 10.1136/jech.45.4.260; SUMMERFIELD D, 1989, LANCET, V2, P551; 1990, UNPUB LEON DOCUMENT; 1991, CENT AM HIST I  0531, P1; 1991, PLAN MAESTRO SALUD 1; 1992, EPIDEMIL B, V13, P1; 1990, PLAN TRIENNAL SALUD; 1990, LANCET, V335, P885	18	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					989	993		10.1001/jama.270.8.989	http://dx.doi.org/10.1001/jama.270.8.989			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LT567	8345652				2022-12-28	WOS:A1993LT56700033
J	REECE, RJ; PTASHNE, M				REECE, RJ; PTASHNE, M			DETERMINANTS OF BINDING-SITE SPECIFICITY AMONG YEAST C6 ZINC CLUSTER PROTEINS	SCIENCE			English	Article							DNA-BINDING; SACCHAROMYCES-CEREVISIAE; REGULATORY GENE; NUCLEOTIDE-SEQUENCE; GAL4; FINGER; ACTIVATOR; ADJACENT; INDUCTION; COMPLEX	Related DNA binding proteins often recognize similar DNA sites but can distinguish among them with the use of different protein-DNA contacts. Here, it is shown that members of the C6 zinc cluster family of yeast transcriptional activators distinguish related DNA sites by a different mechanism. The DNA binding site for each of these proteins contains identical nucleotide triplets (CGG ... CCG) but differs in the spacings between the triplets. It is shown that zinc clusters of these proteins work interchangeably to recognize the conserved triplets and that the region 19 amino acids to the carboxyl-terminal side of the zinc cluster, comprising the linker and the beginning of a dimerization element as inferred from the GAL4 crystal structure, directs the protein to its preferred site.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University					NIGMS NIH HHS [GM32308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; DERIJCKE M, 1992, MOL CELL BIOL, V12, P68, DOI 10.1128/MCB.12.1.68; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; KAMMERER B, 1984, J MOL BIOL, V180, P239, DOI 10.1016/S0022-2836(84)80002-9; KIM J, 1988, CURR GENET, V14, P319, DOI 10.1007/BF00419988; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; MARCZAK JE, 1991, MOL CELL BIOL, V11, P2609, DOI 10.1128/MCB.11.5.2609; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MESSENGUY F, 1986, EUR J BIOCHEM, V157, P77, DOI 10.1111/j.1432-1033.1986.tb09640.x; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; REECE RJ, UNPUB; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TURCOTTE B, 1992, GENE DEV, V6, P2001, DOI 10.1101/gad.6.10.2001; WITTE MM, 1990, MOL CELL BIOL, V10, P5128, DOI 10.1128/MCB.10.10.5128	23	155	159	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1993	261	5123					909	911		10.1126/science.8346441	http://dx.doi.org/10.1126/science.8346441			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346441				2022-12-28	WOS:A1993LR89700037
J	LURIE, N; SLATER, J; MCGOVERN, P; EKSTRUM, J; QUAM, L; MARGOLIS, K				LURIE, N; SLATER, J; MCGOVERN, P; EKSTRUM, J; QUAM, L; MARGOLIS, K			PREVENTIVE CARE FOR WOMEN - DOES THE SEX OF THE PHYSICIAN MATTER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER; GENDER	Background. Emphasis on ensuring women's access to preventive health services has increased over the past decade. Relatively little attention has been paid to whether the sex of the physician affects the rates of cancer screening among women. We examined differences between male and female physicians in the frequency of screening mammograms and Pap smears among women patients enrolled in a large Midwestern health plan. Methods. We identified claims for mammography and Pap tests submitted by primary care physicians for 97,962 women, 18 to 75 years of age, who were enrolled in the health plan in 1990. The sex of the physician was manually coded, and the physician's age was obtained from the state licensing board. After identifying a principal physician for each woman, we calculated the frequency of mammography and Pap smears for each physician, using the number of women in his or her practice during 1990 as the denominator. Using unconditional logistic regression, we also calculated the odds ratio of having a Pap smear or mammogram for women patients with female physicians as compared with those with male physicians, controlling for the physician's and the patient's age. Results. Crude rates for Pap smears and mammography were higher for the patients of female than male physicians in most age groups of physicians. The largest differences between female and male physicians were in the rates of Pap smears among the youngest physicians. For the subgroup of women enrolled in the health plan for a year who saw only one physician, after adjustment for the patient's age and the physician's age and specialty, the odds ratio for having a Pap smear was 1.99 (95 percent confidence interval, 1.72 to 2.30) for the patients of female physicians as compared with those of male physicians. For women 40 years old and older, the odds ratio for having a mammogram was 1.41 (95 percent confidence interval, 1.22 to 1.63). For both Pap smears and mammography, the differences between female and male physicians in screening rates were much more pronounced in internal medicine and family practice than in obstetrics and gynecology. Conclusions. Women are more likely to undergo screening with Pap smears and mammograms if they see female rather than male physicians, particularly if the physician is an internist or family practitioner.	UNITED HEALTHCARE CORP, CTR HLTH CARE POLICY & EVALUAT, MINNEAPOLIS, MN USA; UNIV MINNESOTA, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH PUBL HLTH, MINNEAPOLIS, MN 55455 USA; MINNESOTA DEPT HLTH, CANC CONTROL SECT, MINNEAPOLIS, MN USA	UnitedHealth Group Incorporated; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Minnesota Department of Health (MHD)	LURIE, N (corresponding author), HENNEPIN CTY MED CTR, DEPT MED, MED OFF 814, 701 PK AVE, MINNEAPOLIS, MN 55415 USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Margolis, Karen/0000-0003-1862-7402	NATIONAL CANCER INSTITUTE [R01CA052994] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-52994] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAKE RL, 1990, ACAD MED, V65, P702, DOI 10.1097/00001888-199011000-00014; BURACK RC, 1987, PREV MED, V16, P739, DOI 10.1016/0091-7435(87)90014-4; CAMPBELL JR, 1989, PRIMARY CARE, V16, P251; CLANCY CM, 1992, JAMA-J AM MED ASSOC, V268, P1918, DOI 10.1001/jama.268.14.1918; COMSTOCK LM, 1982, J MED EDUC, V57, P105; FENNEMA K, 1990, J FAM PRACTICE, V30, P441; HALL JA, 1990, MED CARE, V28, P489, DOI 10.1097/00005650-199006000-00002; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; KELLY JM, 1980, J FAM PRACTICE, V11, P427; KISH L, 1987, STATISTICAL DESIGN R; Levy S, 1992, Fam Med, V24, P58; LINK RN, 1991, J GEN INTERN MED, V6, P466; MARGOLIS KL, 1988, ARCH INTERN MED, V148, P2205, DOI 10.1001/archinte.148.10.2205; MARGOLIS KL, IN PRESS J GEN INTER; OSBORN EH, 1991, J FAM PRACTICE, V32, P465; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; 1989, SAS STAT USERS GUIDE; 1990, JAMA-J AM MED ASSOC, V264, P54	18	392	393	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					478	482		10.1056/NEJM199308123290707	http://dx.doi.org/10.1056/NEJM199308123290707			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	8332153	Bronze			2022-12-28	WOS:A1993LR44300007
J	BLACK, H				BLACK, H			TREATMENT OF MILD HYPERTENSION - THE MORE THINGS CHANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LEFT-VENTRICULAR HYPERTROPHY; CONTROLLED TRIAL; BLOOD-PRESSURE				BLACK, H (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PREVENT MED,1725 W HARRISON ST,SUITE 117,CHICAGO,IL 60612, USA.							BLACK HR, 1991, AM HEART J, V121, P707, DOI 10.1016/0002-8703(91)90451-M; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DAHLOF B, 1992, J HYPERTENS, V10, P1513, DOI 10.1097/00004872-199210120-00012; GOTTDIENER J, 1992, Journal of the American College of Cardiology, V19, p85A; GRIMM RH, 1981, ANN INTERN MED, V94, P7, DOI 10.7326/0003-4819-94-1-7; Hypertension Prevention Trial Research Group, 1990, ARCH INTERN MED, V150, P153, DOI [10.1001/archinte.1990.00390130131021, DOI 10.1001/ARCHINTE.1990.00390130131021]; LANGFORD HG, 1991, HYPERTENSION, V17, P210, DOI 10.1161/01.HYP.17.2.210; LEE DK, 1992, JAMA-J AM MED ASSOC, V267, P3294, DOI 10.1001/jama.267.24.3294; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; ROCCHINI AP, 1987, HYPERTENSION, V10, P267, DOI 10.1161/01.HYP.10.3.267; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STEVENS VJ, 1993, ARCH INTERN MED, V153, P849, DOI 10.1001/archinte.153.7.849; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; [No title captured]; 1993, ARCH INTERN MED, V153, P154; 1991, ARCH INTERN MED, V151, P1413	18	7	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1993	270	6					757	759		10.1001/jama.270.6.757	http://dx.doi.org/10.1001/jama.270.6.757			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ338	8336380				2022-12-28	WOS:A1993LQ33800033
J	KREISBERG, RA				KREISBERG, RA			AN ABUNDANCE OF OPTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											KREISBERG, RA (corresponding author), UNIV ALABAMA,BIRMINGHAM,AL 35294, USA.							EDWARDS JC, 1990, ACAD MED, V65, P297, DOI 10.1097/00001888-199005000-00004; KASSIRER JP, 1991, LEARNING CLIN REASON, P109; MCCLAIN JB, 1992, CECILS TXB MED, P1777; SASAKI DM, 1993, AM J TROP MED HYG, V48, P35, DOI 10.4269/ajtmh.1993.48.35; SCHMIDT HG, 1992, ACAD MED, V67, P287; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; THIBAULT GE, 1992, NEW ENGL J MED, V327, P714, DOI 10.1056/NEJM199209033271008	7	8	8	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					413	416		10.1056/NEJM199308053290608	http://dx.doi.org/10.1056/NEJM199308053290608			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8326976				2022-12-28	WOS:A1993LQ33900008
J	BREO, DL				BREO, DL			HUMAN-RIGHTS .2. BASSIOUNI,CHERIF CONDEMNS PSYCHOLOGY OF BALKAN CRIMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					643	644		10.1001/jama.270.5.643	http://dx.doi.org/10.1001/jama.270.5.643			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331770				2022-12-28	WOS:A1993LP43600036
J	ALPER, J				ALPER, J			EEG+MRI - A SUM GREATER-THAN THE PARTS	SCIENCE			English	Editorial Material																		GEVINS A, 1993, IN PRESS BRAIN TOPOG; GEVINS A, 1993, IN PRESS EEG CLIN NE; THATCHER RW, 1993, JUN P SOC MAGN RES M, V1; THATCHER RW, 1993, FUNCTIONAL NEUROSCIE	4	3	4	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					559	559		10.1126/science.8342019	http://dx.doi.org/10.1126/science.8342019			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342019				2022-12-28	WOS:A1993LP72800027
J	LI, JJ; DESHAIES, RJ				LI, JJ; DESHAIES, RJ			EXERCISING SELF-RESTRAINT - DISCOURAGING ILLICIT ACTS OF S AND M IN EUKARYOTES	CELL			English	Review							CELL-CYCLE CHECKPOINTS; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; MITOSIS; COMPLETION; RCC1; INITIATION; MUTANTS		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LI, JJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.		Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DUMAS LB, 1982, MOL GEN GENET, V187, P42, DOI 10.1007/BF00384381; ENGLE DB, 1990, J BIOL CHEM, V265, P132; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1992, RADIAT RES, V132, P141, DOI 10.2307/3578518	26	84	84	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					223	226		10.1016/0092-8674(93)90413-K	http://dx.doi.org/10.1016/0092-8674(93)90413-K			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343950				2022-12-28	WOS:A1993LP72600003
J	HAMER, DH; HU, S; MAGNUSON, VL; HU, N; PATTATUCCI, AML				HAMER, DH; HU, S; MAGNUSON, VL; HU, N; PATTATUCCI, AML			A LINKAGE BETWEEN DNA MARKERS ON THE X-CHROMOSOME AND MALE SEXUAL ORIENTATION	SCIENCE			English	Article							GENETICALLY COMPLEX TRAITS; AFFECTED RELATIVE PAIRS; MALE HOMOSEXUALITY; STRATEGIES; IDENTITY; POWER; POLYMORPHISM; RFLP; MEN	The role of genetics in male sexual orientation was investigated by pedigree and linkage analyses on 114 families of homosexual men. Increased rates of same-sex orientation were found in the maternal uncles and male cousins of these subjects, but not in their fathers or paternal relatives, suggesting the possibility of sex-linked transmission in a portion of the population. DNA linkage analysis of a selected group of 40 families in which there were two gay brothers and no indication of nonmaternal transmission revealed a correlation between homosexual orientation and the inheritance of polymorphic markers on the X chromosome in approximately 64 percent of the sib-pairs tested. The linkage to markers on Xq28, the subtelomeric region of the long arm of the sex chromosome, had a multipoint lod score of 4.0 (P = 10(-5)), indicating a statistical confidence level of more than 99 percent that at least one subtype of male sexual orientation is genetically influenced.			HAMER, DH (corresponding author), NCI,BIOCHEM LAB,BETHESDA,MD 20892, USA.		Hamer, Dean H/L-1248-2015	Hamer, Dean H/0000-0002-6211-5781				ALLEN LS, 1992, P NATL ACAD SCI USA, V89, P7199, DOI 10.1073/pnas.89.15.7199; BAILEY JM, 1993, AM J PSYCHIAT, V150, P272; BAILEY JM, 1993, ARCH GEN PSYCHIAT, V50, P217; BAILEY JM, 1991, ARCH GEN PSYCHIAT, V48, P1089; BAILEY JM, 1991, ARCH SEX BEHAV, V20, P277, DOI 10.1007/BF01541847; Bell AP, 1978, HOMOSEXUALITIES STUD; BISHOP DT, 1990, AM J HUM GENET, V46, P254; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; BUHRICH N, 1991, BEHAV GENET, V21, P75, DOI 10.1007/BF01067668; DUBERMAAN M, 1989, HIDDEN HIST RECLAIMI; FREIJE D, 1992, SCIENCE, V258, P1784, DOI 10.1126/science.1465614; FREIJE D, 1992, AM J HUM GENET, V51, P66; FREUND K, 1977, ARCH SEX BEHAV, V6, P507, DOI 10.1007/BF01541155; FRIEDMAN RM, 1986, PSYCHOANAL REV, V73, P483; GOLDIN LR, 1988, GENET EPIDEMIOL, V5, P35, DOI 10.1002/gepi.1370050104; GORSKI RA, 1991, BRAIN ENDOCRINOLOGY, P71; HENRY GEORGE, 1941, SEX VARIANTS STUDY H; HUGNOT JP, 1991, NUCLEIC ACIDS RES, V19, P3159, DOI 10.1093/nar/19.11.3159; ISAY R, 1989, BEING HOMOSEXUAL; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; KINSEY AC, 1948, SEXUAL BEHAVIOR HUMA; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KURDIHAIDAR B, 1990, AM J HUM GENET, V47, P1013; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; LANDER E, 1988, GENOME ANAL PRACTICA, P171; LANDER ES, 1986, P NATL ACAD SCI USA, V83, P7353, DOI 10.1073/pnas.83.19.7353; LEVAY S, 1991, SCIENCE, V253, P1034, DOI 10.1126/science.1887219; MCEWEN BS, 1991, J STEROID BIOCHEM, V39, P223, DOI 10.1016/0960-0760(91)90067-F; McKusick V.A., 1992, MENDELIAN INHERITANC; MEYERBAHLBURG HF, 1982, CLILN ENDOCRINOL MET, V11, P6861; Ott J., 1991, ANAL HUMAN GENETIC L; PILLARD RC, 1986, ARCH GEN PSYCHIAT, V43, P808; PILLARD RC, 1990, HOMOSEXUALITY HETERO, P88; RISCH N, 1992, HUM HERED, V42, P77, DOI 10.1159/000154047; RISCH N, 1990, AM J HUM GENET, V46, P229; RISCH N, 1990, AM J HUM GENET, V46, P242; RISCH N, 1990, AM J HUM GENET, V46, P222; ROUSE AL, 1977, HOMOSEXUALS HIST; Schow R., 1991, PECULIAR PEOPLE MORM; Spong J. S., 1988, LIVING SIN; SUAREZ BK, 1978, ANN HUM GENET, V42, P87, DOI 10.1111/j.1469-1809.1978.tb00933.x; SURIN VL, 1990, NUCLEIC ACIDS RES, V18, P3432, DOI 10.1093/nar/18.11.3432; SWAAB DF, 1990, BRAIN RES, V537, P141, DOI 10.1016/0006-8993(90)90350-K; THOMSON G, 1986, AM J HUM GENET, V39, P207; Tripp C. A., 1987, HOMOSEXUAL MATRIX; WEINRICH J, 1987, SEXUAL LANDSCAPES; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHITAM FL, 1986, MALE HOMOSEXUALITY 4; YU S, 1992, AM J HUM GENET, V50, P968; ZUGER B, 1989, ARCH SEX BEHAV, V18, P155, DOI 10.1007/BF01543121; 1992, NATURE, V360, P407	51	562	578	9	332	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					321	327		10.1126/science.8332896	http://dx.doi.org/10.1126/science.8332896			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332896	Green Submitted			2022-12-28	WOS:A1993LM67800027
J	SILVER, PA; WAY, JC				SILVER, PA; WAY, JC			EUKARYOTIC DNAJ HOMOLOGS AND THE SPECIFICITY OF HSP70 ACTIVITY	CELL			English	Review							HEAT-SHOCK PROTEIN; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; YEAST HOMOLOG; GENE; TRANSLOCATION; REPLICATION; INITIATION; BINDING		RUTGERS UNIV,DEPT BIOL,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick	SILVER, PA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115, USA.							ALFANO C, 1989, J BIOL CHEM, V264, P10709; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CYR DM, 1992, J BIOL CHEM, V267, P20927; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; HATTORI H, 1993, J CELL SCI, V104, P629; KRISHNAN HB, 1991, MOL MICROBIOL, V5, P737, DOI 10.1111/j.1365-2958.1991.tb00744.x; KURIHARA T, 1992, MEMBRANE BIOGENESIS, P309; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; NELSON MK, 1993, GENETICS, V134, P159; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	25	204	217	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					5	6		10.1016/0092-8674(93)90287-Z	http://dx.doi.org/10.1016/0092-8674(93)90287-Z			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334705				2022-12-28	WOS:A1993LN62500002
J	FENOGLIOPREISER, CM; PESCE, AJ				FENOGLIOPREISER, CM; PESCE, AJ			PATHOLOGY AND LABORATORY MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUBERCULOSIS				FENOGLIOPREISER, CM (corresponding author), UNIV CINCINNATI,CINCINNATI,OH 45221, USA.							Abbas A, 1991, CELLULAR MOL IMMUNOL, P417; ADDINGTON WW, 1979, CHEST, V76, P741, DOI 10.1378/chest.76.6_Supplement.741; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Compton P., 1992, Artificial Intelligence in Medicine, V4, P463, DOI 10.1016/0933-3657(92)90013-F; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; HERRINGTON CS, 1990, NEUROCHEM RES, V15, P467, DOI 10.1007/BF00969934; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; SCHROEDER TJ, 1992, TRANSPLANTATION, V53, P34; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; STEINER P, 1986, AM REV RESPIR DIS, V134, P446; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; 1991, MMWR MORB MORTAL WKL, V40, P585	14	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					245	246		10.1001/jama.270.2.245	http://dx.doi.org/10.1001/jama.270.2.245			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315749				2022-12-28	WOS:A1993LL36800036
J	FREEDMAN, DX; STAHL, SM				FREEDMAN, DX; STAHL, SM			PSYCHIATRY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTCOMES		UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	FREEDMAN, DX (corresponding author), UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA.							BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; FREEDMAN DX, 1984, ARCH GEN PSYCHIAT, V41, P931; FREEDMAN DX, 1992, HEALTH AFFAIR, V11, P157, DOI 10.1377/hlthaff.11.3.157; KELLER MB, 1992, ARCH GEN PSYCHIAT, V49, P809; KLERMAN GL, 1992, ARCH GEN PSYCHIAT, V49, P831; LAMB HR, 1993, BRIT J PSYCHIAT, V162, P587, DOI 10.1192/bjp.162.5.587; MARKOWITZ JS, 1989, ARCH GEN PSYCHIAT, V46, P984; MAVISSAKALIAN M, 1992, ARCH GEN PSYCHIAT, V49, P318; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; NARROW WE, 1993, ARCH GEN PSYCHIAT, V50, P95; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; SCHWEIZER E, 1993, ARCH GEN PSYCHIAT, V50, P51; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WELLS KB, 1992, ARCH GEN PSYCHIAT, V49, P788; 1980, DIAGNOSTIC STATISTIC; 1993, BRIT J PSYCHIAT, V162, P175	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					252	254		10.1001/jama.270.2.252	http://dx.doi.org/10.1001/jama.270.2.252			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL368	8315753				2022-12-28	WOS:A1993LL36800040
J	WANG, MM; REED, RR				WANG, MM; REED, RR			MOLECULAR-CLONING OF THE OLFACTORY NEURONAL TRANSCRIPTION FACTOR OLF-1 BY GENETIC SELECTION IN YEAST	NATURE			English	Article							DNA-BINDING; SIGNAL TRANSDUCTION; MYC HOMOLOGY; PROTEIN; EXPRESSION; ENHANCER; SYSTEM; MYOD; SITE; IDENTIFICATION	A novel genetic selection in yeast has been used to isolate a complementary DNA for the transcriptional activator, Olf-1, which binds to the regulatory sequences of several olfactory-specific genes. The Olf-1 protein, expressed exclusively in the olfactory receptor neurons and their precursors, contains a new helix-loop-helix motif and functions as an apparent homodimer. Olf-1 may be the first member of a family of related proteins that may direct cellular differentiation in a variety of neuronal tissues.			WANG, MM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,HOWARD HUGHES MED INST,725 N WOLFE ST,BALTIMORE,MD 21205, USA.		Reed, Russell/HGU-0528-2022					ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EED RR, 1992, NEURON, V8, P205; ENGLAND BP, 1990, J BIOL CHEM, V265, P5086; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAZIADEI PPC, 1978, OLFACTORY SYSTEM MOD, P131; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MONTIGRAZIADEI GA, 1979, NEURAL GROWTH DIFFER, P373; RODGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; VERHAAGEN J, 1989, J NEUROSCI, V9, P683; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	39	364	394	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					121	126		10.1038/364121a0	http://dx.doi.org/10.1038/364121a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321284				2022-12-28	WOS:A1993LL36700040
J	JONES, A; PECKETT, W; CLARK, E; SHARPE, C; KRIMHOLTZ, S; RUSSELL, M; GOODWIN, T				JONES, A; PECKETT, W; CLARK, E; SHARPE, C; KRIMHOLTZ, S; RUSSELL, M; GOODWIN, T			NURSES KNOWLEDGE OF THE RESUSCITATION STATUS OF PATIENTS AND ACTION IN THE EVENT OF CARDIORESPIRATORY ARREST	BRITISH MEDICAL JOURNAL			English	Article							ORDERS		MT VERNON HOSP,NORTHWOOD HA6 2RN,MIDDX,ENGLAND; HILLINGDON HOSP,MIDDLESEX UB8 3ON,ENGLAND				Sharpe, Claire/B-5619-2015	Sharpe, Claire/0000-0003-1704-8492				AARONS EJ, 1991, BRIT MED J, V303, P1504, DOI 10.1136/bmj.303.6816.1504; ASPLUND K, 1990, J INTERN MED, V228, P139; KAMER RS, 1990, AM J MED, V88, P108, DOI 10.1016/0002-9343(90)90457-O; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; 1984, CODE PROFESSIONAL CO	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1577	1578		10.1136/bmj.306.6892.1577	http://dx.doi.org/10.1136/bmj.306.6892.1577			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329918	Bronze, Green Published			2022-12-28	WOS:A1993LH12800018
J	GROTEWOLD, E; DRUMMOND, BJ; BOWEN, B; PETERSON, T				GROTEWOLD, E; DRUMMOND, BJ; BOWEN, B; PETERSON, T			THE MYB-HOMOLOGOUS P-GENE CONTROLS PHLOBAPHENE PIGMENTATION IN MAIZE FLORAL ORGANS BY DIRECTLY ACTIVATING A FLAVONOID BIOSYNTHETIC GENE SUBSET	CELL			English	Article							HELIX-RELATED MOTIF; DNA-BINDING DOMAIN; ZEA-MAYS; C-MYB; FUNCTIONAL-ANALYSIS; WILD-TYPE; PROTEINS; LOCUS; AC; TRANSCRIPTION	The maize P gene, which specifies red pigmentation of the kernel pericarp, cob, and other floral organs, has been an important model since the early days of modern genetics. Here we show that P encodes a Myb homolog that recognizes the sequence CCT/ACC, in sharp contrast with the (C)/(T)AACGG bound by vertebrate Myb proteins. P binds to and activates transcription of the A1 gene required for 3-deoxy flavonoid and phlobaphene biosynthesis, but not the Bz1 gene required for anthocyanin biosynthesis. The maize C1 gene, which also encodes a Myb homolog, activates both the A1 and Bz1 genes, but only in the presence of basic-helix-loop-helix coactivator encoded by the maize genes R or B. These results indicate that Myb homologs can differentially regulate gene expression by binding different DNA sequences, through combinatorial interactions with other factors, or both.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; PIONEER HI BRED INT INC,JOHNSTON,IA 50131	Cold Spring Harbor Laboratory; DuPont; Pioneer Hi-Bred International, Inc.				Grotewold, Erich/0000-0002-4720-7290				AN GH, 1989, PLANT CELL, V1, P115, DOI 10.1105/tpc.1.1.115; Anderson EG, 1924, GENETICS, V9, P442; ATHMA P, 1992, GENETICS, V131, P199; ATHMA P, 1991, GENETICS, V128, P163; AVILA J, 1993, PLANT J, V3, P553, DOI 10.1046/j.1365-313X.1993.03040553.x; Bowen B., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P163; BRINK RA, 1952, GENETICS, V37, P519; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; Correns C, 1901, BIBLIOTHECA BOT, V53, P1; DEBLOCK M, 1987, EMBO J, V6, P2513, DOI 10.1002/j.1460-2075.1987.tb02537.x; DOONER HK, 1985, MOL GEN GENET, V200, P240, DOI 10.1007/BF00425430; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; Emerson RA, 1917, GENETICS, V2, P1; EMERSON RA, 1911, ANN REPT NEBRASKA AG, V24, P59; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARCIA A, 1991, ONCOGENE, V6, P265; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; GOFF SA, 1990, EMBO J, V9, P2517, DOI 10.1002/j.1460-2075.1990.tb07431.x; GREENBLATT IM, 1963, NATURE, V197, P412, DOI 10.1038/197412a0; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4587, DOI 10.1073/pnas.88.11.4587; GROTEWOLD E, 1994, MOL GEN GENET, V242, P1; GROTEWOLD E, 1991, MOL GEN GENET, V230, P329, DOI 10.1007/BF00290684; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; KLEIN TM, 1989, P NATL ACAD SCI USA, V86, P6681, DOI 10.1073/pnas.86.17.6681; LECHELT C, 1989, MOL GEN GENET, V219, P225, DOI 10.1007/BF00261181; LUDWIG SE, 1990, SCIENCE, V246, P449; LUDWIG SR, 1990, CELL, V62, P849, DOI 10.1016/0092-8674(90)90259-H; Meer I. M. van der, 1993, Control of plant gene expression., P125; MENDEL G, 1950, Genetics, V35, P1; MENSSEN A, 1990, EMBO J, V9, P3051, DOI 10.1002/j.1460-2075.1990.tb07501.x; MORENO MA, 1992, GENETICS, V131, P939; NASH J, 1990, PLANT CELL, V2, P1039, DOI 10.1105/tpc.2.11.1039; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; RALSTON EJ, 1988, GENETICS, V119, P185; RHOADES MM, 1984, ANNU REV GENET, V18, P1, DOI 10.1146/annurev.ge.18.120184.000245; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHWARZSOMMER Z, 1987, EMBO J, V6, P287, DOI 10.1002/j.1460-2075.1987.tb04752.x; SHAH D M, 1983, Journal of Molecular and Applied Genetics, V2, P111; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STYLES ED, 1989, MAYDICA, V34, P227; STYLES ED, 1977, CAN J GENET CYTOL, V19, P289, DOI 10.1139/g77-032; STYLES ED, 1975, PHYTOCHEMISTRY, V14, P413, DOI 10.1016/0031-9422(75)85101-6; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; UNGER E, 1993, PLANT CELL, V5, P831, DOI 10.1105/tpc.5.8.831; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WIENAND U, 1986, MOL GEN GENET, V203, P202, DOI 10.1007/BF00333955	57	528	566	1	80	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					543	553		10.1016/0092-8674(94)90117-1	http://dx.doi.org/10.1016/0092-8674(94)90117-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313474				2022-12-28	WOS:A1994MX20700014
J	EVANS, DGR; FENTIMAN, IS; MCPHERSON, K; ASBURY, D; PONDER, BAJ; HOWELL, A				EVANS, DGR; FENTIMAN, IS; MCPHERSON, K; ASBURY, D; PONDER, BAJ; HOWELL, A			FORTNIGHTLY REVIEW - FAMILIAL BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT THERAPY; REPRODUCTIVE FACTORS; RISK-FACTORS; DISEASE; WOMEN; HISTORY; AGE; INHERITANCE; MUTATIONS; KINDREDS		GUYS HOSP,ICRF,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND; WITHINGTON HOSP,DEPT RADIOL,NIGHTINGALE BREAST SCREENING UNIT,MANCHESTER M20 8LR,LANCS,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1QP,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University of Cambridge; Christie NHS Foundation Trust; Christie Hospital	EVANS, DGR (corresponding author), ST MARYS HOSP,DEPT MED GENET,MANCHESTER M13 0JH,LANCS,ENGLAND.		Fentiman, Ian/AAB-9886-2020; Evans, D Gareth/AAB-4308-2022; Fentiman, Ian S/I-7644-2019	Evans, D Gareth/0000-0002-8482-5784; Howell, Anthony/0000-0002-6233-719X				ANDERSON DE, 1989, CANCER, V63, P349, DOI 10.1002/1097-0142(19890115)63:2<349::AID-CNCR2820630225>3.0.CO;2-R; ANDERSON DE, 1972, J NATL CANCER I, V48, P1029; BLACK MM, 1983, CANCER, V51, P2147, DOI 10.1002/1097-0142(19830601)51:11<2147::AID-CNCR2820511133>3.0.CO;2-X; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; CHILVERS CED, 1990, BRIT J CANCER, V61, P1, DOI 10.1038/bjc.1990.1; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1989, HUM PATHOL, V20, P723, DOI 10.1016/0046-8177(89)90063-4; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; EASTON DF, 1993, AM J HUM GENET, V52, P678; EVANS DGR, 1993, BRIT J CANCER, V67, P612, DOI 10.1038/bjc.1993.112; EVANS DGR, 1992, J MED GENET, V29, P416, DOI 10.1136/jmg.29.6.416; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOOVER R, 1981, J NATL CANCER I, V67, P815; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KING MC, 1992, NAT GENET, V2, P89, DOI 10.1038/ng1092-89; LAVECCHIA C, 1986, INT J CANCER, V38, P853, DOI 10.1002/ijc.2910380612; LI FP, 1988, CANCER RES, V48, P5358; LYNCH HT, 1988, GASTROENTEROL CLIN N, V17, P679; LYNCH HT, 1984, J MED GENET, V21, P96, DOI 10.1136/jmg.21.2.96; LYNCH HT, 1989, CLIN OBSTET GYNECOL, V32, P750, DOI 10.1097/00003081-198912000-00018; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NAROD SA, 1991, LANCET, V338, P82; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; OLSSON H, 1989, J NATL CANCER I, V81, P1000, DOI 10.1093/jnci/81.13.1000; PARAZZINI F, 1992, INT J CANCER, V51, P677, DOI 10.1002/ijc.2910510502; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; PRICE P, 1990, BRIT J CANCER, V61, P869, DOI 10.1038/bjc.1990.194; ROEBUCK EJ, 1986, BRIT MED J, V292, P223, DOI 10.1136/bmj.292.6515.223-a; ROSEMAN DL, 1990, ARCH INTERN MED, V150, P191, DOI 10.1001/archinte.150.1.191; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SARTORIUS OW, 1977, J NATL CANCER I, V59, P1073, DOI 10.1093/jnci/59.4.1073; SHRIVASTAVA S, 1990, NATURE, V348, P747; SKOLNICK MH, 1990, SCIENCE, V250, P1715, DOI 10.1126/science.2270486; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; WHITCROFT SIJ, 1992, CLIN ENDOCRINOL, V36, P15, DOI 10.1111/j.1365-2265.1992.tb02896.x; 1988, BREAST CANCER SCREEN	41	59	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					183	187		10.1136/bmj.308.6922.183	http://dx.doi.org/10.1136/bmj.308.6922.183			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312772	Green Published			2022-12-28	WOS:A1994MR97400024
J	LEVI, M; TENCATE, H; VANDERPOLL, T; VANDEVENTER, SJH				LEVI, M; TENCATE, H; VANDERPOLL, T; VANDEVENTER, SJH			PATHOGENESIS OF DISSEMINATED INTRAVASCULAR COAGULATION IN SEPSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN VASCULAR ENDOTHELIUM; GRAM-NEGATIVE BACTEREMIA; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; CONTACT SYSTEM; TISSUE FACTOR; PROCOAGULANT ACTIVITY; CYTOKINE RELEASE; HAGEMAN FACTOR	Objective.-To review new insights in the pathogenetic mechanisms involved in the development of disseminated intravascular coagulation (DIC) in septic patients, in order to develop new directions for therapeutic intervention. Data Sources.-Articles and published peer-reviewed abstracts on the mechanism of the initiation of DIC in sepsis. Study Selection.-Studies selected for detailed review were those reporting specifics about the mechanism of activation of coagulation and fibrinolysis in experimental human and animal models of sepsis. Data extraction guidelines for assessing data quality included validity of the model, quality of the laboratory assessment of activation of coagulation and fibrinolysis, and methodological considerations, such as the presence of control experiments and statistical analysis. Data Synthesis.-After the presence of endotoxin in the circulation, significant coagulation activation can be detected. This activation is preceded by an increase in the serum levels of various cytokines, such as tumor necrosis factor and interleukins. Inhibition of the increase in tumor necrosis factor results in inhibition of coagulation activation. Measurement of molecular markers for the activation of coagulation proteins at various levels indicates that the activation of coagulation is mediated by the tissue factor-dependent pathway, which is further confirmed by experiments in which the inhibition of the tissue factor-dependent pathway resulted in complete inhibition of coagulation activation. The activation of coagulation seems to be amplified by impaired function of the protein C-protein S inhibitory pathway. An imbalance between coagulation and fibrinolysis, ultimately leading to plasminogen activator inhibitor type 1-mediated inhibition of fibrinolysis, may further promote the procoagulant state. Conclusion.-The increased knowledge of the various pathogenetic mechanisms of coagulation activation and fibrinolysis in sepsis may have therapeutic implications; however, their efficacy needs to be assessed in appropriate clinical trials.	UNIV AMSTERDAM,ACAD MED CTR,CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLAMMAT RES,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam			Levi, Marcel/AAZ-8559-2020					BAUER KA, 1989, BLOOD, V74, P165; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1986, J CLIN INVEST, V78, P587, DOI 10.1172/JCI112613; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BIEMOND B, 1992, CIRCULATION, V86, P679; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; CONKLING PR, 1988, BLOOD, V72, P128; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; FEINSTEIN DI, 1982, BLOOD, V60, P284; KALTER ES, 1985, J INFECT DIS, V151, P1019, DOI 10.1093/infdis/151.6.1019; KAUFMAN N, 1991, BLOOD, V77, P2660; LEVI M, 1991, J CLIN INVEST, V88, P1155, DOI 10.1172/JCI115416; LEVI M, 1991, THROMB HAEMOSTASIS, V65, P793; LEVI M, 1992, FIBRINOLYSIS, V6, P121; MARDER VJ, 1987, HEMOSTASIS THROMBOSI, P975; MASON JW, 1970, ANN INTERN MED, V73, P545, DOI 10.7326/0003-4819-73-4-545; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NUIJENS JH, 1988, BLOOD, V72, P184; OSTERUD B, 1983, THROMB HAEMOSTASIS, V49, P5; PIXLEY RA, 1992, AM J PATHOL, V140, P897; PIXLEY RA, IN PRESS J CLIN INVE; REGOECZI E, 1969, BRIT J HAEMATOL, V17, P73, DOI 10.1111/j.1365-2141.1969.tb05665.x; ROBBOY SJ, 1972, HUM PATHOL, V3, P327, DOI 10.1016/S0046-8177(72)80034-0; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; VANDERPOLL T, 1991, J EXP MED, V174, P729, DOI 10.1084/jem.174.3.729; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; VANDERRPOLL T, 1990, UPDATE INTENSIVE CAR, V14, P21; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; VANDEVENTER SJH, 1988, LANCET, V1, P605; VANDEVENTER SJH, 1993, J INFECT DIS, V167, P461, DOI 10.1093/infdis/167.2.461; VOSS R, 1990, BRIT J HAEMATOL, V75, P99, DOI 10.1111/j.1365-2141.1990.tb02623.x; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; ZABEL P, 1989, LANCET, V2, P1474; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	42	292	306	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					975	979		10.1001/jama.270.8.975	http://dx.doi.org/10.1001/jama.270.8.975			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8345649				2022-12-28	WOS:A1993LT56700029
J	FRANKS, P; CLANCY, CM; GOLD, MR				FRANKS, P; CLANCY, CM; GOLD, MR			HEALTH-INSURANCE AND MORTALITY - EVIDENCE FROM A NATIONAL COHORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORKING-AGE ADULTS; MEDICAL-CARE; SOCIOECONOMIC-STATUS; HOSPITAL PATIENTS; FOLLOW-UP; ACCESS; SERVICES; MASSACHUSETTS; CONSEQUENCES; POOR	Objective.-To examine the relationship between lacking health insurance and the risk of subsequent mortality. Design.-Adults older than 25 years who reported they were uninsured or privately insured in the first National Health and Nutrition Examination Survey, a representative cohort of the US population, were followed prospectively from initial interview in 1971 through 1975 until 1987. Participants.-Complete baseline and follow-up information was obtained on 4694 (91%) persons of the 5161 who reported not receiving publicly funded insurance at baseline. Main Outcome Measure.-The relationship between insurance status and subsequent mortality was examined using Cox proportional hazards survival analysis. The analysis adjusted for gender, race, and baseline age, education, income, employment status, the presence of morbidity on examination, self-rated health, smoking status, leisure exercise, alcohol consumption, and obesity. The effects of interactions between insurance and all other baseline variables were also examined. Results.-By the end of the follow-up period, 9.6% of the insured and 18.4% of the uninsured had died. After adjustment for all other baseline variables, the hazard ratio for lacking insurance was 1.25 (95% confidence interval [CI], 1.00 to 1.55). The effect of insurance on mortality was comparable to that of education, income, and self-rated health. There were no statistically significant (P<.05) interactions. Conclusions.-Lacking health insurance is associated with an increased risk of subsequent mortality, an effect that is evident in all sociodemographic health insurance and mortality groups examined.	AGCY HLTH CARE POLICY & RES, DIV PRIMARY CARE, ROCKVILLE, MD USA; UNIV ROCHESTER, DEPT FAMILY MED, ROCHESTER, NY 14627 USA; OFF DIS PREVENT & HLTH PROMOT, WASHINGTON, DC USA	Agency for Healthcare Research & Quality; University of Rochester								ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; BILLINGS J, 1990, HEALTH AFFAIR, V9, P158, DOI 10.1377/hlthaff.9.4.158; BRAVEMAN P, 1993, JAMA-J AM MED ASSOC, V269, P1285, DOI 10.1001/jama.269.10.1285; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; FARLEY PJ, 1985, MILBANK FUND Q, V63, P476, DOI 10.2307/3349844; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; FIHN SD, 1988, J GEN INTERN MED, V3, P356, DOI 10.1007/BF02595794; FRANKS P, 1993, IN PRESS AM J PUBLIC; FREEMAN HE, 1990, HEALTH SERV RES, V24, P811; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; GOLD MR, 1990, INT J HEALTH SERV, V20, P405, DOI 10.2190/HRTQ-00PU-RGQM-C12N; GREENBERG ER, 1988, NEW ENGL J MED, V318, P612, DOI 10.1056/NEJM198803103181006; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; HAND R, 1991, JAMA-J AM MED ASSOC, V266, P3429, DOI 10.1001/jama.266.24.3429; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; HUBBELL FA, 1990, SOUTHERN MED J, V83, P548, DOI 10.1097/00007611-199005000-00015; KLEINMAN JC, 1981, MED CARE, V19, P1011, DOI 10.1097/00005650-198110000-00004; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P474; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P465; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; NEWACHECK PW, 1988, HEALTH SERV RES, V23, P401; NEWACHECK PW, 1989, PEDIATRICS, V84, P1056; PATRICK DL, 1992, MED CARE, V30, P941, DOI 10.1097/00005650-199210000-00006; RENNER C, 1989, ANNU REV PUBL HEALTH, V10, P85; SHORT P, 1989, PHS893443 US DEP HLT; SHORT PF, 1992, MED CARE, V30, P766, DOI 10.1097/00005650-199209000-00002; SHORT PF, 1988, INQUIRY-J HEALTH CAR, V25, P504; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WOOLHANDLER S, 1988, Journal of the American Medical Association, V259, P2872, DOI 10.1001/jama.259.19.2872; YERGAN J, 1988, MED CARE, V26, P1111, DOI 10.1097/00005650-198811000-00009; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; 1971, VITAL HLTH STAT; 1974, VITAL HLTH STAT, V1; 1982, VITAL HLTH STAT, V22; 1992, SUDAAN PROFESSIONAL; 1992, MONEY INCOME HOUSEHO; 1992, OTABPH99 BACKGR PAP	47	272	272	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1993	270	6					737	741		10.1001/jama.270.6.737	http://dx.doi.org/10.1001/jama.270.6.737			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ338	8336376				2022-12-28	WOS:A1993LQ33800029
J	PONSONBY, AL; DWYER, T; GIBBONS, LE; COCHRANE, JA; WANG, YG				PONSONBY, AL; DWYER, T; GIBBONS, LE; COCHRANE, JA; WANG, YG			FACTORS POTENTIATING THE RISK OF SUDDEN-INFANT-DEATH-SYNDROME ASSOCIATED WITH THE PRONE POSITION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SLEEPING POSITION	Background. In several studies the sudden infant death syndrome (SIDS) has been significantly associated with sleeping in the prone position. It is not known how the prone position increases the risk of SIDS. Methods. We analyzed data from a case-control study (58 infants with SIDS and 120 control infants) and a prospective cohort study (22 infants with SIDS and 213 control infants) in Tasmania. Interactions were examined in matched analyses with a multiplicative model of interaction. Results. In the case-control study, SIDS was significantly associated with sleeping in the prone position, as compared with other positions (unadjusted odds ratio, 4.5; 95 percent confidence interval, 2.1 to 9.6). The strength of this association was increased among infants who slept on natural-fiber mattresses (P = 0.05), infants who were swaddled (P = 0.09), infants who slept in heated rooms (P = 0.006), and infants who had had a recent illness (P = 0.02). These variables had no significant effect on infants who did not sleep in the prone position. A history of recent illness was significantly associated with SIDS among infants who slept prone (odds ratio, 5.7; 95 percent confidence interval, 1.8 to 19) but not among infants who slept in other positions (odds ratio, 0.83). In the cohort study, the risk of SIDS was greater among infants who slept prone on natural-fiber mattresses (odds ratio, 6.6; 95 percent confidence interval, 1.3 to 33) than among infants who slept prone on other types of mattresses (odds ratio, 1.8). Conclusions. When infants sleep prone, the elevated risk of SIDS is increased by each of four factors: the use of natural-fiber mattresses, swaddling, recent illness, and the use of heating in bedrooms.			PONSONBY, AL (corresponding author), UNIV TASMANIA, MENZIES CTR POPULAT HLTH RES, 43 COLLINS ST, HOBART, TAS 7001, AUSTRALIA.		Wang, You-Gan/A-6059-2008; Ponsonby, Anne-Louise/AAE-4351-2019	Wang, You-Gan/0000-0003-0901-4671; Ponsonby, Anne-Louise/0000-0002-6581-3657				BEAL S, 1991, ACTA PAEDIATR SCAND, V80, P278, DOI 10.1111/j.1651-2227.1991.tb11850.x; BEAL S, 1991, MED J AUSTRALIA, V155, P507, DOI 10.5694/j.1326-5377.1991.tb93882.x; BEAL SM, 1991, J PAEDIATR CHILD H, V27, P334, DOI 10.1111/j.1440-1754.1991.tb00414.x; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P196; CHECKOWAY H, 1989, MONOGRAPHS EPIDEMIOL, V13; CORBYN JA, 1992, ENV CAUSES SUDDEN IN; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; DWYER T, 1992, IN PRESS 2ND P FAM I; EMERY JL, 1968, BRIT MED J, V3, P209, DOI 10.1136/bmj.3.5612.209; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; KOOPMAN JS, 1981, AM J EPIDEMIOL, V113, P716, DOI 10.1093/oxfordjournals.aje.a113153; KUPPER LL, 1978, AM J EPIDEMIOL, V108, P447, DOI 10.1093/oxfordjournals.aje.a112643; LITTLE RE, 1990, EPIDEMIOL REV, V12, P241, DOI 10.1093/oxfordjournals.epirev.a036057; MIETTINEN O, 1974, AM J EPIDEMIOL, V100, P350, DOI 10.1093/oxfordjournals.aje.a112044; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; NELSON EAS, 1989, LANCET, V1, P199; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; RYAN E L, 1991, Australasian Physical and Engineering Sciences in Medicine, V14, P112; SCOTT S, 1990, BRIT MED J, V301, P493, DOI 10.1136/bmj.301.6750.493-b; TONKIN S, 1975, PEDIATRICS, V55, P650; 1992, PEDIATRICS, V90, P264	29	295	303	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					377	382		10.1056/NEJM199308053290601	http://dx.doi.org/10.1056/NEJM199308053290601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8326970				2022-12-28	WOS:A1993LQ33900001
J	WINTERKORN, JMS; KUPERSMITH, MJ; WIRTSCHAFTER, JD; FORMAN, S				WINTERKORN, JMS; KUPERSMITH, MJ; WIRTSCHAFTER, JD; FORMAN, S			BRIEF REPORT - TREATMENT OF VASOSPASTIC AMAUROSIS FUGAX WITH CALCIUM-CHANNEL BLOCKERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SYSTEMIC LUPUS-ERYTHEMATOSUS; MIGRAINE; NIFEDIPINE; ATTACKS; TRIAL		NYU MED CTR,DEPT OPHTHALMOL & NEUROL,NEW YORK,NY 10016; UNIV MINNESOTA,DEPT NEUROL & NEUROSURG,MINNEAPOLIS,MN 55455; WESTCHESTER CTY MED CTR,DEPT OPHTHALMOL,VALHALLA,NY 10595	New York University; University of Minnesota System; University of Minnesota Twin Cities; Westchester Medical Center	WINTERKORN, JMS (corresponding author), N SHORE UNIV HOSP,CORNELL UNIV,MED COLL,DEPT OPHTHALMOL,300 COMMUNITY DR,MANHASSET,NY 11030, USA.							BRANDT KD, 1978, ARTHRITIS RHEUM, V21, P7, DOI 10.1002/art.1780210103; BRAUNWALD E, 1982, NEW ENGL J MED, V307, P1618; BURGER SK, 1991, NEW ENGL J MED, V325, P870, DOI 10.1056/NEJM199109193251207; Carpenter WM, 1938, ARCH OPHTHALMOL-CHIC, V19, P111, DOI 10.1001/archopht.1938.00850130123014; COHEN GR, 1984, OPHTHALMOLOGY, V91, P436; Corbett J J, 1983, Neurol Clin, V1, P973; FARACI FM, 1989, STROKE, V20, P242, DOI 10.1161/01.STR.20.2.242; FISHER CM, 1980, CAN J NEUROL SCI, V7, P9; FISHER CM, 1952, ARCH OPHTHALMOL-CHIC, V47, P167; HILLIS LD, 1978, NEW ENGL J MED, V299, P695, DOI 10.1056/NEJM197809282991305; HUPP SL, 1989, SURV OPHTHALMOL, V33, P221, DOI 10.1016/0039-6257(82)90149-7; KLINE LB, 1980, HEADACHE, V20, P253, DOI 10.1111/j.1526-4610.1980.hed2005253.x; KUPERSMITH M, 1993, NEUROVASCULAR NEURO, P441; KUPERSMITH MJ, 1979, STROKE, V10, P299, DOI 10.1161/01.STR.10.3.299; MILLER FW, 1984, NEW ENGL J MED, V311, P921; MOORE JB, 1985, THROMB RES, V40, P401, DOI 10.1016/0049-3848(85)90275-0; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; POOLE CJM, 1987, J NEUROL NEUROSUR PS, V50, P81, DOI 10.1136/jnnp.50.1.81; RODEHEFFER RJ, 1983, NEW ENGL J MED, V308, P880, DOI 10.1056/NEJM198304143081507; SHAW HE, 1979, AM J OPHTHALMOL, V87, P281, DOI 10.1016/0002-9394(79)90063-1; WILLIAMS JK, 1989, J CEREBR BLOOD F MET, V9, P111, DOI 10.1038/jcbfm.1989.15; WINTERKORN JMS, 1991, ANN NEUROL, V30, P423, DOI 10.1002/ana.410300317; 1990, STROKE, V21, P201; 1991, NEW ENGL J MED, V325, P445	24	94	95	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					396	398		10.1056/NEJM199308053290604	http://dx.doi.org/10.1056/NEJM199308053290604			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8326973	Bronze			2022-12-28	WOS:A1993LQ33900004
J	LONGO, ML; BISAGNO, AM; ZASADZINSKI, JAN; BRUNI, R; WARING, AJ				LONGO, ML; BISAGNO, AM; ZASADZINSKI, JAN; BRUNI, R; WARING, AJ			A FUNCTION OF LUNG SURFACTANT PROTEIN SP-B	SCIENCE			English	Article							MODEL MEMBRANE BILAYERS; AMINO-ACID SEQUENCES; PULMONARY SURFACTANT; BIOPHYSICAL ACTIVITY; MONOLAYERS; CDNA; INHIBITION; ADSORPTION; DOMAIN	The primary function of lung surfactant is to form monolayers at the alveolar interface capable of lowering the normal surface tension to near zero. To accomplish this process, the surfactant must be capable of maintaining a coherent, tight y packed monolayer that avoids collapse during expiration. The Positively charged amino-terminal peptide SP-B1-25 of lung surfactant-specific protein SP-B increases the collapse pressure of an important component of lung surfactant, palmitic acid (PA), to nearly 70 millinewtons per meter. This alteration of the PA isotherms removes the driving force for ''squeeze-out'' of the fatty acids from the primarily dipalmitoylphosphatidylcholine monolayers of lung surfactant. An uncharged mutant of SP-B1-25 induced little change in the isotherms, suggesting that a specific charge interaction between the cationic peptide and the anionic lipid is responsible for the stabilization. The effect of SP-B1-25 on fatty acid isotherms is remarkably similar to that of simple poly-cations, suggesting that such polymers might be useful as components of replacement surfactants for the treatment of respiratory distress syndrome.	UNIV CALIF SANTA BARBARA,DEPT CHEM & NUCL ENGN,SANTA BARBARA,CA 93106; UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024; DREW UNIV,KING MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90059	University of California System; University of California Santa Barbara; University of California System; University of California Los Angeles					NCRR NIH HHS [G 12 RRO 302607] Funding Source: Medline; NHLBI NIH HHS [HL 40666] Funding Source: Medline; NIGMS NIH HHS [GM 47334] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON AW, 1990, PHYSICAL CHEM SURFAC, pCH4; AVERY ME, 1959, AM J DIS CHILD, V97, P917; BAATZ JE, 1990, BIOCHEMISTRY-US, V29, P6714, DOI 10.1021/bi00480a022; BAATZ JE, 1991, CHEM PHYS LIPIDS, V60, P163, DOI 10.1016/0009-3084(91)90039-E; BRUNI R, 1991, P NATL ACAD SCI USA, V88, P7451, DOI 10.1073/pnas.88.16.7451; CHI LF, 1991, LANGMUIR, V7, P2323, DOI 10.1021/la00058a058; CHI LF, 1993, SCIENCE, V259, P213, DOI 10.1126/science.259.5092.213; CHUNG JB, 1990, LANGMUIR, V6, P1647, DOI 10.1021/la00101a005; CLEMENTS J A, 1962, Physiologist, V5, P11; CLEMENTS JA, 1961, ARCH ENVIRON HEALTH, V2, P280; COCHRANE CG, 1991, SCIENCE, V254, P566, DOI 10.1126/science.1948032; COCKSHUTT AM, 1991, BIOCHIM BIOPHYS ACTA, V1085, P248, DOI 10.1016/0005-2760(91)90101-M; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; GLASSER SW, 1988, J BIOL CHEM, V263, P9; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HOLM BA, 1990, CHEM PHYS LIPIDS, V52, P243, DOI 10.1016/0009-3084(90)90120-G; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; KEOUGH KMW, 1988, CAN J PHYSIOL PHARM, V66, P1166, DOI 10.1139/y88-192; KNOBLER CM, 1990, ADV CHEM PHYS, V78, P398; LONGO ML, 1992, BIOPHYS J, V63, P760, DOI 10.1016/S0006-3495(92)81643-0; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.physchem.42.1.171; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; RIES HE, 1987, LANGMUIR, V3, P853, DOI 10.1021/la00077a048; SARIN VK, 1990, P NATL ACAD SCI USA, V87, P2633, DOI 10.1073/pnas.87.7.2633; SCHWARTZ DK, 1992, J PHYS CHEM-US, V96, P10444, DOI 10.1021/j100204a059; SEEGER W, 1992, AM J PHYSIOL, V262, pL286, DOI 10.1152/ajplung.1992.262.3.L286; Shapiro D. L, 1989, SURFACTANT REPLACEME; SMITH RD, 1980, J COLLOID INTERF SCI, V74, P273, DOI 10.1016/0021-9797(80)90190-3; SOLL RF, 1992, RESIDENT STAFF PHYSI, V38, P19; STUART JM, 1984, SOLID PHASE PEPTIDE; TANAKA Y, 1986, J LIPID RES, V27, P475; VANDENBUSSCHE G, 1992, BIOCHEMISTRY-US, V31, P9169, DOI 10.1021/bi00153a008; VENKITARAMAN AR, 1990, CHEM PHYS LIPIDS, V53, P157, DOI 10.1016/0009-3084(90)90041-O; VOLLHARDT D, 1992, LANGMUIR, V8, P309, DOI 10.1021/la00037a056; WARING A, 1989, Peptide Research, V2, P308; WARING A, 1991, BIOPHYS J, V59, P507; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915; WHITSETT JA, 1986, PEDIATR RES, V20, P460, DOI 10.1203/00006450-198605000-00016; YU SH, 1992, BIOCHIM BIOPHYS ACTA, V1126, P26, DOI 10.1016/0005-2760(92)90212-E; YU SH, 1986, BIOCHEM J, V236, P85, DOI 10.1042/bj2360085	41	160	163	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					453	456		10.1126/science.8332910	http://dx.doi.org/10.1126/science.8332910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332910				2022-12-28	WOS:A1993LN62300030
J	BLUSTEIN, J				BLUSTEIN, J			HIGH-TECHNOLOGY CARDIAC PROCEDURES - THE IMPACT OF SERVICE AVAILABILITY ON SERVICE USE IN NEW-YORK-STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION; BYPASS-SURGERY; UNITED-STATES; CARE; HOSPITALS; VOLUME	Objective.-To study the impact of the in-hospital availability of three cardiac procedures (cardiac catheterization, bypass surgery, and angioplasty) on their use in patients during the period following acute myocardial infarction (AMI). Design.-Retrospective cohort study, based on a statewide hospital discharge abstract data set. Participants.-Patients admitted with a principal diagnosis of AMI to New York State hospitals during March through June of 1986. Main Outcome Measures.-The odds of utilizing each of the three services either during the initial admission for AMI or during the 6-month postdischarge interval. Odds ratios (ORs) were calculated comparing utilization in three groups of patients: those initially presenting to hospitals lacking all three services, those initially presenting to hospitals offering only cardiac catheterization, and those initially presenting to hospitals offering all three of the cardiac services. Odds were adjusted for age, sex, race, income, primary payer, severity of illness, and geographical distance to hospital. Results.-Relative to patients initially presenting to hospitals lacking all three services, patients initially presenting to hospitals offering only cardiac catheterization were more likely to undergo cardiac catheterization (OR, 3.57; 95% confidence interval [CI], 3.03 to 4.22), but were not significantly more likely to undergo bypass surgery or angioplasty. Relative to patients initially presenting to hospitals lacking all three services, patients initially presenting to hospitals offering all three services were more likely to undergo cardiac catheterization (OR, 5.50; 95% CI, 4.66 to 6.50), bypass surgery (OR, 2.52; 95% CI, 1.95 to 3.24), and angioplasty (OR, 6.85; 95% CI, 4.73 to 10.58). Conclusions.-The availability of cardiac services in the hospital to which patients initially present strongly influences the likelihood of their use in the period following AMI.			BLUSTEIN, J (corresponding author), NYU,WAGNER GRAD SCH,HLTH RES PROGRAM,329 SHIMKIN HALL,50 W 4TH ST,NEW YORK,NY 10003, USA.				AHRQ HHS [5F32HS00034] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALEMI F, 1990, MED CARE, V28, P762, DOI 10.1097/00005650-199009000-00006; [Anonymous], 1982, LANCET, V2, P1173; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BILLINGS J, 1989, PRELIMINARY STUDY US; BRONSTEIN JM, 1990, MED CARE, V28, P853, DOI 10.1097/00005650-199009000-00013; BUNKER JP, 1970, NEW ENGL J MED, V282, P135, DOI 10.1056/NEJM197001152820306; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; FEIT F, 1990, J AM COLL CARDIOL, V16, P1529, DOI 10.1016/0735-1097(90)90295-Z; Finkler S A, 1979, Inquiry, V16, P264; GOLBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473; GRUMET GW, 1989, NEW ENGL J MED, V321, P607, DOI 10.1056/NEJM198908313210909; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; KAUFMAN GR, 1989, COMMUNICATION   0213; Levit K R, 1991, Health Care Financ Rev, V13, P29; MARMOR TR, 1990, AM PROSPECT      FAL, P18; MCGREGOR M, 1981, NEW ENGL J MED, V299, P179; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P2055, DOI 10.1001/jama.268.15.2055; PEDUZZI P, 1979, CIRCULATION, V60, P888, DOI 10.1161/01.CIR.60.4.888; RICE TH, 1989, J HEALTH POLIT POLIC, V14, P587, DOI 10.1215/03616878-14-3-587; ROBINSON JC, 1987, NEW ENGL J MED, V317, P85, DOI 10.1056/NEJM198707093170205; ROEMER M I, 1961, Hospitals, V35, P36; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SIMPSON JB, 1985, AM J PUBLIC HEALTH, V75, P1225, DOI 10.2105/AJPH.75.10.1225; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; SWEDLOW A, 1992, NEW ENGL J MED, V327, P1502, DOI 10.1056/NEJM199211193272107; TUSSIG AD, 1986, SOC SCI MED, V9, P851; WENNBERG JE, 1984, NEW ENGL J MED, V311, P295, DOI 10.1056/NEJM198408023110505; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; YEDIDIA MJ, 1992, ARCH INTERN MED, V152, P595, DOI 10.1001/archinte.152.3.595; YIP W, 1993, SOC SCI MED, V36, P1455, DOI 10.1016/0277-9536(93)90387-J; YOUNG WW, 1982, MED CARE, V20, P501, DOI 10.1097/00005650-198205000-00006; 1990, STATISTICAL ABSTRACT, P92; 1984, NEW ENGL J MED, V310, P750; 1990, 1990 NEW YORK STAT D; 1986, 1986 NEW YORK STAT D; 1986, ELECTRONIC DATAFILES; 1992, DISCHARGE DATA ABSTR; 1991, PATIENT MANAGEMENT C	43	88	88	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					344	349		10.1001/jama.270.3.344	http://dx.doi.org/10.1001/jama.270.3.344			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8315778				2022-12-28	WOS:A1993LM43500029
J	TUOMILEHTOWOLF, E; TUOMILEHTO, J; HITMAN, GA; NISSINEN, A; STENGARD, J; PEKKANEN, J; KIVINEN, P; KAARSALO, E; KARVONEN, MJ				TUOMILEHTOWOLF, E; TUOMILEHTO, J; HITMAN, GA; NISSINEN, A; STENGARD, J; PEKKANEN, J; KIVINEN, P; KAARSALO, E; KARVONEN, MJ			GENETIC SUSCEPTIBILITY TO NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND GLUCOSE-INTOLERANCE ARE LOCATED IN HLA REGION	BRITISH MEDICAL JOURNAL			English	Article							ELDERLY MEN; A ANTIGENS; FREQUENCY; FINLAND; RISK	Objectives-To test the hypothesis that the genetic susceptibility to non-insulin dependent diabetes mellitus is the same as that to insulin dependent disease and to see whether glucose intolerance is associated with specific HLA haplotypes. Design-Population based study of men in 1989 first tested for glucose tolerance in 1984. HLA haplotypes, including HLA-A, C, B, DR, and DQ, were defined serologically. HLA haplotype data from a population based Finnish study of childhood diabetes were used for predicting non-insulin dependent diabetes and impaired glucose tolerance. Setting-Two communities in Finland. Subjects-Representative cohort of Finnish men aged 70-89, comprising 98 men with non-insulin dependent diabetes mellitus and a randomly selected group of 74 men, who served as controls, who were tested for glucose tolerance twice within five years. Main outcome measures-Non-insulin dependent diabetes, impaired glucose tolerance, blood glucose concentration. Results-Diabetes associated HLA haplotypes were present in 94% (85/90) of diabetic subjects, 79% (27/34) of subjects with impaired glucose tolerance, and only 13% (3/23) of non-diabetic subjects. In this group of elderly men sensitivity of the diabetes associated HLA haplotypes for non-insulin dependent diabetes and impaired glucose tolerance was 90%, specificity 87%, and predictive power 97%. Mean fasting blood glucose concentration was only just significantly higher in men with diabetes associated haplotypes than in men with no such haplotypes, but there was a substantial difference in blood glucose values two hours after glucose loading (10.4 and 6.4 mmol/l in men with diabetes associated HLA haplotypes and men with no such haplotypes, respectively (p<0.0001)). Conclusions-These findings support the hypothesis that specific HLA haplotypes exhibit a common genetic determinant for insulin dependent and non-insulin dependent diabetes. Furthermore, HLA is a major genetic determinant of glucose intolerance in elderly Finnish men. The belief that the HLA predisposition to diabetes is specific for insulin dependent diabetes mellitus is largely incorrect.	ROYAL LONDON HOSP,MED UNIT,LONDON E1 1BB,ENGLAND; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,KUOPIO,FINLAND; LOIMAA DIST HOSP,LOIMAA,FINLAND; NATL PUBL HLTH INST,DEPT EPIDEMIOL,SF-00280 HELSINKI 28,FINLAND	Barts Health NHS Trust; Royal London Hospital; University of Eastern Finland; University of Turku; Finland National Institute for Health & Welfare					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037957] Funding Source: NIH RePORTER; NIA NIH HHS [AG087762] Funding Source: Medline; NIDDK NIH HHS [DK-37957] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASMAL AC, 1981, S AFR MED J, V60, P3; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BAUR MP, 1984, HISTOCOMPATIBILITY; BENNETT AH, 1992, INT TXB DIABETES MEL, P147; BHATIA K, 1984, DIABETOLOGIA, V27, P370, DOI 10.1007/BF00304852; BRIGGS BR, 1980, DIABETES, V29, P68, DOI 10.2337/diabetes.29.1.68; CUDWORTH AG, 1975, BRIT MED J, V3, P133, DOI 10.1136/bmj.3.5976.133; DAHLQUIST G, 1989, DIABETOLOGIA, V32, P2; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; GROOP L, 1983, ACTA ENDOCRINOL-COP, V104, P475, DOI 10.1530/acta.0.1040475; HARRIS H, 1950, ANN EUGENIC, V15, P95; KEYS A, 1970, CIRCULATION       S1, V41, P1; Neel J. V, 1976, GENETICS DIABETES ME, P1; NERUP J, 1974, LANCET, V2, P864; NISSINEN A, 1986, AGE AGEING, V15, P203, DOI 10.1093/ageing/15.4.203; OMAR MAK, 1988, DIABETES, V37, P796, DOI 10.2337/diabetes.37.6.796; PEKKANEN J, 1989, BRIT MED J, V299, P81, DOI 10.1136/bmj.299.6691.81; PYKE DA, 1977, CLIN ENDOCRINOL META, V6, P285, DOI 10.1016/S0300-595X(77)80039-X; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; SERJEANTSOIN SW, 1981, MED J AUSTRALIA, V41, P462; SERJEANTSON SW, 1983, DIABETOLOGIA, V25, P13; SINGAL DP, 1973, DIABETES, V22, P429, DOI 10.2337/diab.22.6.429; SPEES EK, 1973, HISTOCOMPATIBILITY T, P345; TIENARI PJ, 1992, DIABETOLOGIA, V35, P254, DOI 10.1007/BF00400926; TIWARI JL, 1985, HLA DISEASE ASS, P210; TUOMILEHTO J, 1991, INT J EPIDEMIOL, V20, P1010, DOI 10.1093/ije/20.4.1010; TUOMILEHTO J, 1992, DIABETOLOGIA, V35, P70, DOI 10.1007/BF00400854; TUOMILEHTO J, 1986, DIABETOLOGIA, V29, P611, DOI 10.1007/BF00869258; TUOMILEHTOWOLF E, 1989, LANCET, V2, P299; TUOMILEHTOWOLF E, 1992, ANN MED, V24, P533, DOI 10.3109/07853899209167007; VELLENA AA, 1980, NEW ENGL J MED, V303, P1065; WILLIAMS RC, 1981, DIABETOLOGIA, V21, P460; WOLF E, 1981, DIABETOLOGIA, V21, pA80; ZHAO TM, 1982, CHINESE MED J-PEKING, V95, P609; 1985, WHO TECH REP SER, V727	35	67	67	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					155	159		10.1136/bmj.307.6897.155	http://dx.doi.org/10.1136/bmj.307.6897.155			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343743	Bronze, Green Published			2022-12-28	WOS:A1993LN18400017
J	KOLCH, W; HEIDECKER, G; KOCHS, G; HUMMEL, R; VAHIDI, H; MISCHAK, H; FINKENZELLER, G; MARME, D; RAPP, UR				KOLCH, W; HEIDECKER, G; KOCHS, G; HUMMEL, R; VAHIDI, H; MISCHAK, H; FINKENZELLER, G; MARME, D; RAPP, UR			PROTEIN KINASE-C-ALPHA ACTIVATES RAF-1 BY DIRECT PHOSPHORYLATION	NATURE			English	Article								THE kinase Raf-1 can be activated by treatment of cells with mitogens and by the protein kinase C (PKC) activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (reviewed in refs 1,2). Activated Raf-1 triggers a protein kinase cascade by direct phosphorylation of MAP kinase kinase3-5, resulting in phosphorylation of ternary complex factor6 and Jun7,8 by MAP kinase. Here we investigate the molecular mechanism and biological consequences of PKCalpha-mediated Raf-1 activation in NIH3T3 fibroblasts. PKCalpha directly phosphorylates and activates Raf-1 both in vitro and in vivo. PKCalpha induces Raf-1 phosphorylation at several sites, including a serine residue at position 499. Mutation of serine at this position or at residue 259 does not abrogate Raf-1 stimulation by a combination of Ras plus the src tyrosine kinase Lck, but severely impedes Raf-1 activation by PKCalpha. Consistent with such a direct interaction is the observation that Raf-1 and PKCalpha cooperate in the transformation of NIH3T3 cells. The Ser499 phosphorylation site is necessary for this synergism.	GODECKE AG,BIOL RES,W-7800 FREIBURG,GERMANY; NCI,FCRDC,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; UNIV FREIBURG,GOEDECKE AG,INST MOLEC CELL BIOL,W-7800 FREIBURG,GERMANY; NCI,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Freiburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011; Kolch, Walter/ABF-2102-2021	Mischak, Harald/0000-0003-0323-0306; Kolch, Walter/0000-0001-5777-5016				APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOCHS G, IN PRESS BIOCHEMICAL; KOLCH W, 1990, ONCOGENE, V5, P713; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LUO K, 1991, METHOD ENZYMOL, V201, pB149; MCGREW BR, 1992, ONCOGENE, V7, P33; PIWINICAWORMS H, 1987, CELL, V49, P75; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOZERI O, 1992, ONCOGENE, V7, P2259; Summers MD, 1987, MANUAL METHODS BACUL; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	19	1239	1263	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					249	252		10.1038/364249a0	http://dx.doi.org/10.1038/364249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321321				2022-12-28	WOS:A1993LM68300061
J	EVENS, RG				EVENS, RG			RADIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MR ANGIOGRAPHY; ARTERIES				EVENS, RG (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							ACKERMAN LV, 1992, RADIOLOGY, V185, P394, DOI 10.1148/radiology.185.2.1410344; BRINK JA, 1992, RADIOLOGY, V185, P469, DOI 10.1148/radiology.185.2.1410356; CAPLAN LR, 1991, AM J NEURORADIOL, V12, P593; COSTELLO P, 1992, RADIOLOGY, V183, P663, DOI 10.1148/radiology.183.3.1584915; DEBATIN JF, 1991, AM J ROENTGENOL, V157, P981, DOI 10.2214/ajr.157.5.1927823; DESTOUET JM, 1992, AM J ROENTGENOL, V159, P973, DOI 10.2214/ajr.159.5.1414810; EDELMAN RR, 1991, RADIOLOGY, V181, P641, DOI 10.1148/radiology.181.3.1947074; HANDEL N, 1992, JAMA-J AM MED ASSOC, V268, P1913, DOI 10.1001/jama.268.14.1913; HEISERMAN JE, 1992, RADIOLOGY, V182, P761, DOI 10.1148/radiology.182.3.1535891; HILLMAN BJ, 1992, JAMA-J AM MED ASSOC, V268, P2050, DOI 10.1001/jama.268.15.2050; HYE RJ, 1990, ARCH SURG-CHICAGO, V125, P1550; Mauro M A, 1993, J Vasc Interv Radiol, V4, P127, DOI 10.1016/S1051-0443(93)71835-7; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; OWEN RS, 1992, NEW ENGL J MED, V326, P1577, DOI 10.1056/NEJM199206113262428; ZYLAK CJ, 1992, RADIOLOGY, V184, P607, DOI 10.1148/radiology.184.3.1509040	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					259	260		10.1001/jama.270.2.259	http://dx.doi.org/10.1001/jama.270.2.259			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315755				2022-12-28	WOS:A1993LL36800042
J	EWEN, ME; SLUSS, HK; SHERR, CJ; MATSUSHIME, H; KATO, JY; LIVINGSTON, DM				EWEN, ME; SLUSS, HK; SHERR, CJ; MATSUSHIME, H; KATO, JY; LIVINGSTON, DM			FUNCTIONAL INTERACTIONS OF THE RETINOBLASTOMA PROTEIN WITH MAMMALIAN D-TYPE CYCLINS	CELL			English	Article							SV40 LARGE-T; ADENOVIRUS E1A PROTEINS; GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; RB PROTEIN; G1 PHASE; PHOSPHORYLATION; BINDING; ONCOGENE	The retinoblastoma gene product (Rb) can interact efficiently with two of three D-type G1 cyclins (D2 and D3) in vitro. Binding depended upon the minimal regions of Rb necessary for its growth-suppressive activity, as well as upon the D-type cyclin sequence motif shared with Rb-binding DNA tumor virus oncoproteins. Coexpression of the three D-type cyclins with the cyclin-dependent kinase (cdk4) in insect cells generated Rb kinase activity. By contrast, cyclins D2 and D3, but not D1, activated another such kinase, cdk2. Introduction of cyclin D2 and Rb into the Rb-deficient cell line SAOS-2 led to overt Rb hyperphosphorylation, whereas Rb, expressed alone or together with cyclin D1, remained unphosphorylated. Cyclin D2-dependent phosphorylation inhibited its binding to the transcription factor E2F and reversed the Rb G1 exit block in the cell cycle. Thus, all D-type cyclins do not function equivalently, and one of them plays a major role in reversing the cycle-blocking function of a known tumor suppressor.	HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital	EWEN, ME (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.		Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206	NATIONAL CANCER INSTITUTE [R35CA047064] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, IN PRESS J CELL BIOL; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNA Z, 1993, IN PRESS ONCOGENE; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHUURING E, 1992, ONCOGENE, V7, P355; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	61	1046	1078	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 7	1993	73	3					487	497		10.1016/0092-8674(93)90136-E	http://dx.doi.org/10.1016/0092-8674(93)90136-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8343202				2022-12-28	WOS:A1993LA74300010
J	CHAPMAN, S; YACH, D; SALOOJEE, Y; SIMPSON, D				CHAPMAN, S; YACH, D; SALOOJEE, Y; SIMPSON, D			ALL AFRICA CONFERENCE ON TOBACCO CONTROL	BRITISH MEDICAL JOURNAL			English	Article								Although the health hazards of smoking are now generally accepted in most Western countries, the arguments have not had much impact on poorer nations. A conference on tobacco control held in Harare, Zimbabwe, in November last year was the largest to tackle this problem. The conference heard how threats of epidemics of tobacco related disease in the distant future held little weight with governments of countries that often already had massive public health problems. More immediate effects needed to be emphasised. Speakers gave three cogent arguments; firstly, the loss of capacity for foreign trade in essential goods, since most African countries are net importers of tobacco; secondly, the extensive deforestation which is occurring to fuel the flue curing of tobacco; thirdly, evidence from Papua New Guinea that raising taxation on tobacco provides governments with increased income for many years before a decrease begins.	UNIV SYDNEY,DEPT COMMUNITY MED,SYDNEY,NSW 2006,AUSTRALIA; S AFRICAN MRC,ESSENTIAL HLTH RES GRP,PRETORIA,SOUTH AFRICA; TOBACCO ACT GRP,JOHANNESBURG,SOUTH AFRICA; INT AGCY TOBACCO & HLTH,LONDON,ENGLAND	University of Sydney; South African Medical Research Council			Chapman, Simon/D-4114-2009					CHAPMAN S, 1990, AM J PUBLIC HEALTH, V80, P537, DOI 10.2105/AJPH.80.5.537; WALKER ARP, 1993, CANCER J - FRANCE, V6, P180; WINKFIELD R, 1992, FARMER ZIMBABWE 0917; Yach D, 1992, TOB CONTROL, V1, P272, DOI DOI 10.1136/TC.1.4.272]; 1992, WORLD HTLH STATISTIC; 1992, CANCER INCIDENCE 5 C; 1993, FARMER ZIMBAWE  1104, P12; 1993, TOBACCO REPORTER JUL, P68	8	11	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					189	191		10.1136/bmj.308.6922.189	http://dx.doi.org/10.1136/bmj.308.6922.189			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312774	Green Published			2022-12-28	WOS:A1994MR97400026
J	RUBIN, HR; GANDEK, B; ROGERS, WH; KOSINSKI, M; MCHORNEY, CA; WARE, JE				RUBIN, HR; GANDEK, B; ROGERS, WH; KOSINSKI, M; MCHORNEY, CA; WARE, JE			PATIENTS RATINGS OF OUTPATIENT VISITS IN DIFFERENT PRACTICE SETTINGS - RESULTS FROM THE MEDICAL OUTCOMES STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; SATISFACTION; SYSTEMS; SPECIALTIES; PROVIDER; PREPAID	Objective.-To determine how patients in different kinds of practices-solo or single specialty (SOLO), multispecialty group (MSG), or health maintenance organizations (HMOs)-and with fee-for-service (FFS) or prepaid physician payment arrangements evaluate their medical care. Design.-Survey of adult outpatients after office visits, with sample weighted to represent population of patients visiting physicians in each practice type. Setting.-Offices of 367 internists, family practitioners, endocrinologists, cardiologists, and nurse practitioners, in HMOs (prepaid only), MSGs (prepaid and FFS), and SOLO practices (prepaid and FFS). Patients.-Adults (N=17 671) at start of the Medical Outcomes Study. Outcome Measures.-Overall rating of the visit (five choices from excellent to poor). A random half of the sample also rated the provider's technical skills, personal manner, and explanations of care as well as time spent during the visit, the appointment wait, the office wait, the convenience of the office location, and telephone access. Results.-Fifty-five percent of patients rated their visit overall as excellent 32% very good, 11% good, and 2% fair or poor. Patients of SOLO practitioners were more likely (64%) to rate their visit excellent than MSG (48%) or HMO (49%) patients (P<.001). Patients of SOLO practitioners rated all aspects of care better than HMO patients did, most markedly appointment waits (64% vs 40% excellent; P<.0001) and telephone access (64% vs 33% excellent; P<.0001). Within SOLO and MSG practices, FFS patients rated most specific aspects better than prepaid patients, but these differences were not statistically significant and were inconsistent across cities. Adjusting for patients' demographics, diagnoses and self-rated health did not change results. Physicians with visit ratings in the lowest 20% were nearly four times as likely to be left by patients within 6 months than physicians in the highest 20% (16.7% vs 4.6%; P<.001). Conclusion.-Of the five practice type and payment method combinations, SOLO FFS patients rated their visits best and HMO patients worst. Whether FFS or prepaid, care was rated better in small than in large practices. Our study shows that a brief visit rating form can be used to compare practice settings and health plans, and that patient ratings predict what proportion of patients, on average, will leave their physicians in the next several months.	JOHNS HOPKINS MED INST,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,PROGRAM MED TECHNOL & PRACTICE ASSESSMENT,BALTIMORE,MD 21205; TUFTS UNIV NEW ENGLAND MED CTR,INST HLTH,BOSTON,MA; RAND,SANTA MONICA,CA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Tufts Medical Center; RAND Corporation					AHRQ HHS [HS06073-0351] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1980, EXPLORATIONS QUALITY; BERKANOVIC E, 1975, MILBANK FUND Q, V53, P241, DOI 10.2307/3349528; BERWICK D, 1990, CURING HLTH CARE NEW, P55; CLEARY P, 1992, QUALITY REV B    FEB, P53; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; COPE DW, 1986, J GEN INTERN MED, V1, P394, DOI 10.1007/BF02596425; DAVIES AR, 1988, HEALTH AFFAIR, V7, P33, DOI 10.1377/hlthaff.7.1.33; DAVIES AR, 1986, HEALTH SERV RES, V21, P429; DAVIES AR, 1991, GHAAS CONSUMER SATIS, P34; FRANCIS AM, 1984, MED CARE, V22, P418, DOI 10.1097/00005650-198405000-00006; FREUDENHEIM M, 1990, NY TIMES        0526, P1; GOLDMAN B, 1990, AM COLL PHYSICIANS O, V10, P6; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; MECHANIC D, 1980, MED CARE, V18, P597, DOI 10.1097/00005650-198006000-00003; MOLONEY TW, 1991, HEALTH AFFAIR, V10, P268, DOI 10.1377/hlthaff.10.4.268; ROGERS W, 1992, MEASURING FUNCTIONAL, P27; Rubin H R, 1990, Med Care Rev, V47, P267, DOI 10.1177/107755879004700302; Rubin HR, 1991, BUSINESS MED PHYSICI, P397; SAFRAN DG, 1992, THESIS HARVARD U BOS, P52; STARR P, 1992, LOGIC HLTH CARE REFO; STEIN SR, 1989, SOUTHERN MED J, V82, P3, DOI 10.1097/00007611-198901000-00003; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; TEMKINGREENER H, 1991, HEALTH SERV RES, V26, P509; Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5; WARE JE, 1988, MED CARE, V26, P393, DOI 10.1097/00005650-198804000-00008; WARE JE, 1988, OTAH386 US C OFF TEC, P231; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298; 1988, OTAH386 US C OFF TEC; 1992, CONSUMER REP     AUG, P519	33	446	450	1	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					835	840		10.1001/jama.270.7.835	http://dx.doi.org/10.1001/jama.270.7.835			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340982				2022-12-28	WOS:A1993LR61200028
J	WONG, DKH; CHEUNG, AM; OROURKE, K; NAYLOR, CD; DETSKY, AS; HEATHCOTE, J				WONG, DKH; CHEUNG, AM; OROURKE, K; NAYLOR, CD; DETSKY, AS; HEATHCOTE, J			EFFECT OF ALPHA-INTERFERON TREATMENT IN PATIENTS WITH HEPATITIS-B E-ANTIGEN-POSITIVE CHRONIC HEPATITIS-B - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED TRIAL; CHRONIC ACTIVE HEPATITIS; HBSAG-CARRIER CHILDREN; VIRUS HBV INFECTION; TERM FOLLOW-UP; LONG-TERM; LYMPHOBLASTOID INTERFERON; RECOMBINANT ALPHA-2-INTERFERON; HEPATOCELLULAR-CARCINOMA; PREDNISONE WITHDRAWAL	Purpose: To determine whether alpha-interferon is effective in terminating viral replication and in eradicating the carrier state in patients with chronic hepatitis B virus (HBV) infection. Data Sources: Randomized controlled studies published in the English literature between January 1966 and June 1992 were identified through a MEDLINE computer search. Study Selection: Fifteen randomized controlled studies with a total of 837 adult chronic HBV carriers who were positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were identified. Studies were included if patients were treated for at least 3 months and followed for at least 6 months after cessation of therapy. Results: Overall, the loss of HBsAg occurred 6% more often in interferon-treated patients than the natural seroconversion seen in controls (7.8% compared with 1.8%, P = 0.001), and the loss of viral replication occurred approximately 20% more often in treated patients than in controls (33% compared with 12% for loss of HBeAg and 37% compared with 17% for the loss of HBV DNA, P = 0.0001) if patients received interferon for 3 to 6 months and were followed for 6 to 12 months. Interferon also had a significant treatment effect on the development of antibodies to HBsAg (anti-HBs), antibodies to HBeAg (anti-HBe), and on the normalization of alanine aminotransferase levels. Conclusions: Alpha-interferon is effective in terminating viral replication and in eradicating the carrier state in patients with chronic HBV infection who are HBeAg positive when these patients are treated for 3 to 6 months and followed for 6 to 12 months after cessation of therapy. Follow-up studies are required to determine whether interferon reduces the risk for developing cirrhosis or hepatocellular carcinoma.	UNIV TORONTO, TORONTO HOSP, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center				Cheung, Angela M./0000-0001-8332-0744; Wong, David/0000-0002-3310-3538	Canadian Institutes of Health Research [44917] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		ALBERTI A, 1986, J INFECT DIS, V154, P562, DOI 10.1093/infdis/154.4.562; ALEXANDER GJM, 1987, LANCET, V2, P66; ALEXANDER GJM, 1986, J HEPATOL, V3, pS183, DOI 10.1016/S0168-8278(86)80118-0; ANDERSON MG, 1987, GUT, V28, P619, DOI 10.1136/gut.28.5.619; ANDERSON MG, 1986, J HEPATOL, V3, pS225, DOI 10.1016/S0168-8278(86)80124-6; BAKER BL, 1991, HEPATOLOGY, V13, P632, DOI 10.1016/0270-9139(91)92556-N; BARBARA L, 1986, J HEPATOL, V3, pS235, DOI 10.1016/S0168-8278(86)80126-X; BEASLEY RP, 1983, LANCET, V2, P1099; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BONINO F, 1981, HEPATOLOGY, V1, P386, DOI 10.1002/hep.1840010503; BORTOLOTTI F, 1990, GASTROENTEROLOGY, V99, P805, DOI 10.1016/0016-5085(90)90972-4; BROOK MG, 1989, HEPATOLOGY, V10, P761, DOI 10.1002/hep.1840100502; BROOK MG, 1989, BRIT MED J, V299, P652, DOI 10.1136/bmj.299.6700.652; BROOK MG, 1989, GUT, V30, P1116, DOI 10.1136/gut.30.8.1116; BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213; CARRENO V, 1987, ANTIVIR RES, V8, P125, DOI 10.1016/0166-3542(87)90066-0; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; Chu CM, 1987, GASTROENTEROLOGY, V92, P220, DOI 10.1016/0016-5085(87)90863-8; COPPENS JP, 1989, LIVER, V9, P307; DAVIS GL, 1985, ANN INTERN MED, V102, P762, DOI 10.7326/0003-4819-102-6-762; DAVIS GL, 1989, SEMIN LIVER DIS, V9, P267, DOI 10.1055/s-2008-1040522; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DODD RY, 1987, J VIROL METHODS, V17, P81, DOI 10.1016/0166-0934(87)90071-1; DUSHEIKO GM, 1986, J HEPATOL, V3, pS199, DOI 10.1016/S0168-8278(86)80121-0; FATTOVICH G, 1986, HEPATOLOGY, V6, P167, DOI 10.1002/hep.1840060203; FATTOVICH G, 1989, J HEPATOL, V9, P331, DOI 10.1016/0168-8278(89)90142-6; FATTOVICH G, 1991, GUT, V32, P294, DOI 10.1136/gut.32.3.294; FATTOVICH G, 1992, HEPATOLOGY, V15, P584, DOI 10.1002/hep.1840150405; FRANCO A, 1986, J HEPATOL, V3, pS239, DOI 10.1016/S0168-8278(86)80127-1; FRASER DAS, 1976, PROBABILITY STATISTI, P294; FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756; HADZIYANNIS SJ, 1983, HEPATOLOGY, V3, P656; HALL AJ, 1985, LANCET, V1, P91; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; HOOFNAGLE JH, 1990, J HEPATOL, V11, pS100, DOI 10.1016/0168-8278(90)90173-O; HSU HC, 1987, J HEPATOL, V5, P45, DOI 10.1016/S0168-8278(87)80060-0; KARAYIANNIS P, 1985, J HEPATOL, V1, P99, DOI 10.1016/S0168-8278(85)80759-5; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAI CL, 1991, Q J MED, V78, P155; LAI CL, 1987, LANCET, V2, P877; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LAUPACIS A, 1992, ANN INTERN MED    S3, V116, pA12; LIAW YF, 1988, AM J MED, V85, P147; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LIAW YF, 1983, GASTROENTEROLOGY, V84, P216; LIAW YF, 1987, HEPATOLOGY, V7, P1, DOI 10.1002/hep.1840070102; LO KJ, 1985, J INFECT DIS, V152, P817, DOI 10.1093/infdis/152.4.817; LOK ASF, 1984, LIVER, V4, P45; LOK ASF, 1988, LANCET, V2, P298; LOK ASF, 1990, J HEPATOL, V10, P29, DOI 10.1016/0168-8278(90)90069-4; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; LOK ASF, 1986, J HEPATOL, V3, pS209, DOI 10.1016/S0168-8278(86)80122-2; LOK ASF, 1990, J HEPATOL, V11, pS121, DOI 10.1016/0168-8278(90)90177-S; LOK ASF, 1992, GASTROENTEROLOGY, V102, P2091, DOI 10.1016/0016-5085(92)90337-X; MAYNARD JE, 1990, VACCINE, V8, pS18, DOI 10.1016/0264-410X(90)90209-5; MAZZELLA G, 1988, AM J MED, V85, P141; Mazzella G, 1988, Chemioterapia, V7 Suppl 3, P12; McCullagh P, 1989, MONOGRAPHS STATISTIC, P160; MCDONALD JA, 1987, HEPATOLOGY, V7, P719, DOI 10.1002/hep.1840070417; MORENO MR, 1990, DIGESTION, V45, P26, DOI 10.1159/000200221; MULLER R, 1990, J HEPATOL, V11, pS137, DOI 10.1016/0168-8278(90)90181-P; PASTORE G, 1992, J HEPATOL, V14, P221, DOI 10.1016/0168-8278(92)90161-H; PASTORE G, 1988, HEPATO-GASTROENTEROL, V35, P57; PERRILLO RP, 1988, ANN INTERN MED, V109, P95, DOI 10.7326/0003-4819-109-2-95; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PORRES JC, 1988, HEPATO-GASTROENTEROL, V35, P300; RAKELA J, 1990, MAYO CLIN PROC, V65, P1330, DOI 10.1016/S0025-6196(12)62144-2; REALDI G, 1990, J HEPATOL, V11, pS129, DOI 10.1016/0168-8278(90)90179-U; RUIZMORENO M, 1991, HEPATOLOGY, V13, P1035, DOI 10.1002/hep.1840130605; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SARACCO G, 1989, HEPATOLOGY, V10, P336, DOI 10.1002/hep.1840100315; SCHALM SW, 1982, HEPATOLOGY, V2, P791, DOI 10.1002/hep.1840020608; SCULLY LJ, 1986, J HEPATOL, V3, pS291, DOI 10.1016/S0168-8278(86)80134-9; TASSOPOULOS NC, 1987, GASTROENTEROLOGY, V92, P1844, DOI 10.1016/0016-5085(87)90614-7; THOMAS HC, 1986, J HEPATOL, V3, pS193, DOI 10.1016/S0168-8278(86)80120-9; UTILI R, 1991, AM J GASTROENTEROL, V86, P327; WAKED I, 1990, J CHEMOTHERAPY, V2, P310, DOI 10.1080/1120009X.1990.11739035; WAKED I, 1988, CHEMIOTERAPIA, V7, P198; WEIMAR W, 1980, LANCET, V1, P336; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WILLIAMS SJ, 1990, AUST NZ J MED, V20, P9, DOI 10.1111/j.1445-5994.1990.tb00362.x; WOLFRAM S, 1991, MATH SYSTEM DOING MA, P558; WONG VCW, 1984, LANCET, V1, P921	87	850	885	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					312	323		10.7326/0003-4819-119-4-199308150-00011	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00011			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328741				2022-12-28	WOS:A1993LV52500011
J	GRUNDY, FJ; HENKIN, TM				GRUNDY, FJ; HENKIN, TM			TRANSFER-RNA AS A POSITIVE REGULATOR OF TRANSCRIPTION ANTITERMINATION IN BACILLUS-SUBTILIS	CELL			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SYNTHETASE GENES; PROTEIN; STEAROTHERMOPHILUS; CLONING; OPERON; TERMINATION; HOMOLOGY	Most Bacillus tRNA synthetase genes are regulated by a common transcription antitermination mechanism but respond individually to limitation for the cognate amino acid. The mRNA leader regions of these genes exhibit extensive structural conservation, with a single codon specific for the appropriate amino acid at the identical position in each structure. Alteration of this sequence in the tyrS gene from UAC (tyrosine) to UUC (phenylalanine) resulted in loss of induction by tyrosine limitation and a switch to induction by phenylalanine limitation. Insertion of an extra base immediately upstream of the codon did not alter regulation, indicating a nontranslational mechanism. A nonsense codon resulted in an uninducible phenotype that was suppressible in a lysyl-tRNA nonsense suppressor mutant, indicating that tRNA acts as an effector.			GRUNDY, FJ (corresponding author), ALBANY MED COLL,DEPT BIOCHEM & MOLEC BIOL,ALBANY,NY 12208, USA.				NIGMS NIH HHS [GM40650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; BARSTOW DA, 1986, GENE, V46, P37, DOI 10.1016/0378-1119(86)90164-2; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P2480, DOI 10.1021/bi00383a012; BRAKHAGE AA, 1990, BIOCHIMIE, V72, P725, DOI 10.1016/0300-9084(90)90157-C; CHOW KC, 1988, GENE, V73, P537; DALE BA, 1971, J BACTERIOL, V108, P586, DOI 10.1128/JB.108.1.586-588.1971; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; GHOSH B, 1984, P NATL ACAD SCI-BIOL, V81, P6305, DOI 10.1073/pnas.81.20.6305; GLASER P, 1990, DNA SEQUENCE, V1, P251; GRAFFE M, 1992, SCIENCE, V255, P994, DOI 10.1126/science.1372129; GRANDONI JA, 1992, J BACTERIOL, V174, P3212, DOI 10.1128/jb.174.10.3212-3219.1992; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GRUNBERGMANAGO M, 1987, ESCHERICHIA COLI SAL, P1386; GRUNDY FJ, 1991, J BACTERIOL, V173, P4595, DOI 10.1128/jb.173.15.4595-4602.1991; HENKIN TM, 1984, MOL GEN GENET, V193, P364, DOI 10.1007/BF00330694; HENKIN TM, 1992, J BACTERIOL, V174, P1299, DOI 10.1128/jb.174.4.1299-1306.1992; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; JIN DJ, 1988, J MOL BIOL, V204, P247, DOI 10.1016/0022-2836(88)90573-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LOVETT PS, 1991, J BACTERIOL, V173, P1810, DOI 10.1128/jb.173.5.1810-1812.1991; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MECHULAM Y, 1991, NUCLEIC ACIDS RES, V19, P3673, DOI 10.1093/nar/19.13.3673; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Miller J.H., 1972, EXPT MOL GENETICS; NASS G, 1967, BIOCHIM BIOPHYS ACTA, V134, P347, DOI 10.1016/0005-2787(67)90012-3; PUTZER H, 1992, EMBO J, V11, P3117, DOI 10.1002/j.1460-2075.1992.tb05384.x; ROBERTS JW, 1993, CELL, V72, P653, DOI 10.1016/0092-8674(93)90394-6; TAYLOR BV, 1993, J BACTERIOL, V175, P2475, DOI 10.1128/JB.175.8.2475-2478.1993; VANDERHORN PB, 1992, J BACTERIOL, V174, P3928, DOI 10.1128/jb.174.12.3928-3935.1992; WAYE MMY, 1986, EUR J BIOCHEM, V158, P505, DOI 10.1111/j.1432-1033.1986.tb09783.x	35	218	222	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					475	482		10.1016/0092-8674(93)80049-K	http://dx.doi.org/10.1016/0092-8674(93)80049-K			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348614				2022-12-28	WOS:A1993LT73900009
J	WULF, WA				WULF, WA			THE COLLABORATORY OPPORTUNITY	SCIENCE			English	Editorial Material											WULF, WA (corresponding author), UNIV VIRGINIA,DEPT COMP SCI,CHARLOTTESVILLE,VA 22901, USA.							WULF WA, 1989, MAR NAT SCI F INV WO; 1993, NATIONAL COLLABORATO	2	99	99	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					854	855		10.1126/science.8346438	http://dx.doi.org/10.1126/science.8346438			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346438				2022-12-28	WOS:A1993LR89700024
J	GIARDINA, C; LIS, JT				GIARDINA, C; LIS, JT			DNA MELTING ON YEAST RNA POLYMERASE-II PROMOTERS	SCIENCE			English	Article							COMPLEX-FORMATION; TRANSCRIPTION; INITIATION; INVIVO; GENES; SACCHAROMYCES; SEQUENCES; MECHANISM; PROTEINS; CLONING	Transcription-dependent DNA melting on the yeast GAL1 and GAL10 promoters was found to be more closely correlated with the TATA box than the transcription start site. On both these genes, melting begins about 20 base pairs downstream of the TATA box. Physical and genetic analyses suggest that RNA polymerase II associates with this region. Thus, the distance between promoter melting and the TATA box in yeast may be similar to that in higher eukaryotes, even though transcription initiates in a region about 10 to 90 base pairs farther downstream in yeast.	CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853	Cornell University								ABOULELA F, 1992, J BIOL CHEM, V267, P1776; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GRIMES E, 1991, NUCLEIC ACIDS RES, V19, P6113, DOI 10.1093/nar/19.22.6113; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; TRECO DA, 1989, CURRENT PROTOCOLS MO; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	24	124	126	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					759	762		10.1126/science.8342041	http://dx.doi.org/10.1126/science.8342041			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8342041				2022-12-28	WOS:A1993LQ73000039
J	BREO, DL				BREO, DL			HUMAN-RIGHTS .1. CARTER,JIMMY CALLS ON AMA TO MAKE A DIFFERENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					640	642		10.1001/jama.270.5.640	http://dx.doi.org/10.1001/jama.270.5.640			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331769				2022-12-28	WOS:A1993LP43600035
J	HODGKINSON, CA; MOORE, KJ; NAKAYAMA, A; STEINGRIMSSON, E; COPELAND, NG; JENKINS, NA; ARNHEITER, H				HODGKINSON, CA; MOORE, KJ; NAKAYAMA, A; STEINGRIMSSON, E; COPELAND, NG; JENKINS, NA; ARNHEITER, H			MUTATIONS AT THE MOUSE MICROPHTHALMIA LOCUS ARE ASSOCIATED WITH DEFECTS IN A GENE ENCODING A NOVEL BASIC-HELIX-LOOP-HELIX-ZIPPER PROTEIN	CELL			English	Article							DNA-BINDING; SPLEEN-CELLS; INSERTIONAL MUTATION; WAARDENBURG SYNDROME; MYC ONCOGENE; C-FOS; MICE; DIFFERENTIATION; MOTIF; TRANSCRIPTION	Mice with mutations at the microphthalmia (mi) locus have some or all of the following defects: loss of pigmentation, reduced eye size, failure of secondary bone resorption, reduced numbers of mast cells, and early onset of deafness. Using a transgenic insertional mutation at this locus, we have identified a gene whose expression is disrupted in transgenic animals. This gene encodes a novel member of the basic-helix-loop-helix-leucine zipper (bHLH-ZIP) protein family of transcription factors, is altered in mice carrying two independent mi alleles (mi and mi(ws)), and is expressed in the developing eye, ear, and skin, all anatomical sites affected by mi. The multiple spontaneous and induced mutations available at mi provide a unique biological resource for studying the role of a bHLH-ZIP protein in mammalian development.	NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LABS,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	HODGKINSON, CA (corresponding author), NINCDS,VIRAL & MOLEC PATHOGENESIS LAB,BETHESDA,MD 20892, USA.			Arnheiter, Heinz/0000-0003-2537-1134; Steingrimsson, Eirikur/0000-0001-5826-7486; Hodgkinson, Colin/0000-0002-5365-8119	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALNAR MA, 1992, SCIENCE, V256, P1014; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BEXEVANIS AD, 1993, CURR OPIN GENE DEV, V3, P278; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARRER LA, 1992, J MED GENET, V27, P618; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; Green MC., 1989, GENETIC VARIANTS STR, P12; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRUNEBERG H, 1953, J GENET, V51, P359, DOI 10.1007/BF03023302; HARA Y, 1990, MOL BRAIN RES, V8, P319, DOI 10.1016/0169-328X(90)90045-F; HERO I, 1991, INVEST OPHTH VIS SCI, V32, P2622; Hertwig P., 1942, ZEITSCHR INDUKT ABSTAMM U VERERBUNGSL, V80, P220, DOI 10.1007/BF01741984; HOLLANDER WF, 1968, GENETICS, V60, P189; HU YF, 1990, GENE DEV, V4, P167; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KONYUKHOV BV, 1968, SOV GENET, V4, P1457; LAMOREUX ML, 1992, J HERED, V83, P435, DOI 10.1093/oxfordjournals.jhered.a111247; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; LERNER AB, 1986, MOUSE NEWS LETT, V74, P125; MARKS SC, 1981, AM J ANAT, V161, P1, DOI 10.1002/aja.1001610102; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MULLER G, 1950, Z MIKROSK ANAT FORSC, V56, P520; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PACKER SO, 1967, J EXP ZOOL, V165, P21, DOI 10.1002/jez.1401650103; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sambrook J, 1989, MOL CLONING LABORATO; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SINGH G, 1991, GENE DEV, V5, P2245, DOI 10.1101/gad.5.12a.2245; SOUTHARD JL, 1974, MOUSE NEWS LETT, V51, P23; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STELZNER KF, 1966, MOUSE NEWS LETT, V34, P41; STELZNER KF, 1964, MOUSE NEWS LETT, V31, P40; TACHIBANA M, 1992, MOL CELL NEUROSCI, V3, P433, DOI 10.1016/1044-7431(92)90055-7; TASASBEHJI M, 1993, NAT GENET, V3, P26; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WALKER DG, 1975, SCIENCE, V190, P785, DOI 10.1126/science.1198094; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WOLFE HG, 1964, GENET RES, V46, P309; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; YOSHITAKA E, 1992, BLOOD, V80, P1454; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	63	929	965	4	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					395	404		10.1016/0092-8674(93)90429-T	http://dx.doi.org/10.1016/0092-8674(93)90429-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343963				2022-12-28	WOS:A1993LP72600019
J	MASSRY, GG; HOLDS, JB; KINCAID, MC				MASSRY, GG; HOLDS, JB; KINCAID, MC			SARCOIDOSIS INVOLVING THE LACRIMAL GLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DIAGNOSIS		ST LOUIS UNIV,SCH MED,DEPT OPHTHALMOL,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT OTOLARYNGOL,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63104	Saint Louis University; Saint Louis University; Saint Louis University	MASSRY, GG (corresponding author), EYE INST,3655 VISTA AVE,ST LOUIS,MO 63110, USA.							JAKOBIEC FA, 1982, AM J OPHTHALMOL, V94, P785, DOI 10.1016/0002-9394(82)90304-X; OBENAUF CD, 1978, AM J OPHTHALMOL, V86, P648, DOI 10.1016/0002-9394(78)90184-8; SMITH B, 1978, ARCH OPHTHALMOL-CHIC, V96, P113; WEINREB RN, 1981, AM J OPHTHALMOL, V92, P16; WEINREB RN, 1984, SURV OPHTHALMOL, V28, P653, DOI 10.1016/0039-6257(84)90186-3	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					508	508						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320793				2022-12-28	WOS:A1993LN42600036
J	HAMELIN, M; ZHOU, YW; SU, MW; SCOTT, IM; CULOTTI, JG				HAMELIN, M; ZHOU, YW; SU, MW; SCOTT, IM; CULOTTI, JG			EXPRESSION OF THE UNC-5 GUIDANCE RECEPTOR IN THE TOUCH NEURONS OF C-ELEGANS STEERS THEIR AXONS DORSALLY	NATURE			English	Article							EMBRYONIC CELL LINEAGES; CAENORHABDITIS-ELEGANS; GUIDES CELL; MIGRATIONS; GENETICS; IMMUNOGLOBULIN; NEMATODE; PROTEIN	GROWTH cones in developing nervous systems encounter a sequence of extracellular cues during migration1,2. In theory, a growth cone can navigate by selectively expressing or activating surface receptor(s) that recognize extracellular cues appropriate to each migratory phase. Using the simple Caenorhabditis elegans nervous system, we attempted to demonstrate that path selection by migrating growth cones can be predictably altered by ectopic expression of a single receptor. The unc-5 gene of C. elegans encodes a unique receptor of the immunoglobulin superfamily (UNC-5), required cell-autonomously to guide growth cone and mesodermal cell migrations in a dorsal direction on the epidermis3,4. We report here that the UNC-5 receptor induces dorsally oriented axon trajectories when ectopically expressed in the touch receptor neurons which normally extend pioneer axons longitudinally or ventrally on the epidermis5. These errant trajectories depend on unc-6, which encodes a putative epidermal path cue6, just as normal dorsally oriented axon trajectories do (such as those of certain motor neurons4), suggesting that UNC-5 acts to reorient the touch cell growth cones by using its normal guidance mechanisms. These results support previous evidence that UNC-5 and UNC-6 play instructive roles in guiding growth cone migrations on the epidermis in C elegans4, and indicate that pioneering growth cones, which normally migrate in different directions may use equivalent intracellular signalling mechanisms for guidance.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; MERCK RES LABS,RAHWAY,NJ 07065	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Merck & Company			Culotti, Joseph/G-6467-2013	Culotti, Joseph/0000-0001-6325-4612				BRENNER S, 1974, GENETICS, V77, P71; BRENNER S, 1973, BRIT MED BULL, V29, P269, DOI 10.1093/oxfordjournals.bmb.a071019; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V2, P61; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086	16	202	211	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					327	330		10.1038/364327a0	http://dx.doi.org/10.1038/364327a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332188				2022-12-28	WOS:A1993LN57000054
J	JONES, RG				JONES, RG			PERSONAL-COMPUTER SOFTWARE FOR HANDLING REFERENCES FROM CD-ROM AND MAINFRAME SOURCES FOR SCIENTIFIC AND MEDICAL REPORTS	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL END-USER; MEDLINE; MICROCOMPUTER; KNOWLEDGE; SYSTEMS				JONES, RG (corresponding author), UNIV LEEDS,DEPT CHEM PATHOL & IMMUNOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							BONHAM MD, 1988, B MED LIBR ASSOC, V76, P22; BOWLER RP, 1986, J OCCUP ENVIRON MED, V28, P370; GARFIELD JM, 1989, J CLIN MONITOR, V5, P177, DOI 10.1007/BF01627450; HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; HAYNES RB, 1986, ANN INTERN MED, V105, P80; LUDWIG L, 1988, B MED LIBR ASSOC, V76, P7; MCKIBBON KA, 1990, COMPUT BIOMED RES, V23, P583, DOI 10.1016/0010-4809(90)90042-B; NUSSEY SS, 1990, J ROY COLL PHYS LOND, V24, P119; ROSENBERG V, 1991, BIOTECHNIQUES, V10, P796; SCHEIDT SS, 1986, J AM COLL CARDIOL, V8, P1211, DOI 10.1016/S0735-1097(86)80402-8; SCHMID K, 1987, INT J BIOMED COMPUT, V20, P107, DOI 10.1016/0020-7101(87)90019-5; SELLU DP, 1986, BMJ-BRIT MED J, V292, P1643, DOI 10.1136/bmj.292.6536.1643; SIMON FA, 1988, J MED EDUC, V63, P331; WALKER CJ, 1991, B MED LIBR ASSOC, V79, P67; WALLINGFORD KT, 1990, M D COMPUT, V7, P166; WETZ RK, 1986, JAMA-J AM MED ASSOC, V256, P376; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W; WYATT J, 1991, LANCET, V338, P1431, DOI 10.1016/0140-6736(91)92731-G	18	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					180	184		10.1136/bmj.307.6897.180	http://dx.doi.org/10.1136/bmj.307.6897.180			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343749	Bronze, Green Published			2022-12-28	WOS:A1993LN18400026
J	HARDY, MA; GOODMAN, ER				HARDY, MA; GOODMAN, ER			TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											HARDY, MA (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032, USA.							BROLSCH CE, 1991, EUR J PEDIATR SURG, V1, P166, DOI 10.1055/s-2008-1042480; CARROLL PB, 1992, MAY M AM SOC TRANSP, P67; FISCHEL RJ, 1991, TRANSPLANT P, V23, P589; GOULET O, 1992, TRANSPLANTATION, V53, P940, DOI 10.1097/00007890-199204000-00046; HABERAL M, 1992, WORLD J SURG, V16, P1183, DOI 10.1007/BF02067097; KAISER LR, 1991, J THORAC CARDIOV SUR, V102, P333; LOW DE, 1992, J THORAC CARDIOVASC, V103, P119; NAJARIAN JS, 1992, TRANSPLANT P, V24, P1293; PASQUE MK, 1992, J THORAC CARDIOV SUR, V103, P475; Pirsch J D, 1990, Clin Transpl, P241; PLATT JL, 1992, ASAIO J, V8, P8; RICORDI C, 1992, TRANSPLANTATION, V53, P407, DOI 10.1097/00007890-199202010-00027; SOLLINGER HW, 1992, WORLD J SURG, V16, P1187; STARNES VA, 1992, ANN THORAC SURG, V53, P306, DOI 10.1016/0003-4975(92)91338-A; STARZL TE, 1993, TRANSPLANT P, V25, P15; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; TARZL TE, 1993, TRANSPLANT P, V25, P469; TODO S, 1992, ANN SURG, V216, P223, DOI 10.1097/00000658-199209000-00002; WHITE DJG, 1992, 14TH P INT C TRANSPL	19	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					262	265		10.1001/jama.270.2.262	http://dx.doi.org/10.1001/jama.270.2.262			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315757				2022-12-28	WOS:A1993LL36800044
J	SWIFT, PGF; HEARNSHAW, JR; BOTHA, JL; WRIGHT, G; RAYMOND, NT; JAMIESON, KF				SWIFT, PGF; HEARNSHAW, JR; BOTHA, JL; WRIGHT, G; RAYMOND, NT; JAMIESON, KF			A DECADE OF DIABETES - KEEPING CHILDREN OUT-OF-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							INSULIN	Objectives-To document the number of children aged less than 15 years who developed diabetes and were managed within one large health district, and to evaluate the outcome of those children managed without hospital admission at diagnosis. Design-A retrospective study over 1979-88, when a paediatrician and a physician with special interests in childhood diabetes initiated joint clinics. Data collected from the district diabetes register and files of consultants and health visitors specialising in diabetes. Setting-Referral of children to consultants in Leicestershire (total population 863 000). Main outcome measures-The proportion of children managed without hospital admission, comparison of readmission rates and glycated haemoglobin concentrations between children admitted and those not admitted. Results-Over 10 years 236 children aged 10-14 years developed diabetes (annual incidence rate 12.8/100 000 child population (95% confidence interval 11.3 to 14.7)). In total 138 were not admitted to hospital but received supervised management based at home. Admitted children were younger or acidotic or their family doctors did not contact the diabetes team. Duration of admission declined from seven days in 1979-80 to three days in 1987-8. Ninety two were not admitted to hospital during the 10 years for any reason. Significantly fewer children who received management at home were readmitted for reasons related to diabetes than the group treated in hospital (30 (22%) v 40 (41%); p = 0.004). Concentrations of glycated haemoglobin were no different between the two groups. Conclusions-Children with newly diagnosed diabetes may be safely and effectively managed out of hospital. Domiciliary or community based management depends on the commitment of consultants specialising in diabetes working in close cooperation with general practitioners, specialist nurses in diabetes, and dietitians.	UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE1 7RH,ENGLAND	University of Leicester	SWIFT, PGF (corresponding author), LEICESTER ROYAL INFIRM,LEICESTER LE1 5WW,ENGLAND.			Raymond, Neil/0000-0003-2855-2117				GALATZER A, 1982, DIABETES CARE, V5, P414, DOI 10.2337/diacare.5.4.414; HEARNSHAW JR, 1986, DIABETES 1985, P31; Laron Z, 1979, Diabetes Care, V2, P342, DOI 10.2337/diacare.2.4.342; LESSING DN, 1992, ARCH DIS CHILD, V67, P1011, DOI 10.1136/adc.67.8.1011; Lindsay M., 1985, CARE CHILD DIABETES; LIPMAN T, 1986, DIABETES ED, V14, P41; MCNALLY PG, 1990, Q J MED, V76, P831; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; RAYNER PHW, 1984, PRACTICAL DIABETES, V1, P5; SCHNEIDER AJ, 1983, AM J DIS CHILD, V137, P782, DOI 10.1001/archpedi.1983.02140340062017; SIMELL T, 1991, LANCET, V337, P656, DOI 10.1016/0140-6736(91)92464-D; Walker J., 1989, CHRONICLE DIABETIC S; WALKER JB, 1953, LANCET, V2, P445; 1990, DIABETES CARE, V13, P1118; 1990, DIABETIC MED, V7, P457; 1985, SAS USERS GUIDE BASI; 1986, MINIMAL ED FACILITIE; 1991, LANCET, V337, P648; 1990, DIABETES, V39, P858	19	34	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					96	98		10.1136/bmj.307.6896.96	http://dx.doi.org/10.1136/bmj.307.6896.96			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343736	Bronze, Green Published			2022-12-28	WOS:A1993LM58500023
J	BUCHER, HC; SCHMIDT, JG				BUCHER, HC; SCHMIDT, JG			DOES ROUTINE ULTRASOUND SCANNING IMPROVE OUTCOME IN PREGNANCY - METAANALYSIS OF VARIOUS OUTCOME MEASURES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; GESTATIONAL-AGE; TERM	Objective-To evaluate the effectiveness of routine ultrasound scanning in pregnancy by a meta-analysis of various outcome measures. Design-Meta-analysis of randomised controlled trials evaluating the effect of routine ultrasound scanning on perinatal mortality and morbidity. Live birth rate (that is, live births per pregnancy) is included as a measure of pregnancy outcome in addition to the conventional perinatal mortality. Subjects-15935 pregnancies (7992 in which routine ultrasound scanning was used and 7943 controls with selective scanning) from four randomised controlled trials. Main outcome measures-Perinatal mortality, live birth rate, rate of miscarriage, Apgar score < 7 at 1 minute, and number of induced labours. Results-The live birth rate was identical in both screening and control groups (odds ratio=0.99; 95% confidence interval 0.88 to 1.12) although the perinatal mortality was significantly lower in the group who had routine ultrasonography (0.64, 0.43 to 0.97). Differences in perinatal morbidity between the two groups as measured by the proportion of newborn babies with Apgar score < 7 at 1 minute were not significant (1.05; 0.93 to 1.19). Conclusion-Routine ultrasound scanning does not improve the outcome of pregnancy in terms of an increased number of live births or of reduced perinatal morbidity. Routine ultrasound scanning may be effective and useful as a screening for malformation. Its use for this purpose, however, should be made explicit and take into account the risk of false positive diagnosis in addition to ethical issues.	FAMILY PRACTICE & CLIN EPIDEMIOL, CH-8840 EINSIEDELN, SWITZERLAND		BUCHER, HC (corresponding author), KANTONSSPITAL, UNIV POLYCLIN, DEPT INTERNAL MED, CH-4031 BASEL, SWITZERLAND.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; BAKKETEIG LS, 1984, LANCET, V2, P207; BENNETT MJ, 1982, BRIT J OBSTET GYNAEC, V89, P338, DOI 10.1111/j.1471-0528.1982.tb05074.x; BLONDEL B, 1989, BRIT J OBSTET GYNAEC, V96, P44, DOI 10.1111/j.1471-0528.1989.tb01575.x; CAMPBELL S, 1985, OBSTET GYNECOL, V65, P613; CHITTY LS, 1991, BRIT MED J, V303, P165; CROWLEY P, 1991, OXFORD DATABASE PERI; EWIGMAN B, 1990, OBSTET GYNECOL, V76, P189; GRENNERT L, 1978, ACTA OBSTET GYN SCAN, P5; HACKELORER BJ, 1981, Z GEBURTSCH PERINAT, V186, P119; HANNAH ME, 1992, NEW ENGL J MED, V326, P1587, DOI 10.1056/NEJM199206113262402; LARSEN T, 1992, BRIT J OBSTET GYNAEC, V99, P469, DOI 10.1111/j.1471-0528.1992.tb13783.x; LAURIN J, 1987, ACTA OBSTET GYN SCAN, V66, P407, DOI 10.3109/00016348709022043; LUCK CA, 1992, BRIT MED J, V304, P1474, DOI 10.1136/bmj.304.6840.1474; MANTEL N, 1959, J NATL CANCER I, V22, P719; MINTZ MC, 1988, CLIN OBSTET GYNECOL, V31, P44, DOI 10.1097/00003081-198803000-00007; NEILSON JP, 1984, BRIT MED J, V289, P1179, DOI 10.1136/bmj.289.6453.1179; NEILSON JP, 1991, OXFORD DATABASE PERI; NES SHE, 1987, LANCET, V1, P1347; PERSSON PH, 1983, AM J OBSTET GYNECOL, V146, P942, DOI 10.1016/0002-9378(83)90970-5; RINGA V, 1989, INT J EPIDEMIOL, V18, P489, DOI 10.1093/ije/18.3.489; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; SAUNDERS N, 1991, LANCET, V338, P1190, DOI 10.1016/0140-6736(91)92044-3; SECHER NJ, 1987, BRIT J OBSTET GYNAEC, V94, P105, DOI 10.1111/j.1471-0528.1987.tb02334.x; SIMPSON GF, 1984, CLIN OBSTET GYNAECOL, V11, P481; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; WALDENSTROM U, 1988, LANCET, V2, P585; 1984, ROUTINE ULTRASOUND E	28	80	82	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1993	307	6895					13	17		10.1136/bmj.307.6895.13	http://dx.doi.org/10.1136/bmj.307.6895.13			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL369	8343659	Bronze, Green Published			2022-12-28	WOS:A1993LL36900017
J	VANROSSUM, E; FREDERIKS, CMA; PHILIPSEN, H; PORTENGEN, K; WISKERKE, J; KNIPSCHILD, P				VANROSSUM, E; FREDERIKS, CMA; PHILIPSEN, H; PORTENGEN, K; WISKERKE, J; KNIPSCHILD, P			EFFECTS OF PREVENTIVE HOME VISITS TO ELDERLY PEOPLE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL	Objectives-To assess the effect of preventive home visits by public health nurses on the state of health of and use of services by elderly people living at home. Design-Randomised controlled trial. Setting-General population of elderly people in one of the southern regions of the Netherlands. Subjects-580 subjects aged between 75 and 84 years randomly allocated to intervention (292) or control (288) group. Interventions-Four visits a year over three years in intervention group. Control group received no home visits. Main outcome measures-Self rated health, functional state, well being, loneliness, aspects of the mental state (depressive complaints, memory disturbances), and mortality. Use of services and costs. Results-Visits had no effect on the health of the subjects. In the group visited no higher scores were seen on health related measures, fewer died (42 (14%) v 50 (17%)), and community care increased slightly. In the control group more were referred to outpatient clinics (166 (66%) v 132 (55%)), and they had a 40% increased risk of admission (incidence rate ratio 1.4; 90% confidence interval 1.2 to 1.6). No differences were found in long term institutional care, and overall expenditure per person in the intervention group exceeded that in the control group by 4%. Additional analyses showed that visits were effective for subjects who initially rated their health as poor. Conclusions-Preventive home visits are not beneficial for the general population of elderly people living at home but might be effective when restricted to subjects with poor health.	PROV PUBL HLTH NURSE ASSOC LIMBURG, SITTARD, NETHERLANDS; PUBL HLTH NURSES ASSOC MIDDEN LIMBURG, ROERMOND, NETHERLANDS		VANROSSUM, E (corresponding author), UNIV LIMBURG, DEPT EPIDEMIOL, POB 616, 6200 MD MAASTRICHT, NETHERLANDS.							BROWN K, 1992, BRIT MED J, V305, P619, DOI 10.1136/bmj.305.6854.619; BUCKLEY EG, 1988, BMJ-BRIT MED J, V296, P1144, DOI 10.1136/bmj.296.6630.1144-a; DEJONGGIERVELD J, 1985, APPL PSYCH MEAS, V9, P289, DOI 10.1177/014662168500900307; Frederiks C M, 1992, J Community Health, V17, P131, DOI 10.1007/BF01324402; Frederiks C M, 1986, Tijdschr Gerontol Geriatr, V17, P205; HALL N, 1992, CAN J AGING, V11, P72, DOI 10.1017/S0714980800014537; HARRIS A, 1992, BMJ-BRIT MED J, V305, P599, DOI 10.1136/bmj.305.6854.599; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; MCEWAN RT, 1990, BRIT J GEN PRACT, V40, P94; PATHY MSJ, 1992, LANCET, V340, P890, DOI 10.1016/0140-6736(92)93294-W; Qureshi K N, 1974, Age Ageing, V3, P152, DOI 10.1093/ageing/3.3.152; ROSSUM E, 1991, NURS RES, V40, P185; TEMPLEMAN CJJ, 1987, THESIS U GRONINGEN, P56; TREMELLEN J, 1992, BMJ-BRIT MED J, V305, P621, DOI 10.1136/bmj.305.6854.621; Tulloch A J, 1979, J R Coll Gen Pract, V29, P733; VANROSSUM E, 1993, THESIS MAASTRICHT; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; VETTER NJ, 1984, EFFECTIVENESS HLTH V, V1; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; 1992, STATISTICH JB 1992; 1991, JB VERGPLEEGHUAZEN	22	109	109	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1993	307	6895					27	32		10.1136/bmj.307.6895.27	http://dx.doi.org/10.1136/bmj.307.6895.27			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL369	8343668	Green Published, Bronze			2022-12-28	WOS:A1993LL36900026
J	JARMAN, AP; GRAU, Y; JAN, LY; JAN, YN				JARMAN, AP; GRAU, Y; JAN, LY; JAN, YN			ATONAL IS A PRONEURAL GENE THAT DIRECTS CHORDOTONAL ORGAN FORMATION IN THE DROSOPHILA PERIPHERAL NERVOUS-SYSTEM	CELL			English	Article							ACHAETE-SCUTE COMPLEX; HAIRY-WING MUTATIONS; LOOP-HELIX PROTEINS; SENSORY ORGANS; EARLY NEUROGENESIS; SEX DETERMINATION; DNA-BINDING; MELANOGASTER; EXPRESSION; EMBRYOS	In the Drosophila peripheral nervous system, proneural genes of the achaete-scute complex (ASC) are required for formation of the precursors of external sense organs but not of chordotonal organs. We report the isolation of a gene, atonal (ato), with evidence that it is a proneural gene for the formation of chordotonal organs. This gene is expressed in the proneural clusters and sense organ precursors that give rise to the embryonic and adult chordotonal, but not external sense, organs. Chordotonal organs are eliminated in embryos carrying chromosomal deficiencies that remove ato. Like the ASC products, ato protein contains a basic-helix-loop-helix region and heterodimerizes with daughterless protein to bind to E boxes. Moreover, ectopic expression of ato promotes the formation of extra sense organs. Despite similar proneural properties, we find that ectopic expression of the ASC genes promotes external sense organ formation exclusively, whereas ato promotes chordotonal organ formation preferentially. Thus, proneural genes are major determinants of neuronal identity.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	JARMAN, AP (corresponding author), HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498; Jarman, Andrew/0000-0003-4036-5701				ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; BAKER BS, 1991, GENETICS, V127, P125; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; Bate C.M., 1978, HDB SENSORY PHYSL, V9, P1, DOI [10.1007/978-3-642-66880-7_1, DOI 10.1007/978-3-642-66880-7_1]; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; Bryant PJ., 1978, GENET BIOL DROSOPHIL, P229; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CAMPUZANO S, 1986, CELL, V44, P303, DOI 10.1016/0092-8674(86)90764-6; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; Ghysen Alain, 1992, P225; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; GORIELY A, 1991, DEVELOPMENT, V113, P1395; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P101, DOI 10.1007/BF00402031; HUANG F, 1991, DEVELOPMENT, V111, P1087; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARTINBERMUDO MD, 1991, DEVELOPMENT, V113, P445; McIver S.B., 1985, P71; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; Miller A., 1950, BIOL DROSOPHILA, P420; Moulins M., 1976, STRUCTURE FUNCTION P; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARKHURST SM, 1991, DEVELOPMENT, V111, P1121; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SKEATH JB, 1992, DEVELOPMENT, V114, P939; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VINSON CR, 1992, NEW BIOL, V4, P396; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT BR, 1976, STRUCTURE FUNCTION P, P33; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	72	458	474	1	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1307	1321		10.1016/0092-8674(93)90358-W	http://dx.doi.org/10.1016/0092-8674(93)90358-W			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324823				2022-12-28	WOS:A1993LL20900007
J	NELSEN, B; TIAN, G; ERMAN, B; GREGOIRE, J; MAKI, R; GRAVES, B; SEN, R				NELSEN, B; TIAN, G; ERMAN, B; GREGOIRE, J; MAKI, R; GRAVES, B; SEN, R			REGULATION OF LYMPHOID-SPECIFIC IMMUNOGLOBULIN-MU HEAVY-CHAIN GENE ENHANCER BY ETS-DOMAIN PROTEINS	SCIENCE			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; BINDING SITES; DNA; TRANSCRIPTION; REARRANGEMENT; ONCOGENE; SEQUENCE; LINEAGE; COMPLEX	The enhancer for the immunoglobulin mu heavy chain gene (IgH) activates a heterologous gene at the pre-B cell stage of B lymphocyte differentiation. A lymphoid-specific element, muB, is necessary for enhancer function in pre-B cells. A muB binding protein is encoded by the PU.1/Spi-1 proto-oncogene. Another sequence element, muA, was identified in the mu enhancer that binds the product of the ets-1 proto-oncogene. The muA motif was required for muB-dependent enhancer activity, which suggests that a minimal B cell-specific enhancer is composed of both the PU.1 and Ets-1 binding sites. Co-expression of both PU.1 and Ets-1 in nonlymphoid cells trans-activated reporter plasmids that contained the minimal mu enhancer. These results implicate two members of the Ets family in the activation of IgH gene expression.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; UNIV UTAH,SCH MED,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84132; LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Brandeis University; Brandeis University; Utah System of Higher Education; University of Utah; Sanford Burnham Prebys Medical Discovery Institute			erman, burak/F-5900-2015; erman, batu/AAE-1963-2020	erman, burak/0000-0002-2496-6059; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038925, K04GM000563, R01GM038925, R01GM038663, R29GM038663] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38925, GM38663, 1K04GM00563] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GNTER CV, 1990, GENE DEV, V4, P677; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KILEDJIAN M, 1988, MOL CELL BIOL, V8, P145, DOI 10.1128/MCB.8.1.145; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; NELSEN B, 1988, MOL CELL BIOL, V8, P3526, DOI 10.1128/MCB.8.8.3526; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; NELSEN B, 1992, ANN REV CYTOL, V133, P121; NELSEN B, UNPUB; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; REIK W, 1987, EUR J IMMUNOL, V17, P465, DOI 10.1002/eji.1830170405; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSAO BP, 1988, NUCLEIC ACIDS RES, V16, P3239, DOI 10.1093/nar/16.8.3239; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	42	210	211	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					82	86		10.1126/science.8316859	http://dx.doi.org/10.1126/science.8316859			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316859				2022-12-28	WOS:A1993LK43400036
J	VESSEY, MP; VILLARDMACKINTOSH, L; PAINTER, R				VESSEY, MP; VILLARDMACKINTOSH, L; PAINTER, R			EPIDEMIOLOGY OF ENDOMETRIOSIS IN WOMEN ATTENDING FAMILY-PLANNING CLINICS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To describe the epidemiology of endometriosis in women attending family planning clinics with special reference to contraceptive methods. Design-Non-randomised cohort study with follow up of subjects for up to 23 years. Disease was measured by first hospital admission rates since endometriosis can be diagnosed with accuracy only at laparotomy or laparoscopy. Setting-17 family planning centres in England and Scotland. Subjects-17 032 married white women aged 25-39 years at entry during 1968-74 who were taking oral contraceptives or using an intrauterine device or diaphragm. About 99% of the women approached agreed to participate and annual loss to follow up was about 0.3%. Main outcome measures-Diagnosis of endometriosis, age, parity, and history of contraceptive use. Results-Endometriosis was significantly related to age, peaking at ages 40-44 (chi2 for heterogeneity=30.9, p<0.001). Endometriosis was not linked to duration of taking oral contraceptives. Nevertheless, the risk of endometriosis was low in women currently taking oral contraceptives (relative risk 0.4; 95% confidence interval 0.2 to 0.7), but higher in women who had formerly taken them (1.8; 1.0 to 3.1 in women who had stopped 25-48 months previously) compared with women who had never taken the pill. A similar pattern was seen for use of intrauterine devices (relative risk 0.4 (0.2 to 0.7) in current users and 1.4 (0.4 to 3.2) in users 49-72 months previously compared with never users). No association was found between endometriosis and use of the diaphragm. Conclusions-Oral contraceptives seem to temporarily suppress endometriosis. Endometriosis may be diagnosed late in women using intrauterine devices as pain and bleeding occur with both.			VESSEY, MP (corresponding author), RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.							BUTTRAM VC, 1979, FERTIL STERIL, V31, P347; CRAMER DW, 1986, JAMA-J AM MED ASSOC, V255, P1904; KIRSHON B, 1988, OBSTET GYNECOL, V71, P829; MAHMOOD TA, 1991, HUM REPROD, V6, P544, DOI 10.1093/oxfordjournals.humrep.a137377; MOEN MH, 1987, ACTA OBSTET GYN SCAN, V66, P451, DOI 10.3109/00016348709022053; OBERMEYER CM, 1986, AM J EPIDEMIOL, V124, P762, DOI 10.1093/oxfordjournals.aje.a114452; RAMCHARAN S, 1981, 81564 NAT I HLTH CTR, V3; VESSEY M, 1976, Journal of Biosocial Science, V8, P373; 1974, ORAL CONTRACEPTIVES	9	150	157	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					182	184		10.1136/bmj.306.6871.182	http://dx.doi.org/10.1136/bmj.306.6871.182			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8338516	Green Published, Bronze			2022-12-28	WOS:A1993KH51300022
J	SPEER, SN				SPEER, SN			DISPATCH FROM THE FRONT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					913	913		10.1001/jama.270.8.913	http://dx.doi.org/10.1001/jama.270.8.913			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8345630				2022-12-28	WOS:A1993LT56700001
J	GRIFFITHS, CEM; RUSSMAN, AN; MAJMUDAR, G; SINGER, RS; HAMILTON, TA; VOORHEES, JJ				GRIFFITHS, CEM; RUSSMAN, AN; MAJMUDAR, G; SINGER, RS; HAMILTON, TA; VOORHEES, JJ			RESTORATION OF COLLAGEN FORMATION IN PHOTODAMAGED HUMAN SKIN BY TRETINOIN (RETINOIC ACID)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IRRADIATED HAIRLESS MOUSE; TOPICAL TRETINOIN; PHOTOAGED SKIN; ANCHORING FIBRILS; DERMAL DAMAGE; AGED SKIN; INVIVO; BIOSYNTHESIS; FIBROBLASTS; WRINKLES	Background. Topical tretinoin (retinoic acid) modifies fine wrinkles and certain other features of human skin damaged by exposure to the sun (photodamage), but histologic changes do not account for this improvement. In mice with photodamage induced by ultraviolet light, effacement of fine wrinkles by tretinoin is correlated with dermal collagen synthesis but not with histologic changes. We investigated whether collagen synthesis was reduced in photodamaged human skin and, if so, whether it could be restored by treatment with topical tretinoin. Methods. Biopsies of photodamaged skin from the extensor aspect of the forearm and skin from the buttocks, which had been protected from the sun, were performed on 26 healthy subjects. In addition, 29 patients with photodamaged skin were treated for 10 to 12 months with a daily application of 0.1 percent tretinoin cream (15 patients) or vehicle cream (14 patients). Skin-biopsy specimens obtained at base line and after treatment were assessed immunohistologically for evidence of dermal collagen I formation (collagen synthesis). Results. Collagen I formation was 56 percent less in the papillary dermis of photodamaged skin than in skin protected from the sun (P<0.001) and was correlated with the clinical severity of photodamage (r = -0.58, P = 0.002). Treatment of photodamaged skin with tretinoin produced an 80 percent increase in collagen I formation, as compared with a 14 percent decrease in collagen formation with the use of vehicle alone (P = 0.006). Conclusions. The formation of collagen I is significantly decreased in photodamaged human skin, and this process is partly restored by treatment with tretinoin.	UNIV MICHIGAN,MED CTR,DEPT DERMATOL,DERMATOPHARMACOL UNIT,1910 TAUBMAN CTR,1500 E MED CTR DR,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Griffiths, Christopher E.M./P-5448-2014	Griffiths, Christopher E.M./0000-0001-5371-4427	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD062915] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-6-2915] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGELES AM, 1990, J INVEST DERMATOL, V94, pA504; BAUER EA, 1982, J AM ACAD DERMATOL, V6, P603, DOI 10.1016/S0190-9622(82)70049-0; BHAWAN J, 1991, ARCH DERMATOL, V127, P1382; BHAWAN J, 1991, ARCH DERMATOL, V127, P666, DOI 10.1001/archderm.127.5.666; BISSETT DL, 1987, PHOTOCHEM PHOTOBIOL, V46, P367, DOI 10.1111/j.1751-1097.1987.tb04783.x; BRUCKNERTUDERMAN L, 1989, J INVEST DERMATOL, V93, P3, DOI 10.1111/1523-1747.ep12277331; BRYCE GF, 1988, J INVEST DERMATOL, V91, P175, DOI 10.1111/1523-1747.ep12464445; CHEN S, 1992, J INVEST DERMATOL, V98, P248, DOI 10.1111/1523-1747.ep12556066; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; ELLIS CN, 1990, J AM ACAD DERMATOL, V23, P629, DOI 10.1016/0190-9622(90)70265-J; FEDERSPIEL SJ, 1991, LAB INVEST, V65, P441; FLEISCHMAJER R, 1983, P NATL ACAD SCI-BIOL, V80, P3354, DOI 10.1073/pnas.80.11.3354; FOELLMER HG, 1983, EUR J BIOCHEM, V134, P183, DOI 10.1111/j.1432-1033.1983.tb07549.x; KLIGMAN AM, 1985, BRIT J DERMATOL, V113, P37, DOI 10.1111/j.1365-2133.1985.tb02042.x; KLIGMAN AM, 1986, J AM ACAD DERMATOL, V15, P836, DOI 10.1016/S0190-9622(86)70242-9; KLIGMAN AM, 1969, J AMER MED ASSOC, V210, P2377, DOI 10.1001/jama.210.13.2377; KLIGMAN LH, 1989, J AM ACAD DERMATOL, V21, P623, DOI 10.1016/S0190-9622(89)70229-2; KLIGMAN LH, 1984, CONNECT TISSUE RES, V12, P139, DOI 10.3109/03008208408992779; LAVKER RM, 1988, J INVEST DERMATOL, V90, P325, DOI 10.1111/1523-1747.ep12456193; LAVKER RM, 1979, J INVEST DERMATOL, V73, P59, DOI 10.1111/1523-1747.ep12532763; LEVER L, 1990, BRIT J DERMATOL, V122, P91, DOI 10.1111/j.1365-2133.1990.tb08244.x; OIKARINEN A, 1992, J INVEST DERMATOL, V98, P220, DOI 10.1111/1523-1747.ep12555884; OLSEN EA, 1992, J AM ACAD DERMATOL, V26, P215, DOI 10.1016/0190-9622(92)70030-J; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; SCHARFFETTER K, 1991, ARCH DERMATOL RES, V283, P506, DOI 10.1007/BF00371923; SCHWARTZ E, 1991, J INVEST DERMATOL, V96, P975, DOI 10.1111/1523-1747.ep12476385; SMITH JG, 1962, J INVEST DERMATOL, V39, P347, DOI 10.1038/jid.1962.122; SMITH LT, 1986, AM J ANAT, V175, P507, DOI 10.1002/aja.1001750409; WEINSTEIN GD, 1991, ARCH DERMATOL, V127, P659, DOI 10.1001/archderm.127.5.659; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P527, DOI 10.1001/jama.259.4.527; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P3274; WEISS JS, 1988, JAMA-J AM MED ASSOC, V260, P962; WOODLEY DT, 1990, JAMA-J AM MED ASSOC, V263, P3057, DOI 10.1001/jama.263.22.3057; WOODLEY DT, 1986, J INVEST DERMATOL, V86, P418, DOI 10.1111/1523-1747.ep12285689; Woolley D.E., 1984, EXTRACELLULAR MATRIX, P119	36	337	353	3	43	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					530	535		10.1056/NEJM199308193290803	http://dx.doi.org/10.1056/NEJM199308193290803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8336752				2022-12-28	WOS:A1993LR89200003
J	COUPLAND, RM				COUPLAND, RM			HAND GRENADE INJURIES AMONG CIVILIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							WAR WOUND EXCISION; RED-CROSS; INTERNATIONAL-COMMITTEE; ANTIPERSONNEL MINES; EXPERIENCE; MANAGEMENT	Objectives.-To describe how noncombatants are injured by hand grenades in camps for displaced people, and to categorize grenade wounds according to the Red Cross wound classification. Design.-Case series. Setting.-A surgical hospital in Khao I Dang refugee camp on the Thailand-Cambodia border. Patients.-Seventy-four patients injured by hand grenades. Interventions.-Intravenous antibiotics and primary wound surgery. Main Outcome Measures.-Combatant status of the patients, categorization of the wounds, surgical outcome, number of operations, and number of blood transfusions. Results.-Only 7% of the patients sustained their wounds in battle and 50% were women, children, or older men. Seventy had 91 wounds that could be categorized; 59% of the wounds were small, affecting only soft tissue. Few wounds were associated with fractures and none with comminuted fractures. Twenty-four soft-tissue wounds were treated conservatively with minimal morbidity and no mortality. Conclusions.-Missiles (fragments or bullets) from hand grenades tend to produce wounds with little tissue damage. Serious injury is due to penetration of vital structures. The results permit a recommendation that certain small and uncomplicated fragment wounds can be treated initially without surgery.			COUPLAND, RM (corresponding author), INT COMM RED CROSS,DIV MED,17 AV DE LA PAIX,CH-1202 GENEVA,SWITZERLAND.							ADAMS DB, 1990, J TRAUMA S, V6, P48; COOPER GJ, 1990, BRIT J SURG, V77, P606, DOI 10.1002/bjs.1800770604; Coupland R.M., 1991, RED CROSS WOUND CLAS, P18; COUPLAND RM, 1990, BRIT J SURG, V77, P833, DOI 10.1002/bjs.1800770738; COUPLAND RM, 1992, WORLD J SURG, V16, P910, DOI 10.1007/BF02066991; COUPLAND RM, 1989, BRIT J SURG, V76, P663, DOI 10.1002/bjs.1800760704; COUPLAND RM, 1992, LANCET, V339, P35, DOI 10.1016/0140-6736(92)90152-S; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; COUPLAND RM, 1992, BRIT MED J, V304, P1509, DOI 10.1136/bmj.304.6840.1509-c; DUFOUR D, 1988, SURGERY VICTIMS WAR; ESHAYACHAUVIN B, 1992, BRIT J ANAESTH, V68, P221, DOI 10.1093/bja/68.2.221; Fackler M. L., 1990, J TRAUMA CHINA, V6, P32; FACKLER ML, 1989, SURGERY, V105, P576; FACKLER ML, 1989, BRIT J SURG, V76, P1217, DOI 10.1002/bjs.1800761133; HAYWOOD IR, 1991, BRIT J SURG, V78, P123; HOGG IV, 1991, JANES INFANTRY WEAPO, P570; SMITH MSO, 1981, HIGH VELOCITY MISSIL; WANG ZG, 1988, J TRAUMA, V28, pS89, DOI 10.1097/00005373-198801001-00020	18	24	25	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					624	626		10.1001/jama.270.5.624	http://dx.doi.org/10.1001/jama.270.5.624			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331764				2022-12-28	WOS:A1993LP43600030
J	KUZMAN, M; TOMIC, B; STEVANOVIC, R; LJUBICIC, M; KATALINIC, D; RODIN, U				KUZMAN, M; TOMIC, B; STEVANOVIC, R; LJUBICIC, M; KATALINIC, D; RODIN, U			FATALITIES IN THE WAR IN CROATIA, 1991 AND 1992 - UNDERLYING AND EXTERNAL CAUSES OF DEATH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							GULF-WAR; INJURIES; MANAGEMENT	Objective.-To show the underlying and external causes of death and selected characteristics of those killed in the war in Croatia between March 1991 and December 1992. Design.-Analysis of 4339 fatalities recorded on two national mortality statistics documents that specified war operations as the cause of death: a demography mortality statistical form and a death certificate. Main Outcome Measures.-The frequency of clinical causes of death and their association with methods of wounding, length of survival, and attendant diagnoses. Results.-Half of those killed were men aged 21 to 35 years. Among women killed, the majority were aged 61 to 75 years. Skull fracture with intracranial injuries was the leading cause of death (28.9%), followed by multiple traumas and injuries of unspecified site (17.9%), and thoracic wounds with lung and heart injuries (17.6%). The most common methods of wounding were bombs and fragments of other explosive devices involving 1907 persons (43.9%), followed by deaths from bullet wounds (33.0%). More than 50% of those killed had sustained multiple injuries. In 78.6% of the cases, death immediately followed the wounding.			KUZMAN, M (corresponding author), PUBL HLTH INST REPUBL CROATIA,ROCKEFELLEROVA 7,41000 ZAGREB,CROATIA.							ARABI B, 1990, NEUROSURGERY, V27, P692; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; COUPLAND RM, 1988, INJURY, V19, P259, DOI 10.1016/0020-1383(88)90041-1; DOBSON JE, 1989, BRIT J ORAL MAX SURG, V27, P441, DOI 10.1016/S0266-4356(89)80001-4; DUDLEY HAF, 1968, BRIT J SURG, V55, P332, DOI 10.1002/bjs.1800550503; GARFIELD RM, 1991, JAMA-J AM MED ASSOC, V266, P688, DOI 10.1001/jama.266.5.688; HASHMONAI M, 1984, ISRAEL J MED SCI, V20, P327; HEBRANG A, 1992, ZDRAVSTVO, V1, P11; LANG S, 1993, CROAT MED J, V34, P5; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; MORRIS DS, 1991, BRIT J SURG, V78, P1301, DOI 10.1002/bjs.1800781108; NASSOURA Z, 1991, J TRAUMA, V31, P1596, DOI 10.1097/00005373-199112000-00005; SLATER PE, 1991, LANCET, V338, P1336, DOI 10.1016/0140-6736(91)92636-G; SOUKA HM, 1992, BRIT J SURG, V79, P1307, DOI 10.1002/bjs.1800791221; 1993, CIVILIAN VICTIMS WAR	15	23	24	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					626	628		10.1001/jama.270.5.626	http://dx.doi.org/10.1001/jama.270.5.626			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331765				2022-12-28	WOS:A1993LP43600031
J	ARGETSINGER, LS; CAMPBELL, GS; YANG, XN; WITTHUHN, BA; SILVENNOINEN, O; IHLE, JN; CARTERSU, C				ARGETSINGER, LS; CAMPBELL, GS; YANG, XN; WITTHUHN, BA; SILVENNOINEN, O; IHLE, JN; CARTERSU, C			IDENTIFICATION OF JAK2 AS A GROWTH-HORMONE RECEPTOR-ASSOCIATED TYROSINE KINASE	CELL			English	Article							BINDING-PROTEIN; CELLS; METABOLISM; GH; PHOSPHORYLATION; PURIFICATION; DOMAINS; PRODUCT; SERUM; DNA	Growth hormone receptor (GHR) forms a complex with a tyrosine kinase, suggesting involvement of a ligand-activated tyrosine kinase in intracellular signaling by growth hormone (GH). Here we identify JAK2, a nonreceptor tyrosine kinase, as a GHR-associated tyrosine kinase. Immunological approaches were used to establish GH-dependent complex formation between JAK2 and GHR, activation of JAK2 tyrosine kinase activity, and tyrosyl phosphorylation of both JAK2 and GHR. The JAK2-GHR and JAK2-erythropoietin receptor interactions described here and in the accompanying paper provide a molecular basis for involvement of tyrosyl phosphorylation in physiological responses to these ligands and suggest a shared signaling mechanism among members of the cytokine/hematopoietin receptor family.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	Harvard University; Harvard Medical School; St Jude Children's Research Hospital	ARGETSINGER, LS (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA.		witthuhn, bruce/GSE-3193-2022		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK034171, R01-DK34171, R01 DK042932, R01-DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHEEK DB, 1974, HDB PHYSIOLOGY END 2, V4, P159; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MOLLER C, 1992, THESIS NOVUM HUDDING, P1; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; SCHWARTZ J, 1988, ENDOCRINOLOGY, V122, P2247; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; TAI PKK, 1990, J BIOL CHEM, V265, P21828; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG XY, 1993, J BIOL CHEM, V268, P3573; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	34	854	873	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 30	1993	74	2					237	244		10.1016/0092-8674(93)90415-M	http://dx.doi.org/10.1016/0092-8674(93)90415-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343952	Green Submitted			2022-12-28	WOS:A1993LP72600005
J	CHENG, XD; KUMAR, S; POSFAI, J; PFLUGRATH, JW; ROBERTS, RJ				CHENG, XD; KUMAR, S; POSFAI, J; PFLUGRATH, JW; ROBERTS, RJ			CRYSTAL-STRUCTURE OF THE HHAL DNA METHYLTRANSFERASE COMPLEXED WITH S-ADENOSYL-L-METHIONINE	CELL			English	Article							TARGET-RECOGNIZING DOMAINS; MACROMOLECULAR CRYSTALLOGRAPHY; DETERMINES METHYLATION; CATALYTIC MECHANISM; ESCHERICHIA-COLI; SEQUENCE MOTIFS; MET REPRESSOR; BINDING; PROTEIN; EXPRESSION	The first three-dimensional structure of a DNA methyltransferase is presented. The crystal structure of the DNA (cytosine-5)-methyltransferase, M.Hhal (recognition sequence: GCGC), complexed with S-adenosyl-L-methionine has been determined and refined at 2.5 angstrom resolution. The core of the structure is dominated by sequence motifs conserved among all DNA (cytosine-5)-methyltransferases, and these are responsible for cofactor binding and methyltransferase function.	NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915		CHENG, XD (corresponding author), COLD SPRING HARBOR LAB,WM KECK STRUCT BIOL LAB,COLD SPRING HARBOR,NY 11724, USA.		Kumar, Sanjay/AAO-2593-2021	Roberts, Richard/0000-0002-4348-0169	NCI NIH HHS [CA 45508] Funding Source: Medline; NIGMS NIH HHS [GM 46127, GM 49245] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049245, R01GM046127] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASERTA M, 1987, J BIOL CHEM, V262, P4770; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; FRIEDMAN S, 1992, NUCLEIC ACIDS RES, V20, P3241, DOI 10.1093/nar/20.12.3241; FRIEDMAN S, 1986, NUCLEIC ACIDS RES, V14, P4543, DOI 10.1093/nar/14.11.4543; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GUNTHERT U, 1986, EUR J BIOCHEM, V159, P485, DOI 10.1111/j.1432-1033.1986.tb09912.x; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; INGROSSO D, 1989, J BIOL CHEM, V264, P20130; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KLIMASAUSKAS S, 1991, NUCLEIC ACIDS RES, V19, P6183, DOI 10.1093/nar/19.22.6183; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANN MB, 1979, P C TRANSMETHYLATION, P483; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MI S, 1993, NUCLEIC ACIDS RES, V21, P2459, DOI 10.1093/nar/21.10.2459; MI S, 1992, NUCLEIC ACIDS RES, V20, P4811, DOI 10.1093/nar/20.18.4811; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; ROBERTS RJ, 1992, NUCLEIC ACIDS RES, V20, P2167, DOI 10.1093/nar/20.suppl.2167; ROBERTS RJ, 1976, J MOL BIOL, V103, P199, DOI 10.1016/0022-2836(76)90060-7; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; SANTI DV, 1984, FOLATES PTERIDINES, V1, P343; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STEIGEMANN W, 1974, THESIS TU MUNCHEN; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WU JC, 1987, J BIOL CHEM, V262, P4778; WU JC, 1988, NUCLEIC ACIDS RES, V16, P703, DOI 10.1093/nar/16.2.703; WU JC, 1985, BIOCH BIOL DNA METHY, P119; WYSZYNSKI MW, 1992, NUCLEIC ACIDS RES, V20, P319, DOI 10.1093/nar/20.2.319; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	53	364	370	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					299	307		10.1016/0092-8674(93)90421-L	http://dx.doi.org/10.1016/0092-8674(93)90421-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343957				2022-12-28	WOS:A1993LP72600011
J	CREASE, RP				CREASE, RP			BIOMEDICINE IN THE AGE OF IMAGING	SCIENCE			English	Editorial Material																		Hall S., 1992, MAPPING NEXT MILLENN; [No title captured]; [No title captured]; [No title captured]	4	19	22	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					554	&		10.1126/science.8342016	http://dx.doi.org/10.1126/science.8342016			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342016				2022-12-28	WOS:A1993LP72800024
J	HIRT, RP; HUGHES, GJ; FRUTIGER, S; MICHETTI, P; PERREGAUX, C; POULAINGODEFROY, O; JEANGUENAT, N; NEUTRA, MR; KRAEHENBUHL, JP				HIRT, RP; HUGHES, GJ; FRUTIGER, S; MICHETTI, P; PERREGAUX, C; POULAINGODEFROY, O; JEANGUENAT, N; NEUTRA, MR; KRAEHENBUHL, JP			TRANSCYTOSIS OF THE POLYMERIC IG RECEPTOR REQUIRES PHOSPHORYLATION OF SERINE-664 IN THE ABSENCE BUT NOT THE PRESENCE OF DIMERIC IGA	CELL			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; TRANS-EPITHELIAL TRANSPORT; SODIUM DODECYL-SULFATE; AMINO-ACID CHANGE; CYTOPLASMIC DOMAIN; IMMUNOGLOBULIN RECEPTOR; MDCK CELLS; SECRETORY COMPONENT; COATED PITS; PROTEINS	MDCK cells expressing the polymeric immunoglobulin (poly-Ig) receptor, cocultured with IgA-producing hybridoma cells, transported dimeric IgA (dIgA) from the basolateral into the lumenal compartment, where it was recovered as secretory component-dIgA complexes. The tail of the receptor was phosphorylated on serines 664 and 726. Each serine was mutated to alanine. Appearance of A726 receptor at the basolateral surface was reduced approximately 5-fold. This was accompanied by a approximately 5-fold reduction in dIgA transcytosis. Basolateral delivery of receptor was not affected by mutation A664, and in the absence of dIgA, the receptor accumulated in recycling basolateral endosomes. In coculture, however, dIgA transcytosis by A664 receptor was normal. Thus, entry of receptor into the transcytotic pathway requires Ser-664 phosphorylation only in the absence of dIgA.	SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND; UNIV GENEVA, CTR MED, DEPT MED BIOCHEM, CH-1211 GENEVA, SWITZERLAND; CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Swiss Institute Experimental Cancer Research; University of Lausanne; University of Geneva; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Poulain-Godefroy, Odile/AAF-5474-2021; Hirt, Robert/R-5429-2017	Hirt, Robert/0000-0002-3760-9958; POULAIN-GODEFROY, Odile/0000-0001-8805-9450	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017557, R37HD017557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021505] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17557] Funding Source: Medline; NIDDK NIH HHS [DK21505] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; Breitfeld PP, 1989, CURR OPIN CELL BIOL, V1, P617, DOI 10.1016/0955-0674(89)90024-0; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; EGGERT M, 1991, FEBS LETT, V292, P205, DOI 10.1016/0014-5793(91)80868-4; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; FULLER S, 1984, CELL, V38, P65, DOI 10.1016/0092-8674(84)90527-0; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; HANLY WC, 1987, J IMMUNOL, V139, P1597; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUHN LC, 1981, J BIOL CHEM, V256, P2490; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARKIN JM, 1986, P NATL ACAD SCI USA, V83, P4759, DOI 10.1073/pnas.83.13.4759; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; PACCOLAT MP, 1987, AM J PHYSIOL, V252, pC468, DOI 10.1152/ajpcell.1987.252.5.C468; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERER E, 1990, J CELL BIOL, V110, P987, DOI 10.1083/jcb.110.4.987; SCHAERER E, 1991, J MEMBRANE BIOL, V123, P93, DOI 10.1007/BF01998081; SCHULTE TH, 1978, BIOCHIM BIOPHYS ACTA, V508, P425, DOI 10.1016/0005-2736(78)90089-5; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SOLARI R, 1985, J BIOL CHEM, V260, P1141; Solari R., 1987, The mammary gland. Development, regulation, and function., P269; SOLARI R, 1985, IMMUNOL TODAY, V6, P17, DOI 10.1016/0167-5699(85)90163-X; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991	47	83	86	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 30	1993	74	2					245	255		10.1016/0092-8674(93)90416-N	http://dx.doi.org/10.1016/0092-8674(93)90416-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343953				2022-12-28	WOS:A1993LP72600006
J	SAKA, Y; YANAGIDA, M				SAKA, Y; YANAGIDA, M			FISSION YEAST CUT5+, REQUIRED FOR S-PHASE ONSET AND M-PHASE RESTRAINT, IS IDENTICAL TO THE RADIATION-DAMAGE REPAIR GENE RAD4+	CELL			English	Article							CELL-DIVISION CYCLE; SISTER-CHROMATID EXCHANGE; DNA TOPOISOMERASE-II; STRAND-BREAK REPAIR; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASE; TYROSINE PHOSPHATASE; ACTIVATES P34CDC2; CDC25 PROTEIN; MITOSIS	Fission yeast cut5 mutants cause cytokinesis in the absence of normal nuclear division. We show here that cut5+ is required for both the onset of S phase and the restraint of M phase before the completion of S phase. The primary defects in cut5 mutants occur prior to S phase, but cells suffer lethal damage during M phase. Mitosis and cytokinesis occur in the presence of hydroxyurea or in the double mutant cdc10-cut5 (the cdc10 mutation alone blocks progression from G1 to S). Gene cloning shows that cut5+ is identical to the fission yeast rad4+ gene, which is similar to human XRCC1. The rad4+/cut5+ gene is unique in its positive role for replication/repair and in its negative role for mitosis/cytokinesis. We propose a single/twin chromatid marking model for rad4+/cut5+ function in cell cycle control.			SAKA, Y (corresponding author), KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KITASHIRAKAWA OIWAKECHO,SAKYO KU,KYOTO 606,JAPAN.							ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1992, EMBO J, V114, P59; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DUCK P, 1976, J BACTERIOL, V128, P536, DOI 10.1128/JB.128.2.536-539.1976; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FAN JB, 1988, NUCLEIC ACIDS RES, V17, P2801; FENECH M, 1991, NUCLEIC ACIDS RES, V19, P6737, DOI 10.1093/nar/19.24.6737; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HAGAN IM, 1988, J CELL SCI, V89, P343; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HONDA R, 1992, BIOCHEM BIOPH RES CO, V186, P1333, DOI 10.1016/S0006-291X(05)81552-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Phipps J, 1985, Adv Genet, V23, P1, DOI 10.1016/S0065-2660(08)60511-8; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAMEJIMA I, 1993, IN PRESS J CELL SCI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	56	205	209	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					383	393		10.1016/0092-8674(93)90428-S	http://dx.doi.org/10.1016/0092-8674(93)90428-S			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343962				2022-12-28	WOS:A1993LP72600018
J	DODDS, L; MARRETT, LD; TOMKINS, DJ; GREEN, B; SHERMAN, G				DODDS, L; MARRETT, LD; TOMKINS, DJ; GREEN, B; SHERMAN, G			CASE-CONTROL STUDY OF CONGENITAL-ANOMALIES IN CHILDREN OF CANCER-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD-CANCER; SURVIVORS; PREGNANCY; POPULATION; FERTILITY; MUTATION; MICE	Objectives-To determine whether the offspring of cancer survivors are at an increased risk of congenital anomalies and whether cancer therapy before conception is associated with such an increase. Design-Case-control study using computerised record linkage. Setting-Ontario, Canada. Subjects-Parents of children born during April 1979 to December 1986 who had a congenital anomaly diagnosed within the first year of life (45 200 mothers and 41 158 fathers) and a matched sample of parents whose children did not have a congenital anomaly (45 200 mothers and 41 158 fathers). Main outcome measures-Cancer diagnosed in either parent before conception and radiotherapy to the pelvis or abdomen or chemotherapy with an alkylating agent. Results-Among the mothers, 54 cases and 52 controls were identified as having had cancer diagnosed in Ontario (relative risk=1.04, 95% confidence interval 0.7 to 1.5) and among the fathers, 61 cases and 65 controls were identified (0.9, 0.7 to 1.4). No significant associations were found between congenital anomalies in the offspring and any type of cancer treatment in either the mothers or the fathers. Conclusions-The risk of congenital anomalies among liveborn offspring whose parents have had cancer or been treated for cancer is not higher than that in the general population.	ONTARIO CANC TREATMENT & RES FDN,TORONTO M4H 1A8,ON,CANADA; HLTH & WELF CANADA,LAB CTR DIS CONTROL,OTTAWA K1A 0L2,ONTARIO,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO M5S 1A8,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8N 3Z5,ONTARIO,CANADA	University of Toronto; McMaster University								BAIRD PA, 1988, AM J HUM GENET, V42, P677; BALIS FM, 1989, PRINCIPLES PRACTICE, P165; BLATT J, 1989, PRINCIPLES PRACTICE, P1003; BRESLOW NE, 1980, IARC32 INT AG RES CA; BYRNE J, 1987, NEW ENGL J MED, V317, P1315, DOI 10.1056/NEJM198711193172104; Chabner B. A., 1982, CANCER PRINCIPLES PR, P156; CZEIZEL A, 1989, MUTAT RES, V212, P3, DOI 10.1016/0027-5107(89)90017-1; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GREEN DM, 1991, NEW ENGL J MED, V325, P141, DOI 10.1056/NEJM199107183250301; HAWKINS MM, 1991, J NATL CANCER I, V83, P1643, DOI 10.1093/jnci/83.22.1643; HAWKINS MM, 1989, ARCH DIS CHILD, V64, P798, DOI 10.1136/adc.64.6.798; HAWKINS MM, 1989, INT J CANCER, V43, P399, DOI 10.1002/ijc.2910430309; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; KIRK M, 1982, MUTAT RES, V106, P73, DOI 10.1016/0027-5107(82)90191-9; LI FP, 1987, JAMA-J AM MED ASSOC, V257, P216, DOI 10.1001/jama.257.2.216; MULVIHILL JJ, 1987, CANCER, V60, P1143, DOI 10.1002/1097-0142(19870901)60:5<1143::AID-CNCR2820600537>3.0.CO;2-E; MULVIHILL JJ, 1990, PROG CLIN BIOL RES, V340, P179; NOMURA T, 1988, MUTAT RES, V198, P309, DOI 10.1016/0027-5107(88)90008-5; ROTHMAN KJ, 1986, MODERN EPIDMIOLOGY; TRASLER JM, 1985, NATURE, V316, P144, DOI 10.1038/316144a0; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; 1985, SAS VERSION 5; 1977, INT CLASSIFICATION C; 1988, EGRET	24	70	71	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					164	168		10.1136/bmj.307.6897.164	http://dx.doi.org/10.1136/bmj.307.6897.164			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343744	Bronze, Green Published			2022-12-28	WOS:A1993LN18400019
J	VOJTEK, AB; HOLLENBERG, SM; COOPER, JA				VOJTEK, AB; HOLLENBERG, SM; COOPER, JA			MAMMALIAN RAS INTERACTS DIRECTLY WITH THE SERINE THREONINE KINASE RAF	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; NEUROFIBROMATOSIS TYPE-1 GENE; SACCHAROMYCES-CEREVISIAE; ADENYLATE-CYCLASE; TYROSINE KINASE; SIGNAL TRANSDUCTION; VULVAR INDUCTION; MAP KINASE; V-RAF; YEAST	We have identified proteins that interact with H-Ras using a two hybrid system screen of a mouse cDNA library. Approximately 50% of the clones identified encoded portions of the c-Raf and A-Raf serine/threonine kinases. Overlaps among these clones define a conserved 81 residue region of the N-terminus of Raf as the Ras interaction region. We show that Raf interacts with wild-type and activated Ras, but not with an effector domain mutant of Ras or with a dominant-interfering Ras mutant. Using purified bacterially expressed fusion proteins, we show, furthermore, that Ras and the N-terminal region of Raf associate directly in vitro and that this interaction is dependent on GTP bound to Ras.			VOJTEK, AB (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOLE HJ, 1993, GENE DEV, V7, P633; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HAN M, 1993, CELL, V363, P133; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NADINDAVIS SA, 1986, EMBO J, V5, P2963, DOI 10.1002/j.1460-2075.1986.tb04593.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; ROSE MD, 1990, LABORATORY COURSE MA; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOZERI O, 1992, ONCOGENE, V7, P2259; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STORM SM, 1990, ONCOGENE, V5, P345; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOJTEK AB, 1993, IN PRESS J CELL SCI; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	73	1753	1818	0	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					205	214		10.1016/0092-8674(93)90307-C	http://dx.doi.org/10.1016/0092-8674(93)90307-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334704				2022-12-28	WOS:A1993LN62500020
J	JOYNT, RJ				JOYNT, RJ			NEUROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											JOYNT, RJ (corresponding author), UNIV ROCHESTER,ROCHESTER,NY 14627, USA.							ACHIRON A, 1992, ARCH NEUROL-CHICAGO, V49, P1233, DOI 10.1001/archneur.1992.00530360031013; BARNETT HJM, 1993, NEW ENGL J MED, V328, P276, DOI 10.1056/NEJM199301283280410; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; CHOI DW, 1992, NEW ENGL J MED, V326, P1493, DOI 10.1056/NEJM199205283262210; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; ENGELHARDT JI, 1993, ARCH NEUROL-CHICAGO, V50, P30, DOI 10.1001/archneur.1993.00540010026013; GAUR A, 1992, SCIENCE, V258, P1491, DOI 10.1126/science.1279812; GROWDON JH, 1992, NEW ENGL J MED, V327, P1306, DOI 10.1056/NEJM199210293271810; HOBSON RW, 1993, NEW ENGL J MED, V328, P222; LINDVALL O, 1992, ANN NEUROL, V31, P155, DOI 10.1002/ana.410310206; OTTERVANGER JP, 1993, LANCET, V341, P861, DOI 10.1016/0140-6736(93)93064-8; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; SAWLE GV, 1992, ANN NEUROL, V31, P166, DOI 10.1002/ana.410310207; SMALL GW, 1992, JAMA-J AM MED ASSOC, V268, P2564, DOI 10.1001/jama.268.18.2564; TAN E, 1993, ARCH NEUROL-CHICAGO, V50, P137, DOI 10.1001/archneur.1993.00540020015010; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; THORNTON CA, 1993, ARCH NEUROL-CHICAGO, V50, P135, DOI 10.1001/archneur.1993.00540020013009; 1993, CELL, V72, P971	19	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					228	230		10.1001/jama.270.2.228	http://dx.doi.org/10.1001/jama.270.2.228			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315742				2022-12-28	WOS:A1993LL36800028
J	WILSON, FAW; SCALAIDHE, SPO; GOLDMANRAKIC, PS				WILSON, FAW; SCALAIDHE, SPO; GOLDMANRAKIC, PS			DISSOCIATION OF OBJECT AND SPATIAL PROCESSING DOMAINS IN PRIMATE PREFRONTAL CORTEX	SCIENCE			English	Article							INFERIOR TEMPORAL CORTEX; RHESUS-MONKEY; VISUAL NEURONS; UNIT-ACTIVITY; PERFORMANCE; MACAQUE; MEMORY; SEGREGATION; ANATOMY; COLOR	Areas and pathways subserving object and spatial vision are segregated in the visual system. Experiments show that the primate prefrontal cortex is similarly segregated into object and spatial domains. Neurons that code information related to stimulus identity are dissociable, both by function and region, from those that code information related to stimulus location. These findings indicate that the prefrontal cortex contains separate processing mechanisms for remembering ''what'' and ''where'' an object is.			WILSON, FAW (corresponding author), YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06511 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038546, R37MH038546] Funding Source: NIH RePORTER; NIMH NIH HHS [MH38546] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; BOCH RA, 1989, J NEUROPHYSIOL, V61, P1064, DOI 10.1152/jn.1989.61.5.1064; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; INCISADELLAROCCHETTA A, 1986, CORTEX, V22, P189, DOI 10.1016/S0010-9452(86)80045-4; KAWAMURA K, 1984, Neuroscience Research, V1, P89, DOI 10.1016/S0168-0102(84)80007-3; KOWALSKA DM, 1991, NEUROPSYCHOLOGIA, V29, P583, DOI 10.1016/0028-3932(91)90012-W; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MACKO KA, 1982, SCIENCE, V218, P394, DOI 10.1126/science.7123241; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; MIKAMI A, 1982, J NEUROPHYSIOL, V47, P593, DOI 10.1152/jn.1982.47.4.593; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MOREL A, 1990, VISUAL NEUROSCI, V4, P555, DOI 10.1017/S0952523800005769; PASSINGHAM R, 1975, BRAIN RES, V92, P89, DOI 10.1016/0006-8993(75)90529-6; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; QUINTANA J, 1993, CEREB CORTEX, V3, P122, DOI 10.1093/cercor/3.2.122; RICHES IP, 1991, J NEUROSCI, V11, P1763; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SCHWARTZ ML, 1984, J COMP NEUROL, V226, P403, DOI 10.1002/cne.902260309; SELEMON LD, 1988, J NEUROSCI, V8, P4049; STAMM JS, 1973, NEUROPSYCHOLOGIA, V11, P181, DOI 10.1016/0028-3932(73)90006-7; SUZUKI H, 1983, EXP BRAIN RES, V53, P47; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	34	1034	1046	4	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1993	260	5116					1955	1958		10.1126/science.8316836	http://dx.doi.org/10.1126/science.8316836			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8316836				2022-12-28	WOS:A1993LJ34900047
J	FRANK, A				FRANK, A			LOW-BACK-PAIN	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ELECTRICAL NERVE-STIMULATION; CLINICAL-TRIAL; CONSERVATIVE TREATMENT; OUTPATIENT TREATMENT; INJECTION THERAPY; DOUBLE-BLIND; MANIPULATION; DISABILITY; MANAGEMENT; REHABILITATION	The studies reviewed here show that the duration and severity of individual episodes of back pain can be lessened, reducing recurrences and their cost in terms of suffering and lost work. Frank examines differential diagnosis; acute, chronic, and intractable pain; and service implications. Modern management emphasises self care, and bed rest should usually not be longer than 48 hours. A return to physical fitness and other activities, including employment, is actively encouraged. Medication has a role in facilitating these objectives. Two points are especially emphasised: strategies to manage low back pain must be long term and preventive; and the responsibility to keep fit, maintain an exercise programme, and remain relaxed so as to avoid physically stressing the spine is that of the individual, not of the professionals.			FRANK, A (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR, HARROW HA1 3UJ, MIDDX, ENGLAND.							ALDRIDGE D, 1989, BRIT MED J, V299, P1121; BATTIE MC, 1991, SPINE, V16, P15; BELL GR, 1984, SPINE, V9, P552, DOI 10.1097/00007632-198409000-00004; BENZON HT, 1986, PAIN, V24, P277, DOI 10.1016/0304-3959(86)90115-6; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P1; BUTLER D, 1990, SPINE, V15, P111, DOI 10.1097/00007632-199002000-00012; CARETTE S, 1991, NEW ENGL J MED, V325, P1002, DOI 10.1056/NEJM199110033251405; CHEATLE MD, 1991, SPINE, V16, P1379, DOI 10.1097/00007632-199112000-00008; COAN RM, 1980, AM J CHINESE MED, V8, P181, DOI 10.1142/S0192415X80000141; COLLEE G, 1991, J RHEUMATOL, V18, P1060; DEYO RA, 1991, NEW ENGL J MED, V325, P1039, DOI 10.1056/NEJM199110033251411; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DONCHIN M, 1990, SPINE, V15, P1317, DOI 10.1097/00007632-199012000-00015; Dunnell Karen, 1972, MED TAKERS PRESCRIBE; ELNAGGAR IM, 1991, SPINE, V16, P967, DOI 10.1097/00007632-199108000-00018; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; Fordyce W E, 1988, Int Disabil Stud, V10, P29; FORDYCE WE, 1986, J BEHAV MED, V9, P127, DOI 10.1007/BF00848473; FRANK A, 1990, PRACTITIONER, V234, P113; FRANK AO, 1988, DISABLING DISEASES P; FRANK AO, IN PRESS OXFORD TXB; FRANK AO, 1987, CARE SCI PRACTICE, V5, P29; GARVEY TA, 1989, SPINE, V14, P962, DOI 10.1097/00007632-198909000-00008; GAVIN MB, 1991, URR OPINION RHE 0203, P65; GERSH MR, 1985, PHYS THER, V65, P314, DOI 10.1093/ptj/65.3.314; GIBSON T, 1985, LANCET, V1, P1258; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; HARKAPAA K, 1990, SCAND J REHABIL MED, V22, P181; HODKINSON M, 1988, DISABLING DISEASES P; HSIEH CYJ, 1992, J MANIP PHYSIOL THER, V15, P4; JAYSON MIV, 1986, BRIT MED J, V293, P1454, DOI 10.1136/bmj.293.6560.1454; JAYSON MIV, 1987, LUMBAR SPINE BACK PA; KAPLAN RM, 1987, SPINE STATE ART REV, V2, P61; KELSEY JL, 1984, SPINE, V9, P608, DOI 10.1097/00007632-198409000-00012; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; LEHMANN TR, 1986, PAIN, V26, P277, DOI 10.1016/0304-3959(86)90057-6; LILIUS G, 1989, REV CHIR ORTHOP, V75, P493; LINDSTROM I, 1992, SPINE, V17, P641, DOI 10.1097/00007632-199206000-00003; MACDONALD RS, 1990, SPINE, V15, P364, DOI 10.1097/00007632-199005000-00005; MAIN CJ, 1992, SPINE, V17, P42, DOI 10.1097/00007632-199201000-00007; MANNICHE C, 1988, LANCET, V2, P1473; MANNICHE C, 1991, PAIN, V47, P53, DOI 10.1016/0304-3959(91)90011-L; MATHEWS JA, 1987, BRIT J RHEUMATOL, V26, P416; MAYER TG, 1987, JAMA-J AM MED ASSOC, V258, P1763, DOI 10.1001/jama.258.13.1763; MCCAULEY JD, 1983, ARCH PHYS MED REHAB, V64, P548; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; MILLION R, 1982, SPINE, V7, P204, DOI 10.1097/00007632-198205000-00004; MITCHELL RI, 1990, SPINE, V15, P514, DOI 10.1097/00007632-199006000-00016; MOFFETT JAK, 1986, SPINE, V11, P120, DOI 10.1097/00007632-198603000-00003; Mooney V, 1976, Clin Orthop Relat Res, P149; Morrell D C, 1976, J R Coll Gen Pract, V26, P398; MORRISON GEC, 1988, ARCH PHYS MED REHAB, V69, P605; NAGI SZ, 1973, J CHRON DIS, V26, P769, DOI 10.1016/0021-9681(73)90012-X; OLAND G, 1991, SPINE, V16, P457, DOI 10.1097/00007632-199104000-00012; ONGLEY MJ, 1987, LANCET, V2, P143; OVERMAN SS, 1988, PHYS THER, V68, P199, DOI 10.1093/ptj/68.2.199; PARRY CBW, 1988, INT DISABIL STUD, V10, P25; PHILIPS HC, 1991, BEHAV RES THER, V29, P435, DOI 10.1016/0005-7967(91)90127-O; PHILIPS HC, 1991, BEHAV RES THER, V29, P443, DOI 10.1016/0005-7967(91)90128-P; ROLAND M, 1989, J ROY COLL GEN PRACT, V39, P244; SHEA DD, 1991, SPINE, V16, P560, DOI 10.1097/00007632-199105000-00013; SIMMONS JW, 1992, SPINE, V17, pS172, DOI 10.1097/00007632-199206001-00019; SPITZER WO, 1987, SPINE, V12, pS7; STANKOVIC R, 1990, SPINE, V15, P120, DOI 10.1097/00007632-199002000-00014; TRIEF PM, 1983, ARCH PHYS MED REHAB, V64, P53; TURNER JA, 1990, J CONSULT CLIN PSYCH, V58, P573, DOI 10.1037/0022-006X.58.5.573; TURNERSTOKES L, 1992, J ROY SOC MED, V85, P389; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WADDELL G, 1982, BRIT J HOSP MED, V28, P187; WARD NG, 1986, SPINE, V11, P661, DOI 10.1097/00007632-198609000-00003; Wiesel S W, 1988, J Spinal Disord, V1, P50; WILLIAMS ME, 1985, ARTHRITIS SOC; WOOD PHN, 1980, LUMBAR SPINE BACK PA, P29; 1992, CM 1986; 1989, ACTA ORTHOP SCAND, V60, P633	79	105	106	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	1993	306	6882					901	909		10.1136/bmj.306.6882.901	http://dx.doi.org/10.1136/bmj.306.6882.901			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8347190	Bronze, Green Published			2022-12-28	WOS:A1993KW38700027
J	LAMB, CJ				LAMB, CJ			PLANT-DISEASE RESISTANCE GENES IN SIGNAL PERCEPTION AND TRANSDUCTION	CELL			English	Review							PATHOGEN INTERACTIONS; AVIRULENCE GENE; INCOMPATIBILITY; RECOGNITION; ACTIVATION				LAMB, CJ (corresponding author), SALK INST BIOL STUDIES,PLANT BIOL LAB,LA JOLLA,CA 92037, USA.							BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; CARLAND FM, 1993, MOL GEN GENET, V239, P17, DOI 10.1007/BF00281596; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; HEROUART D, 1993, P NATL ACAD SCI USA, V90, P3108, DOI 10.1073/pnas.90.7.3108; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HODGKIN T, 1988, NEW PHYTOL, V110, P557, DOI 10.1111/j.1469-8137.1988.tb00296.x; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KEEN NT, 1990, MOL PLANT MICROBE IN, V3, P112, DOI 10.1094/MPMI-3-112; KIEDROWSKI S, 1992, EMBO J, V11, P4677, DOI 10.1002/j.1460-2075.1992.tb05572.x; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LEGENDRE L, 1992, J BIOL CHEM, V267, P20140; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; NASRALLAH JB, 1993, PLANT CELL, V5, P1325, DOI 10.2307/3869785; NASRALLAH JB, 1994, IN PRESS PLANT J; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1111/j.1365-313X.1992.00359.x; YU LM, 1993, PLANT J, V3, P805, DOI 10.1111/j.1365-313X.1993.00805.x	18	140	145	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					419	422		10.1016/0092-8674(94)90106-6	http://dx.doi.org/10.1016/0092-8674(94)90106-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313464				2022-12-28	WOS:A1994MX20700003
J	SCOTT, EA; STOKOE, RA				SCOTT, EA; STOKOE, RA			CHALLENGING PROFESSIONAL OPINION - THE USE OF INDEPENDENT ARBITRATION	BRITISH MEDICAL JOURNAL			English	Article									NW HERTFORDSHIRE HLTH,ST ALBANS AL3 5TL,HERTS,ENGLAND									1992, ALLERGY CONVENTIONAL	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					177	178		10.1136/bmj.308.6922.177a	http://dx.doi.org/10.1136/bmj.308.6922.177a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312770	Green Published			2022-12-28	WOS:A1994MR97400022
J	NOVACK, DH				NOVACK, DH			ADRIENNE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											NOVACK, DH (corresponding author), RHODE ISL HOSP, 593 EDDY ST, PROVIDENCE, RI 02903 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					424	425		10.7326/0003-4819-119-5-199309010-00013	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338298				2022-12-28	WOS:A1993LZ47600013
J	BENNETT, PR; KIM, CL; COLIN, Y; WARWICK, RM; CHERIFZAHAR, B; FISK, NM; CARTRON, JP				BENNETT, PR; KIM, CL; COLIN, Y; WARWICK, RM; CHERIFZAHAR, B; FISK, NM; CARTRON, JP			PRENATAL DETERMINATION OF FETAL RHD TYPE BY DNA AMPLIFICATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETOMATERNAL HEMORRHAGE; EARLY AMNIOCENTESIS; 1ST TRIMESTER; MANAGEMENT; PREGNANCY; CLONING	Background. An RhD-negative woman whose partner is heterozygous may have preexisting anti-RhD antibodies that may or may not affect a subsequent fetus, depending on whether it is heterozygous. A safe method of determining fetal RhD type early in pregnancy would eliminate the risks to an RhD-negative fetus of fetal-blood sampling or serial amniocenteses. Methods. We determined the RhD type in 15 fetuses using the polymerase chain reaction in amniotic cells and serologic methods in fetal blood collected simultaneously. In another 15 fetuses, the RhD type determined from chorionic-villus samples was compared with that identified by typing of DNA from the fetus itself. Results. RhD typing of DNA from amniotic cells correctly indicated the serologic type in every fetus. Of 10 fetuses with RhD-negative mothers, 4 were identified as RhD-negative and 6 as RhD-positive. Of five fetuses with RhD-positive mothers, four were identified as RhD-positive and one as RhD-negative. There was also complete agreement between the results of RhD typing of DNA from chorionic-villus samples and the results of typing of DNA from fetal tissue. Eleven fetuses were RhD-positive, and four were RhD-negative. Four RhD-positive fetuses had RhD-negative mothers. Three RhD-negative fetuses had RhD-positive mothers. There was no contamination by maternal RhD-positive DNA of the samples from RhD-negative fetuses. Conclusions. Determining fetal RhD type in amniotic cells without invading the fetomaternal circulation is a reliable method that will be valuable in the management of Rh alloimmunization.	INST NATL TRANSFUS SANGUINE,INSERM,U76,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	BENNETT, PR (corresponding author), QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON W6 OXG,ENGLAND.		colin, yves/O-1910-2017; Fisk, Nicholas M/B-2126-2009; le van kim, caroline/O-7030-2017	colin, yves/0000-0001-5196-4254; Fisk, Nicholas M/0000-0003-0031-7975; Cherif-Zahar, Baya/0000-0002-4965-7252; le van kim, caroline/0000-0002-3251-1310; Bennett, Phillip/0000-0002-6253-4919				[Anonymous], 1991, LANCET, V337, P1491; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; BLAKEMORE KJ, 1986, AM J OBSTET GYNECOL, V155, P988, DOI 10.1016/0002-9378(86)90332-7; BLANCHARD D, 1988, BLOOD, V72, P1424; BOWMAN JM, 1965, PEDIATRICS, V35, P815; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; BYRNE D, 1991, ULTRASOUND OBST GYN, V1, P235, DOI 10.1046/j.1469-0705.1991.01040235.x; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; CLARKE CA, 1987, BRIT MED J, V294, P1001, DOI 10.1136/bmj.294.6578.1001; COLIN Y, 1991, BLOOD, V78, P2747; FUHRMAN HC, 1987, PRENATAL DIAG, V7, P17, DOI 10.1002/pd.1970070104; GEMKE RJBJ, 1986, BRIT J HAEMATOL, V64, P689, DOI 10.1111/j.1365-2141.1986.tb02230.x; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HANSON FW, 1992, AM J OBSTET GYNECOL, V166, P1707, DOI 10.1016/0002-9378(92)91560-W; KANHAI HH, 1987, AM J OBSTET GYNECOL, V156, P120, DOI 10.1016/0002-9378(87)90219-5; KIM CL, 1992, BLOOD, V80, P1074; KIM CL, 1992, P NATL ACAD SCI USA, V89, P10925; MARSH WL, 1974, SCIENCE, V183, P966, DOI 10.1126/science.183.4128.966; NICOLAIDES K H, 1986, Fetal Therapy, V1, P185; NICOLINI U, 1988, BRIT MED J, V297, P1379, DOI 10.1136/bmj.297.6660.1379; POISSONNIER MH, 1989, AM J OBSTET GYNECOL, V161, P709, DOI 10.1016/0002-9378(89)90386-4; PRICE JO, 1991, AM J OBSTET GYNECOL, V165, P1731, DOI 10.1016/0002-9378(91)90024-L; Race RR., 1975, BLOOD GROUPS MAN; RODECK CH, 1989, BRIT J OBSTET GYNAEC, V96, P759, DOI 10.1111/j.1471-0528.1989.tb03312.x; WARREN RC, 1985, LANCET, V1, P691	27	208	232	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					607	610		10.1056/NEJM199308263290903	http://dx.doi.org/10.1056/NEJM199308263290903			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341334	Bronze			2022-12-28	WOS:A1993LU21700003
J	BROOK, RH				BROOK, RH			MAINTAINING HOSPITAL QUALITY - THE NEED FOR INTERNATIONAL-COOPERATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROSPECTIVE PAYMENT SYSTEM; BYPASS-SURGERY; CARE		UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT HLTH SERV, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	BROOK, RH (corresponding author), RAND, HLTH SCI PROGRAM, 1700 MAIN ST, POB 2138, SANTA MONICA, CA 90407 USA.							BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1991, RAND R3931HCFA PUBL; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; Nightingale F., 1857, MORTALITY BRIT ARMY; PILPEL D, 1992, PUBLIC HLTH REV, V93, P20; Pilpel Dina, 1992, Public Health Reviews, V20, P61; WILLIAMS SV, 1991, JAMA-J AM MED ASSOC, V266, P810, DOI 10.1001/jama.266.6.810; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; 1992, CONSUMER GUIDE CORON	16	22	22	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					985	987		10.1001/jama.270.8.985	http://dx.doi.org/10.1001/jama.270.8.985			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8345650				2022-12-28	WOS:A1993LT56700031
J	KAUFMAN, JL				KAUFMAN, JL			TREATMENT FOR CRAMPING OF PERIPHERAL VASCULAR OCCLUSIVE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							MUSCLE CRAMPS				KAUFMAN, JL (corresponding author), BAYSTATE MED CTR,SPRINGFIELD,MA 01107, USA.							BALTODANO N, 1988, ARCH INTERN MED, V148, P1969, DOI 10.1001/archinte.148.9.1969; GORLICH HD, 1991, ARZNEIMITTEL-FORSCH, V41-1, P167; MCGEE SR, 1990, ARCH INTERN MED, V150, P511, DOI 10.1001/archinte.150.3.511; WEINER IH, 1980, JAMA-J AM MED ASSOC, V244, P2332, DOI 10.1001/jama.244.20.2332	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					879	880						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340992				2022-12-28	WOS:A1993LR61200040
J	HEALD, R; MCLOUGHLIN, M; MCKEON, F				HEALD, R; MCLOUGHLIN, M; MCKEON, F			HUMAN WEE-1 MAINTAINS MITOTIC TIMING BY PROTECTING THE NUCLEUS FROM CYTOPLASMICALLY ACTIVATED CDC2 KINASE	CELL			English	Article							I-KAPPA-B; CELL-CYCLE; PROTEIN-KINASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; M-PHASE; MAMMALIAN-CELLS; HUMAN HOMOLOG	The wee1 tyrosine kinase and cdc25 tyrosine phosphatase of fission yeast play antagonistic roles in the induction of mitosis through cdc2 regulation. We show here that the human wee1-like tyrosine kinase is a nuclear protein that ensures the completion of DNA replication prior to mitosis in cells expressing otherwise catastrophic levels of cdc2 activators. Paradoxically, wee1-rescued cells display very high levels of mitotic cdc2 kinase activity. We account for this anomaly by our observation that the cdc2 activator, cdc25C, is a cytoplasmic protein that, like cyclin B1, enters the nucleus at the G2/M transition. Thus, cdc2 is likely to be activated in the cytoplasm and requires nuclear localization to initiate both cytoplasmic and nuclear mitotic transformations. The human wee1 kinase appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from this cytoplasmically activated cdc2 kinase.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Heald, Rebecca/0000-0001-6671-6528	NIGMS NIH HHS [GM37977] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037977] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEILOTTER H, 1991, GENETICS, V127, P309; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GIRARD F, 1992, J CELL BIOL, V118, P785, DOI 10.1083/jcb.118.4.785; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HOFFMAN I, 1993, IN PESS EMBO J, V12; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAO PN, 1977, J CELL PHYSIOL, V91, P131, DOI 10.1002/jcp.1040910113; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	62	398	407	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					463	474		10.1016/0092-8674(93)80048-J	http://dx.doi.org/10.1016/0092-8674(93)80048-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348613				2022-12-28	WOS:A1993LT73900008
J	TRAUTWEIN, C; CAELLES, C; VANDERGEER, P; HUNTER, T; KARIN, M; CHOJKIER, M				TRAUTWEIN, C; CAELLES, C; VANDERGEER, P; HUNTER, T; KARIN, M; CHOJKIER, M			TRANSACTIVATION BY NF-IL6 LAP IS ENHANCED BY PHOSPHORYLATION OF ITS ACTIVATION DOMAIN	NATURE			English	Article							HEPATOCYTE-STIMULATING FACTOR; NECROSIS FACTOR-ALPHA; ACUTE PHASE RESPONSE; PROTEIN-KINASE; C-JUN; NUCLEAR-PROTEIN; PHORBOL ESTERS; C/EBP; CELLS; GENE	ONE of the members of the bZIP family of transcriptional activators1-5 is NF-IL6/LAP (IL-6 DBP, C/EBPbeta, CRP2). NF-IL6/LAP protein is highly expressed in liver nuclei2, where it has been implicated as a master regulator of the acute-phase response1,3,6,7, induced by interleukin-6 (IL-6) and other inflammatory mediators3,8. Also, NF-IL6/LAP is involved in the activation of the IL-6 promoter in response to IL-1 and bacterial lipopolysaccharide1,6. The control of NF-IL6/LAP expression and activity is complex and poorly understood. Under some conditions the NF-IL6/LAP gene is transcriptionally activated by IL-1 and lipopolysaccharide1, whereas in other instances, its binding to cognate DNA sequences is enhanced by cytokines1,3. Additionally, the ability of constitutively expressed NF-IL6/LAP to activate transcription is strongly augmented by IL-6, through an unknown signalling pathway. We now show that stimulation of the protein kinase C pathway increases the phosphorylation of Ser 105 within the activation domain of NF-IL6/LAP, and enhances its transcriptional efficacy.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; VET AFFAIRS MED CTR, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Salk Institute								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS E, 1987, J BIOL CHEM, V262, P10850; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; METCALF D, 1985, LEUKEMIA RES, V9, P35, DOI 10.1016/0145-2126(85)90020-7; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NISHIZAWA M, 1990, J BIOL CHEM, V265, P5897; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SEELENTAG WK, 1987, EMBO J, V6, P2261, DOI 10.1002/j.1460-2075.1987.tb02499.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	31	333	339	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1993	364	6437					544	547		10.1038/364544a0	http://dx.doi.org/10.1038/364544a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8336793				2022-12-28	WOS:A1993LQ66700060
J	VASSAR, R; NGAI, J; AXEL, R				VASSAR, R; NGAI, J; AXEL, R			SPATIAL SEGREGATION OF ODORANT RECEPTOR EXPRESSION IN THE MAMMALIAN OLFACTORY EPITHELIUM	CELL			English	Article							SALMONID FISHES; MARKER PROTEIN; RAINBOW-TROUT; BULB; CELLS; RAT; PATTERNS; LOCALIZATION; PROJECTIONS; STIMULATION	The signal elicited by the interaction of odorous ligands with receptors on olfactory sensory neurons must be decoded by the brain to determine which of the numerous receptors have been activated. We have examined the-patterns of odorant receptor expression in the rat olfactory epithelium to determine whether the mammalian olfactory system employs spatial segregation of sensory input to encode the identity of an odorant stimulus. In situ hybridization experiments with probes for 11 different odorant receptors demonstrate that sensory neurons expressing distinct receptors are topologically segregated into a small number of broad, yet circumscribed, zones within the olfactory epithelium. Within a given zone, however, olfactory neurons expressing a specific receptor appear to be randomly distributed, rather than spatially localized. The complex mammalian olfactory system may therefore compartmentalize the epithelium into anatomically and functionally discrete units, such that each zone expresses only a subset of the entire receptor repertoire.			VASSAR, R (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.			Axel, Richard/0000-0002-3141-4076	PHS HHS [R01-20336] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASTIC L, 1986, BRAIN RES BULL, V16, P445, DOI 10.1016/0361-9230(86)90172-3; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DOVING KB, 1980, ACTA PHYSIOL SCAND, V108, P123, DOI 10.1111/j.1748-1716.1980.tb06509.x; DUNCAN HJ, 1990, J COMP NEUROL, V299, P299, DOI 10.1002/cne.902990304; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; GREER CA, 1981, BRAIN RES, V217, P279, DOI 10.1016/0006-8993(81)90004-4; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; JASTREBOFF PJ, 1984, P NATL ACAD SCI-BIOL, V81, P5250, DOI 10.1073/pnas.81.16.5250; JOURDAN F, 1982, BRAIN RES, V240, P341, DOI 10.1016/0006-8993(82)90232-3; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; KAUER JS, 1974, J PHYSIOL-LONDON, V243, P717, DOI 10.1113/jphysiol.1974.sp010773; KAUER JS, 1991, OLFACTION MODEL SYST; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Liebich H G, 1975, Anat Anz, V138, P170; MACKAYSIM A, 1984, ANAT EMBRYOL, V170, P93, DOI 10.1007/BF00319463; MACKAYSIM A, 1982, J NEUROPHYSIOL, V48, P584, DOI 10.1152/jn.1982.48.2.584; MACLEOD NK, 1976, EXP BRAIN RES, V25, P267; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORI K, 1985, J COMP NEUROL, V242, P214, DOI 10.1002/cne.902420205; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RIDDLE DR, 1991, J NEUROSCI, V11, P3752; ROGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704, DOI 10.1073/pnas.84.6.1704; ROYET JP, 1987, BRAIN RES, V417, P1, DOI 10.1016/0006-8993(87)90173-9; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; Shepherd G. M., 1991, OLFACTION MODEL SYST; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; THOMMESEN G, 1983, ACTA PHYSIOL SCAND, V117, P241, DOI 10.1111/j.1748-1716.1983.tb07203.x; THOMMESEN G, 1977, ACTA PHYSIOL SCAND, V99, P270, DOI 10.1111/j.1748-1716.1977.tb10380.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	39	701	713	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					309	318		10.1016/0092-8674(93)90422-M	http://dx.doi.org/10.1016/0092-8674(93)90422-M			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343958				2022-12-28	WOS:A1993LP72600012
J	VEAUTE, X; FUCHS, RPP				VEAUTE, X; FUCHS, RPP			GREATER SUSCEPTIBILITY TO MUTATIONS IN LAGGING-STRAND OF DNA-REPLICATION IN ESCHERICHIA-COLI THAN IN LEADING-STRAND	SCIENCE			English	Article							POLYMERASE-III HOLOENZYME; FRAMESHIFT MUTAGENESIS; SEQUENCES; SYSTEM	Models of DNA replication in Escherichia coli involve an asymmetric DNA polymerase complex that replicates concurrently the leading and the lagging strands of double-stranded DNA. The effect of asymmetry on mutagenesis was tested with pairs of plasmids containing the unidirectional ColE1 origin of replication and a single lesion located in the leading or lagging strand. The lesion used was the covalent adduct that the chemical carcinogen N-2-acetylaminofluorene (AAF) forms with the C-8 position of guanine. Whether SOS was induced or not, mutations arose at about a 20-fold higher frequency when the AAF adduct was located in the lagging strand than when in the leading strand.			VEAUTE, X (corresponding author), CNRS,INST BIOL MOLEC & CELLULAIRE,UNITE PROPRE RECH CANCEROGENESE & MUTAGENESE MOLEC & STRUCT,F-67084 STRASBOURG,FRANCE.							BACKMAN K, 1978, COLD SPRING HARB SYM, V43, P69; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; Kaderlik R. K., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P152; KOFFELSCHWARTZ N, 1989, MOL GEN GENET, V215, P306, DOI 10.1007/BF00339733; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; MAENHAUTMICHEL G, 1992, MOL GEN GENET, V235, P373, DOI 10.1007/BF00279383; MAKI H, 1988, J BIOL CHEM, V263, P6570; MARIANS KT, 1992, ANN REV BIOCH, V61, P67; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; TOMIZAWA JI, 1974, P NATL ACAD SCI USA, V71, P2260, DOI 10.1073/pnas.71.6.2260; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; VEAUTE X, IN PRESS P NATL ACAD; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	17	112	113	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					598	600		10.1126/science.8342022	http://dx.doi.org/10.1126/science.8342022			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342022				2022-12-28	WOS:A1993LP72800035
J	LI, J; TAYLOR, B				LI, J; TAYLOR, B			FACTORS AFFECTING UPTAKE OF MEASLES, MUMPS, AND RUBELLA IMMUNIZATION	BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION POLICY; CHILDREN; DISTRICT; RATES	Objective-To study factors affecting uptake of measles, mumps, and rubella immunisation. Design-Cohort study using data from computerised child health systems. Setting-10 health districts in North East Thames and North West Thames regions. Subjects-7841 children born in January to March 1990 and resident in the districts up till the end of October 1991. Main outcome measures-Overall uptake of measles, mumps, and rubella immunisation, variation of uptake among groups of children, and odds ratio of being vaccinated against measles, mumps, and rubella. Results-The overall uptake rate of measles, mumps, and rubella immunisation for the study cohort in the 10 districts was 82%. Wide variation was identified among children with different demographic characteristics. Lower uptake was associated with absent or incomplete primary immunisation, including omission of pertussis vaccine. Other factors affecting uptake included the type of resident district, birth order, where registered for immunisation (general practitioner or clinic), and one parent family status. Conclusions-Many districts have difficulties in meeting the 90% target for measles, mumps, and rubella immunisation, mainly because of the characteristics of their local population. To increase overall coverage, the health service should target families with adverse factors, especially those whose children have missed previous immunisations.			LI, J (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT COMMUNITY CHILD HLTH,LONDON NW3 2QG,ENGLAND.							BEGG NT, 1985, BRIT MED J, V291, P1370, DOI 10.1136/bmj.291.6506.1370; CAMPBELL AGM, 1983, ARCH DIS CHILD, V58, P3, DOI 10.1136/adc.58.1.3; HERTOGS D, 1989, PUBLIC HEALTH, V103, P421, DOI 10.1016/S0033-3506(89)80051-4; HODES DT, 1990, PUBLIC HEALTH, V104, P27, DOI 10.1016/S0033-3506(05)80342-7; HULL D, 1987, J ROY COLL PHYS LOND, V21, P28; JARMAN B, 1988, BRIT MED J, V296, P1775, DOI 10.1136/bmj.296.6639.1775; JARMAN B, 1983, BRIT MED J, V286, P1704; JEFFERIES S, 1991, J PUBLIC HEALTH MED, V13, P312; JEFFERSON N, 1987, BRIT MED J, V294, P423, DOI 10.1136/bmj.294.6569.423; LI J, 1991, BRIT MED J, V303, P1035, DOI 10.1136/bmj.303.6809.1035; Li J, 1993, Health Trends, V25, P16; MARKS JS, 1979, PEDIATRICS, V64, P304; MILLER C, 1986, LANCET, V2, P732; NICOLL A, 1989, BRIT MED J, V299, P808, DOI 10.1136/bmj.299.6703.808; PECKHAM C, 1989, PECKHAM REPORT NATIO; RILEY DJ, 1991, BRIT MED J, V302, P31, DOI 10.1136/bmj.302.6767.31; TCHIE LD, 1992, BMJ, V304, P816; WALKER D, 1986, BRIT MED J, V292, P1501, DOI 10.1136/bmj.292.6534.1501; White J M, 1992, Commun Dis Rep CDR Rev, V2, pR96; WHITE JM, 1992, BRIT MED J, V304, P682, DOI 10.1136/bmj.304.6828.682; 1991, CM 1523; 1985, SAS USERS GUIDE STAT; 1990, IMMUNISATION INFECTI; 1986, LANCET, V2, P671; 1988, IMMUNISATION INFECTI	25	48	48	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					168	171		10.1136/bmj.307.6897.168	http://dx.doi.org/10.1136/bmj.307.6897.168			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343745	Green Published, Bronze			2022-12-28	WOS:A1993LN18400020
J	LIS, J; WU, C				LIS, J; WU, C			PROTEIN TRAFFIC ON THE HEAT-SHOCK PROMOTER - PARKING, STALLING, AND TRUCKING ALONG	CELL			English	Review							RNA POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION DOMAIN; DNA-BINDING; NUCLEOSOMAL TEMPLATES; MOLECULAR-CLONING; FACTOR CONTAINS; GENE; INVITRO; EXPRESSION; ELONGATION		NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LIS, J (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14850, USA.							ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BONNER JJ, 1992, MOL CELL BIOL, V12, P1021, DOI 10.1128/MCB.12.3.1021; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LEE MS, 1992, P NATL ACAD SCI USA, V89, P9166, DOI 10.1073/pnas.89.19.9166; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETERANDERL R, 1993, IN PRESS BIOCHEMISTR; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RASMUSSEN E, 1993, IN PRESS P NATL ACAD, V90; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124	42	358	366	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					1	4		10.1016/0092-8674(93)90286-Y	http://dx.doi.org/10.1016/0092-8674(93)90286-Y			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334697				2022-12-28	WOS:A1993LN62500001
J	CATALONA, WJ				CATALONA, WJ			UROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSTATE-SPECIFIC ANTIGEN; CANCER				CATALONA, WJ (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BOSLAND MC, 1992, J CELL BIOCH S H, V6, P135; BRAWN PN, 1991, CANCER, V68, P1592, DOI 10.1002/1097-0142(19911001)68:7<1592::AID-CNCR2820680721>3.0.CO;2-M; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1992, J UROL S, V147, P450; GELLER DM, 1993, NEW ENGL J MED, V328, P442; GERBER GS, 1993, JAMA-J AM MED ASSOC, V269, P61, DOI 10.1001/jama.269.1.61; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; GORMLEY GJ, 1992, J CELL BIOCH S, V16, P113; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LANGE PH, 1992, NEW ENGL J MED, V327, P1234, DOI 10.1056/NEJM199210223271709; LEPOR H, 1992, J UROLOGY, V148, P1467, DOI 10.1016/S0022-5347(17)36941-0; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; POLLARD M, 1991, CANCER RES, V51, P3610; POLLARD M, 1992, J CELL BIOCH H S, V16, P84; PRESTI JC, 1992, J UROLOGY, V148, P1201, DOI 10.1016/S0022-5347(17)36860-X; SIMPSON KN, 1993, J UROLOGY, V49, pA413; STRMONT TJ, 1993, UROLOGY, V41, P3; 1992, AM UROLOGICAL ASS 19, P420	21	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					265	266		10.1001/jama.270.2.265	http://dx.doi.org/10.1001/jama.270.2.265			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315758				2022-12-28	WOS:A1993LL36800045
J	STEVENS, CF; WANG, YY				STEVENS, CF; WANG, YY			REVERSAL OF LONG-TERM POTENTIATION BY INHIBITORS OF HEME OXYGENASE	NATURE			English	Article							DENTATE GYRUS; TRANSMISSION; HIPPOCAMPUS; ZINC; RAT	EVIDENCE that carbon monoxide can serve as an intercellular messenger in brain1-3, a role much like that demonstrated for nitric oxide in various tissues4, prompted us to investigate whether carbon monoxide participates in long-term potentiation (LTP), the cellular mechanism that may underlie certain forms of learning and memory. Although LTP is triggered in the postsynaptic neuron, at least some fraction of LTP is expressed presynaptically as an increase in the quantity of neurotransmitter released5-14. Thus, a retrograde signal must form the communication link between the postsynaptic site of induction and the presynaptic site of expression. To test whether carbon monoxide might act as a retrograde signal in LTP, we have investigated the effect on LTP of inhibitors of the enzyme haem oxygenase-2, which catalyses the production of carbon monoxide in the brain. We find that these inhibitors prevent the induction of LTP and have no effect on one form of long-term depression. Furthermore, they will reverse LTP that is already established.			STEVENS, CF (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BASKYS A, 1991, NEUROSCI LETT, V127, P169, DOI 10.1016/0304-3940(91)90786-S; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLOOMER JR, 1983, GASTROENTEROLOGY, V95, P663; CULOTTA E, 1992, SCIENCE, V258, P1862, DOI 10.1126/science.1361684; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; MAYER ML, 1989, J PHYSIOL-LONDON, V415, P351, DOI 10.1113/jphysiol.1989.sp017725; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VORONIN LL, 1988, SYNAPTIC PLASTICITY, P27; VREMAN HJ, 1991, AM J MED SCI, V302, P335, DOI 10.1097/00000441-199112000-00002; ZHOU M, IN PRESS SCIENCE	23	256	260	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					147	149		10.1038/364147a0	http://dx.doi.org/10.1038/364147a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321285				2022-12-28	WOS:A1993LL36700049
J	SLATER, SJ; COX, KJA; LOMBARDI, JV; HO, C; KELLY, MB; RUBIN, E; STUBBS, CD				SLATER, SJ; COX, KJA; LOMBARDI, JV; HO, C; KELLY, MB; RUBIN, E; STUBBS, CD			INHIBITION OF PROTEIN-KINASE-C BY ALCOHOLS AND ANESTHETICS	NATURE			English	Article							GENERAL-ANESTHETICS; LOCAL-ANESTHETICS; MOLECULAR MECHANISMS; ACTIVATION; SITE; MEMBRANES; ALKANOLS; TORPEDO; BINDING	DESPITE almost a century of research, the mechanism of anaesthesia remains obscure and there is still no agreement on the location of the site(s) of action1-7. Because the potencies of general anaesthetics increase in proportion to their solubility in olive oil, this led to a consensus that the site is within the cell membrane 8-10. This led to theories that lipid bilayer perturbation was the primary event, which was then transmitted to a membrane protein11. But at the concentrations used clinically, such perturbations are small3. A plausible site would be in or on ion channels at the synapse, where a number of modulatory effects have been described6. A possible location for such a site would be at the protein-lipid interface5,12,13. We report here that anaesthetics inhibit protein kinase C, a key component in signal transduction. The potency is a linear function of the octanol-water partition coefficient (the Meyer-Overton rule of anaesthesia). The effect was obtained in a lipid-free assay, implicating a hydrophobic site in the protein, supporting the contention that a (membrane) protein may be a target for anaesthetic interactions14-17. In a lipid-dependent assay, a potential role of lipids in the protein-site model was demonstrated. The inhibition was absent in the isolated catalytic domain, suggesting that the site of inhibition is on the regulatory subunit, which is unique to protein kinase C.	THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107	Jefferson University				Lombardi, Joseph/0000-0002-2665-8084				ALIFIMOFF JK, 1989, BRIT J PHARMACOL, V96, P9, DOI 10.1111/j.1476-5381.1989.tb11777.x; BELL RM, 1991, J BIOL CHEM, V266, P4661; CURRY S, 1990, BIOCHEMISTRY-US, V29, P4641, DOI 10.1021/bi00471a020; DLUZEWSKI AR, 1983, MOL ASPECTS MED, V6, P459, DOI 10.1016/0098-2997(83)90001-8; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; FRASER DM, 1990, BIOCHEMISTRY-US, V29, P2664, DOI 10.1021/bi00463a007; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYDON DA, 1977, NATURE, V268, P356, DOI 10.1038/268356a0; INOUE M, 1977, J BIOL CHEM, V252, P7610; Kitano T, 1986, Methods Enzymol, V124, P349; LEE MH, 1986, J BIOL CHEM, V261, P4867; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; MATTHEWS R, 1992, SCIENCE, V255, P156, DOI 10.1126/science.1553540; Meyer H, 1901, ARCH EXP PATHOL PHAR, V46, P338, DOI 10.1007/BF01978064; MEYER H, 1989, ARCH EXP PATHOL PH, V42, P109; MIKAWA K, 1990, J INT MED RES, V18, P153, DOI 10.1177/030006059001800209; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; MOSS GWJ, 1991, P NATL ACAD SCI USA, V88, P134, DOI 10.1073/pnas.88.1.134; Overton E., 1901, STUDIEN NARKOSE; RICHARDS CD, 1978, NATURE, V276, P775, DOI 10.1038/276775a0; RUBIN E, 1991, ANN NY ACAD SCI, V625; SEEMAN P, 1972, PHARMACOL REV, V24, P583; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V775, P374, DOI 10.1016/0005-2736(84)90193-7; TAS PWL, 1991, BIOCHIM BIOPHYS ACTA, V1091, P401, DOI 10.1016/0167-4889(91)90206-D; TRUDELL JR, 1991, ANN NY ACAD SCI, V625, P743, DOI 10.1111/j.1749-6632.1991.tb33907.x; TRUDELL JR, 1973, BIOCHIM BIOPHYS ACTA, V291, P321, DOI 10.1016/0005-2736(73)90485-9; WOOD SC, 1991, MOL PHARMACOL, V39, P332	29	219	220	3	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					82	84		10.1038/364082a0	http://dx.doi.org/10.1038/364082a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316305				2022-12-28	WOS:A1993LK81800064
J	TINGLEY, WG; ROCHE, KW; THOMPSON, AK; HUGANIR, RL				TINGLEY, WG; ROCHE, KW; THOMPSON, AK; HUGANIR, RL			REGULATION OF NMDA RECEPTOR PHOSPHORYLATION BY ALTERNATIVE SPLICING OF THE C-TERMINAL DOMAIN	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; PROTEIN-KINASE; SEQUENCES	THE NMDA (N-methyl D-aspartate) receptors in the brain play a critical role in synaptic plasticity, synaptogenesis and excitotoxicity1-3. Molecular cloning has demonstrated that NMDA receptors consist of several homologous subunits (NMDAR1, 2A-2D)4-7. A variety of studies have suggested that protein phosphorylation of NMDA receptors may regulate their function7-12 and play a role in many forms of synaptic plasticity such as long-term potentiation13,14. We have examined the phosphorylation of the NMDA receptor subunit NMDAR1 (NR1) by protein kinase C (PKC) in cells transiently expressing recombinant NR1 and in primary cultures of cortical neurons. PKC phosphorylation occurs on several distinct sites on the NR1 subunit. Most of these sites are contained within a single alternatively spliced exon in the C-terminal domain, which has previously been proposed to be on the extracellular side of the membrane4,5,15. These results demonstrate that alternative splicing of the NR1 messenger RNA regulates its phosphorylation by PKC, and that mRNA splicing is a novel mechanism for regulating the sensitivity of glutamate receptors to protein phosphorylation. These results also provide evidence that the C-terminal domain of the NR1 protein is located intracellularly, suggesting that the proposed transmembrane topology model for glutamate receptors may be incorrect.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University			Roche, Katherine/W-9893-2019	Roche, Katherine/0000-0001-7282-6539				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CHOI DW, 1990, REV NEUROSCI, V13, P171; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; CONSTANTINEPATO.M, 1990, REV NEUROSCI, V13, P129; DURANDD GM, 1992, P NATN ACADD SCI US, V89, P1; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MARKRAM H, 1992, J PHYSIOL-LONDON, V457, P491, DOI 10.1113/jphysiol.1992.sp019389; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MOLNAR E, 1993, NEUROSCIENCE, V53, P307, DOI 10.1016/0306-4522(93)90198-O; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MURPHY TH, 1990, DEV BRAIN RES, V57, P146, DOI 10.1016/0165-3806(90)90195-5; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; URUSHIHARA H, 1992, J BIOL CHEM, V267, P11697	28	372	387	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					70	73		10.1038/364070a0	http://dx.doi.org/10.1038/364070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316301				2022-12-28	WOS:A1993LK81800060
J	RAI, AS; STEER, H				RAI, AS; STEER, H			LESSON OF THE WEEK - THE 1ST 15 CM ARE IMPORTANT IN UPPER GASTROINTESTINAL ENDOSCOPY	BRITISH MEDICAL JOURNAL			English	Article									SOUTHAMPTON GEN HOSP,DEPT ACCID & EMERGENCY,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton									0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1742	1742		10.1136/bmj.306.6894.1742	http://dx.doi.org/10.1136/bmj.306.6894.1742			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343634	Bronze, Green Published			2022-12-28	WOS:A1993LK36700030
J	HAWTON, K; FAGG, J; PLATT, S; HAWKINS, M				HAWTON, K; FAGG, J; PLATT, S; HAWKINS, M			FACTORS ASSOCIATED WITH SUICIDE AFTER PARASUICIDE IN YOUNG-PEOPLE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMPLETED SUICIDE; MENTAL-DISORDERS; UNEMPLOYMENT; EDINBURGH; ADOLESCENTS; PERSONALITY; CHILDREN; BEHAVIOR; TRENDS; RISK	Objective-To determine factors associated with completed suicide in young parasuicide patients. Design-Case-control study. Setting-Regional poisoning treatment centre in a teaching general hospital. Subjects-Patients who, between 1968 and 1985 when aged 15-24 years, were admitted to the regional poisoning treatment centre because of deliberate self poisoning or self injury. Cases (n=62) consisted of those who by the end of 1985 had died locally from either suicide (n=41) or possible suicide (n=21). Controls (n=124) were patients who were known not to have died locally during the study period. Two controls were selected for each case, matched by sex, age (within two years), and length of follow up. Main outcome measures-Possible predictors of completed suicide. Results-Univariate analysis (conditional logistic regression) showed that risk of death due to suicide and possible suicide was associated with six factors: social class V (odds ratio 2.7, 95% confidence interval 1.1 to 6.7), unemployment (2.8, 1.4 to 5.8), previous inpatient psychiatric treatment (4.9, 2.2 to 10.9), substance misuse (3.3, 1.6 to 6.8), personality disorder (2.1, 1.03 to 4.4), and previous attempted suicide (2.3, 1.2 to 4.4). Multivariate analysis identified two factors as significantly contributing to the model that best discriminated between the cases and controls: substance misuse (alcohol or drugs, or both) (adjusted odds ratio 3.9) and previous inpatient psychiatric treatment (3.7). These factors seemed to be associated with suicide after attempted suicide in both the short term (less than 12 months) and the long term (one year or more) and were also identified when the analysis was restricted to subjects who definitely died by suicide and their controls. Conclusions-Suicide after parasuicide in young people is associated with substance misuse. This suggests that prevention of suicide in young people who attempt suicide might be improved by close liaison between general hospital services for patients who have attempted suicide and services for young substance misusers and by measures aimed at preventing substance misuse in young people.	HLTH EDUC BOARD SCOTLAND, EDINBURGH EH10 4SG, SCOTLAND; UNIV OXFORD, DEPT PAEDIAT, CHILDHOOD CANC RES GRP, OXFORD OX2 6HJ, ENGLAND	University of Oxford	HAWTON, K (corresponding author), UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OXFORD OX3 7JX, ENGLAND.							ALLEBECK P, 1988, BRIT MED J, V297, P176, DOI 10.1136/bmj.297.6642.176; Breslow N, 1980, STATISTICAL METHODS, V32; CASEY PR, 1989, ACTA PSYCHIAT SCAND, V79, P290, DOI 10.1111/j.1600-0447.1989.tb10260.x; FOWLER RC, 1986, ARCH GEN PSYCHIAT, V43, P962; GOLDACRE M, 1985, BRIT J PSYCHIAT, V146, P395, DOI 10.1192/bjp.146.4.395; HAWTON K, 1988, BRIT J PSYCHIAT, V152, P632, DOI 10.1192/bjp.152.5.632; HAWTON K, 1989, ALCOHOL ALCOHOLISM, V24, P3; HAWTON K, 1992, BMJ-BRIT MED J, V304, P1000, DOI 10.1136/bmj.304.6833.1000; HAWTON K, 1987, BRIT J PSYCHIAT, V150, P145, DOI 10.1192/bjp.150.2.145; HAWTON K, 1992, BRIT MED J, V304, P1409, DOI 10.1136/bmj.304.6839.1409; HAWTON K, 1988, BRIT J PSYCHIAT, V152, P359, DOI 10.1192/bjp.152.3.359; KREITMAN N, 1979, PSYCHOL MED, V9, P469, DOI 10.1017/S0033291700032013; Kreitman N., 1977, PARASUICIDE; KREITMAN N, 1982, NEW TRENDS SUICIDE P, P77; MARTTUNEN MJ, 1991, ARCH GEN PSYCHIAT, V48, P834; MURPHY GE, 1984, AM J PSYCHOTHER, V38, P341, DOI 10.1176/appi.psychotherapy.1984.38.3.341; OTTO V, 1972, ACTA PSYCHIAT SCAND, V233, P7; PALLIS DJ, 1982, BRIT J PSYCHIAT, V141, P37, DOI 10.1192/bjp.141.1.37; PLATT S, 1984, BMJ-BRIT MED J, V289, P1029, DOI 10.1136/bmj.289.6451.1029; PLATT S, 1986, BRIT J PSYCHIAT, V149, P401, DOI 10.1192/bjp.149.4.401; PLATT S, 1984, SOC SCI MED, V19, P93, DOI 10.1016/0277-9536(84)90276-4; Platt S, 1991, Int J Soc Psychiatry, V37, P159, DOI 10.1177/002076409103700302; PLATT S, 1988, PSYCHOL MED, V18, P405, DOI 10.1017/S0033291700007959; ROBINSON A, 1986, MRC1985 UN EP STUD P; Rose N., 1986, HLTH TRENDS, V2, P29; RUNESON B, 1989, ACTA PSYCHIAT SCAND, V79, P490, DOI 10.1111/j.1600-0447.1989.tb10292.x; SHAFFER D, 1988, J AM ACAD CHILD PSY, V27, P675, DOI 10.1097/00004583-198811000-00001; SHAFII M, 1988, J AFFECT DISORDERS, V15, P227, DOI 10.1016/0165-0327(88)90020-1; SHAFII M, 1985, AM J PSYCHIAT, V142, P1061; SUOKAS J, 1991, ACTA PSYCHIAT SCAND, V84, P545, DOI 10.1111/j.1600-0447.1991.tb03191.x; TUCKMAN J, 1968, J CLIN PSYCHOL, V24, P17, DOI 10.1002/1097-4679(196801)24:1<17::AID-JCLP2270240104>3.0.CO;2-T; [No title captured]; 1990, EGRET REFERENCE MANU	33	153	155	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	1993	306	6893					1641	1644		10.1136/bmj.306.6893.1641	http://dx.doi.org/10.1136/bmj.306.6893.1641			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324431	Bronze, Green Published			2022-12-28	WOS:A1993LJ33700017
J	ANDREWS, K				ANDREWS, K			RECOVERY OF PATIENTS AFTER 4 MONTHS OR MORE IN THE PERSISTENT VEGETATIVE STATE	BRITISH MEDICAL JOURNAL			English	Article							SEVERE HEAD-INJURY; TRAUMATIC COMA; PROGNOSIS	A retrospective review was made of the case notes of 43 consecutive patients admitted to a unit specialising in the rehabilitation of people in the persistent vegetative state. Eleven of these patients regained awareness four months or more after suffering brain damage. The time to the first reported incidence of eye tracking was between four months and three years, and the time to the first response to command was between four and 12 months. Only one patient was eventually unable to communicate, six could use non-verbal methods of indicating at least a yes or no response, and four were able to speak. Six patients remained totally dependent while two became independent in daily activities. Four patients became independent in feeding, three required help, and four remained on gastrostomy feeding. Thus some patients can regain awareness after more than four months in a vegetative state, and, although few reach full independence, most can achieve an improved quality of life within the limitations of their disabilities. The recovery period is prolonged and may continue for several years. Even patients with profound brain damage should be offered the opportunity of a specialist rehabilitation programme.	ROYAL HOSP & HOME,RES SERV,LONDON SW15 3SW,ENGLAND		ANDREWS, K (corresponding author), ROYAL HOSP & HOME,MED SERV,LONDON SW15 3SW,ENGLAND.							ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; CRAIG CW, 1986, J NEUROSURG, V65, P9; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; HEIDEN JS, 1983, PHYS THER, V63, P1946, DOI 10.1093/ptj/63.12.1946; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; JENNETT B, 1991, BMJ-BRIT MED J, V302, P1256, DOI 10.1136/bmj.302.6787.1256; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1992, BRIT MED J, V305, P1305, DOI 10.1136/bmj.305.6865.1305; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Levy D E, 1978, Ann N Y Acad Sci, V315, P293, DOI 10.1111/j.1749-6632.1978.tb50347.x; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MAY PG, 1968, DIS NERV SYST, V29, P837; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; Roberts AH., 1979, SEVERE ACCIDENTAL HE; ROSENBERG GA, 1977, ANN NEUROL, V2, P167, DOI 10.1002/ana.410020215; ROSIN AJ, 1978, SCAND J REHABIL MED, V10, P33; SAZBON L, 1992, BRAIN INJURY, V4, P359; STEINBOCK B, 1989, HASTINGS CENT REP, V19, P14, DOI 10.2307/3562294; TANHEHCO J, 1982, ARCH PHYS MED REHAB, V63, P36; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; [No title captured]; 1993, BMA NEWS REV, V19, P9	30	64	65	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1597	1600		10.1136/bmj.306.6892.1597	http://dx.doi.org/10.1136/bmj.306.6892.1597			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329926	Green Published, Bronze			2022-12-28	WOS:A1993LH12800027
J	FERRELL, BA; OSTERWEIL, D; CHRISTENSON, P				FERRELL, BA; OSTERWEIL, D; CHRISTENSON, P			A RANDOMIZED TRIAL OF LOW-AIR-LOSS BEDS FOR TREATMENT OF PRESSURE ULCERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SORES; THERAPY	Objective.-To assess the effectiveness of low-air-loss beds for the treatment of pressure ulcers in nursing homes. Design.-Prospective, randomized, clinical trial. Setting.-Three teaching nursing homes in Los Angeles, Calif. Subjects.-Eighty-four nursing home residents with trunk or trochanter pressure ulcers (Shea stage greater-than-or-equal-to 2). Interventions.-Subjects were randomly assigned to use either a low-air-loss bed (n=43) or a 10-cm corrugated foam mattress (n=41) throughout the healing of their ulcers. Outcome Measures.-Ulcers were assessed twice weekly using surface area and two observational scales (median follow-up, 37.5 days; range, 4 to 571 days). Results.-Groups were similar with respect to demographics, medical variables, wound care, and early dropouts. Results indicate more than a threefold improvement in median rate of healing for low-air-loss beds compared with foam mattresses (9.0 vs 2.5 mm2/d; P=.0002). This finding was true for deep as well as superficial ulcers (deep ulcers, 9.9 vs 0.7 mm2/d; P=.02; superficial ulcers, 9.0 vs 3.2 mm2/d; P=.004). Cox regression models revealed that the bed, ulcer depth, and fecal continence had independent effects on healing. After controlling for fecal continence, the deep and superficial subgroups using low-air-loss beds remained 2.5 times more likely to heal in a given length of time compared with those using foam mattresses (combined cure probability ratio, 2.66; 95% confidence interval, 1.34 to 5.17; P<.004). Conclusion.-Low-air-loss beds provide substantial improvement compared with foam mattresses despite other factors in pressure ulcer healing.	JEWISH HOME AGING GREATER LOS ANGELES, RESEDA, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, DEPT BIOMATH, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	FERRELL, BA (corresponding author), SEPULVEDA VET AFFAIRS MED CTR, CTR GERIATR RES EDUC & CLIN, 16111 PLUMMER ST, SEPULVEDA, CA 91343 USA.							ALLMAN RM, 1987, ANN INTERN MED, V107, P641, DOI 10.7326/0003-4819-107-5-641; ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; ALLMAN RM, 1989, NEW ENGL J MED, V320, P850; BENNETT RG, 1989, J AM GERIATR SOC, V37, P235, DOI 10.1111/j.1532-5415.1989.tb06813.x; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; BERLOWITZ DR, 1990, J AM GERIATR SOC, V38, P748, DOI 10.1111/j.1532-5415.1990.tb01464.x; BRANDEIS GH, 1990, JAMA-J AM MED ASSOC, V264, P2905, DOI 10.1001/jama.264.22.2905; BRISTOW JV, 1987, GERIATR NURS     MAY, P120; COX DR, 1984, ANAL SURVIVAL DATA, P91; DOLEZAL R, 1985, ANN PLAS SURG, V14, P33, DOI 10.1097/00000637-198501000-00007; FERRELL BA, 1989, GERIATR MED TODAY, V8, P81; FRANZINI PJ, 1989, CERN8908 REP, V2, P59; HIBBS P, 1989, DECUBITUS, V2, P32; Newsome M W, 1972, Am J Surg, V124, P52; SCALES JT, 1974, PARAPLEGIA, V12, P118, DOI 10.1038/sc.1974.19; SHEA JD, 1975, CLIN ORTHOP RELAT R, P89; STRAUSS MJ, 1991, J FAM PRACTICE, V33, P52; 1992, 920047 US DEP HLTH H	18	81	81	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					494	497		10.1001/jama.269.4.494	http://dx.doi.org/10.1001/jama.269.4.494			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8338511				2022-12-28	WOS:A1993KH38500033
J	DUFFY, TP				DUFFY, TP			SOUNDS IN THE ATTIC	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																		BENTLEY DW, 1988, HOSP PRACT, V23, P99; BRANDT LJ, 1991, ANNU REV MED, V42, P107, DOI 10.1146/annurev.med.42.1.107; COPE Z, 1955, DIAGNOSIS ACUTE ABDO, P25; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; MANN CV, 1992, BAILEY LOVES SHORT P, P1194; OSMER JC, 1966, SOUTHERN MED J, V59, P75, DOI 10.1097/00007611-196601000-00014; PATERSONBROWN S, 1991, BMJ-BRIT MED J, V303, P1115, DOI 10.1136/bmj.303.6810.1115; SPITERI MA, 1988, LANCET, V1, P873	8	3	3	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1993	328	1					44	47						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF507	8338510				2022-12-28	WOS:A1993KF50700008
J	LI, YQ; ERZURUMLU, RS; CHEN, C; JHAVERI, S; TONEGAWA, S				LI, YQ; ERZURUMLU, RS; CHEN, C; JHAVERI, S; TONEGAWA, S			WHISKER-RELATED NEURONAL PATTERNS FAIL TO DEVELOP IN THE TRIGEMINAL BRAIN-STEM NUCLEI OF NMDAR1 KNOCKOUT MICE	CELL			English	Article							VIBRISSA-RELATED PATTERNS; SOMATOSENSORY CORTEX; RECEPTOR ANTAGONIST; STRIATE CORTEX; NEONATAL RAT; MOUSE; BLOCKADE; DISRUPT; SYSTEM; ORGANIZATION	Sensory pathways of the brain generally develop from crudely wired networks to precisely organized systems. Several studies have implicated neural activity-dependent mechanisms, including N-methyl-D-aspartate (NMDA) receptors, in this refinement process. We applied the gene targeting to the NMDAR1 gene and created a mutant mouse that lacks functional NMDA receptors. The development of whisker-related patterns in the trigeminal nuclei of the mutant mice and their normal littermates was compared. We show that in the mutant mice pathfinding, initial targeting, and crude topographic projection of trigeminal axons in the brainstem are unaffected, but that whisker-specific patches fail to form. Our results provide a direct demonstration of the involvement of the NMDA receptor in the formation of periphery-related neural patterns in the mammalian brain.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	LI, YQ (corresponding author), MIT, CTR CANC RES, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Li, Yuqing/G-1596-2011; Li, Yuqing/AAR-9383-2021	Li, Yuqing/0000-0003-1211-5529; Li, Yuqing/0000-0003-1211-5529	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027678] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27678] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMANO T, 1992, MOL BRAIN RES, V14, P35, DOI 10.1016/0169-328X(92)90007-X; BATES CA, 1985, J COMP NEUROL, V240, P265, DOI 10.1002/cne.902400305; BEAR MF, 1990, J NEUROSCI, V10, P909; BELFORD GR, 1980, J COMP NEUROL, V193, P335, DOI 10.1002/cne.901930203; BELFORD GR, 1979, J COMP NEUROL, V183, P305, DOI 10.1002/cne.901830207; Blue ME, 1991, CEREB CORTEX, V1, P380, DOI 10.1093/cercor/1.5.380; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHIAIA NL, 1992, NEUROSCIENCE, V49, P141, DOI 10.1016/0306-4522(92)90082-D; CHIAIA NL, 1993, J NEUROPHYSIOL, V69, P1171, DOI 10.1152/jn.1993.69.4.1171; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; CHIAIA NL, 1992, J NEUROSCI, V12, P62; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; CROSSIN KL, 1989, DEV BIOL, V136, P381, DOI 10.1016/0012-1606(89)90264-9; DURHAM D, 1984, J COMP NEUROL, V223, P424, DOI 10.1002/cne.902230308; EASTER SS, 1993, J NEUROSCI, V13, P285; ERZURUMLU RS, 1990, DEV BRAIN RES, V56, P229; ERZURUMLU RS, 1992, J NEUROSCI, V12, P3946; FAVARON M, 1993, NEUROREPORT, V4, P1171; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GWAG BJ, 1993, NEUROREPORT, V5, P125, DOI 10.1097/00001756-199311180-00007; GWAG BJ, 1993, EXP NEUROL, V121, P160, DOI 10.1006/exnr.1993.1083; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HENDERSON TA, 1992, DEV BRAIN RES, V66, P146, DOI 10.1016/0165-3806(92)90152-M; HENDERSON TA, 1993, J COMP NEUROL, V336, P243, DOI 10.1002/cne.903360207; HENDERSON TA, 1994, IN PRESS J NEUROSCI; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; JEANMONOD D, 1981, NEUROSCIENCE, V6, P1503, DOI 10.1016/0306-4522(81)90222-0; JHAVERI S, 1991, P NATL ACAD SCI USA, V88, P4489, DOI 10.1073/pnas.88.10.4489; Jhaveri S, 1992, DEV CENTRAL NERVOUS, P167; Katz L C, 1993, Curr Opin Neurobiol, V3, P93, DOI 10.1016/0959-4388(93)90041-V; KATZ LC, 1993, NATURE, V364, P578, DOI 10.1038/364578a0; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; MA PM, 1993, J COMP NEUROL, V327, P376, DOI 10.1002/cne.903270306; MA PM, 1991, J COMP NEUROL, V309, P161, DOI 10.1002/cne.903090202; MA PM, 1984, BRAIN RES, V306, P374, DOI 10.1016/0006-8993(84)90390-1; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Schlaggar B L, 1993, Perspect Dev Neurobiol, V1, P81; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; STAINIER DYR, 1990, P NATL ACAD SCI USA, V87, P923, DOI 10.1073/pnas.87.3.923; VANDERLOOS H, 1985, DEV ORG PROCESSING S, P53; VONGDOKMAI R, 1980, J COMP NEUROL, V191, P283, DOI 10.1002/cne.901910209; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; Woolsey T.A., 1990, P461; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	52	391	395	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					427	437		10.1016/0092-8674(94)90108-2	http://dx.doi.org/10.1016/0092-8674(94)90108-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313466				2022-12-28	WOS:A1994MX20700005
J	THOMAS, S; ACTON, C; NIXON, J; BATTISTUTTA, D; PITT, WR; CLARK, R				THOMAS, S; ACTON, C; NIXON, J; BATTISTUTTA, D; PITT, WR; CLARK, R			EFFECTIVENESS OF BICYCLE HELMETS IN PREVENTING HEAD-INJURY IN CHILDREN - CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the risk of injury to the head and the effect of wearing helmets in bicycle accidents among children. Design-Case-control study by questionnaire completed by the children and their carers. Setting-Two large children's hospitals in Brisbane, Australia. Subjects-445 children presenting with bicycle related injuries during 15 April 1991 to 30 June 1992. The cases comprised 102 children who had sustained injury to the upper head including the skull, forehead and scalp or loss of consciousness. The controls were 278 cyclists presenting with injuries other than to the head or face. A further 65 children with injuries to the face were considered as an extra comparison group. Main outcome measures-Cause and type of injury, wearing of helmet. Results-Most children (230) were injured after losing control and falling from their bicycle. Only 31 had contact with another moving vehicle. Children with head injury were significantly more likely to have made contact with a moving vehicle than control children (19 (19%) v 12 (4%), P<0.001). Head injuries were more likely to occur on paved surfaces than on grass, gravel, or dirt. Wearing a helmet reduced the risk of head injury by 63% (95% confidence interval 34% to 80%) and of loss of consciousness by 86% (62% to 95%). Conclusions-The risk of head injury in bicycle accidents is reduced among children wearing a helmet. Current helmet design maximises protection in the type of accident most commonly occurring in this study. Legislation enforcing helmet use among children should be considered.	QUEENSLAND RADIUM INST,HERSTON,QLD 4029,AUSTRALIA; QUEENSLAND INST MED RES,EPIDEMIOL UNIT,HERSTON,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT CHILD HLTH,HERSTON,QLD 4029,AUSTRALIA; MATER CHILDRENS HOSP,BRISBANE,QLD 4101,AUSTRALIA; ROYAL CHILDRENS HOSP,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Queensland; Royal Children's Hospital Brisbane								DIX W, 1992, 6 MONTHS REV COMPULS; NIXON J, 1987, BRIT MED J, V294, P1267, DOI 10.1136/bmj.294.6582.1267; PITT WR, 1994, BRIT MED J, V308, P177, DOI 10.1136/bmj.308.6922.177; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; Schlesselman JJ, 1982, CASE CONTROL STUDIES; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; TRIPPE HR, 1992, BRIT MED J, V305, P843, DOI 10.1136/bmj.305.6858.843; 1989, 24810 AUSTR BUR STAT, P28; 1986, 206311986 STAND AS 1; 1989, BRIT STANDARDS SPECI	10	130	132	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					173	176		10.1136/bmj.308.6922.173	http://dx.doi.org/10.1136/bmj.308.6922.173			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312768	Green Published			2022-12-28	WOS:A1994MR97400019
J	ONEIL, AC; PETERSEN, LA; COOK, EF; BATES, DW; LEE, TH; BRENNAN, TA				ONEIL, AC; PETERSEN, LA; COOK, EF; BATES, DW; LEE, TH; BRENNAN, TA			PHYSICIAN REPORTING COMPARED WITH MEDICAL-RECORD REVIEW TO IDENTIFY ADVERSE MEDICAL EVENTS	ANNALS OF INTERNAL MEDICINE			English	Article						QUALITY OF HEALTH CARE; MEDICAL RECORDS; QUALITY ASSURANCE, HEALTH CARE; ADVERSE EVENT REPORTING; PHYSICIANS ROLE	HOSPITALIZED-PATIENTS; HEALTH-CARE; QUALITY; RELIABILITY; JUDGMENTS; RATES; MIX	Objective: To assess the effectiveness of housestaff physician reporting as a method for identifying adverse events on a medical service and to compare the physician reporting mechanism with a retrospective record review mechanism. Setting: Medical service of an urban, university-affiliated teaching hospital. Design: Concurrent physician reporting mechanism using the hospital electronic mail system compared with a retrospective record review using a screening mechanism followed by structured, implicit physician review of the record. Patients: All 3146 admissions to the medical service from 13 November 1990 to 14 March 1991. Results: The housestaff physician reporting method identified nearly the same number (89) of adverse events as did the record review (85). However, the two methods identified only 41 of the same patients (kappa = 0.52). No statistically significant clinical or socioeconomic differences occurred between the patients identified as having had an adverse event, using the two reporting methods (physician versus record review). The housestaff did report statistically more preventable adverse events (62.5% compared with 32%; P = 0.003). The physician reporting mechanism was also less costly (approximately $15 000 compared with $54 000). Conclusion: An adverse event identification strategy based on physician self-referral uncovers as many adverse events as does a record review and is less costly. In addition, physician-identified events are more likely to be preventable and, thus, are targets for quality improvement.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, 667 HUNTINGTON AVE, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV GEN MED, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital			Bates, David/AAE-7283-2019					BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GROVE WM, 1981, ARCH GEN PSYCHIAT, V38, P408; Imai M, 1988, KAIZEN KEY JAPANS CO; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; NELSON EC, 1990, MED CARE, V28, pS18, DOI 10.1097/00005650-199009001-00006; REYNARD WD, 1992, CALLBACK         SPR, P4; REYNARD WD, 1992, CALLBACK         SPR, P1; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; Weiler PC, 1993, MEASURE MALPRACTICE; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; [No title captured]; 1990, PATIENTS DOCTORS LAW	20	240	244	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					370	376		10.7326/0003-4819-119-5-199309010-00004	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338290				2022-12-28	WOS:A1993LZ47600004
J	KRONTIRIS, TG; DEVLIN, B; KARP, DD; ROBERT, NJ; RISCH, N				KRONTIRIS, TG; DEVLIN, B; KARP, DD; ROBERT, NJ; RISCH, N			AN ASSOCIATION BETWEEN THE RISK OF CANCER AND MUTATIONS IN THE HRAS1 MINISATELLITE LOCUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FRAGMENT LENGTH POLYMORPHISMS; C-HA-RAS-1 PROTO-ONCOGENE; FAMILIAL BREAST-CANCER; HA-RAS ALLELES; LUNG-CANCER; MALIGNANT-MELANOMA; COLORECTAL-CANCER; HA-RAS-1 ALLELES; RARE ALLELES; GENE	Background. The role of mutations in protooncogenes and their regulatory sequences in the pathogenesis of cancer is under close scrutiny. Minisatellites are unstable repetitive sequences of DNA that are present throughout the human genome. The highly polymorphic HRAS1 minisatellite locus just downstream from the protooncogene H-ras-1 consists of four common progenitor alleles and several dozen rare alleles, which apparently derive from mutations of the progenitors. We previously observed an association of the rare mutant alleles with many forms of cancer, and we undertook the present study to pursue this observation further. Methods. We conducted a case-control study, typing 736 HRAS1 alleles from patients with cancer and 652 from controls by Southern blotting of leukocyte DNA. We also carried out a meta-analysis of this study and 22 other published studies, estimating the relative risk of cancer (such as bladder, breast, or colorectal cancer) when one of the rare HRAS1 alleles was present. Results. Both the present case-control study (odds ratio, 1.83; 95 percent confidence interval, 1.28 to 2.67; P = 0.002) and the present study combined with our previous study (odds ratio, 2.07; 95 percent confidence interval, 1.47 to 2.92; P<0.001), as well as the meta-analysis of all 23 studies (odds ratio, 1.93; 95 percent confidence interval, 1.63 to 2.30; chi-square = 57.58; P<0.001), replicated our original finding and demonstrated a significant association of rare HRAS1 alleles with cancer. We found significant associations for four types of cancer: carcinomas of the breast, colorectum, and urinary bladder and acute leukemia. We also identified suggestive but not statistically significant associations for cancers of the lung and prostate and for non-Hodgkin's lymphoma. Conclusions. Mutant alleles of the HRAS1 minisatellite locus represent a major risk factor for common types of cancer. Although the relative risk associated with the presence of one rare allele is moderate, the aggregate prevalence of this class of mutant alleles implies an extremely important attributable risk: 1 in 11 cancers of the breast, colorectum, and bladder.	TUFTS UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02111; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Tufts University; Yale University; Yale University	KRONTIRIS, TG (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,BOX 245,750 WASHINGTON ST,BOSTON,MA 02111, USA.				NCI NIH HHS [CA-45052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARKARDOTTIR RB, 1989, INT J CANCER, V44, P251, DOI 10.1002/ijc.2910440211; BOEHM TLJ, 1987, EUR J CANCER CLIN ON, V23, P623, DOI 10.1016/0277-5379(87)90257-4; BRESLOW N, 1981, BIOMETRIKA, V68, P73, DOI 10.1093/biomet/68.1.73; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CARTER G, 1988, LEUKEMIA RES, V12, P385, DOI 10.1016/0145-2126(88)90057-4; CECCHERININELLI L, 1987, BRIT J CANCER, V56, P1, DOI 10.1038/bjc.1987.143; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CORELL B, 1988, HUM GENET, V79, P255, DOI 10.1007/BF00366247; Dear K.B.G., 1992, STAT SCI, V7, P237, DOI DOI 10.1214/SS/1177011363; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIEDRICH U, 1988, NEUROLOGY, V38, P587, DOI 10.1212/WNL.38.4.587; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DOVER GA, 1989, NATURE, V342, P347, DOI 10.1038/342347a0; GERHARD DS, 1987, NATURE, V325, P73, DOI 10.1038/325073a0; GREEN M, 1993, GENOMICS, V17, P429, DOI 10.1006/geno.1993.1343; HALL JM, 1990, GENOMICS, V6, P188, DOI 10.1016/0888-7543(90)90466-8; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HAUGEN A, 1989, MOL CARCINOGEN, V2, P68, DOI 10.1002/mc.2940020204; HAYWARD NK, 1988, HUM GENET, V78, P115, DOI 10.1007/BF00278178; HEIGHWAY J, 1986, BRIT J CANCER, V53, P453, DOI 10.1038/bjc.1986.72; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KASPERCZYK A, 1989, AM J HUM GENET, V45, P689; KASPERCZYK A, 1990, AM J HUM GENET, V47, P854; KLINGEL R, 1991, GUT, V32, P1508, DOI 10.1136/gut.32.12.1508; KRONTIRIS TG, 1986, J CELL BIOCHEM, V30, P319, DOI 10.1002/jcb.240300405; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; KRONTIRIS TG, 1990, DETECTION CANC PREDI, P129; LIDEREAU R, 1986, JNCI-J NATL CANCER I, V77, P697, DOI 10.1093/jnci/77.3.697; Light R.J., 1984, SUMMING SCI REV RES; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; MANTEL N, 1959, J NATL CANCER I, V22, P719; PETO TEA, 1988, AM J HUM GENET, V42, P615; RADICE P, 1987, ONCOGENE, V2, P91; RAFFEL LJ, 1991, DIABETOLOGIA, V34, P680, DOI 10.1007/BF00400999; RIOU G, 1988, ONCOGENE, V3, P329; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; RYBERG D, 1990, HUM GENET, V86, P40; SAGLIO G, 1988, BREAST CANCER RES TR, V11, P147, DOI 10.1007/BF01805838; SHENG ZM, 1988, ONCOGENE RES, V2, P245; TAKEDA J, 1989, FEBS LETT, V247, P41, DOI 10.1016/0014-5793(89)81236-0; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TREPICCHIO WL, 1993, NUCLEIC ACIDS RES, V21, P977, DOI 10.1093/nar/21.4.977; WESTON A, 1991, MOL CARCINOGEN, V4, P265, DOI 10.1002/mc.2940040404; WHITE GRM, 1990, BRIT J CANCER, V61, P186, DOI 10.1038/bjc.1990.33; WYLLIE FS, 1988, BRIT J CANCER, V57, P135, DOI 10.1038/bjc.1988.28	50	302	308	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					517	523		10.1056/NEJM199308193290801	http://dx.doi.org/10.1056/NEJM199308193290801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8336750	Bronze			2022-12-28	WOS:A1993LR89200001
J	VELAZQUEZ, H; PERAZELLA, MA; WRIGHT, FS; ELLISON, DH				VELAZQUEZ, H; PERAZELLA, MA; WRIGHT, FS; ELLISON, DH			RENAL MECHANISM OF TRIMETHOPRIM-INDUCED HYPERKALEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERKALEMIA; TRIMETHOPRIM; SODIUM CHANNELS; POTASSIUM; KIDNEY TUBULES, DISTAL	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; POTASSIUM SECRETION; LUMINAL INFLUENCES; SULFAMETHOXAZOLE; THERAPY; VIRUS; MANIFESTATIONS; INFECTION; PNEUMONIA; CHLORIDE	Objectives: 1) To determine the incidence and severity of hyperkalemia during trimethoprim therapy. 2) To test the hypothesis that trimethoprim inhibits renal potassium excretion by blocking sodium channels in the mammalian distal nephron. Patients: Thirty consecutive patients who were treated with trimethoprim-containing drugs. All patients included in the study had the acquired immunodeficiency syndrome (AIDS). Experimental animals: Thirty-nine male Sprague-Dawley rats receiving normal rat chow and tap water (allowed free access). Intervention: Humans: high dose (20 mg/kg per day) of trimethoprim therapy. Rats: trimethoprim (9.6 mg/h, per kg body weight) was infused intravenously or into the renal distal tubules (1 mmol/L). Measurements: Humans: Serum and urine electrolyte levels, serum creatinine, renin, aldosterone, and cortisol levels were measured, and the transtubular potassium gradient was calculated. Rats: The effects of trimethoprim infusion on urinary sodium, chloride, and potassium concentration and urine volume were measured. Sodium, chloride, potassium, and inulin concentrations were measured in fluid samples obtained from kidney distal tubules. The voltage across the wall of the distal tubule was measured. Results: Humans: Trimethoprim increased the serum potassium concentration by 0.6 mmol/L (95% CI, 0.29 to 0.95 mmol/L) despite normal adrenocortical function and glomerular filtration rate. Serum potassium levels greater than 5 mmol/L were observed during trimethoprim treatment in 15 of 30 patients. Rats: Intravenous trimethoprim inhibited renal potassium excretion by 40% (CI, 21% to 60%) and increased renal sodium excretion by 46% (CI, 9% to 83%). Trimethoprim (1 mmol/L) in tubule fluid inhibited distal tubule potassium secretion by 59% (CI, 26% to 92%) and depolarized the lumen-negative transepithelial voltage by 66% (CI, 46% to 85%). Conclusions: Trimethoprim (an organic cation) acts like amiloride and blocks apical membrane sodium channels in the mammalian distal nephron. As a consequence, the transepithelial voltage is reduced and potassium secretion is inhibited. Decreased renal potassium excretion secondary to these direct effects on kidney tubules leads to hyperkalemia in a substantial number of patients being treated with trimethoprim-containing drugs.	DEPT VET AFFAIRS MED CTR, W HAVEN, CT 06516 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	VELAZQUEZ, H (corresponding author), YALE UNIV, SCH MED, DEPT MED NEPHROL, 333 CEDAR ST, 2073 LMP, NEW HAVEN, CT 06510 USA.		, David/X-5730-2019	Ellison, David/0000-0003-2915-265X				BERNS JS, 1991, J AM SOC NEPHROL, V1, P1061; CHOI M J, 1992, Journal of the American Society of Nephrology, V3, P325; ELANSARY EH, 1983, BRIT MED J, V286, P1861, DOI 10.1136/bmj.286.6381.1861-a; ELLISON DH, 1985, AM J PHYSIOL, V248, pF638, DOI 10.1152/ajprenal.1985.248.5.F638; FONSECA PD, 1991, EUR J PHARM-MOLEC PH, V207, P337, DOI 10.1016/0922-4106(91)90008-6; GOOD DW, 1979, AM J PHYSIOL, V236, pF192, DOI 10.1152/ajprenal.1979.236.2.F192; GOOD DW, 1980, AM J PHYSIOL, V239, pF289, DOI 10.1152/ajprenal.1980.239.3.F289; GREENBERG S, 1992, Journal of the American Society of Nephrology, V3, P327; GRINSPOON SK, 1992, NEW ENGL J MED, V327, P1360, DOI 10.1056/NEJM199211053271906; KALIN MF, 1987, AM J MED, V82, P1035, DOI 10.1016/0002-9343(87)90171-9; KAUFMAN AM, 1983, MT SINAI J MED, V50, P238; LACHAAL M, 1989, AM J MED, V87, P260, DOI 10.1016/S0002-9343(89)80147-0; LEE BL, 1989, ANN INTERN MED, V110, P606, DOI 10.7326/0003-4819-110-8-606; LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903; MARKS JB, 1991, AM J MED SCI, V302, P110, DOI 10.1097/00000441-199108000-00009; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MERENICH JA, 1990, J CLIN ENDOCR METAB, V70, P566, DOI 10.1210/jcem-70-3-566; OKUSA MD, 1991, AM J PHYSIOL, V260, pF459, DOI 10.1152/ajprenal.1991.260.3.F459; PORETSKY L, 1990, MT SINAI J MED, V57, P236; STRAUSS KW, 1991, ARCH INTERN MED, V151, P1441, DOI 10.1001/archinte.151.7.1441; VELAZQUEZ H, 1982, AM J PHYSIOL, V242, pF46, DOI 10.1152/ajprenal.1982.242.1.F46; VELAZQUEZ H, 1986, AM J PHYSIOL, V250, P1013, DOI 10.1152/ajprenal.1986.250.6.F1013; WEST ML, 1986, MINER ELECTROL METAB, V12, P234; ZETTLE RM, 1987, AM J NEPHROL, V7, P360, DOI 10.1159/000167502; 1992, PHYSICIANS DESK REFE	25	136	140	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					296	301		10.7326/0003-4819-119-4-199308150-00008	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328738				2022-12-28	WOS:A1993LV52500008
J	FIELDING, JE; LANCRY, PJ				FIELDING, JE; LANCRY, PJ			LESSONS FROM FRANCE - VIVE-LA-DIFFERENCE - THE FRENCH HEALTH-CARE SYSTEM AND UNITED-STATES HEALTH SYSTEM REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA USA; UNIV PARIS 12, F-94010 CRETEIL, FRANCE; CTR RECH ETUD & DOCUMENTAT ECON SANTE, PARIS, FRANCE	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	FIELDING, JE (corresponding author), UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT HLTH SERV, 31-236 CHS, 10833 LE CONTE AVE, LOS ANGELES, CA 90024 USA.							BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; BOCOGNANO A, 1992, CREDES; BOCOGNANO A, 1992, CREDES, V934; BROWN ML, 1990, ANN INTERN MED, V113, P547, DOI 10.7326/0003-4819-113-7-547; DEVEVEY J, 1985, CNAMTS18 BLOC NOT; DEVEY J, 1989, CNAMTS45 BLOC NOT; GODT PJ, 1985, PUBLIC ADMIN, V63, P151, DOI 10.1111/j.1467-9299.1985.tb00897.x; JULLIEN D, 1992, LAMY SOCIAL DROIT TR; LAMIOT D, 1989, PROTECTION SOCIALE E; LANCRY PJ, 1990, REV EC POL, V99, P854; LANCRY PJ, 1989, EVALUATION EC DEPIST, P61; LOTH A, 1991, LETT INF HOSP LETT S, V7, P1; MEYER C, 1989, INVESTIR GESTION SYS, P220; MOREAUX C, 1992, PHARMACEUTIQUES, V1, P149; Poullier J P, 1992, Health Care Financ Rev, V13, P167; Rodwin V G, 1981, Inquiry, V18, P139; RODWIN VG, 1981, MILBANK Q, V59, P17; SANDIER S, 1992, CREDES, V938; Schieber G J, 1992, Health Care Financ Rev, V13, P1; VELL S, 1993, JUN PRESS C MIN SOC; WILSFORD D, 1987, J HEALTH POLIT POLIC, V12, P481, DOI 10.1215/03616878-12-3-481; 1992, EMPLOYER COSTS EMPLO; 1989, HOSPITAL STATISTICS; 1993, CNAMTS, V64; 1993, LIAISONS SOCIALES; 1993, TEXTE OFFICIEL CONSE; 1991, INDICATEUR STATISTIQ; 1992, IMPACT MED      1015; 1992, 1992 NABP SURVEY PHA; 1992, HOSPITAL STATISTICS; 1992, CNAMTS QUELQUES CHIF; 1991, HLTH AFF, V10, P4; 1992, ENQUETE HOSPITALISAT; 1987, 5333 MIN SOC AFF CIR	34	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1993	270	6					748	756		10.1001/jama.270.6.748	http://dx.doi.org/10.1001/jama.270.6.748			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ338	8336379				2022-12-28	WOS:A1993LQ33800032
J	SORKIN, A; CARPENTER, G				SORKIN, A; CARPENTER, G			INTERACTION OF ACTIVATED EGF RECEPTORS WITH COATED PIT ADAPTINS	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; HUMAN-FIBROBLASTS; DOWN-REGULATION; CLATHRIN; INTERNALIZATION; PROTEINS; BINDING	The epidermal growth factor (EGF) receptor interacts with plasma membrane-associated adapter proteins during endocytosis through coated pits. Almost 50 percent of the total pool of alpha-adaptins was coimmunoprecipitated with the EGF receptor when A-431 cells were treated with EGF at 37-degrees-C, but not at 4-degrees-C. Partial proteolysis of alpha-adaptin suggested that the amino-terminal domain is the region that associates with the EGF receptor. The extent of receptor-adaptin association was increased in cells depleted of potassium to block endocytosis. These data suggest that receptor-adaptin association occurs in intact cells before coated pits are fully assembled.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University	SORKIN, A (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA.			Sorkin, Alexander/0000-0002-4446-1920	NCI NIH HHS [CA24071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; KAMATA N, 1986, CANCER RES, V46, P1648; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, UNPUB; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1991, J BIOL CHEM, V266, P11083; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	31	238	243	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1993	261	5121					612	615		10.1126/science.8342026	http://dx.doi.org/10.1126/science.8342026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342026				2022-12-28	WOS:A1993LP72800040
J	WARNE, PH; VICIANA, PR; DOWNWARD, J				WARNE, PH; VICIANA, PR; DOWNWARD, J			DIRECT INTERACTION OF RAS AND THE AMINO-TERMINAL REGION OF RAF-1 IN-VITRO	NATURE			English	Article							PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; BINDING; DOMAIN; GAP; EXPRESSION; ACTIVATION; MUTATIONS; GROWTH; CELLS	THE Ras proteins are key regulators of the growth of eukaryotic cells, but their direct target enzymes, or 'effectors', are unknown1. The protein encoded by the c-raf-1 proto-oncogene is thought to function downstream of p21ras because disruption of Raf blocks signalling by Ras in a number of systems2-5. Here we report that the amino-terminal cysteine-rich regulatory region of p74c-raf-1 expressed as a glutathione-S-transferase (GST) fusion protein binds directly to Ras with relatively high affinity (50 nM). The binding is strictly dependent on the Ras protein being in the active GTP-bound conformation rather than the inactive GDP-bound state. Raf-GST interacts with wild-type and oncogenic Ras (Val 12) but fails to interact with a biologically inert effector mutant of Ras (Ala 38) and a dominant negative mutant (Asn 17). A peptide based on the effector region of Ras inhibits the interaction. Raf-GST acts as a potent competitive inhibitor of the GTPase-activating proteins p120GAP and neurofibromin. In addition, Raf itself displays weak GTPase-stimulating activity towards Ras. It is therefore likely that Raf is a direct effector of Ras.	IMPERIAL CANC RES FUND,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BOURNE HR, 1992, NATURE, V358, P541, DOI 10.1038/358541a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313	18	668	682	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					352	355		10.1038/364352a0	http://dx.doi.org/10.1038/364352a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332195				2022-12-28	WOS:A1993LN57000062
J	HAMMER, J; VALSASNINI, P; TOLBA, K; BOLIN, D; HIGELIN, J; TAKACS, B; SINIGAGLIA, F				HAMMER, J; VALSASNINI, P; TOLBA, K; BOLIN, D; HIGELIN, J; TAKACS, B; SINIGAGLIA, F			PROMISCUOUS AND ALLELE-SPECIFIC ANCHORS IN HLA-DR-BINDING PEPTIDES	CELL			English	Article							MHC CLASS-II; T-CELL EPITOPES; MOLECULES; HLA-DR1; IDENTIFICATION; RECOGNITION; LIBRARIES; LIGANDS; COMPLEX; HLA-B27	The major histocompatibility complex (MHC) class II molecules are highly polymorphic membrane glycoproteins that bind peptide fragments of proteins and display them for recognition by CD4+ T cells. To understand the effect of human MHC class II polymorphism on peptide-MHC interaction, we have isolated M13 phage from a large M13 peptide display library by selection with DRB1*0401 and DRB1*1101 molecules, as recently described for DRB1*0101. Sequence analysis of the peptide-encoding region of DR-bound phage led to the identification of position-specific anchor residues, defining motifs for peptide binding to DR molecules. The three DR motifs share two anchor residues at relative positions 1 and 4, while allele-specific anchor residues have been identified at position 6. These results provide a biophysical basis for both the promiscuity and the specificity of peptide recognition by DR molecules.	F HOFFMANN LA ROCHE & CO LTD, DEPT PHARMACEUT RES NEW TECHNOL, CH-4002 BASEL, SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD, DEPT INFLAMMAT & AUTOIMMUNE DIS, CH-4002 BASEL, SWITZERLAND	Roche Holding; Roche Holding	HAMMER, J (corresponding author), ROCHE MILANO RIC, VIA OLGETTINA 58, I-20132 MILAN, ITALY.							BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KOURILSKY P, 1989, CELL, V56, P327, DOI 10.1016/0092-8674(89)90233-X; KROPSHOFER H, 1992, J EXP MED, V175, P1799, DOI 10.1084/jem.175.6.1799; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MOLLER G, 1987, IMMUNOL REV, V98; ONG B, 1991, P NATL ACAD SCI USA, V88, P7343, DOI 10.1073/pnas.88.16.7343; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHEIRLE A, 1992, J IMMUNOL, V149, P1994; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; SINIGAGLIA F, 1991, METHOD ENZYMOL, V203, P370; VANBLEEK GM, 1990, NATURE, V348, P213	28	375	415	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					197	203		10.1016/0092-8674(93)90306-B	http://dx.doi.org/10.1016/0092-8674(93)90306-B			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334703				2022-12-28	WOS:A1993LN62500019
J	KISHIHARA, K; PENNINGER, J; WALLACE, VA; KUNDIG, TM; KAWAI, K; WAKEHAM, A; TIMMS, E; PFEFFER, K; OHASHI, PS; THOMAS, ML; FURLONGER, C; PAIGE, CJ; MAK, TW				KISHIHARA, K; PENNINGER, J; WALLACE, VA; KUNDIG, TM; KAWAI, K; WAKEHAM, A; TIMMS, E; PFEFFER, K; OHASHI, PS; THOMAS, ML; FURLONGER, C; PAIGE, CJ; MAK, TW			NORMAL B-LYMPHOCYTE DEVELOPMENT BUT IMPAIRED T-CELL MATURATION IN CD45-EXON6 PROTEIN-TYROSINE-PHOSPHATASE DEFICIENT MICE	CELL			English	Article							LEUKOCYTE-COMMON ANTIGEN; PRE-MESSENGER-RNA; SIGNAL TRANSDUCTION; SELECTIVE EXPRESSION; SURFACE-ANTIGENS; BONE-MARROW; KINASE-C; RECEPTOR; CD45; ACTIVATION	The transmembrane tyrosine phosphatase CD45 is expressed in multiple isoforms on all nucleated hematopoietic cells, resulting from alternative splicing of variable exons. We generated mice with a mutation in the variable CD45 exon 6, using homologous recombination. In mice homozygous for the CD45-exon6 mutation, B cells and most T cells did not express CD45. Development of B cells appeared normal, although Igmu-induced proliferation was completely abrogated. Thymocyte maturation was blocked at the transitional stage from immature CD4+CD8+ to mature CD4+ or CD8+ cells, and only a few T cells could be detected in peripheral lymphoid organs. Clonal deletion of superantigen-reactive T cells still occurred. Cytotoxic T cell responses to lymphocytic choriomeningitis virus were absent in CD45-exon6-/- mice. These data imply that CD45 is differentially required for the development and function of B and T lymphocytes.	UNIV TORONTO, AMGEN INST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS & IMMUNOL, TORONTO M4X 1K9, ONTARIO, CANADA; WELLESLEY COLL HOSP, RES INST, TORONTO M4Y 1J3, ONTARIO, CANADA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Howard Hughes Medical Institute; Washington University (WUSTL)			Penninger, Josef M/I-6860-2013; Kawai, Kazuhiro/D-4998-2011	Penninger, Josef M/0000-0002-8194-3777; Kawai, Kazuhiro/0000-0001-9375-0713; Pfeffer, Klaus/0000-0002-5652-6330; Ohashi, Pamela S./0000-0003-2915-9317				ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; AKBAR AN, 1988, J IMMUNOL, V140, P2171; ALESMARTINEZ JE, 1991, IMMUNOL TODAY, V12, P201, DOI 10.1016/0167-5699(91)90054-W; ALEXANDER D, 1992, IMMUNOL TODAY, V13, P477, DOI 10.1016/0167-5699(92)90021-X; ALSINET E, 1990, EUR J IMMUNOL, V20, P2801, DOI 10.1002/eji.1830201240; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BROXMEYER HE, 1991, J EXP MED, V174, P447, DOI 10.1084/jem.174.2.447; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CERROTINI JC, 1974, ADV IMMUNOL, V18, P67; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; COLLINS LS, 1987, J IMMUNOL, V138, P1082; CUMANO A, 1990, EUR J IMMUNOL, V20, P2183, DOI 10.1002/eji.1830201006; CUMANO A, 1992, EMBO J, V11, P593, DOI 10.1002/j.1460-2075.1992.tb05091.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HATHCOCK KS, 1992, J IMMUNOL, V148, P19; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HORGAN KJ, 1990, EUR J IMMUNOL, V20, P1111, DOI 10.1002/eji.1830200525; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; JONG R, 1991, J IMMUNOL, V146, P2088; JULIUS MH, 1984, EUR J IMMUNOL, V14, P753, DOI 10.1002/eji.1830140816; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KINCADE PW, 1981, J IMMUNOL, V127, P2262; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LANSDORP PM, 1990, J EXP MED, V172, P363, DOI 10.1084/jem.172.1.363; LEFRANCOIS L, 1987, J IMMUNOL, V139, P3718; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; LEIST TP, 1987, J IMMUNOL, V138, P2278; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LUQMAN M, 1992, J IMMUNOL, V149, P2300; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MITTLER RS, 1987, J IMMUNOL, V138, P3159; MIZUGUCHI J, 1986, J IMMUNOL, V21, P2373; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, ONCOGENE, V5, P809; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PENNINGER J, 1993, SCIENCE, V260, P358, DOI 10.1126/science.8469988; PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAGA Y, 1990, P NATL ACAD SCI USA, V87, P3728, DOI 10.1073/pnas.87.10.3728; SAUTER H, 1987, P NATL ACAD SCI USA, V84, P4989, DOI 10.1073/pnas.84.14.4989; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TSAI AYM, 1989, MOL CELL BIOL, V9, P4550, DOI 10.1128/MCB.9.10.4550; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WALLACE VA, 1992, J EXP MED, V176, P1657, DOI 10.1084/jem.176.6.1657; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WELLS FB, 1993, J EXP MED, V177, P1061, DOI 10.1084/jem.177.4.1061	83	464	475	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					143	156		10.1016/0092-8674(93)90302-7	http://dx.doi.org/10.1016/0092-8674(93)90302-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334701				2022-12-28	WOS:A1993LN62500015
J	REBA, RC				REBA, RC			NUCLEAR-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MONOCLONAL-ANTIBODY; CARCINOMA; ANTIGEN				REBA, RC (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637, USA.							ABDELNABI H, 1993, SEMIN NUCL MED, V23, P99, DOI 10.1016/S0001-2998(05)80091-1; CARP JS, 1990, J NUCL MED, V31, P617; COLLIER BD, 1992, RADIOLOGY, V185, P179, DOI 10.1148/radiology.185.1.1523304; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; FREEMAN LM, 1992, SEMIN NUCL MED, P1; GOLDENBERG DM, 1992, J NUCL MED, V33, P803; GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; GOLDENBERG DM, 1990, CANCER RES, V50, pF909; HASEMAN MK, 1992, J NUCL MED, V33, P1750; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; LIND P, 1991, J NUCL MED, V32, P1319; MAZZIOTTA JC, 1985, ANN NY ACAD SCI, V444, P269, DOI 10.1111/j.1749-6632.1985.tb37596.x; REBA RC, 1992, P WORKSHOP MOL NUCLE; ROBINSON RG, 1990, J NUCL MED, V31, P1326; SERAFINI AN, 1993, SEMIN NUCL MED, V23, P87; STRAUSS HW, 1993, J NUCL MED, V34, P531	17	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					230	232		10.1001/jama.270.2.230	http://dx.doi.org/10.1001/jama.270.2.230			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315743				2022-12-28	WOS:A1993LL36800029
J	TORGERSON, DJ; GARTON, MJ; DONALDSON, C; RUSSELL, IT; REID, DM				TORGERSON, DJ; GARTON, MJ; DONALDSON, C; RUSSELL, IT; REID, DM			RECRUITMENT METHODS FOR SCREENING PROGRAMS - TRIAL OF AN IMPROVED METHOD WITHIN A REGIONAL OSTEOPOROSIS STUDY	BRITISH MEDICAL JOURNAL			English	Article									CITY HOSP,DEPT RHEUMATOL,ABERDEEN AB9 8AU,SCOTLAND; UNIV ABERDEEN,HLTH SERV RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen	TORGERSON, DJ (corresponding author), UNIV ABERDEEN,HLTH ECON RES UNIT,POLWARTH BLDG,ABERDEEN AB9 2ZD,SCOTLAND.		Torgerson, David/L-4566-2019; Russell, Ian T/H-1181-2012	Torgerson, David/0000-0002-1667-4275; Donaldson, Cam/0000-0003-4670-5340				ANDREWS R, 1989, ARCH DIS CHILD, V65, P192; GARTON MJ, 1992, BMJ-BRIT MED J, V305, P82, DOI 10.1136/bmj.305.6845.82; MCEWEN J, 1989, BRIT MED J, V299, P104, DOI 10.1136/bmj.299.6691.104; MCGLADE KJ, 1988, BRIT MED J, V297, P1246, DOI 10.1136/bmj.297.6658.1246; 1990, CONSOLIDATED GUIDANC, P7	5	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					99	99		10.1136/bmj.307.6896.99	http://dx.doi.org/10.1136/bmj.307.6896.99			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343737	Bronze, Green Published			2022-12-28	WOS:A1993LM58500024
J	BEUTLER, M; HARTMANN, K; KUHN, M; GARTMANN, J				BEUTLER, M; HARTMANN, K; KUHN, M; GARTMANN, J			TASTE DISORDERS AND TERBINAFINE	BRITISH MEDICAL JOURNAL			English	Letter											BEUTLER, M (corresponding author), SWISS DRUG MONITORING CTR,CHUR,SWITZERLAND.							ABUHAMDAUR DK, 1988, AM J HYPERTENS, V1, P303; BALFOUR JA, 1992, DRUGS, V43, P259, DOI 10.2165/00003495-199243020-00010; JAFFE IA, 1986, AM J MED, V80, P471, DOI 10.1016/0002-9343(86)90722-9; SCHIFFMAN SS, 1983, NEW ENGL J MED, V308, P1275	4	28	29	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					26	26		10.1136/bmj.307.6895.26-b	http://dx.doi.org/10.1136/bmj.307.6895.26-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343667	Green Published, Bronze			2022-12-28	WOS:A1993LL36900025
J	LOGIE, DE; WOODROFFE, J				LOGIE, DE; WOODROFFE, J			STRUCTURAL ADJUSTMENT - THE WRONG PRESCRIPTION FOR AFRICA	BRITISH MEDICAL JOURNAL			English	Article									HLTH CTR,EARLSTON,BERWICK,SCOTLAND; CHRISTIAN AID,LONDON SE1 7RT,ENGLAND									BRUMMER A, 1993, GUARDIAN        0514; CORNIA GA, 1992, AFRICAS RECOVERY 199, P19; GEORGE S, 1992, DEBT BOOMERANG, pR16; HULTMAN T, 1993, GUARDIAN        0524, P8; LOGIE D, 1993, LANCET, V341, P950; 1992, 1992 UN DEV PROGR HU, P39; 1989, AFRICAN ALTERNATIVE, P9; 1993, AFRICA MAKE BREAK; 1993, DEV REPORT; 1993, NEW INT          APR, P30; 1990, WORLD SUMMIT CHILDRE; 1991, ANAL SITUATION INFAN; 1992, STRUCTURAL ADJUSTMEN; 1993, STATE WORLDS CHILDRE	14	26	26	0	23	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					41	44		10.1136/bmj.307.6895.41	http://dx.doi.org/10.1136/bmj.307.6895.41			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343672	Bronze, Green Published			2022-12-28	WOS:A1993LL36900029
J	PETER, L				PETER, L			ABC OF ONE TO 7 - AUDIT IN PRIMARY-CARE PEDIATRICS	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					51	53		10.1136/bmj.307.6895.51	http://dx.doi.org/10.1136/bmj.307.6895.51			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343676	Green Published, Bronze			2022-12-28	WOS:A1993LL36900033
J	SKOLNIK, EY; BATZER, A; LI, N; LEE, CH; LOWENSTEIN, E; MOHAMMADI, M; MARGOLIS, B; SCHLESSINGER, J				SKOLNIK, EY; BATZER, A; LI, N; LEE, CH; LOWENSTEIN, E; MOHAMMADI, M; MARGOLIS, B; SCHLESSINGER, J			THE FUNCTION OF GRB2 IN LINKING THE INSULIN-RECEPTOR TO RAS SIGNALING PATHWAYS	SCIENCE			English	Article							MAP KINASE; PROTEIN; ACTIVATION	Insulin-induced activation of extracellular signal-regulated kinases [ERKs, also known as mitogen-activated protein (MAP) kinases] is mediated by Ras. Insulin activates Ras primarily by increasing the rate of guanine nucleotide-releasing activity. Here, we show that insulin-induced activation of ERKs was enhanced by stable overexpression of growth factor receptor-bound protein 2 (GRB2) but not by overexpression of GRB2 proteins with point mutations in the Src homology 2 and 3 domains. Moreover, a dominant negative form of Ras (with Ser17 substituted with Asn) blocked insulin-induced activation of ERKs in cells that overexpressed GRB2. GRB2 overexpression led to increased formation of a complex between the guanine nucleotide-releasing factor Sos (the product of the mammalian homolog of son of sevenless gene) and GRB2. In response to insulin stimulation, this complex bound to tyrosine-phosphorylated IRS-1 (insulin receptor substrate-1) and Shc. In contrast to the activated epidermal growth factor receptor that binds the GRB2-Sos complex directly, activation of the insulin receptor results in the interaction of GRB2-Sos with IRS-1 and Shc, thus linking the insulin receptor to Ras signaling pathways.			SKOLNIK, EY (corresponding author), NYU MED CTR, DEPT PHARMACOL, 550 1ST AVE, NEW YORK, NY 10016 USA.		Mohammadi, Moosa/ABA-6745-2020; Lee, Chi-Hon/G-9190-2012	Mohammadi, Moosa/0000-0003-2434-9437; Lee, Chi-Hon/0000-0002-6138-711X	NIDDK NIH HHS [DK01927] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001927] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BATTENSPERGER K, 1993, SCIENCE, V260, P1950; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOULTON TG, 1991, CELL REGUL, V2, P257; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, UNPUB; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	45	578	588	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1953	1955		10.1126/science.8316835	http://dx.doi.org/10.1126/science.8316835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8316835				2022-12-28	WOS:A1993LJ34900046
J	KORNER, RJ; REEVES, DS; MACGOWAN, AP				KORNER, RJ; REEVES, DS; MACGOWAN, AP			LESSON OF THE WEEK - DANGERS OF ORAL FLUOROQUINOLONE TREATMENT IN COMMUNITY-ACQUIRED UPPER RESPIRATORY-TRACT INFECTIONS	BRITISH MEDICAL JOURNAL			English	Article							CIPROFLOXACIN; PNEUMONIA		NATL HLTH SERV,SOUTHMEAD HLTH SERV,REG ANTIMICROBIAL REFERENCE LAB,BRISTOL BS10 5NB,ENGLAND	NHS Blood & Transplant (NHSBT)	KORNER, RJ (corresponding author), NATL HLTH SERV,SOUTHMEAD HLTH SERV,DEPT MED MICROBIOL,WESTBURY ON TRYM,BRISTOL BS10 5NB,ENGLAND.		MacGowan, Alasdair/AAM-1582-2020	MacGowan, Alasdair/0000-0002-6720-5268				BERGOGNEBEREZIN E, 1986, EUR J CLIN MICROBIOL, V5, P197, DOI 10.1007/BF02013986; FRIEDEN TR, 1990, JAMA-J AM MED ASSOC, V264, P1438, DOI 10.1001/jama.264.11.1438; GOSH K, 1992, J INFECTION, V25, P221; LEE BL, 1991, NEW ENGL J MED, V325, P520; MANDELL GL, 1990, PRINCIPLE PRACTICE I, P511; MANDELL GL, 1990, PRINCIPLE PRACTICE I, P1544; NIELSEN SV, 1992, CLIN INFECT DIS, V15, P794, DOI 10.1093/clind/15.5.794; PEREZTRALLERO E, 1990, EUR J CLIN MICROBIOL, V9, P905; PIDDOCK LJV, 1992, J ANTIMICROB CHEMOTH, V30, P190; SANBE B, 1984, CHEMOTHERAPY TOKY S1, V32, P1019; SUGITA R, 1984, CHEMOTHERAPY TOKY S1, V32, P1013; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; WALKER G, 1993, APBP DATA SHEET COMP, P141; WOODHEAD MA, 1987, LANCET, V1, P671; 1993, ABPI DATA SHEET COMP, P629	15	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					191	192						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312775				2022-12-28	WOS:A1994MR97400027
J	FRAME, PS; FRYBACK, DG; PATTERSON, C				FRAME, PS; FRYBACK, DG; PATTERSON, C			SCREENING FOR ABDOMINAL AORTIC-ANEURYSM IN MEN AGES 60 TO 80 YEARS - A COST-EFFECTIVENESS ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							PHYSICAL-EXAMINATION; VARIABLES; SURGERY; HEALTH	Purpose: To evaluate the cost-effectiveness of screening by physical examination or abdominal ultrasonography for abdominal aortic aneurysm (AAA) in men aged 60 to 80 years. Data Sources: A systematic review of the pertinent literature by the Canadian Task Force on the Periodic Health Examination, augmented by an additional computerized search (MEDLINE) and references identified from bibliographies of pertinent articles. Several experts reviewed the data for completeness. Study Selection: Published English-language studies that present data relevant to screening for abdominal aortic aneurysm. Data Extraction: Several reviewers determined a range of data and the most probable value for each parameter. Data Synthesis: A computer spreadsheet model was constructed to simulate the costs and effectiveness of various screening protocols in a cohort of 10 000 men during a period of 20 years. The primary cost-effectiveness measure computed was incremental present-value dollar expenditures for screening and treatment per incremental present-value life-year saved by the screening program. Using the ''most probable'' values for the simulation parameters, a single screening procedure of abdominal palpation followed by abdominal ultrasound scan for patients with positive screening results is estimated to gain 20 life-years at a cost of $28 741 per life-year. A single ultrasound screen gains 57 life-years at a cost of $41 550 per life-year. A repeated ultrasound screen after 5 years gains 1 additional life-year at a cost of $906 769. Conclusions: A single screen for AAA by abdominal palpation in men from age 60 to 80 years might be considered cost-effective but of small benefit. A single screen with ultrasonography is at the high end of the cost-per-life-year range that might be considered cost-effective and also is of modest benefit. Repeated screening is not cost-effective.	TRICOUNTY FAMILY MED PROGRAM, DANSVILLE, NY USA; UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY 14642 USA; UNIV WISCONSIN, SCH MED, MADISON, WI 53706 USA; MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	University of Rochester; University of Wisconsin System; University of Wisconsin Madison; McMaster University					AHRQ HHS [HSO6283] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006283] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALLEN PIM, 1987, LANCET, V2, P736; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BALLARD DF, 1992, RAND JRA04 PUBL; BENGTSSON H, 1989, WORLD J SURG, V13, P266, DOI 10.1007/BF01659032; BRECKWOLDT WL, 1991, J VASC SURG, V13, P798, DOI 10.1016/0741-5214(91)90044-U; Collin J, 1991, Eur J Vasc Surg, V5, P141, DOI 10.1016/S0950-821X(05)80678-4; COLLIN J, 1988, BRIT J HOSP MED, V40, P64; COLLIN J, 1988, LANCET, V2, P613; COOLEY DA, 1984, CIRCULATION, V70, P5; CRONENWETT JL, 1990, J VASC SURG, V11, P260, DOI 10.1067/mva.1990.16697; CRONENWETT JL, 1985, SURGERY, V98, P472; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; KATZ DA, 1992, JAMA-J AM MED ASSOC, V268, P2678, DOI 10.1001/jama.268.19.2678; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; LEDERLE FA, 1990, J CLIN EPIDEMIOL, V43, P101, DOI 10.1016/0895-4356(90)90062-T; LINDHOLM L, 1985, ACTA MED SCAND, V218, P305; NEVITT MP, 1989, NEW ENGL J MED, V321, P1009, DOI 10.1056/NEJM198910123211504; NUSBAUM JW, 1971, ARCH SURG-CHICAGO, V102, P385; OBOLER SK, 1989, ANN INTERN MED, V110, P214, DOI 10.7326/0003-4819-110-3-214; OKELLY TJ, 1989, BRIT J SURG, V76, P479, DOI 10.1002/bjs.1800760517; QUILL DS, 1989, SURG CLIN N AM, V69, P713; RUSSELL JGB, 1990, CLIN RADIOL, V41, P182, DOI 10.1016/S0009-9260(05)80964-X; SALERNO TA, 1981, CAN J SURG, V24, P71; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; 1991, CAN MED ASSOC J, V145, P783; 1974, PHS791101 US DHEW PU	27	72	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					411	416		10.7326/0003-4819-119-5-199309010-00010	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338295				2022-12-28	WOS:A1993LZ47600010
J	PELLEGRINO, ED				PELLEGRINO, ED			COMPASSION NEEDS REASON TOO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											PELLEGRINO, ED (corresponding author), GEORGETOWN UNIV,MED CTR,WASHINGTON,DC 20007, USA.							ARKES H, 1992, 1ST THINGS, V20, P46; BRODY H, 1993, J CLIN ETHIC, V4, P112; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; JONSEN AR, 1991, THEOR MED, V12, P295, DOI 10.1007/BF00489890; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; KASS LR, 1989, PUBLIC INTEREST, V94, P25; KEVORKIAN J, 1991, PRESCRIPTION MED GOO; Lynn J, 1988, J Palliat Care, V4, P100; Pellegrino E D, 1992, J Clin Ethics, V3, P95; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; UBEL PA, 1993, ISSUES LAW MED, V8, P487; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WESLEY P, 1993, J LAW MED, V8, P467; 1988, JAMA-J AM MED ASSOC, V259, P272; 1991, JAMA-J AM MED ASSOC, V267, P2229	16	38	38	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					874	875		10.1001/jama.270.7.874	http://dx.doi.org/10.1001/jama.270.7.874			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR612	8340989				2022-12-28	WOS:A1993LR61200036
J	SCHMIDTZACHMANN, MS; DARGEMONT, C; KUHN, LC; NIGG, EA				SCHMIDTZACHMANN, MS; DARGEMONT, C; KUHN, LC; NIGG, EA			NUCLEAR EXPORT OF PROTEINS - THE ROLE OF NUCLEAR RETENTION	CELL			English	Article							XENOPUS-LAEVIS OOCYTES; PORE COMPLEX; MESSENGER-RNA; NUCLEOCYTOPLASMIC TRANSPORT; MONOCLONAL-ANTIBODIES; LOCALIZATION SIGNAL; BINDING-PROTEIN; MITOTIC EVENTS; LAMIN PROTEINS; CAAX MOTIF	Proteins that shuttle between nucleus and cytoplasm are implicated in transport and signal transduction processes. Using assays based on interspecies heterokaryons and microinjection of Xenopus oocytes, we examined what structural features determine nuclear export of shuttling proteins. Three classes of proteins were studied: first, wild-type and mutant forms of nucleolin, one of the first shuttling proteins identified; second, artificial nuclear reporter proteins derived from cytoplasmic pyruvate kinase; and third, wild-type and mutant lamins differing in their abilities to be incorporated into the lamina. Our results show that a protein does not require positively acting export signals to be transported from nucleus to cytoplasm; instead, its shuttling ability is limited primarily by intranuclear interactions. We conclude that nucleocytoplasmic shuttling is a general phenomenon not restricted to proteins involved in nucleocytoplasmic transport.	SWISS INST EXPTL CANC RES,CELL PROLIFERAT UNIT,CH-1066 EPALINGES,SWITZERLAND; SWISS INST EXPTL CANC RES,GENET UNIT,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research; Swiss Institute Experimental Cancer Research				nigg, erich/0000-0003-4835-5719				AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P1148, DOI 10.1016/S0955-0674(89)80065-1; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DAVIS L I, 1992, Current Opinion in Cell Biology, V4, P424, DOI 10.1016/0955-0674(92)90007-Y; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GOLDFARB D S, 1991, Current Biology, V1, P212, DOI 10.1016/0960-9822(91)90059-6; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; GOLDSTEIN L, 1958, EXP CELL RES, V15, P635, DOI 10.1016/0014-4827(58)90118-6; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HEITLINGER E, 1992, J STRUCT BIOL, V108, P74, DOI 10.1016/1047-8477(92)90009-Y; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KHANNAGUPTA A, 1989, P NATL ACAD SCI USA, V86, P1791, DOI 10.1073/pnas.86.6.1791; KITTEN GT, 1991, J CELL BIOL, V113, P13, DOI 10.1083/jcb.113.1.13; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KROHNE G, 1989, J CELL BIOL, V109, P2003, DOI 10.1083/jcb.109.5.2003; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LEHNER CF, 1986, J BIOL CHEM, V261, P3293; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEIER UT, 1992, CELL, V70, P127; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOIR RD, 1991, J CELL SCI, V99, P363; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NAKAGAWA J, 1989, J CELL SCI, V94, P449; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Ris H., 1989, I PHYS C SER, V98, P657; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SCHMIDTZACHMANN MS, 1993, IN PRESS J CELL SCI, V105; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Stewart M, 1992, Semin Cell Biol, V3, P267, DOI 10.1016/1043-4682(92)90028-T; STICK R, 1988, J CELL BIOL, V107, P397, DOI 10.1083/jcb.107.2.397; Yamasaki L, 1992, Trends Cell Biol, V2, P123, DOI 10.1016/0962-8924(92)90083-Y; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; [No title captured]	73	191	194	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					493	504		10.1016/0092-8674(93)80051-F	http://dx.doi.org/10.1016/0092-8674(93)80051-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348616				2022-12-28	WOS:A1993LT73900011
J	MASON, JW				MASON, JW			A COMPARISON OF 7 ANTIARRHYTHMIC DRUGS IN PATIENTS WITH VENTRICULAR TACHYARRHYTHMIAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; AMIODARONE; MORTALITY; ARRHYTHMIAS; SURVIVAL; THERAPY	Background. The relative efficacies of various antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias are not well known. This study examined the effectiveness of imipramine, mexiletine, pirmenol, procainamide, propafenone, quinidine, and sotalol in patients with ventricular tachyarrhythmias who were enrolled in the Electrophysiologic Study versus Electrocardiographic Monitoring trial. Methods. Patients were randomly assigned to undergo serial testing of the efficacy of the seven antiarrhythmic drugs by one of two strategies: electrophysiologic study or Holter monitoring together with exercise testing. The seven drugs were then tested for efficacy in random order in patients who were eligible to receive them. The frequencies of predictions of drug efficacy and of adverse drug effects during the initial drug titration were tabulated for all 486 randomized subjects. Patients received long-term treatment with the first antiarrhythmic drug that was predicted to be effective on the basis of drug testing. Recurrences of arrhythmia, deaths, and adverse drug effects during long-term follow-up were recorded for the 296 patients in whom an antiarrhythmic drug was predicted to be effective. Results. In the electrophysiologic-study group, the percentage of patients who had predictions of drug efficacy was higher with sotalol (35 percent) than with the other drugs (16 percent, P<0.001). There, was no significant difference among the drugs in the Holter-monitoring group. The percentage of patients with adverse drug effects was lowest among those receiving sotalol. The actuarial probability of a recurrence of arrhythmia after a prediction of drug efficacy by either strategy was significantly lower for patients treated with sotalol than for patients treated with the other drugs (risk ratio, 0.43; 95 percent confidence interval, 0.29 to 0.62; P<0.001). With sotalol, as compared with the other drugs combined, there were lower risks of death from any cause (risk ratio, 0.50; 95 percent confidence interval, 0.30 to 0.80; P = 0.004), death from cardiac causes (0.50; P = 0.02), and death from arrhythmia (0.50; P = 0.04). The cumulative percentage of patients in whom a drug was predicted to be effective and in whom it remained effective and tolerated was higher for sotalol than for the other drugs (P<0.001). Conclusions. Sotalol was more effective than the other six antiarrhythmic drugs in preventing death and recurrences of arrhythmia. In patients similar to those in this study, if antiarrhythmic-drug therapy is to be used to prevent recurrences of ventricular tachyarrhythmias, treatment with sotalol and assessment of its potential efficacy by Holter monitoring are a reasonable initial strategy.			MASON, JW (corresponding author), UNIV UTAH,MED CTR,DIV CARDIOL,50 N MED DR,SALT LAKE CITY,UT 84132, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034071] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NHLBI NIH HHS [R0-1-HL34071] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, CIRCULATION, V79, P1354; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; COX DR, 1972, J R STAT SOC B, V34, P187; GIARDINA EGV, 1979, CIRCULATION, V60, P1045, DOI 10.1161/01.CIR.60.5.1045; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GREENE HL, 1992, CIRCULATION, V86, P656; HERRE JM, 1989, J AM COLL CARDIOL, V13, P442, DOI 10.1016/0735-1097(89)90525-1; HONDEGHEM LM, 1992, BASIC CLIN PHARM, P190; JACKMAN WM, 1984, MED CLIN N AM, V68, P1079, DOI 10.1016/S0025-7125(16)31087-2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAY GN, 1987, J AM COLL CARDIOL, V9, P877; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; SALATHIA KS, 1985, EUR HEART J, V6, P190, DOI 10.1093/oxfordjournals.eurheartj.a061844; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SINGH BN, 1970, BRIT J PHARMACOL, V39, P675, DOI 10.1111/j.1476-5381.1970.tb09893.x; SINGH BN, 1987, AM HEART J, V114, P121, DOI 10.1016/0002-8703(87)90316-4; VAUGHANWILLIAMS EM, 1990, S CARDIAC ARRHYTHMIA, P449; 1993, CIRCULATION, V87, P323; 1977, BMJ, V2, P419; 1982, JAMA-J AM MED ASSOC, V247, P1707; 1980, STATISTICAL ANAL FAI, P16; 1981, NEW ENGL J MED, V304, P801	23	368	378	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					452	458		10.1056/NEJM199308123290702	http://dx.doi.org/10.1056/NEJM199308123290702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	8332150				2022-12-28	WOS:A1993LR44300002
J	LIPPARD, SJ				LIPPARD, SJ			BIOINORGANIC CHEMISTRY - A MATURING FRONTIER	SCIENCE			English	Editorial Material											LIPPARD, SJ (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							ABRAMS MJ, 1993, SCIENCE, V261, P725, DOI 10.1126/science.8102010; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BERTINI I, 1993, BIOINORGANIC CHEM; Frausto da Silva J.J.R., 1991, BIOL CHEM ELEMENTS I; KAIM W, 1991, BIOANORGANISCHE CHEM; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; LIPPARD SJ, 1993, PRINCIPLES BIOINORGA; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; ORMEJOHNSON WH, 1992, SCIENCE, V257, P1639, DOI 10.1126/science.1529351; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; QUE L, 1991, SCIENCE, V253, P273, DOI 10.1126/science.1857963; ROSENBERG B, 1980, NUCLEIC ACID METAL I, V1, P1	12	52	52	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					699	700		10.1126/science.8342037	http://dx.doi.org/10.1126/science.8342037			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8342037				2022-12-28	WOS:A1993LQ73000025
J	JEPPESEN, P; TURNER, BM				JEPPESEN, P; TURNER, BM			THE INACTIVE X-CHROMOSOME IN FEMALE MAMMALS IS DISTINGUISHED BY A LACK OF HISTONE-H4 ACETYLATION, A CYTOGENETIC MARKER FOR GENE-EXPRESSION	CELL			English	Article							HUMAN METAPHASE CHROMOSOMES; HUMAN-CELLS; XIST GENE; HETEROCHROMATIN; ANTIBODIES; ISLANDS; LOCALIZATION; REPLICATION; ISOFORMS; NUCLEUS	We have immunolabeled human and mouse metaphase chromosomes with antibodies specific for the acetylated isoforms of histone H4. All chromosomes were labeled in regions corresponding to conventional R bands (regions enriched in coding DNA), except for a single chromosome in female cells, which was largely unlabeled and which we have identified as the inactive X (Xi). Three sharply defined immunofluorescent bands, enhanced by butyrate pretreatment, were observed in homologous positions on the human and mouse Xi, showing limited, regional persistence of H4 acetylation. Two of these bands are in cytogenetic regions known to contain genes expressed on Xi. We propose that H4 hyperacetylation defines regions of the genome containing potentially transcriptionally active chromatin, while virtual absence of H4 acetylation defines both constitutive and facultative heterochromatin.	UNIV BIRMINGHAM,SCH MED,DEPT ANAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	JEPPESEN, P (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BARR ML, 1949, NATURE, V163, P676, DOI 10.1038/163676a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN CJ, 1990, AM J HUM GENET, V46, P273; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DAVIES K, 1991, NATURE, V349, P15, DOI 10.1038/349015a0; DAVIES KE, 1991, CYTOGENET CELL GENET, V58, P853, DOI 10.1159/000133183; DAVISSON M T, 1987, Genomics, V1, P213, DOI 10.1016/0888-7543(87)90047-4; DUTRILLAUX B, 1971, CR ACAD SCI D NAT, V272, P2638; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; KANDA N, 1973, EXP CELL RES, V80, P463, DOI 10.1016/0014-4827(73)90324-8; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LATT SA, 1973, P NATL ACAD SCI USA, V70, P3395, DOI 10.1073/pnas.70.12.3395; LUCCHESI JC, 1987, ADV GENET, V24, P271; LYON MF, 1986, NATURE, V320, P313, DOI 10.1038/320313b0; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MATTEI MG, 1981, HUM GENET, V56, P401, DOI 10.1007/BF00274702; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; MORISHIMA A, 1962, P NATL ACAD SCI USA, V48, P756, DOI 10.1073/pnas.48.5.756; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RASTAN S, 1992, GENET RES, V8, P169; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; SAUNDERS WS, 1993, J CELL SCI, V104, P573; SAVAGE JRK, 1984, J MED GENET, V21, P204, DOI 10.1136/jmg.21.3.204; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; TURNER BM, 1990, J CELL SCI, V96, P335; TURNER BM, 1989, EXP CELL RES, V182, P206, DOI 10.1016/0014-4827(89)90292-9; TURNER BM, 1991, J CELL SCI, V99, P13	44	603	608	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					281	289		10.1016/0092-8674(93)90419-Q	http://dx.doi.org/10.1016/0092-8674(93)90419-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343956				2022-12-28	WOS:A1993LP72600009
J	PERRIMON, N				PERRIMON, N			THE TORSO RECEPTOR PROTEIN-TYROSINE KINASE SIGNALING PATHWAY - AN ENDLESS STORY	CELL			English	Review							DROSOPHILA EMBRYO; TERMINAL ANLAGEN; GENE TAILLESS; GROWTH-FACTOR; POLARITY; PATTERN; CELLS; TRANSDUCTION; MELANOGASTER; REQUIREMENT				PERRIMON, N (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.			Perrimon, Norbert/0000-0001-7542-472X				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, NATURE, V356, P285, DOI 10.1038/356285a0; PAWSON T, 1991, NATURE, V5, P521; Perkins L A, 1991, In Vivo, V5, P521; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PERRIMON N, 1989, GENETICS, V121, P333; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PIGNONI F, 1992, DEVELOPMENT, V115, P239; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RONCHI E, 1993, CELL, V74, P347, DOI 10.1016/0092-8674(93)90425-P; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1992, CELL, V68, P201; TISHLER AS, 1975, NATURE, V258, P341; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217	42	98	100	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					219	222		10.1016/0092-8674(93)90412-J	http://dx.doi.org/10.1016/0092-8674(93)90412-J			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343949				2022-12-28	WOS:A1993LP72600002
J	RITCHIE, EC				RITCHIE, EC			WASHING CLOTHES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					435	435						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320775				2022-12-28	WOS:A1993LN42600009
J	COLOTTA, F; RE, F; MUZIO, M; BERTINI, R; POLENTARUTTI, N; SIRONI, M; GIRI, JG; DOWER, SK; SIMS, JE; MANTOVANI, A				COLOTTA, F; RE, F; MUZIO, M; BERTINI, R; POLENTARUTTI, N; SIRONI, M; GIRI, JG; DOWER, SK; SIMS, JE; MANTOVANI, A			INTERLEUKIN-1 TYPE-II RECEPTOR - A DECOY TARGET FOR IL-1 THAT IS REGULATED BY IL-4	SCIENCE			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; MOLECULAR-PROPERTIES; ENDOTHELIAL-CELLS; BINDING-SITES; T-CELLS; B-CELLS; EXPRESSION; IDENTIFICATION; PURIFICATION; LYMPHOCYTES	Interleukin-1 (IL-1) interacts with cells through two types of binding molecules, IL-1 type I receptor (IL-1R I) and IL-1R II. The function of IL-1R II is unknown. In studies using monoclonal antibodies, IL-1 prolonged the in vitro survival of polymorphonuclear cells (PMN) through IL-1R I, and IL-4 antagonized the action of IL-1 by inducing expression and release of IL-1R II. Dexamethasone also induced expression and release of the IL-1R II in PMN. These results, together with the effect of antibodies to IL-1R on IL-1-induced production of cytokines in monocytes, indicate that IL-1 acts on myelomonocytic cells through IL-1R I and that IL-1R II inhibits IL-1 activity by acting as a decoy target for IL-1. The existence of multiple pathways of regulation emphasizes the need for tight control of IL-1 action.	IMMUNEX RES & DEV CORP,DEPT IMMUNOL,SEATTLE,WA 98101		COLOTTA, F (corresponding author), MARIO NEGRI INST PHARMACOL RES,CTR DANIELA & CATULLO BORGOMAINERIO,VIA ERITREA 62,I-20157 MILAN,ITALY.		Mantovani, Alberto/HCI-7449-2022; Muzio, Marta/J-9360-2018; sironi, marina/AAB-5757-2020	Mantovani, Alberto/0000-0001-5578-236X; Muzio, Marta/0000-0002-7761-759X; sironi, marina/0000-0002-3342-1149; dower, steve/0000-0002-4675-4225; Sims, John/0000-0002-5667-9185; Colotta, Francesco/0000-0001-8601-2309				AKAHOSHI T, 1988, J EXP MED, V167, P924, DOI 10.1084/jem.167.3.924; BENJAMIN D, 1990, J BIOL CHEM, V265, P9943; BENSIMON C, 1989, J IMMUNOL, V143, P1168; BIRD TA, 1988, J BIOL CHEM, V263, P12063; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BORASCHI D, 1991, BLOOD, V78, P1262; BORMSTYK K, 1989, P NATL ACAD SCI USA, V86, P8034; CHIN J, 1987, J EXP MED, V165, P70, DOI 10.1084/jem.165.1.70; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; COLOTTA F, 1992, BLOOD, V80, P2012; COLOTTA F, 1993, BLOOD, V81, P1347; COLOTTA F, 1992, J IMMUNOL, V148, P760; COLOTTA F, 1987, J EXP MED, V165, P122; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; GIRI JG, 1990, J BIOL CHEM, V265, P17416; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; HORUK R, 1987, J BIOL CHEM, V262, P16275; KILIAN PL, 1986, J IMMUNOL, V136, P4509; KOCH KC, 1992, EUR J IMMUNOL, V22, P153, DOI 10.1002/eji.1830220123; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; PAUL WE, 1991, BLOOD, V77, P1859; RHYNE JA, 1988, CLIN IMMUNOL IMMUNOP, V48, P354, DOI 10.1016/0090-1229(88)90029-3; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SIRONI M, 1989, J IMMUNOL, V142, P549; SPRIGGS MK, 1992, CYTOKINE, V4, P90, DOI 10.1016/1043-4666(92)90042-P; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SPRIGGS MK, 1992, CELL, V71, P153; SPRIGGS MK, 1990, J BIOL CHEM, V265, P2249; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; TIKU K, 1986, J IMMUNOL, V136, P3677; URDAL DL, 1988, J BIOL CHEM, V263, P2870; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	39	870	898	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					472	475		10.1126/science.8332913	http://dx.doi.org/10.1126/science.8332913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332913				2022-12-28	WOS:A1993LN62300036
J	WENGER, NK; SPEROFF, L; PACKARD, B				WENGER, NK; SPEROFF, L; PACKARD, B			CARDIOVASCULAR HEALTH AND DISEASE IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; CONGENITAL HEART-DISEASE; MYOCARDIAL PERFUSION SCINTIGRAPHY; VENOUS THROMBOEMBOLIC DISEASE; QUALITY-OF-LIFE; FOLLOW-UP; EXERCISE-ELECTROCARDIOGRAPHY; PERIPARTUM CARDIOMYOPATHY; VALVE-REPLACEMENT; BYPASS-SURGERY		OREGON HLTH SCI UNIV, DEPT OBSTET & GYNECOL, PORTLAND, OR 97201 USA; NHLBI, BETHESDA, MD 20892 USA	Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	WENGER, NK (corresponding author), EMORY UNIV, SCH MED, DEPT MED, DIV CARDIOL, 69 BUTLER ST SE, ATLANTA, GA 30303 USA.							ALLAN LD, 1986, AM J CARDIOL, V58, P334, DOI 10.1016/0002-9149(86)90072-X; [Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; ARROLL B, 1992, J CLIN EPIDEMIOL, V45, P439, DOI 10.1016/0895-4356(92)90093-3; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BARNETT HJM, 1990, CAN J CARDIOL, V6, pB11; Barrett-Connor E, 1989, Cardiovasc Clin, V19, P159; BELL MR, 1993, JAMA-J AM MED ASSOC, V269, P2091, DOI 10.1001/jama.269.16.2091; Bernal J M, 1986, Obstet Gynecol Surv, V41, P1, DOI 10.1097/00006254-198601000-00001; BERNSTEIN EF, 1990, ANN SURG, V212, P629, DOI 10.1097/00000658-199011000-00011; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; Boogard M, 1985, J CARDIOPULM REHABIL, V5, P379; BOOTHKEWLEY S, 1987, PSYCHOL BULL, V101, P343, DOI 10.1037/0033-2909.101.3.343; BRAY GA, 1988, WESTERN J MED, V149, P429; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CASALE PN, 1993, AM J CARDIOL, V71, P1221, DOI 10.1016/0002-9149(93)90650-2; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COHN PF, 1988, ANN INTERN MED, V109, P312, DOI 10.7326/0003-4819-109-4-312; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; CULLIFORD AT, 1991, AM J CARDIOL, V67, P1256, DOI 10.1016/0002-9149(91)90937-G; CURRIE PJ, 1985, CIRCULATION, V71, P1162, DOI 10.1161/01.CIR.71.6.1162; DARLING RC, 1989, J VASC SURG, V10, P39, DOI 10.1067/mva.1989.vs0100039; DEBAKEY ME, 1985, ANN SURG, V201, P115; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DEVIRI E, 1985, SURG GYNECOL OBSTET, V160, P437; DIMSDALE JE, 1988, STRESS COPING DEV, P215; DRISCOLL DJ, 1993, CIRCULATION, V87, P114; EPSTEIN AE, 1992, CIRCULATION, V86, P1206, DOI 10.1161/01.CIR.86.4.1206; FINTEL DJ, 1989, J AM COLL CARDIOL, V13, P600, DOI 10.1016/0735-1097(89)90600-1; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; FREMES SE, 1989, CIRCULATION, V80, P77; FRIEDMAN TD, 1982, AM J CARDIOL, V49, P1632, DOI 10.1016/0002-9149(82)90239-9; GARDNER TJ, 1985, ANN SURG, V201, P780, DOI 10.1097/00000658-198506000-00016; GIBBONS RJ, 1981, CIRCULATION, V64, P952, DOI 10.1161/01.CIR.64.5.952; GIBBONS RJ, 1983, CIRCULATION, V68, P740, DOI 10.1161/01.CIR.68.4.740; GIBBONS RJ, 1988, J AM COLL CARDIOL, V11, P28, DOI 10.1016/0735-1097(88)90162-3; GILCHRIST LD, 1989, PREV MED, V18, P235, DOI 10.1016/0091-7435(89)90071-6; GINSBERG JS, 1989, THROMB HAEMOSTASIS, V61, P189; GINSBERG JS, 1992, THROMB HAEMOSTASIS, V67, P519; GOODGOLD HM, 1987, RADIOLOGY, V165, P361, DOI 10.1148/radiology.165.2.3659357; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENBERG PS, 1983, CLIN CARDIOL, V6, P312, DOI 10.1002/clc.4960060703; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; GUANIERI T, 1991, CIRCULATION S2, V84, P428; Guleria R, 1990, J Assoc Physicians India, V38, P902; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; HALLSTROM T, 1986, J PSYCHOSOM RES, V30, P451, DOI 10.1016/0022-3999(86)90084-X; HERSHEY LA, 1991, AM J MED, V91, P288, DOI 10.1016/0002-9343(91)90130-P; HIGGINBOTHAM MB, 1984, CIRCULATION, V70, P357, DOI 10.1161/01.CIR.70.3.357; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; HONG MK, 1992, AM J CARDIOL, V69, P176, DOI 10.1016/0002-9149(92)91300-S; HUBBARD BL, 1992, ARCH INTERN MED, V152, P309, DOI 10.1001/archinte.152.2.309; HULL RD, 1990, ANN INTERN MED, V112, P663, DOI 10.7326/0003-4819-112-9-663; HUNG J, 1984, J AM COLL CARDIOL, V4, P8, DOI 10.1016/S0735-1097(84)80312-5; IMPERIALE TF, 1991, JAMA-J AM MED ASSOC, V266, P261; ISMAIL MB, 1986, BRIT HEART J, V55, P101; JECKER NS, 1991, JAMA-J AM MED ASSOC, V266, P3012, DOI 10.1001/jama.266.21.3012; KANNEL WB, 1972, AM J CARDIOL, V29, P154, DOI 10.1016/0002-9149(72)90624-8; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KANNEL WB, 1970, CIRCULATION, V41, P875, DOI 10.1161/01.CIR.41.5.875; KANNEL WB, 1987, CORONARY HEART DISEA, P208; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KENNEDY JW, 1981, CIRCULATION, V63, P793, DOI 10.1161/01.CIR.63.4.793; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KIRKLIN JW, 1991, CIRCULATION, V83, P1125; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; LASKEY WK, 1992, ANN INTERN MED, V116, P869, DOI 10.7326/0003-4819-116-10-869; LEE W, 1989, CLIN OBSTET GYNECOL, V32, P54, DOI 10.1097/00003081-198903000-00009; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MASINI M, 1988, J AM COLL CARDIOL, V12, P682, DOI 10.1016/S0735-1097(88)80056-1; MAYNARD C, 1991, AM J CARDIOL, V68, P529, DOI 10.1016/0002-9149(91)90791-I; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MELIN JA, 1985, CIRCULATION, V71, P535, DOI 10.1161/01.CIR.71.3.535; MELVIN KR, 1982, NEW ENGL J MED, V307, P731, DOI 10.1056/NEJM198209163071207; Menzoian J O, 1989, Ann Vasc Surg, V3, P224, DOI 10.1016/S0890-5096(07)60028-4; MIDEI MG, 1990, CIRCULATION, V81, P922, DOI 10.1161/01.CIR.81.3.922; MORISE AP, 1991, CIRCULATION S2, V84, P152; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NAGORNEY DM, 1981, OBSTET GYNECOL, V57, P386; OCONNELL JB, 1986, J AM COLL CARDIOL, V8, P52, DOI 10.1016/S0735-1097(86)80091-2; OLDRIDGE NB, 1980, AM HEART J, V100, P755, DOI 10.1016/0002-8703(80)90244-6; ONEILL WW, 1991, J AM COLL CARDIOL, V17, P193; OURIEL K, 1987, J VASC SURG, V5, P702, DOI 10.1067/mva.1987.avs0050702; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PASTERNAK RC, 1979, J THORAC CARDIOV SUR, V78, P614; PEDERSEN TR, 1985, NEW ENGL J MED, V313, P1055; PERLOFF JK, 1991, J AM COLL CARDIOL, V18, P340, DOI 10.1016/0735-1097(91)90583-U; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PITKIN RM, 1990, ANN INTERN MED, V112, P445, DOI 10.7326/0003-4819-76-3-112-6-445; PRYOR DB, 1991, AM J MED, V90, P553; PYERITZ RE, 1989, J AM COLL CARDIOL, V13, P1458, DOI 10.1016/0735-1097(89)90333-1; REAVEN PD, 1991, CIRCULATION, V83, P559, DOI 10.1161/01.CIR.83.2.559; ROBERT AR, 1991, CIRCULATION, V83, P1202, DOI 10.1161/01.CIR.83.4.1202; ROCCELLA EJ, 1990, PREVENTIVE ASPECTS C, V20, P49; ROGERS WJ, 1990, CIRCULATION, V82, P1647, DOI 10.1161/01.CIR.82.5.1647; ROSENBERG L, 1990, NEW ENGL J MED, V322, P213, DOI 10.1056/NEJM199001253220401; SANDERSON JE, 1986, BRIT HEART J, V56, P285; SAWADA SG, 1989, J AM COLL CARDIOL, V14, P1440, DOI 10.1016/0735-1097(89)90378-1; SCHOLL JM, 1988, AM HEART J, V115, P559, DOI 10.1016/0002-8703(88)90804-6; SHIME, 1987, AM J OBSTET GYNECOL, V156, P1361; SHIME J, 1987, AM J OBSTET GYNECOL, V156, P313, DOI 10.1016/0002-9378(87)90275-4; SIPES SL, 1990, SEMIN PERINATOL, V14, P103; SIVENIUS J, 1991, ANN NEUROL, V29, P596, DOI 10.1002/ana.410290605; SMITH WM, 1985, AM J CARDIOL, V55, pA3, DOI 10.1016/0002-9149(85)90789-1; STAMPFER MJ, 1990, AM J OBSTET GYNECOL, V163, P285, DOI 10.1016/0002-9378(90)90569-S; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; VAITKUS PT, 1991, AM J CARDIOL, V67, P537, DOI 10.1016/0002-9149(91)90020-L; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; Wald E R, 1992, Heart Dis Stroke, V1, P391; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613; WEINER CP, 1989, CLIN THROMBOSIS, P291; WEINER DA, 1979, NEW ENGL J MED, V301, P230, DOI 10.1056/NEJM197908023010502; WEINTRAUB WS, 1992, CIRCULATION, V86, P772; WEINTRAUB WS, 1992, CIRCULATION, V86, P253; WEINTRAUB WS, 1992, CIRCULATION, V86, P100; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; WENGER NK, 1992, JAMA-J AM MED ASSOC, V268, P1460, DOI 10.1001/jama.268.11.1460; WENGER NK, 1992, IN PRESS CARDIOVASCU; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1991, NIH913029 DHHS PUBL; 1990, DHHS CDC908416 PUBL; 1989, DHHS CDC898411 PUBL; 1991, DHHS PHS911232 PUBL; 1992, HEART STROKE FACTS; 1992, GAO HRD9317 GEN ACC, P1; 1987, VITAL HLTH STATIST 1, V22; 1977, NCRP54 NAT COUNC RAD	140	532	543	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					247	256		10.1056/NEJM199307223290406	http://dx.doi.org/10.1056/NEJM199307223290406			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM682	8316269	Green Submitted			2022-12-28	WOS:A1993LM68200006
J	ROLLNICK, S; KINNERSLEY, P; STOTT, N				ROLLNICK, S; KINNERSLEY, P; STOTT, N			METHODS OF HELPING PATIENTS WITH BEHAVIOR-CHANGE	BRITISH MEDICAL JOURNAL			English	Article							SMOKING CESSATION; HEALTH PROMOTION; PROBLEM DRINKERS; INTERVENTIONS; TRIAL		UNIV WALES COLL MED,DEPT GEN PRACTICE,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University								BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; DAVIDSON R, 1992, BRIT J ADDICT, V87, P821; DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P295, DOI 10.1037/0022-006X.59.2.295; FELD J, 1993, BETTER LIVING BETTER; HEATHER N, 1987, J ROY COLL GEN PRACT, V37, P358; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; MCCONNAUGHY EA, 1983, PSYCHOTHER-THEOR RES, V20, P368, DOI 10.1037/h0090198; MCWHINNEY IR, 1989, TXB FAMILY MED, P87; MILLER WR, 1983, BEHAV PSYCHOTHER, V11, P147, DOI 10.1017/S0141347300006583; MILLER WR, 1991, MOTIVATIONAL INNTERV; MILLER WR, IN PRESS BEHAVIOURAL; MILLER WR, IN PRESS J CONSULT C; OCKENE JK, 1991, J GEN INTERN MED, V6, P1, DOI 10.1007/BF02599381; Orford J., 1985, EXCESSIVE APPETITES; PILL RM, 1989, J ROY COLL GEN PRACT, V39, P196; Prochasca J.O., 1986, TREATING ADDICTIVE B; PROCHASKA JO, 1992, BRIT J ADDICT, V87, P825; RICHMOND R, 1991, SMOKESCREEN 1990S ST; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; Rollnick S, 1992, J MENT HEALTH, V1, P25, DOI DOI 10.3109/09638239209034509; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; STOTT NCH, 1990, FAM PRACT, V7, P125, DOI 10.1093/fampra/7.2.125; STOTT NCH, 1990, MAKING CHANGES STUDY; Tuckett D., 1985, M EXPERTS APPROACH S; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; 1989, GENERAL PRACTICE NAT; 1991, DRINKING REASONABLY; 1986, 24 ROY COLL GEN PRAC; [No title captured]	29	121	123	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					188	190		10.1136/bmj.307.6897.188	http://dx.doi.org/10.1136/bmj.307.6897.188			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN184	8343750	Green Published, Bronze			2022-12-28	WOS:A1993LN18400028
J	ALLEN, JC; SCHAFFER, WM; ROSKO, D				ALLEN, JC; SCHAFFER, WM; ROSKO, D			CHAOS REDUCES SPECIES EXTINCTION BY AMPLIFYING LOCAL-POPULATION NOISE	NATURE			English	Article							SPACE-LIMITED SUBPOPULATIONS; ECOLOGICAL-SYSTEMS; TIME-SERIES; DYNAMICS; MODELS; RARITY; GROWTH	IN the mid-1970s, theoretical ecologists were responsible for stimulating interest in nonlinear dynamics and chaos1-3. Ironically, the importance of chaos in ecology itself remains controversial4-17. Proponents of ecological chaos point to its ubiquity in mathematical models and to various empirical findings15,16,18. Sceptics12,19,20 maintain that the models are unrealistic and that the experimental evidence is equally consistent with stochastic models. More generally, it has been argued9,11,21-23 that interdemic selection and/or enhanced rates of species extinction will eliminate populations and species that evolve into chaotic regions of parameter space. Fundamental to this opinion is the belief24,25 that violent oscillations and low minimum population densities are inevitable correlates of the chaotic state. In fact, rarity is not a necessary consequence of complex dynamical behaviour26,27. But even when chaos is associated with frequent rarity, its consequences to survival are necessarily deleterious only in the case of species composed of a single population. Of course, the majority of real world species (for example, most insects) consist of multiple populations weakly coupled by migration, and in this circumstance chaos can actually reduce the probability of extinction. Here we show that although low densities lead to more frequent extinction at the local level28, the decorrelating effect of chaotic oscillations reduces the degree of synchrony among populations and thus the likelihood that all are simultaneously extinguished.	UNIV ARIZONA,DEPT ECOL & EVOLUTIONARY BIOL,TUCSON,AZ 85721	University of Arizona	ALLEN, JC (corresponding author), UNIV FLORIDA,DEPT ENTOMOL & NEMATOL,GAINESVILLE,FL 32611, USA.							BERRYMAN AA, 1989, TRENDS ECOL EVOL, V4, P26, DOI 10.1016/0169-5347(89)90014-1; BERRYMAN AA, 1991, CHAOS INSECT ECOLOGY, P23; CASDAGLI M, 1989, PHYSICA D, V35, P335, DOI 10.1016/0167-2789(89)90074-2; Collet Pierre, 1980, ITERATED MAPS INTERV; CRUTCHFIELD JP, 1982, PHYS REP, V92, P45, DOI 10.1016/0370-1573(82)90089-8; ELLNER S, 1991, VA EXP STAF INF SERI, V9193, P63; Gilpin M.E., 1991, METAPOPULATION DYNAM; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; HASSELL MP, 1976, J ANIM ECOL, V45, P473; IWASA Y, 1986, THEOR POPUL BIOL, V30, P194, DOI 10.1016/0040-5809(86)90033-X; LICHTENBERG AJ, 1983, REGULAR STOCHASTIC M; LOGAN JA, 1992, ANNU REV ENTOMOL, V37, P455, DOI 10.1146/annurev.en.37.010192.002323; LOMNICKI A, 1989, TRENDS ECOL EVOL, V4, P239; MANI GS, 1989, TRENDS ECOL EVOL, V4, P239; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; MAY RM, 1976, AM NAT, V110, P573, DOI 10.1086/283092; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MILTON JG, 1990, THEOR POPUL BIOL, V37, P273, DOI 10.1016/0040-5809(90)90040-3; MORRIS WF, 1990, ECOLOGY, V71, P1849, DOI 10.2307/1937593; MUELLER LD, 1981, ECOLOGY, V62, P1148, DOI 10.2307/1937278; NISBET R, 1989, TRENDS ECOL EVOL, V4, P238, DOI 10.1016/0169-5347(89)90168-7; PHILIPPI TE, 1987, ECOLOGY, V68, P154, DOI 10.2307/1938815; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; RICKER W. E., 1954, JOUR FISH RES BD CANADA, V11, P559; ROGERS TD, 1984, MATH BIOSCI, V72, P13, DOI 10.1016/0025-5564(84)90058-0; ROUGHGARDEN J, 1986, THEOR POPUL BIOL, V29, P235, DOI 10.1016/0040-5809(86)90010-9; RUELLE D, 1990, P ROY SOC LOND A MAT, V427, P241, DOI 10.1098/rspa.1990.0010; RUELLE D, 1979, BIFURCATION THEORY A, V316, P408; SCHAFFER WM, 1986, TRENDS ECOL EVOL, V1, P58, DOI 10.1016/0169-5347(86)90018-2; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; THOMAS WR, 1980, ECOLOGY, V61, P13; TILLMAN D, 1991, NATURE, V353, P653; TURCHIN P, 1990, NATURE, V344, P660, DOI 10.1038/344660a0; TURCHIN P, 1991, VA EXP STAF INF, V9193, P39; VANDERMEER J, 1982, ECOLOGY, V63, P1167, DOI 10.2307/1937252; VANDERMEER J, 1982, THEOR POPUL BIOL, V22, P17, DOI 10.1016/0040-5809(82)90033-8; YORKE JA, 1979, AM J EPIDEMIOL, V109, P103, DOI 10.1093/oxfordjournals.aje.a112666	37	272	283	1	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					229	232		10.1038/364229a0	http://dx.doi.org/10.1038/364229a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321317				2022-12-28	WOS:A1993LM68300054
J	REIDENBERG, MM				REIDENBERG, MM			CLINICAL-PHARMACOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											REIDENBERG, MM (corresponding author), CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021, USA.							BERGSTROM RF, 1992, CLIN PHARMACOL THER, V51, P239, DOI 10.1038/clpt.1992.18; CHOLERTON S, 1992, TRENDS PHARMACOL SCI, V13, P434, DOI 10.1016/0165-6147(92)90140-2; FEDERMAN DJ, 1992, NEW ENGL J MED, V327, P1316; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; Kaufman DW, 1991, DRUG ETIOLOGY AGRANU; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEIZOROVICZ A, 1992, LANCET, V340, P1102, DOI 10.1016/0140-6736(92)93126-8; LEVY G, 1992, CLIN PHARMACOL THER, V52, P115, DOI 10.1038/clpt.1992.119; LOWN K, 1992, CLIN PHARMACOL THER, V51, P229, DOI 10.1038/clpt.1992.17; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; MONCADA S, 1991, PHARMACOL REV, V43, P109; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; TURGEON DK, 1992, CLIN PHARMACOL THER, V52, P471, DOI 10.1038/clpt.1992.174; VALLANCE P, 1992, LANCET, V339, P572; WATKINS PB, 1989, J CLIN INVEST, V83, P688, DOI 10.1172/JCI113933; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68	19	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					192	194		10.1001/jama.270.2.192	http://dx.doi.org/10.1001/jama.270.2.192			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315726				2022-12-28	WOS:A1993LL36800012
J	CRUM, JE				CRUM, JE			PEAK EXPIRATORY FLOW-RATE IN SCHOOLCHILDREN LIVING CLOSE TO BRAER OIL-SPILL	BRITISH MEDICAL JOURNAL			English	Article																		GODFREY S, 1970, British Journal of Diseases of the Chest, V64, P15, DOI 10.1016/S0007-0971(70)80045-6; READ C, 1991, AIR POLLUTION CHILD	2	21	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					23	24		10.1136/bmj.307.6895.23	http://dx.doi.org/10.1136/bmj.307.6895.23			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343663	Green Published, Bronze			2022-12-28	WOS:A1993LL36900020
J	BROWN, JH; JARDETZKY, TS; GORGA, JC; STERN, LJ; URBAN, RG; STROMINGER, JL; WILEY, DC				BROWN, JH; JARDETZKY, TS; GORGA, JC; STERN, LJ; URBAN, RG; STROMINGER, JL; WILEY, DC			3-DIMENSIONAL STRUCTURE OF THE HUMAN CLASS-II HISTOCOMPATIBILITY ANTIGEN HLA-DR1	NATURE			English	Article							MHC CLASS-II; NONOBESE DIABETIC MICE; T-CELL RECOGNITION; HLA-DR; CRYSTALLOGRAPHIC REFINEMENT; SURFACE EXPRESSION; PEPTIDE ANTIGENS; MOLECULAR-BASIS; BINDING SITE; BETA-CHAIN	The three-dimensional structure of the class II histocompatibility glycoprotein HLA-DR1 from human B-cell membranes has been determined by X-ray crystallography and is similar to that of class I HLA. Peptides are bound in an extended conformation that projects from both ends of an 'open-ended' antigen-binding groove. A prominent non-polar pocket into which an 'anchoring' peptide side chain fits is near one end of the binding groove. A dimer of the class II alphabeta heterodimers is seen in the crystal forms of HLA-DR1, suggesting class II HLA dimerization as a mechanism for initiating the cytoplasmic signalling events in T-cell activation.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA; CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Harvard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Howard Hughes Medical Institute								ALEXANDER J, 1993, J IMMUNOL, V150, P1; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUSCH R, 1991, J IMMUNOL, V147, P1292; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GELUK A, 1992, J IMMUNOL, V149, P2864; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GORGA JC, 1991, RES IMMUNOL, V142, P401, DOI 10.1016/0923-2494(91)90038-K; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GORGA JC, 1992, CRIT REV IMMUNOL, V11, P305; GRIFFITH IJ, 1988, J EXP MED, V167, P541, DOI 10.1084/jem.167.2.541; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HORN GT, 1988, P NATL ACAD SCI USA, V85, P6012, DOI 10.1073/pnas.85.16.6012; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JANEWAY CA, 1989, COLD SH Q B, V54, P657; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KLINMAN NR, 1972, J EXP MED, V136, P241, DOI 10.1084/jem.136.2.241; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KROPSHOFER H, 1991, BIOCHEMISTRY-US, V30, P9177, DOI 10.1021/bi00102a008; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NEWTONNASH DK, 1993, J IMMUNOL, V150, P1813; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RACIOPPI L, 1991, J IMMUNOL, V147, P3718; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SETTE A, 1989, J IMMUNOL, V143, P3289; SIDNEY J, 1992, J IMMUNOL, V149, P2634; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; SLATTERY RM, 1990, NATURE, V345, P724, DOI 10.1038/345724a0; SPRINGER TA, 1977, NATURE, V268, P213, DOI 10.1038/268213a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STUART D, 1984, ACTA CRYSTALLOGR A, V40, P713, DOI 10.1107/S0108767384001471; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TIWARI J, 1985, DISEASE ASS; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; WETTS TH, 1993, IMMUN, V150, P2192	69	2129	2197	4	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	1993	364	6432					33	39		10.1038/364033a0	http://dx.doi.org/10.1038/364033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316295				2022-12-28	WOS:A1993LK81800048
J	DABKOWSKI, PL; ANGUS, PW; SMALLWOOD, RA; IRETON, J; JONES, RM				DABKOWSKI, PL; ANGUS, PW; SMALLWOOD, RA; IRETON, J; JONES, RM			SITE OF PRINCIPAL METABOLIC DEFECT IN IDIOPATHIC HEMOCHROMATOSIS - INSIGHTS FROM TRANSPLANTATION OF AN AFFECTED ORGAN	BRITISH MEDICAL JOURNAL			English	Article							HEPATIC IRON; HEMOCHROMATOSIS		AUSTIN HOSP,VICTORIAN LIVER TRANSPLANT UNIT,HEIDELBERG,VIC 3084,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health								ADAMS PC, 1989, TRANSPLANTATION, V48, P19, DOI 10.1097/00007890-198907000-00005; BATEY RG, 1978, GASTROENTEROLOGY, V75, P856; BOTHWELL TH, 1989, METABOLIC BASIS INHE, P1433; LOMBARD M, 1990, GASTROENTEROLOGY, V98, P976, DOI 10.1016/0016-5085(90)90022-S; POWELL LW, 1970, GUT, V11, P727, DOI 10.1136/gut.11.9.727	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1726	1726		10.1136/bmj.306.6894.1726	http://dx.doi.org/10.1136/bmj.306.6894.1726			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343629	Green Published, Bronze			2022-12-28	WOS:A1993LK36700020
J	BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; PIJLS, NHJ; KNAPE, JTA				BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; PIJLS, NHJ; KNAPE, JTA			HOW FREQUENTLY SHOULD BASIC CARDIOPULMONARY-RESUSCITATION TRAINING BE REPEATED TO MAINTAIN ADEQUATE SKILLS	BRITISH MEDICAL JOURNAL			English	Article							RETENTION		CATHOLIC UNIV NIJMEGEN,RADBOUD HOSP,DEPT CARDIOL,NIJMEGEN,NETHERLANDS; CATHARINA HOSP,DEPT CARDIOL,EINDHOVEN,NETHERLANDS; UNIV UTRECHT HOSP,DEPT ANAESTHESIOL,3511 GV UTRECHT,NETHERLANDS	Radboud University Nijmegen; Catharina Hospital; Utrecht University; Utrecht University Medical Center	BERDEN, HJJM (corresponding author), DUTCH COLL GEN PRACTITIONERS,POSTBOX 3231,3502 GE UTRECHT,NETHERLANDS.		Berden, Hubert/GQB-0441-2022					BERDEN HJJ, 1992, RESUSCITATION, V23, P31; KAYE W, 1986, CRIT CARE MED, V14, P620, DOI 10.1097/00003246-198607000-00007; KAYE W, 1991, RESUSCITATION, V21, P67, DOI 10.1016/0300-9572(91)90080-I; SERAJ MA, 1990, RESUSCITATION, V20, P31, DOI 10.1016/0300-9572(90)90084-R; WEAVER FJ, 1979, JAMA-J AM MED ASSOC, V241, P901, DOI 10.1001/jama.241.9.901	5	136	142	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1576	1577		10.1136/bmj.306.6892.1576	http://dx.doi.org/10.1136/bmj.306.6892.1576			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329917	Bronze, Green Published			2022-12-28	WOS:A1993LH12800017
J	BOUMPAS, DT; AUSTIN, HA; VAUGHAN, EM; YARBORO, CH; KLIPPEL, JH; BALOW, JE				BOUMPAS, DT; AUSTIN, HA; VAUGHAN, EM; YARBORO, CH; KLIPPEL, JH; BALOW, JE			RISK FOR SUSTAINED AMENORRHEA IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS RECEIVING INTERMITTENT PULSE CYCLOPHOSPHAMIDE THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						AMENORRHEA; LUPUS-ERYTHEMATOSUS; CYCLOPHOSPHAMIDE; AGE FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG	DOSE INTRAVENOUS CYCLOPHOSPHAMIDE; PROGRESSIVE MULTIPLE-SCLEROSIS; INDUCED OVARIAN FAILURE; HODGKINS-DISEASE; CONTROLLED TRIAL; FOLLICLE NUMBER; NEPHRITIS; CHEMOTHERAPY; CANCER; WOMEN	Objective: To determine the risk for secondary amenorrhea after pulse cyclophosphamide therapy in premenopausal women with systemic lupus erythematosus. Design: Controlled, retrospective clinical study. Setting: Government referral-based research hospital. Patients: Thirty-nine women younger than 40 years treated with pulse cyclophosphamide therapy for active lupus nephritis or neuropsychiatric lupus. Sixteen women who received pulses of intravenous methylprednisolone were controls. Interventions: Sixteen patients received pulse cyclophosphamide (0.5 to 1.0 g/m2 body surface area) monthly for a total of 7 doses (short-CY), and 23 patients received 15 or more doses (long-CY). Control patients were treated with monthly pulses of methylprednisolone (1.0 g/m2) for a total of nine doses. Measurements: Rates of amenorrhea were evaluated according to duration of treatment (number of doses) and age at the initiation of pulse therapy. Results: Two of 16 patients (12%) in the Short-CY group and 9 of 23 (39%) in the long-CY group developed sustained amenorrhea (P = 0.07). Rates of sustained amenorrhea (short- and long-CY) according to age at the start of pulse therapy were: less-than-or-equal-to 25 years, 2/16 (12%); 26 to 30 years, 4/15 (27%); greater-than-or-equal-to 31 years, 5/8 (62%) (P = 0.04). The increased risk for sustained amenorrhea in patients treated with long-CY was most evident in patients older than 25 years (short-CY [2/12] compared with long-CY [7/11]; P = 0.03). Three other patients with short-CY had reversal of amenorrhea fewer than 12 months after cessation of therapy. Amenorrhea was not observed in any of the 16 control patients. Conclusions: Intermittent pulse cyclophosphamide therapy in patients with systemic lupus erythematosus is associated with sustained amenorrhea, which is related to both age and number of doses of cyclophosphamide.	NIH, CTR CLIN, DEPT NURSING, BETHESDA, MD 20892 USA; NIAMS, ARTHRITIS & RHEUMAT BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	BOUMPAS, DT (corresponding author), NIDDK, KIDNEY DIS SECT, BLDG 10, ROOM 3N-112, BETHESDA, MD 20892 USA.							ALJANADI M, 1989, J RHEUMATOL, V16, P1592; ARNOLD MH, 1989, ARTHRITIS RHEUM, V32, P933; ATAYA K, 1990, SELECT CANCER THER, V6, P83, DOI 10.1089/sct.1990.6.83; ATAYA KM, 1985, CANCER RES, V45, P3651; ATAYA KM, 1989, CANCER RES, V49, P1660; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BALOW JE, 1987, ANN INTERN MED, V106, P79, DOI 10.7326/0003-4819-106-1-79; BOMBARDIERI S, 1989, LANCET, V1, P1138; BOUMPAS DT, 1991, Q J MED, V81, P975, DOI 10.1093/qjmed/81.3.975; BOUMPAS DT, 1990, ANN INTERN MED, V112, P674, DOI 10.7326/0003-4819-112-9-674; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; BYRNE J, 1987, NEW ENGL J MED, V317, P1315, DOI 10.1056/NEJM198711193172104; CHAPMAN RM, 1981, BLOOD, V58, P849; CHAPMAN RM, 1982, SEMIN ONCOL, V9, P84; CHAPMAN RM, 1979, JAMA-J AM MED ASSOC, V242, P1877, DOI 10.1001/jama.242.17.1877; CRONIN ME, 1989, J RHEUMATOL, V16, P1225; DEVITA S, 1991, CLIN EXP RHEUMATOL, V9, P179; DNISTRIAN AM, 1983, CANCER, V51, P803, DOI 10.1002/1097-0142(19830301)51:5<803::AID-CNCR2820510509>3.0.CO;2-V; FALK RJ, 1990, KIDNEY INT, V38, P998, DOI 10.1038/ki.1990.304; FALK RJ, 1992, ANN INTERN MED, V116, P438, DOI 10.7326/0003-4819-116-6-438; FOSDICK WM, 1968, ARTHRITIS RHEUM, V11, P151, DOI 10.1002/art.1780110205; GOODKIN DE, 1987, ARCH NEUROL-CHICAGO, V44, P823, DOI 10.1001/archneur.1987.00520200027013; GREKAS D, 1987, NEPHRON, V47, P236, DOI 10.1159/000184502; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; HOFFMAN GS, 1990, AM J MED, V89, P403, DOI 10.1016/0002-9343(90)90367-M; KOYAMA H, 1977, CANCER, V39, P1403, DOI 10.1002/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8; KUMAR R, 1972, LANCET, V1, P1212; LEHMAN TJA, 1989, J PEDIATR-US, V114, P1055, DOI 10.1016/S0022-3476(89)80463-9; LEROY JP, 1990, ARTHRITIS RHEUM, V33, P1579, DOI 10.1002/art.1780331017; LINSSEN WHJP, 1987, ACTA NEUROL SCAND, V76, P204, DOI 10.1111/j.1600-0404.1987.tb03568.x; MATTISON DR, 1981, RES COMMUN CHEM PATH, V31, P155; MCCUNE WJ, 1988, NEW ENGL J MED, V318, P1423, DOI 10.1056/NEJM198806023182203; MONTZ FJ, 1991, CANCER RES, V51, P2124; SCHILSKY RL, 1981, AM J MED, V71, P552, DOI 10.1016/0002-9343(81)90205-9; SCHILSKY RL, 1980, ANN INTERN MED, V93, P109, DOI 10.7326/0003-4819-93-1-109; SCOTT DGI, 1984, AM J MED, V76, P377, DOI 10.1016/0002-9343(84)90654-5; SHIROMIZU K, 1984, PEDIATR PHARMACOL, V4, P213; STEINBERG AD, 1991, ARTHRITIS RHEUM-US, V34, P945, DOI 10.1002/art.1780340803; TIETJEN DP, 1990, NEPHRON, V55, P69, DOI 10.1159/000185921; ULDALL PR, 1972, LANCET, V1, P693; WARNE GL, 1973, NEW ENGL J MED, V289, P1159, DOI 10.1056/NEJM197311292892202; WEINERMAN B, 1974, CAN MED ASSOC J, V111, P1100	42	418	441	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					366	369		10.7326/0003-4819-119-5-199309010-00003	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00003			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338289				2022-12-28	WOS:A1993LZ47600003
J	CONNOR, BA; SHLIM, DR; SCHOLES, JV; RAYBURN, JL; REIDY, J; RAJAH, R				CONNOR, BA; SHLIM, DR; SCHOLES, JV; RAYBURN, JL; REIDY, J; RAJAH, R			PATHOLOGICAL-CHANGES IN THE SMALL-BOWEL IN 9 PATIENTS WITH DIARRHEA ASSOCIATED WITH A COCCIDIA-LIKE BODY	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; CYANOBACTERIA; INTESTINE, SMALL; FATIGUE; ANOREXIA	TRAVELERS	Objective: To confirm a suspected small-bowel injury in patients with a syndrome of protracted diarrhea associated with a coccidia-like body (CLB). Design: Investigation of an epidemic including a case-control study. Setting: Outpatient clinic in Kathmandu serving primarily the tourist and expatriate community in Nepal. Patients: Nine patients with diarrhea with at least one stool specimen that was positive for the presence of a CLB and seven noninfected volunteer controls. Measurements: Clinical data, microscopic examination of stool, bacteriologic and viral studies on submitted stool specimens, upper gastrointestinal endoscopy including duodenal aspiration and microscopy, small-bowel biopsy with subsequent light and electron microscopy. Results: Endoscopic evidence of inflammation of the distal duodenum was present in five of nine patients with CLB and in none of the seven controls. All nine patients with CLB were noted to have histologic evidence of small-bowel injury, which included acute and chronic inflammation, surface epithelial disarray, and varying degrees of villous atrophy and crypt hyperplasia. One of the seven controls had similar pathologic findings and developed CLB-related diarrhea 5 days later. The other controls had normal distal duodenal histologic results. The organism was found in two of nine duodenal aspirates but was not present in the preserved biopsy specimens as determined by light or electron microscopy. Conclusions: The pathologic basis of CLB-associated diarrhea appears to be small-bowel injury whose cause remains to be elucidated.	CANADIAN INT WATER & ENERGY CONSULTANTS CLIN, Kathmandu, NEPAL; NYU, SCH MED, NEW YORK, NY 10003 USA; BETH ISRAEL HOSP, THORNDIKE LAB, DEPT PATHOL, BOSTON, MA 02215 USA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	New York University; Harvard University; Beth Israel Deaconess Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Connor, Bradley/AAX-6032-2020					HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; KATELARIS PH, 1992, GUT, V33, P295, DOI 10.1136/gut.33.3.295; LEVINE N D, 1973, P406; LIPSON SM, 1989, AM J CLIN PATHOL, V92, P637, DOI 10.1093/ajcp/92.5.637; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; MCDOWELL EM, 1976, ARCH PATHOL LAB MED, V100, P405; OLIVE DM, 1988, MOL CELL PROBE, V2, P47, DOI 10.1016/0890-8508(88)90043-6; Ortega Y. R., 1992, American Journal of Tropical Medicine and Hygiene, V47, P210; POLLOK RCG, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91759-2; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; 1991, MMWR, V40, P325	12	69	75	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					377	382		10.7326/0003-4819-119-5-199309010-00005	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338291				2022-12-28	WOS:A1993LZ47600005
J	MCFARLAND, KF				MCFARLAND, KF			WALKING SHOES	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									UNIV S CAROLINA, SCH MED, COLUMBIA, SC 29203 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia									0	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					423	423		10.7326/0003-4819-119-5-199309010-00012	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338297				2022-12-28	WOS:A1993LZ47600012
J	KIRCHHOFF, LV				KIRCHHOFF, LV			CURRENT CONCEPTS - AMERICAN TRYPANOSOMIASIS (CHAGAS-DISEASE) - A TROPICAL DISEASE NOW IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RENAL-TRANSPLANTATION; CRUZI INFECTION; TRANSMISSION; PREVALENCE; REACTIVATION; CALIFORNIA; COMMUNITY; ANTIBODY; BOLIVIA; THERAPY		DEPT VET AFFAIRS MED CTR, IOWA CITY, IA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	KIRCHHOFF, LV (corresponding author), UNIV IOWA, EMRB 300G, IOWA CITY, IA 52242 USA.							ACQUATELLA H, 1987, CIRCULATION, V76, P556, DOI 10.1161/01.CIR.76.3.556; APPLEMAN MD, 1993, TRANSFUSION, V33, P61, DOI 10.1046/j.1537-2995.1993.33193142312.x; AZOGUE E, 1985, T ROY SOC TROP MED H, V79, P176, DOI 10.1016/0035-9203(85)90328-1; BAROUSSE AP, 1980, MEDICINA-BUENOS AIRE, V40, P896; BEARD CB, 1988, J PARASITOL, V74, P343, DOI 10.2307/3282467; BERGOGLIO RM, 1984, PRENSA MED ARGENT, V71, P49; BITTENCOURT AL, 1976, AM J DIS CHILD, V130, P97, DOI 10.1001/archpedi.1976.02120020099020; BOCCHI EA, 1993, TRANSPLANT P, V25, P1329; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; BRENER Z, 1982, B WORLD HEALTH ORGAN, V60, P463; Brener Z., 1984, Genes and antigens of parasites. A laboratory manual. Proceedings of a course held 14 November-17 December 1983, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil., P3; CAMARGO ME, 1988, LABORATORY DIAGNOSIS, V1, P744; CARRASCO R, 1990, MEM I OSWALDO CRUZ, V85, P69, DOI 10.1590/S0074-02761990000100011; Cedillos R A, 1975, Bull Pan Am Health Organ, V9, P135; Chagas C, 1909, MEM I OSWALDO CRUZ, V1, P159, DOI DOI 10.1590/S0074-02761909000200008; CHAGAS Carlos, 1916, Memorias do Instituto Oswaldo Cruz, V8, P37; Chiari E, 1989, Rev Soc Bras Med Trop, V22, P19, DOI 10.1590/S0037-86821989000100004; Chocair P. R., 1985, Revista da Sociedade Brasileira de Medicina Tropical, V18, P43, DOI 10.1590/S0037-86821985000100009; CHUIT R, 1992, AM J TROP MED HYG, V46, P444, DOI 10.4269/ajtmh.1992.46.444; CHUSTER M, 1985, CARDIOPATIA CHAGASIC, P289; DEARTEAGA J, 1992, TRANSPLANT P, V24, P1900; Dias J. C. P., 1984, Memorias do Instituto Oswaldo Cruz, V79, P85, DOI 10.1590/S0074-02761984000500017; DIAS JCP, 1987, PARASITOL TODAY, V3, P336, DOI 10.1016/0169-4758(87)90117-7; FERREIRA HO, 1988, J PEDIAT-BRAZIL, V64, P1; FIGUEIREDO JFC, 1990, T ROY SOC TROP MED H, V84, P61, DOI 10.1016/0035-9203(90)90383-P; GEISELER PJ, 1987, 27 INT C ANT AG CHEM, P169; GLUCKSTEIN D, 1992, AM J MED, V92, P429, DOI 10.1016/0002-9343(92)90275-G; GOTTESDIENER KM, 1989, ANN INTERN MED, V110, P1001, DOI 10.7326/0003-4819-110-12-1001; GRANT IH, 1989, ANN INTERN MED, V111, P849, DOI 10.7326/0003-4819-111-10-849; HAGAR JM, 1991, NEW ENGL J MED, V325, P763, DOI 10.1056/NEJM199109123251103; HERWALDT BL, 1993, AM J TROP MED HYG, V48, P313, DOI 10.4269/ajtmh.1993.48.313; HOFF R, 1978, NEW ENGL J MED, V298, P604, DOI 10.1056/NEJM197803162981106; HUDSON L, 1985, CURR TOP MICROBIOL, V117, P167; KERNDT PR, 1991, TRANSFUSION, V31, P814, DOI 10.1046/j.1537-2995.1991.31992094668.x; Kierszenbaum F, 1985, Parasitol Today, V1, P4, DOI 10.1016/0169-4758(85)90098-5; Kirchhoff L. V., 1990, Principles and practice of infectious diseases., P2077; KIRCHHOFF LV, 1989, ANN INTERN MED, V111, P773, DOI 10.7326/0003-4819-111-10-773; KIRCHHOFF LV, 1987, J INFECT DIS, V155, P561, DOI 10.1093/infdis/155.3.561; KIRCHHOFF LV, 1985, JAMA-J AM MED ASSOC, V254, P3058, DOI 10.1001/jama.254.21.3058; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; KOHL S, 1982, CANCER, V50, P827, DOI 10.1002/1097-0142(19820901)50:5<827::AID-CNCR2820500503>3.0.CO;2-#; LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035; LEIGUARDA R, 1990, NEUROLOGY, V40, P850, DOI 10.1212/WNL.40.5.850; LIBOW LF, 1991, CUTIS, V48, P37; Lopez Blanco O. A., 1992, Transplantation Proceedings, V24, P3089; LUDERS C, 1992, TRANSPL P, V24, P1878; MAGUIRE JH, 1987, CIRCULATION, V75, P1140, DOI 10.1161/01.CIR.75.6.1140; MARR JJ, 1986, REV INFECT DIS, V8, P884; MILES MA, 1992, PARASITOL TODAY, V8, P221, DOI 10.1016/0169-4758(92)90113-G; MOCELIN AJ, 1977, TRANSPLANTATION, V23, P163, DOI 10.1097/00007890-197702000-00011; MONTEVERDE DA, 1976, REV NEUROL ARG, V2, P260; MOTA EA, 1990, AM J TROP MED HYG, V42, P429, DOI 10.4269/ajtmh.1990.42.429; NETO VA, 1975, REV GOIANA MED, V21, P1; NICKERSON P, 1989, ANN INTERN MED, V111, P851, DOI 10.7326/0003-4819-111-10-851; PETRY K, 1989, PARASITOL TODAY, V5, P111, DOI 10.1016/0169-4758(89)90052-5; PIZZI T, 1982, REV MED CHILE, V110, P1207; RASSI A., 1971, Revista da Sociedade Brasileira de Medicina Tropical, V5, P235, DOI 10.1590/S0037-86821971000500001; RIVERO I, 1974, NEW ENGL J MED, V290, P285; SCHIFFLER RJ, 1984, JAMA-J AM MED ASSOC, V251, P2983, DOI 10.1001/jama.251.22.2983; SCHMUNIS GA, 1991, TRANSFUSION, V31, P547, DOI 10.1046/j.1537-2995.1991.31691306255.x; SCHMUNIS GA, 1977, MEDICINA-BUENOS AIRE, V37, P47; SHIKANAIYASUDA MA, 1990, REV INST MED TROP SP, V32, P16, DOI 10.1590/S0036-46651990000100004; SPENCER HC, 1980, AM J TROP MED HYG, V29, P179, DOI 10.4269/ajtmh.1980.29.179; STOLF NAG, 1987, J HEART TRANSPLANT, V6, P307; TANOWITZ HB, 1992, CLIN MICROBIOL REV, V5, P400, DOI 10.1128/CMR.5.4.400-419.1992; TEIXEIRA ARL, 1990, J COMP PATHOL, V103, P37, DOI 10.1016/S0021-9975(08)80133-8; TEIXEIRA ARL, 1990, AM J TROP MED HYG, V43, P146, DOI 10.4269/ajtmh.1990.43.146; VANVOORHIS WC, 1989, J EXP MED, V169, P641, DOI 10.1084/jem.169.3.641; YAEGER RG, 1988, AM J TROP MED HYG, V38, P323, DOI 10.4269/ajtmh.1988.38.323; 1991, WHO TECH REP SER, V811, P27	70	304	314	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					639	644						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341339				2022-12-28	WOS:A1993LU21700009
J	FLEGEL, K				FLEGEL, K			ON LOSING ONES PARENTS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											FLEGEL, K (corresponding author), ROYAL VICTORIA HOSP, MONTREAL H3A 1A1, QUEBEC, CANADA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					336	336		10.7326/0003-4819-119-4-199308150-00014	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328744				2022-12-28	WOS:A1993LV52500014
J	HALL, CG; SANCHO, J; TERHORST, C				HALL, CG; SANCHO, J; TERHORST, C			RECONSTITUTION OF T-CELL RECEPTOR ZETA-MEDIATED CALCIUM MOBILIZATION IN NONLYMPHOID CELLS	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; MOLECULAR-CLONING; PHOSPHATASE CD45; ACTIVATION; PHOSPHORYLATION; CHAIN; STIMULATION	T cell antigen receptor (TCR) activation involves interactions between receptor subunits and nonreceptor protein tyrosine kinases (PTKs). Early steps in signaling through the zeta chain of the TCR were examined in transfected COS-1 cells. Coexpression of the PTK p59fynT, but not p56lck, with zeta or with a homodimeric TCRbeta-zeta fusion protein produced tyrosine phosphorylation of both zeta and phospholipase C (PLC)-gamma1, as well as calcium ion mobilization in response to receptor cross-linking. CD45 coexpression enhanced these effects. No requirement for the PTKZAP-70 was observed. Thus, p59fynT may link zeta directly to the PLC-gamma1 activation pathway.			HALL, CG (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV IMMUNOL,BOSTON,MA 02215, USA.		Sancho, Jaime/K-5989-2019; Sancho, Jaime/O-3228-2013	Sancho, Jaime/0000-0003-3852-7951; Sancho, Jaime/0000-0003-3852-7951	NATIONAL CANCER INSTITUTE [K08CA001486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI015066, R01AI015066] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01486] Funding Source: Medline; NIAID NIH HHS [AI 15066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; HALL CA, UNPUB; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KOYASU S, 1992, J BIOL CHEM, V267, P3375; Ledbetter J A, 1990, Semin Immunol, V2, P99; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MASLINSKI W, UNPUB; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; SANCHO J, 1992, J BIOL CHEM, V267, P7871; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	45	80	83	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					915	918		10.1126/science.8346442	http://dx.doi.org/10.1126/science.8346442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346442				2022-12-28	WOS:A1993LR89700039
J	JARAMILLO, F; MARKIN, VS; HUDSPETH, AJ				JARAMILLO, F; MARKIN, VS; HUDSPETH, AJ			AUDITORY ILLUSIONS AND THE SINGLE HAIR CELL	NATURE			English	Article							DISTORTION PRODUCTS F2-F1; BASILAR-MEMBRANE; MECHANOELECTRICAL TRANSDUCTION; BULLFROGS SACCULUS; COMBINATION TONES; CHANNELS; ADAPTATION; RESPONSES; COCHLEA; BUNDLES	LIKE our other senses, the auditory system can produce illusions. Prominent among these are distortion products1-5: when listening to two tones, one of frequency f1 and the second of a higher frequency f2, an individual may hear not only these primary tones, but also a difference tone of frequency f2-f1, a sum tone of frequency f2+f1, and combination tones of frequencies such as 2f1-f2 and 2f2-f1. Discovered by Tartini early in the eighteenth century6,7, these illusory sounds are sufficiently conspicuous that they were employed to carry melodies in classical compositions. Distortion products originate within the cochlea, where they manifest themselves in the basilar membrane's vibration8. Here we demonstrate distortion products in individual hair cells of the bullfrog's sacculus, where they emerge from a nonlinearity inherent in the mechanoelectrical transduction process. In addition to offering an explanation for cochlear distortion products, our results suggest that the mechanical properties of hair bundles significantly influence the basilar membrane's motion.			JARAMILLO, F (corresponding author), UNIV TEXAS,SW MED CTR,CTR BASIC NEUROSCI RES,DALLAS,TX 75235, USA.							ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASSAD JA, 1991, NEURON, V7, P985, DOI 10.1016/0896-6273(91)90343-X; BENSER ME, IN PRESS HEARING RES; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; COREY DP, 1983, J NEUROSCI, V3, P962; COREY DP, 1979, BIOPHYS J, V26, P499, DOI 10.1016/S0006-3495(79)85267-4; COREY DP, 1983, J NEUROSCI, V3, P942; CRAWFORD AC, 1985, J PHYSIOL-LONDON, V364, P359, DOI 10.1113/jphysiol.1985.sp015750; CRAWFORD AC, 1989, J PHYSIOL-LONDON, V419, P405, DOI 10.1113/jphysiol.1989.sp017878; DENK W, 1992, HEARING RES, V60, P89, DOI 10.1016/0378-5955(92)90062-R; GILLESPIE PG, 1993, P NATL ACAD SCI USA, V90, P2710, DOI 10.1073/pnas.90.7.2710; GOLDSTEIN JL, 1967, J ACOUST SOC AM, V41, P676, DOI 10.1121/1.1910396; GUMMER AW, 1981, J ACOUST SOC AM, V70, P1298, DOI 10.1121/1.387144; HALL JL, 1972, J ACOUST SOC AM, V51, P1863, DOI 10.1121/1.1913045; HOLTON T, 1986, J PHYSIOL-LONDON, V375, P195, DOI 10.1113/jphysiol.1986.sp016113; HOWARD J, 1987, P NATL ACAD SCI USA, V84, P3064, DOI 10.1073/pnas.84.9.3064; HOWARD J, 1988, ANNU REV BIOPHYS BIO, V17, P99; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; HUMES LE, 1980, J ACOUST SOC AM, V67, P2073, DOI 10.1121/1.384451; JARAMILLO F, 1993, P NATL ACAD SCI USA, V90, P1330, DOI 10.1073/pnas.90.4.1330; JARAMILLO F, 1991, NEURON, V7, P409, DOI 10.1016/0896-6273(91)90293-9; KROESE ABA, 1989, HEARING RES, V37, P203, DOI 10.1016/0378-5955(89)90023-3; MILLER CE, 1985, J ACOUST SOC AM, V77, P1465, DOI 10.1121/1.392041; OHMORI H, 1987, J PHYSIOL-LONDON, V387, P589, DOI 10.1113/jphysiol.1987.sp016590; OLSON ES, 1991, J ACOUST SOC AM, V89, P1262, DOI 10.1121/1.400535; PICKLES JO, 1984, HEARING RES, V15, P103, DOI 10.1016/0378-5955(84)90041-8; RHODE WS, 1967, J ACOUST SOC AM, V42, P185, DOI 10.1121/1.1910547; ROBERTS WM, 1988, ANNU REV CELL BIOL, V4, P63, DOI 10.1146/annurev.cb.04.110188.000431; ROBLES L, 1991, NATURE, V349, P413, DOI 10.1038/349413a0; Ruggero M A, 1992, Curr Opin Neurobiol, V2, P449, DOI 10.1016/0959-4388(92)90179-O; RUSSELL IJ, 1992, P ROY SOC B-BIOL SCI, V250, P217, DOI 10.1098/rspb.1992.0152; SIEGEL JH, 1982, J NEUROPHYSIOL, V47, P303, DOI 10.1152/jn.1982.47.2.303; SMOORENBURG GF, 1972, J ACOUST SOC AM, V52, P615, DOI 10.1121/1.1913152; SMOORENBURG GF, 1972, J ACOUST SOC AM, V52, P603, DOI 10.1121/1.1913151; TARTINI G, 1967, PRINCIPJ ARMONIA MUS, P4; WALKER DP, 1978, STUDIES MUSICAL SCI, P136; ZUREK PM, 1979, SCIENCE, V205, P600, DOI 10.1126/science.451625	38	102	102	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					527	529		10.1038/364527a0	http://dx.doi.org/10.1038/364527a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8336792				2022-12-28	WOS:A1993LQ66700054
J	ALPER, J				ALPER, J			TRANSILLUMINATION - LOOKING RIGHT THROUGH YOU	SCIENCE			English	Editorial Material																		BENARON DA, 1993, SCIENCE, V259, P1463, DOI 10.1126/science.8451643; BENARON DA, 1993, IN PRESS SPIE P, V1888; FENG L, 1993, APPL OPTICS, V32, P554, DOI 10.1364/AO.32.000554; LIU CH, 1992, J PHOTOCH PHOTOBIO B, V16, P187, DOI 10.1016/1011-1344(92)80008-J	4	5	6	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1993	261	5121					560	560		10.1126/science.8342020	http://dx.doi.org/10.1126/science.8342020			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342020				2022-12-28	WOS:A1993LP72800028
J	TSUJINO, S; SHANSKE, S; DIMAURO, S				TSUJINO, S; SHANSKE, S; DIMAURO, S			MOLECULAR-GENETIC HETEROGENEITY OF MYOPHOSPHORYLASE DEFICIENCY (MCARDLES-DISEASE)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUSCLE PHOSPHORYLASE-DEFICIENCY; GLYCOGEN-PHOSPHORYLASE; SEQUENCE-ANALYSIS; HUMAN-LIVER; RESOLUTION	Background and Methods. Myophosphorylase deficiency (McArdle's disease) is one of the most common causes of exercise intolerance, muscle cramps, and recurrent myoglobinuria. The myophosphorylase gene has been sequenced and assigned to chromosome 11, but the molecular basis of McArdle's disease is not known. We sequenced complementary DNA in 4 patients and studied genomic DNA by restriction-endonuclease analysis in 40 patients with McArdle's disease. Results. Sequence analysis revealed three distinct point mutations: the substitution of thymine for cytosine at codon 49 in exon 1, changing an encoded arginine to a stop codon; the substitution of adenine for guanine at codon 204 in exon 5, changing glycine to serine; and the substitution of cytosine for adenine at codon 542 in exon 14, changing lysine to threonine. Analysis of restriction-fragment-length polymorphisms of appropriate fragments of genomic DNA after amplification with the polymerase chain reaction showed that 18 patients were homozygous for the stop-codon mutation, 6 had different mutations in the two alleles (compound heterozygotes), and 11 were presumed to be compound heterozygotes for a known mutation and an unknown one; only 5 patients had none of the three mutations. All three mutations were present in various combinations in five members of a family in which transmission appeared to be autosomal dominant. Conclusions. McArdle's disease is genetically heterogeneous, but the most common mutation is the substitution of thymine for cytosine at codon 49. These results suggest that in about 90 percent of patients the diagnosis of McArdle's disease can be made from a patient's leukocytes, thus avoiding the need for muscle biopsy.	COLUMBIA PRESBYTERIAN MED CTR, COLL PHYS & SURG 4420, 630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA PRESBYTERIAN MED CTR, H HOUSTON MERRITT CLIN RES CTR MUSCULAR DYSTROPHY, NEW YORK, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital					NINDS NIH HHS [NS-11766] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011766, P01NS011766] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEGRADER P, 1993, P NATL ACAD SCI USA, V90, P482; BURKE J, 1987, PROTEINS, V2, P177, DOI 10.1002/prot.340020303; CHUI LA, 1976, ARCH NEUROL-CHICAGO, V33, P636, DOI 10.1001/archneur.1976.00500090042008; Dahl H.-H. M., 1992, Human Mutation, V1, P97, DOI 10.1002/humu.1380010203; DELAMAZA M, 1980, NEUROLOGY, V30, P402; DIMAURO S, 1978, NEUROLOGY, V28, P1124, DOI 10.1212/WNL.28.11.1124; DIMAURO S, 1986, MYOLOGY, P1585; GAUTRON S, 1987, J CLIN INVEST, V79, P275, DOI 10.1172/JCI112794; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; LEBO RV, 1990, HUM GENET, V86, P17; LEBO RV, 1984, SCIENCE, V225, P57, DOI 10.1126/science.6587566; LEWIS SF, 1986, J APPL PHYSIOL, V61, P391, DOI 10.1152/jappl.1986.61.2.391; MASHIMA Y, 1992, AM J HUM GENET, V51, P81; MCARDLE B, 1951, CLIN SCI, V10, P12; MCCONCHIE SM, 1990, BIOCHIM BIOPHYS ACTA, V1096, P26, DOI 10.1016/0925-4439(90)90008-D; MILSTEIN JM, 1989, J CHILD NEUROL, V4, P186, DOI 10.1177/088307388900400305; MIRANDA AF, 1979, NEUROLOGY, V29, P1538, DOI 10.1212/WNL.29.11.1538; MOMMAERTS WFHM, 1959, P NATL ACAD SCI USA, V45, P791, DOI 10.1073/pnas.45.6.791; NEWGARD CB, 1988, J BIOL CHEM, V263, P3850; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; PAPADIMITRIOU A, 1990, J NEUROL, V237, P267, DOI 10.1007/BF00314633; SCHIMRIG.K, 1967, KLIN WOCHENSCHR, V45, P1, DOI 10.1007/BF01745732; SCHMID R, 1959, J CLIN INVEST, V38, P2044, DOI 10.1172/JCI103983; SCHMIDT B, 1987, NEUROLOGY, V37, P1558, DOI 10.1212/WNL.37.9.1558; SERVIDEI S, 1988, ANN NEUROL, V24, P774, DOI 10.1002/ana.410240612; SHANSKE S, 1987, J BIOL CHEM, V262, P14612; SPRANG S, 1979, J MOL BIOL, V131, P523, DOI 10.1016/0022-2836(79)90006-8; TARONI F, 1992, P NATL ACAD SCI USA, V89, P8429, DOI 10.1073/pnas.89.18.8429	28	172	174	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					241	245		10.1056/NEJM199307223290404	http://dx.doi.org/10.1056/NEJM199307223290404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM682	8316268	Bronze			2022-12-28	WOS:A1993LM68200004
J	ZHANG, XF; SETTLEMAN, J; KYRIAKIS, JM; TAKEUCHISUZUKI, E; ELLEDGE, SJ; MARSHALL, MS; BRUDER, JT; RAPP, UR; AVRUCH, J				ZHANG, XF; SETTLEMAN, J; KYRIAKIS, JM; TAKEUCHISUZUKI, E; ELLEDGE, SJ; MARSHALL, MS; BRUDER, JT; RAPP, UR; AVRUCH, J			NORMAL AND ONCOGENIC P21(RAS) PROTEINS BIND TO THE AMINO-TERMINAL REGULATORY DOMAIN OF C-RAF-1	NATURE			English	Article							S6 KINASE-II; XENOPUS OOCYTES; SIGNAL TRANSDUCTION; SUPPRESSOR ACTIVITY; RAS-P21 GTPASE; RAS; ACTIVATION; SERINE; RAF-1; GROWTH	In higher eukaryotes, the Ras and Raf-1 proto-oncoproteins transduce growth and differentiation signals initiated by tyrosine kinases. The Ras polypeptide and the amino-terminal regulatory domain of Raf-1(residues 1-257) are shown to interact, directly in vitro and in a yeast expression system. Raf-1(1-257) binds GTP-Ras in preference to GDP-Ras, and inhibits Ras-GAP activity. Mutations in and around the Ras effector domain impair Ras binding to Raf-1(1-257) and Ras transforming activity in parallel.	HARVARD UNIV, SCH MED, DIABET UNIT, 149 13TH ST, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, MED SERV, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP E, CTR CANC, BOSTON, MA 02129 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; INDIANA UNIV, SCH MED, DEPT MED, HEMATOL ONCOL SECT, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute								AHN NG, 1991, J BIOL CHEM, V266, P4220; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, pCH13; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GOMEZ N, 1991, NATURE, V351, P69; GROVE JR, IN PRESS BIOCHEMISTR; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HATTORI G, J BIOL CHEM, V267, P20346; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; ITOH T, 1993, J BIOL CHEM, V268, P3025; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, IN PRESS J BIOL CHEM; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARSHALL MS, 1993, ONCOGENE, V8, P425; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WOOD KW, 1992, J CELL, V68, P1041	48	805	825	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 22	1993	364	6435					308	313		10.1038/364308a0	http://dx.doi.org/10.1038/364308a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332187				2022-12-28	WOS:A1993LN57000047
J	BRUNGER, AT; CLORE, GM; GRONENBORN, AM; SAFFRICH, R; NILGES, M				BRUNGER, AT; CLORE, GM; GRONENBORN, AM; SAFFRICH, R; NILGES, M			ASSESSING THE QUALITY OF SOLUTION NUCLEAR-MAGNETIC-RESONANCE STRUCTURES BY COMPLETE CROSS-VALIDATION	SCIENCE			English	Article							DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURE; MACROMOLECULAR STRUCTURES; PROTEIN CONFORMATIONS; MOLECULAR-DYNAMICS; TRYPSIN-INHIBITOR; REFINEMENT; SPECTROSCOPY; CONSTRAINTS; RESTRAINTS	Structure determination of macromolecules in solution by nuclear magnetic resonance (NMR) spectroscopy involves the fitting of atomic models to the observed nuclear Over-hauser effect (NOE) data. Complete cross-validation has been used to define reliable and unbiased criteria for the quality of solution NMR structures. The method is based on the partitioning of NOE data into test sets and the cross-validation of statistical quantities for each of the test sets. A high correlation between cross-validated measures of fit, such as distance bound violations and NMR R values, and the quality of solution NMR structures was observed. Less complete data resulted in poorer satisfaction of the cross-validated measures of fit. Optimization of cross-validated measures of fit will likely produce solution NMR structures with maximal information content.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Yale University; European Molecular Biology Laboratory (EMBL)	BRUNGER, AT (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511, USA.		Nilges, Michael/E-4803-2011; Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Nilges, Michael/0000-0002-1451-8092; Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Saffrich, Rainer/0000-0002-0547-4550; Gronenborn, Angela M/0000-0001-9072-3525; Brunger, Axel/0000-0001-5121-2036				[Anonymous], 1982, JACKKNIFE BOOTSTRAP; BONVIN AMJ, 1993, COMPUTER SIMULATION, V2; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; BRUNGER AT, IN PRESS Q REV BIOPH; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1993, J MOL BIOL, V231, P82, DOI 10.1006/jmbi.1993.1259; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; EFRON B, 1988, SIAM REV, V30, P421, DOI 10.1137/1030093; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; GONZALEZ C, 1991, J MAGN RESON, V91, P659, DOI 10.1016/0022-2364(91)90397-C; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HAVEL TF, 1985, J MOL BIOL, V182, P281, DOI 10.1016/0022-2836(85)90346-8; HAVEL TF, 1983, B MATH BIOL, V45, P665; Hendrickson W. A., 1991, MACROMOLECULAR STRUC; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOLAK TA, 1989, J MOL BIOL, V210, P635, DOI 10.1016/0022-2836(89)90137-X; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; James TL, 1991, CURR OPIN STRUC BIOL, V1, P1042, DOI 10.1016/0959-440X(91)90104-2; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OSHIRO CM, 1991, BIOPOLYMERS, V31, P1049, DOI 10.1002/bip.360310905; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; STONE M, 1974, J R STAT SOC B, V36, P111, DOI 10.1111/j.2517-6161.1974.tb00994.x; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; THOMAS PD, 1991, P NATL ACAD SCI USA, V88, P1237, DOI 10.1073/pnas.88.4.1237; TORDA AE, 1990, J MOL BIOL, V214, P223, DOI 10.1016/0022-2836(90)90157-H; TORDA AE, 1989, CHEM PHYS LETT, V157, P289, DOI 10.1016/0009-2614(89)87249-5; WHITE SA, 1992, BIOCHEMISTRY-US, V31, P1610, DOI 10.1021/bi00121a005; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WITHKA JM, 1992, J MAGN RESON, V98, P611, DOI 10.1016/0022-2364(92)90014-X; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YIP P, 1989, J MAGN RESON, V83, P643, DOI 10.1016/0022-2364(89)90360-0; YIP PF, 1989, CHEM PHYS LETT, V161, P50, DOI 10.1016/S0009-2614(89)87030-7	43	148	148	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					328	331		10.1126/science.8332897	http://dx.doi.org/10.1126/science.8332897			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332897				2022-12-28	WOS:A1993LM67800028
J	THOMAS, JD; SIDERAS, P; SMITH, CIE; VORECHOVSKY, I; CHAPMAN, V; PAUL, WE				THOMAS, JD; SIDERAS, P; SMITH, CIE; VORECHOVSKY, I; CHAPMAN, V; PAUL, WE			COLOCALIZATION OF X-LINKED AGAMMAGLOBULINEMIA AND X-LINKED IMMUNODEFICIENCY GENES	SCIENCE			English	Article							B-CELLS; IMMUNE-DEFICIENCY; LYMPHOCYTES-B; SRC GENE; 5' EXONS; C-SRC; MICE; MUTATION; PROTEIN; MOUSE	Mice that bear the X-linked immunodeficiency (xid) mutation have a B lymphocyte-specific defect resulting in an inability to make antibody responses to polysaccharide antigens. A backcross of 1114 progeny revealed the colocalization of xid with Bruton's agammaglobulinemia tyrosine kinase (btk) gene, which is implicated in the human immune deficiency, X-linked agammaglobulinemia. Mice that carry xid have a missense mutation that alters a highly conserved arginine near the amino-terminus of the btk protein, Btk. Because this region of Btk lies outside any obvious kinase domain, the xid mutation may define another aspect of tyrosine kinase function.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN; UMEA UNIV,APPL CELL & MOLEC BIOL UNIT,S-90187 UMEA,SWEDEN; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT MOLEC BIOL,BUFFALO,NY 14263	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Karolinska Institutet; Umea University; Roswell Park Cancer Institute				Sideras, Paschalis/0000-0003-0701-1258; SMITH, C. I. Edvard/0000-0003-1907-3392	NHGRI NIH HHS [HG00277] Funding Source: Medline; NIGMS NIH HHS [GM33160] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033160] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNING AK, 1980, J IMMUNOL, V124, P1875; BONA C, 1980, J EXP MED, V151, P224, DOI 10.1084/jem.151.1.224; BROWN S, IN PRESS MAMM GENOME; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V1, pCH3; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V1, pCH2; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; COOKE MF, 1988, NEW BIOL, V1, P66; CROSS FR, 1984, MOL CELL BIOL, V4, P1824; DESIDERIO S, 1993, NATURE, V361, P202, DOI 10.1038/361202a0; DIETRICH W, 1992, GENETICS, V131, P4232; DIUGUID DL, 1989, BLOOD, V74, P193; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; FORRESTER LM, 1987, J EXP MED, V165, P949, DOI 10.1084/jem.165.4.949; GREEN MC, 1991, HDB GENETICALLY STAN, P14; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KUSUMI K, IN PRESS MAMM GENOME; LORENZO F, 1993, BRIT J HAEMATOL, V83, P152, DOI 10.1111/j.1365-2141.1993.tb04646.x; MANO, 1993, ONCOGENE, V8, P417; MOND JJ, 1982, J EXP MED, V155, P924, DOI 10.1084/jem.155.3.924; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; NAHM MH, 1983, J EXP MED, V158, P920, DOI 10.1084/jem.158.3.920; PRIOR L, 1992, AM J HUM GENET, V51, P143; ROSSI JM, 1992, P NATL ACAD SCI USA, V89, P2456, DOI 10.1073/pnas.89.6.2456; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SIDERAS P, UNPUB; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SPRENT J, 1984, J EXP MED, V160, P335, DOI 10.1084/jem.160.1.335; STEPHENSON DA, 1988, NUCLEIC ACIDS RES, V16, P1642, DOI 10.1093/nar/16.4.1642; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VINCENT WS, 1989, GENE DEV, V3, P334, DOI 10.1101/gad.3.3.334; WORTIS HH, 1982, J EXP MED, V155, P903, DOI 10.1084/jem.155.3.903; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; [No title captured]	40	576	584	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					355	358		10.1126/science.8332900	http://dx.doi.org/10.1126/science.8332900			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332900				2022-12-28	WOS:A1993LM67800037
J	BINDER, LS				BINDER, LS			EMERGENCY-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											BINDER, LS (corresponding author), TEXAS TECH UNIV,HLTH SCI CTR,EL PASO,TX, USA.							AUFDERHEIDE TP, 1992, ANN EMERG MED, V21, P379, DOI 10.1016/S0196-0644(05)82654-X; BARAFF LJ, 1992, ANN EMERG MED, V21, P153, DOI 10.1016/S0196-0644(05)80150-7; BAXT WG, 1992, ANN EMERG MED, V21, P1439, DOI 10.1016/S0196-0644(05)80056-3; BRADDOCK M, 1992, ANN EMERG MED, V21, P273, DOI 10.1016/S0196-0644(05)80887-X; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; GIBLER WB, 1992, ANN EMERG MED, V21, P504; HEDGES JR, 1992, ANN EMERG MED, V21, P1445, DOI 10.1016/S0196-0644(05)80057-5; HENNEMAN PL, 1992, ANN EMERG MED, V21, P545, DOI 10.1016/S0196-0644(05)82522-3; MCCABE JL, 1992, ANN EMERG MED, V21, P358, DOI 10.1016/S0196-0644(05)82650-2; MURPHYMACABOBBY M, 1992, ANN EMERG MED, V21, P664, DOI 10.1016/S0196-0644(05)82776-3; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; 1992, JAMA-J AM MED ASSOC, V268, P2171	13	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					200	202		10.1001/jama.270.2.200	http://dx.doi.org/10.1001/jama.270.2.200			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315730				2022-12-28	WOS:A1993LL36800016
J	CULLEN, KE; KLADDE, MP; SEYFRED, MA				CULLEN, KE; KLADDE, MP; SEYFRED, MA			INTERACTION BETWEEN TRANSCRIPTION REGULATORY REGIONS OF PROLACTIN CHROMATIN	SCIENCE			English	Article							COOPERATIVE BINDING; GENE-REGULATION; DNA LOOP; ENHANCER; ACTIVATION; PROMOTER; ELEMENTS; ESTROGEN; DISTANCE; PROTEIN	The regulation of transcription requires complex interactions between proteins bound to DNA sequences that are often separated by hundreds of base pairs. As demonstrated by a nuclear ligation assay, the distal enhancer and the proximal promoter regions of the rat prolactin gene were found to be juxtaposed. By acting through its receptor bound to the distal enhancer, estrogen stimulated the interaction between the distal and proximal regulatory regions two- to threefold compared to control values. Thus, the chromatin structure of the prolactin gene may facilitate the occurrence of protein-protein interactions between transcription factors bound to widely separated regulatory elements.	VANDERBILT UNIV,DEPT MOLEC BIOL,NASHVILLE,TN 37235; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	Vanderbilt University; University of Wisconsin System; University of Wisconsin Madison					NICHD NIH HHS [T32HD07048] Funding Source: Medline; NIDDK NIH HHS [DK42731] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042731] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAMPER SA, 1985, J BIOL CHEM, V260; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; CULLEN KE, UNPUB; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FELSENFELD G, 1986, CELL, V44, P375, DOI 10.1016/0092-8674(86)90456-3; GRALLA JD, 1989, CELL, V57, P193, DOI 10.1016/0092-8674(89)90955-0; GRIFFITH J, 1986, NATURE, V322, P750, DOI 10.1038/322750a0; HANN S, 1986, J MOL BIOL, V188, P355; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MAURER RA, 1982, J BIOL CHEM, V257, P2133; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; ROTHBERG I, 1991, NUCLEIC ACIDS RES, V19, P5713, DOI 10.1093/nar/19.20.5713; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SCHLEIF R, 1987, NATURE, V327, P369, DOI 10.1038/327369a0; SEYFRED MA, 1990, MOL ENDOCRINOL, V4, P1226, DOI 10.1210/mend-4-8-1226; SEYFRED MA, 1989, MOL ENDOCRINOL, V3, P305, DOI 10.1210/mend-3-2-305; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUPOWIT SC, 1984, P NATL ACAD SCI-BIOL, V81, P2975, DOI 10.1073/pnas.81.10.2975; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14	35	157	160	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					203	206		10.1126/science.8327891	http://dx.doi.org/10.1126/science.8327891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8327891				2022-12-28	WOS:A1993LL59600038
J	MELLANBY, A; PHELPS, F; TRIPP, JH				MELLANBY, A; PHELPS, F; TRIPP, JH			TEENAGERS, SEX, AND RISK-TAKING	BRITISH MEDICAL JOURNAL			English	Article									UNIV EXETER,DEPT CHILD HLTH,EXETER EX2 5SQ,ENGLAND	University of Exeter								BARCOHEN A, 1990, J SCHOOL HEALTH, V60, P418, DOI 10.1111/j.1746-1561.1990.tb05962.x; BLUM RW, 1982, PEDIATR ANN, V11, P797, DOI 10.3928/0090-4481-19821001-07; CURTIS HA, 1988, ARCH DIS CHILD, V63, P373, DOI 10.1136/adc.63.4.373; Ford N., 1992, British Journal of Family Planning, V18, P52; 1991, REPORT UNPLANNED PRE	5	34	34	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					25	25		10.1136/bmj.307.6895.25	http://dx.doi.org/10.1136/bmj.307.6895.25			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343664	Bronze, Green Published			2022-12-28	WOS:A1993LL36900022
J	VELLA, EJ; EDWARDS, CW				VELLA, EJ; EDWARDS, CW			DEATH FROM PULMONARY MICROEMBOLISATION AFTER INTRAVENOUS-INJECTION OF TEMAZEPAM	BRITISH MEDICAL JOURNAL			English	Letter									E BIRMINGHAM DIST GEN HOSP,DEPT PATHOL,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND		VELLA, EJ (corresponding author), PATHOL LAB,LAKIN RD,WARWICK CV34 5BJ,ENGLAND.							ADISESHIAH M, 1992, BRIT MED J, V304, P1630, DOI 10.1136/bmj.304.6842.1630-a; Drake Jack, COMMUNICATION; FOX R, 1992, BRIT MED J, V305, P253, DOI 10.1136/bmj.305.6847.253; INNES CF, 1992, BRIT MED J, V305, P832, DOI 10.1136/bmj.305.6857.832-c; SCOTT RN, 1992, BMJ, V30, P1630	5	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					26	26		10.1136/bmj.307.6895.26	http://dx.doi.org/10.1136/bmj.307.6895.26			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343665	Green Published, Bronze			2022-12-28	WOS:A1993LL36900023
J	ANDREWS, K				ANDREWS, K			PATIENTS IN THE PERSISTENT VEGETATIVE STATE - PROBLEMS IN THEIR LONG-TERM MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article								Physicians responsible for the long term management of patients in the persistent vegetative state face several problems. These include deciding whether tube feeding is treatment or nutritional care, whether withdrawal of tube feeding is an appropriate form of management, what clinical advantage there is in active treatment; at what level of awareness can a patient be said to have a quality of life; and who should determine a patient's right to die. These problems are determined more by social, legal, emotional, cultural, religious, and economic forces than by clinical facts.	ROYAL HOSP & HOME,RES SERV,LONDON SW15 3SW,ENGLAND		ANDREWS, K (corresponding author), ROYAL HOSP & HOME,MED SERV,LONDON SW15 3SW,ENGLAND.							ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597	1	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1600	1602		10.1136/bmj.306.6892.1600	http://dx.doi.org/10.1136/bmj.306.6892.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329927	Bronze, Green Published			2022-12-28	WOS:A1993LH12800028
J	SHAPIRO, CM; DEMENT, WC				SHAPIRO, CM; DEMENT, WC			ABC OF SLEEP DISORDERS - IMPACT AND EPIDEMIOLOGY OF SLEEP DISORDERS	BRITISH MEDICAL JOURNAL			English	Article									STANFORD UNIV,STANFORD,CA 94305	Stanford University	SHAPIRO, CM (corresponding author), UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA.								0	41	41	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1604	1607		10.1136/bmj.306.6892.1604	http://dx.doi.org/10.1136/bmj.306.6892.1604			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329929	Bronze, Green Published			2022-12-28	WOS:A1993LH12800031
J	RHYU, MS; JAN, LY; JAN, YN				RHYU, MS; JAN, LY; JAN, YN			ASYMMETRIC DISTRIBUTION OF NUMB PROTEIN DURING DIVISION OF THE SENSORY ORGAN PRECURSOR CELL CONFERS DISTINCT FATES TO DAUGHTER CELLS	CELL			English	Article							DROSOPHILA NERVOUS-SYSTEM; CAENORHABDITIS-ELEGANS; MONOCLONAL-ANTIBODIES; NOTCH LOCUS; GENE; MELANOGASTER; EMBRYOS; DIFFERENTIATION; EXPRESSION; HAIRLESS	The four cells of an external sense organ in the Drosophila peripheral nervous system, the neuron, its sheath cell, and two ''outer support cells'' that form the hair and socket, are derived from a common precursor, the sensory organ precursor (SOP), after two rounds of division. We determined by immunocytochemistry that numb is a membrane-associated protein which localizes asymmetrically to one-half of the predivisional SOP cell. Upon division, numb segregates differentially to one daughter. Loss of numb function causes the descendants of the SOP to differentiate inappropriately, producing four outer support cells and no neuron or sheath. Ectopic expression of numb during the time of SOP division results in a transformation that is opposite to the null mutant transformation. Thus, numb functions to determine the fates of the secondary precursors; the differential distribution of numb as the SOP divides generates an asymmetric division in which the daughter cells acquire distinct identities.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	RHYU, MS (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; ASHBURNER M, 1982, GENETICS, V101, P447; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BANG AG, 1991, DEVELOPMENT, V111, P89; BANG AG, 1992, GENE DEV, V6, P1752, DOI 10.1101/gad.6.9.1752; Bate C.M., 1978, HDB SENSORY PHYSL, V9, P1, DOI [10.1007/978-3-642-66880-7_1, DOI 10.1007/978-3-642-66880-7_1]; Bauer V, 1904, ZOOL JB ABT ANAT ONT, V20, P123; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, CELL, V68, P1062; BRAND M, 1993, DEVELOPMENT, V119, P1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CANAL I, 1986, J NEUROGENET, V3, P293, DOI 10.3109/01677068609106856; Davidson E. H., 1986, GENE ACTIVITY EARLY; DOE CQ, 1992, DEVELOPMENT, V116, P855; FERGUSON EL, 1985, GENETICS, V110, P17; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOBER JW, 1991, BIOESSAYS, V13, P277, DOI 10.1002/bies.950130604; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HIGASHIJIMA S, 1992, GENE DEV, V6, P1005, DOI 10.1101/gad.6.6.1005; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JARMAN AP, 1993, DEVELOPMENT, V119, P19; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; Lees AD, 1942, PROC R SOC SER B-BIO, V131, P87, DOI 10.1098/rspb.1942.0019; LEPTIN M, 1990, DEVELOPMENT, V110, P73; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MALER D, 1992, MECH DEVELOP, V38, P143; McIver S.B., 1985, P71; NASH D, 1970, GENETICS, V64, P471; NASH D, 1965, GENET RES, V6, P175, DOI 10.1017/S0016672300004079; PARKS AL, 1993, DEV BIOL, V157, P484, DOI 10.1006/dbio.1993.1151; POINDEXTER JS, 1964, BACTERIOL REV, V28, P231, DOI 10.1128/MMBR.28.3.231-295.1964; RAO Y, 1991, GENE DEV, V5, P1577, DOI 10.1101/gad.5.9.1577; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; XU T, 1993, DEVELOPMENT, V117, P1223; Zacharuk R.Y., 1985, COMPREHENSIVE INSECT, P1; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	58	632	652	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					477	491		10.1016/0092-8674(94)90112-0	http://dx.doi.org/10.1016/0092-8674(94)90112-0			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313469				2022-12-28	WOS:A1994MX20700009
J	TAKAI, T; LI, M; SYLVESTRE, D; CLYNES, R; RAVETCH, JV				TAKAI, T; LI, M; SYLVESTRE, D; CLYNES, R; RAVETCH, JV			FCR GAMMA-CHAIN DELETION RESULTS IN PLEIOTROPIC EFFECTOR CELL DEFECTS	CELL			English	Article							NATURAL-KILLER-CELLS; IGG FC; T-CELL; HIGH-AFFINITY; RECEPTOR; MACROPHAGE; HETEROGENEITY; EXPRESSION; RIII; LYMPHOCYTES	The gamma subunit of immunoglobulin Fc receptors is an essential component of the high-affinity receptor for IgE (Fc epsilon RI) and the low-affinity receptor for IgG (Fc gamma RIII) and is associated with the high-affinity receptor for IgG (Fc gamma RI) and the T cell receptor-CD3 complex. It is required for both receptor assembly and signal transduction. Targeted disruption of this subunit results in immunocompromised mice. Activated macrophages from gamma chain-deficient mice unexpectedly lack the ability to phagocytose antibody-coated particles, despite normal binding. Defects in NK cell-mediated antibody-dependent cytotoxicity and mast cell-mediated allergic responses are evident in these animals, establishing the indispensable role of FcRs in these responses. However, loss of gamma chain does not appear to perturb T cell development, since both thymic and peripheral T cell populations appear normal. These mice thus represent an important tool for evaluating the role of these receptors in humoral and cellular immune responses.	SLOAN KETTERING INST, DEWITT WALLACE RES LAB, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center			Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				ALCARAZ G, 1987, BIOCHEMISTRY-US, V26, P2569, DOI 10.1021/bi00383a024; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ASKENASE PW, 1974, IMMUNOLOGY, V27, P563; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAERON M, 1992, J IMMUNOL, V149, P1365; DIAMOND B, 1978, J IMMUNOL, V121, P1329; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; HEUSSER CH, 1977, J EXP MED, V145, P1316, DOI 10.1084/jem.145.5.1316; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KINET JP, IN PRESS COMMUNICATI; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; KUROSAKI T, 1994, IN PRESS NATURE; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MATSUDA H, 1990, J IMMUNOL, V144, P259; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; NATHAN CF, 1980, NEW ENGL J MED, V303, P622, DOI 10.1056/NEJM198009113031106; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; PARKER CW, 1987, ANNU REV IMMUNOL, V5, P65, DOI 10.1146/annurev.iy.05.040187.000433; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; Ravetch J.V., 1990, FC RECEPTORS ACTION, P211; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UHER F, 1985, CELL IMMUNOL, V95, P368, DOI 10.1016/0008-8749(85)90324-7; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WEINSHANK RL, 1988, J EXP MED, V167, P1909, DOI 10.1084/jem.167.6.1909; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381	44	813	880	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					519	529		10.1016/0092-8674(94)90115-5	http://dx.doi.org/10.1016/0092-8674(94)90115-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313472				2022-12-28	WOS:A1994MX20700012
J	SIKORA, K				SIKORA, K			ENRAGED ABOUT RADIOTHERAPY	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER	The use of radiotherapy in treating breast cancer has meant that many women are able to avoid mastectomy, which is both physically and psychologically damaging. The side effects of radiotherapy, however, are given little attention. Many women have developed brachial plexus injury after radiotherapy for breast cancer, often resulting in severe pain and loss of use of the arm. There is no effective treatment for this injury and little help can be offered. In addition, many of the women did not require radiotherapy of nodal areas. A pressure group has been formed to support these women, to establish the right to compensation, and to ensure that radiotherapy regimens given to future patients will not damage the brachial plexus.			SIKORA, K (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0NN,ENGLAND.							CUZICK J, 1987, CANCER TREAT REP, V71, P15; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; POWELL S, 1990, RADIOTHER ONCOL, V18, P213, DOI 10.1016/0167-8140(90)90057-4; Priestman T J, 1989, Clin Oncol (R Coll Radiol), V1, P39, DOI 10.1016/S0936-6555(89)80010-X; STOLL BA, 1966, BRIT MED J, V1, P834, DOI 10.1136/bmj.1.5491.834; SVENSSON H, 1975, ACTA RADIOL, V15, P228; YARNOLD JR, 1984, RADIOTHER ONCOL, V2, P79, DOI 10.1016/S0167-8140(84)80043-2; 1991, MED MANPOWER WORKLOA	8	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					188	189		10.1136/bmj.308.6922.188	http://dx.doi.org/10.1136/bmj.308.6922.188			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312773	Green Published			2022-12-28	WOS:A1994MR97400025
J	WHITTLE, J; CONIGLIARO, J; GOOD, CB; LOFGREN, RP				WHITTLE, J; CONIGLIARO, J; GOOD, CB; LOFGREN, RP			RACIAL-DIFFERENCES IN THE USE OF INVASIVE CARDIOVASCULAR PROCEDURES IN THE DEPARTMENT-OF-VETERANS-AFFAIRS MEDICAL SYSTEM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; PROSPECTIVE-PAYMENT SYSTEM; ISCHEMIC HEART-DISEASE; PREHOSPITAL DELAY; SURGERY; CARE; BLACKS; RATES; INEQUALITIES	Background. Previous studies have found racial differences in the use of invasive cardiovascular procedures, which may be due in part to the greater financial incentives to perform such procedures in white patients. In Department of Veterans Affairs hospitals, direct financial incentives affecting use of the procedures are minimized for both patients and physicians. Methods. We analyzed retrospectively the use of cardiovascular procedures among black and white male veterans discharged from Veterans Affairs hospitals with primary diagnoses of cardiovascular disease or chest pain during fiscal years 1987 through 1991. We used coded discharge data to determine whether cardiac catheterization, percutaneous transluminal coronary angioplasty, or coronary artery bypass grafting was performed during or immediately after such admissions. We used logistic-regression analysis to adjust for the primary discharge diagnosis, the presence of coexisting conditions, age, marital status, type of eligibility to receive care at Veterans Affairs hospitals, geographic region, and whether the hospital was equipped to perform bypass surgery. We classified the primary diagnosis as myocardial infarction, unstable angina, angina, chronic ischemia, chest pain, or ''other'' cardiovascular diagnosis. Results. After we adjusted for all the potential confounders, we found that white veterans were more likely than black veterans to undergo cardiac catheterization (odds ratio, 1.38; 95 percent confidence interval, 1.34 to 1.42), angioplasty (odds ratio, 1.50; 95 percent confidence interval, 1.38 to 1.64), and coronary artery bypass surgery (odds ratio, 2.22; 95 percent confidence interval, 2.09 to 2.36). Conclusions. Even when financial incentives are absent, whites are more likely than blacks to undergo invasive cardiac procedures. These findings suggest that social or clinical factors affect the use of these procedures differently in blacks and whites.	UNIV PITTSBURGH,MED CTR,DEPT MED,GEN INTERNAL MED SECT,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	WHITTLE, J (corresponding author), VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,11A,UNIV DR C,PITTSBURGH,PA 15240, USA.		Good, Chester B/K-2818-2019	Good, Chester B/0000-0003-4388-4558; Whittle, Jeff/0000-0002-9544-838X				ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CLARK LT, 1992, J NATL MED ASSOC, V84, P931; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; HOLMES MD, 1989, JAMA-J AM MED ASSOC, V261, P3242, DOI 10.1001/jama.261.22.3242; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KAHN HA, 1983, INTRO EPIDEMIOLOGIC; LLOYD SS, 1985, JAMA-J AM MED ASSOC, V254, P1330, DOI 10.1001/jama.254.10.1330; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MAYNARD C, 1986, CIRCULATION, V74, P64, DOI 10.1161/01.CIR.74.1.64; OBERMAN A, 1984, AM HEART J, V108, P688, DOI 10.1016/0002-8703(84)90656-2; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; STROGATZ DS, 1990, AM J PUBLIC HEALTH, V80, P290, DOI 10.2105/AJPH.80.3.290; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; 1977, RELIABILITY HOSPITAL; 1985, SAS USERS GUIDE STAT; 1985, SAS USERS GUIDE BASI; 1980, DHHS PHS801260 PUBL	30	391	391	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					621	627		10.1056/NEJM199308263290907	http://dx.doi.org/10.1056/NEJM199308263290907			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341338				2022-12-28	WOS:A1993LU21700007
J	THOMSEN, GH; MELTON, DA				THOMSEN, GH; MELTON, DA			PROCESSED VG1 PROTEIN IS AN AXIAL MESODERM INDUCER IN XENOPUS	CELL			English	Article							MATERNAL MESSENGER-RNA; ERYTHROID-DIFFERENTIATION FACTOR; BONE MORPHOGENETIC PROTEIN-4; DORSAL-VENTRAL POLARITY; EARLY AMPHIBIAN EMBRYOS; TGF-BETA FAMILY; DROSOPHILA EMBRYO; ACTIVIN-A; CRESCENT FORMATION; SPEMANN ORGANIZER	Vg1 is a TGFbeta-related growth factor encoded by a maternal mRNA localized to vegetal blastomeres in Xenopus embryos. Vg1 precursor protein is abundant in vegetal cells, but the processed mature form has not been readily detected and no activity has been demonstrated for the putative Vg1 mature protein. We have engineered a BMP2-Vg1 fusion (BVg1) that promotes formation of mature Vg1 protein in vivo. Injection of BVg1 mRNA induces dorsal mesoderm in animal cap cells, and BVg1 expression in ultraviolet-ventralized embryos fully restores a normal dorsal axis. Blastomeres expressing BVg1 act as a Nieuwkoop center, the region that induces the Spemann organizer. Our results lead us to suggest that localized posttranslational processing of Vg1 precursor protein on the future dorsal side of the embryo is a key step in generating dorsal mesoderm and the body axis in Xenopus.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BOLCE ME, 1992, DEVELOPMENT, V115, P681; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DALE L, 1992, DEVELOPMENT, V115, P573; ELINSON RP, 1989, DEV GROWTH DIFFER, V31, P423; FERGUSON EL, 1991, CURR TOP DEV BIOL, V25, P17; GALLAGHER BC, 1991, DEVELOPMENT, V112, P1103; GERHART J, 1986, ANNU REV CELL BIOL, V2, P201, DOI 10.1146/annurev.cb.02.110186.001221; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLOW E, 1989, ANTIBODIES LABORATOR, V106, P611; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO K, 1991, METHOD CELL BIOL, V36, P271; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANES ME, 1980, ROUX ARCH DEV BIOL, V189, P73, DOI 10.1007/BF00848569; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; New HV, 1991, CURR OPIN GENET DEV, V1, P196, DOI 10.1016/S0959-437X(05)80070-X; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SAMBROOK J, 1990, MOL CLONING LABORATO; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WU M, 1991, METHOD CELL BIOL, V36, P3; YOUN BW, 1981, DEV BIOL, V83, P339, DOI 10.1016/0012-1606(81)90479-6	61	390	405	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 13	1993	74	3					433	441		10.1016/0092-8674(93)80045-G	http://dx.doi.org/10.1016/0092-8674(93)80045-G			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348610				2022-12-28	WOS:A1993LT73900005
J	ROGERS, DE; OSBORN, JE				ROGERS, DE; OSBORN, JE			AIDS POLICY - 2 DIVISIVE ISSUES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NATL COMMISS AIDS,WASHINGTON,DC									1993, HIV AIDS PANDEMIC 19; 1993, SOCIAL IMPACT AIDS U; 1993, NEEDLE EXCHANGE PROG; 1993, AIDS EXPANDING TRAGE; 1991, TWIN EPIDEMICS SUBST	5	15	15	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					494	495						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320790				2022-12-28	WOS:A1993LN42600031
J	HAUSER, MD				HAUSER, MD			RIGHT-HEMISPHERE DOMINANCE FOR THE PRODUCTION OF FACIAL EXPRESSION IN MONKEYS	SCIENCE			English	Article							SPECIES-SPECIFIC VOCALIZATIONS; MACAQUES; PERCEPTION; FACES	In humans, the left side of the face (right hemisphere of the brain) is dominant in emotional expression. In rhesus monkeys, the left side of the face begins to display facial expression earlier than the right side and is more expressive. Humans perceive rhesus chimeras created by pairing the left half of the face with its mirror-reversed duplicate as more expressive than chimeras created by right-right pairings. That the right hemisphere determines facial expression, and the left hemisphere processes species-typical vocal signals, suggests that human and nonhuman primates exhibit the same pattern of brain asymmetry for communication.	HARVARD UNIV,PROGRAM NEUROSCI,DEPT PSYCHOL,CAMBRIDGE,MA 02138	Harvard University	HAUSER, MD (corresponding author), HARVARD UNIV,PROGRAM NEUROSCI,DEPT BIOL ANTHROPOL,CAMBRIDGE,MA 02138, USA.							Bradshaw JL., 1993, EVOLUTION LATERAL AS; Cheney D. L., 1990, MONKEYS SEE WORLD IN; CORBALLIS M, 1991, LOPSIDED APE; DAVIDSON RJ, 1992, PSYCHOL SCI, V3, P39, DOI 10.1111/j.1467-9280.1992.tb00254.x; DEWAAL FBM, 1988, BEHAVIOUR, V106, P183, DOI 10.1163/156853988X00269; DIMOND S, 1984, NEUROPSYCHOLOGIA, V26, P445; FALK D, 1986, FOLIA PRIMATOL, V46, P98, DOI 10.1159/000156242; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; HAMILTON CR, 1991, CEREBRAL LATERALITY, P19; HAUSER MD, 1991, ETHOLOGY, V89, P29; HAUSER MD, 1993, ANIM BEHAV, V45, P423, DOI 10.1006/anbe.1993.1054; HEFFNER HE, 1984, SCIENCE, V226, P75, DOI 10.1126/science.6474192; HEILBRONER PL, 1988, AM J PHYS ANTHROPOL, V76, P39, DOI 10.1002/ajpa.1330760105; Hellige J. B., 1993, HEMISPHERIC ASYMMETR; IFUNE CK, 1985, BEHAV NEURAL BIOL, V41, P231; LEVY J, 1983, BRAIN COGNITION, V2, P404, DOI 10.1016/0278-2626(83)90021-0; MacNeilage Peter F., 1991, P165; MARIER P, 1992, HUMAN NONHUMAN ANIMA, P66; NOTTEBOHM F, 1990, PHILOS T R SOC LON B, V292, P205; OVERMAN WH, 1982, NEUROPSYCHOLOGIA, V20, P113, DOI 10.1016/0028-3932(82)90002-1; PETERSEN MR, 1978, SCIENCE, V202, P324, DOI 10.1126/science.99817	21	162	163	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					475	477		10.1126/science.8332914	http://dx.doi.org/10.1126/science.8332914			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332914				2022-12-28	WOS:A1993LN62300037
J	MILLER, KB; SCHENKEIN, DP				MILLER, KB; SCHENKEIN, DP			HEMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PROGRAMMED CELL-DEATH; TRANS-RETINOIC ACID; TRANSPLANTATION; TRANSLOCATION; BCL-2		TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts University	MILLER, KB (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.							BROMEYER HE, 1992, P NATL ACAD SCI USA, V89, P4109; CHOMIENNE C, 1990, BLOOD, V76, P1710; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; MCGLAVE PB, 1991, BLOOD CELLS, V17, P330; MIYASHITA T, 1993, BLOOD, V81, P151; NOMURA N, 1991, TRANSPLANT P, V23, P431; ROBERTSON LE, 1993, BLOOD, V81, P143; SIEGEL RM, 1992, P NATL ACAD SCI USA, V89, P7003, DOI 10.1073/pnas.89.15.7003; WAGNER JE, 1992, BLOOD, V79, P1874; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G	16	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					216	217		10.1001/jama.270.2.216	http://dx.doi.org/10.1001/jama.270.2.216			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315737				2022-12-28	WOS:A1993LL36800023
J	TWOMEY, P				TWOMEY, P			GENERAL-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LASER				TWOMEY, P (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							ALIN S, 1992, ANN SURG, V216, P3; BONE RC, 1993, CRIT CARE MED, V21, P311, DOI 10.1097/00003246-199303000-00001; CERRA FB, 1992, ARCH SURG-CHICAGO, V127, P163; DAVIDOFF AM, 1991, ANN SURG, V215, P196; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; HUNTER JG, 1989, BRIT J SURG, V76, P949, DOI 10.1002/bjs.1800760925; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; PARRA RO, 1992, J UROLOGY, V3, P2; PELLEGRINI C, 1992, ANN SURG, V216, P291, DOI 10.1097/00000658-199209000-00008; Spaw A T, 1991, J Laparoendosc Surg, V1, P269, DOI 10.1089/lps.1991.1.269; WAKABAYASHI A, 1991, LANCET, V337, P881, DOI 10.1016/0140-6736(91)90206-5; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WAY LW, 1992, ANN SURG, V215, P195, DOI 10.1097/00000658-199203000-00001; 1992, B AM COLL SURG, V77, P7; 1993, B AM COLL SURG, V78, P20	15	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					211	213		10.1001/jama.270.2.211	http://dx.doi.org/10.1001/jama.270.2.211			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315735				2022-12-28	WOS:A1993LL36800021
J	CZEIZEL, AE				CZEIZEL, AE			PREVENTION OF CONGENITAL-ABNORMALITIES BY PERICONCEPTIONAL MULTIVITAMIN SUPPLEMENTATION	BRITISH MEDICAL JOURNAL			English	Article							NEURAL-TUBE DEFECTS; FOLATE METABOLISM; RECURRENCE	Objective-To study the effect of periconceptional multivitamin supplementation on neural tube defects and other congenital abnormality entities. Design-Randomised controlled trial of supplementation with multivitamins and trace elements. Setting-Hungarian family planning programme. Subjects-4156 pregnancies with known outcome and 3713 infants evaluated in the eighth month of life. Interventions-A single tablet of a multivitamin including 0.8 mg of folic acid or trace elements supplement daily for at least one month before conception and at least two months after conception. Main outcome measures-Number of major and mild congenital abnormalities. Results-The rate of all major congenital abnormalities was significantly lower in the group given vitamins than in the group given trace elements and this difference cannot be explained totally by the significant reduction of neural tube defects. The rate of major congenital abnormalities other than neural tube defects and genetic syndromes was 9.0/1000 in pregnancies with known outcome in the vitamin group and 16.6/1000 in the trace element group; relative risk 1.85 (95% confidence interval 1.02 to 3.38); difference, 7.6/1000. The rate of all major congenital abnormalities other than neural tube defects and genetic syndromes diagnosed up to the eighth month of life was 14.7/1000 informative pregnancies in the vitamin group and 28.3/1000 in the trace element group; relative risk 1.95 (1.23 to 3.09); difference, 13.6/1000. The rate of some congenital abnormalities was lower in the vitamin group than in the trace element group but the differences for each group of abnormalities were not significant. Conclusions-Periconceptional multivitamin supplementation can reduce not only the rate of neural tube defects but also the rate of other major non-genetic syndromatic congenital abnormalities. Further studies are needed to differentiate the chance effect and vitamin dependent effect.	WHO,COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DIS,NATL INST HYG,DEPT HUMAN GENET & TERATOL,BUDAPEST,HUNGARY	World Health Organization								BAIRD CDC, 1954, CIRC RES, V2, P544, DOI 10.1161/01.RES.2.6.544; CZEIZEL A, 1970, BRIT J PREV SOC MED, V24, P205; CZEIZEL A, 1972, BRIT J PREV SOC MED, V26, P15; CZEIZEL A, 1988, J MED GENET, V25, P2, DOI 10.1136/jmg.25.1.2; CZEIZEL A E, 1992, Genetic Counseling, V3, P61; CZEIZEL AE, 1992, ARCH GYNECOL OBSTET, V251, P181, DOI 10.1007/BF02718384; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; CZEIZEL AE, 1993, BRIT MED J, V306, P499, DOI 10.1136/bmj.306.6876.499; CZEIZEL AE, 1988, MULTIPLE CONGENITAL; ERBE RW, 1984, AM J MED GENET, V17, P277, DOI 10.1002/ajmg.1320170120; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; LORBER J, 1984, BRIT MED J, V289, P281, DOI 10.1136/bmj.289.6440.281; MILUNSKY A, 1968, J PEDIATR-US, V72, P790, DOI 10.1016/S0022-3476(68)80430-5; MONIE IW, 1957, ANAT REC, V127, P711, DOI 10.1002/ar.1091270407; MONIE IW, 1963, ANAT REC, V147, P397, DOI 10.1002/ar.1091470311; NELSON MM, 1952, J NUTR, V48, P61, DOI 10.1093/jn/48.1.61; SMITHELLS RW, 1989, LANCET, V2, P498; SMITHELLS RW, 1980, LANCET, V1, P339; THIERSCH JB, 1952, AM J OBSTET GYNECOL, V63, P1298; TOLAROVA M, 1982, LANCET, V2, P217; YATES JRW, 1987, CLIN GENET, V31, P279; ZEIZEL A, 1974, BR J PREV SOC MED, V28, P265; 1991, LANCET, V338, P131	23	266	281	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1645	1648		10.1136/bmj.306.6893.1645	http://dx.doi.org/10.1136/bmj.306.6893.1645			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324432	Green Published, Bronze			2022-12-28	WOS:A1993LJ33700018
J	RADER, DJ; BREWER, HB				RADER, DJ; BREWER, HB			ABETALIPOPROTEINEMIA - NEW INSIGHTS INTO LIPOPROTEIN ASSEMBLY AND VITAMIN-E METABOLISM FROM A RARE GENETIC-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APOLIPOPROTEIN-B GENE; TRIGLYCERIDE-TRANSFER PROTEIN; NORMOTRIGLYCERIDEMIC ABETALIPOPROTEINEMIA; E-DEFICIENCY; 2 FAMILIES; TOCOPHEROL; ABSENCE; MALABSORPTION; EXCLUSION				RADER, DJ (corresponding author), NHLBI,MOLEC DIS BRANCH,BLDG 10,ROOM 7N117,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BASSEN FA, 1950, BLOOD, V5, P381, DOI 10.1182/blood.V5.4.381.381; BIERI JG, 1984, ANN INTERN MED, V100, P238, DOI 10.7326/0003-4819-100-2-238; BOUMA ME, 1990, J LIPID RES, V31, P1; BURTON GW, 1990, ANNU REV NUTR, V10, P357, DOI [10.1146/annurev.nu.10.070190.002041, 10.1146/annurev.nutr.10.1.357]; CABALLERO FM, 1980, PEDIATRICS, V65, P161; COGAN DG, 1984, OPHTHALMOLOGY, V91, P991; DULLAART RPF, 1986, J CLIN INVEST, V78, P1397, DOI 10.1172/JCI112727; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; HARDMAN DA, 1991, J CLIN INVEST, V88, P1722, DOI 10.1172/JCI115490; HUANG LS, 1990, AM J HUM GENET, V46, P1141; JAMPEL RS, 1958, ARCH OPHTHALMOL-CHIC, V59, P818; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; Kayden H J, 1986, Adv Exp Med Biol, V201, P67; KAYDEN HJ, 1983, J LIPID RES, V24, P652; KAYDEN HJ, 1993, J LIPID RES, V34, P343; KAYDEN HJ, 1990, PRIMARY HYPERLIPOPRO, P249; LACKNER KJ, 1986, J CLIN INVEST, V78, P1707, DOI 10.1172/JCI112766; LEVY RI, 1966, J CLIN INVEST, V45, P531, DOI 10.1172/JCI105367; LINTON MF, 1993, J LIPID RES, V34, P521; MALLOY MJ, 1981, J CLIN INVEST, V67, P1441, DOI 10.1172/JCI110173; MULLER DPR, 1982, VITAMIN E BIOCH HEMA, P133; PESSAH M, 1991, J CLIN INVEST, V87, P367, DOI 10.1172/JCI114996; ROY CC, 1987, GASTROENTEROLOGY, V92, P390, DOI 10.1016/0016-5085(87)90133-8; RUNGE P, 1986, BRIT J OPHTHALMOL, V70, P166, DOI 10.1136/bjo.70.3.166; SALT HB, 1960, LANCET, V2, P325; SINGER K, 1952, BLOOD, V71, P577; SOBREVILLA LA, 1964, AM J MED, V37, P821, DOI 10.1016/0002-9343(64)90030-0; SOKOL RJ, 1988, J LAB CLIN MED, V111, P548; SOKOL RJ, 1984, NEW ENGL J MED, V310, P1209, DOI 10.1056/NEJM198405103101901; TALMUD PJ, 1988, J CLIN INVEST, V82, P1803, DOI 10.1172/JCI113795; TRABER MG, 1989, AM J CLIN NUTR, V49, P517, DOI 10.1093/ajcn/49.3.517; TRABER MG, 1992, LIPIDS, V27, P657, DOI 10.1007/BF02536020; TRABER MG, 1984, AM J CLIN NUTR, V40, P747, DOI 10.1093/ajcn/40.4.747; TRABER MG, 1987, NEW ENGL J MED, V317, P262, DOI 10.1056/NEJM198707303170502; WAYS PO, 1967, J CLIN INVEST, V46, P35, DOI 10.1172/JCI105509; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WETZEL MD, 1989, PROGR CLIN BIOL RES, P427; WICHMAN A, 1985, NEUROLOGY, V9, P1279	39	92	94	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					865	869		10.1001/jama.270.7.865	http://dx.doi.org/10.1001/jama.270.7.865			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340987				2022-12-28	WOS:A1993LR61200034
J	CHUNG, JH; WHITELEY, M; FELSENFELD, G				CHUNG, JH; WHITELEY, M; FELSENFELD, G			A 5' ELEMENT OF THE CHICKEN BETA-GLOBIN DOMAIN SERVES AS AN INSULATOR IN HUMAN ERYTHROID-CELLS AND PROTECTS AGAINST POSITION EFFECT IN DROSOPHILA	CELL			English	Article							LOCUS-CONTROL REGION; DOMINANT CONTROL REGION; TOPOISOMERASE-II SITES; GENE-EXPRESSION; WHITE GENE; HYPERSENSITIVE SITES; ACTIVATION REGION; SENSITIVE DOMAIN; CHROMATIN DOMAIN; TRANSGENIC MICE	We have characterized an element near the 5' boundary of the chicken beta-globin domain that insulates a reporter gene from the activating effects of a nearby beta-globin locus control region (5'HS2) when assayed in the human erythroid cell line K562. We show that the insulation mechanism is directional, that it operates at the level of transcription, and that it involves the alteration of chromatin structure over the promoter of the gene. The insulator has no significant stimulatory or inhibitory effects of its own. In transgenic Drosophila, the insulator protects the white minigene from position effects. The action of the insulator thus is not restricted to erythroid or mammalian cells, suggesting that such elements may serve an important and widely distributed function in the organization of chromatin structure.	US FDA,DIV CELLULAR & GENE THERAPY,BETHESDA,MD 20892	US Food & Drug Administration (FDA)	CHUNG, JH (corresponding author), NIH,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							BENYAJATI C, 1976, CELL, V9, P393, DOI 10.1016/0092-8674(76)90084-2; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; ELDER JT, 1990, MOL CELL BIOL, V10, P1382, DOI 10.1128/MCB.10.4.1382; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GARRARD WT, 1990, NUCLEIC ACIDS MOL BI, V4, P163; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P10618, DOI 10.1073/pnas.89.22.10618; JIMENEZ G, 1992, NUCLEIC ACIDS RES, V20, P5797, DOI 10.1093/nar/20.21.5797; KASSIS JA, 1991, GENETICS, V128, P751; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; LAWSON GM, 1982, J BIOL CHEM, V257, P1501; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; MULLER MM, 1988, EUR J BIOCHEM, V176, P485, DOI 10.1111/j.1432-1033.1988.tb14306.x; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; PIRROTTA V, 1985, EMBO J, V4, P3501, DOI 10.1002/j.1460-2075.1985.tb04109.x; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PSRADLING AC, 1985, DROSOPHILA PRACTICAL, P175; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; RENKAWITZ R, 1990, TRENDS GENET, V6, P162; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; STALDER J, 1980, CELL, V20, P451, DOI 10.1016/0092-8674(80)90631-5; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; VANHOLDE KE, 1989, CHROMATIN, P355; WHITELEY M, 1992, MECH DEVELOP, V36, P117, DOI 10.1016/0925-4773(92)90063-P; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; WU CT, 1989, TRENDS GENET, V5, P189, DOI 10.1016/0168-9525(89)90074-7	51	755	820	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					505	514		10.1016/0092-8674(93)80052-G	http://dx.doi.org/10.1016/0092-8674(93)80052-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348617				2022-12-28	WOS:A1993LT73900012
J	WALTER, HJ; VAUGHAN, RD				WALTER, HJ; VAUGHAN, RD			AIDS RISK REDUCTION AMONG A MULTIETHNIC SAMPLE OF URBAN HIGH-SCHOOL-STUDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED DISEASES; UNITED-STATES; PRIMARY PREVENTION; SELF-EFFICACY; ADOLESCENTS; BEHAVIORS; HIV; INTERVENTION; INFECTION	Objective.-To evaluate the effectiveness of a teacher-delivered curriculum in favorably modifying acquired immunodeficiency syndrome (AIDS)-related knowledge and beliefs, self-efficacy related to AIDS-preventive actions, and involvement in AIDS risk behaviors among an eligible population of 1316 New York City high school students. Design.-Students in two pairs of demographically similar high schools were assigned to receive either a special six-lesson AIDS-preventive curriculum (intervention group) or no formal AIDS-preventive curriculum (comparison group). Participants.-Study participants were ninth- and 11th-grade students, 12 to 20 years of age (mean, 15.7 years), 41.5% male, and 72.1% black or Hispanic. Intervention.-The special curriculum focused on conveying facts about AIDS, fostering theoretically derived beliefs favorable to AIDS prevention, and teaching skills necessary for the successful performance of AIDS-preventive behaviors. Main Outcome Measures.-AIDS-related knowledge, beliefs, self-efficacy, and behaviors were assessed among students in intervention and comparison groups at study baseline and at 3 months' follow-up. Results.-Significant (albeit modest) effects favoring intervention were observed for knowledge, beliefs, self-efficacy, and risk behavior scores. Conclusions.-School-based AIDS-preventive curricula may play a role in curtailing transmission of the human immunodeficiency virus among multiethnic groups of urban adolescents; however, such curricula may need supplementation by a broader-based prevention effort to achieve substantial risk behavior change.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY 10032	Columbia University	WALTER, HJ (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,CTR POPULAT & FAMILY HLTH,60 HAVEN AVE,NEW YORK,NY 10032, USA.				NIMH NIH HHS [5-P50-MH43520] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH043520] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BANDURA A, 1986, SOCIAL F THOUGHT ACT; BASENENGQUIST K, 1992, HEALTH EDUC QUART, V19, P263, DOI 10.1177/109019819201900209; Becker MH, 1974, HLTH ED MONOGR, V2; BIGLAN A, 1990, J BEHAV MED, V13, P245, DOI 10.1007/BF00846833; BROWN LK, 1989, J ADOLESC HLTH CARE, V10, P286; BURKE DS, 1990, JAMA-J AM MED ASSOC, V263, P2074, DOI 10.1001/jama.263.15.2074; COHEN J, 1988, STATISTICAL POWER AN; COHEN J., 1983, APPL MULTIPLE REGRES, V2; DICLEMENTE RJ, 1989, J SEX RES, V26, P188, DOI 10.1080/00224498909551505; DICLEMENTE RJ, 1989, HLTH ED, V2, P39; ELLICKSON PL, 1990, SCIENCE, V247, P1299, DOI 10.1126/science.2180065; FISHER JD, 1988, AM PSYCHOL, V43, P914, DOI 10.1037/0003-066X.43.11.914; FLAY BR, 1986, PREV MED, V15, P451, DOI 10.1016/0091-7435(86)90024-1; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; GLADIS MM, 1992, HEALTH PSYCHOL, V11, P307, DOI 10.1037/0278-6133.11.5.307; GOODMAN E, 1989, PEDIATRICS, V84, P36; Green LW., 1980, HLTH ED PLANNING DIA, V1; HANSEN WB, 1985, J BEHAV MED, V8, P261, DOI 10.1007/BF00870313; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HINGSON RW, 1990, AM J PUBLIC HEALTH, V80, P295, DOI 10.2105/AJPH.80.3.295; HOSMER DW, 1981, APPLIED LOGISTIC REG; HUSZTI HC, 1989, PEDIATRICS, V84, P986; JEMMOTT JB, 1992, AM J PUBLIC HEALTH, V82, P372, DOI 10.2105/AJPH.82.3.372; JOHNSON JA, 1988, J MED EDUC, V63, P522; KASEN S, 1992, HEALTH EDUC QUART, V19, P187, DOI 10.1177/109019819201900204; KELLER SE, 1991, J ADOLESCENT HEALTH, V12, P44, DOI 10.1016/0197-0070(91)90040-S; KILLEN JD, 1988, JAMA-J AM MED ASSOC, V260, P1728, DOI 10.1001/jama.260.12.1728; KIRBY D, 1991, FAM PLANN PERSPECT, V23, P253, DOI 10.2307/2135776; KIRBY D, 1992, ADOLESCENTS AIDS GEN; PENTZ MA, 1989, JAMA-J AM MED ASSOC, V261, P3259, DOI 10.1001/jama.261.22.3259; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; ROTHERAMBORUS MJ, 1991, JAMA-J AM MED ASSOC, V266, P1237, DOI 10.1001/jama.266.9.1237; RUDER AM, 1990, NEW YORK STATE J MED, V90, P129; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; SHAFER MA, 1991, J PEDIATR-US, V119, P826, DOI 10.1016/S0022-3476(05)80312-9; STLOUIS ME, 1991, JAMA-J AM MED ASSOC, V266, P2387, DOI 10.1001/jama.266.17.2387; UPCHURCH DM, 1991, AM J EPIDEMIOL, V134, P1159, DOI 10.1093/oxfordjournals.aje.a116019; VAUGHAN RD, 1991, AIDS, V5, P112, DOI 10.1097/00002030-199101000-00021; WALTER HJ, 1991, PEDIATRICS, V88, P846; WALTER HJ, 1991, J AM ACAD CHILD PSY, V30, P556, DOI 10.1097/00004583-199107000-00005; WALTER HJ, 1992, AM J PUBLIC HEALTH, V82, P528, DOI 10.2105/AJPH.82.4.528; WALTER HJ, 1988, NEW ENGL J MED, V318, P1093, DOI 10.1056/NEJM198804283181704; WALTER HJ, 1989, J NATL CANCER I, V81, P995, DOI 10.1093/jnci/81.13.995; WALTER HJ, IN PRESS J AM ACAD C; WALTER HJ, IN PRESS AIDS ED PRE; WALTER HJ, INPRESS J APPL SOC P; WALTER HJ, IN PRESS PREV MED; WALTER HJ, IN PRESS HLTH ED Q; 1988, CDC HHS888404 US DEP; 1992, HIV AIDS SURVEILLANC; 1991, CHANCELLORS EXPANDED	51	135	135	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1993	270	6					725	730		10.1001/jama.270.6.725	http://dx.doi.org/10.1001/jama.270.6.725			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LQ338	8336374				2022-12-28	WOS:A1993LQ33800027
J	LIMBURG, PJ; KATZ, H; GRANT, CS; SERVICE, FJ				LIMBURG, PJ; KATZ, H; GRANT, CS; SERVICE, FJ			QUININE-INDUCED HYPOGLYCEMIA	ANNALS OF INTERNAL MEDICINE			English	Note							SEVERE FALCIPARUM-MALARIA		MAYO CLIN & MAYO GRAD SCH MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA	Mayo Clinic								ARYA TVS, 1989, TROP GEOGR MED, V41, P73; DAS BS, 1988, T ROY SOC TROP MED H, V82, P197, DOI 10.1016/0035-9203(88)90407-5; HARATS N, 1984, NEW ENGL J MED, V310, P1331; HENQUIN JC, 1975, FEBS LETT, V57, P280, DOI 10.1016/0014-5793(75)80317-6; JONES RG, 1986, J ROY SOC MED, V79, P426, DOI 10.1177/014107688607900714; KADISH AH, 1968, CLIN CHEM, V14, P116; OKITOLONDA W, 1987, BMJ-BRIT MED J, V295, P716, DOI 10.1136/bmj.295.6600.716; SERVICE FJ, 1992, J CLIN ENDOCR METAB, V74, P204, DOI 10.1210/jc.74.1.204; SERVICE FJ, 1993, J CLIN ENDOCR METAB, V76, P655, DOI 10.1210/jc.76.3.655; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201	10	26	26	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					218	219		10.7326/0003-4819-119-3-199308010-00007	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8323090				2022-12-28	WOS:A1993LU90300007
J	REUBER, TL; WALKER, GC				REUBER, TL; WALKER, GC			BIOSYNTHESIS OF SUCCINOGLYCAN, A SYMBIOTICALLY IMPORTANT EXOPOLYSACCHARIDE OF RHIZOBIUM-MELILOTI	CELL			English	Article							CALCOFLUOR-BINDING EXOPOLYSACCHARIDE; FORM INEFFECTIVE NODULES; LIPID-BOUND SACCHARIDES; EXO MUTANTS; STRUCTURAL ELUCIDATION; ESCHERICHIA-COLI; GENETIC-ANALYSIS; NODULATION; POLYSACCHARIDES; HOMOLOGY	The exo genes of Rhizobium meliloti are needed for the synthesis of an acidic exopolysaccharide, succinoglycan. We have assigned biosynthetic roles to the products of the exo genes by characterizing succinoglycan biosynthetic intermediates from exo mutant strains. We propose a model of succinoglycan biosynthesis in which the products of the exoY and exoF genes function in the addition of the first sugar, galactose, to the lipid carrier; the products of the exoA, exoL, exoM, exoO, exoU, and exoW genes function in subsequent sugar additions; and the product of the exoV gene functions in the addition of pyruvate. The products of the exoP, exoQ, and exoT genes are required for polymerization of the octasaccharide subunits or transport of the completed polymer.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)				Reuber, Lynne/0000-0001-7806-2437; /0000-0001-7243-8261	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031030] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31030] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAN P, 1981, CARBOHYD RES, V95, P263, DOI 10.1016/S0008-6215(00)85582-2; AMEMURA A, 1974, BIOCHIM BIOPHYS ACTA, V334, P398, DOI 10.1016/0005-2744(74)90183-1; BATTISTI L, 1992, P NATL ACAD SCI USA, V89, P5625, DOI 10.1073/pnas.89.12.5625; BECKER A, 1993, MOL GEN GENET, V238, P145, DOI 10.1007/BF00279541; Betlach M.R, 1987, IND POLYSACCHARIDES, P35; BOULNOIS GJ, 1989, MOL MICROBIOL, V3, P1819, DOI 10.1111/j.1365-2958.1989.tb00168.x; BUENDIA AM, 1991, MOL MICROBIOL, V5, P1519, DOI 10.1111/j.1365-2958.1991.tb00799.x; CAPAGE MA, 1987, Patent No. 5938; CREMERS HCJC, 1990, J BIOL CHEM, V265, P21122; DOHERTY D, 1988, J BACTERIOL, V170, P4249, DOI 10.1128/jb.170.9.4249-4256.1988; FINAN TM, 1985, CELL, V40, P869, DOI 10.1016/0092-8674(85)90346-0; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; FINAN TM, 1984, J BACTERIOL, V159, P120, DOI 10.1128/JB.159.1.120-124.1984; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; FREIFELDER D, 1982, PHYSICAL BIOCH; HARADA T, 1979, CARBOHYD RES, V77, P285, DOI 10.1016/S0008-6215(00)83821-5; HISAMATSU M, 1980, AGR BIOL CHEM TOKYO, V44, P1049, DOI 10.1080/00021369.1980.10864074; HYNES MF, 1986, MOL GEN GENET, V202, P356, DOI 10.1007/BF00333262; IELPI L, 1981, FEBS LETT, V130, P253, DOI 10.1016/0014-5793(81)81132-5; IELPI L, 1983, BIOCHEM INT, V6, P323; JANN B, 1991, TOPICS MICROBIOL IMM, V150, P19; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; Keller M., 1988, Molecular Plant-Microbe Interactions, V1, P267, DOI 10.1094/MPMI-1-267; KLEIN S, 1988, J BACTERIOL, V170, P1003, DOI 10.1128/jb.170.2.1003-1006.1988; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LEIGH JA, 1987, CELL, V51, P579, DOI 10.1016/0092-8674(87)90127-9; LEIGH JA, 1985, P NATL ACAD SCI USA, V82, P6231, DOI 10.1073/pnas.82.18.6231; LEIGH JA, 1988, J BACTERIOL, V170, P3327, DOI 10.1128/jb.170.8.3327-3332.1988; LOEWUS FA, 1952, ANAL CHEM, V24, P219, DOI 10.1021/ac60061a050; LONG S, 1988, J BACTERIOL, V170, P4239, DOI 10.1128/jb.170.9.4239-4248.1988; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; Maniatis T., 1982, MOL CLONING; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MULLER P, 1988, MOL GEN GENET, V211, P17, DOI 10.1007/BF00338388; MULLER P, 1993, MOL PLANT MICROBE IN, V6, P55, DOI 10.1094/MPMI-6-055; OSBORN MJ, 1968, J BIOL CHEM, V243, P5145; OSBORN MJ, 1983, HARVEY LECT, V78, P87; OSMAN SF, 1989, J BACTERIOL, V171, P1760, DOI 10.1128/jb.171.3.1760-1762.1989; PAZZANI C, 1991, BIOCHEM SOC T, V19, P628, DOI 10.1042/bst0190628; REED JW, 1991, J BACTERIOL, V173, P3776, DOI 10.1128/JB.173.12.3776-3788.1991; REED JW, 1991, J BACTERIOL, V173, P3789, DOI 10.1128/JB.173.12.3789-3794.1991; REUBER TL, 1993, J BACTERIOL, V175, P3653, DOI 10.1128/jb.175.11.3653-3655.1993; REUBER TL, 1991, J BACTERIOL, V173, P426, DOI 10.1128/jb.173.2.426-434.1991; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; ROLFE BG, 1988, ANNU REV PLANT PHYS, V39, P297, DOI 10.1146/annurev.pp.39.060188.001501; RUVKUN GB, 1982, CELL, V29, P551, DOI 10.1016/0092-8674(82)90171-4; SALMOND GPC, 1993, TRENDS BIOCHEM SCI, V18, P7, DOI 10.1016/0968-0004(93)90080-7; STANELONI RJ, 1984, J GEN MICROBIOL, V130, P869; SUTHERLAND IW, 1982, ADV MICROB PHYSIOL, V23, P79, DOI 10.1016/S0065-2911(08)60336-7; SUTHERLAND IW, 1985, ANNU REV MICROBIOL, V39, P243; TOLMASKY ME, 1980, ARCH BIOCHEM BIOPHYS, V203, P358, DOI 10.1016/0003-9861(80)90187-3; TOLMASKY ME, 1982, J BIOL CHEM, V257, P6751; URZAINQUI A, 1992, J BACTERIOL, V174, P3403, DOI 10.1128/jb.174.10.3403-3406.1992; VANDERSLICE RW, 1988, BIOMEDICAL BIOTECHNO, P145; VIMR ER, 1992, J BACTERIOL, V174, P5127, DOI 10.1128/JB.174.15.5127-5131.1992; ZHAN HJ, 1990, J BACTERIOL, V172, P5254, DOI 10.1128/jb.172.9.5254-5259.1990; ZHAN HJ, 1990, J BACTERIOL, V172, P5245, DOI 10.1128/jb.172.9.5245-5253.1990	57	241	246	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 30	1993	74	2					269	280		10.1016/0092-8674(93)90418-P	http://dx.doi.org/10.1016/0092-8674(93)90418-P			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343955				2022-12-28	WOS:A1993LP72600008
J	CLARK, KL; HALAY, ED; LAI, ES; BURLEY, SK				CLARK, KL; HALAY, ED; LAI, ES; BURLEY, SK			CO-CRYSTAL STRUCTURE OF THE HNF-3/FORK HEAD DNA-RECOGNITION MOTIF RESEMBLES HISTONE-H5	NATURE			English	Article							GENE FORK-HEAD; TRANSCRIPTION FACTORS; PROTEIN STRUCTURES; OPERATOR COMPLEX; BINDING DOMAINS; TRP REPRESSOR; REFINEMENT; RESOLUTION; HOMOLOGY; SEQUENCE	The three-dimensional structure of an HNF-3/fork head DNA-recognition motif complexed with DNA has been determined by X-ray crystallography at 2.5 angstrom resolution. This alpha/beta protein binds B-DNA as a monomer, through interactions with the DNA backbone and through both direct and water-mediated major and minor groove base contacts, inducing a 13-degrees bend. The transcription factor fold is very similar to the structure of histone H5. In its amino-terminal half, three alpha-helices adopt a compact structure that presents the third helix to the major groove. The remainder of the protein includes a twisted, antiparallel beta-structure and random coil that interacts with the minor groove.	ROCKEFELLER UNIV, MOLEC BIOPHYS LABS, 1230 YORK AVE, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, ENDOCRINOL SERV, NEW YORK, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				Burley, Stephen K./0000-0002-2487-9713				ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR V 3 0 MANUAL; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; BURLEY SK, 1986, J AM CHEM SOC, V108, P7995, DOI 10.1021/ja00285a019; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; CRANEROBINSON C, 1989, PROTEIN ENG, V2, P577, DOI 10.1093/protein/2.8.577; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAI E, IN PRESS P NATN ACAD; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PANI L, 1992, MOL CELL BIOL, V12; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REID KSC, 1985, FEBS LETT, V190, P209, DOI 10.1016/0014-5793(85)81285-0; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P359; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	49	1095	1121	3	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1993	364	6436					412	420		10.1038/364412a0	http://dx.doi.org/10.1038/364412a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332212				2022-12-28	WOS:A1993LP64000045
J	BENNETT, JC				BENNETT, JC			INCLUSION OF WOMEN IN CLINICAL-TRIALS - POLICIES FOR POPULATION SUBGROUPS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METHODOLOGY; SURVIVAL; THERAPY		NATL ACAD SCI,INST MED,BOARD HLTH SCI POLICY,WASHINGTON,DC 20418	National Academies of Sciences, Engineering & Medicine								COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; DAVIS CE, 1990, CONTROL CLIN TRIALS, V11, P37, DOI 10.1016/0197-2456(90)90030-6; DONALDSON MS, 1991, PATIENT OUTCOMES RES; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; Goble F C, 1975, Adv Pharmacol Chemother, V13, P173, DOI 10.1016/S1054-3589(08)60232-X; HAMILTON JA, 1985, WOMENS HLTH REPORT P, V2; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; MENDELSON JH, 1988, J PHARMACOL EXP THER, V245, P407; MERKATZ RB, 1993, NEW ENGL J MED, V329, P292, DOI 10.1056/NEJM199307223290429; PASSAMANI E, 1985, NEW ENGL J MED, V312, P1665, DOI 10.1056/NEJM198506273122603; PETO R, 1978, BIOMEDICINE, V28, P24; RODIN J, 1990, AM PSYCHOL, V45, P1018, DOI 10.1037/0003-066X.45.9.1018; SIMON R, 1982, BRIT J CLIN PHARMACO, V14, P473, DOI 10.1111/j.1365-2125.1982.tb02015.x; WEISSMAN MM, 1991, ASSESSING FUTURE RES, P1; WILSON K, 1984, CLIN PHARMACOKINET, V9, P189, DOI 10.2165/00003088-198409030-00001; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; 1980, NEW ENGL J MED, V303, P1038; 1991, JAMA-J AM MED ASSOC, V266, P559; 1990, NIH189 INSTR INF MEC; 1988, GUIDELINE FORMAT CON; 1984, JAMA-J AM MED ASSOC, V251, P351; 1990, POLICY INCLUSION WOM; 1992, LANCET, V339, P71; 1990, VITAL HLTH STATIS 10, V176; 1984, NEW ENGL J MED, V311, P1333	28	91	91	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					288	292		10.1056/NEJM199307223290428	http://dx.doi.org/10.1056/NEJM199307223290428			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM682	8316288				2022-12-28	WOS:A1993LM68200035
J	RABIZADEH, S; OH, J; ZHONG, LT; YANG, J; BITLER, CM; BUTCHER, LL; BREDESEN, DE				RABIZADEH, S; OH, J; ZHONG, LT; YANG, J; BITLER, CM; BUTCHER, LL; BREDESEN, DE			INDUCTION OF APOPTOSIS BY THE LOW-AFFINITY NGF RECEPTOR	SCIENCE			English	Article							NERVE GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; TRK PROTOONCOGENE; MOLECULAR-CLONING; BASAL FOREBRAIN; GENE-TRANSFER; EXPRESSION; ANTIBODY; SYSTEM	Nerve growth factor (NGF) binding to cellular receptors is required for the survival of some neural cells. In contrast to Trk A, the high-affinity NGF receptor that transduces NGF signals for survival and differentiation, the function of the low-affinity NGF receptor, p75NGFR, remains uncertain. Expression of p75NGFR induced neural cell death constitutively when p75NGFR was unbound; binding by NGF or monoclonal antibody, however, inhibited cell death induced by p75NGFR. Thus, expression of p75NGFR may explain the dependence of some neural cells on NGF for survival. These findings also suggest that p75NGFR has some functional similarities to other members of a superfamily of receptors that include tumor necrosis factor receptors, Fas (Apo-1), and CD40.	UNIV CALIF LOS ANGELES,DEPT NEUROL,LOS ANGELES,CA 90024; STANFORD RES INST,MENLO PK,CA 94025; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PSYCHOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; SRI International; Stanford University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010671] Funding Source: NIH RePORTER; NIA NIH HHS [AG10671] Funding Source: Medline; NINDS NIH HHS [NS10928] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; Chan-Palay V., 1990, DEMENT GERIATR COGN, V1, P138, DOI [DOI 10.1159/0001, 10.1159/000107133, DOI 10.1159/000107133]; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURAND M M, 1990, Society for Neuroscience Abstracts, V16, P40; GOEDERT M, 1989, MOL BRAIN RES, V5, P1, DOI 10.1016/0169-328X(89)90011-9; GREENBERG ME, 1984, P NATL ACAD SCI-BIOL, V81, P969, DOI 10.1073/pnas.81.3.969; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KERR JFR, 1991, APOPTOSIS, V3, P321; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KORDOWER JH, 1989, NEUROBIOL AGING, V10, P67, DOI 10.1016/S0197-4580(89)80013-2; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LIU YJ, 1989, NATURE, V342, P21; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; RABIZADEH S, UNPUB; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WOOLE NJ, 1989, NEUROSCIENCE, V30, P143, DOI 10.1016/0306-4522(89)90360-6; WOOLF NJ, 1989, NEUROSCI LETT, V96, P277, DOI 10.1016/0304-3940(89)90391-1; Zhong L. T., 1992, Society for Neuroscience Abstracts, V18, P44; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	33	755	805	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					345	348		10.1126/science.8332899	http://dx.doi.org/10.1126/science.8332899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332899				2022-12-28	WOS:A1993LM67800034
J	NOWAK, M; SIGMUND, K				NOWAK, M; SIGMUND, K			A STRATEGY OF WIN STAY, LOSE SHIFT THAT OUTPERFORMS TIT-FOR-TAT IN THE PRISONERS-DILEMMA GAME	NATURE			English	Article							EVOLUTION; COOPERATION	THE Prisoner's Dilemma is the leading metaphor for the evolution of cooperative behaviour in populations of selfish agents, especially since the well-known computer tournaments of Axelrod1 and their application to biological communities2,3. In Axelrod's simulations, the simple strategy tit-for-tat did outstandingly well and subsequently became the major paradigm for reciprocal altruism4-12. Here we present extended evolutionary simulations of heterogeneous ensembles of probabilistic strategies including mutation and selection, and report the unexpected success of another protagonist: Pavlov. This strategy is as simple as tit-for-tat and embodies the fundamental behavioural mechanism win-stay, lose-shift, which seems to be a widespread rule13. Pavlov's success is based on two important advantages over tit-for-tat: it can correct occasional mistakes and exploit unconditional cooperators. This second feature prevents Pavlov populations from being undermined by unconditional cooperators, which in turn invite defectors. Pavlov seems to be more robust than tit-for-tat, suggesting that cooperative behaviour in natural situations may often be based on win-stay, lose-shift.	UNIV VIENNA, INST MATH, A-1090 VIENNA, AUSTRIA	University of Vienna	NOWAK, M (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Nowak, Martin A/A-6977-2008					AXELROD R, 1988, SCIENCE, V242, P1385, DOI 10.1126/science.242.4884.1385; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R., 1987, GENETIC ALGORITHMS S; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; BOYD R, 1989, J THEOR BIOL, V136, P47, DOI 10.1016/S0022-5193(89)80188-2; BOYD R, 1987, NATURE, V327, P58, DOI 10.1038/327058a0; Dawkins R, 1988, SELFISH GENE; Domjan M., 1986, PRINCIPLES LEARNING, V2nd; DUGATKIN LA, 1988, BEHAV ECOL SOCIOBIOL, V23, P395, DOI 10.1007/BF00303714; Hofbauer J., 1988, THEORY EVOLUTION DYN; KRAINES D, 1989, THEOR DECIS, V26, P47, DOI 10.1007/BF00134056; KREBS JR, 1981, INTRO BEHAVIOURAL EC; LINDGREN K, 1991, ARTIFICIAL LIFE, V2; LOMBARDO MP, 1985, SCIENCE, V227, P1363, DOI 10.1126/science.227.4692.1363; MAY RM, 1987, NATURE, V327, P15, DOI 10.1038/327015a0; Maynard Smith J., 1982, pi; MILINSKI M, 1987, NATURE, V325, P433, DOI 10.1038/325433a0; NOWAK M, 1993, P NATL ACAD SCI USA, V90, P5091, DOI 10.1073/pnas.90.11.5091; NOWAK M, 1990, ACTA APPL MATH, V20, P247, DOI 10.1007/BF00049570; NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; Rapoport A, 1965, PRISONERS DILEMMA; REBOREDA JC, 1993, J EXP ANIMAL BEHAV, V60, P176; SELTEN R, 1984, BEHAV BRAIN SCI, V7, P115, DOI 10.1017/S0140525X00026479; Sigmund K., 1993, GAMES LIFE; SMITH JM, 1984, BEHAV BRAIN SCI, V7, P95, DOI 10.1017/S0140525X00026327; WILKINSON GS, 1984, NATURE, V308, P181, DOI 10.1038/308181a0	27	1017	1040	3	206	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 1	1993	364	6432					56	58		10.1038/364056a0	http://dx.doi.org/10.1038/364056a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316296				2022-12-28	WOS:A1993LK81800055
J	MEADE, TW; COOPER, JA; PEART, WS				MEADE, TW; COOPER, JA; PEART, WS			PLASMA-RENIN ACTIVITY AND ISCHEMIC-HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERTENSION	Background. An earlier prospective study reported an association between high levels of plasma renin activity (as measured by the renin-sodium profile) and the incidence of myocardial infarction in patients with hypertension. We have investigated the relation between plasma renin activity and ischemic heart disease in the Northwick Park Heart Study. Methods. The study included 803 white men 40 to 64 years of age selected from industrial workers in London. Plasma renin activity and established risk factors for ischemic heart disease were measured at entry, which was between 1972 and 1978. Ascertainment of the primary clinical end points of fatal or nonfatal myocardial infarction and sudden death from coronary causes was carried out until the end of 1991. Results. In an analysis of the 86 first coronary events, we found an independent relation between higher systolic blood pressure and coronary end points (relative risk per 1 SD increase in blood pressure, 1.47; 95 percent confidence interval, 1.16 to 1.85; P<0.001), but no relation between plasma renin activity and coronary end points (relative risk per 1 SD increase in the level of plasma renin activity, 1.04; 95 percent confidence interval, 0.84 to 1.30). In the 242 men who had hypertension of a degree similar to that of the subjects in the earlier prospective study of the renin profile, and in whom 44 of the 86 coronary events occurred, the relative risk of those in the highest as compared with the lowest third for plasma renin activity was 1.26 (95 percent confidence interval, 0.63 to 2.56). Conclusions. Our results suggest that there is no association between plasma renin activity and myocardial infarction or sudden death from coronary causes, at least in normotensive men.			MEADE, TW (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,MRC,EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND.							ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; ARMITAGE P, 1971, STATISTICAL METHODS; BROWN JJ, 1966, BMJ-BRIT MED J, V1, P505, DOI 10.1136/bmj.1.5486.505; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; HANENSON IB, 1959, CIRCULATION, V20, P498, DOI 10.1161/01.CIR.20.4.498; HOPKINS A, 1988, BMDP STATISTICAL SOF, P719; MEADE TW, 1983, CLIN SCI, V64, P273, DOI 10.1042/cs0640273; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; 1977, PUBLIC HLTH EUROPE, V5	9	89	89	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					616	619		10.1056/NEJM199308263290905	http://dx.doi.org/10.1056/NEJM199308263290905			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341336				2022-12-28	WOS:A1993LU21700005
J	BENINI, F; JOHNSTON, CC; FAUCHER, D; ARANDA, JV				BENINI, F; JOHNSTON, CC; FAUCHER, D; ARANDA, JV			TOPICAL ANESTHESIA DURING CIRCUMCISION IN NEWBORN-INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORTISOL RESPONSE; PAIN; ANALGESIA; STRESS; SURGERY	Objective.-To determine the efficacy of topical anesthetic cream, eutectic mixture of local anesthetics (EMLA), in alleviating pain from neonatal circumcision. Design.-Randomized, controlled trial. Setting.-Normal newborn nursery in a university teaching hospital. Patients.-Twenty-seven newborn, full-term male neonates, aged 1 to 3 days. Outcome Measures.-Heart rate, transcutaneous oxygen saturation, facial activity, and crying. Results.-Compared with baseline, all newborns experienced pain as evidenced by increased heart rate of an average of 40 beats per minute (F [8, 25]=14.12; P<.0001), decreased oxygen saturation of 3% (F [8, 25]=15.02; P<.0001), and more facial actions indicative of pain (F [8, 25]=5.25; P<.002) during all phases of the procedure. Compared with placebo, EMLA significantly attenuated the pain response as shown by lower heart rate of an average of 25 beats per minute (F [1, 25]=14.92; P<.001), higher oxygen saturation of 5%, particularly during the clamping and lysis phases (F [1, 25]=19.83; P<.0001), 20% less facial activity (F [1, 25]=12.01; P<.002), and 15% less crying during the clamping, Gomco clamp application, and incision of the foreskin. There were no differences between groups in the spectral crying parameters. Conclusions.-Circumcision procedure produces pain responses that EMLA diminishes. Thus, EMLA may be a useful agent for pain management in neonatal circumcision.	MCGILL UNIV, MONTREAL CHILDRENS HOSP, RES CTR, DIV NURSING RES & DEV PHARMACOL, MONTREAL H3H 1P3, QUEBEC, CANADA; MCGILL UNIV, MONTREAL CHILDRENS HOSP, RES CTR, PERINATAL RES UNIT, MONTREAL H3H 1P3, QUEBEC, CANADA	McGill University; McGill University								ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1989, PEDIATR CLIN N AM, V36, P795; ANAND KJS, 1990, ADV PAIN RES THER, V15, P113; ANDERSEN KH, 1989, ANAESTHESIA, V44, P118, DOI 10.1111/j.1365-2044.1989.tb11158.x; BLASS EM, 1991, PEDIATRICS, V87, P215; Colton T., 1974, STAT MED, V1; FITZGERALD M, 1989, PAIN, V39, P31, DOI 10.1016/0304-3959(89)90172-3; FULLER BF, 1991, NURS RES, V40, P156; GRUNAU RVE, 1990, PAIN, V42, P295, DOI 10.1016/0304-3959(90)91142-6; GRUNAU RVE, 1990, ADV PAIN RES THER, V15, P147; HOLVE RL, 1983, CLIN PEDIATR, V22, P813, DOI 10.1177/000992288302201205; JOHNSTON CC, 1988, PAIN RES CLIN MANAGE, V3, P336; Juhlin L, 1990, Adv Dermatol, V5, P75; Lester B. M, 1984, ADV INFANT RES, P167, DOI DOI 10.1126/sciadv.aao5838; MILENKOVIC P, 1990, CSPEECH; MUDGE D, 1989, J NURSE-MIDWIFERY, V34, P335, DOI 10.1016/0091-2182(89)90007-4; Myron A V, 1991, J Prof Nurs, V7, P188, DOI 10.1016/8755-7223(91)90055-P; STANG HJ, 1988, JAMA-J AM MED ASSOC, V259, P1507, DOI 10.1001/jama.259.10.1507; WILLIAMSON PS, 1983, PEDIATRICS, V71, P36; WILLIAMSON PS, 1986, CLIN PEDIATR, V25, P412, DOI 10.1177/000992288602500807	21	108	108	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					850	853		10.1001/jama.270.7.850	http://dx.doi.org/10.1001/jama.270.7.850			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340985				2022-12-28	WOS:A1993LR61200031
J	STRUHL, G; FITZGERALD, K; GREENWALD, I				STRUHL, G; FITZGERALD, K; GREENWALD, I			INTRINSIC ACTIVITY OF THE LIN-12 AND NOTCH INTRACELLULAR DOMAINS IN-VIVO	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; EPIDERMAL GROWTH-FACTOR; CELL-CELL-INTERACTIONS; CAENORHABDITIS-ELEGANS; C-ELEGANS; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; LATERAL INHIBITION; EARLY NEUROGENESIS; HOMOLOGOUS GENES	The lin-12 gene of C. elegans and the Notch gene of D. melanogaster encode structurally related transmembrane proteins that mediate intercellular signaling. We show that truncated forms of these proteins consisting of only the intracellular domains cause cell fate transformations associated with constitutive activity in their respective organisms. This activity does not depend on endogenous gene function. Our results indicate that the intracellular domains of Lin-12 and Notch have intrinsic activity and that the principal role of the extracellular domains in the intact proteins is to regulate this activity. Our results also suggest that equivalent truncated forms of lin-12/Notch family members in vertebrates, including known oncogenes, are similarly active.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Columbia University; Princeton University	STRUHL, G (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.				NIGMS NIH HHS [GM37602] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037602] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BRENNER S, 1974, GENETICS, V77, P71; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CHOU TB, 1992, GENETICS, V131, P643; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1991, P NATL ACAD SCI USA, V88, P632, DOI 10.1073/pnas.88.2.632; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FREYD G, 1991, THESIS MIT CAMBRIDGE; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HELD LI, 1991, BIOESSAYS, V13, P633, DOI 10.1002/bies.950131203; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HOPPE PE, 1990, DEVELOPMENT, V109, P875; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JIMENEZ F, 1982, ROUX ARCH DEVEL BIOL, V191, P62; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V81, P208; LAMBIE E, 1990, DEVELOPMENT, V112, P231; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MANGO SE, 1991, NATURE, V352, P811, DOI 10.1038/352811a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; MULLER HJ, 1932, P INT C GENET, V6, P213; PALKA J, 1990, DEVELOPMENT, V109, P167; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1993, IN PRESS DEV BIOL; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SIMPSON P, 1989, DEVELOPMENT, V106, P57; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	77	442	456	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					331	345		10.1016/0092-8674(93)90424-O	http://dx.doi.org/10.1016/0092-8674(93)90424-O			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343960				2022-12-28	WOS:A1993LP72600014
J	SCHIEBER, MH; HIBBARD, LS				SCHIEBER, MH; HIBBARD, LS			HOW SOMATOTOPIC IS THE MOTOR CORTEX HAND AREA	SCIENCE			English	Article							ELECTRICAL-STIMULATION; SPATIAL-ORGANIZATION; PRECENTRAL CORTEX; FINGER MOVEMENTS; AWAKE PRIMATES; MONKEY; FORELIMB; MUSCLES; REPRESENTATION; NEURONS	The primary motor cortex (M1) is thought to control movements of different body parts from somatatopically organized cortical territories. Electrical stimulation suggests, however, that territories controlling different fingers overlap. Such overlap might be artifactual or else might indicate that activation of M1 to produce a finger movement occurs over a more widespread cortical area than usually assumed. These possibilities were distinguished in monkeys moving different fingers. Recordings showed that single M1 neurons were active with movements of different fingers. Neuronal populations active with movements of different fingers overlapped extensively. Control of any finger movement thus appears to utilize a population of neurons distributed throughout the M1 hand area rather than a somatotopically segregated population.	WASHINGTON UNIV, SCH MED, DEPT NEUROSURG NEUROL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	SCHIEBER, MH (corresponding author), WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027686] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS27686] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN P, 1975, PROC R SOC SER B-BIO, V188, P31, DOI 10.1098/rspb.1975.0002; ASANUMA H, 1972, EXP BRAIN RES, V14, P243, DOI 10.1007/BF00816161; BUYS EJ, 1986, J PHYSIOL-LONDON, V381, P529, DOI 10.1113/jphysiol.1986.sp016342; DEFELIPE J, 1986, J NEUROSCI, V6, P3749, DOI 10.1523/jneurosci.06-12-03749.1986; DONOGHUE JP, 1992, EXP BRAIN RES, V89, P1; FETZ EE, 1980, J NEUROPHYSIOL, V44, P751, DOI 10.1152/jn.1980.44.4.751; FISH J, 1992, EXP BRAIN RES, V91, P327; FLANDERS M, 1992, J NEUROPHYSIOL, V67, P1264, DOI 10.1152/jn.1992.67.5.1264; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; HIBBARD LS, 1988, J NEUROSCI METH, V26, P55, DOI 10.1016/0165-0270(88)90129-X; Humphrey D R, 1982, Electroencephalogr Clin Neurophysiol Suppl, V36, P393; HUMPHREY DR, 1986, FED PROC, V45, P2687; HUNTLEY GW, 1991, J NEUROPHYSIOL, V66, P390, DOI 10.1152/jn.1991.66.2.390; KWAN HC, 1978, J NEUROPHYSIOL, V41, P1120, DOI 10.1152/jn.1978.41.5.1120; LEMON RN, 1981, J PHYSIOL-LONDON, V311, P521, DOI 10.1113/jphysiol.1981.sp013602; Leyton ASF, 1917, Q J EXP PHYSIOL, V11, P135, DOI 10.1113/expphysiol.1917.sp000240; O'Donnell T. J., 1981, Computer Graphics, V15, P133, DOI 10.1145/965161.806799; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Penfield W., 1950, CEREBRAL CORTEX MAN; REED D, 1983, MOTOR CONTROL MECHAN, P347; SATO KC, 1989, J NEUROPHYSIOL, V62, P959, DOI 10.1152/jn.1989.62.4.959; SCHIEBER MH, 1990, TRENDS NEUROSCI, V13, P440, DOI 10.1016/0166-2236(90)90093-P; SCHIEBER MH, 1991, J NEUROPHYSIOL, V65, P1381, DOI 10.1152/jn.1991.65.6.1381; SERLIN DM, 1993, ACTA ANAT, V146, P255; SHINODA Y, 1981, NEUROSCI LETT, V23, P7, DOI 10.1016/0304-3940(81)90182-8; STRICK PL, 1978, BRAIN RES, V154, P366, DOI 10.1016/0006-8993(78)90707-2; WANNIER TMJ, 1989, NEUROSCI LETT, V98, P63, DOI 10.1016/0304-3940(89)90374-1; WATERS RS, 1990, SOMATOSENS MOT RES, V7, P485, DOI 10.3109/08990229009144721; WONG YC, 1978, J NEUROPHYSIOL, V41, P1107, DOI 10.1152/jn.1978.41.5.1107; WOOLSEY CN, 1979, J NEUROSURG, V51, P476, DOI 10.3171/jns.1979.51.4.0476; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238	32	318	319	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1993	261	5120					489	492		10.1126/science.8332915	http://dx.doi.org/10.1126/science.8332915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332915				2022-12-28	WOS:A1993LN62300042
J	STATHAM, H; GREEN, J				STATHAM, H; GREEN, J			SERUM SCREENING FOR DOWNS-SYNDROME - SOME WOMENS EXPERIENCES	BRITISH MEDICAL JOURNAL			English	Article							AMNIOCENTESIS	Objectives-To describe the experiences of a small group of women who had positive results after serum screening for Down's syndrome. Design-Semistructured telephone interviews and correspondence with women after a positive screening result (four women) negative amniocentesis results (eight), or termination of a pregnancy with a confirmed abnormality (eight). Subjects-20 women who contacted Support After Termination For Abnormality about their experiences of serum screening for Down's syndrome. Main outcome measures-Women's knowledge and understanding of the test; staff misconceptions; communication of results; how women coped with the diagnostic process; attitudes to the test and to termination of abnormal fetuses. Results-All women were made anxious by their positive screening test, no matter how they were told. The women's experiences suggested that medical staff were unclear about the implications of screening tests and how to interpret risk. Even after receipt of negative amniocentesis results some women remained anxious. Staff did not always recognise women's concerns while awaiting amniocentesis results. Conclusions-The way in which serum screening is being implemented does not always meet the needs of women with positive results. Some of the problems were not specific to screening for Down's syndrome. When screening tests are introduced policies should be adopted to ensure appropriate support for participants.			STATHAM, H (corresponding author), UNIV CAMBRIDGE,CTR FAMILY RES,CAMBRIDGE CB2 3RF,ENGLAND.							CLARKE A, 1993, BRIT MED J, V306, P209, DOI 10.1136/bmj.306.6871.209-a; CUCKLE HS, 1988, LANCET, V2, P851; FARRANT W, 1980, BRIT MED J, V281, P452, DOI 10.1136/bmj.281.6237.452; GREEN J, 1990, CRITICAL REV PSYCHOL; GREEN J, 1993, PREGNANCY TESTING TI; KEATINGE RM, 1991, BRIT MED J, V303, P54, DOI 10.1136/bmj.303.6793.54-d; MARTEAU TM, 1988, BRIT MED J, V297, P1469, DOI 10.1136/bmj.297.6661.1469-b; MARTEAU TM, 1989, BRIT J OBSTET GYNAEC, V96, P739, DOI 10.1111/j.1471-0528.1989.tb03295.x; MARTEAU TM, 1992, BMJ, V305, P1434; ROELOFSEN EEC, 1993, J REPROD INFANT PSYC, V11, P41; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; SPENCER K, 1992, BRIT MED J, V305, P769, DOI 10.1136/bmj.305.6856.769; WALD N, 1992, LANCET, V340, P494, DOI 10.1016/0140-6736(92)91822-P; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391	14	74	75	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					174	176		10.1136/bmj.307.6897.174	http://dx.doi.org/10.1136/bmj.307.6897.174			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343748	Green Published, Bronze			2022-12-28	WOS:A1993LN18400023
J	KOLANUS, W; ROMEO, C; SEED, B				KOLANUS, W; ROMEO, C; SEED, B			T-CELL ACTIVATION BY CLUSTERED TYROSINE KINASES	CELL			English	Article							BASOPHILIC LEUKEMIA-CELLS; AMINO-TERMINAL DOMAIN; RECEPTOR ZETA-CHAIN; FC-GAMMA-RII; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; LYMPHOCYTES-T; SRC-FAMILY; CYTOPLASMIC TAIL	Many cellular recognition events in the immune system are initiated by aggregation of cell surface receptors that lack intrinsic protein-tyrosine kinase activity. Receptor-associated kinases related to the src proto-oncogene product have been found to be essential for cellular activation and may interact with the cytoplasmic domains of the antigen receptor chains. We show here that anti-CD16 antibody-mediated clustering of chimeric transmembrane proteins bearing a CD16 extracellular domain and a Src family kinase intracellular domain is not sufficient to initiate a cellular activation signal in T cells, whereas clustering of similar chimeras bearing Syk or ZAP-70 kinase sequences triggers calcium mobilization. Aggregation of the Syk chimera alone, or coaggregation of chimeras bearing Fyn and ZAP-70 kinases, suffices to initiate cytolytic effector function. The pattern of tyrosine phosphorylation induced by clustering of the Syk chimera is similar to the pattern induced by aggregation of T cell receptor.	MIT, DEPT MOLEC BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	KOLANUS, W (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027849, R37AI027849] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27849] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Balk S, 1989, Immunol Ser, V45, P411; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK EA, 1989, ADV CANCER RES, V52, P81; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DEFRANCO AL, 1992, EUR J BIOCHEM, V210, P381, DOI 10.1111/j.1432-1033.1992.tb17432.x; EISEMAN E, 1992, NATURE, V355, P78; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; KROCZEK RA, 1986, NATURE, V322, P181, DOI 10.1038/322181a0; LANE PJL, 1991, J IMMUNOL, V146, P715; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHEN L, 1989, MOL IMMUNOL, V26, P959, DOI 10.1016/0161-5890(89)90114-4; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, ANNU REV GENET, V25, P487, DOI 10.1146/annurev.ge.25.120191.002415; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WONG S, 1992, ONCOGENE, V7, P2407; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YEH ETH, 1987, J IMMUNOL, V138, P91; Yokoyama W M, 1989, Year Immunol, V4, P110; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	88	344	357	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					171	183		10.1016/0092-8674(93)90304-9	http://dx.doi.org/10.1016/0092-8674(93)90304-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334702				2022-12-28	WOS:A1993LN62500017
J	ROME, LC; SWANK, D; CORDA, D				ROME, LC; SWANK, D; CORDA, D			HOW FISH POWER SWIMMING	SCIENCE			English	Article							MUSCLE POWER; OUTPUT; CARP; TEMPERATURE; LOCOMOTION	It is thought that fish generate the power needed for steady swimming with their anterior musculature, whereas the posterior musculature only transmits forces to the tail and does negative work. Isolated red muscle bundles driven through the length changes and stimulation pattern that muscles normally undergo during steady swimming showed the opposite pattern. Most of the power for swimming came from muscle in the posterior region of the fish, and relatively little came from the anterior musculature. In addition, the contractile properties of the muscle along the length of the fish are significantly adapted to enhance power generation.	UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; MARINE BIOL LAB,WOODS HOLE,MA 02543; WOODS HOLE OCEANOG INST,COASTAL RES CTR,WOODS HOLE,MA 02543	University of Pennsylvania; Marine Biological Laboratory - Woods Hole; Woods Hole Oceanographic Institution	ROME, LC (corresponding author), UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104, USA.				NIAMS NIH HHS [AR38404] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038404, R01AR038404] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTRINGHAM JD, 1990, J EXP BIOL, V148, P395; ALTRINGHAM JD, 1990, J EXP BIOL, V151, P453; HESS F, 1984, J EXP BIOL, V109, P229; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; JOSEPHSON RK, 1989, J EXP BIOL, V147, P533; JOSEPHSON RK, 1985, J EXP BIOL, V114, P493; LIGHTHILL MJ, 1971, PROC R SOC SER B-BIO, V179, P125, DOI 10.1098/rspb.1971.0085; MARSH RL, 1992, NATURE, V357, P411, DOI 10.1038/357411a0; ROME LC, 1990, J EXP BIOL, V154, P163; ROME LC, 1988, NATURE, V335, P824, DOI 10.1038/335824a0; ROME LC, 1992, J EXP BIOL, V163, P281; ROME LC, 1992, J EXP BIOL, V163, P259; ROME LC, 1991, AM J PHYSIOL, V260, pC289, DOI 10.1152/ajpcell.1991.260.2.C289; ROME LC, 1992, J EXP BIOL, V171, P261; ROME LC, 1984, AM J PHYSIOL, V247, pR272, DOI 10.1152/ajpregu.1984.247.2.R272; ROME LC, IN PRESS J BIOMECH; SCHMIDTNIELSEN K, 1972, SCIENCE, V177, P222, DOI 10.1126/science.177.4045.222; TANG J, 1992, J EXP BIOL, V166, P33; VANLEEUWEN JL, 1990, J ZOOL, V220, P123; WAINWRIGHT S, 1983, FISH BIOMECHANICS, pCH3	20	186	188	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					340	343		10.1126/science.8332898	http://dx.doi.org/10.1126/science.8332898			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332898				2022-12-28	WOS:A1993LM67800032
J	GUARIGLIA, C; PADOVANI, A; PANTANO, P; PIZZAMIGLIO, L				GUARIGLIA, C; PADOVANI, A; PANTANO, P; PIZZAMIGLIO, L			UNILATERAL NEGLECT RESTRICTED TO VISUAL-IMAGERY	NATURE			English	Article							CEREBRAL HEMISPHERES; MENTAL-IMAGERY; SPACE	DISORDERS in perceiving and exploring the visual space contralateral to a brain lesion have been frequently described. Many patients with hemi-neglect for extrapersonal space also show neglect in a representational domain when the task requires imagining a well-known piazza from a given vantage point1,2 or comparing two visual images3-5. Cognitive6 and psychophysiological7 studies show a functional parallelism between the perceptual and imaginative domain7, indicating that spatial perception and imagery share the same neural substrata. Here we describe a patient with a persistent disorder in visual imagery for familiar piazzas in the absence of any neglect for stimuli located in a far8 or near9 space or on his own body10. Contrary to previous cases involving imagery disorders, computerized tomography scans showed a lesion confined to the right frontal lobe, suggesting the role of the frontal lobe in some specific types of mental imagery.	UNIV ROMA LA SAPIENZA,DEPT PSYCHOL,VIA MARSI 78,I-00185 ROME,ITALY; UNIV ROMA LA SAPIENZA,DEPT NEUROL,I-00185 ROME,ITALY; CLIN S LUCIA,I-00179 ROME,ITALY	Sapienza University Rome; Sapienza University Rome			Padovani, Alessandro/B-7594-2011; Padovani, Alessandro/ABI-7312-2020; guariglia, cecilia/J-9898-2018; Patrizia, Pantano/C-8214-2009	Padovani, Alessandro/0000-0002-0119-3639; Patrizia, Pantano/0000-0001-9659-8294; guariglia, cecilia/0000-0001-7474-6030				BISIACH E, 1978, CORTEX, V14, P129, DOI 10.1016/S0010-9452(78)80016-1; BISIACH E, 1979, BRAIN, V102, P609, DOI 10.1093/brain/102.3.609; BISIACH E, 1987, NEUROPHYSIOLOGICAL N; DEVREESE LP, 1991, NEUROPSYCHOLOGIA, V29, P1, DOI 10.1016/0028-3932(91)90090-U; Ekstrom R.B., 1976, MANUAL KIT FACTOR RE; Farah M J, 1989, J Cogn Neurosci, V1, P302, DOI 10.1162/jocn.1989.1.4.302; FARAH MJ, 1984, COGNITION, V18, P245, DOI 10.1016/0010-0277(84)90026-X; Finke RA., 1989, PRINCIPLES MENTAL IM; GROSSI D, 1989, BRAIN COGNITION, V10, P18, DOI 10.1016/0278-2626(89)90072-9; GUARIGLIA C, 1992, NEUROPSYCHOLOGIA, V30, P1001, DOI 10.1016/0028-3932(92)90051-M; HALLIGAN PW, 1991, NATURE, V350, P498, DOI 10.1038/350498a0; Halligan PW, 1992, NEUROPSYCHOL REHABIL, V2, P125; KINSBOURNE M, 1962, J NEUROL NEUROSUR PS, V25, P339, DOI 10.1136/jnnp.25.4.339; KOSSLYN SM, 1987, PSYCHOL REV, V94, P148, DOI 10.1037/0033-295X.94.2.148; OGDEN JA, 1985, NEUROPSYCHOLOGIA, V23, P273, DOI 10.1016/0028-3932(85)90112-5; PIZZAMIGLIO L, 1990, CORTEX, V56, P551; RIZZOLATTI G, 1983, BRAIN, V106, P655, DOI 10.1093/brain/106.3.655; TEGNER R, 1991, BRAIN, V114, P1943, DOI 10.1093/brain/114.4.1943; Zoccolotti P., 1991, NEUROPSYCHOL REHABIL, V1, P33, DOI [10.1080/09602019108401378, DOI 10.1080/09602019108401378]	19	161	163	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					235	237		10.1038/364235a0	http://dx.doi.org/10.1038/364235a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321319				2022-12-28	WOS:A1993LM68300056
J	OBRIEN, TP				OBRIEN, TP			OPHTHALMOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADIAL KERATOTOMY PERK; MYOPIC PHOTOREFRACTIVE KERATECTOMY; EXCIMER LASER; SIGHTED EYES; SURGERY				OBRIEN, TP (corresponding author), JOHNS HOPKINS UNIV,SCH MED,WILMER EYE INST,BALTIMORE,MD 21205, USA.							BORES LD, 1981, ANN OPHTHALMOL, V13, P941; DEITZ MR, 1987, AM J OPHTHALMOL, V103, P417, DOI 10.1016/S0002-9394(14)77765-7; FYODOROV SN, 1979, ANN OPHTHALMOL, V11, P1885; HARR D, 1992, J REFRACT CORNEAL SU, V8, P8; MCDONALD MB, 1991, OPHTHALMOLOGY, V98, P1327; SALZ JJ, 1991, J REFRACT CORNEAL SU, V7, P12; SATO T, 1953, AM J OPHTHALMOL, V36, P823, DOI 10.1016/0002-9394(53)90183-4; SEILER T, 1991, OPHTHALMOLOGY, V98, P1156; SHER NA, 1991, ARCH OPHTHALMOL-CHIC, V109, P1525, DOI 10.1001/archopht.1991.01080110061035; TROKEL S, 1989, J CATARACT REFR SURG, V15, P373, DOI 10.1016/S0886-3350(89)80054-9; WALLMAN J, 1993, PROG RETIN RES, V12, P133, DOI 10.1016/0278-4327(93)90007-G; WARING GO, 1991, OPHTHALMOLOGY, V98, P1164; WARING GO, 1985, OPHTHALMOLOGY, V92, P177; WARING GO, 1990, JAMA-J AM MED ASSOC, V263, P1083, DOI 10.1001/jama.263.8.1083; WARING GO, 1983, OPHTHALMOLOGY, V90, P40; YAMAGUCHI T, 1982, AM J OPHTHALMOL, V93, P600, DOI 10.1016/S0002-9394(14)77375-1; 1989, HYOPIA PREVALENCE PR	17	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					239	240		10.1001/jama.270.2.239	http://dx.doi.org/10.1001/jama.270.2.239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315747				2022-12-28	WOS:A1993LL36800033
J	STOECKLE, MY; DOUGLAS, RG				STOECKLE, MY; DOUGLAS, RG			INFECTIOUS-DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MERCK & CO INC,WHITE HOUSE STN,NJ	Merck & Company	STOECKLE, MY (corresponding author), CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021, USA.		Stoeckle, Mark/D-3729-2011	Stoeckle, Mark/0000-0002-8280-4795				[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; SPERA RV, 1992, JAMA-J AM MED ASSOC, V268, P2563, DOI 10.1001/jama.268.18.2563; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; 1992, CITY HLTH INFO, V11, P1; 1992, MMWR MORB MORTAL WKL, V41, P61; 1993, CLIN ALERT	13	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					223	224		10.1001/jama.270.2.223	http://dx.doi.org/10.1001/jama.270.2.223			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315739				2022-12-28	WOS:A1993LL36800025
J	TIITINEN, H; SINKKONEN, J; REINIKAINEN, K; ALHO, K; LAVIKAINEN, J; NAATANEN, R				TIITINEN, H; SINKKONEN, J; REINIKAINEN, K; ALHO, K; LAVIKAINEN, J; NAATANEN, R			SELECTIVE ATTENTION ENHANCES THE AUDITORY 40-HZ TRANSIENT-RESPONSE IN HUMANS	NATURE			English	Article							EVOKED-POTENTIALS	STUDIES of human auditory1-3 and somatosensory3 modalities have shown that there is an oscillatory response in the gamma-band (at about 40 Hz) frequency which is elicited by either steady state1-3 or transient4 stimulation. The auditory 40-Hz response is generated at least partially in the auditory cortex4,5 as a result of thalamocortical interaction6 and may serve perceptual integration7,8 and conscious perception9. A connection to selective attention has been implied in human10 and animal11 studies, although the evidence is inconclusive12. Moreover, fundamental differences between the human and animal 40-Hz responses13 prohibit generalization. Furthermore, most experiments have used steady-state stimulation during which the brain does not regain its resting state between stimuli as it does when transient stimulation is used14. Here we study the effect of selective attention on the auditory gamma-band (40-Hz) transient response using subjects listening to tone pips presented in one ear while ignoring a concurrent sequence of tone pips in the other ear. The 40-Hz response was larger when subjects paid attention to stimuli rather than ignored them. This attention effect was most pronounced over the frontal and central scalp areas. Our results demonstrate a physiological correlate of selective attention in the 40-Hz transient response in humans.			TIITINEN, H (corresponding author), UNIV HELSINKI,DEPT PSYCHOL,COGNIT PSYCHOPHYSIOL RES UNIT,RITARIKATU 5,SF-00170 HELSINKI 17,FINLAND.		Alho, Kimmo/G-2997-2013	Alho, Kimmo/0000-0001-8563-2792				DAUBECHIES I, 1990, IEEE T INFORM THEORY, V36, P961, DOI 10.1109/18.57199; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; Gabor D., 1946, J I ELECT ENG LOND, V93, P429, DOI DOI 10.1049/JI-3-2.1946.0074; GALAMBOS R, 1982, ANN NY ACAD SCI, V388, P722, DOI 10.1111/j.1749-6632.1982.tb50841.x; GALAMBOS R, 1981, P NATL ACAD SCI-BIOL, V78, P2643, DOI 10.1073/pnas.78.4.2643; GALAMBOS R, 1991, INDDUCED RHYTHMS BRA, P201; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HARTER MR, 1984, VARIATIES ATTENTION; HILLYARD SA, 1984, CURRENT TRENDS EVE S, V40, P61; KAUFMAN L, 1990, AUDITORY EVOKED MAGN, P283; LINDEN RD, 1987, ELECTROEN CLIN NEURO, V66, P145, DOI 10.1016/0013-4694(87)90184-2; LLINAS RR, 1991, NEUROSCIENCE, V44, P521, DOI 10.1016/0306-4522(91)90075-Y; MAKEIG S, 1989, Society for Neuroscience Abstracts, V15, P113; MAKELA JP, 1987, ELECTROEN CLIN NEURO, V66, P539, DOI 10.1016/0013-4694(87)90101-5; OATMAN LC, 1971, EXP NEUROL, V32, P341, DOI 10.1016/0014-4886(71)90003-3; PANTEV C, 1991, P NATL ACAD SCI USA, V88, P8996, DOI 10.1073/pnas.88.20.8996; RIBARY U, 1991, P NATL ACAD SCI USA, V88, P11037, DOI 10.1073/pnas.88.24.11037; RIBARY U, 1989, ADV BIOMAGNETISM, P311; RIBARY U, 1988, EUR J NEUROSCI S, V1; ROUGEUL A, 1979, ELECTROEN CLIN NEURO, V46, P310, DOI 10.1016/0013-4694(79)90205-0; Sheer D.E., 1984, SELF REGULATION BRAI, P64, DOI DOI 10.1007/978-3-642-69379-3_6; Skinner JE, 1977, ATTENTION VOLUNTARY, P30	22	493	499	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					59	60		10.1038/364059a0	http://dx.doi.org/10.1038/364059a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316297				2022-12-28	WOS:A1993LK81800056
J	BURK, DL; BAROVSKY, K; MONROY, GH				BURK, DL; BAROVSKY, K; MONROY, GH			BIODIVERSITY AND BIOTECHNOLOGY	SCIENCE			English	Article									MORRISON & FOERSTER,755 PAGE MILL RD,PALO ALTO,CA 94304					Burk, Dan/0000-0001-8039-2224				HATHAWAY CM, 1992, ABA J, V78, P42; KOSMO E, 1988, SO CALIF LAW REV, V61, P1055; STONE R, 1992, SCIENCE, V256, P1624, DOI 10.1126/science.256.5064.1624; WAGNER AB, 1987, J PATENT TRADEMARK, V69, P329	4	9	9	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1900	1901		10.1126/science.8316830	http://dx.doi.org/10.1126/science.8316830			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LJ349	8316830				2022-12-28	WOS:A1993LJ34900029
J	VONGS, A; KAKUTANI, T; MARTIENSSEN, RA; RICHARDS, EJ				VONGS, A; KAKUTANI, T; MARTIENSSEN, RA; RICHARDS, EJ			ARABIDOPSIS-THALIANA DNA METHYLATION MUTANTS	SCIENCE			English	Article							SEQUENCE SPECIFICITY; TRANSPOSABLE ELEMENTS; CHROMATIN STRUCTURE; GENE-EXPRESSION; MAIZE; METHYLTRANSFERASES; INACTIVATION; CELLS; AC	Three DNA hypomethylation mutants of the flowering plant Arabidopsis thaliana were isolated by screening mutagenized populations for plants containing centromeric repetitive DNA arrays susceptible to digestion by a restriction endonuclease that was sensitive to methylated cytosines. The mutations are recessive, and at least two are alleles of a single locus, designated DDM1 (for decrease in DNA methylation). Amounts of 5-methylcytosine were reduced over 70 percent in ddm1 mutants. Despite this reduction in DNA methylation levels, ddm1 mutants developed normally and exhibited no striking morphological phenotypes. However, the ddm1 mutations are associated with a segregation distortion phenotype. The ddm1 mutations were used to demonstrate that de novo DNA methylation in vivo is slow.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Richards, Eric/E-6866-2012	Richards, Eric/0000-0002-8665-7470				BENNETZEN JL, 1987, MOL GEN GENET, V208, P45, DOI 10.1007/BF00330420; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CAMPELL BR, 1992, GENE, V112, P225, DOI 10.1016/0378-1119(92)90380-8; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1979, NUCLEIC ACIDS RES, V6, P2125, DOI 10.1093/nar/6.6.2125; CHANDLER VL, 1986, P NATL ACAD SCI USA, V83, P1767, DOI 10.1073/pnas.83.6.1767; CHOMET PS, 1987, EMBO J, V6, P295, DOI 10.1002/j.1460-2075.1987.tb04753.x; FEDOROFF NV, 1989, CELL, V56, P181, DOI 10.1016/0092-8674(89)90891-X; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; GRUENBAUM Y, 1981, NATURE, V292, P860, DOI 10.1038/292860a0; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINN F, 1990, MOL GEN GENET, V222, P329, DOI 10.1007/BF00633837; LYTTLE TW, 1991, ANNU REV GENET, V25, P511, DOI 10.1146/annurev.ge.25.120191.002455; MALUSZYNSKA J, 1991, PLANT J, V1, P159, DOI 10.1111/j.1365-313X.1991.00159.x; MARTIENSSEN R, 1990, GENE DEV, V4, P331, DOI 10.1101/gad.4.3.331; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; MATZKE MA, 1989, EMBO J, V8, P643, DOI 10.1002/j.1460-2075.1989.tb03421.x; NELSON M, 1991, NUCLEIC ACIDS RES, V19, P2045, DOI 10.1093/nar/19.suppl.2045; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; RICHARDS EA, UNPUB; RICHARDS EJ, 1992, NUCLEIC ACIDS RES, V20, P4039, DOI 10.1093/nar/20.15.4039; SCHWARTZ D, 1986, MOL GEN GENET, V205, P476, DOI 10.1007/BF00338085; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; VONGS A, UNPUB	36	529	551	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1926	1928		10.1126/science.8316832	http://dx.doi.org/10.1126/science.8316832			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8316832				2022-12-28	WOS:A1993LJ34900038
J	SUOMINEN, J; VIERULA, M				SUOMINEN, J; VIERULA, M			SEMEN QUALITY OF FINNISH MEN	BRITISH MEDICAL JOURNAL			English	Article											SUOMINEN, J (corresponding author), UNIV TURKU,DEPT MED BIOL,SF-20520 TURKU 52,FINLAND.							CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; IIROLA T, 1991, J DUODECIM, V107, P1069; LEIKKOLA A, 1955, THESIS U TURKU TURKU; NIKKANEN V, 1979, ANDROLOGIA, V11, P123; Saaranen M, 1986, 5 P WORLD C HUM REPR, P298; SUOMINEN J, 1983, INT J ANDROL, V6, P405, DOI 10.1111/j.1365-2605.1983.tb00555.x; TAKALA ME, 1958, THESIS U TURKU TURKU; WICHMANN L, 1992, THESIS U TAMPERE	8	64	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1579	1579		10.1136/bmj.306.6892.1579	http://dx.doi.org/10.1136/bmj.306.6892.1579			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329920	Bronze, Green Published			2022-12-28	WOS:A1993LH12800020
J	WASSENEGGER, M; HEIMES, S; RIEDEL, L; SANGER, HL				WASSENEGGER, M; HEIMES, S; RIEDEL, L; SANGER, HL			RNA-DIRECTED DE-NOVO METHYLATION OF GENOMIC SEQUENCES IN PLANTS	CELL			English	Article							TUBER VIROID PSTV; TOMATO LEAF TISSUE; DNA METHYLATION; GENE-EXPRESSION; CO-SUPPRESSION; HOMOLOGOUS GENES; TOBACCO PLANTS; INACTIVATION; RECOGNITION; PETUNIA	One monomeric and three oligomeric potato spindle tuber viroid (PSTVd) cDNA units were introduced into the tobacco genome via the Agrobacterium-mediated leaf-disc transformation. Southern analysis of the integrates revealed that only their PSTVd-specific sequences become fully methylated, whereas the flanking T-DNA and the genomic plant DNA remain unaltered. Viroid cDNA methylation could only be observed after autonomous viroid RNA-RNA replication had taken place in these plants. These findings demonstrate that a mechanism of de novo methylation of genes might exist that can be induced and targeted in a sequence-specific manner by their own mRNA.			WASSENEGGER, M (corresponding author), MAX PLANCK INST BIOCHEM,VIROIDFORSCH ABT,D-82152 MARTINSRIED,GERMANY.		Wassenegger, Michael/AAF-6507-2020	Wassenegger, Michael/0000-0002-7926-2454				AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BEDBROOK J, 1981, PLANT MOL BIOL NEWSL, V2, P24; BOLDEN A, 1984, J BIOL CHEM, V259, P2437; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; ESCUDE C, 1992, CR ACAD SCI III-VIE, V315, P521; GRIERSON D, 1991, TRENDS BIOTECHNOL, V9, P122, DOI 10.1016/0167-7799(91)90042-G; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HAAS B, 1988, EMBO J, V7, P4063, DOI 10.1002/j.1460-2075.1988.tb03300.x; HARDERS J, 1989, EMBO J, V8, P3941, DOI 10.1002/j.1460-2075.1989.tb08577.x; HOBBS SLA, 1993, PLANT MOL BIOL, V21, P17, DOI 10.1007/BF00039614; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; JORGENSEN R, 1991, TRENDS BIOTECHNOL, V9, P266, DOI 10.1016/0167-7799(91)90087-X; Jorgensen R, 1992, AGBIOTECH NEWS INFOR, V4, P265; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KONOZ C, 1986, MOL GEN GENET, V204, P383; KOOTER JM, 1993, BIOTECHNOLOGY, V4, P166; LINN F, 1990, MOL GEN GENET, V222, P329, DOI 10.1007/BF00633837; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MATZKE MA, 1991, PLANT MOL BIOL, V16, P821, DOI 10.1007/BF00015074; MATZKE MA, 1989, EMBO J, V8, P643, DOI 10.1002/j.1460-2075.1989.tb03421.x; MOL J, 1991, TRENDS BIOTECHNOL, V9, P182, DOI 10.1016/0167-7799(91)90060-U; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; PALOMARES R, 1991, J PHOTOCH PHOTOBIO B, V11, P151, DOI 10.1016/1011-1344(91)80257-I; PFITZNER UM, 1987, NUCLEIC ACIDS RES, V15, P4449; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Sambrook J, 1989, MOL CLONING LABORATO; SCHEID OM, 1991, MOL GEN GENET, V228, P104, DOI 10.1007/BF00282454; SCHMIDTPUCHTA W, 1989, MOL GEN GENET, V219, P17, DOI 10.1007/BF00261152; SCHNOLZER M, 1985, EMBO J, V4, P2181, DOI 10.1002/j.1460-2075.1985.tb03913.x; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; SMITH SS, 1992, BIOCHEMISTRY-US, V31, P850, DOI 10.1021/bi00118a030; SPLESMACHER E, 1985, BIOSCIENCE REP, V5, P251; TABLER M, 1985, EMBO J, V4, P2191, DOI 10.1002/j.1460-2075.1985.tb03914.x; TABLER M, 1984, EMBO J, V3, P3055, DOI 10.1002/j.1460-2075.1984.tb02257.x; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; [No title captured]	40	664	737	3	102	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					567	576		10.1016/0092-8674(94)90119-8	http://dx.doi.org/10.1016/0092-8674(94)90119-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313476				2022-12-28	WOS:A1994MX20700016
J	SPITZ, IM; BARDIN, CW				SPITZ, IM; BARDIN, CW			DRUG-THERAPY - MIFEPRISTONE (RU-486) - A MODULATOR OF PROGESTIN AND GLUCOCORTICOID ACTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRANS-PLACENTAL PASSAGE; BREAST-CANCER-CELLS; EARLY-PREGNANCY; ANTAGONIST RU-486; LUTEAL PHASE; MENSTRUAL-CYCLE; ANTIPROGESTERONE RU-486; 1ST TRIMESTER; LONG-TERM; GONADOTROPIN-SECRETION				SPITZ, IM (corresponding author), POPULAT COUNCIL, CTR BIOMED RES, 1230 YORK AVE, NEW YORK, NY 10021 USA.							BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAKKER GH, 1990, J STEROID BIOCHEM, V37, P789, DOI 10.1016/0960-0760(90)90421-G; BARDON S, 1985, J CLIN ENDOCR METAB, V60, P692, DOI 10.1210/jcem-60-4-692; BATISTA MC, 1992, J CLIN ENDOCR METAB, V74, P565, DOI 10.1210/jc.74.3.565; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BERTHOIS Y, 1991, FERTIL STERIL, V55, P547; BIRGERSON L, 1988, CONTRACEPTION, V38, P391, DOI 10.1016/0010-7824(88)90080-7; BLANKENSTEIN MA, 1987, CLIN CHIM ACTA, V165, P189, DOI 10.1016/0009-8981(87)90162-8; BYGDEMAN M, 1985, CONTRACEPTION, V32, P45, DOI 10.1016/0010-7824(85)90115-5; CABROL D, 1990, AM J OBSTET GYNECOL, V163, P540, DOI 10.1016/0002-9378(90)91193-G; CAMERON IT, 1988, BRIT J OBSTET GYNAEC, V95, P271, DOI 10.1111/j.1471-0528.1988.tb06868.x; CHROUSOS GP, 1989, ADRENAL HYPERTENSION, V57, P273; COLLINS FS, 1983, J PEDIATR-US, V102, P620, DOI 10.1016/S0022-3476(83)80204-2; COUZINET B, 1990, FERTIL STERIL, V54, P1039; COUZINET B, 1986, NEW ENGL J MED, V315, P1565, DOI 10.1056/NEJM198612183152501; CROXATTO HB, 1989, CLIN ENDOCRINOL, V31, P15, DOI 10.1111/j.1365-2265.1989.tb00449.x; CROXATTO HB, 1987, J CLIN ENDOCR METAB, V65, P1272, DOI 10.1210/jcem-65-6-1272; CSAPO AI, 1973, PROSTAGLANDINS, V3, P245, DOI 10.1016/0090-6980(73)90066-X; DAS C, 1987, LANCET, V2, P599; DERAEDT R, 1985, ANTIPROGESTIN STEROI, P123; Deraedt R., 1985, ANTIPROGESTIN STEROI, P103; DIMATTINA M, 1986, CONTRACEPTION, V34, P199, DOI 10.1016/0010-7824(86)90072-7; DUBOIS C, 1988, FERTIL STERIL, V50, P593; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; FRYDMAN R, 1985, LANCET, V2, P1252; FRYDMAN R, 1991, LANCET, V337, P488, DOI 10.1016/0140-6736(91)93421-5; GAILLARD RC, 1984, P NATL ACAD SCI-BIOL, V81, P3879, DOI 10.1073/pnas.81.12.3879; GAILLARD RC, 1985, J CLIN ENDOCR METAB, V61, P1009, DOI 10.1210/jcem-61-6-1009; GARZO VG, 1988, J CLIN ENDOCR METAB, V66, P508, DOI 10.1210/jcem-66-3-508; GLASIER A, 1992, NEW ENGL J MED, V327, P1041, DOI 10.1056/NEJM199210083271501; GRAVANIS A, 1985, J CLIN ENDOCR METAB, V60, P156, DOI 10.1210/jcem-60-1-156; GREENE KE, 1992, FERTIL STERIL, V58, P338; GRUNBERG SM, 1991, J NEUROSURG, V74, P861, DOI 10.3171/jns.1991.74.6.0861; GUPTA JK, 1990, LANCET, V335, P1238, DOI 10.1016/0140-6736(90)91303-R; HEIKINHEIMO O, 1990, ACTA ENDOCRINOL-COP, V123, P298, DOI 10.1530/acta.0.1230298; HENSHAW RC, 1991, BRIT J OBSTET GYNAEC, V98, P1025, DOI 10.1111/j.1471-0528.1991.tb15341.x; HERRMANN W, 1982, CR ACAD SCI III-VIE, V294, P933; HILL NCW, 1990, BRIT J OBSTET GYNAEC, V97, P406, DOI 10.1111/j.1471-0528.1990.tb01827.x; HILL NCW, 1990, AM J OBSTET GYNECOL, V162, P414, DOI 10.1016/0002-9378(90)90398-Q; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; HSUEH AJW, 1975, NATURE, V254, P337, DOI 10.1038/254337a0; JOST A, 1986, CR ACAD SCI III-VIE, V303, P281; KEKKONEN R, 1990, FERTIL STERIL, V53, P747; KETTEL LM, 1991, FERTIL STERIL, V56, P402; KLITSCH M, 1991, FAM PLANN PERSPECT, V23, P275, DOI 10.2307/2135779; KOERING MJ, 1986, FERTIL STERIL, V45, P280; LAHTEENMAKI P, 1987, J STEROID BIOCHEM, V27, P859, DOI 10.1016/0022-4731(87)90160-9; LAHTEENMAKI P, 1988, FERTIL STERIL, V50, P36; LAMBERTS SWJ, 1991, J CLIN ENDOCR METAB, V73, P187, DOI 10.1210/jcem-73-1-187; LAUE L, 1990, J CLIN ENDOCR METAB, V71, P1474, DOI 10.1210/jcem-71-6-1474; LEDGER WL, 1992, HUM REPROD, V7, P945, DOI 10.1093/oxfordjournals.humrep.a137776; LI TC, 1988, FERTIL STERIL, V50, P732; LIM BH, 1990, LANCET, V336, P257; LIU JH, 1987, J CLIN ENDOCR METAB, V65, P1135, DOI 10.1210/jcem-65-6-1135; LUUKKAINEN T, 1988, FERTIL STERIL, V49, P961; MISHELL DR, 1987, CONTRACEPTION, V35, P307, DOI 10.1016/0010-7824(87)90068-0; MURPHY AA, 1993, J CLIN ENDOCR METAB, V76, P513, DOI 10.1210/jc.76.2.513; NIEMAN LK, 1985, J CLIN ENDOCR METAB, V61, P536, DOI 10.1210/jcem-61-3-536; NIEMAN LK, 1987, NEW ENGL J MED, V316, P187, DOI 10.1056/NEJM198701223160404; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; NORMAN JE, 1991, CONTRACEPTION, V44, P89, DOI 10.1016/0010-7824(91)90109-S; NORMAN JE, 1991, HUM REPROD, V6, P740, DOI 10.1093/oxfordjournals.humrep.a137420; NORMAN JE, 1992, BRIT J OBSTET GYNAEC, V99, P601, DOI 10.1111/j.1471-0528.1992.tb13830.x; PERMEZEL JM, 1989, J CLIN ENDOCR METAB, V68, P960, DOI 10.1210/jcem-68-5-960; PEYRON R, 1993, NEW ENGL J MED, V328, P1509, DOI 10.1056/NEJM199305273282101; PHILIBERT D, 1984, ADRENAL STEROID ANTA, P77; PHILIBERT D, 1981, 8 INT C PHARM TOK; PHILLIPS CI, 1984, LANCET, V1, P767; PONS JC, 1991, LANCET, V338, P763, DOI 10.1016/0140-6736(91)91490-L; RADESTAD A, 1990, CONTRACEPTION, V41, P283, DOI 10.1016/0010-7824(90)90069-8; REGELSON W, 1990, JAMA-J AM MED ASSOC, V264, P1026, DOI 10.1001/jama.264.8.1026; RODGER MW, 1990, BRIT J OBSTET GYNAEC, V97, P41, DOI 10.1111/j.1471-0528.1990.tb01714.x; RODGER MW, 1989, CONTRACEPTION, V40, P439, DOI 10.1016/0010-7824(89)90051-6; RODGER MW, 1989, CONTRACEPTION, V39, P497, DOI 10.1016/0010-7824(89)90104-2; ROMIEU G, 1987, B CANCER, V74, P455; SHOUPE D, 1987, AM J OBSTET GYNECOL, V157, P1414, DOI 10.1016/S0002-9378(87)80235-1; SHOUPE D, 1986, CONTRACEPTION, V33, P455, DOI 10.1016/S0010-7824(86)80004-X; SHOUPE D, 1987, AM J OBSTET GYNECOL, V157, P1421, DOI 10.1016/S0002-9378(87)80236-3; SILVESTRE L, 1990, NEW ENGL J MED, V322, P645, DOI 10.1056/NEJM199003083221001; SMITH SK, 1987, J CLIN ENDOCR METAB, V65, P527, DOI 10.1210/jcem-65-3-527; SPITZ IM, 1993, FERTIL STERIL, V59, P971; SPITZ IM, 1993, ACTA ENDOCRINOL-COP, V128, P459, DOI 10.1530/acta.0.1280459; SWAHN ML, 1988, HUM REPROD, V3, P915, DOI 10.1093/oxfordjournals.humrep.a136809; SWAHN ML, 1990, HUM REPROD, V5, P402, DOI 10.1093/oxfordjournals.humrep.a137111; SWAHN ML, 1991, LANCET, V338, P942, DOI 10.1016/0140-6736(91)91805-5; TEMPLETON A, 1990, BRIT J OBSTET GYNAEC, V97, P480; TEUTSCH G, 1985, ANTIPROGESTIN STEROI, P27; Tietze C, 1986, INDUCED ABORTION WOR; ULMANN A, 1987, Contraception, V36, P27, DOI 10.1016/0010-7824(87)90119-3; URQUHART DR, 1990, CONTRACEPTION, V42, P191, DOI 10.1016/0010-7824(90)90102-2; VANSANTEN MR, 1987, CONTRACEPTION, V35, P433, DOI 10.1016/0010-7824(87)90079-5; VANUEM JFHM, 1989, CONTRACEPTION, V40, P171, DOI 10.1016/0010-7824(89)90004-8; VERVEST HAM, 1985, FERTIL STERIL, V44, P627; WEBB A M C, 1991, Advances in Contraception, V7, P271, DOI 10.1007/BF01849417; WOLF JP, 1988, AM J OBSTET GYNECOL, V159, P238, DOI 10.1016/0002-9378(88)90528-5; WOLF JP, 1989, FERTIL STERIL, V52, P1055; WOLF JP, 1989, CONTRACEPTION, V40, P185, DOI 10.1016/0010-7824(89)90005-X; WOLF JP, 1990, CONTRACEPTION, V41, P85, DOI 10.1016/0010-7824(90)90129-J	100	167	176	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					404	412						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8326975				2022-12-28	WOS:A1993LQ33900007
J	CHARYCH, DH; NAGY, JO; SPEVAK, W; BEDNARSKI, MD				CHARYCH, DH; NAGY, JO; SPEVAK, W; BEDNARSKI, MD			DIRECT COLORIMETRIC DETECTION OF A RECEPTOR-LIGAND INTERACTION BY A POLYMERIZED BILAYER ASSEMBLY	SCIENCE			English	Article							LANGMUIR-BLODGETT-FILMS; GAS-WATER INTERFACE; POLYDIACETYLENE FILMS; COLOR TRANSITIONS; PHASE-TRANSITIONS; ACID MONOLAYERS; GLUCOSE SENSOR; DIACETYLENE	Detection of receptor-ligand interactions is generally accomplished by indirect assays such as enzyme-linked immunosorbent assay. A direct colorimetric detection method based on a polydiacetylene bilayer assembled on glass microscope slides has been developed. The bilayer is composed of a self-assembled monolayer of octadecylsilane and a Langmuir-Blodgett monolayer of polydiacetylene. The polydiacetylene layer is functionalized with an analog of sialic acid, the receptor-specific ligand for the influenza virus hemagglutinin. The sialic acid ligand serves as a molecular recognition element and the conjugated polymer backbone signals binding at the surface by a chromatic transition. The color transition is readily visible to the naked eye as a blue to red color change and can be quantified by visible absorption spectroscopy. Direct colorimetric detection by polydiacetylene films offers new possibilities for diagnostic applications and screening for new drug candidates or binding ligands.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	CHARYCH, DH (corresponding author), LAWRENCE BERKELEY LAB,CTR ADV MAT,BERKELEY,CA 94720, USA.							AIR GM, 1989, PROTEINS, V6, P341, DOI 10.1002/prot.340060402; ANZAI JI, 1990, SELECT ELECTR REV, V12, P3; ARISAWA S, 1992, THIN SOLID FILMS, V210, P443; BESWICK RB, 1988, J COLLOID INTERF SCI, V124, P146, DOI 10.1016/0021-9797(88)90335-9; BILEWICZ R, 1991, LANGMUIR, V7, P2794, DOI 10.1021/la00059a063; CHANCE RR, 1979, J CHEM PHYS, V71, P206, DOI 10.1063/1.438117; DAY D, 1980, MACROMOLECULES, V13, P1478, DOI 10.1021/ma60078a023; DAY D, 1978, J POLYM SCI POL LETT, V16, P205, DOI 10.1002/pol.1978.130160501; DEPALMA V, 1989, LANGMUIR, V5, P868, DOI 10.1021/la00087a049; FISCHETTI RF, 1988, PHYS REV B, V37, P4714, DOI 10.1103/PhysRevB.37.4714; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FURUKI M, 1992, THIN SOLID FILMS, V210, P471, DOI 10.1016/0040-6090(92)90315-3; Gaines GL, 1966, INSOLUBLE MONOLAYERS; KANEKO F, 1992, THIN SOLID FILMS, V210, P548, DOI 10.1016/0040-6090(92)90338-C; KEPLEY LJ, 1992, ANAL CHEM, V64, P3191, DOI 10.1021/ac00048a018; LIESER G, 1980, THIN SOLID FILMS, V68, P77, DOI 10.1016/0040-6090(80)90138-8; MAOZ R, 1984, J COLLOID INTERF SCI, V100, P465, DOI 10.1016/0021-9797(84)90452-1; MINO N, 1992, LANGMUIR, V8, P594, DOI 10.1021/la00038a047; MINO N, 1991, LANGMUIR, V7, P2336, DOI 10.1021/la00058a060; MIYASAKA T, 1990, CHEM LETT, P627, DOI 10.1246/cl.1990.627; NOVOTNY V, 1989, LANGMUIR, V5, P485, DOI 10.1021/la00086a034; OKAHATA Y, 1989, THIN SOLID FILMS, V180, P65, DOI 10.1016/0040-6090(89)90055-2; ROBERTS GG, 1990, LANGMUIRBLODGETT FIL; SHIBATA M, 1989, THIN SOLID FILMS, V179, P433, DOI 10.1016/0040-6090(89)90217-4; SPEVAK W, 1993, J AM CHEM SOC, V115, P1146, DOI 10.1021/ja00056a047; SWALEN JD, 1987, LANGMUIR, V3, P932, DOI 10.1021/la00078a011; TIEKE B, 1977, COLLOID POLYM SCI, V255, P36; WENZEL M, 1989, J AM CHEM SOC, V111, P6123, DOI 10.1021/ja00198a020; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013; ZHAO S, 1992, LANGMUIR, V8, P2785, DOI 10.1021/la00047a034	30	670	718	4	212	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					585	588		10.1126/science.8342021	http://dx.doi.org/10.1126/science.8342021			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342021				2022-12-28	WOS:A1993LP72800031
J	POWER, EJ				POWER, EJ			HOME DRUG INFUSION THERAPY UNDER MEDICARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											POWER, EJ (corresponding author), US OFF TECHNOL ASSESSMENT,HLTH PROGRAM,WASHINGTON,DC 20510, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					427	427						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320771				2022-12-28	WOS:A1993LN42600005
J	TRAYNOR, MP; BEGAY, ME; GLANTZ, SA				TRAYNOR, MP; BEGAY, ME; GLANTZ, SA			NEW TOBACCO INDUSTRY STRATEGY TO PREVENT LOCAL TOBACCO CONTROL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALIFORNIA	We examined the tobacco industry's new strategy to defeat and then repeal tobacco control ordinances in California and the efforts of health professionals to pass and defend these ordinances. Case studies were conducted in California communities in 1991 and 1992, using published reports, public documents, attendance at public meetings, and interviews. The tobacco industry is spending millions of dollars to intervene in California communities to oppose legislation protecting nonsmokers from secondhand smoke. The tobacco industry has moved beyond organizing smokers to use professional public affairs and political campaign firms to defeat or weaken local tobacco control ordinances. The industry used front groups to conceal its involvement because public knowledge of the industry's involvement increases support for legislation controlling smoking. Some firms closely monitor developing ordinances, while others actively organize and direct local opposition. If these efforts do not weaken or defeat an ordinance, the tobacco industry initiates a referendum petition drive to suspend it to pressure local elected officials to repeal or weaken it. If this tactic fails, the industry often finances an election campaign to repeal the ordinance by popular vote. Although the tobacco industry's new strategy has hindered the passage of some local tobacco control ordinances, when health professionals and elected officials remained active and committed, the industry's efforts have failed and the ordinances have been upheld.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANGUS D, 1991, COMMUNICATION   0625; ANGUS D, 1991, COMMUNICATION   1025; BONTA D, 1991, MAR LONG BEACH CAL C; BONTA D, 1991, COMMUNICATION   0703; BORLAND R, 1992, JAMA-J AM MED ASSOC, V268, P749, DOI 10.1001/jama.268.6.749; CAVIGLIA L, 1991, COMMUNICATION   1028; COLE R, 1991, COMMUNICATION   0522; EDISON C, 1991, LONG BEACH BUSI 0521; FONTAINE V, 1991, AUBURN J        1115; FREEDMAN A, 1988, WALL STREET J   0411; GAMBEE P, 1991, EC IMPACTS SMOKING B; GLANTZ S, 1992, U CALIFORNIA MONOGRA; GLANTZ S, 1992, TOBACCO CONTROL, V3, P166; GRISWOLD L, 1991, VISALIA TIMES D 0921; MALMGREN K, 1992, COMMUNICATION   0401; MEGALLI M, 1991, ESSENTIAL INFORM DEC; MOORE J, 1992, METHODS; PRICE C, 1992, CALIF J          NOV; RHODES K, 1991, FAIR EQUITABLE SMOKI; ROGERS D, 1991, COMMUNICATION   0524; ROGERS DA, 1991, FAIR EQUITABLE SMOKI; SAMUELS B, 1991, JAMA-J AM MED ASSOC, V266, P2110, DOI 10.1001/jama.266.15.2110; SAMUELS BE, 1991, U CALIFORNIA MONOGRA; SIMPSON J, 1991, COMMUNICATION   1108; SIMPSON J, 1992, COMMUNICATION   0117; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2723; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2721, DOI 10.1001/jama.267.20.2721; WOODRUFF T, IN PRESS ARCH INTERN; 1992, WISCONSIN STATE 1013; 1982, KERN COUNTY SMOKING; 1990, IND GOAL IS OBJECTIV; 1992, EPA600690006F PUBL; 1992, BUSINESS J      0413; 1978, PUBLIC ATTITUDES CIG	34	66	66	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					479	486		10.1001/jama.270.4.479	http://dx.doi.org/10.1001/jama.270.4.479			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN426	8320788				2022-12-28	WOS:A1993LN42600028
J	BRUNET, AP; HUANG, ES; HUFFINE, ME; LOEB, JE; WELTMAN, RJ; HECHT, MH				BRUNET, AP; HUANG, ES; HUFFINE, ME; LOEB, JE; WELTMAN, RJ; HECHT, MH			THE ROLE OF TURNS IN THE STRUCTURE OF AN ALPHA-HELICAL PROTEIN	NATURE			English	Article							FOLDING UNFOLDING PATHWAYS; MONTE-CARLO SIMULATIONS; PEPTIDE-FRAGMENTS; ESCHERICHIA-COLI; DENOVO DESIGN; MUTAGENESIS; SEQUENCE; CYTOCHROME-B562; CONFORMATION; PENTAPEPTIDES	THE turns joining segments of secondary structure have been proposed to be key elements in dictating the folded structures of native proteins1-9. An alternative view assumes that turns play a passive role and are merely default structures that occur as a consequence of interactions between antiparallel segments of secondary structure, with chain reversal being dictated by the context surrounding the turn and not by the sequence of the turn itself10,11. The solvent-exposure of turns and their tolerance to evolutionary variance suggests that they may have little or no effect on the formation of native structures. Previous investigations have focused on various types of beta-turns that connect antiparallel beta-strands1-3,12,13, with comparatively little reported on the structural role of interhelical turns. Here we probe the structural importance of such a turn in an antiparallel 4-helix bundle by randomly substituting an interhelical tripeptide in cytochrome b-562 with many different amino-acid sequences. Thirty-one of the resulting substituted proteins were characterized and all of them were shown to fold into stable, native-like structures. These results suggest that this interhelical turn does not does not play a dominant role in determining the folded structure of this antiparallel 4-helix bundle.	PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University; Princeton University				Hecht, Michael/0000-0002-5538-9813				ARGOS P, 1987, J MOL BIOL, V197, P331, DOI 10.1016/0022-2836(87)90127-6; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHOU KC, 1992, P NATL ACAD SCI USA, V89, P7315, DOI 10.1073/pnas.89.16.7315; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DENTE L, 1987, METHOD ENZYMOL, V155, P111; DILL KA, 1991, REV BIOCH, V60, P795; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; EISENBEIS SJ, 1985, P NATL ACAD SCI USA, V82, P1084, DOI 10.1073/pnas.82.4.1084; FEDOROV AN, 1992, J MOL BIOL, V225, P927, DOI 10.1016/0022-2836(92)90092-X; FISHER MT, 1991, BIOCHEMISTRY-US, V30, P10012, DOI 10.1021/bi00105a028; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HERTZBERG O, 1990, PROTEIN-STRUCT FUNCT, V11, P223; HYNES TR, 1989, NATURE, V339, P73, DOI 10.1038/339073a0; ITAGAKI E, 1966, J BIOL CHEM, V241, P3687; KABSCH W, 1984, P NATL ACAD SCI-BIOL, V81, P1075, DOI 10.1073/pnas.81.4.1075; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEDERER F, 1981, J MOL BIOL, V148, P427, DOI 10.1016/0022-2836(81)90185-6; MATHEWS FS, 1979, J BIOL CHEM, V254, P1699; MILBURN PJ, 1988, INT J PEPT PROT RES, V31, P311; NIKKILA H, 1991, EUR J BIOCHEM, V202, P309, DOI 10.1111/j.1432-1033.1991.tb16377.x; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; SAMBROOK J, 1990, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; SIKORSKI A, 1990, J MOL BIOL, V212, P819, DOI 10.1016/0022-2836(90)90238-H; SKOLNICK J, 1990, J MOL BIOL, V212, P787, DOI 10.1016/0022-2836(90)90237-G; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; YOUNG HD, 1962, STATISTICAL TREATMEN, pCH2	37	104	105	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 22	1993	364	6435					355	358		10.1038/364355a0	http://dx.doi.org/10.1038/364355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332196				2022-12-28	WOS:A1993LN57000063
J	PETERS, LL; BARKER, JE				PETERS, LL; BARKER, JE			NOVEL INHERITANCE OF THE MURINE SEVERE COMBINED ANEMIA AND THROMBOCYTOPENIA (SCAT) PHENOTYPE	CELL			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; NATURAL-KILLER-CELLS; BONE-MARROW; MOUSE; PURPURA; MICE; EXPRESSION; DISEASE; GENE; ASSOCIATION	The phenotype of the autosomal recessive mutation scat includes severe intermittent bleeding, depletion of platelets, and circulating anti-platelet antibodies. In this study, we have mapped the scat mutation to mouse chromosome 8 and shown that the immune component is a secondary consequence of the gene defect. Surprisingly, the phenotype of the scat/scat pups depends on the genotype of the mother. Maternal homozygosity prevents disease transmission; crosses between scat homozygotes produce few affected young, while the expected frequency is generated from normal (+/+) mice bearing scat/scat ovaries. The results suggest a novel method of maternal-fetal interaction that relies neither on transfer of maternal mitochondria nor on parental imprinting. We conclude that contribution from the maternal wild-type allele is required for expression of the scat phenotype in homozygotes.	JACKSON LAB, BAR HARBOR, ME 04609 USA	Jackson Laboratory				Peters, Luanne/0000-0002-0784-0534	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049761, R01HL029305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027726] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49761, HL29305] Funding Source: Medline; NIDDK NIH HHS [DK27726] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLEM PJ, 1987, J CLIN INVEST, V80, P33, DOI 10.1172/JCI113060; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BRANEHOG I, 1975, BLOOD, V45, P551; BROWN B, 1984, HEMATOLOGY PRINCIPLE; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; CZITROM AA, 1985, J IMMUNOL, V134, P2276; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EISENBERG RA, 1980, J IMMUNOL, V125, P1032; FRANKEL WN, 1989, J VIROL, V63, P1763, DOI 10.1128/JVI.63.4.1763-1774.1989; GARNIWAGNER BA, 1990, J IMMUNOL, V144, P796; HALLER JA, 1964, TRANSPLANTATION, V2, P287, DOI 10.1097/00007890-196403000-00016; HAYES MM, 1985, J CLIN PATHOL, V38, P985, DOI 10.1136/jcp.38.9.985; HOLME S, 1988, BRIT J HAEMATOL, V68, P431, DOI 10.1111/j.1365-2141.1988.tb04231.x; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; JOHNSON KR, 1991, MAMM GENOME, V1, P260, DOI 10.1007/BF00352334; JYONOUCHI H, 1981, J IMMUNOL, V127, P1232; KARPATKIN S, 1985, SEMIN HEMATOL, V22, P260; KARPATKIN S, 1972, BRIT J HAEMATOL, V23, P167, DOI 10.1111/j.1365-2141.1972.tb03470.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI WC, 1990, J INFECT DIS, V161, P1269, DOI 10.1093/infdis/161.6.1269; LYNCH DM, 1986, BRIT J HAEMATOL, V63, P301; MCMILLAN R, 1976, IMMUNOASPECTS SPLEEN, P227; NAIDU S, 1983, ARCH NEUROL-CHICAGO, V40, P552, DOI 10.1001/archneur.1983.04050080052009; PETERS LL, 1990, BLOOD, V76, P745; Robertson GG, 1940, P SOC EXP BIOL MED, V44, P302; RODER JC, 1979, J IMMUNOL, V123, P2168; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOYE JP, 1988, J VIROL, V62, P168, DOI 10.1128/JVI.62.1.168-175.1988; THEOFILOPOULOS AN, 1989, ADV IMMUNOL, V46, P61, DOI 10.1016/S0065-2776(08)60651-3; THEOFILOPOULOS AN, 1985, J EXP MED, V162, P1, DOI 10.1084/jem.162.1.1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGSTAFF J, 1992, NAT GENET, V1, P291, DOI 10.1038/ng0792-291; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WHITE RA, 1992, MAMM GENOME, V3, P281, DOI 10.1007/BF00292156	37	30	31	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					135	142		10.1016/0092-8674(93)90301-6	http://dx.doi.org/10.1016/0092-8674(93)90301-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334700				2022-12-28	WOS:A1993LN62500014
J	WITHERS, GS; FAHRBACH, SE; ROBINSON, GE				WITHERS, GS; FAHRBACH, SE; ROBINSON, GE			SELECTIVE NEUROANATOMICAL PLASTICITY AND DIVISION-OF-LABOR IN THE HONEYBEE	NATURE			English	Article							MUSHROOM BODIES; APIS-MELLIFERA; SYNAPTOGENESIS; MORPHOLOGY; CORTEX; BRAIN; BEE	THE mushroom bodies in the protocerebrum are believed to be the structures of the insect brain most closely associated with higher-order sensory integration and learning1. Drosophila melanogaster mutants with olfactory learning deficit have anatomically abnormal mushroom bodies or altered patterns of gene expression in mushroom body neurons2-4. In addition, anatomical reorganization of the mushroom bodies occurs in adult flies5, and possibly in adult honeybees6,7; disturbance of electrical activity in this region disrupts memory formation in honeybees8. Little is known, however, about the relationship of naturally occurring anatomical changes in the mushroom bodies to naturally occurring behavioural plasticity. We now report that age-based division of labour in adult worker honeybees (Apis mellifera) is associated with substantial changes in certain brain regions, notably the mushroom bodies. Moreover, these striking changes in brain structure are dependent, not on the age of the bee, but on its foraging experience, thus demonstrating a robust anatomical plasticity associated with complex behaviour in an adult insect.	UNIV ILLINOIS,DEPT ENTOMOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	WITHERS, GS (corresponding author), UNIV ILLINOIS,NEUROSCI PROGRAM,URBANA,IL 61801, USA.			Withers, Ginger/0000-0002-7004-7846				BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; BRANDON JG, 1982, BRAIN RES, V252, P51, DOI 10.1016/0006-8993(82)90977-5; Cajal S.R.y., 1894, P R SOC LOND, V55, P444; COSS RG, 1980, BRAIN RES, V192, P49, DOI 10.1016/0006-8993(80)91007-0; DEVOOGD TJ, 1985, BRAIN RES, V329, P304, DOI 10.1016/0006-8993(85)90539-6; ERBER J, 1980, PHYSIOL ENTOMOL, V5, P343, DOI 10.1111/j.1365-3032.1980.tb00244.x; ERBER J, 1987, ARTHROPOD BRAIN ITS, P484; GOULD JL, 1986, ANNU REV PSYCHOL, V37, P163; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; HUANG ZY, 1993, P NATL ACAD SCI USA, V89, P11726; Kenyon F., 1896, J COMP NEUROL, V6, P133, DOI DOI 10.1002/CNE.910060302; LAIDLAW HH, 1977, INSTRUMENTAL INSEMIN; Menzel R., 1990, NEUROBIOLOGY COMP CO, P237; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MOBBS PG, 1984, J INSECT PHYSIOL, V30, P43, DOI 10.1016/0022-1910(84)90107-0; MOBBS PG, 1982, PHILOS T ROY SOC B, V298, P309, DOI 10.1098/rstb.1982.0086; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; ROBINSON GE, 1992, ANNU REV ENTOMOL, V37, P637, DOI 10.1146/annurev.en.37.010192.003225; ROBINSON GE, 1989, SCIENCE, V246, P109, DOI 10.1126/science.246.4926.109; Tanzi E., 1893, RIV SPER FRENIAT MED, V19, P419; Technau GM, 1984, J NEUROGENET, V1, P113, DOI 10.3109/01677068409107077; TURNER AM, 1985, BRAIN RES, V329, P195, DOI 10.1016/0006-8993(85)90525-6; von Frisch K., 1967, DANCE LANGUAGE ORIEN; WINSTON ML, 1987, BIOL HONEY BEE, P89; 1985, SAS USERS GUIDE STAT	27	311	314	1	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					238	240		10.1038/364238a0	http://dx.doi.org/10.1038/364238a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321320				2022-12-28	WOS:A1993LM68300057
J	BARASH, PG				BARASH, PG			ANESTHESIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									YALE NEW HAVEN MED CTR,NEW HAVEN,CT	Yale University	BARASH, PG (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.							ALON E, 1992, ANESTH ANALG, V75, P561; [Anonymous], 1993, ANESTHESIOLOGY, V78, P597; [Anonymous], 1992, ACUTE PAIN MANAGEMEN; BENNETT JA, 1992, J CLIN ANESTH, V4, P378, DOI 10.1016/0952-8180(92)90159-X; EJLERSEN E, 1992, ANESTH ANALG, V74, P495; GABA DM, 1992, ANESTHESIOLOGY, V76, P491; HALPERN NA, 1992, CRIT CARE MED, V20, P1637, DOI 10.1097/00003246-199212000-00006; HOWARD SK, 1992, AVIAT SPACE ENVIR MD, V63, P763; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; MATHEW JP, 1992, ANESTHESIOLOGY, V77, P635, DOI 10.1097/00000542-199210000-00004; MCLINTIC AJ, 1992, ANESTH ANALG, V74, P51; MCQUAY HJ, 1992, BRIT J ANAESTH, V69, P1, DOI 10.1093/bja/69.1.1; ROBIN ED, 1992, CHEST, V102, P1842, DOI 10.1378/chest.102.6.1842; SCHWID HA, 1992, ANESTHESIOLOGY, V76, P495, DOI 10.1097/00000542-199204000-00002; ZAKOWSKI MI, 1993, ANESTH ANALG, V76, P162; 1993, ANESTHESIOLOGY, V78, P380	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					188	190		10.1001/jama.270.2.188	http://dx.doi.org/10.1001/jama.270.2.188			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315724				2022-12-28	WOS:A1993LL36800010
J	CLINTON, JJ				CLINTON, JJ			DEPRESSION IN PRIMARY-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					172	172		10.1001/jama.270.2.172	http://dx.doi.org/10.1001/jama.270.2.172			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315720				2022-12-28	WOS:A1993LL36800006
J	FRANKLIN, JE				FRANKLIN, JE			ADDICTION MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FRANKLIN, JE (corresponding author), NORTHWESTERN UNIV, SCH MED, CHICAGO, IL 60611 USA.							ARNDT IO, 1992, ARCH GEN PSYCHIAT, V49, P888; BRESLAU N, 1993, ARCH GEN PSYCHIAT, V50, P31; BRESLAU N, 1992, AM J PSYCHIAT, V149, P464; CARMELLI D, 1992, NEW ENGL J MED, V327, P829, DOI 10.1056/NEJM199209173271201; DAUNNO T, 1992, JAMA-J AM MED ASSOC, V267, P253, DOI 10.1001/jama.267.2.253; GOODMAN AC, 1992, MED CARE, V30, P795, DOI 10.1097/00005650-199209000-00004; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P36; KENDLER KS, 1992, JAMA-J AM MED ASSOC, V268, P1877, DOI 10.1001/jama.268.14.1877; KOSTEN TR, 1992, ARCH GEN PSYCHIAT, V49, P894; LITT MD, 1992, ARCH GEN PSYCHIAT, V49, P609; MANN K, 1992, ALCOHOL CLIN EXP RES, V16, P1052, DOI 10.1111/j.1530-0277.1992.tb00698.x; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; NARANJO CA, 1992, CLIN PHARMACOL THER, V51, P729, DOI 10.1038/clpt.1992.85; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WEISNER C, 1992, JAMA-J AM MED ASSOC, V268, P1872, DOI 10.1001/jama.268.14.1872	20	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					184	185		10.1001/jama.270.2.184	http://dx.doi.org/10.1001/jama.270.2.184			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL368	8315722				2022-12-28	WOS:A1993LL36800008
J	HUGGINS, GR; WENTZ, AC				HUGGINS, GR; WENTZ, AC			OBSTETRICS AND GYNECOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER		NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611	Northwestern University	HUGGINS, GR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.							CULLINS VE, 1993, CONTRACEPTION, V47, P193, DOI 10.1016/0010-7824(93)90091-K; DINNERSTEIN AJ, 1986, OBSTET GYNECOL, V31, P654; EASTON DF, 1993, AM J HUM GENET, V52, P678; FRANK ML, 1992, FAM PLANN PERSPECT, V24, P208, DOI 10.2307/2135871; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARTGE P, 1989, AM J OBSTET GYNECOL, V161, P10, DOI 10.1016/0002-9378(89)90221-4; LAIS CW, 1988, FERTIL STERIL, V49, P551; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; RON E, 1987, AM J EPIDEMIOL, V125, P780, DOI 10.1093/oxfordjournals.aje.a114595; TESTART J, 1991, 7TH WORLD C INV FERT; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WILLEMSEN W, 1993, LANCET, V341, P986, DOI 10.1016/0140-6736(93)91071-S; 1992, FERTIL STERIL, V57, P15; 1991, LANCET, V338, P833; 1992, CONTRACEPTION REPORT, V3, P1; 1991, FERTIL STERIL, V55, P14	16	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					234	236		10.1001/jama.270.2.234	http://dx.doi.org/10.1001/jama.270.2.234			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315745				2022-12-28	WOS:A1993LL36800031
J	MCCARTY, DJ				MCCARTY, DJ			RHEUMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTHRITIS; TIME				MCCARTY, DJ (corresponding author), MED COLL WISCONSIN,MILWAUKEE,WI 53226, USA.							BUCKLANDWRIGHT JC, 1989, ANN RHEUM DIS, V48, P25, DOI 10.1136/ard.48.1.25; DAVENPORT A, 1992, CLIN NEPHROL, V37, P124; EWERT BH, 1992, KIDNEY INT, V41, P1037; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; Germain B F, 1991, Bull Rheum Dis, V41, P1; HAWLEY DJ, 1991, J RHEUMATOL, V18, P1008; HESS EV, 1989, J RHEUMATOL, V16, P1175; JENNETTE JC, 1992, B RHEUM DIS, V41, P3; KESSLER DA, 1992, NEW ENGL J MED, V3269, P713; MCMATY DJ, 1993, ARTHRITIS ALLIED CON; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; PINCUS T, 1986, J RHEUMATOL, V13, P841; SERGENT JS, 1992, SILICONE GEL BREAST; SMYTH CJ, 1972, POSTGRAD MED, V51, P31, DOI 10.1080/00325481.1972.11698261; WERB Z, 1974, J EXP MED, V140, P1482, DOI 10.1084/jem.140.6.1482; WILSKE KR, 1989, J RHEUMATOL, V16, P565	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					260	262		10.1001/jama.270.2.260	http://dx.doi.org/10.1001/jama.270.2.260			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315756				2022-12-28	WOS:A1993LL36800043
J	CHILVERS, CED				CHILVERS, CED			BREAST-FEEDING AND RISK OF BREAST-CANCER IN YOUNG-WOMEN	BRITISH MEDICAL JOURNAL			English	Article							LACTATION	Objective-To investigate whether breast feeding is related to subsequent risk of breast cancer. Design-Population based case-control study designed primarily to investigate the relation between oral contraceptives and risk of breast cancer; data obtained from questionnaires administered by interviewers, general practitioner notes, and family planning clinic records. Setting-11 health regions in Britain. Subjects-Women diagnosed with breast cancer before age 36 living in the defined study areas. One control per case, matched for age, was selected from the list of the case's general practitioner. 755 case-control pairs were interviewed. Main outcome measures-Duration of breast feeding each liveborn infant; timing of return of menses; hormone use; other risk factors for breast cancer. Results-Risk of breast cancer fell with increasing duration of breast feeding (relative risk=0.94 per three months' breast feeding; test for trend p=0.026) and with number of babies breast fed (relative risk=0.86; test for trend, p=0.017). Breast feeding each baby for longer than three months conferred no additional benefit. Breast feeding was more strongly negatively associated with risk of breast cancer than duration of postpartum amenorrhoea (chi2 test for trend, p=0.69). Hormonal suppression of lactation was unrelated to risk of breast cancer (relative risk=0.96 per episode of suppressed lactation; test for trend, p=0.72). Conclusions-These results suggest that breast feeding protects against the development of breast cancer in young women.			CHILVERS, CED (corresponding author), UNIV NOTTINGHAM,SCH MED,DEPT PUBL HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND.							ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; KVALE G, 1987, J EPIDEMIOL COMMUN H, V42, P30; LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3; LONDON SJ, 1990, AM J EPIDEMIOL, V132, P17, DOI 10.1093/oxfordjournals.aje.a115629; MCTIERNAN A, 1986, AM J EPIDEMIOL, V124, P353, DOI 10.1093/oxfordjournals.aje.a114405; SISKIND V, 1989, AM J EPIDEMIOL, V130, P229; 1990, LANCET, V335, P1507; 1989, LANCET, V1, P973	10	49	52	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					17	20						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343660	Green Published, Bronze			2022-12-28	WOS:A1993LL36900018
J	HO, RK; KIMMEL, CB				HO, RK; KIMMEL, CB			COMMITMENT OF CELL FATE IN THE EARLY ZEBRAFISH EMBRYO	SCIENCE			English	Article							LINEAGE; GASTRULATION; XENOPUS	When do single cells in the early zebrafish embryo become irreversibly committed to a specific fate? Work with lineage tracing and fate mapping has shown that the marginal cells of the blastoderm give rise to hypoblast-derived fates (mesoderm and endoderm). However, experiments described here show that these marginal blastoderm cells remain pluripotent and uncommitted throughout the late blastula and early gastrula stages. Embryonic cells become committed to a hypoblast-derived fate at mid-gastrulation. Time-lapse photographic analysis reveals that committed cells, when transplanted heterotopically and heterochronically, can migrate along atypical pathways to reposition themselves within a more correct environment.	UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403	University of Oregon					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22486] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		DAVIS RL, 1987, CELL, V56, P607; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; HATTA K, 1991, NATURE, V350, P39; HEASMAN J, 1985, PHILOS T ROY SOC B, V312, P145, DOI 10.1098/rstb.1985.0184; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; HOLTFRETER JOHANNES, 1939, WILHELM ROUX ARCH ENTWICKLUNGSMECH ORGAN, V139, P110, DOI 10.1007/BF00576387; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; KELLER R, 1992, DEV DYNAM, V193, P199, DOI 10.1002/aja.1001930302; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KIMMEL CB, 1987, DEV BIOL, V124, P269, DOI 10.1016/0012-1606(87)90478-7; Lawrence P., 1992, MAKING FLY GENETICS; LIN S, 1992, P NATL ACAD SCI USA, V89, P4519, DOI 10.1073/pnas.89.10.4519; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEINBERG MS, 1963, SCIENCE, V141, P401, DOI 10.1126/science.141.3579.401; STENT GS, 1985, PHILOS T R SOC B, V312, P3, DOI 10.1098/rstb.1985.0174; TECHNAU G M, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P445; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P489, DOI 10.1007/BF00375889; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Trinkaus J.P., 1984, CELLS ORGANS; WARGA RM, 1990, DEVELOPMENT, V108, P569; WEISBLAT DA, 1988, MESSAGE MIND; WILSON P, 1991, DEVELOPMENT, V112, P289	25	150	150	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					109	111		10.1126/science.8316841	http://dx.doi.org/10.1126/science.8316841			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316841				2022-12-28	WOS:A1993LK43400045
J	HARRIS, H; SCOTCHER, D; HARTLEY, N; WALLACE, A; CRAUFURD, D; HARRIS, R				HARRIS, H; SCOTCHER, D; HARTLEY, N; WALLACE, A; CRAUFURD, D; HARRIS, R			CYSTIC-FIBROSIS CARRIER TESTING IN EARLY-PREGNANCY BY GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the feasibility of genetic counselling in general practice by using cystic fibrosis carrier screening at the booking appointment as an integral part of routine antenatal care and as a paradigm for the wider participation of general practitioners in medical genetics. Design-Maternal testing (male partner tested only if woman screens positive) and couple testing for cystic fibrosis carrier status in the antenatal population attending one general practice and, later, in a further six (outreach) practices also. Setting-Two partner urban training practice (pilot practice) in south Manchester, and six north west practices (two inner city, three urban, one rural dispensing). Subjects-Total practice population of 50 000 (pilot practice plus six outreach practices) with an estimated 500-800 pregnancies per year. Main outcome measures-(a) Proportion of carriers of cystic fibrosis identified, counselled, and appropriately managed within the first trimester of pregnancy; (b) questionnaire and interview measures of patient satisfaction and stress. Results-Eleven carriers of cystic fibrosis were detected including one carrier couple. This carrier couple, after extensive counselling, elected to have prenatal diagnosis by chorionic villus biopsy. The fetus was homozygous normal. Conclusions-General practitioners can successfully integrate genetic counselling and cystic fibrosis carrier screening into the first antenatal booking appointment. When a carrier couple is identified clinical geneticists can help with the discussion of reproductive options, and prenatal diagnosis by chorionic villus biopsy can be completed within the first trimester. The results suggest that general practitioners will have an increasingly important role in medical genetics, subject to continuing evaluation of patient acceptability and stress.	BROOKLANDS MED PRACTICE,MANCHESTER M23 9JH,ENGLAND				Craufurd, David/G-5277-2013					FERRIE RM, 1992, AM J HUM GENET, V51, P251; HARRIS HJ, 1992, LANCET, V339, P1539, DOI 10.1016/0140-6736(92)91303-P; RIORDAN JR, 1989, SCIENCE, V245, P1066; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; WILLIAMSON R, IN PRESS NATURE GENE; 1992, CYSTIC FIBROSIS DNA	6	63	63	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1580	1583		10.1136/bmj.306.6892.1580	http://dx.doi.org/10.1136/bmj.306.6892.1580			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329921	Bronze, Green Published			2022-12-28	WOS:A1993LH12800021
J	HELGREN, ME; SQUINTO, SP; DAVIS, HL; PARRY, DJ; BOULTON, TG; HECK, CS; ZHU, Y; YANCOPOULOS, GD; LINDSAY, RM; DISTEFANO, PS				HELGREN, ME; SQUINTO, SP; DAVIS, HL; PARRY, DJ; BOULTON, TG; HECK, CS; ZHU, Y; YANCOPOULOS, GD; LINDSAY, RM; DISTEFANO, PS			TROPHIC EFFECT OF CILIARY NEUROTROPHIC FACTOR ON DENERVATED SKELETAL-MUSCLE	CELL			English	Article							DIGITORUM LONGUS MUSCLE; RAT SOLEUS MUSCLE; NERVE EXTRACT; NEURONOTROPHIC FACTOR; SCIATIC-NERVE; CHOLINERGIC DIFFERENTIATION; ACETYLCHOLINE RECEPTORS; EMBRYONIC MOTONEURONS; SIGNAL TRANSDUCER; PERIPHERAL-NERVE	The actions and receptor for ciliary neurotrophic factor (CNTF) are largely restricted to cells of the nervous system, although one of the CNTF receptor components, CNTFR alpha, is expressed by skeletal muscle. Here we show that the other CNTF receptor components, LIFR beta and gp130, are also expressed by skeletal muscle and that expression of all three CNTF receptor components is greatly increased in denervated muscle. In vivo, administration of CNTF activates these receptors on skeletal muscle by inducing receptor phosphorylation and immediate-early gene responses. Furthermore, CNTF reduces the denervation-induced atrophy of muscle and attenuates the reduced twitch and tetanic tensions that result from muscle denervation. Our findings reveal that, in addition to its known neurotrophic actions, CNTF exerts myotrophic effects by attenuating the morphological and functional changes associated with denervation of rat skeletal muscle.	UNIV OTTAWA,PHYSIOTHERAPY PROGRAM,OTTAWA,ON,CANADA; UNIV OTTAWA,DEPT PHYSIOL,OTTAWA,ON,CANADA; UNIV WESTERN ONTARIO,DEPT PHYSIOTHERAPY,LONDON,ON,CANADA	University of Ottawa; University of Ottawa; Western University (University of Western Ontario)	HELGREN, ME (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022					ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ALOE L, 1975, ARCH ITAL BIOL, V113, P236; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIMIJOIN S, 1988, NERVE MUSCLE CELL TR, P23; CALCUTT NA, 1992, BRAIN RES, V575, P320, DOI 10.1016/0006-8993(92)90097-S; CAMERON NE, 1992, EXP PHYSIOL, V77, P89, DOI 10.1113/expphysiol.1992.sp003585; CARD DJ, 1977, EXP NEUROL, V54, P251, DOI 10.1016/0014-4886(77)90268-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVEY B, 1978, EXP NEUROL, V59, P168; DAVIS HL, 1985, BRAIN RES, V343, P176, DOI 10.1016/0006-8993(85)91174-6; DAVIS HL, 1981, EXP NEUROL, V72, P582, DOI 10.1016/0014-4886(81)90007-8; DAVIS HL, 1980, EXP NEUROL, V69, P124, DOI 10.1016/0014-4886(80)90148-X; DAVIS HL, 1983, EXP NEUROL, V80, P383, DOI 10.1016/0014-4886(83)90290-X; DAVIS HL, 1985, EXP NEUROL, V89, P159, DOI 10.1016/0014-4886(85)90273-0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; FISCHBACH GD, 1969, J PHYSIOL-LONDON, V201, P305, DOI 10.1113/jphysiol.1969.sp008757; FITTS RH, 1986, J APPL PHYSIOL, V60, P1946, DOI 10.1152/jappl.1986.60.6.1946; FLORINI JR, 1987, MUSCLE NERVE, V10, P577, DOI 10.1002/mus.880100702; FORGERNG, 1993, J NEUROSCI, V13, P4720; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HELD IR, 1983, J NEUROSCI, V3, P2054; HENDERSON CE, 1983, NATURE, V302, P609, DOI 10.1038/302609a0; HILL MA, 1986, DEV BRAIN RES, V24, P305, DOI 10.1016/0165-3806(86)90201-4; HOUENOU LJ, 1991, J NEUROSCI, V11, P2829; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; JOHNSON DJ, 1982, EXP NEUROL, V76, P414, DOI 10.1016/0014-4886(82)90218-7; JOLESZ F, 1981, ANNU REV PHYSIOL, V43, P531, DOI 10.1146/annurev.ph.43.030181.002531; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MANTHORPE M, 1986, BRAIN RES, V367, P282, DOI 10.1016/0006-8993(86)91603-3; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MATHERS DA, 1978, J PHYSIOL-LONDON, V282, P105, DOI 10.1113/jphysiol.1978.sp012451; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NIEDERLE B, 1978, ANAT EMBRYOL, V153, P9, DOI 10.1007/BF00569846; PESTRONK A, 1976, NATURE, V260, P352, DOI 10.1038/260352a0; RASSENDREN FA, 1992, P NATL ACAD SCI USA, V89, P7194, DOI 10.1073/pnas.89.15.7194; RENDE M, 1992, GLIA, V5, P25, DOI 10.1002/glia.440050105; RILEY DA, 1973, EXP NEUROL, V40, P391, DOI 10.1016/0014-4886(73)90082-4; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHMALBRUCH H, 1985, SKELETAL MUSCLE; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SPECTOR SA, 1985, J NEUROSCI, V5, P2177; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TEMPLETON GH, 1984, J APPL PHYSIOL, V56, P278, DOI 10.1152/jappl.1984.56.2.278; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; UCHITEL O, 1978, BRAIN RES, V153, P539, DOI 10.1016/0006-8993(78)90338-4; VARON SS, 1978, ANNU REV NEUROSCI, V1, P327, DOI 10.1146/annurev.ne.01.030178.001551; WILLIAMS LR, 1984, INT J DEV NEUROSCI, V2, P177, DOI 10.1016/0736-5748(84)90009-1; WITZMANN FA, 1982, J APPL PHYSIOL, V53, P335, DOI 10.1152/jappl.1982.53.2.335; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x	69	209	221	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					493	504		10.1016/0092-8674(94)90113-9	http://dx.doi.org/10.1016/0092-8674(94)90113-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313470				2022-12-28	WOS:A1994MX20700010
J	WICKHAM, JEA				WICKHAM, JEA			MINIMALLY INVASIVE SURGERY - FUTURE-DEVELOPMENTS	BRITISH MEDICAL JOURNAL			English	Article							BOWEL ANASTOMOSIS; DESTRUCTION; RING	The rapid development of minimally invasive surgery means that there will be fundamental changes in interventional treatment. Technological advances will allow new minimally invasive procedures to be developed. Application of robotics will allow some procedures to be done automatically, and coupling of slave robotic instruments with virtual reality images will allow surgeons to perform operations by remote control. Miniature motors and instruments designed by microengineering could be introduced into body cavities to perform operations that are currently impossible. New materials will allow changes in instrument construction, such as use of memory metals to make heat activated scissors or forceps. With the reduced trauma associated with minimally invasive surgery, fewer operations will require long hospital stays. Traditional surgical wards will become largely redundant, and hospitals will need to cope with increased throughput of patients. Operating theatres will have to be equipped with complex high technology equipment, and hospital staff will need to be trained to manage it. Conventional nursing care will be carried out more in the community. Many traditional specialties will be merged, and surgical training will need fundamental revision to ensure that surgeons are competent to carry out the new procedures.			WICKHAM, JEA (corresponding author), GUYS HOSP,DEPT MINIMALLY INVAS THERAPY,LONDON SE1 9RT,ENGLAND.							ADAM A, 1991, AM J ROENTGENOL, V156, P321, DOI 10.2214/ajr.156.2.1702574; BIRCH BRP, 1990, BRIT J UROL, V66, P342, DOI 10.1111/j.1464-410X.1990.tb14952.x; BRADSHAW EG, 1989, DAY CARE SURGERY ANA; BROUGH W, 1992, IN PRESS MINIMALLY I, V5; CAHILL CJ, 1989, BRIT J SURG, V76, P344, DOI 10.1002/bjs.1800760409; COPTCOAT MJ, 1979, WORLD J UROL, V7, P138; CUSCHIERI A, 1992, MINIM INVASIV THER, V1, P115, DOI 10.3109/13645709209152933; DANDY DJ, 1991, MINIM INVASIV THER, V1, P51, DOI 10.3109/13645709109152796; DOUGHERTY T J, 1986, Seminars in Surgical Oncology, V2, P24, DOI 10.1002/ssu.2980020104; GOLDRATH MH, 1985, BASIC ADV LASER SURG, P357; GRONEMEYER D, 1992, MINIMALLY INVASIV S1, V1, P46; HARDY TG, 1985, DIS COLON RECTUM, V28, P484, DOI 10.1007/BF02554090; LINKE CA, 1973, ARCH SURG-CHICAGO, V107, P887; MEBUST WK, 1989, PROSTATE, P159; MILLER RA, 1990, COMMUNICATION    JUN; NEUHAUS H, 1991, SEMIN INTERVENT RAD, V8, P305, DOI 10.1055/s-2008-1074658; ORNSTEIN MH, IN PRESS SURGERY; PREMINGER G, 1992, MINIMALLY INVASIV S1, V1, P19; RAMSDALE DR, 1993, HOSPITAL UPDATE, V1, P404; RASSWEILER J, 1992, MINIM INVASIV THER, V1, P141, DOI 10.3109/13645709209152937; SATAVA RM, 1992, MINIM INVASIV THER, V1, P357; Semm K, 1987, OPERATIVE MANUAL END; SERVADIO C, 1990, EUR UROL, V18, P169; SHIMOJI K, 1991, ANESTHESIOLOGY, V75, P341, DOI 10.1097/00000542-199108000-00024; STEGER AC, 1989, BRIT MED J, V299, P362, DOI 10.1136/bmj.299.6695.362; STUDT T, 1990, R D MAGAZINE     DEC, P36; SUTTON C, 1992, CURRENT OBSTETRICS G, V2, P225; TAYLOR RH, 1990, J ROBOTIC SOC JAPAN, V111, P116; TIMONEY A, 1991, J ENDOUROL, V5, P2; VALENCIEN G, 1990, EUR UROL S1, V18, P285; VORWERK D, 1991, SEMIN INTERVENT RAD, V8, P264, DOI 10.1055/s-2008-1074654; Wickham J. E. A., 1991, MINIM INVASIV THER, V1, P5; WICKHAM JEA, 1986, BRIT MED BULL, V42, P221, DOI 10.1093/oxfordjournals.bmb.a072127; WICKHAM JEA, 1987, BRIT MED J, V295, P1581, DOI 10.1136/bmj.295.6613.1581	34	48	50	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					193	196		10.1136/bmj.308.6922.193	http://dx.doi.org/10.1136/bmj.308.6922.193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312776	Green Published			2022-12-28	WOS:A1994MR97400028
J	DURCH, JS; LOHR, KN				DURCH, JS; LOHR, KN			EMERGENCY MEDICAL-SERVICES FOR CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											DURCH, JS (corresponding author), INST MED,COMM PEDIAT EMERGENCY MED SERV,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.							1982, ANN EMERG MED, V11, P170; 1991, J EMERG NURS, V17, P152; 1991, PEDIATRICS, V88, P223; 1990, ANN EMERG MED, V19, P532; 1984, J TRAUMA, V24, P818; 1991, EMERG MED CLIN N AM, V9, P459; 1986, PEDIATRICS, V78, P808	7	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					929	929		10.1001/jama.270.8.929	http://dx.doi.org/10.1001/jama.270.8.929			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8345634				2022-12-28	WOS:A1993LT56700006
J	GRAHAM, DY; WHITE, RH; MORELAND, LW; SCHUBERT, TT; KATZ, R; JASZEWSKI, R; TINDALL, E; TRIADAFILOPOULOS, G; STROMATT, SC; TEOH, LS				GRAHAM, DY; WHITE, RH; MORELAND, LW; SCHUBERT, TT; KATZ, R; JASZEWSKI, R; TINDALL, E; TRIADAFILOPOULOS, G; STROMATT, SC; TEOH, LS			DUODENAL AND GASTRIC-ULCER PREVENTION WITH MISOPROSTOL IN ARTHRITIS PATIENTS TAKING NSAIDS	ANNALS OF INTERNAL MEDICINE			English	Article						MISOPROSTOL; PEPTIC ULCER; GASTRODUODENAL ULCER; ANTIINFLAMMATORY AGENTS, NONSTEROIDAL; ARTHRITIS	ANTI-INFLAMMATORY DRUGS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CHRONIC ASPIRIN THERAPY; PEPTIC-ULCER; CONTROLLED TRIAL; ELDERLY PERSONS; DISEASE; PERFORATION; ANALGESICS; RANITIDINE	Objectives: To determine the efficacy of misoprostol for the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced duodenal and gastric ulcers in arthritis patients receiving NSAID therapy. Design: A randomized, double-blind, multicenter, placebo-controlled trial. Setting: Six hundred thirty-eight private, Veterans Affairs, health maintenance, and academic practices. Patients: Six hundred thirty-eight patients with chronic inflammatory or noninflammatory arthritis who were taking an NSAID but who did not have a gastric or duodenal ulcer on screening endoscopy received treatment with ibuprofen, piroxicam, naproxen, sulindac, tolmetin, indomethacin, or diclofenac daily for 3 months. Four hundred fifty-five (71%) patients completed the trial. Interventions: Patients meeting the entry criteria were randomized to receive either misoprostol, 200 mug, or placebo, four times a day for 12 weeks. Main Outcome Measures: The endoscopy was repeated at 4, 8, and 12 weeks. The development of a duodenal or gastric ulcer (defined as a circumscribed mucosal defect less-than-or-equal-to 0.5 cm in diameter and with perceptible depth) was regarded as prophylactic failure. Results: By 12 weeks, a duodenal ulcer developed in 2 of 320 (0.6%; 95% CI, 0.2% to 3.9%) patients randomized to receive misoprostol, compared with 15 of 323 (4.6%; CI, 2.8% to 8%) patients receiving placebo (P = 0.002). A gastric ulcer developed in 6 of 320 (1.9%; (CI, 0.8% to 4.4%) patients, compared with in 25 of 323 (7.7%; CI, 5.1% to 11.4%), respectively. Conclusion: Misoprostol significantly lowers the frequency of both duodenal and gastric ulcer development in patients who require long-term therapy with NSAIDS.	UNIV CALIF DAVIS, SACRAMENTO MED CTR, SACRAMENTO, CA 95817 USA; UNIV ALABAMA, BIRMINGHAM, AL 35294 USA; HENRY FORD HOSP, DETROIT, MI 48202 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL 60612 USA; WAYNE STATE UNIV, VET AFFAIRS MED CTR, SCH MED, ALLEN PK, MI USA; VET AFFAIRS MED CTR, MARTINEZ, CA USA	University of California System; University of California Davis; University of Alabama System; University of Alabama Birmingham; Henry Ford Health System; Henry Ford Hospital; Rush University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Wayne State University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	GRAHAM, DY (corresponding author), BAYLOR COLL MED, VET AFFAIRS MED CTR, DIGEST DIS SECT 111D, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.		Graham, David/AAL-2165-2021	Triadafilopoulos, George/0000-0002-4233-3773; Moreland, Larry/0000-0003-4483-0359				AGRAWAL NM, 1991, ANN INTERN MED, V115, P195, DOI 10.7326/0003-4819-115-3-195; ALEXANDER AM, 1985, J CLIN HOSP PHARM, V10, P89; ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; CARUSO I, 1980, BRIT MED J, V280, P75, DOI 10.1136/bmj.280.6207.75; COLES LS, 1983, AM J MED, V74, P820, DOI 10.1016/0002-9343(83)91073-2; COLLIER DS, 1985, GUT, V26, P359, DOI 10.1136/gut.26.4.359; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; FARAH D, 1988, ANN RHEUM DIS, V47, P478, DOI 10.1136/ard.47.6.478; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; FRIES JF, 1991, J MUSCULOSKEL MED, V8, P21; GRAHAM DY, 1988, LANCET, V2, P1277; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P675, DOI 10.1016/S0016-5085(89)80064-2; GRAHAM DY, 1990, GASTROENTEROL CLIN N, V19, P171; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; JORDE R, 1987, SCAND J GASTROENTERO, V22, P129, DOI 10.3109/00365528708991869; KNODEL LC, 1989, CONSULTANT PHARM, V4, P37; KURATA JH, 1990, J CLIN GASTROENTEROL, V12, P260, DOI 10.1097/00004836-199006000-00005; Langman M J, 1986, Med Toxicol, V1 Suppl 1, P34; Langman MJS., 1986, ADVERS DRUG REACT BU, V120, P448; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LLEWELYN JG, 1983, ANN RHEUM DIS, V42, P228; LOCKARD OO, 1980, GASTROINTEST ENDOSC, V26, P5, DOI 10.1016/S0016-5107(80)73248-0; NOBUNAGA M, 1990, JUL NSAID ULC S GUAM; ODDSSON E, 1990, SCAND J GASTROE S176, V25, P13; Peltier A P, 1989, Scand J Rheumatol Suppl, V78, P12; PIPER JM, 1991, ANN INTERN MED, V114, P735, DOI 10.7326/0003-4819-114-9-735; ROBINSON MG, 1989, DIGEST DIS SCI, V34, P424, DOI 10.1007/BF01536266; ROTH SH, 1988, J RHEUMATOL, V15, P912; SILVOSO GR, 1979, ANN INTERN MED, V91, P517, DOI 10.7326/0003-4819-91-4-517; SOLL AH, 1989, GASTROENTEROLOGY, V96, P561, DOI 10.1016/S0016-5085(89)80051-4; SOLL AH, 1990, NEW ENGL J MED, V322, P909; SOMERVILLE K, 1986, LANCET, V1, P462; WALT R, 1986, LANCET, V1, P489	34	253	262	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					257	262		10.7326/0003-4819-119-4-199308150-00001	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328732				2022-12-28	WOS:A1993LV52500001
J	JERNIGAN, JA; FARR, BM				JERNIGAN, JA; FARR, BM			SHORT-COURSE THERAPY OF CATHETER-RELATED STAPHYLOCOCCUS-AUREUS BACTEREMIA - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							TEICHOIC-ACID ANTIBODY; SEMIQUANTITATIVE CULTURE METHOD; TOTAL PARENTERAL NUTRITION; ENDOCARDITIS; COMPLICATIONS; INFECTION; MANAGEMENT; DIAGNOSIS; PATTERNS; ADDICTS	Objective: To determine, through structured methodologic review of published articles, the effectiveness of short-course (less-than-or-equal-to 2 weeks) antibiotic therapy for catheter-related Staphylococcus aureus bacteremia. Data Sources: English-language publications on catheter-related S. aureus bacteremia identified using MEDLINE (1966 to the present) and bibliographic review of relevant articles and textbooks. Study Selection: Any study reporting outcome data for patients with catheter-related S. aureus bacteremia who were treated with short-course therapy. Data Extraction: Epidemiologic criteria were applied to assess the quality of protection provided by each study against four important types of biases. In addition, the statistical precision of each study was assessed. Data Synthesis: Eleven studies were identified. Reported late complication rates varied from 0% to 29%; the pooled estimate of the late complication rate was 6.1% (95% CI, 2.0% to 10.2%). Ten of the 11 studies were uncontrolled. Only three provided adequate protection against treatment allocation bias. None of the studies adequately defined the illness under study, and only four provided adequate follow-up. The relapse rates in all 11 studies had low statistical precision. The complication and mortality rates for catheter-related S. aureus bacteremia when published data were pooled, regardless of duration of therapy, were 24% and 15%, respectively. Conclusions: The available data regarding the safety of short-course therapy for catheter-related S. aureus bacteremia are potentially flawed by both bias and statistical imprecision. The optimal duration of treatment remains unknown. Short-course therapy should be viewed with caution in treating this serious infection until randomized trials determine the comparative rates of late complication.	UNIV VIRGINIA, HLTH SCI CTR, BOX 473, CHARLOTTESVILLE, VA 22908 USA	University of Virginia				Jernigan, John/0000-0001-8163-925X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007046] Funding Source: NIH RePORTER; NIAID NIH HHS [T32AI07046] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS B, 1979, ANN INTERN MED, V90, P789, DOI 10.7326/0003-4819-90-5-789; ALMIRALL J, 1989, AM J NEPHROL, V9, P454, DOI 10.1159/000168012; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; BAYER AS, 1987, ARCH INTERN MED, V147, P457, DOI 10.1001/archinte.147.3.457; BAYER AS, 1980, WESTERN J MED, V132, P294; BENTLEY DW, 1968, J AMER MED ASSOC, V206, P1749, DOI 10.1001/jama.206.8.1749; BERNHARDT LL, 1979, AM J MED, V66, P355, DOI 10.1016/0002-9343(79)90564-3; BRYAN CS, 1984, SOUTHERN MED J, V77, P693, DOI 10.1097/00007611-198406000-00007; CHEESBROUGH JS, 1986, J INFECT DIS, V154, P579, DOI 10.1093/infdis/154.4.579; CLERI DJ, 1980, J INFECT DIS, V141, P781, DOI 10.1093/infdis/141.6.781; CLUFF LE, 1968, ANN INTERN MED, V69, P859, DOI 10.7326/0003-4819-69-5-859; COLLIGNON PJ, 1984, MED J AUSTRALIA, V141, P345, DOI 10.5694/j.1326-5377.1984.tb132802.x; COLLIGNON PJ, 1986, J CLIN MICROBIOL, V24, P532, DOI 10.1128/JCM.24.4.532-535.1986; COOPER G, 1982, AM J MED, V73, P658, DOI 10.1016/0002-9343(82)90407-7; DIEM K, 1962, GEIGY SCI TABLES, P85; DUGDALE DC, 1990, AM J MED, V89, P137, DOI 10.1016/0002-9343(90)90290-T; EHNI WF, 1989, ARCH INTERN MED, V149, P533, DOI 10.1001/archinte.149.3.533; ELIASEN K, 1986, J HYG-CAMBRIDGE, V97, P471, DOI 10.1017/S0022172400063646; FINKELSTEIN R, 1984, J MED, V15, P193; GRAHAM DR, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90351-W; HAMBURGER MORTON, 1964, MOD TREAT, V1, P1003; HEDSTROM SA, 1983, SCAND J INFECT DIS, P38; HENDRICK AM, 1985, SOUTHERN MED J, V78, P639, DOI 10.1097/00007611-198506000-00005; IANNINI PB, 1976, ANN INTERN MED, V84, P558, DOI 10.7326/0003-4819-84-5-558; KAPLAN JE, 1981, AM J MED, V70, P769, DOI 10.1016/0002-9343(81)90531-3; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LERNER PI, 1966, NEW ENGL J MED, V274, P388, DOI 10.1056/NEJM196602172740706; LIBMAN H, 1984, ARCH INTERN MED, V144, P541, DOI 10.1001/archinte.144.3.541; LINARES J, 1985, J CLIN MICROBIOL, V21, P357; MAKI DG, 1981, AM J MED, V70, P719, DOI 10.1016/0002-9343(81)90603-3; MAKI DG, 1977, J SURG RES, V22, P513, DOI 10.1016/0022-4804(77)90034-8; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MIRIMANOFF RO, 1982, ARCH INTERN MED, V142, P1311, DOI 10.1001/archinte.142.7.1311; MYLOTTE JM, 1987, REV INFECT DIS, V9, P891; MYLOTTE JM, 1983, SOUTHERN MED J, V76, P1131, DOI 10.1097/00007611-198309000-00017; NOLAN CM, 1976, AM J MED, V60, P495, DOI 10.1016/0002-9343(76)90715-4; PITTET D, 1991, 31ST INT C ANT AG CH, P174; RAAD II, 1992, CLIN INFECT DIS, V14, P75, DOI 10.1093/clinids/14.1.75; RABINOVICH S, 1968, MED CLIN N AM, V52, P1091, DOI 10.1016/S0025-7125(16)32852-8; RAHAL JJ, 1989, ARCH INTERN MED, V149, P503, DOI 10.1001/archinte.149.3.503; RAHAL JJ, 1986, AM J MED, V81, P43, DOI 10.1016/0002-9343(86)90180-4; RAJASHEKARAIAH KR, 1980, ANN INTERN MED, V93, P796, DOI 10.7326/0003-4819-93-6-796; RAWSON D, 1979, CLIN RES, V27, pA753; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P170; RYAN JA, 1974, NEW ENGL J MED, V290, P757, DOI 10.1056/NEJM197404042901401; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SHAH M, 1979, AM J MED SCI, V278, P115, DOI 10.1097/00000441-197909000-00002; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; SMITS H, 1967, NEW ENGL J MED, V276, P1229, DOI 10.1056/NEJM196706012762204; SNYDMAN DR, 1982, AM J MED, V73, P695, DOI 10.1016/0002-9343(82)90412-0; TUAZON CU, 1978, J INFECT DIS, V137, P57, DOI 10.1093/infdis/137.1.57; WATANAKUNAKORN C, 1977, AM J MED, V63, P253, DOI 10.1016/0002-9343(77)90239-X; WATANAKUNAKORN C, 1973, GERIATRICS, V28, P168; WATANAKUNAKORN C, 1973, AM J MED, V54, P473, DOI 10.1016/0002-9343(73)90043-0; WEISS NS, 1986, MONOGRAPHS EPIDEMIOL, V11, P72; WHEAT LJ, 1978, ANN INTERN MED, V89, P467, DOI 10.7326/0003-4819-89-4-467; WILSON R, 1957, AM J MED, V22, P437, DOI 10.1016/0002-9343(57)90099-2	57	116	119	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					304	311		10.7326/0003-4819-119-4-199308150-00010	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328740				2022-12-28	WOS:A1993LV52500010
J	MASON, JW				MASON, JW			A COMPARISON OF ELECTROPHYSIOLOGIC TESTING WITH HOLTER MONITORING TO PREDICT ANTIARRHYTHMIC-DRUG EFFICACY FOR VENTRICULAR TACHYARRHYTHMIAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TACHYCARDIA; THERAPY; DETERMINANTS; SURVIVAL	Background. Invasive electrophysiologic study and noninvasive Holter monitoring (in conjunction with exercise testing) have both been used to evaluate the efficacy of antiarrhythmic drugs in patients with sustained ventricular tachycardia and in survivors of cardiac arrest. We directly compared these two approaches to the prediction of drug efficacy. Methods. A total of 486 patients who had documented ventricular tachyarrhythmias that were inducible during electrophysiologic study and 10 or more premature ventricular complexes per hour during Holter monitoring were randomly assigned to undergo serial testing of antiarrhythmic-drug efficacy by electrophysiologic study or Holter monitoring. The patients received up to six drugs in random order until one was predicted to be effective either in suppressing inducible arrhythmia (in the electrophysiologic-study group) or in suppressing premature ventricular complexes (in the Holter-monitoring group). The patients were then followed for recurrences of arrhythmia or death. Results. In the electrophysiologic-study group, 108 of 242 patients (45 percent) received a prediction of efficacy, as compared with 188 of 244 patients (77 percent) in the Holter-monitoring group (P<0.001). Over a six-year follow-up period, there were 150 recurrences of arrhythmia and 46 deaths among the 296 patients receiving drugs predicted to be effective. Thirty-four of the deaths were from arrhythmic causes, and eight were f rom cardiac causes. There was no significant difference between the two study groups in the actuarial probabilities of these events. The risk of a recurrence of arrhythmia was significantly lower in patients who received sotalol than in those who received other antiarrhythmic drugs, and the risk was lower in those who had not previously failed to respond to antiarrhythmic drugs than in those who had. Conclusions. Although Holter monitoring led to predictions of antiarrhythmic-drug efficacy more often than did electrophysiologic study in patients with sustained ventricular tachyarrhythmias, there was no significant difference in the success of drug therapy as selected by the two methods.			MASON, JW (corresponding author), UNIV UTAH,SCH MED,DIV CARDIOL,50 N MED DR,SALT LAKE CITY,UT 84132, USA.				NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NHLBI NIH HHS [R0-1-HL34071] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034071] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, CIRCULATION, V79, P1354; COX DR, 1972, J R STAT SOC B, V34, P187; EZRI MD, 1984, AM HEART J, V108, P1229, DOI 10.1016/0002-8703(84)90746-4; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GRABOYS TB, 1982, AM J CARDIOL, V50, P437, DOI 10.1016/0002-9149(82)90307-1; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MASON JW, 1984, CLIN PHARM ANTIARRHY, V10, P229; MITCHELL LB, 1987, NEW ENGL J MED, V317, P1681, DOI 10.1056/NEJM198712313172701; PLATIA EV, 1984, J AM COLL CARDIOL, V4, P493, DOI 10.1016/S0735-1097(84)80092-3; RAE AP, 1985, AM J CARDIOL, V55, P1494, DOI 10.1016/0002-9149(85)90960-9; SCHOENFELD MH, 1985, J AM COLL CARDIOL, V6, P298, DOI 10.1016/S0735-1097(85)80164-9; SKALE BT, 1986, AM J CARDIOL, V57, P113, DOI 10.1016/0002-9149(86)90962-8; STEINBECK G, 1992, NEW ENGL J MED, V327, P987, DOI 10.1056/NEJM199210013271404; SWERDLOW CD, 1983, NEW ENGL J MED, V308, P1436, DOI 10.1056/NEJM198306163082402; SWERDLOW CD, 1983, J AM COLL CARDIOL, V1, P409, DOI 10.1016/S0735-1097(83)80067-9; WALLER TJ, 1987, J AM COLL CARDIOL, V10, P83, DOI 10.1016/S0735-1097(87)80164-X; 1993, CIRCULATION, V87, P323; 1988, INGRES VERSION 5002A; 1990, SAS STAT RELEASE 604	21	284	285	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					445	451		10.1056/NEJM199308123290701	http://dx.doi.org/10.1056/NEJM199308123290701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	8332149				2022-12-28	WOS:A1993LR44300001
J	OHALLORAN, TV				OHALLORAN, TV			TRANSITION-METALS IN CONTROL OF GENE-EXPRESSION	SCIENCE			English	Article							IRON-RESPONSIVE ELEMENT; FERRITIN MESSENGER-RNA; ACE1 TRANSCRIPTION FACTOR; NUCLEIC-ACID-BINDING; DNA-BINDING; ESCHERICHIA-COLI; ZINC-FINGER; COPPER-THIOLATE; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL REPRESSION	Metalloproteins play structural and catalytic roles in gene expression. The metalloregulatory proteins are a subclass that exerts metal-responsive control of genes involved in respiration, metabolism, and metal-specific homeostasis or stress-response systems, such as iron uptake and storage, copper efflux, and mercury detoxification. Two allosteric mechanisms for control of gene expression were first discovered in metalloregulatory systems: an iron-responsive translational control mechanism for ferritin production and a mercury-responsive DNA-distortion mechanism for transcriptional control of detoxification genes. These otherwise unrelated mechanisms give rise to a rapid physiological response when metal ion concentrations exceed a dangerous threshold. Molecular recognition in these allosteric metal ion receptors is achieved through atypical coordination geometries, cluster formation, or complexes with prosthetic groups, such as sulfide and heme. Thus, many of the inorganic assemblies that otherwise buttress the structure of biopolymers or catalyze substrate transformation in active sites of enzymes have also been adapted to serve sensor functions in the metalloregulatory proteins. Mechanistic studies of these metal-sensor protein interactions are providing new insights into fundamental aspects of inorganic chemistry, molecular biology, and cellular physiology.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	Northwestern University	OHALLORAN, TV (corresponding author), NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA.		O'Halloran, Thomas/ABE-6125-2021; Johnson, Michael D. L./B-4352-2012	O'Halloran, Thomas/0000-0001-8732-5059; 	NIGMS NIH HHS [R01 GM038784] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN ET, 1977, J MOL BIOL, V112, P113, DOI 10.1016/S0022-2836(77)80159-9; ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; AVERILL BA, 1973, J AM CHEM SOC, V95, P3523, DOI 10.1021/ja00792a013; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BERG JM, 1989, PROG INORG CHEM, V37, P143; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BHASKER CR, 1993, J BIOL CHEM, V268, P12699; Brown N. J., UNPUB; BROWN PH, 1989, J BIOL CHEM, V264, P13383; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; Bryson J. W., 1993, BIOINORGANIC CHEM CO, P101; BUCHMAN C, 1990, MOL CELL BIOL, V10, P4778, DOI 10.1128/MCB.10.9.4778; BYRD J, 1988, J BIOL CHEM, V263, P6688; CASASFINET JR, 1992, BIOCHEMISTRY-US, V31, P6617, DOI 10.1021/bi00143a036; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CONDEE CW, 1992, J BACTERIOL, V174, P8094, DOI 10.1128/JB.174.24.8094-8101.1992; COOKSEY DA, 1993, MOL MICROBIOL, V7, P1, DOI 10.1111/j.1365-2958.1993.tb01091.x; COX LA, 1993, BIOCHEMISTRY-US, V32, P4738, DOI 10.1021/bi00069a007; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COY M, 1991, BIOCHEMISTRY-US, V30, P8201, DOI 10.1021/bi00247a016; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DOBOSON NJ, 1973, NATURE, V249, P425; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; EICHHORN GL, 1981, ADV INORG BIOCHEM, V3, P1; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; ERDMAN SE, 1993, EMBO J, V12, P527, DOI 10.1002/j.1460-2075.1993.tb05684.x; FISCHER HM, 1988, NUCLEIC ACIDS RES, V16, P2207, DOI 10.1093/nar/16.5.2207; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FOSTER JW, 1992, J BACTERIOL, V174, P4317, DOI 10.1128/JB.174.13.4317-4323.1992; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; FURST P, 1989, P NATL ACAD SCI USA, V86, P5267, DOI 10.1073/pnas.86.14.5267; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GARDNER PR, 1987, J BIOL CHEM, V262, P17591; GOLDBERG MB, 1990, J BACTERIOL, V172, P6863, DOI 10.1128/jb.172.12.6863-6870.1990; GROSSMAN SR, 1989, ONCOGENE, V4, P1089; GRUFF ES, 1990, J AM CHEM SOC, V112, P1245, DOI 10.1021/ja00159a054; GUARENTE L, COMMUNICATION; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HAMED MY, 1993, J INORG BIOCHEM, V50, P193, DOI 10.1016/0162-0134(93)80025-5; HANTKE K, 1984, MOL GEN GENET, V197, P337, DOI 10.1007/BF00330982; HARRISON PM, 1989, IRON CARRIERS IRON P, V5, P123; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; Helmann J D, 1990, Adv Inorg Biochem, V8, P33; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HOLM RH, 1992, ADV INORG CHEM, V38, P1, DOI 10.1016/S0898-8838(08)60061-6; HOOBER JK, 1988, CARLSBERG RES COMMUN, V53, P27; HUBBARD SR, 1991, SCIENCE, V254, P1776; IBERS JA, 1980, SCIENCE, V209, P223, DOI 10.1126/science.7384796; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAPTEIN R, 1991, CURR OPIN STRUC BIOL, V2, P109; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; KRIZEK BA, 1993, INORG CHEM, V32, P937, DOI 10.1021/ic00058a030; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUISI B, 1992, NATURE, V356, P379, DOI 10.1038/356379a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUND PA, 1989, J MOL BIOL, V205, P343, DOI 10.1016/0022-2836(89)90345-8; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Martell A. E., 1982, CRITICAL STABILITY C, V5; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MEYES AM, 1987, J BIOL CHEM, V262, P16822; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLS SD, 1993, J BACTERIOL, V175, P1656, DOI 10.1128/JB.175.6.1656-1664.1993; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; NEILANDS JB, 1990, METAL ION INDUCED RE, V8, P63; NICKOL J, 1992, J MOL BIOL, V228, P1115, DOI 10.1016/0022-2836(92)90319-F; NIES DH, 1992, PLASMID, V27, P17, DOI 10.1016/0147-619X(92)90003-S; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OHALLORAN TV, 1989, MET IONS BIOL SYST, V25, P105; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; PAN T, 1991, BIOCHEMISTRY-US, V30, P4212, DOI 10.1021/bi00231a016; PARKHILL J, 1993, EMBO J, V12, P413, DOI 10.1002/j.1460-2075.1993.tb05673.x; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PRIVALLE CT, 1993, J BIOL CHEM, V268, P5178; Ralston D M, 1990, Adv Inorg Biochem, V8, P1; RALSTON DM, 1990, P NATL ACAD SCI USA, V87, P3846, DOI 10.1073/pnas.87.10.3846; RALSTON DM, UNPUB; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; RICHARDSON DR, 1992, J BIOL CHEM, V267, P21384; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SAITO T, 1991, EUR J BIOCHEM, V197, P29, DOI 10.1111/j.1432-1033.1991.tb15878.x; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; SCHMITT MP, 1991, INFECT IMMUN, V59, P1899, DOI 10.1128/IAI.59.6.1899-1904.1991; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SOOUTH TL, 1993, PROTEIN SCI, V2, P563; SOUTH TL, 1990, METAL ION INDUCED RE, V8, P199; SPIRO S, 1989, MOL MICROBIOL, V3, P601, DOI 10.1111/j.1365-2958.1989.tb00207.x; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; SZCZYPKA MS, 1989, MOL CELL BIOL, V9, P421, DOI 10.1128/MCB.9.2.421; TAFT KL, 1993, SCIENCE, V259, P1302, DOI 10.1126/science.8446898; TAO X, 1992, P NATL ACAD SCI USA, V89, P5897, DOI 10.1073/pnas.89.13.5897; THEIL EC, 1990, J BIOL CHEM, V265, P4771; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; TRAGESER M, 1989, MOL MICROBIOL, V3, P593, DOI 10.1111/j.1365-2958.1989.tb00206.x; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VANHOVE B, 1990, J BACTERIOL, V172, P6749, DOI 10.1128/jb.172.12.6749-6758.1990; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WATENPAUGH KD, 1979, J MOL BIOL, V131, P509, DOI 10.1016/0022-2836(79)90005-6; WATTON SP, 1990, J AM CHEM SOC, V112, P2824, DOI 10.1021/ja00163a067; WATTON SP, 1992, J CHEM SOC DA, P1393; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; WILLIAMS RJP, 1990, BIOCHEM SOC T, V18, P689, DOI 10.1042/bst0180689; WRIGHT JG, 1990, PROG INORG CHEM, V38, P323; XU T, 1992, J BIOL CHEM, V267, P21761; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; ZHANG L, 1993, P NATL ACAD SCI USA, V90, P2851, DOI 10.1073/pnas.90.7.2851; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112	137	578	588	3	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1993	261	5122					715	725		10.1126/science.8342038	http://dx.doi.org/10.1126/science.8342038			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8342038				2022-12-28	WOS:A1993LQ73000028
J	TONEY, MD; HOHENESTER, E; COWAN, SW; JANSONIUS, JN				TONEY, MD; HOHENESTER, E; COWAN, SW; JANSONIUS, JN			DIALKYLGLYCINE DECARBOXYLASE STRUCTURE - BIFUNCTIONAL ACTIVE-SITE AND ALKALI-METAL SITES	SCIENCE			English	Article							MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; MACROMOLECULAR CRYSTALLOGRAPHY; REFINEMENT; ENZYME; RESOLUTION; BINDING; FORMS; ACID	The structure of the bifunctional, pyridoxal phosphate-dependent enzyme dialkylglycine decarboxylase was determined to 2.1-angstrom resolution. Model building suggests that a single cleavage site catalyzes both decarboxylation and transamination by maximizing stereoelectronic advantages and providing electrostatic and general base catalysis. The enzyme contains two binding sites for alkali metal ions. One is located near the active site and accounts for the dependence of activity on potassium ions. The other is located at the carboxyl terminus of an alpha helix. These sites help show how proteins can specifically bind alkali metals and how these ions can exert functional effects.	UNIV BASEL,BIOCTR,DEPT STRUCT BIOL,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND	University of Basel					NIGMS NIH HHS [GM13854] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM013854, R01GM013854] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLESTAD HG, 1968, PYRIDOXAL CATALYSIS, P479; ANTSON AA, 1993, BIOCHEMISTRY-US, V32, P4195, DOI 10.1021/bi00067a006; ASHLEY JA, 1993, J AM CHEM SOC, V115, P2515, DOI 10.1021/ja00059a061; BAILEY GB, 1967, BIOCHEMISTRY-US, V6, P1526, DOI 10.1021/bi00857a039; BRAUNSHTEIN AE, 1953, BIOKHIMIYA, V18, P393; BRUNGER AT, 1990, XPLOR MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CRAM DJ, 1986, ANGEW CHEM INT EDIT, V25, P1039, DOI 10.1002/anie.198610393; Dobler M., 1981, IONOPHORES THEIR STR; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; EISENMAN G, 1987, ANNU REV BIOPHYS BIO, V16, P205; FORD GC, 1980, P NATL ACAD SCI-BIOL, V77, P2559, DOI 10.1073/pnas.77.5.2559; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GROS P, 1989, J MOL BIOL, V210, P347, DOI 10.1016/0022-2836(89)90336-7; GURSKY O, 1992, BIOPHYS J, V61, P604, DOI 10.1016/S0006-3495(92)81865-9; IZATT RM, 1985, CHEM REV, V85, P271, DOI 10.1021/cr00068a003; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JONES TA, 1990, MANUAL O; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KELLER JW, 1990, J BIOL CHEM, V265, P5531; LESLIE AGW, 1986, CCP4 NEWSLETTER, V18, P33; MARLIER JF, 1986, J AM CHEM SOC, V108, P4896, DOI 10.1021/ja00276a031; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MCPHALEN CA, 1990, P NATL ACAD SCI USA, V87, P5648; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; METZLER DE, 1954, J AM CHEM SOC, V76, P648, DOI 10.1021/ja01632a004; MUIRHEAD H, 1987, BIOL MACROMOL, V3, P143; OLEARY MH, 1988, ACCOUNTS CHEM RES, V21, P450, DOI 10.1021/ar00156a003; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TONEY MD, 1991, J MOL BIOL, V222, P873, DOI 10.1016/0022-2836(91)90580-Y; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; TONEY MD, 1993, BIOCHEMISTRY-US, V32, P1471, DOI 10.1021/bi00057a010; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Vogtle F., 1985, HOST GUEST COMPLEX C; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WATANABE N, 1989, J BIOCHEM, V105, P1, DOI 10.1093/oxfordjournals.jbchem.a122600; 1979, CCP4 SERC UK COLL CO	39	195	196	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					756	759		10.1126/science.8342040	http://dx.doi.org/10.1126/science.8342040			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8342040				2022-12-28	WOS:A1993LQ73000038
J	ARTINIAN, MA; LEUNG, AT; TISHLER, PV				ARTINIAN, MA; LEUNG, AT; TISHLER, PV			IMAGES IN CLINICAL MEDICINE - VERTEBRAL-OSTEOMYELITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ARTINIAN, MA (corresponding author), BROCKTON W ROXBURY VET AFFAIRS MED CTR,BROCKTON,MA 02401, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					399	399						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8326974				2022-12-28	WOS:A1993LQ33900005
J	THOMAS, JM				THOMAS, JM			ARCHITECTURE OF THE INVISIBLE	NATURE			English	Note							ELECTRON-MICROSCOPY; MODEL		UNIV CAMBRIDGE, CAMBRIDGE CB2 1QY, ENGLAND	University of Cambridge	THOMAS, JM (corresponding author), ROYAL INST GREAT BRITIAN, 21 ALBEMARLE ST, LONDON W1X 4BS, ENGLAND.							Bragg W.L., 1934, PROC R SOC LONDON SE, V145, P699, DOI DOI 10.1098/RSPA.1934.0132; Bragg WH., 1915, XRAYS CRYSTAL STRUCT, DOI DOI 10.2307/91108; Bragg WL, 1929, P R SOC LOND A-CONTA, V123, P537, DOI 10.1098/rspa.1929.0083; BROWN RS, 1983, NATURE, V303, P543, DOI 10.1038/303543a0; CHEETHAM AK, 1992, ANGEW CHEM INT EDIT, V31, P1557, DOI 10.1002/anie.199215571; COREY RB, 1950, J AM CHEM SOC, V72, P5349; COUVES JW, 1991, NATURE, V354, P465, DOI 10.1038/354465a0; CROWTHER RA, 1970, PROC R SOC LON SER-A, V317, P319, DOI 10.1098/rspa.1970.0119; Cruickshank D. W. J., 1992, PHILOS T R SOC A, V340, P167; DEISENHOFER J, 1989, PRIX NOBEL 1988, P134; Dunitz J.D., 1979, XRAY ANAL STRUCTURE; GAIBOYES PL, 1992, ADV SUPERCONDUCTING, P1; HAWKINS JM, 1991, SCIENCE, V252, P312, DOI 10.1126/science.252.5003.312; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; Hodgkin D. C., 1965, PRIX NOBEL 1964, P71; KARLE IL, 1958, ACTA CRYSTALLOGR, V11, P257, DOI 10.1107/S0365110X58000645; KLUG A, 1983, PRIX NOBEL 1982, P93; KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0; MAGNELI A, 1953, ACTA CRYSTALLOGR, V6, P495, DOI 10.1107/S0365110X53001381; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; PERUTZ MF, 1992, LEGACY L BRAGG, P71; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Robertson JM, 1937, J CHEM SOC, P219, DOI 10.1039/jr9370000219; SMITH TJ, 1993, J VIROL, V67, P1148, DOI 10.1128/JVI.67.3.1148-1158.1993; SOUZA VTD, 1985, BIOCHEM BIOPH RES CO, V129, P727; Terasaki O, 1989, CHEM MATER, V1, P158, DOI 10.1021/cm00001a028; THOMAS JM, 1974, PHILOS T R SOC A, V277, P251, DOI 10.1098/rsta.1974.0051; UNWIN PNT, 1993, J MOL BIOL, V229, P1101; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WADSLEY AD, 1964, NONSTOICHIOMETRIC CO, pCH9; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WEISSBUCH I, 1991, SCIENCE, V253, P637, DOI 10.1126/science.253.5020.637	34	18	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					478	482		10.1038/364478a0	http://dx.doi.org/10.1038/364478a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8336786				2022-12-28	WOS:A1993LQ66700023
J	ALPER, J				ALPER, J			OCT - IMAGES OF COHERENCE	SCIENCE			English	Editorial Material																		HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; IZATT JA, 1993, IN PRESS SPIE P, V1877	2	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					555	555		10.1126/science.8342017	http://dx.doi.org/10.1126/science.8342017			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342017				2022-12-28	WOS:A1993LP72800025
J	IGLEHART, JK				IGLEHART, JK			THE AMERICAN HEALTH-CARE SYSTEM - COMMUNITY HOSPITALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICARE											ANDERS G, 1993, WALL ST J       1109, pB1; ANDERSON H, 1991, HOSPITALS, P32; BURDA D, 1992, MODERN HEALTHCA 0615, P22; DAY K, 1993, WASHINGTON POST 0606, pH1; FELSENTHAL E, 1993, WALL ST J       0907, pB1; GREEN J, 1993, AHA NEWS, V29, pP1; IGLEHART JK, 1983, NEW ENGL J MED, V308, P1428, DOI 10.1056/NEJM198306093082331; IGLEHART JK, 1992, NEW ENGL J MED, V327, P1467, DOI 10.1056/NEJM199211123272027; IGLEHART JK, 1992, NEW ENGL J MED, V326, P1715, DOI 10.1056/NEJM199206183262526; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; IGLEHART JK, 1993, NEW ENGL J MED, V328, P896, DOI 10.1056/NEJM199303253281226; IGLEHART JK, 1993, NEW ENGL J MED, V328, P366, DOI 10.1056/NEJM199302043280528; IGLEHART JK, 1992, NEW ENGL J MED, V326, P926; KASSIRER JP, 1992, NEW ENGL J MED, V326, P945, DOI 10.1056/NEJM199204023261408; LETSCH SW, 1993, HEALTH AFFAIR, V12, P94, DOI 10.1377/hlthaff.12.1.94; MELNICK G, 1993, WALL STREET J   0602, pA14; Miller M E, 1992, Health Care Financ Rev, V14, P135; MORRISEY MA, 1993, HOSPITAL PRICING COS; PEAR R, 1993, NY TIMES        0203, pA16; REDELMEIER DA, 1993, NEW ENGL J MED, V328, P772, DOI 10.1056/NEJM199303183281107; Rosenberg Charles E., 1987, CARE STRANGERS RISE; SHORTELL SM, 1993, HEALTHCARE FORUM MAR, P20; STARR P, 1982, SOCIALL TRANSFORMATI; Stevens Rosemary, 1989, SICKNESS WEALTH AM H; WINSLOW R, 1993, WALL STREET J, pB1; Winslow Ron., 1990, WALL STR J, pA1; Winslow Ron, 1993, WALL STREET J   1230, pA1; 1992, STRUCTURE HOSPITAL I; 1992, 1992 GREEN BOOK; 1993, MAY JOINT COMM ACCR; 1993, OECD HLTH SYSTEMS FA; 1992, MEDICARE AM HLTH CAR; 1993, RESPONSES UNCOMPENSA; 1992, AMBULATORY CARE TREN; 1993, 1993 BOARD TRUST FED; 1992, HOSPITAL STATISTICS; 1993, NEW ENGL J MED, V328, P1208; 1991, HJOSPITAL LIABILITY	38	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					372	376		10.1056/NEJM199307293290528	http://dx.doi.org/10.1056/NEJM199307293290528			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8321278				2022-12-28	WOS:A1993LN62100031
J	WILSON, J				WILSON, J			ABC OF ONE TO 7 - HEALTH-SERVICES FOR CHILDREN - THE COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article																			0	3	3	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					191	195		10.1136/bmj.307.6897.191	http://dx.doi.org/10.1136/bmj.307.6897.191			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN184	8343751	Bronze, Green Published			2022-12-28	WOS:A1993LN18400030
J	PEPPERKOK, R; SCHEEL, J; HORSTMANN, H; HAURI, HP; GRIFFITHS, G; KREIS, TE				PEPPERKOK, R; SCHEEL, J; HORSTMANN, H; HAURI, HP; GRIFFITHS, G; KREIS, TE			BETA-COP IS ESSENTIAL FOR BIOSYNTHETIC MEMBRANE-TRANSPORT FROM THE ENDOPLASMIC-RETICULUM TO THE GOLGI-COMPLEX IN-VIVO	CELL			English	Article							CLATHRIN-COATED VESICLES; BREFELDIN-A; PROTEIN-TRANSPORT; VESICULAR TRANSPORT; SECRETORY PATHWAY; CAPILLARY MICROINJECTION; INTERMEDIATE COMPARTMENT; ELECTRON-MICROSCOPY; GUANINE-NUCLEOTIDE; BINDING PROTEIN	Microinjection of antibodies against a synthetic peptide of a non-clathrin-coated vesicle-associated coat protein, beta-COP, blocks transport of a temperature-sensitive vesicular stomatitis virus glycoprotein (ts-O45-G) to the cell surface. Transport is inhibited upon release of the viral glycoprotein from temperature blocks at 39.5-degrees-C (endoplasmic reticulum [ER]) and 15-degrees-C (intermediate compartment), but not at 20-degrees-C (trans-Golgi network). Ts-O45-G is arrested in tubular membrane structures containing p53 at the interface of the ER and the Golgi stack. This is consistent with inhibition of acquisition of endoglycosidase H resistance of ts-O45-G in injected cells. Secretion of endogenous proteins and maturation of cathepsin D are also inhibited. These data provide in vivo evidence that beta-COP has an important function in biosynthetic membrane traffic in mammalian cells.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY; BIOCENTER,DEPT PHARMACOL,CH-4065 BASEL,SWITZERLAND	European Molecular Biology Laboratory (EMBL)				Pepperkok, Rainer/0000-0002-9762-3583				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HENDRICKS LC, 1992, EUR J CELL BIOL, V58, P202; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KREIS T E, 1992, Current Opinion in Cell Biology, V4, P609, DOI 10.1016/0955-0674(92)90079-R; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LEO AH, 1993, MODERN TECHNIQUES BI, P157; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEPPERKOK R, 1988, EXP CELL RES, V178, P369, DOI 10.1016/0014-4827(88)90406-5; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; Rasure J., 1990, International Journal of Imaging Systems and Technology, V2, P183, DOI 10.1002/ima.1850020304; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; VANGENDEREN IL, 1991, J CELL BIOL, V115, P1009, DOI 10.1083/jcb.115.4.1009; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171	53	308	311	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					71	82		10.1016/0092-8674(93)90295-2	http://dx.doi.org/10.1016/0092-8674(93)90295-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334707				2022-12-28	WOS:A1993LN62500008
J	WATERSTON, T; ZWI, A				WATERSTON, T; ZWI, A			HEALTH-PROFESSIONALS AND SOUTH-AFRICA - SUPPORTING CHANGE IN THE HEALTH SECTOR	BRITISH MEDICAL JOURNAL			English	Article							BIKO	Now that political change is on the way in South Africa, what should be the position of doctors who are invited to visit the country? Does the ''academic boycott'' still have relevance? Waterston and Zwi review the case for and against an academic boycott policy, using evidence collected during the recent visit by Physicians for Human Rights (UK) and the Johannes Wier Foundation. The health system in South Africa is still inequitable, and despite progress towards desegregation in hospitals there is little momentum towards universal provision of primary health care, especially in the rapidly growing townships around big cities. The authors consider that pressure on the government should be maintained by outside organisations but that support directed towards appropriate health care should be encouraged, particularly in public health and primary health care.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	WATERSTON, T (corresponding author), NEWCASTLE GEN HOSP,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.		Zwi, Anthony/AAP-8731-2020; Zwi, Anthony/AAP-7026-2021	Zwi, Anthony/0000-0001-6902-6602				BENATAR SR, 1989, S AFR MED J, V75, P362; LEE NC, 1991, S AFR MED J, V79, P635; SILOVE D, 1990, SOC SCI MED, V30, P417, DOI 10.1016/0277-9536(90)90344-R; 1990, NAMDA SPECIAL B, V3; 1989, NAMDA SPECIAL B, V2; 1991, CHANGING HLTH S AFRI; 1992, S AFRICA 1991 APARTH	7	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					110	112		10.1136/bmj.307.6896.110	http://dx.doi.org/10.1136/bmj.307.6896.110			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343707	Green Published, Bronze			2022-12-28	WOS:A1993LM58500030
J	PORTER, K; WALL, PG; EVANS, BG				PORTER, K; WALL, PG; EVANS, BG			FACTORS ASSOCIATED WITH LACK OF AWARENESS OF HIV-INFECTION BEFORE DIAGNOSIS OF AIDS	BRITISH MEDICAL JOURNAL			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; CONTROLLED TRIAL; ZIDOVUDINE; COHORT	Objective-To identify characteristics of people likely to be unaware of their HIV infection before diagnosis of AIDS defining disease. Design-Survey of continuing surveillance of voluntarily reported AIDS cases. Subjects-4127 adults with AIDS diagnosed during 1989-92 and reported to the Public Health Laboratory Service AIDS Centre. Setting-England and Wales. Main outcome measure-Lack of prolonged awareness of infection before diagnosis of AIDS, defined as an interval of nine months or less between first positive test result and diagnosis of AIDS. Results-Of 3556 adults with known dates of first positive HIV test result and AIDS diagnosis, 1742 (49%) had been unaware of their infection for up to nine months before AIDS was diagnosed. Lack of awareness was independently and positively associated with infection through heterosexual contact (odds ratio 4.46, 95% confidence interval 3.15 to 6.33), AIDS reported outside the Thames regions (1.64, 1.38 to 1.96), and being non-white (1.99, 1.51 to 2.61). Women were less likely to be unaware than men (0.50, 0.33 to 0.76), and people diagnosed in 1992 were least likely to be unaware (0.48, 0.39 to 0.60). Those aged 25-49 years at diagnosis were less likely to be unaware than those aged 15-24 years and those aged 50 and over. Conclusions-People with certain characteristics are more likely than others to be unaware of their HIV infection before AIDS is diagnosed and are therefore less likely to receive prophylaxis. Methods for educating this heterogeneous group need to be investigated.			PORTER, K (corresponding author), PUBL HLTH LAB SERV,CTR AIDS,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.			Porter, Kholoud/0000-0002-9226-6206				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; BAUM MK, 1991, J ACQ IMMUN DEF SYND, V4, P1122; BECK EJ, 1992, INT J STD AIDS, V3, P182, DOI 10.1177/095646249200300305; DEMARTINO M, 1992, AIDS, V6, P991, DOI 10.1097/00002030-199209000-00013; DROTMAN DP, 1989, ANN INTERN MED, V110, P680, DOI 10.7326/0003-4819-110-9-680; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; KLEIN RS, 1992, 8 P INT C AIDS AMST; KUO JM, 1991, AM J EPIDEMIOL, V133, P1050, DOI 10.1093/oxfordjournals.aje.a115814; PAYNE C, 1983, GLIM SYSTEM MANUAL R; RAGNI MV, 1992, J ACQ IMMUN DEF SYND, V5, P120; REGEVIK N, 1992, 8 P INT C AIDS AMST; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1991, COMMUNICABLE DISEASE, V5, pR51; 1992, IMMUNISATION INFECTI; 1991, LANCET, V337, P253; 1992, MMWR, V41, pRR4	20	59	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					20	23		10.1136/bmj.307.6895.20	http://dx.doi.org/10.1136/bmj.307.6895.20			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343662	Bronze, Green Published			2022-12-28	WOS:A1993LL36900019
J	BROWN, DD				BROWN, DD			NIH FUNDING MECHANISMS NEED APPRAISAL	SCIENCE			English	Article											BROWN, DD (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,115 W UNIV PKWY,BALTIMORE,MD 21210, USA.							1992, NIH DATA BOOK 1992	1	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					16	&		10.1126/science.8316845	http://dx.doi.org/10.1126/science.8316845			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316845				2022-12-28	WOS:A1993LK43400011
J	EDWARDS, JD				EDWARDS, JD			MANAGEMENT OF SEPTIC SHOCK	BRITISH MEDICAL JOURNAL			English	Review							OXYGEN-TRANSPORT; RESPIRATORY INSUFFICIENCY; NOREPINEPHRINE THERAPY; SEPSIS; PERFORMANCE; DOBUTAMINE; VARIABLES	There have been important advances in the resuscitation of patients in septic shock in recent years. Survival can be improved by earlier recognition and therefore eradication of the sepsis combined with logical supportive measures. As with any acutely ill patient consultation with intensive care unit staff may be useful. Consultation with the intensive care unit does not necessarily imply the need for admission and mechanical ventilation; helpful advice may be forthcoming. Equally, referral to the intensive care unit does not mean an admission of failure but merely a recognition that additional skills and technical facilities are necessary for the patient's survival.			EDWARDS, JD (corresponding author), UNIV HOSP S MANCHESTER,INTENS CARE UNIT,MANCHESTER M20 8LR,LANCS,ENGLAND.							ABRAHAM E, 1983, CRIT CARE MED, V11, P799, DOI 10.1097/00003246-198310000-00007; [Anonymous], 1992, CRIT CARE MED, V20, P864; BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589; BAKKER J, 1991, CHEST, V99, P956, DOI 10.1378/chest.99.4.956; CREAMER JE, 1990, AM J CARDIOL, V65, P1297, DOI 10.1016/0002-9149(90)91316-X; DESJARS P, 1987, CRIT CARE MED, V15, P134, DOI 10.1097/00003246-198702000-00011; DHAINAUT JF, 1990, INTENS CARE MED, V16, P179; DUFF JH, 1969, SURG GYNECOL OBSTETR, V128, P1051; EDWARDS JD, 1989, CRIT CARE MED, V17, P1098, DOI 10.1097/00003246-198911000-00002; EDWARDS JD, 1989, CRIT CARE MED, V17, P996, DOI 10.1097/00003246-198910000-00006; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LOEB HS, 1967, BRIT HEART J, V29, P883; MACKENZIE SJ, 1991, INTENS CARE MED, V17, P36, DOI 10.1007/BF01708407; MACLEAN LD, 1967, ANN SURG, V166, P543, DOI 10.1097/00000658-196710000-00004; MARTIN C, 1990, ACTA ANAESTH SCAND, V34, P413, DOI 10.1111/j.1399-6576.1990.tb03114.x; MEADOWS D, 1988, CRIT CARE MED, V16, P663, DOI 10.1097/00003246-198807000-00003; OGNIBENE FP, 1988, CHEST, V93, P903, DOI 10.1378/chest.93.5.903; SAMSEL PW, 1992, YB INTENSIVE CARE EM, P271; SCHNEIDER AJ, 1988, AM HEART J, V116, P103, DOI 10.1016/0002-8703(88)90256-6; SHOEMAKER WC, 1986, CRIT CARE MED, V14, P1032, DOI 10.1097/00003246-198612000-00008; SUCHYTA MR, 1991, CHEST, V99, P951, DOI 10.1378/chest.99.4.951; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; VINCENT JL, 1981, AM J SURG, V142, P262, DOI 10.1016/0002-9610(81)90290-7; VINCENT JL, 1993, YB INTENSIVE CARE EM, P49; VITO L, 1974, SURG GYNECOL OBSTET, V138, P896; WILSON W, 1992, ANAESTH INTENS CARE, V20, P470, DOI 10.1177/0310057X9202000413; WOLF YG, 1987, CRIT CARE MED, V15, P198, DOI 10.1097/00003246-198703000-00003; WOODS I, 1987, CRIT CARE MED, V15, P850, DOI 10.1097/00003246-198709000-00010	28	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1661	1664		10.1136/bmj.306.6893.1661	http://dx.doi.org/10.1136/bmj.306.6893.1661			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324438	Bronze, Green Published			2022-12-28	WOS:A1993LJ33700027
J	POSAKONY, JW				POSAKONY, JW			NATURE VERSUS NURTURE - ASYMMETRIC CELL DIVISIONS IN DROSOPHILA BRISTLE DEVELOPMENT	CELL			English	Review							BINDING-PROTEIN; NOTCH LOCUS; WING DISK; GENE; HAIRLESS; MELANOGASTER; EXPRESSION; ENCODES; FATE; NEUROGENESIS		UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	POSAKONY, JW (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.							ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ASHBURNER M, 1982, GENETICS, V101, P447; BANG AG, 1991, DEVELOPMENT, V111, P89; BANG AG, 1992, GENE DEV, V6, P1752, DOI 10.1101/gad.6.9.1752; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GORIELY A, 1991, DEVELOPMENT, V113, P1395; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Lees AD, 1942, PROC R SOC SER B-BIO, V131, P87, DOI 10.1098/rspb.1942.0019; MAIER D, 1992, MECH DEVELOP, V38, P143, DOI 10.1016/0925-4773(92)90006-6; PALKA J, 1990, DEVELOPMENT, V109, P167; PARKS AL, 1993, DEV BIOL, V157, P484, DOI 10.1006/dbio.1993.1151; RHYU M, 1994, CELL, V76; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; USUI K, 1992, DEVELOPMENT, V116, P601; VASSIN H, 1985, J NEUROGENET, V2, P291, DOI 10.3109/01677068509102325; WRIGHT KA, 1992, MICROSC RES TECHNIQ, V22, P285, DOI 10.1002/jemt.1070220306	26	145	146	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					415	418		10.1016/0092-8674(94)90105-8	http://dx.doi.org/10.1016/0092-8674(94)90105-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313463				2022-12-28	WOS:A1994MX20700002
J	THOMPSON, DF				THOMPSON, DF			UNDERSTANDING FINANCIAL CONFLICTS-OF-INTEREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIANS; BIOTECHNOLOGY; UNIVERSITY				THOMPSON, DF (corresponding author), HARVARD UNIV,CAMBRIDGE,MA 02138, USA.							BLUMENTHAL D, 1986, SCIENCE, V232, P1361, DOI 10.1126/science.3715452; BLUMENTHAL D, 1986, SCIENCE, V231, P242, DOI 10.1126/science.3941897; GREEN RM, 1990, THEOR MED, V11, P287, DOI 10.1007/BF00489819; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; KASSIRER JP, 1993, NEW ENGL J MED, V328, P1268, DOI 10.1056/NEJM199304293281710; KUSSEROW RP, 1991, PROMOTION PRESCRIPTI; MCCORMICK B, 1992, AM MED NEWS     0427, P1; MCDOWELL TN, 1989, AM J LAW MED, V15, P61; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; RELMAN AS, 1980, NEW ENGL J MED, V303, P963, DOI 10.1056/NEJM198010233031703; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; RODWIN M, 1993, MED MONEY MORALS; RODWIN MA, 1989, NEW ENGL J MED, V321, P1405, DOI 10.1056/NEJM198911163212010; ROTHMAN KJ, 1993, JAMA-J AM MED ASSOC, V269, P2782, DOI 10.1001/jama.269.21.2782; ROTHMAN KJ, 1991, J CLIN EPIDEMIOL, V44, pS25; SHIMM DS, 1991, ANN INTERN MED, V115, P148, DOI 10.7326/0003-4819-115-2-148; TODD JS, 1992, JAMA-J AM MED ASSOC, V268, P98, DOI 10.1001/jama.268.1.98; 1987, COMMENTS DEV REGULAT; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1990, JAMA-J AM MED ASSOC, V263, P2790	21	549	585	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					573	576		10.1056/NEJM199308193290812	http://dx.doi.org/10.1056/NEJM199308193290812			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8336759	Green Published			2022-12-28	WOS:A1993LR89200012
J	BROWN, SJ; KELLETT, PJ; LIPPARD, SJ				BROWN, SJ; KELLETT, PJ; LIPPARD, SJ			IXR1, A YEAST PROTEIN THAT BINDS TO PLATINATED DNA AND CONFERS SENSITIVITY TO CISPLATIN	SCIENCE			English	Article							ANTICANCER DRUG CISPLATIN; SACCHAROMYCES-CEREVISIAE; INTRASTRAND D(GPG); NUCLEAR; MITOCHONDRIA; EXTRACTS; REPAIR; CELLS	Structure-specific recognition proteins (SSRPs) bind to DNA containing intrastrand cross-links formed by the anticancer drug cisplatin. A yeast gene encoding an SSRP, designated IXR1, was cloned and sequenced. The Ixr1 protein, a member of the high mobility group-box protein family, bound specifically to DNA modified with cisplatin but not inactive platinum compounds. A yeast strain with an inactivated IXR1 gene was half as sensitive to cisplatin and accumulated one-third as many platinum-DNA lesions after treatment with cisplatin as the parental strain. These findings suggest that SSRPs play a role in mediating the cytotoxicity of cisplatin.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)								BROWN SDM, UNPUB; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KELLEY SL, 1989, EUR J CANCER CLIN ON, V25, P1135, DOI 10.1016/0277-5379(89)90405-7; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; WANG ZG, 1992, BIOCHEMISTRY-US, V31, P3694, DOI 10.1021/bi00129a019	22	181	187	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1993	261	5121					603	605		10.1126/science.8342024	http://dx.doi.org/10.1126/science.8342024			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342024				2022-12-28	WOS:A1993LP72800037
J	REBAY, I; FEHON, RG; ARTAVANISTSAKONAS, S				REBAY, I; FEHON, RG; ARTAVANISTSAKONAS, S			SPECIFIC TRUNCATIONS OF DROSOPHILA NOTCH DEFINE DOMINANT ACTIVATED AND DOMINANT-NEGATIVE FORMS OF THE RECEPTOR	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; GENE SERRATE ENCODES; CELL FATE; TRANSMEMBRANE PROTEIN; EXPRESSION PATTERN; EARLY NEUROGENESIS; LOCUS; MELANOGASTER; HOMOLOG; REPEATS	The Notch gene of Drosophila plays an important role in cell fate specification throughout development. To investigate the functions of specific structural domains of the Notch protein in vivo, a series of deletion mutants have been ectopically expressed under the hsp70 heat shock promoter. Two classes of dominant phenotypes are observed, one suggestive of Notch loss-of-function mutations and the other of Notch gain-of-function,mutations. Dominant activated phenotypes result from overexpression of a protein lacking most extracellular sequences, while dominant negative phenotypes result from overexpression of a protein lacking most intracellular sequences. These results support the notion that Notch functions as a receptor whose extracellular domain mediates ligand binding, resulting in the transmission of developmental signals by the cytoplasmic domain. Finally, the phenotypes observed suggest that the cdc10/ankyrin repeat region within the intracellular domain plays an essential role in the postulated signal transduction events.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06536	Yale University	REBAY, I (corresponding author), YALE UNIV,DEPT CELL BIOL,HOWARD HUGHES MED INST,NEW HAVEN,CT 06536, USA.				NIGMS NIH HHS [GM29093] Funding Source: Medline; NINDS NIH HHS [NS26084] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026084, R37NS026084] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; APPELLA E, 1987, FEBS LETT, V231, P1; ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DELIDAKIS C, 1991, GENETICS, V129, P803; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1978, GENETICS, V88, P469; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; Maniatis T, 1989, DECONTAMINATION DILU; MOFFAT KG, 1992, DEVELOPMENT, V114, P681; PALKA J, 1990, DEVELOPMENT, V109, P167; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; Poulson DF, 1937, P NATL ACAD SCI USA, V23, P133, DOI 10.1073/pnas.23.3.133; RAMOS RGP, 1989, GENETICS, V123, P337; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROBERTSON HM, 1988, GENETICS, V118, P461; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; THOMAS U, 1991, DEVELOPMENT, V111, P749; THOMPSON JN, 1974, HEREDITY, V33, P389, DOI 10.1038/hdy.1974.105; THUMMEL CS, 1991, DROSOPH INFO NEWS, V2; VAESSIN H, 1987, EMBO (European Molecular Biology Organization) Journal, V6, P3431; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1992, DEVELOPMENT, V115, P913; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	53	375	393	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					319	329		10.1016/0092-8674(93)90423-N	http://dx.doi.org/10.1016/0092-8674(93)90423-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343959				2022-12-28	WOS:A1993LP72600013
J	YAMASHITA, S; HISATAKE, K; KOKUBO, T; DOI, K; ROEDER, RG; HORIKOSHI, M; NAKATANI, Y				YAMASHITA, S; HISATAKE, K; KOKUBO, T; DOI, K; ROEDER, RG; HORIKOSHI, M; NAKATANI, Y			TRANSCRIPTION FACTOR TFIIB SITES IMPORTANT FOR INTERACTION WITH PROMOTER-BOUND TFIID	SCIENCE			English	Article							RNA POLYMERASE-II; INITIATION; SELECTION; COMPLEX; DOMAIN	Transcription initiation factor TFIIB recruits RNA polymerase II to the promoter subsequent to interaction with a preformed TFIID-promoter complex. The domains of TFIIB required for binding to the TFIID-promoter complex and for transcription initiation have been determined. The carboxyl-terminal two-thirds of TFIIB, which contains two direct repeats and two basic residue repeats, is sufficient for interaction with the TFIID-promoter complex. An extra 84-residue amino-terminal region, with no obvious known structural motifs, is required for basal transcription activity. Basic residues within the second basic repeat of TFIIB are necessary for stable interaction with the TFIID-promoter complex, whereas the basic character of the first basic repeat is not. Functional roles of other potential structural motifs are discussed in light of the present study.	NINCDS,BETHESDA,MD 20892; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; NIDCD,NEUROCHEM LAB,BETHESDA,MD 20892; UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Tokyo				Hisatake, Koji/0000-0002-5795-3115	NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline; NIGMS NIH HHS [GM45258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P6636; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839	16	50	50	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					463	466		10.1126/science.8332911	http://dx.doi.org/10.1126/science.8332911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332911				2022-12-28	WOS:A1993LN62300033
J	CAPPUCCIO, FP; STRAZZULLO, P; FARINARO, E; TREVISAN, M				CAPPUCCIO, FP; STRAZZULLO, P; FARINARO, E; TREVISAN, M			URIC-ACID METABOLISM AND TUBULAR SODIUM HANDLING - RESULTS FROM A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL LITHIUM CLEARANCE; ESSENTIAL-HYPERTENSION; COUNTERTRANSPORT; HYPERINSULINEMIA; INSULIN; MEN; RESISTANCE; EXCRETION; DISEASE	Objective.-To define the relationship, if any, between uric acid metabolism (serum and urinary levels) and proximal tubular sodium handling in a sample of general male population. Design.-Cross-sectional survey of a sample of the male working population conducted as part of a nationwide survey of the prevalence of cardiovascular risk factors. Setting.-The Olivetti factory in Pozzuoli, a suburb of Naples, Italy. Participants.-Five hundred sixty-eight untreated male workers aged 21 to 68 years (90.8% of those eligible). Measurements.-Anthropometry, blood pressure, blood tests, a detailed questionnaire, and urinary measurements on a fasting timed collection after a 300-mg lithium carbonate capsule was taken the night before the investigation. Results.-Serum uric acid level was inversely and significantly associated with the fractional excretion of lithium (r=-.22, P<.001), ie, the higher the serum uric acid level, the greater the amount of sodium reabsorbed at nephron sites proximal to the distal tubule. The association was graded and independent of possible confounders such as age, body mass, smoking, wine consumption, blood pressure, fractional excretion of sodium, and serum creatinine (R2=.34, P<.001). Conclusions.-High serum uric acid levels are independently associated with increased proximal tubular sodium reabsorption in men. This relationship suggests an altered tubular sodium handling and uric acid metabolism consistent with hyperinsulinemia, insulin resistance being the possible pathophysiological link.	UNIV NAPLES, SCH MED 2, INST INTERNAL MED & METAB DIS, I-80138 NAPLES, ITALY; SUNY Buffalo, DEPT SOCIAL & PREVENT MED, BUFFALO, NY 14260 USA	University of Naples Federico II; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	CAPPUCCIO, FP (corresponding author), ST GEORGE HOSP, SCH MED, DEPT MED, BLOOD PRESSURE UNIT, CRANMER TERRACE, LONDON SW17 0RE, ENGLAND.		Cappuccio, Francesco/D-3028-2009	Cappuccio, Francesco Paolo/0000-0002-7842-5493				BRAND FN, 1985, AM J EPIDEMIOL, V121, P11, DOI 10.1093/oxfordjournals.aje.a113972; BRECKENRIDGE A, 1966, LANCET, V1, P15; CANNON PJ, 1966, NEW ENGL J MED, V275, P457, DOI 10.1056/NEJM196609012750902; CAPPUCCIO FP, 1991, EUR J CLIN INVEST, V21, P40, DOI 10.1111/j.1365-2362.1991.tb01356.x; CAPPUCCIO FP, 1990, BRIT MED J, V300, P1234, DOI 10.1136/bmj.300.6734.1234; DEFRONZO RA, 1981, DIABETOLOGIA, V21, P165, DOI 10.1007/BF00252649; DOLLERY CT, 1960, BRIT MED J, V2, P832, DOI 10.1136/bmj.2.5202.832; DORIA A, 1991, AM J PHYSIOL, V261, pE684, DOI 10.1152/ajpendo.1991.261.6.E684; FACCHINI F, 1991, JAMA-J AM MED ASSOC, V266, P3008, DOI 10.1001/jama.266.21.3008; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; GERTLER MM, 1951, ANN INTERN MED, V34, P1421, DOI 10.7326/0003-4819-34-6-1421; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MESSERLI FH, 1980, ANN INTERN MED, V93, P817, DOI 10.7326/0003-4819-93-6-817; MODAN M, 1987, DIABETOLOGIA, V30, P713, DOI 10.1007/BF00296994; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; SELBY JV, 1990, AM J EPIDEMIOL, V131, P1017, DOI 10.1093/oxfordjournals.aje.a115593; SHIRLEY DG, 1991, CLIN SCI, V81, P59, DOI 10.1042/cs0810059; SHIRLEY DG, 1990, AM J MED SCI, V299, P326, DOI 10.1097/00000441-199005000-00007; SOLOMON LR, 1987, CLIN SCI, V72, P201, DOI 10.1042/cs0720201; STEELE TH, 1971, NEW ENGL J MED, V284, P1193, DOI 10.1056/NEJM197105272842106; STRAZZULLO P, 1989, CLIN SCI, V77, P337, DOI 10.1042/cs0770337; STRAZZULLO P, 1988, CLIN SCI, V74, P651, DOI 10.1042/cs0740651; STRAZZULLO P, 1989, AM J HYPERTENS, V2, P634, DOI 10.1093/ajh/2.8.634; THOMSEN K, 1984, NEPHRON, V37, P217, DOI 10.1159/000183252; TREVISAN M, 1991, CIRCULATION, V84, P2011, DOI 10.1161/01.CIR.84.5.2011; TUOMILEHTO J, 1988, AM J EPIDEMIOL, V127, P321, DOI 10.1093/oxfordjournals.aje.a114807; WEDER AB, 1986, NEW ENGL J MED, V314, P198, DOI 10.1056/NEJM198601233140402; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	28	197	212	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					354	359		10.1001/jama.270.3.354	http://dx.doi.org/10.1001/jama.270.3.354			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8315780				2022-12-28	WOS:A1993LM43500031
J	RANSOHOFF, DF				RANSOHOFF, DF			GASTROENTEROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATURAL-HISTORY; GALLSTONE				RANSOHOFF, DF (corresponding author), UNIV N CAROLINA,CHAPEL HILL,NC 27514, USA.							AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; GRACIE WA, 1982, NEW ENGL J MED, V307, P798, DOI 10.1056/NEJM198209233071305; GRAHAM DY, 1993, NEW ENGL J MED, V328, P349, DOI 10.1056/NEJM199302043280512; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; NENNER RP, 1992, NEW YORK STATE J MED, V92, P179; NEWMAN HF, 1968, AM J GASTROENTEROL, V50, P476; PETERSON WL, 1993, IN PRESS PHARM APPRO; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1993, ANN INTERN MED, V118, P1, DOI 10.7326/0003-4819-118-1-199301010-00001; SELBY JV, 1993, JAMA-J AM MED ASSOC, V269, P1294, DOI 10.1001/jama.269.10.1294; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; STJOHN DGB, IN PRESS ANN INTERN; THISTLE JL, 1984, ANN INTERN MED, V101, P171, DOI 10.7326/0003-4819-101-2-171; 1993, JAMA-J AM MED ASSOC, V269, P1018	20	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					206	209		10.1001/jama.270.2.206	http://dx.doi.org/10.1001/jama.270.2.206			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315733				2022-12-28	WOS:A1993LL36800019
J	BURGESS, SM; GUTHRIE, C				BURGESS, SM; GUTHRIE, C			A MECHANISM TO ENHANCE MESSENGER-RNA SPLICING FIDELITY - THE RNA-DEPENDENT ATPASE PRP16 GOVERNS USAGE OF A DISCARD PATHWAY FOR ABERRANT LARIAT INTERMEDIATES	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; SACCHAROMYCES-CEREVISIAE; BRANCH SITE; TRANSLATION INITIATION; ESCHERICHIA-COLI; YEAST INTRON; SPLICEOSOME; PROTEIN; HELICASE	PRP16 encodes an RNA-dependent ATPase required for the second step of mRNA splicing in S. cerevisiae. We have isolated seven alleles of PRP16 that, like the original allele prp16-1, allow splicing of introns with a mutant branch site (UACUAAC to UACUACC), by forming lariat intermediates at the mutant C nucleotide. Every suppressor mutation maps to the region of PRP16 common to RNA-dependent ATPases. We purified three of the mutant proteins and found that all exhibit reduced ATPase activity, as does Prp16-1. An in vivo analysis of the steady-state levels of the splicing intermediates and products provides evidence for a pathway, under the genetic control of PRP16, to discard incorrectly branched substrates. We propose that decreasing the rate of ATP hydrolysis by Prp16 allows aberrantly formed lariat intermediates more time to proceed through the productive rather than the discard branch of this pathway.			BURGESS, SM (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NIGMS NIH HHS [GM21119] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; BILGIN N, 1992, J MOL BIOL, V224, P1011, DOI 10.1016/0022-2836(92)90466-W; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; CHENG SC, 1986, P NATL ACAD SCI USA, V83, P2387, DOI 10.1073/pnas.83.8.2387; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; COUTO JR, 1987, GENE DEV, V1, P445, DOI 10.1101/gad.1.5.445; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; Dowdy S, 1983, STAT RES; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; HAMM J, 1987, EMBO J, V6, P3479, DOI 10.1002/j.1460-2075.1987.tb02672.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; KUTCHA RD, 1988, BIOCHEMISTRY-US, V27, P6716; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; LESSER CF, 1993, GENETICS, V133, P851; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Maniatis T., 1982, MOL CLONING; MENDENHALL MD, 1988, P NATL ACAD SCI USA, V85, P4426, DOI 10.1073/pnas.85.12.4426; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RYMOND BC, 1983, N PRESS MOL CELL BIO, V2; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SAWA H, 1988, NUCLEIC ACIDS RES, V16, P3157; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHWER B, 1992, MOL CELL BIOL, V12, P3540, DOI 10.1128/MCB.12.8.3540; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SILICIANO PG, 1987, SCIENCE, V237, P1484, DOI 10.1126/science.3306922; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; Taylor J. R., 1982, INTRO ERROR ANAL STU; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; YARUS M, 1992, TRENDS BIOCHEM SCI, V17, P130, DOI 10.1016/0968-0004(92)90320-9; YOUDERIAN P, 1983, CELL, V35, P777, DOI 10.1016/0092-8674(83)90110-1; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	71	148	152	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1377	1391		10.1016/0092-8674(93)90363-U	http://dx.doi.org/10.1016/0092-8674(93)90363-U			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324826	Bronze			2022-12-28	WOS:A1993LL20900012
J	OLIVECRONA, H; ERICSSON, S; BERGLUND, L; ANGELIN, B				OLIVECRONA, H; ERICSSON, S; BERGLUND, L; ANGELIN, B			INCREASED CONCENTRATIONS OF SERUM LIPOPROTEIN(A) IN RESPONSE TO GROWTH-HORMONE TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED,METAB UNIT,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT SURG,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet				Berglund, Lars/0000-0001-6705-1791				HENRIKSSON P, 1992, J CLIN INVEST, V89, P1166, DOI 10.1172/JCI115699; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326	5	69	69	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1726	1727		10.1136/bmj.306.6894.1726-a	http://dx.doi.org/10.1136/bmj.306.6894.1726-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343630	Bronze, Green Published			2022-12-28	WOS:A1993LK36700021
J	DOLPH, PJ; RANGANATHAN, R; COLLEY, NJ; HARDY, RW; SOCOLICH, M; ZUKER, CS				DOLPH, PJ; RANGANATHAN, R; COLLEY, NJ; HARDY, RW; SOCOLICH, M; ZUKER, CS			ARRESTIN FUNCTION IN INACTIVATION OF G-PROTEIN COUPLED RECEPTOR RHODOPSIN INVIVO	SCIENCE			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; A-BINDING-PROTEIN; VISUAL-SYSTEM; DROSOPHILA PHOTORECEPTOR; GENE ENCODES; S-ANTIGEN; HOMOLOG; UVEITIS; PHOTOTRANSDUCTION; TRANSDUCTION	Arrestins have been implicated in the regulation of many G protein-coupled receptor signaling cascades. Mutations in two Drosophila photoreceptor-specific arrestin genes, arrestin 1 and arrestin 2, were generated. Analysis of the light response in these mutants shows that the Arr1 and Arr2 proteins are mediators of rhodopsin inactivation and are essential for the termination of the phototransduction cascade in vivo. The saturation of arrestin function by an excess of activated rhodopsin is responsible for a continuously activated state of the photoreceptors known as the prolonged depolarized afterpotential. In the absence of arrestins, photoreceptors undergo light-dependent retinal degeneration as a result of the continued activity of the phototransduction cascade. These results demonstrate the fundamental requirement for members of the arrestin protein family in the regulation of G protein-coupled receptors and signaling cascades in vivo.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego				Socolich, Michael/0000-0002-0702-1061	NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008768] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATTRAMADA H, 1982, J BIOL CHEM, V267, P17882; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Bockaert J, 1991, Curr Opin Neurobiol, V1, P32, DOI 10.1016/0959-4388(91)90008-U; COLLEY N, UNPUB; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COLLINS S, 1990, BIOCHEM SOC T, V18, P541, DOI 10.1042/bst0180541; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOLPH PJ, UNPUB; FAIN GL, 1990, TRENDS NEUROSCI, V13, P378, DOI 10.1016/0166-2236(90)90023-4; FEILER R, 1992, J NEUROSCI, V12, P3862; FUORTES MGF, 1964, J PHYSIOL-LONDON, V172, P239, DOI 10.1113/jphysiol.1964.sp007415; Grigliati T., 1986, DROSOPHILA PRACTICAL, P39; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KALSOW CM, 1977, INVEST OPHTH VIS SCI, V16, P181; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUHN H, 1987, J RECEPTOR RES, V7, P298; KUHN H, 1984, PROGR RETINAL RES, V3, P124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEVINE H, 1991, MECH DEVELOP, V33, P19; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MATSUMOTO H, 1987, P NATL ACAD SCI USA, V84, P985, DOI 10.1073/pnas.84.4.985; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; MINKE B, 1992, PROGR RETINAL RES, V11, P99; MIRSHAHI M, 1991, THROMB RES, V64, P551, DOI 10.1016/S0049-3848(05)80004-0; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; NUSSENBLATT RB, 1981, ARCH OPHTHALMOL-CHIC, V99, P1090, DOI 10.1001/archopht.1981.03930011090021; NUSSENBLATT RB, 1980, AM J OPHTHALMOL, V89, P173, DOI 10.1016/0002-9394(80)90108-7; ONDEK B, 1992, J BIOL CHEM, V267, P16460; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; RANGANATHAN R, 1991, TRENDS NEUROSCI, V14, P486, DOI 10.1016/0166-2236(91)90060-8; RANGANATHAN RS, UNPUB; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; RICHARD EA, 1992, NATURE, V356, P336, DOI 10.1038/356336a0; ROTH NS, 1991, ADV EXP MED BIOL, V308, P223; SCHEURING U, 1990, FEBS LETT, V276, P192, DOI 10.1016/0014-5793(90)80540-Y; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SMITH DP, 1991, ANNU REV CELL BIOL, V7, P161; STEPHENSON RS, 1983, BIOL PHOTORECEPTION, P477; STRYER L, 1991, J BIOL CHEM, V266, P10711; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; WACKER WB, 1977, J IMMUNOL, V119, P1949; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	59	269	272	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1910	1916		10.1126/science.8316831	http://dx.doi.org/10.1126/science.8316831			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8316831				2022-12-28	WOS:A1993LJ34900033
J	VALMAN, HB				VALMAN, HB			ABC OF ONE TO 7 - BRONCHIAL-ASTHMA	BRITISH MEDICAL JOURNAL			English	Article																			0	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1676	1681		10.1136/bmj.306.6893.1676	http://dx.doi.org/10.1136/bmj.306.6893.1676			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324443	Green Published, Bronze			2022-12-28	WOS:A1993LJ33700034
J	NEGRI, E; FRANZOSI, MG; LAVECCHIA, C; SANTORO, L; NOBILI, A; TOGNONI, G				NEGRI, E; FRANZOSI, MG; LAVECCHIA, C; SANTORO, L; NOBILI, A; TOGNONI, G			TAR YIELD OF CIGARETTES AND RISK OF ACUTE MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							CARBON-MONOXIDE; NICOTINE; DISEASE; SMOKE	Objective-To analyse the relation between tar and nicotine yield of cigarettes smoked in the recent past and the risk of myocardial infarction. Design-Multicentre case-control study conducted between September 1988 and June 1989. Setting-Over 80 coronary care units in various Italian regions. Subjects-916 patients with acute myocardial infarction without history of ischaemic heart disease and 1106 controls admitted to hospital for acute conditions not related to known or suspected risk factors for ischaemic heart disease. Main outcome measures-Relative risk of myocardial infarction according to type of cigarette smoked adjusted for identified potential confounding factors. Brands of cigarettes classified according to yield of tar and nicotine. Results-Patients with acute myocardial infarction were more often smokers and among smokers they tended to smoke more cigarettes. Compared with non-smokers their estimated relative risks were 3.8, 4.3, 3.2, and 3.7 in the four categories of tar yield (< 10, 10-15, > 15-20, and > 20 mg, respectively). No trend in risk across yields was evident when analysis was restricted to smokers and allowance was made for number of cigarettes. Compared with risks in subjects in the lowest category of tar yield the relative risks were 1.2, 0.8, and 1.0 for the subsequent yields. Compared with risks in non-smokers the relative risks ranged from 9.3 to 12.6 below the age of 50 but no trend was observed with increasing yield. Conclusions-Changing to cigarettes with a lower tar yield is not an effective means of reducing tobacco related morbidity from myocardial infarction.	MARIO NEGRI INST PHARMACOL RES,CLIN DRUG EVALUAT LAB,I-20157 MILAN,ITALY; MARIO NEGRI INST PHARMACOL RES,NAT PHILOSOPHY LAB,I-20157 MILAN,ITALY; MARIO NEGRI INST PHARMACOL RES,CLIN PHARMACOL LAB,I-20157 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	NEGRI, E (corresponding author), MARIO NEGRI INST PHARMACOL RES,EPIDEMIOL METHODS UNIT,VIA ERITREA 62,I-20157 MILAN,ITALY.		Nobili, Alessandro/ABG-4516-2020; Negri, Eva/B-7244-2013; Negri, Eva Vanna Lorenza/AAC-5698-2019; Alessandro, Nobili/AAA-7512-2020	Nobili, Alessandro/0000-0002-7813-0572; Negri, Eva/0000-0001-9712-8526; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; La Vecchia, Carlo/0000-0003-1441-897X				[Anonymous], 1990, Lancet, V336, P65; BORLAND C, 1983, BRIT MED J, V287, P1583, DOI 10.1136/bmj.287.6405.1583; Breslow N, 1980, STATISTICAL METHODS, V32; CASTELLI WP, 1981, LANCET, V2, P109, DOI 10.1016/S0140-6736(81)90297-X; FAIRWEATHER FA, 1981, HLTH TRENDS, V13, P77; HAMMOND EC, 1976, ENVIRON RES, V12, P263, DOI 10.1016/0013-9351(76)90036-0; KAUFMAN DW, 1983, NEW ENGL J MED, V308, P409, DOI 10.1056/NEJM198302243080801; LAVECCHIA C, 1988, INT J EPIDEMIOL, V17, P50; NEGRI E, 1992, PREV MED, V21, P292, DOI 10.1016/0091-7435(92)90028-G; PALMER JR, 1989, NEW ENGL J MED, V320, P1569, DOI 10.1056/NEJM198906153202401; PETITTI DB, 1985, J CHRON DIS, V38, P581, DOI 10.1016/0021-9681(85)90047-5; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; WALD N, 1981, BRIT MED J, V282, P763, DOI 10.1136/bmj.282.6266.763; WALD NJ, 1976, BRIT MED J, V1, P434, DOI 10.1136/bmj.1.6007.434-a; 1983, HLTH CONSEQUENCES SM; 1985, IARC MONOGR EVAL CAR, V38, P37; [No title captured]; 1989, REDUCING HLTH CONSEQ; 1991, GAZZETTA UFFICIALE R, V247, P3	19	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1567	1570		10.1136/bmj.306.6892.1567	http://dx.doi.org/10.1136/bmj.306.6892.1567			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329914	Bronze, Green Published			2022-12-28	WOS:A1993LH12800014
J	DUFFY, TP				DUFFY, TP			THE SOONER THE BETTER	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MENINGOCOCCEMIA; SEPTICEMIA; PURPURA				DUFFY, TP (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,HEMATOL SECT,WWW403,POB 3333,NEW HAVEN,CT 06510, USA.							BAXTER P, 1988, LANCET, V1, P1166; BECK EA, 1988, SEMIN HEMATOL, V25, P91; BROZNA JP, 1990, SEMIN THROMB HEMOST, V16, P326, DOI 10.1055/s-2007-1002685; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CORRIGAN JJ, 1970, NEW ENGL J MED, V283, P778, DOI 10.1056/NEJM197010082831502; DRAPKIN MS, 1989, PEDIATR INFECT DIS J, V8, P399, DOI 10.1097/00006454-198906000-00015; GASKINS RA, 1976, ARCH PATHOL LAB MED, V100, P318; GIRAUD T, 1991, ARCH INTERN MED, V151, P310, DOI 10.1001/archinte.151.2.310; Herrick WW, 1919, ARCH INTERN MED, V23, P409, DOI 10.1001/archinte.1919.00090210003001; HOYNE AL, 1948, ANN INTERN MED, V28, P248, DOI 10.7326/0003-4819-28-2-248; LEHNER PJ, 1992, LANCET, V340, P1379, DOI 10.1016/0140-6736(92)92561-S; POWARS DR, 1987, NEW ENGL J MED, V317, P571; TOEWS WH, 1974, AM J DIS CHILD, V127, P173, DOI 10.1001/archpedi.1974.02110210023003; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; 1993, TRAVEL MED ADVISOR P	15	10	10	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					710	713		10.1056/NEJM199309023291007	http://dx.doi.org/10.1056/NEJM199309023291007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8345857				2022-12-28	WOS:A1993LU58300007
J	WILT, JL; MINNEMA, AM; JOHNSON, RF; ROSENBLUM, AM				WILT, JL; MINNEMA, AM; JOHNSON, RF; ROSENBLUM, AM			TORSADE-DE-POINTES ASSOCIATED WITH THE USE OF INTRAVENOUS HALOPERIDOL	ANNALS OF INTERNAL MEDICINE			English	Note							DE-POINTES; PROLONGATION; DRUGS		ST MARYS HLTH SERV, GRAND RAPIDS, MI USA; BLODGETT MEM MED CTR, DEPT CRIT CARE MED, GRAND RAPIDS, MI 49506 USA				Johnson, Robert F/AAC-4208-2019					FAYER SA, 1986, J CLIN PSYCHOPHARM, V6, P375, DOI 10.1097/00004714-198612000-00018; FOWLER NO, 1976, AM J CARDIOL, V37, P223, DOI 10.1016/0002-9149(76)90316-7; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; KAY GN, 1983, J AM COLL CARDIOL, V2, P806; KHAN MM, 1981, AM J CARDIOL, V47, P1301, DOI 10.1016/0002-9149(81)90263-0; KRIWISKY M, 1990, CHEST, V98, P482, DOI 10.1378/chest.98.2.482; LAAKSO M, 1987, AM J CARDIOL, V59, P862, DOI 10.1016/0002-9149(87)91107-6; Sanders KM, 1989, J INTENSIVE CARE MED, V4, P201; TESAR GE, 1988, J INTENSIVE CARE MED, V3, P195; ZEECHENG CS, 1985, ANN INTERN MED, V102, P418, DOI 10.7326/0003-4819-102-3-418_2	10	88	89	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					391	394		10.7326/0003-4819-119-5-199309010-00007	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338292				2022-12-28	WOS:A1993LZ47600007
J	MICHELS, R; MARZUK, PM				MICHELS, R; MARZUK, PM			MEDICAL PROGRESS - PROGRESS IN PSYCHIATRY .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MENTAL-HEALTH-SERVICES; DORSOLATERAL PREFRONTAL CORTEX; D2-DOPAMINE RECEPTOR OCCUPANCY; NEUROLEPTIC-INDUCED AKATHISIA; MONOZYGOTIC TWINS DISCORDANT; BIPOLAR AFFECTIVE-DISORDER; EYE-MOVEMENT DYSFUNCTIONS; SCHIZOPHRENIC-PATIENTS; PANIC DISORDER; FOLLOW-UP		CORNELL UNIV, MED CTR, COLL MED, OFF DEAN, NEW YORK, NY 10021 USA	Cornell University	MICHELS, R (corresponding author), CORNELL UNIV, MED CTR, COLL MED, DEPT PSYCHIAT, 1300 YORK AVE, NEW YORK, NY 10021 USA.				NIDA NIH HHS [1-RO1 DAO6534-01] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADLER LA, 1989, PSYCHOPHARMACOLOGY, V97, P1, DOI 10.1007/BF00443404; ANDERSON CM, 1980, SCHIZOPHRENIA BULL, V6, P490, DOI 10.1093/schbul/6.3.490; ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789; ARANA GW, 1991, HDB PSYCHIATRIC DRUG, P4; BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79; BARON M, 1987, NATURE, V326, P289, DOI 10.1038/326289a0; BARON M, 1993, NAT GENET, V3, P49, DOI 10.1038/ng0193-49; BARON M, 1987, J PSYCHIAT RES, V21, P257, DOI 10.1016/0022-3956(87)90027-6; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100; BECK AT, 1991, AM J PSYCHIAT, V148, P1195; Berman K. F., 1991, REV PSYCHIATRY, V10, P24; BERMAN KF, 1988, ARCH GEN PSYCHIAT, V45, P616; BLACK DW, 1985, JAMA-J AM MED ASSOC, V253, P58, DOI 10.1001/jama.253.1.58; BLEICH A, 1988, SCHIZOPHRENIA BULL, V14, P297, DOI 10.1093/schbul/14.2.297; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BORLAND A, 1989, HOSP COMMUNITY PSYCH, V40, P369; BOYD JH, 1986, AM J PUBLIC HEALTH, V76, P1240, DOI 10.2105/AJPH.76.10.1240; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; BROWN GW, 1958, LANCET, V2, P685; BROWN R, 1986, ARCH GEN PSYCHIAT, V43, P36; CARPENTER WT, 1988, AM J PSYCHIAT, V145, P578; CARPENTER WT, 1987, AM J PSYCHIAT, V144, P1466; CARROLL BJ, 1981, ARCH GEN PSYCHIAT, V38, P15; CHRISTIE KA, 1988, AM J PSYCHIAT, V145, P971; CONRAD AJ, 1987, SCHIZOPHRENIA BULL, V13, P577, DOI 10.1093/schbul/13.4.577; CREED F, 1989, BRIT J PSYCHIAT, V154, P300, DOI 10.1192/bjp.154.3.300; CROW TJ, 1980, BRIT MED J, V280, P66, DOI 10.1136/bmj.280.6207.66; CROWE RR, 1983, ARCH GEN PSYCHIAT, V40, P1065; CROWE RR, 1974, ARCH GEN PSYCHIAT, V31, P785; DENBOER JA, 1987, PSYCHOPHARMACOL BULL, V23, P206; DETERAWADLEIGH SD, 1989, NATURE, V340, P391, DOI 10.1038/340391a0; DICOSTANZO E, 1991, ACTA PSYCHIAT SCAND, V83, P456; DORPAT TL, 1967, COMPR PSYCHIAT, V8, P74, DOI 10.1016/S0010-440X(67)80071-3; DORWART RA, 1990, HOSP COMMUNITY PSYCH, V41, P1087; DORWART RA, 1991, CURRENT OPINION PSYC, V4, P789; EGELAND JA, 1987, NATURE, V325, P783, DOI 10.1038/325783a0; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; FALLOON IRH, 1982, NEW ENGL J MED, V306, P1437, DOI 10.1056/NEJM198206173062401; FARDE L, 1988, PSYCHOPHARMACOLOGY, V94, P1, DOI 10.1007/BF00735871; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; FILIPEK PA, 1989, ANN NEUROL, V25, P61, DOI 10.1002/ana.410250110; FLEISCHHACKER WW, 1990, J CLIN PSYCHOPHARM, V10, P12, DOI 10.1097/00004714-199002000-00003; FORNAZZARI X, 1989, CAN J PSYCHIAT, V34, P700, DOI 10.1177/070674378903400713; FRIEDMAN S, 1992, AM J PSYCHIAT, V149, P680; FYER AJ, 1990, ARCH GEN PSYCHIAT, V47, P252; GARDOS G, 1988, J CLIN PSYCHOPHARM, V8, pS31; GARDOS G, 1987, AM J PSYCHIAT, V144, P895; GELDERS YG, 1991, CLIN NEUROPHARMAC S2, V13, P182; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GERSHON ES, 1987, BIOL PSYCHIAT, V22, P1388, DOI 10.1016/0006-3223(87)90073-4; GLASSMAN AH, 1987, AM J PSYCHIAT, V144, P1253; GOLDBERG TE, 1990, ARCH GEN PSYCHIAT, V47, P1066; GOLDBERG TE, 1991, REV PSYCHIATRY, V10, P60; GOLDIN LR, 1983, PSYCHIAT DEV, V1, P387; GOLDSTEIN JM, 1988, AM J PSYCHIAT, V145, P684; GOULD MS, 1990, AM J EPIDEMIOL, V131, P71, DOI 10.1093/oxfordjournals.aje.a115487; GOULD MS, 1986, NEW ENGL J MED, V315, P690, DOI 10.1056/NEJM198609113151107; GRANDE TP, 1984, PSYCHOL REP, V55, P455, DOI 10.2466/pr0.1984.55.2.455; HARDING CM, 1987, AM J PSYCHIAT, V144, P727; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; HESSELBROCK MN, 1985, ARCH GEN PSYCHIAT, V42, P1050; HIDAY VA, 1989, HOSP COMMUNITY PSYCH, V40, P52; HODGKINSON S, 1987, NATURE, V325, P805, DOI 10.1038/325805a0; HOGARTY GE, 1988, ARCH GEN PSYCHIAT, V45, P797; HOLZMAN PS, 1988, ARCH GEN PSYCHIAT, V45, P641; HOLZMAN PS, 1984, ARCH GEN PSYCHIAT, V41, P136; HOLZMAN PS, 1985, INT REV NEUROBIOL, V27, P179, DOI 10.1016/S0074-7742(08)60558-9; HYDE TM, 1991, REV PSYCHIATRY, V10, P7; HYTTEL J, 1985, DYSKINESIA RES TREAT, P9; ILLOWSKY BP, 1988, J NEUROL NEUROSUR PS, V51, P209, DOI 10.1136/jnnp.51.2.209; JACOB RG, 1988, REV PSYCHIAT, V7, P67; JESTE DV, 1989, ARCH GEN PSYCHIAT, V46, P1019; JOLLEY AG, 1989, BRIT MED J, V298, P985, DOI 10.1136/bmj.298.6679.985; KANE JM, 1988, PSYCHOPHARMACOL BULL, V24, P62; KARNO M, 1988, ARCH GEN PSYCHIAT, V45, P1094, DOI 10.1001/archpsyc.1988.01800360042006; KAUFMANN CA, 1989, SCHIZOPHRENIA BULL, V15, P441, DOI 10.1093/schbul/15.3.441; KEEFE RSE, 1987, AM J PSYCHIAT, V144, P889; KELSOE JR, 1989, NATURE, V342, P238, DOI 10.1038/342238a0; KENDLER KS, 1988, AM J PSYCHIAT, V145, P57; KENDLER KS, 1981, ARCH GEN PSYCHIAT, V38, P982; KENDLER KS, 1987, BIOL PERSPECTIVES SC, V40, P19; KENNEDY JL, 1988, NATURE, V336, P167, DOI 10.1038/336167a0; KILOH LG, 1988, BRIT J PSYCHIAT, V153, P752, DOI 10.1192/bjp.153.6.752; KLERMAN GL, 1989, JAMA-J AM MED ASSOC, V261, P2229, DOI 10.1001/jama.261.15.2229; KRUPP P, 1989, PSYCHOPHARMACOLOGY, V99, pS118, DOI 10.1007/BF00442575; KULKA RA, 1990, NATIONAL VIETNAM VET; LEE AS, 1988, BRIT J PSYCHIAT, V153, P741, DOI 10.1192/bjp.153.6.741; LERNER Y, 1988, BRIT J PSYCHIAT, V153, P359, DOI 10.1192/bjp.153.3.359; LIEBERMAN JA, 1989, PSYCHOPHARMACOL BULL, V25, P57; LIEBOWITZ MR, 1992, ARCH GEN PSYCHIAT, V49, P290; LIN KM, 1988, SCHIZOPHRENIA BULL, V14, P555, DOI 10.1093/schbul/14.4.555; LINDSTROM LH, 1990, BIOL PSYCHIAT, V28, P435, DOI 10.1016/0006-3223(90)90411-T; LYON M, 1989, SCHIZOPHRENIA BULL, V15, P149, DOI 10.1093/schbul/15.1.149; Mann J. J., 1986, PSYCHOBIOLOGY SUICID; MARDER SR, 1988, ARCH GEN PSYCHIAT, V45, P865; MARDER SR, 1987, ARCH GEN PSYCHIAT, V44, P518; MARKOWITZ JS, 1989, ARCH GEN PSYCHIAT, V46, P984; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MASARYK TJ, 1989, RADIOLOGY, V171, P793, DOI 10.1148/radiology.171.3.2717754; Maser J.D., 1990, COMORBIDITY MOOD ANX; MCGLASHAN TH, 1987, J NERV MENT DIS, V175, P467, DOI 10.1097/00005053-198708000-00004; MCGLASHAN TH, 1988, SCHIZOPHRENIA BULL, V14, P515, DOI 10.1093/schbul/14.4.515; MCLELLAN AT, 1983, ARCH GEN PSYCHIAT, V40, P620; MCNEIL TF, 1988, HDB SCHIZOPHRENIA, V3, P319; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013; Meltzer H. Y., 1991, CURR OPIN PSYCHIATR, V4, P90, DOI [10.1097/00001504-199102000-00021, DOI 10.1097/00001504-199102000-00021]; MELTZER HY, 1989, PSYCHOPHARMACOLOGY, V99, pS68, DOI 10.1007/BF00442563; MIYAUCHI T, 1990, BIOL PSYCHIAT, V28, P488, DOI 10.1016/0006-3223(90)90482-H; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MURPHY GE, 1980, ARCH GEN PSYCHIAT, V37, P519; Nasrallah HA, 1989, ANN CLIN PSYCHIATRY, V1, P51; NELSON JC, 1991, ARCH GEN PSYCHIAT, V48, P303; NURNBERGER JI, 1988, NEUROPSYCHOPHARMACOL, V1, P217, DOI 10.1016/0893-133X(88)90020-6; OKUMA T, 1989, ACTA PSYCHIAT SCAND, V80, P250, DOI 10.1111/j.1600-0447.1989.tb01334.x; OST LG, 1985, BEHAV RES THER, V23, P27, DOI 10.1016/0005-7967(85)90139-1; PAULS DL, 1986, NEW ENGL J MED, V315, P993, DOI 10.1056/NEJM198610163151604; PEREZSTABLE EJ, 1990, ARCH INTERN MED, V150, P1083, DOI 10.1001/archinte.150.5.1083; PEROUTKA SJ, 1980, AM J PSYCHIAT, V137, P1518; PERT CB, 1988, SCHIZOPHRENIA BULL, V14, P243, DOI 10.1093/schbul/14.2.243; PETIT M, 1987, BRIT J PSYCHIAT, V150, P270, DOI 10.1192/bjp.150.2.270a; PHILLIPS DP, 1986, NEW ENGL J MED, V315, P685, DOI 10.1056/NEJM198609113151106; Pickar D, 1990, Mod Probl Pharmacopsychiatry, V24, P124; PICKAR D, 1992, ARCH GEN PSYCHIAT, V49, P345; PICKAR D, 1988, SCHIZOPHRENIA BULL, V14, P255, DOI 10.1093/schbul/14.2.255; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; REGIER DA, 1978, ARCH GEN PSYCHIAT, V35, P685; REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934; REGIER DA, 1989, COMPREHENSIVE TXB PS, V1, P308; RICH CL, 1986, ARCH GEN PSYCHIAT, V43, P577; RIFKIN A, 1987, PSYCHOPHARMACOLOGY 3, P1095; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; ROSIE JS, 1987, HOSP COMMUNITY PSYCH, V38, P1291; SHAFFER D, 1988, J CLIN PSYCHIAT, V49, P36; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SHARFSTEIN SS, 1990, AM J PSYCHIAT, V147, P965; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SHERRINGTON R, 1988, NATURE, V336, P164, DOI 10.1038/336164a0; SIRIS SG, 1987, ARCH GEN PSYCHIAT, V44, P533; SITARAM N, 1987, J PSYCHIAT RES, V21, P487, DOI 10.1016/0022-3956(87)90097-5; SPIEGEL D, 1984, PSYCHIAT CLIN N AM, V7, P101; STCLAIR D, 1989, NATURE, V339, P305; STROUL BA, 1988, HOSP COMMUNITY PSYCH, V39, P1095; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; TISCHLER GL, 1990, AM J PSYCHIAT, V147, P967; Vaillant G.E., 1995, WISDOM EGO; VOLAVKA J, 1992, ARCH GEN PSYCHIAT, V49, P354; WEINBERGER DR, 1988, ARCH GEN PSYCHIAT, V45, P609; WEISSMAN MM, 1988, AM J PSYCHIAT, V145, P815; WEISSMAN MM, 1989, NEW ENGL J MED, V321, P1209, DOI 10.1056/NEJM198911023211801; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WESTERMEYER JF, 1988, HDB SCHIZOPHRENIA, V3, P205; WILK RJ, 1988, AM J ORTHOPSYCHIAT, V58, P580, DOI 10.1111/j.1939-0025.1988.tb01622.x; WOLKOWITZ OM, 1988, ARCH GEN PSYCHIAT, V45, P664; [No title captured]	155	52	53	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					552	560		10.1056/NEJM199308193290808	http://dx.doi.org/10.1056/NEJM199308193290808			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8336756				2022-12-28	WOS:A1993LR89200008
J	DODSON, WE; DELORENZO, RJ; PEDLEY, TA; SHINNAR, S; TREIMAN, DM; WANNAMAKER, BB				DODSON, WE; DELORENZO, RJ; PEDLEY, TA; SHINNAR, S; TREIMAN, DM; WANNAMAKER, BB			TREATMENT OF CONVULSIVE STATUS EPILEPTICUS - RECOMMENDATIONS OF THE EPILEPSY-FOUNDATION-OF-AMERICA WORKING GROUP ON STATUS EPILEPTICUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							1ST UNPROVOKED SEIZURE; INTRAVENOUS PHENYTOIN; FEBRILE SEIZURES; CHILDREN; DIAZEPAM; LORAZEPAM; RECURRENCE; CHILDHOOD; VALPROATE; INFANTS	Convulsive status epilepticus is an emergency that is associated with high morbidity and mortality. The outcome largely depends on etiology, but prompt and appropriate pharmacological therapy can reduce morbidity and mortality. Etiology varies in children and adults and reflects the distribution of disease in these age groups. Antiepileptic drug administration should be initiated whenever a seizure has lasted 10 minutes. Immediate concerns include supporting respiration, maintaining blood pressure, gaining intravenous access, and identifying and treating the underlying cause. Initial therapeutic and diagnostic measures are conducted simultaneously. The goal of therapy is rapid termination of clinical and electrical seizure activity; the longer a seizure continues, the greater the likelihood of an adverse outcome. Several drug protocols now in use will terminate status epilepticus. Common to all patients is the need for a clear plan, prompt administration of appropriate drugs in adequate doses, and attention to the possibility of apnea, hypoventilation, or other metabolic abnormalities.			DODSON, WE (corresponding author), EPILEPSY FDN AMER,4351 GARDEN CITY DR,LANDOVER,MD 20785, USA.							AICARDI J, 1970, EPILEPSIA, V11, P187, DOI 10.1111/j.1528-1157.1970.tb03880.x; AMINOFF MJ, 1980, AM J MED, V69, P657, DOI 10.1016/0002-9343(80)90415-5; ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; [Anonymous], 1981, EPILEPSIA, V22, P489; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; CARTER CH, 1958, ARCH NEURO PSYCHIATR, V79, P136, DOI 10.1001/archneurpsyc.1958.02340020016003; CRANFORD RE, 1978, NEUROLOGY, V28, P874, DOI 10.1212/WNL.28.9.874; CRANFORD RE, 1979, NEUROLOGY, V29, P1474, DOI 10.1212/WNL.29.11.1474; CURLESS RG, 1983, ARCH NEUROL-CHICAGO, V40, P477, DOI 10.1001/archneur.1983.04210070017006; DELORENZO RJ, 1992, EPILEPSIA, V33, pS15; DODRILL CB, 1990, NEUROLOGY, V40, P23; DRISCOLL S M, 1990, Neurology, V40, P297; DULAC O, 1978, J PEDIATR-US, V93, P1039, DOI 10.1016/S0022-3476(78)81254-2; DUNDEE JW, 1979, BRIT J ANAESTH, V51, P439, DOI 10.1093/bja/51.5.439; DUNN DW, 1988, J CHILD NEUROL, V3, P167, DOI 10.1177/088307388800300303; ELLENBERG JH, 1978, ARCH NEUROL-CHICAGO, V35, P17, DOI 10.1001/archneur.1978.00500250021004; GASTAUT H, 1970, EPILEPSIA, V11, P102, DOI 10.1111/j.1528-1157.1970.tb03871.x; GEORGE KA, 1977, BRIT J CLIN PHARMACO, V4, P45, DOI 10.1111/j.1365-2125.1977.tb00665.x; GIACOIA GP, 1984, J PEDIATR-US, V104, P291; Hauser W, 1990, EPILEPSY FREQUENCY C; HAUSER WA, 1990, NEUROLOGY, V40, P9; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; LEPPIK IE, 1983, JAMA-J AM MED ASSOC, V249, P1452, DOI 10.1001/jama.249.11.1452; LOTHMAN E, 1990, NEUROLOGY, V40, P13; MAYTAL J, 1989, PEDIATRICS, V83, P323; MAYTAL J, 1990, PEDIATRICS, V86, P611; MCWILLIAM PKA, 1958, LANCET, V2, P1147; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V28, P1; NELSON KB, 1978, PEDIATRICS, V61, P720; ROWAN AJ, 1970, ACTA NEUROL SCAND, V46, P573, DOI 10.1111/j.1600-0404.1970.tb05814.x; SHANER DM, 1988, NEUROLOGY, V38, P202, DOI 10.1212/WNL.38.2.202; SHINNAR S, 1992, ANN NEUROL, V31, P598, DOI 10.1002/ana.410310606; SHINNAR S, 1990, PEDIATRICS, V85, P1076; SIMON R, 1985, RECENT ADV EPILEPSY, V2, P137; SIMON RP, 1985, EPILEPSIA, V26, pS58, DOI 10.1111/j.1528-1157.1985.tb05725.x; SNEAD OC, 1985, J PEDIATR-US, V106, P323; THORPY MJ, 1980, NEUROLOGY, V30, P1113, DOI 10.1212/WNL.30.10.1113; TOWNE A R, 1990, Neurology, V40, P299; Treiman D M, 1983, Adv Neurol, V34, P377; TREIMAN D M, 1991, Epilepsia, V32, P93; TREIMAN DM, 1990, NEUROLOGY, V40, P32; TREIMAN DM, 1989, EPILEPSIA, V30, pS4, DOI 10.1111/j.1528-1157.1989.tb05824.x; TREIMAN DM, 1993, TXB EPILEPSY, P205; TREIMAN DM, 1980, CRITICAL CARE NEUROL, P53; TREIMAN DM, 1990, EPILEPSY CURRENT APP, P155; TREIMAN DM, 1987, CURRENT THERAPY NEUR, P38; VANDONSELAAR CA, 1992, ARCH NEUROL-CHICAGO, V49, P231, DOI 10.1001/archneur.1992.00530270045017; WALLIS W, 1968, NEUROLOGY, V18, P513, DOI 10.1212/WNL.18.6.513; WALTON NY, 1988, EXP NEUROL, V101, P267, DOI 10.1016/0014-4886(88)90010-6; WALTON NY, 1990, NEUROLOGY, V40, P990, DOI 10.1212/WNL.40.6.990; WILDER BJ, 1977, ANN NEUROL, V1, P511, DOI 10.1002/ana.410010602; 1980, FEBRILE SEIZURES CON, V3	52	441	444	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					854	859						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340986				2022-12-28	WOS:A1993LR61200032
J	MERMEL, LA; MAKI, DG				MERMEL, LA; MAKI, DG			DETECTION OF BACTEREMIA IN ADULTS - CONSEQUENCES OF CULTURING AN INADEQUATE VOLUME OF BLOOD	ANNALS OF INTERNAL MEDICINE			English	Article						BACTEREMIA; BACTERIOLOGICAL TECHNIQUES; CELLS, CULTURED; SENSITIVITY AND SPECIFICITY; QUALITY ASSURANCE, HEALTH; CARE	LYSIS-CENTRIFUGATION; CLINICAL-EVALUATION; FUNGEMIA; SYSTEM; MEDIA; YIELD; PLUS	The yield of blood cultures depends on the volume of blood cultured. We recently discovered that 15% of blood-culture specimens from adults in our hospital were being collected in 3.5-mL pediatric tubes and that another 5%, drawn in 10-mL adult tubes, contained less than 5 mL of blood. A comparison of 829 matched pairs of standard-volume (mean, 8.7 mL) and low-volume (mean, 2.7 mL) blood cultures showed that standard-volume cultures had a substantially higher detection rate for bloodstream infection than did low-volume cultures (92% compared with 69%; difference, 23% [95% CI, 9% to 37%]; P < 0.001). Our data, together with an analysis of previous studies, show that the yield of blood cultures in adults increases approximately 3% per millilitre of blood cultured. A survey of 158 U.S. clinical microbiology laboratory directors in the American Society of Clinical Pathologists showed that only 20% of 71 responding laboratories record the volume of blood submitted for culture and that the practice of culturing suboptimal volumes of blood from adults is widespread. Clinical laboratories should routinely monitor the volume of blood cultured as a quality-assurance measure. Blood-culture specimens from adults should not be drawn using small pediatric tubes.	UNIV WISCONSIN HOSP & CLIN, MADISON, WI USA	University of Wisconsin System; University of Wisconsin Madison			Mermel, Leonard/Z-1475-2019					ARONSON MD, 1987, ANN INTERN MED, V106, P246, DOI 10.7326/0003-4819-106-2-246; ARPI M, 1989, EUR J CLIN MICROBIOL, V8, P838, DOI 10.1007/BF02185857; BRANNON P, 1985, J CLIN MICROBIOL, V22, P951, DOI 10.1128/JCM.22.6.951-954.1985; BROWN DFJ, 1990, J CLIN PATHOL, V43, P777, DOI 10.1136/jcp.43.9.777; BRYAN CS, 1986, AM J EPIDEMIOL, V123, P113, DOI 10.1093/oxfordjournals.aje.a114205; DORN GL, 1976, J CLIN MICROBIOL, V3, P258; HALL MM, 1976, J CLIN MICROBIOL, V3, P643; HENRY NK, 1983, J CLIN MICROBIOL, V17, P864, DOI 10.1128/JCM.17.5.864-869.1983; ILSTRUP DM, 1983, DIAGN MICR INFEC DIS, V1, P107, DOI 10.1016/0732-8893(83)90039-1; ISENBERG HD, 1985, MANUAL CLIN MICROBIO, P73; KELLOGG JA, 1984, J CLIN MICROBIOL, V20, P618, DOI 10.1128/JCM.20.4.618-623.1984; KOONTZ FP, 1991, DIAGN MICR INFEC DIS, V14, P111, DOI 10.1016/0732-8893(91)90044-G; LO P, 1991, 30TH INT C ANT AG CH; PLORDE JJ, 1985, J CLIN MICROBIOL, V22, P292, DOI 10.1128/JCM.22.2.292-295.1985; RELLER LB, 1982, CUMULATIVE TECHNIQUE, P1; SALVENTI JF, 1979, J CLIN MICROBIOL, V9, P248; SANDVEN P, 1981, ACTA PATH MICRO IM B, V89, P149; SHANSON DC, 1984, J CLIN PATHOL, V37, P568, DOI 10.1136/jcp.37.5.568; STRAND CL, 1988, BLOODSTREAM INFECTIO, P7; TARRAND JJ, 1991, J CLIN MICROBIOL, V29, P2245, DOI 10.1128/JCM.29.10.2245-2249.1991; TELENTI A, 1991, MAYO CLIN PROC, V66, P1120, DOI 10.1016/S0025-6196(12)65791-7; TENNEY JH, 1982, J CLIN MICROBIOL, V15, P558, DOI 10.1128/JCM.15.4.558-561.1982; WASHINGTON JA, 1986, REV INFECT DIS, V8, P792; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54; WICHER K, 1984, J CLIN MICROBIOL, V20, P668, DOI 10.1128/JCM.20.4.668-671.1984; 1990, HOSPITAL INFECT  AUG, P1; 1990, MMWR, V39, P31	27	173	187	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					270	272		10.7326/0003-4819-119-4-199308150-00003	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00003			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328734				2022-12-28	WOS:A1993LV52500003
J	HANDEL, TM; WILLIAMS, SA; DEGRADO, WF				HANDEL, TM; WILLIAMS, SA; DEGRADO, WF			METAL-ION DEPENDENT MODULATION OF THE DYNAMICS OF A DESIGNED PROTEIN	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 4-HELIX BUNDLE PROTEIN; MOLTEN GLOBULE STATE; FOLDING INTERMEDIATE; STRUCTURAL CHARACTERIZATION; SECONDARY STRUCTURE; HYDROGEN-EXCHANGE; ALPHA-LACTALBUMIN; DENOVO DESIGN; CYTOCHROME-C	The peptide a 4 is a designed four-helix bundle that contains a highly simplified hydrophobic core composed exclusively of leucine residues; its tertiary structure is therefore largely dictated by hydrophobic forces. This small protein adopts a structure with properties intermediate between those of the native and molten globule states of proteins: it is compact, globular, and has very stable helices, but its apolar side chains are mobile and not as well packed as in many natural proteins. To induce a more native-like state, two Zn2+-binding sites were introduced into the protein, thereby replacing some of the nonspecific hydrophobic interactions with more geometrically restrictive metal-ligand interactions. In the metal-bound state, this protein has properties that approach those of native proteins. Thus, hydrophobic interactions alone are sufficient to drive polypeptide chain folding nearly to completion, but specific interactions are required for a unique structure.	UNIV PENN,REG LASER & BIOTECHNOL LAB,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOCHEM & BIOPHYS,JOHNSON RES FDN,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	HANDEL, TM (corresponding author), DUPONT MERCK PHARMACEUT CO,POB 80328,WILMINGTON,DE 19880, USA.		Williams, Scott/AAG-7029-2020					AKKE M, 1991, J MOL BIOL, V220, P173, DOI 10.1016/0022-2836(91)90389-N; AKKE M, 1992, BIOCHEMISTRY-US, V31, P1011, DOI 10.1021/bi00119a009; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BALDWIN R L, 1991, Current Biology, V1, P218, DOI 10.1016/0960-9822(91)90061-Z; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHEN BL, 1989, BIOCHEMISTRY-US, V28, P685, DOI 10.1021/bi00428a041; DEGRADO WF, 1987, COLD SPRING HARB SYM, V52, P521, DOI 10.1101/SQB.1987.052.01.059; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; GODZIK A, IN PRESS P NATL ACAD; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HO SP, 1987, J AM CHEM SOC, V109, P6751, DOI 10.1021/ja00256a032; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7609, DOI 10.1021/bi00244a033; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; MATOUSCHEK A, 1992, J MOL BIOL, V224, P837, DOI 10.1016/0022-2836(92)90565-2; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MICHAEL SF, 1992, P NATL ACAD SCI USA, V89, P4796, DOI 10.1073/pnas.89.11.4796; MORII H, 1991, PROTEINS, V11, P133, DOI 10.1002/prot.340110206; MULQUEEN PM, 1982, ARCH BIOCHEM BIOPHYS, V215, P28, DOI 10.1016/0003-9861(82)90275-2; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSTERHOUT JJ, 1992, J AM CHEM SOC, V114, P331, DOI 10.1021/ja00027a043; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RALEIGH DP, 1992, J AM CHEM SOC, V114, P10079, DOI 10.1021/ja00051a061; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; REGAN L, 1988, SCIENCE, V241, P76; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; STEINER RF, 1984, BIOPOLYMERS, V22, P1121; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; Wuthrich K., 1986, NMR PROTEINS NUCL AC	52	268	274	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					879	885		10.1126/science.8346440	http://dx.doi.org/10.1126/science.8346440			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346440				2022-12-28	WOS:A1993LR89700028
J	ALPER, J				ALPER, J			ECHO-PLANAR MRI - LEARNING TO READ MINDS	SCIENCE			English	Editorial Material																		COHEN MS, 1992, MAGNETIC RESONANCE, V26; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560	3	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					556	556		10.1126/science.8342018	http://dx.doi.org/10.1126/science.8342018			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP728	8342018				2022-12-28	WOS:A1993LP72800026
J	MAHMOUD, HH; RIVERA, GK; HANCOCK, ML; KRANCE, RA; KUN, LE; BEHM, FG; RIBEIRO, RC; SANDLUND, JT; CRIST, WM; PUI, CH				MAHMOUD, HH; RIVERA, GK; HANCOCK, ML; KRANCE, RA; KUN, LE; BEHM, FG; RIBEIRO, RC; SANDLUND, JT; CRIST, WM; PUI, CH			LOW LEUKOCYTE COUNTS WITH BLAST CELLS IN CEREBROSPINAL-FLUID OF CHILDREN WITH NEWLY-DIAGNOSED ACUTE LYMPHOBLASTIC-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CENTRAL NERVOUS-SYSTEM; CANCER STUDY-GROUP; INTRATHECAL METHOTREXATE; CRANIAL IRRADIATION; CHILDHOOD LEUKEMIA; CNS PROPHYLAXIS; DOSAGE REGIMEN; THERAPY; RELAPSE; CHEMOTHERAPY	Background. Treatment of the central nervous system is crucial to the successful treatment of acute lymphoblastic leukemia in children. The intensity and timing of the therapy are based on the presence or predicted risk of central nervous system leukemia as assessed according to criteria that remain controversial. Methods. The clinical importance of leukemic blast cells detected in cerebrospinal fluid at the time of diagnosis was evaluated in 351 children with acute lymphoblastic leukemia in a randomized trial of intensive chemotherapy. All patients received intrathecal chemotherapy during the first year. Patients considered to be at high risk of relapse because of their clinical and cytogenetic features also received cranial irradiation and intrathecal chemotherapy one year after remission. Patients were considered to have central nervous system leukemia at diagnosis if they had at least 5 leukocytes per microliter of cerebrospinal fluid, with leukemic blast cells apparent in cytocentrifuged preparations, or cranial-nerve palsy; they received additional intrathecal injections of chemotherapeutic agents and cranial irradiation. Patients were retrospectively classified on the basis of cerebrospinal fluid findings: 291 patients had no detectable blast cells, 42 had fewer than 5 leukocytes per microliter and blast cells, and 18 had central nervous system leukemia as defined above. The clinical characteristics and outcomes of treatment in these groups were analyzed. Results. The five-year probability of survival free of relapses confined to the central nervous system in patients with detectable blast cells and fewer than 5 leukocytes per microliter of cerebrospinal fluid was lower than in patients without blast cells (mean [+/-SE], 87+/-13 vs. 96+/-2 percent), but was not different from the probability in patients with central nervous system leukemia at diagnosis. All such isolated relapses of leukemia in patients with detectable blast cells occurred during the first year of treatment, before scheduled cranial irradiation. In a multivariate analysis, the presence of cerebrospinal fluid blast cells with fewer than 5 leukocytes per microliter was independently related to the risk of relapse confined to the central nervous system. Conclusions. Patients with leukemic blast cells in their cerebrospinal fluid are at increased risk for central nervous system relapse when cranial irradiation is delayed. Such patients require intensified central nervous system treatment early in the course of therapy.	ST JUDE CHILDRENS RES HOSP, DEPT RADIAT ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PHYSIOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	MAHMOUD, HH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 332 N LAUDERDALE, MEMPHIS, TN 38101 USA.		Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NCI NIH HHS [CA-20180, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA020180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABROMOWITCH M, 1985, P AN M AM SOC CLIN, V4, P174; AUR RJA, 1973, BLOOD, V42, P349, DOI 10.1182/blood.V42.3.349.349; BAEHNER RL, 1973, NEW ENGL J MED, V289, P1209, DOI 10.1056/NEJM197312062892301; BEHRENDT H, 1989, CANCER, V63, P2066, DOI 10.1002/1097-0142(19890515)63:10<2066::AID-CNCR2820631032>3.0.CO;2-I; BLEYER WA, 1988, PEDIATR CLIN N AM, V35, P789; BLEYER WA, 1985, SEMIN ONCOL, V12, P131; BLEYER WA, 1977, CANCER TREAT REP, V61, P1419; BLEYER WA, 1983, J CLIN ONCOL, V1, P317, DOI 10.1200/JCO.1983.1.5.317; BRUNDEN MN, 1972, BIOMETRICS, V28, P603, DOI 10.2307/2556175; Buhrer C, 1990, Haematol Blood Transfus, V33, P500; CHESSELLS JM, 1992, LEUKEMIA, V6, P157; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; GAYNON P, 1989, P AN M AM SOC CLIN, V8, P212; GEORGE SL, 1985, J CLIN ONCOL, V3, P776, DOI 10.1200/JCO.1985.3.6.776; GILCHRIST G, 1990, P AN M AM SOC CLIN, V9, P217; INATI A, 1983, BLOOD, V61, P297; LITTMAN P, 1987, INT J RADIAT ONCOL, V13, P1443, DOI 10.1016/0360-3016(87)90308-7; MASTRANGELO R, 1986, MED PEDIATR ONCOL, V14, P191, DOI 10.1002/mpo.2950140317; NESBIT ME, 1981, LANCET, V1, P322; NESBIT ME, 1981, LANCET, V1, P461; OCHS JJ, 1985, J CLIN ONCOL, V3, P622, DOI 10.1200/JCO.1985.3.5.622; OCHS JJ, 1989, AM J PEDIAT HEMATOL, V11, P93; OLIFF A, 1978, LANCET, V2, P13; ORTEGA JA, 1987, J CLIN ONCOL, V5, P1646, DOI 10.1200/JCO.1987.5.10.1646; PACKER RJ, 1987, MED PEDIATR ONCOL, V15, P241, DOI 10.1002/mpo.2950150505; PINKERTON CR, 1984, BRIT J HAEMATOL, V57, P553, DOI 10.1111/j.1365-2141.1984.tb08544.x; POPLACK DG, 1989, P AN M AM SOC CLIN, V8, P213; Riehm H, 1990, Haematol Blood Transfus, V33, P439; RIVERA GK, 1986, MED PEDIATR ONCOL, V14, P177, DOI 10.1002/mpo.2950140313; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; ROWLAND JH, 1984, J CLIN ONCOL, V2, P1327, DOI 10.1200/JCO.1984.2.12.1327; Steinherz P G, 1989, Oncology (Williston Park), V3, P47; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P520, DOI 10.1200/JCO.1993.11.3.520	33	158	169	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					314	319		10.1056/NEJM199307293290504	http://dx.doi.org/10.1056/NEJM199307293290504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8321259				2022-12-28	WOS:A1993LN62100004
J	SOLESSIO, E; ENGBRETSON, GA				SOLESSIO, E; ENGBRETSON, GA			ANTAGONISTIC CHROMATIC MECHANISMS IN PHOTORECEPTORS OF THE PARIETAL EYE OF LIZARDS	NATURE			English	Article							PINEAL ORGAN; CELLS	PHOTORECEPTORS are the first in the chain of neurons that process visual information. In lateral eyes of vertebrates, light hyperpolarizes rod and cone photoreceptors that synapse onto bipolar and horizontal cells in the first synaptic layer of the retina. The sign of the photoreceptor signal is either conserved or inverted in bipolar cells, resulting in chromatically dependent depolarizing and hyperpolarizing responses to visual stimuli. Visual information is then conveyed to the second synaptic layer for encoding and transmission to the brain by ganglion cells. The parietal (third) eve of lizards does not contain bipolar cells or other interneurons. Photoreceptors synapse directly onto ganglion cells1-4 and yet, even in the absence of interneurons, antagonistic chromatic mechanisms modulate the ganglion cell responses5,6. We report here that chromatic antagonism in the third eye originates in the chromatically dependent hyperpolarizing and depolarizing response of the photoreceptors to light. We also suggest that the antagonistic nature of these photoresponses may provide lizards with a mechanism for the enhanced detection of dawn and dusk.	SYRACUSE UNIV,DEPT BIOENGN & NEUROSCI,SYRACUSE,NY 13244	Syracuse University	SOLESSIO, E (corresponding author), SYRACUSE UNIV,INST SENSORY RES,SYRACUSE,NY 13244, USA.							AHMED J, IN PRESS VISION RES; BAYLOR DA, 1970, J PHYSIOL-LONDON, V207, P77, DOI 10.1113/jphysiol.1970.sp009049; DODT E, 1968, VISION RES, V8, P61, DOI 10.1016/0042-6989(68)90064-3; DODT E, 1973, HDB SENSORY PHYSL, P113; EAKIN RM, 1973, 3 EYE; EKSTROM P, 1988, NEUROSCIENCE, V25, P1061, DOI 10.1016/0306-4522(88)90059-0; ELDRED WD, 1978, VISION RES, V18, P29, DOI 10.1016/0042-6989(78)90073-1; ENGBRETSON GA, 1981, J COMP NEUROL, V198, P155, DOI 10.1002/cne.901980113; ENGBRETSON GA, 1990, VISUAL NEUROSCI, V5, P395, DOI 10.1017/S0952523800000481; HAMASAKI DI, 1969, PFLUG ARCH EUR J PHY, V313, P19, DOI 10.1007/BF00586325; HAMDORF K, 1979, BIOPHYS STRUCT MECH, V5, P137, DOI 10.1007/BF00535444; JENISON GL, 1979, BRAIN RES, V168, P615, DOI 10.1016/0006-8993(79)90315-9; KORF HW, 1981, CELL TISSUE RES, V219, P567; MILLER WH, 1962, SCIENCE, V135, P316, DOI 10.1126/science.135.3500.316; MINKE B, 1973, J GEN PHYSIOL, V62, P87, DOI 10.1085/jgp.62.1.87; NOLTE J, 1972, J GEN PHYSIOL, V59, P186, DOI 10.1085/jgp.59.2.186; PETIT A, 1968, Z ZELLFORSCH MIK ANA, V92, P70, DOI 10.1007/BF00339404; PORTER WP, 1989, SOLRAD SINE CLEAR SK; PU GA, 1981, J NEUROPHYSIOL, V46, P1018, DOI 10.1152/jn.1981.46.5.1018; TABATA M, 1975, VISION RES, V15, P737, DOI 10.1016/0042-6989(75)90293-X; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	21	94	96	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					442	445		10.1038/364442a0	http://dx.doi.org/10.1038/364442a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332214				2022-12-28	WOS:A1993LP64000054
J	OMICHINSKI, JG; CLORE, GM; SCHAAD, O; FELSENFELD, G; TRAINOR, C; APPELLA, E; STAHL, SJ; GRONENBORN, AM				OMICHINSKI, JG; CLORE, GM; SCHAAD, O; FELSENFELD, G; TRAINOR, C; APPELLA, E; STAHL, SJ; GRONENBORN, AM			NMR STRUCTURE OF A SPECIFIC DNA COMPLEX OF ZN-CONTAINING DNA-BINDING DOMAIN OF GATA-1	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ERYTHROID TRANSCRIPTION FACTOR; RESTRAINED MOLECULAR-DYNAMICS; PUTATIVE ZINC FINGER; OVERHAUSER ENHANCEMENT MEASUREMENTS; 3-DIMENSIONAL SOLUTION STRUCTURE; INTERPROTON DISTANCE RESTRAINTS; NITROGEN REGULATORY GENE; DOUBLE-HELICAL FRAGMENTS; CRYSTAL-STRUCTURE	The three-dimensional solution structure of a complex between the DNA binding domain of the chicken erythroid transcription factor GATA-1 and its cognate DNA site has been determined with multidimensional heteronuclear magnetic resonance spectroscopy. The DNA binding domain consists of a core which contains a zinc coordinated by four cysteines and alpha carboxyl-terminal tail. The core is composed of two irregular antiparallel beta sheets and an ot helix, followed by a long loop that leads into the carboxyl-terminal tail. The amino-terminal part of the core, including the helix, is similar in structure, although not in sequence, to the amino-terminal zinc module of the glucocorticoid receptor DNA binding domain. In the other regions, the structures of these two DNA binding domains are entirely different. The DNA target site in contact with the protein spans eight base pairs. The helix and the loop connecting the two antiparallel beta sheets interact with the major groove of the DNA. The carboxyl-terminal tail, which is an essential determinant of specific binding, wraps around into the minor groove. The complex resembles a hand holding a rope with the palm and fingers representing the protein core and the thumb, the carboxyl-terminal tail. The specific interactions between GATA-1 and DNA in the major groove are mainly hydrophobic in nature, which accounts for the preponderance of thymines in the target site. A large number of interactions are observed with the phosphate backbone.	NIDDKD, CHEM PHYS LAB, BLDG 5, BETHESDA, MD 20892 USA; NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA; NIH, OFF DIRECTOR, PROT EXPRESS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA			Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; ARNOTT S, 1982, COLD SPRING HARB SYM, V47, P53, DOI 10.1101/SQB.1983.047.01.008; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1992, IN PRESS J AM CHEM S, V114, P6924; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A.T, 1993, XPLOR VERSION 31 SYS; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; CLORE GM, 1983, EMBO J, V2, P2109, DOI 10.1002/j.1460-2075.1983.tb01710.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; CLORE GM, IN PRESS METHODS ENZ; CLORE GM, UNPUB; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; DECASTRO E, 1992, VISP 1 0 USERS GUIDE; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; DICKERSON RE, 1991, COLD SPRING HARB SYM, V30, P1254; DIEKMANN S, 1989, J MOL BIOL, V205, P787, DOI 10.1016/0022-2836(89)90324-0; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; GRONENBORN AM, 1989, BIOCHEMISTRY-US, V28, P5978, DOI 10.1021/bi00440a039; GRONENBORN AM, 1985, PROG NUCL MAG RES SP, V17, P1, DOI 10.1016/0079-6565(85)80004-2; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JONES TA, 1990, O VERSION 5 MANUAL; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLEY C, IN PRESS DEVELOPMENT; KIM JG, 1992, MOL CELL BIOL, V12, P5632, DOI 10.1128/MCB.12.12.5632; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; MINIE M, 1992, J CELL SCI, P15; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILSSON L, 1986, J COMPUT CHEM, V7, P591, DOI 10.1002/jcc.540070502; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1992, BIOCHEMISTRY-US, V31, P3907, DOI 10.1021/bi00131a004; ORKIN SH, 1992, BLOOD, V80, P575; PATEL DJ, 1987, ANNU REV BIOPHYS BIO, V16, P423; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; POWERS R, IN PRESS BIOCHEMISTR; REID BR, 1987, Q REV BIOPHYS, V20, P1, DOI 10.1017/S0033583500004212; REIHER WE, 1985, THESIS HARVARD U CAM; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; ROSENBERG JM, 1976, J MOL BIOL, V104, P145, DOI 10.1016/0022-2836(76)90006-1; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7306; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCHEEK RM, 1983, J AM CHEM SOC, V105, P2914, DOI 10.1021/ja00347a075; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SEEMAN NC, 1976, J MOL BIOL, V104, P109, DOI 10.1016/0022-2836(76)90005-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VONKITZING E, 1987, EUR BIOPHYS J BIOPHY, V15, P13, DOI 10.1007/BF00255031; VUISTER GW, INPRESS METHODS ENZY; VUISTER GW, IN PRESS J AM CHEM S; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WEISS MA, 1984, P NATL ACAD SCI-BIOL, V81, P130, DOI 10.1073/pnas.81.1.130; WIDER G, 1990, J AM CHEM SOC, V112, P9015, DOI 10.1021/ja00180a076; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	99	413	421	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1993	261	5120					438	446		10.1126/science.8332909	http://dx.doi.org/10.1126/science.8332909			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332909				2022-12-28	WOS:A1993LN62300027
J	SWACKHAMER, K				SWACKHAMER, K			BELIEVER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					312	312		10.1001/jama.270.3.312	http://dx.doi.org/10.1001/jama.270.3.312			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8315767				2022-12-28	WOS:A1993LM43500011
J	VEGSUNDVAG, J; NORDEIDE, J; REIKVAM, A; JENUM, P				VEGSUNDVAG, J; NORDEIDE, J; REIKVAM, A; JENUM, P			LATE CARDIAC MANIFESTATION OF INFECTION WITH BORRELIA-BURGDORFERI (LYME-DISEASE)	BRITISH MEDICAL JOURNAL			English	Article									CENT HOSP SOGN & FJORDANE,DEPT RHEUMATOL,N-6800 FORDE,NORWAY; NATL INST PUBL HLTH,DEPT BACTERIOL,N-0462 OSLO,NORWAY		VEGSUNDVAG, J (corresponding author), CENT HOSP SOGN & FJORDANE,DEPT MED,CARDIOL SECT,N-6800 FORDE,NORWAY.							HOFSTAD H, 1987, Tidsskrift for den Norske Laegeforening, V107, P3038; STANEK G, 1991, SCAND J INFECT DIS, V77, P85	2	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					173	173		10.1136/bmj.307.6897.173	http://dx.doi.org/10.1136/bmj.307.6897.173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343747	Bronze, Green Published			2022-12-28	WOS:A1993LN18400022
J	MEERAN, K; JACOBS, MG; SCOTT, J; MCNEIL, NI; LYNN, WA; COHEN, J; PUSEY, CD; PHILLIPS, JA; WALLIS, SC; DAVIES, KAA				MEERAN, K; JACOBS, MG; SCOTT, J; MCNEIL, NI; LYNN, WA; COHEN, J; PUSEY, CD; PHILLIPS, JA; WALLIS, SC; DAVIES, KAA			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - CHLOROQUINE POISONING	BRITISH MEDICAL JOURNAL			English	Discussion							DIAZEPAM; HEART				MEERAN, K (corresponding author), EALING GEN HOSP,DEPT MED,EALING UB1 3HW,MIDDX,ENGLAND.							CROUZETTE J, 1983, J TOXICOL-CLIN TOXIC, V20, P271, DOI 10.3109/15563658308990070; Guillon C., 1982, SUICIDE MODE EMPLOI; GUSTAFSSON LL, 1983, BRIT J CLIN PHARMACO, V15, P471, DOI 10.1111/j.1365-2125.1983.tb01532.x; KOUDOGBO B, 1986, J TOXICOL CLIN EXPER, V6, P307; MESTRE M, 1984, LIFE SCI, V35, P953, DOI 10.1016/0024-3205(84)90661-1; MICHAEL TAD, 1970, AM HEART J, V79, P831, DOI 10.1016/0002-8703(70)90371-6; NDRI KD, 1976, AFR MED, V15, P103; RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101; RIOU B, 1988, INTENS CARE MED, V14, P610; Weniger H., 1979, WHO/MAL/79.906	10	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					49	50		10.1136/bmj.307.6895.49	http://dx.doi.org/10.1136/bmj.307.6895.49			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343674	Green Published, Bronze			2022-12-28	WOS:A1993LL36900032
J	NAZARETH, I; KING, M; HAINES, A; RANGEL, L; MYERS, S				NAZARETH, I; KING, M; HAINES, A; RANGEL, L; MYERS, S			ACCURACY OF DIAGNOSIS OF PSYCHOSIS ON GENERAL-PRACTICE COMPUTER-SYSTEM	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine the accuracy of diagnoses of schizophrenia and non-affective psychosis entered by general practitioners on a computer system. To compare recording of clinical events on computer with written records. Design-Examination of case notes of all patients with a computer diagnosis of psychosis. Search of 8000 randomly selected patient records to identify patients with psychosis not recorded on computer and comparison of 141 computer and written entries for prescribing and consultation in each practice. Setting-13 London practices on the VAMP research bank. Main outcome measures-Accuracy of record of psychosis compared with ICD 9, American Psychiatric Association diagnostic manual, and syndrome checklist criteria. Results-Computer search revealed 102 patients with schizophrenia, 78 with other psychoses, and 71 with non-affective psychosis who had adequate case notes. The sensitivity and positive predictive value of the computer diagnosis of schizophrenia were 88% (95% confidence interval 62% to 98%) and 71% (48% to 88%). For all non-organic psychoses sensitivity was 91% (74% to 97%) and positive predictive value was 91% (74% to 98%). On average 95% of all known prescriptions and 74% of all consultations were recorded on computer compared with 42% and 75% in written records. Conclusions-Recording of psychotic illness on the VAMP computer is accurate and complete. Prescribing was more fully recorded on the computer than on the written records. Computer databases of well motivated general practitioners could be used for research.	ROYAL FREE HOSP, SCH MED, ACAD DEPT PSYCHIAT, LONDON NW3 2QG, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	NAZARETH, I (corresponding author), UCL, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY HLTH CARE, LONDON N19 5NF, ENGLAND.		King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171; Haines, Andy/0000-0002-8053-4605; Nazareth, Irwin/0000-0003-2146-9628				FARMER AE, 1992, BRIT J PSYCHIAT, V161, P824, DOI 10.1192/bjp.161.6.824; GRAY DP, 1992, PLANNING PRIMARY CAR; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JOHNSON N, 1991, BRIT MED J, V302, P763, DOI 10.1136/bmj.302.6779.763; MANN RD, 1992, POSTMARKETING SURVEI, V5, P259; MARCUS A, 1988, LANCET, V2, P1242; Perry J, 1971, OXMIS PROBLEM CODE P; PRINGLE M, 1990, BRIT MED J, V301, P827, DOI 10.1136/bmj.301.6756.827; WING JK, 1974, DERIVATION SYNDROMES, P40; 1978, MENTAL DISORDERS GLO; 1987, DIAGNOSTIC STATISTIC; 1992, COMPUTING SURVEY 199; 1991, 1991 HARR HLTH DISTR, P4; 1977, STATISTICAL CLASSIFI, V1; 1977, STATISTICAL CLASSIFI, V2; 1989, COMPUTING SURVEY 198	16	164	164	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					32	34		10.1136/bmj.307.6895.32	http://dx.doi.org/10.1136/bmj.307.6895.32			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL369	8343670	Green Published, Bronze			2022-12-28	WOS:A1993LL36900027
J	TAYLOR, EW				TAYLOR, EW			MOLECULAR MUSCLE	SCIENCE			English	Editorial Material							MYOSIN SUBFRAGMENT-1; ACTIN; MODEL				TAYLOR, EW (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58 ST,CHICAGO,IL 60637, USA.							BOTTS J, 1989, P NATL ACAD SCI USA, V86, P2204, DOI 10.1073/pnas.86.7.2204; FAJER PG, 1990, P NATL ACAD SCI USA, V87, P5538, DOI 10.1073/pnas.87.14.5538; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; HACKNEY DD, 1992, PHILOS T ROY SOC B, V336, P13, DOI 10.1098/rstb.1992.0038; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LOWEY S, 1993, BIOPHYS J, V64, pA7; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SADHU A, 1992, J BIOL CHEM, V267, P11352; SUTOH K, 1989, J MOL BIOL, V206, P357, DOI 10.1016/0022-2836(89)90485-3; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; VALE RD, 1992, TRENDS BIOCHEM SCI, V17, P300, DOI 10.1016/0968-0004(92)90440-K; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537	19	14	14	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					35	36		10.1126/science.8316856	http://dx.doi.org/10.1126/science.8316856			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316856				2022-12-28	WOS:A1993LK43400025
J	ADDINGTONHALL, JM; WEIR, MW; ZOLLMAN, C; MCILLMURRAY, MB				ADDINGTONHALL, JM; WEIR, MW; ZOLLMAN, C; MCILLMURRAY, MB			A NATIONAL SURVEY OF THE PROVISION OF SUPPORT SERVICES FOR PEOPLE WITH CANCER	BRITISH MEDICAL JOURNAL			English	Article									WIRRAL HLTH AUTHOR, WIRRAL, ENGLAND; BRISTOL HOSP SICK CHILDREN, ONCOL UNIT, BRISTOL, ENGLAND; ROYAL LANCASTER INFIRM, LANCASTER, ENGLAND	Bristol Royal Hospital For Children	ADDINGTONHALL, JM (corresponding author), UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND.							Fallowfield L., 1992, PSYCHOL HEALTH, V6, P107; MCILLMURRAY MB, 1986, BRIT MED J, V292, P669, DOI 10.1136/bmj.292.6521.669; SMITH T, 1990, BRIT MED J, V301, P1406, DOI 10.1136/bmj.301.6766.1406; WATSON PG, 1990, CANCER NURS, V13, P2	4	12	12	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1649	1650		10.1136/bmj.306.6893.1649-a	http://dx.doi.org/10.1136/bmj.306.6893.1649-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324434	Bronze, Green Published			2022-12-28	WOS:A1993LJ33700021
J	HOELDTKE, RD; STREETEN, DHP				HOELDTKE, RD; STREETEN, DHP			TREATMENT OF ORTHOSTATIC HYPOTENSION WITH ERYTHROPOIETIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; PLASMA NOREPINEPHRINE; HYPERTENSION; EPINEPHRINE	Background and Methods. Patients with orthostatic hypotension caused by autonomic neuropathy frequently have a decreased red-cell mass. This would be expected to compromise their effective circulating blood volume and aggravate the orthostatic hypotension. We studied the effect of increasing the red-cell mass with erythropoietin, given subcutaneously in a dose of 50 U per kilogram of body weight three times a week for 6 to 10 weeks to eight patients with orthostatic hypotension - four men, one teenage boy, and three women (age range, 17 to 68 years). Four patients had type I diabetes mellitus and autonomic neuropathy, three patients had pure autonomic failure, and one patient had sympathotonic orthostatic hypotension. Seven patients received fludrocortisone (0.1 or 0.2 mg per day) before, during, and after the trial of erythropoietin. The red-cell volume, plasma volume, and hemodynamic response to orthostatic stress were measured before and after therapy. Results. Erythropoietin increased the mean (+/-SD) hematocrit from 0.34+/-0.04 to 0.45+/-0.04 (P<0.005) and increased the red-cell volume from 16.8+/-3.9 to 25.3+/-3.1 ml per kilogram (P<0.005), but had no effect on plasma volume. The systolic blood pressure increased from 81+/-11 to 100+/-24 mm Hg (P<0.01) and the diastolic blood pressure increased from 46+/-10 to 63+/-18 mm Hg (P<0.01) while the patients were standing. The average systolic and diastolic blood pressure while the patients were supine did not increase significantly, although hypertension in the supine position developed in three patients. Orthostatic dizziness improved during treatment in six of the eight patients. Conclusions. In patients with orthostatic hypotension, increasing the red-cell volume with erythropoietin elevates blood pressure while standing. Possible long-term adverse effects are not known.	W VIRGINIA UNIV,DEPT MED,MORGANTOWN,WV 26506; SUNY HLTH SCI CTR,DEPT MED,SYRACUSE,NY	West Virginia University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	HOELDTKE, RD (corresponding author), TEMPLE UNIV,DEPT MED,PHILADELPHIA,PA 19122, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM032239] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG003055, R37AG003055] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00349] Funding Source: Medline; NIADDK NIH HHS [AM-32239] Funding Source: Medline; NIA NIH HHS [AG-03055] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASKIN S, 1990, NEW ENGL J MED, V323, P999; BERSON SA, 1953, J CLIN INVEST, V32, P746, DOI 10.1172/JCI102789; BIAGGIONI I, 1993, J CLIN ENDOCR METAB, V76, P580, DOI 10.1210/jc.76.3.580; BIAGGIONI I, 1991, CLIN RES, V30, P300; CHOBANIAN AV, 1979, NEW ENGL J MED, V301, P68, DOI 10.1056/NEJM197907123010202; CHOKROVERTY S, 1969, BRAIN, V92, P743, DOI 10.1093/brain/92.4.743; EGRIE JC, 1987, J IMMUNOL METHODS, V99, P235, DOI 10.1016/0022-1759(87)90133-5; EWING DJ, 1980, ANN INTERN MED, V92, P308, DOI 10.7326/0003-4819-92-2-308; HEIDENREICH S, 1991, KIDNEY INT, V39, P259, DOI 10.1038/ki.1991.31; HOELDTKE RD, 1989, NEUROLOGY, V39, P34, DOI 10.1212/WNL.39.1.34; HOELDTKE RD, 1991, J CLIN ENDOCR METAB, V73, P132, DOI 10.1210/jcem-73-1-132; HOELDTKE RD, 1992, MUSCLE NERVE, V15, P926, DOI 10.1002/mus.880150810; International Committee for Standardization in Hematology, 1973, British Journal of Haematology, V25, P801, DOI 10.1111/j.1365-2141.1973.tb01792.x; LONDON GM, 1989, KIDNEY INT, V36, P878, DOI 10.1038/ki.1989.274; MARTIN W, 1986, BRIT J PHARMACOL, V89, P563, DOI 10.1111/j.1476-5381.1986.tb11157.x; NUSYNOWITZ ML, 1974, AM J ROENTGENOL, V120, P549, DOI 10.2214/ajr.120.3.549; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; SLATON PE, 1967, J CLIN ENDOCR METAB, V27, P37, DOI 10.1210/jcem-27-1-37; STREETEN DHP, 1990, J CLIN INVEST, V86, P1582, DOI 10.1172/JCI114878; WATSON E, 1981, LIFE SCI, V28, P493, DOI 10.1016/0024-3205(81)90142-9; WILCOX CS, 1983, AUTONOMIC FAILURE TX, P115	21	166	169	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					611	615		10.1056/NEJM199308263290904	http://dx.doi.org/10.1056/NEJM199308263290904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341335	Green Published			2022-12-28	WOS:A1993LU21700004
J	ROSENFIELD, K; ISNER, JM				ROSENFIELD, K; ISNER, JM			ENDOVASCULAR STENTS FOR ILIAC ARTERIAL-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ROSENFIELD, K (corresponding author), ST ELIZABETHS HOSP BOSTON,BOSTON,MA 02135, USA.								0	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					620	620						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341337				2022-12-28	WOS:A1993LU21700006
J	FARMER, RG; GOODMAN, RA; BALDWIN, RJ				FARMER, RG; GOODMAN, RA; BALDWIN, RJ			HEALTH-CARE AND PUBLIC-HEALTH IN THE FORMER SOVIET-UNION, 1992 - UKRAINE - A CASE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							CHERNOBYL; TRANSITION	The dissolution of the Soviet Union created many problems for the health care systems of the New Independent States (NIS). To address these problems, the U.S. Secretary of State convened a coordinating conference in Washington, D.C., on 22-23 January 1992 at which more than 50 nations and organizations were represented. After this conference, an expert medical working group visited 10 republics of the NIS during February and March 1992. Hospitals, public health facilities, and pharmaceutical plants and distribution sites were visited to assess the health care needs of a large population in a vast geographic area. It was concluded that the massive health care system of the Soviet Union remains largely intact but has major economic and supply deficiencies. The assessment process and findings in one republic, Ukraine, are presented. Ukraine was chosen because of its size, location, and representativeness.	CTR DIS CONTROL, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	FARMER, RG (corresponding author), US AGCY INT DEV, BUR EUROPE, ROOM 4720-NS, WASHINGTON, DC 20523 USA.							ALBERT A, 1992, JAMA-J AM MED ASSOC, V267, P2461, DOI 10.1001/jama.267.18.2461; CASSEL CK, 1989, NEW ENGL J MED, V321, P254, DOI 10.1056/NEJM198907273210409; DAVIS AM, 1992, PSR Q, V2, P3; DELAMOTHE T, 1992, BRIT MED J, V304, P1432, DOI 10.1136/bmj.304.6839.1432; ESCOVITZ GH, 1992, ANN INTERN MED, V116, P499, DOI 10.7326/0003-4819-116-6-499; GALE RP, 1987, JAMA-J AM MED ASSOC, V258, P625, DOI 10.1001/jama.258.5.625; GELLERT GA, 1992, NEW ENGL J MED, V326, P1021, DOI 10.1056/NEJM199204093261512; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Ryan Michael, 1978, ORG SOVIET MED CARE; 1992, EPIDEMIOLOGY STATIST; 1992, MMWR, V41, P89; 1992, STATISTICAL ABSTRACT	12	9	9	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					324	328		10.7326/0003-4819-119-4-199308150-00012	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328742				2022-12-28	WOS:A1993LV52500012
J	NELSON, JL; HUGHES, KA; SMITH, AG; NISPEROS, BB; BRANCHAUD, AM; HANSEN, JA				NELSON, JL; HUGHES, KA; SMITH, AG; NISPEROS, BB; BRANCHAUD, AM; HANSEN, JA			MATERNAL-FETAL DISPARITY IN HLA CLASS-II ALLOANTIGENS AND THE PREGNANCY-INDUCED AMELIORATION OF RHEUMATOID-ARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ELUTED GAMMA-GLOBULINS; SUPPRESSOR T-CELLS; ANKYLOSING-SPONDYLITIS; SEQUENCE-ANALYSIS; ANTIBODIES; HLA-DR4; DISEASE; POLYMORPHISM; ASSOCIATION; MOLECULES	Background. Rheumatoid arthritis frequently remits during pregnancy, for unknown reasons. Since an immune response to paternally inherited fetal HLA can occur during normal pregnancy and since rheumatoid arthritis is an autoimmune disorder with a known HLA class II antigen association, we tested the hypothesis that maternal-fetal disparity in HLA alloantigens might be associated with the pregnancy-induced remission of rheumatoid arthritis. Methods. We studied 57 pregnancies of 41 women with rheumatoid arthritis, 18 prospectively and 39 retrospectively. Serologic and DNA techniques were used to study HLA class I and II antigens. For newborns, typing was performed from cord-blood samples obtained at delivery. For four young children, typing was performed from DNA extracted from hair samples. Results. We found significantly more maternal-fetal disparity in HLA-DR and DQ antigens in pregnancies characterized by the remission or improvement of rheumatoid arthritis than in pregnancies characterized by active disease. Further studies using DNA-typing techniques to define allelic variants of HLA-DR and DQ antigens confirmed this observation. Maternal-fetal disparity in alleles of HLA-DRB1, DQA, and DQB occurred in 26 of 34 pregnancies characterized by remission or improvement (76 percent), as compared with 3 of 12 pregnancies characterized by active arthritis (25 percent) (odds ratio, 9.7; P = 0.003). The difference between the two groups was most marked for alleles of HLA-DQA. Conclusions. Amelioration of rheumatoid arthritis during pregnancy is associated with a disparity in HLA class II antigens between mother and fetus. These findings suggest that the maternal immune response to paternal HLA antigens may have a role in the pregnancy-induced remission of rheumatoid arthritis.			NELSON, JL (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, HUMAN IMMUNOGENET PROGRAM, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039153, R29AR039282] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29 AR39282, AR39153] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BIJLSMA JWJ, 1992, AM J REPROD IMMUNOL, V28, P231, DOI 10.1111/j.1600-0897.1992.tb00800.x; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1988, NATURE, V333, P786, DOI 10.1038/333786a0; CALIN A, 1989, ARTHRITIS RHEUM, V32, P1221, DOI 10.1002/anr.1780321006; COMBE B, 1985, AM J MED, V78, P920, DOI 10.1016/0002-9343(85)90213-X; GILBERT M, 1964, JAMA-J AM MED ASSOC, V190, P235; HANSEN JA, 1990, CRIT REV IMMUNOL, V10, P307; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Hench P.S., 1938, P STAFF M MAYO CLIN, V13, P161; LOKE YW, 1991, CURR OPIN IMMUNOL, V3, P762, DOI 10.1016/0952-7915(91)90110-M; Miller R.G., 1981, SIMULTANEOUS STAT IN, Ved 2nd, DOI DOI 10.1007/s11263-015-0816-y; MOREL C, 1990, HUM IMMUNOL, V29, P64, DOI 10.1016/0198-8859(90)90070-6; MORINPAPUNEN L, 1984, MED BIOL, V62, P323; MOYNIER M, 1987, ARTHRITIS RHEUM, V30, P375, DOI 10.1002/art.1780300403; NEELY NT, 1977, TEX MED, V73, P59; NELSON JL, 1991, CRIT REV IMMUNOL, V10, P454; NISHIMURA Y, 1983, NATURE, V302, P67, DOI 10.1038/302067a0; OKA M, 1958, Acta Rheumatol Scand, V4, P243; OSTENSEN M, 1983, ARTHRITIS RHEUM, V26, P1155, DOI 10.1002/art.1780260915; OSTENSEN M, 1983, SCAND J RHEUMATOL, V12, P315, DOI 10.3109/03009748309098556; OTTENHOFF THM, 1986, NATURE, V322, P462, DOI 10.1038/322462a0; PAYNE R, 1957, ARCH INTERN MED, V99, P587, DOI 10.1001/archinte.1957.00260040087010; Persellin R H, 1976, Bull Rheum Dis, V27, P922; PERSELLIN R H, 1982, Arthritis and Rheumatism, V25, pS6; PETERSDORF EW, 1991, IMMUNOGENETICS, V33, P267; PETERSDORF EW, 1991, TISSUE ANTIGENS, V38, P169, DOI 10.1111/j.1399-0039.1991.tb01891.x; PINALS RS, 1981, ARTHRITIS RHEUM, V24, P1308, DOI 10.1002/art.1780241012; Ray JG., 1977, DHEW PUBLICATION; REDMAN CWG, 1987, IMMUNOREGULATION FET, P210; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SALGAME P, 1991, P NATL ACAD SCI USA, V88, P2598, DOI 10.1073/pnas.88.6.2598; SANY J, 1982, ARTHRITIS RHEUM, V25, P17, DOI 10.1002/art.1780250103; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; SUCIUFOCA N, 1983, P NATL ACAD SCI-BIOL, V80, P830, DOI 10.1073/pnas.80.3.830; VANZEBEN D, 1991, ARTHRITIS RHEUM, V34, P822, DOI 10.1002/art.1780340707; VONBEROLDINGEN CH, 1989, PCR TECHNOLOGY PRINC, P20; WALDOR MK, 1983, P NATL ACAD SCI-BIOL, V80, P2713, DOI 10.1073/pnas.80.9.2713; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WINCHESTER R, 1992, RHEUM DIS CLIN N AM, V18, P761; WOLFSON W Q, 1951, J Mich State Med Soc, V50, P1019; WOOLEY PH, 1985, J IMMUNOL, V134, P2366; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	44	241	257	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					466	471		10.1056/NEJM199308123290704	http://dx.doi.org/10.1056/NEJM199308123290704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	8332151				2022-12-28	WOS:A1993LR44300004
J	YIP, R; SHARP, TW				YIP, R; SHARP, TW			ACUTE MALNUTRITION AND HIGH CHILDHOOD MORTALITY RELATED TO DIARRHEA - LESSONS FROM THE 1991 KURDISH REFUGEE CRISIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine the extent, major causes, and contributory factors of high rates of morbidity.and mortality among children at mountain camps along the Turkey-Iraq border during the 1991 Kurdish refugee crisis. Design.-A cross-sectional rapid nutrition survey among children and a retrospective mortality survey covering a 2-month period from the onset of the crisis. Population Studied.-Households of Kurdish refugees at resettlement camp 1 near Zakho in northern Iraq. Main Outcome Measures.-Prevalence of wasting (low weight-for-height) and mean weight-for-height status, prevalence of diarrhea, and crude and age-specific mortality rates. Results.-Weight-for-height measurements indicated that children under 2 years of age had suffered significant (P<.001) recent malnutrition. The elevated prevalence of wasting and the reduced mean weight-for-height status in this group indicated generalized weight loss. This weight loss was likely the result of the high rates of diarrhea, which still affected 50% of the younger children at the time of survey. The crude mortality rate for all ages was 8.9 per 1000 per month (expected rate, 0.6 per 1000); two thirds of the deaths occurred among children aged 5 years or younger, and half among infants younger than 1 year. An estimated 12% of all infants died during the first 2 months of the crisis. Most deaths were due to diarrhea, dehydration, and resulting malnutrition. Conclusions.-The high rates of malnutrition and mortality related to diarrhea in infants and younger children of Kurdish refugees took place rapidly despite prompt relief efforts and a previously healthy population. This experience underscores the need for early and aggressive public health management of sanitation, water sources, and diarrhea control programs to augment the traditional focus on food and medical relief during the emergency phase of a refugee crisis.	USN,MED RES INST,BETHESDA,MD 20814	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy	YIP, R (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV NUTR,4770 BUFORD HWY NE,ATLANTA,GA 30341, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; BHAN MK, 1989, B WORLD HEALTH ORGAN, V67, P281; CARLSON BA, 1990, UNICEF7 STAFF WORK P; Dean A. G., 1990, EPI INFO VERSION 5 W; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P749, DOI 10.1093/ajcn/46.5.749; Duggan C, 1992, MMWR Recomm Rep, V41, P1; HAMILL PV, 1977, VITAL HLTH STATIS 11, V165; NIEBURG P, 1988, DISASTERS, V12, P253, DOI 10.1111/j.1467-7717.1988.tb00674.x; PECOUL B, 1991, LANCET, V338, P190; SAYEGH J, 1992, CHILD SURVIVAL WAR T; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; Yip Ray, 1992, Morbidity and Mortality Weekly Report, V41, P1; 1991, MMWR MORB MORTAL WKL, V40, P443; 1990, STATE WORLDS CHILDRE; 1981, TREATMENT MANAGEMENT	16	67	68	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					587	590		10.1001/jama.270.5.587	http://dx.doi.org/10.1001/jama.270.5.587			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331756				2022-12-28	WOS:A1993LP43600022
J	FISHBEYN, VA; NORTON, JA; BENYA, RV; PISEGNA, JR; VENZON, DJ; METZ, DC; JENSEN, RT				FISHBEYN, VA; NORTON, JA; BENYA, RV; PISEGNA, JR; VENZON, DJ; METZ, DC; JENSEN, RT			ASSESSMENT AND PREDICTION OF LONG-TERM CURE IN PATIENTS WITH THE ZOLLINGER-ELLISON SYNDROME - THE BEST APPROACH	ANNALS OF INTERNAL MEDICINE			English	Article						ZOLLINGER-ELLISON SYNDROME; GASTRINOMA; SECRETIN; GASTRIC ACIDITY DETERMINATION; GASTRIN	ISLET CELL TUMORS; GASTRINOMAS; MANAGEMENT; RESECTION; LOCALIZATION; DIAGNOSIS; ANGIOGRAPHY; EXCISION; SECRETIN; SURGERY	Objective: To identify the best method for determining freedom from disease after gastrinoma resection and for predicting long-term disease-free status in patients with the Zollinger-Ellison syndrome. Design: Prospective study in consecutive patients. Setting: Referral-based clinical research center. Patients: Eighty-one consecutive patients with the Zollinger-Ellison syndrome who underwent surgical exploration for gastrinoma resection. Intervention: Patients were evaluated after gastrinoma resection, before discharge, 3 to 6 months after surgery, and yearly thereafter. Evaluation included secretin provocative testing and fasting serum gastrin determinations. Follow-up examinations after the initial postoperative evaluations included a clinical assessment, acid secretion studies, a calcium provocative test, and various imaging studies. Measurements and Main Results. Most patients (96%) had gastrinomas. Freedom from disease was defined by improved symptoms, reduced acid output and antisecretory drug requirements, and a normal gastrin level, normal imaging studies, and negative gastrin provocative studies. Fifty-two percent of patients (n = 42) were disease-free immediately after surgery, 44% at 3 to 6 months, 42% at 1 year, and 35% by 5 years (mean follow-up, 39 months). The secretin provocative test was the first test to become positive in 45% of patients with a recurrence, the serum gastrin determination was the first test to become positive in 36%, and both tests became positive at the same time in 18%. No recurrence was first detected by imaging studies or by calcium provocative testing. Fasting serum gastrin levels and secretin provocative test results at different postoperative times can be used to predict the probability of a patient remaining disease free at 3 years. Patients with a normal gastrin level and a normal secretin provocative test immediately after surgery had a 3-year disease-free probability of 75%, and normal results on both tests at 6 months, 1 year, and 2 years yielded respective probabilities of 88%, 95%, and 100%. Conclusions: Both the secretin provocative test and fasting serum gastrin determination are necessary for the early diagnosis of cases of recurrent disease after gastrinoma resection. The calcium provocative test and imaging studies do not detect any recurrences first. Fasting serum gastrin determinations and secretin provocative testing at different postoperative times can be used to predict the probability of a patient remaining disease free at 3 years.	NIH, BLDG 10, ROOM 9C-103, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA			Venzon, David J/B-3078-2008		NIDDK NIH HHS [P30 DK041301] Funding Source: Medline; RRD VA [I01 RX000194] Funding Source: Medline; BLRD VA [I01 BX004560] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); RRD VA; BLRD VA		ANDERSEN DK, 1989, ANN SURG, V210, P685, DOI 10.1097/00000658-198912000-00001; BARDRAM L, 1988, GASTROINTESTINAL APU; BONFILS S, 1989, GASTROENTEROL INT, V2, P9; BROWN WB, 1977, BIOMEDICAL INTRO, P150; CREUTZFELDT W, 1975, HUM PATHOL, V6, P47, DOI 10.1016/S0046-8177(75)80109-2; DAWSONSANDERS B, 1990, BASIC CLIN BIOSTATIC; DELCORE R, 1988, ANN SURG, V208, P291, DOI 10.1097/00000658-198809000-00006; DEVENEY CW, 1983, ANN SURG, V198, P546, DOI 10.1097/00000658-198310000-00015; DIEPSTRATEN A, 1990, BRIT J SURG, V77, P1403, DOI 10.1002/bjs.1800771226; ELLISON EC, 1987, AM J MED, V82, P17, DOI 10.1016/0002-9343(87)90423-2; ELLISON EH, 1964, ANN SURG, V160, P512, DOI 10.1097/00000658-196409000-00013; FELDMAN M, 1987, GASTROENTEROLOGY, V93, P59, DOI 10.1016/0016-5085(87)90314-3; FOX PS, 1974, SURG CLIN N AM, V54, P395; FRUCHT H, 1989, RADIOLOGY, V171, P713, DOI 10.1148/radiology.171.3.2655004; FRUCHT H, 1989, ANN INTERN MED, V111, P713, DOI 10.7326/0003-4819-111-9-713; FRUCHT H, 1991, DIGEST DIS SCI, V36, P394, DOI 10.1007/BF01298865; FRUCHT H, 1990, GASTROENTEROLOGY, V99, P1622, DOI 10.1016/0016-5085(90)90466-E; HAHNE W F, 1991, Gastroenterology, V100, pA79; HOWARD TJ, 1990, ANN SURG, V211, P9, DOI 10.1097/00000658-199001000-00002; IMAMURA M, 1989, ANN SURG, V210, P710, DOI 10.1097/00000658-198912000-00004; JENSEN RT, 1983, ANN INTERN MED, V98, P59, DOI 10.7326/0003-4819-98-1-59; JENSEN RT, 1986, EXOCRINE PANCREAS BI, P727; JENSEN RT, 1991, TXB GASTROENTEROLOGY, P1912; JENSEN RT, 1991, STOMACH, P341; LONDON JF, 1991, RADIOLOGY, V178, P763, DOI 10.1148/radiology.178.3.1994415; MATON PN, 1989, GASTROENTEROL CLIN N, V18, P847; MATON PN, 1987, GASTROENTEROLOGY, V92, P913, DOI 10.1016/0016-5085(87)90964-4; MCCARTHY DM, 1980, NEW ENGL J MED, V302, P1344, DOI 10.1056/NEJM198006123022404; MIGNON M, 1986, WORLD J SURG, V10, P703, DOI 10.1007/BF01655562; NORTON JA, 1986, ANN SURG, V203, P352, DOI 10.1097/00000658-198604000-00003; NORTON JA, 1986, ANN SURG, V204, P468, DOI 10.1097/00000658-198610000-00015; NORTON JA, 1988, ANN SURG, V207, P160, DOI 10.1097/00000658-198802000-00008; NORTON JA, 1991, WORLD J SURG, V15, P151, DOI 10.1007/BF01658992; NORTON JA, 1992, ANN SURG, V215, P8, DOI 10.1097/00000658-199201000-00012; PIPELEERSMARICHAL M, 1990, NEW ENGL J MED, V322, P723, DOI 10.1056/NEJM199003153221103; PISEGNA JR, 1992, GASTROENTEROLOGY, V102, P767, DOI 10.1016/0016-5085(92)90157-T; RAUFMAN JP, 1983, GASTROENTEROLOGY, V84, P108; ROCHE A, 1982, RADIOLOGY, V145, P621, DOI 10.1148/radiology.145.3.6292994; ROTHMAN KJ, 1978, J CHRON DIS, V31, P557, DOI 10.1016/0021-9681(78)90043-7; SAEED ZA, 1989, GASTROENTEROLOGY, V96, P1393, DOI 10.1016/0016-5085(89)90504-0; STABILE BE, 1984, AM J SURG, V147, P25, DOI 10.1016/0002-9610(84)90029-1; STADIL F, 1979, CLIN ENDOCRINOL META, V8, P433, DOI 10.1016/S0300-595X(79)80051-1; THOMPSON JC, 1975, SURG GYNECOL OBSTET, V140, P721; THOMPSON NW, 1989, ANN SURG, V209, P396, DOI 10.1097/00000658-198904000-00002; VINAYEK R, 1990, GASTROENTEROLOGY, V99, P10, DOI 10.1016/0016-5085(90)91223-S; VINAYEK R, 1986, AM J MED, V81, P49, DOI 10.1016/0002-9343(86)90600-5; WANK SA, 1987, GASTROENTEROLOGY, V92, P905, DOI 10.1016/0016-5085(87)90963-2; WOLFE MM, 1985, ANN INTERN MED, V103, P215, DOI 10.7326/0003-4819-103-2-215; WOLFE MM, 1987, NEW ENGL J MED, V317, P1200, DOI 10.1056/NEJM198711053171907; ZOLLINGER RM, 1980, ANN SURG, V192, P422, DOI 10.1097/00000658-198009000-00018	50	112	113	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					199	206		10.7326/0003-4819-119-3-199308010-00004	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8323088	Green Accepted			2022-12-28	WOS:A1993LU90300004
J	LICHTENSTEIN, LM				LICHTENSTEIN, LM			NIH FUNDING MECHANISMS NEED LITTLE DEFENSE	SCIENCE			English	Article											LICHTENSTEIN, LM (corresponding author), FRANCIS SCOTT KEY MED CTR,JOHNS HOPKINS ASTHMA & ALLERGY CTR,BALTIMORE,MD 21224, USA.								0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					17	&		10.1126/science.8316846	http://dx.doi.org/10.1126/science.8316846			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316846				2022-12-28	WOS:A1993LK43400012
J	THOMPSON, CM; KOLESKE, AJ; CHAO, DM; YOUNG, RA				THOMPSON, CM; KOLESKE, AJ; CHAO, DM; YOUNG, RA			A MULTISUBUNIT COMPLEX-ASSOCIATED WITH THE RNA POLYMERASE-II CTD AND TATA-BINDING PROTEIN IN YEAST	CELL			English	Article							TRANSCRIPTION FACTOR-IIF; C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; PREINITIATION COMPLEX; LARGEST SUBUNIT; HEPTAPEPTIDE REPEAT; INITIATION-FACTOR; ESCHERICHIA-COLI; TFIID COMPLEX; ACTIVATION	We report genetic and biochemical evidence that the RNA polymerase II carboxy-terminal domain (CTD) interacts with a large multisubunit complex that contains TATA-binding protein (TBP) and is an integral part of the transcription initiation complex. The isolation and characterization of extragenic suppressors of S. cerevisiae RNA polymerase II CTD truncation mutations led us to identify SRB2, SRB4, SRB5, and SRB6 as genes involved in CTD function in vivo. SRB2 was previously isolated and shown to encode a 23 kd TBP-binding protein. The four SRB proteins and a portion of cellular TBP are components of a high molecular weight multisubunit complex that is tightly bound to RNA polymerase II. This SRB-TBP complex binds specifically to recombinant CTD protein. In vitro transcription and template commitment assays confirm that SRB2 and SRB5 are components of a functional preinitiation complex and are required for efficient transcription initiation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	THOMPSON, CM (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Chao, David/0000-0001-9198-337X				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GERARD M, 1991, J BIOL CHEM, V266, P20940; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HARLOW E, 1989, ANTIBODIES LABORATOR; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAADOGO M, 1990, ANNU REV BIOCHEM, V59, P711; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS M, 1982, J BIOL CHEM, V267, P679; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	80	403	416	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1361	1375		10.1016/0092-8674(93)90362-T	http://dx.doi.org/10.1016/0092-8674(93)90362-T			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324825				2022-12-28	WOS:A1993LL20900011
J	JAMES, GL; GOLDSTEIN, JL; BROWN, MS; RAWSON, TE; SOMERS, TC; MCDOWELL, RS; CROWLEY, CW; LUCAS, BK; LEVINSON, AD; MARSTERS, JC				JAMES, GL; GOLDSTEIN, JL; BROWN, MS; RAWSON, TE; SOMERS, TC; MCDOWELL, RS; CROWLEY, CW; LUCAS, BK; LEVINSON, AD; MARSTERS, JC			BENZODIAZEPINE PEPTIDOMIMETICS - POTENT INHIBITORS OF RAS FARNESYLATION IN ANIMAL-CELLS	SCIENCE			English	Article							P21RAS PROTEIN FARNESYLTRANSFERASE; NON-PEPTIDE LIGANDS; POSTTRANSLATIONAL MODIFICATION; ALPHA-SUBUNIT; EXPRESSION; TRANSFORMATION; REQUIREMENT; ISOPRENOIDS; RESOLUTION; RECEPTORS	Oncogenic Ras proteins transform animal cells to a malignant phenotype only when modified by farnesyl residues attached to cysteines near their carboxyl termini. The farnesyltransferase that catalyzes this reaction recognizes tetrapeptides of the sequence CAAX, where C is cysteine, A is an aliphatic amino acid, and X is a carboxyl-terminal methionine or serine. Replacement of the two aliphatic residues with a benzodiazepine-based mimic of a peptide turn generated potent inhibitors of farnesyltransferase [50 percent inhibitory concentration (IC50) < 1 nM]. Unlike tetrapeptides, the benzodiazepine peptidomimetics enter cells and block attachment of farnesyl to Ras, nuclear lamins, and several other proteins. At micromolar concentrations, these inhibitors restored a normal growth pattern to Ras-transformed cells. The benzodiazepine peptidomimetics may be useful in the design of treatments for tumors in which oncogenic Ras proteins contribute to abnormal growth, such as that of the colon, lung, and pancreas.	GENENTECH INC, DEPT BIOORGAN CHEM, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT CELL GENET, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	JAMES, GL (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; Ball J B, 1990, J Mol Recognit, V3, P55, DOI 10.1002/jmr.300030202; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1987, J CELL PHYSIOL, P69; BOCK MG, 1987, J ORG CHEM, V52, P3232, DOI 10.1021/jo00391a010; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BUNDGAARD H, 1985, DESIGN PRODRUGS, P1; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; EVANS BE, 1988, J MED CHEM, V31, P2235, DOI 10.1021/jm00120a002; Farmer P. S., 1980, DRUG DESIGN, VX, P119; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FAUST J, 1987, J BIOL CHEM, V262, P1996; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; FREIDINGER RM, 1989, TRENDS PHARMACOL SCI, V10, P270, DOI 10.1016/0165-6147(89)90026-6; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; HEILMEYER LMG, 1992, P NATL ACAD SCI USA, V89, P9554, DOI 10.1073/pnas.89.20.9554; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JAMES GE, UNPUB; KIM CM, 1992, J BIOL CHEM, V267, P23113; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MORGAN BA, 1989, ANNU REP MED CHEM, V24, P243; OMURA S, 1993, J ANTIBIOT, V46, P222, DOI 10.7164/antibiotics.46.222; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; REISS Y, 1990, Methods (Orlando), V1, P241, DOI 10.1016/S1046-2023(05)80323-8; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHIOMI K, 1993, J ANTIBIOT, V46, P229, DOI 10.7164/antibiotics.46.229; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VANDERPYL D, 1992, J ANTIBIOT, V45, P1802; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055	60	618	701	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1993	260	5116					1937	1942		10.1126/science.8316834	http://dx.doi.org/10.1126/science.8316834			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	LJ349	8316834				2022-12-28	WOS:A1993LJ34900042
J	NORDENTOFT, M; BREUM, L; MUNCK, LK; NORDESTGAARD, AG; HUNDING, A; BJAELDAGER, PAL				NORDENTOFT, M; BREUM, L; MUNCK, LK; NORDESTGAARD, AG; HUNDING, A; BJAELDAGER, PAL			HIGH MORTALITY BY NATURAL AND UNNATURAL CAUSES - A 10-YEAR FOLLOW-UP-STUDY OF PATIENTS ADMITTED TO A POISONING TREATMENT CENTER AFTER SUICIDE ATTEMPTS	BRITISH MEDICAL JOURNAL			English	Article							MODELS; DEATH	Objective-To describe mortality by suicide and other causes of death in a group of patients who attempted suicide, and to identify predictive factors. Design-10 year follow up study based on records of suicide attempters in 1980. Setting-Poisoning treatment centre at a general hospital. Subjects-974 patients aged 15 and over referred to the poisoning treatment centre after deliberate self poisoning. Main outcome measures-Death by different causes registered in the Danish death cause register. Results-In 10 years of follow up 306 patients died: 103 by suicide, 131 from natural causes, and 31 by accidents; five were murdered, and in 36 cases the cause of death was uncertain. The standard mortality ratio was 550. Cause specific standardised mortality rates were 2960 for suicide, 236 for natural causes, 1256 for accidents, and 5459 for uncertain causes. In a Cox regression analysis, high risk factors for subsequent suicide were: more than one previous suicide attempt (relative risk 2.25), living alone (2.28), and age (1.03 per year). Predictors of death by natural causes were receiving a pension (1.69), drug misuse (2.72), more than one previous suicide attempt (2.25), age (1.06 per year), and male sex (2.49). The group of patients fulfilling at least one high risk criterion for later suicide differed significantly from the rest of the patient group in incidence of suicide, but both sensitivity and specificity were low. Conclusions-Most patients who attempted suicide were at high risk of succeeding because the risk factors, though significant, are not very specific. A strategy to prevent suicide must be directed toward the majority of those who attempt suicide.	BISPEBJERG HOSP,DEPT MED C,COPENHAGEN,DENMARK; BISPEBJERG HOSP,CTR POISONING TREATMENT,COPENHAGEN,DENMARK; UNIV COPENHAGEN,INST CHEM,DK-1168 COPENHAGEN,DENMARK	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen	NORDENTOFT, M (corresponding author), UNIV COPENHAGEN,BISPEBJERG HOSP,DEPT PSYCHIAT,DK-2400 COPENHAGEN NV,DENMARK.		Nordentoft, Merete/AAH-3253-2019	Nordentoft, Merete/0000-0003-4895-7023; Munck, Lars Kristian/0000-0002-5014-8260				ANDERSEN PK, 1988, STATISTISK ANAL OVER; Bjaeldager P A, 1983, Ugeskr Laeger, V145, P2833; BRATFOS O, 1971, ACTA PSYCHIAT SCAND, V38, P38; BRESLOW NE, 1975, J CHRON DIS, V28, P289, DOI 10.1016/0021-9681(75)90010-7; COX DR, 1972, J R STAT SOC B, V34, P187; CULLBERG J, 1988, ACTA PSYCHIAT SCAND, V77, P598, DOI 10.1111/j.1600-0447.1988.tb05173.x; DAHLGREN KG, 1977, SUICIDE LIFE-THREAT, V7, P75; EGMOND EJ, 1989, SUICIDE ITS PREVENTI; EKEBERG O, 1991, ACTA PSYCHIAT SCAND, V83, P432, DOI 10.1111/j.1600-0447.1991.tb05570.x; ETTLINGER RW, 1975, ACTA PSYCHIATR SCA S, V260, P84; GOODWIN JS, 1987, JAMA-J AM MED ASSOC, V258, P3125, DOI 10.1001/jama.258.21.3125; HAWTON K, 1988, BRIT J PSYCHIAT, V152, P359, DOI 10.1192/bjp.152.3.359; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kreitman N., 1977, PARASUICIDE; LESTER D, 1992, ACTA PSYCHIAT SCAND, V85, P15, DOI 10.1111/j.1600-0447.1992.tb01435.x; NIELSEN B, 1990, ACTA PSYCHIAT SCAND, V81, P250, DOI 10.1111/j.1600-0447.1990.tb06490.x; PAERREGAARD G, 1975, SUICIDE, V5, P140; RYGNESTAD T, 1988, ACTA PSYCHIAT SCAND, V77, P328, DOI 10.1111/j.1600-0447.1988.tb05129.x; SUNDQVISTSTENSM.UB, 1988, OPUSC MED, V3, P71; SUOKAS J, 1991, ACTA PSYCHIAT SCAND, V84, P545, DOI 10.1111/j.1600-0447.1991.tb03191.x; 1982, CAUSES DEATH DENMARK; 1981, COPENHAGEN STATISTIC; 1991, WHO1990 WORLD HLTH S; 1991, 1989 DAN NAT BUR STA	24	184	184	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1637	1641		10.1136/bmj.306.6893.1637	http://dx.doi.org/10.1136/bmj.306.6893.1637			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LJ337	8324430	Green Published, Bronze			2022-12-28	WOS:A1993LJ33700016
J	SWAI, ABM; LUTALE, JL; MCLARTY, DG				SWAI, ABM; LUTALE, JL; MCLARTY, DG			PROSPECTIVE-STUDY OF INCIDENCE OF JUVENILE DIABETES-MELLITUS OVER 10 YEARS IN DAR-ES-SALAAM, TANZANIA	BRITISH MEDICAL JOURNAL			English	Article							TROPICAL AFRICA; EPIDEMIOLOGY; CHILDHOOD; IDDM	Objective-To ascertain the annual incidence of diabetes requiring treatment with insulin in children and adolescents aged 0-19 years in Dar es Salaam, Tanzania, during a 10 year period from 1 january 1982 to 31 December 1991. Design-Prospective registration at a major urban hospital of all patients with newly diagnosed diabetes who were resident in Dar es Salaam. Setting-Muhimbili Medical Centre, Dar es Salaam, Tanzania. Patients-86 patients: 45 male, 41 female. Results-The annual incidence of juvenile diabetes for both sexes was 1.5 per 100000 population aged 0-19 years (95% confidence interval 1.3 to 1.7). Incidence per 100 000 population per year increased with age: 0.6 (0.0 to 0.13) in the age group 0-4 years, 0.5 (0.3 to 0.7) at 5-9 years, 2.2 (1.8 to 2.6) at 10-14 years, and 3.4 (2.9 to 3.9) at 15-19 years. Conclusion-Juvenile diabetes mellitus is fairly rare in sub-Saharan Africa. If environmental factors such as infection and material deprivation were important determinants of insulin dependent diabetes in Africans, as they may be in Europeans, much higher rates would have been expected unless genetic factors possibly exert a protective role. The eightfold greater incidence in African Americans than in Tanzanians may be related to greater genetic admixture in African Americans with people from countries in Europe with a high incidence.			SWAI, ABM (corresponding author), UNIV DAR ES SALAAM,MUHIMBILI MED CTR,DEPT MED,POB 65001,DAR ES SALAAM,TANZANIA.							BRAHAMS D, 1990, LANCET, V335, P652, DOI 10.1016/0140-6736(90)90427-7; BRAHAMS D, 1990, LANCET, V335, P595, DOI 10.1016/0140-6736(90)90366-D; CROW YJ, 1991, BRIT MED J, V303, P158, DOI 10.1136/bmj.303.6795.158; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; EKOE JM, 1992, INT TXB DIABETES MEL, P129; ELAMIN A, 1989, DIABETES CARE, V12, P430, DOI 10.2337/diacare.12.6.430; MAKAME MH, 1992, DIABETIC MED, V9, P571, DOI 10.1111/j.1464-5491.1992.tb01841.x; MCLARTY DG, 1989, DIABETIC MED, V6, P762, DOI 10.1111/j.1464-5491.1989.tb01275.x; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; PAPOZ L, 1991, ACTA DIABETOL, V28, P140, DOI 10.1007/BF00579716; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; RWIZA HT, 1986, DIABETIC MED, V3, P1811; SWAI ABM, 1990, BMJ-BRIT MED J, V300, P1103, DOI 10.1136/bmj.300.6732.1103; TROWELL HC, 1981, W DISEASES THEIR EME, P25; TULL ES, 1991, DIABETES CARE, V14, P558, DOI 10.2337/diacare.14.7.558; TULL ES, 1992, DIABETIC MED, V9, P13	16	48	49	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1570	1572		10.1136/bmj.306.6892.1570	http://dx.doi.org/10.1136/bmj.306.6892.1570			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329915	Bronze, Green Published			2022-12-28	WOS:A1993LH12800015
J	GREENBERG, S; REISER, IW; CHOU, SY; PORUSH, JG				GREENBERG, S; REISER, IW; CHOU, SY; PORUSH, JG			TRIMETHOPRIM-SULFAMETHOXAZOLE INDUCES REVERSIBLE HYPERKALEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; HYPERKALEMIA; POTASSIUM; ACQUIRED IMMUNODEFICIENCY SYNDROME; PNEUMONIA, PNEUMOCYSTIS-CARINII	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNE-DEFICIENCY SYNDROME; CO-TRIMOXAZOLE; INTERSTITIAL NEPHRITIS; ADVERSE REACTIONS; MINERALOCORTICOID DEFICIENCY; HIV INFECTION; NEPHROTOXICITY; CREATININE	Objective: To determine the effect of trimethoprim-sulfamethoxazole (Tmp-Smx) on serum potassium concentration. Design: Retrospective cohort study. Setting: An urban teaching hospital. Patients: Fifty-one persons hospitalized for symptomatic infection with human immunodeficiency virus (HIV). Twenty-five patients who were taking high-dose Tmp-Smx (trimethoprim 20 mg/kg per day; sulfamethoxazole, 100 mg/kg per day) for Pneumocystis carinii pneumonia were the study group. Twenty-six patients who had not received the drug were the control group. Patients who received potassium supplements, those taking medications known to alter potassium homeostasis or renal function, or those with a serum creatinine level more than 186 mumol/L were excluded. Measurements and Main Results: Serum potassium concentration in the study group was 4.1 +/- 0.1 mmol/L (mean +/- SE) and increased by 1.1 mmol/L (CI, 0.8 to 1.5 mmol/L) (P < 0.0001) 9.8 +/- 0.5 days after starting Tmp-Smx therapy. Patients followed longitudinally showed a progressive increase in serum potassium levels during therapy and a progressive decline after discontinuing Tmp-Smx. Blood urea nitrogen and serum creatinine levels increased mildly from 4.3 +/- 0.5 mmol/L and 85 +/- 6 mumol/L to 6.4 +/- 0.7 mmol/L and 113 +/- 8 mumol/L, respectively. The serum potassium level in the control group was 4.3 +/- 0.1 mmol/L and remained unchanged during hospitalization. Conclusions: High-dose Tmp-Smx therapy used for the treatment of P. carinii pneumonia in HIV-infected patients leads to an increase in the serum potassium concentration and may result in life-threatening hyperkalemia. Patients receiving high doses of Tmp-Smx require close monitoring of their serum potassium concentration, particularly 7 to 10 days after the start of therapy.	BROOKDALE HOSP MED CTR, DIV NEPHROL & HYPERTENS, BROOKLYN, NY 11212 USA									APPEL GB, 1977, NEW ENGL J MED, V296, P784, DOI 10.1056/NEJM197704072961404; BERGLUND F, 1975, J UROLOGY, V114, P802, DOI 10.1016/S0022-5347(17)67149-0; CHOI M J, 1992, Journal of the American Society of Nephrology, V3, P325; CRYST C, 1988, AM J NEPHROL, V8, P483, DOI 10.1159/000167666; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREENE LW, 1984, ANN INTERN MED, V101, P497, DOI 10.7326/0003-4819-101-4-497; GUY RJC, 1989, BRIT MED J, V298, P496, DOI 10.1136/bmj.298.6672.496; JAFFE HS, 1983, LANCET, V2, P1109; JICK H, 1982, REV INFECT DIS, V4, P426; KALIN MF, 1987, AM J MED, V82, P1035, DOI 10.1016/0002-9343(87)90171-9; LACHAAL M, 1989, AM J MED, V87, P260, DOI 10.1016/S0002-9343(89)80147-0; LAWSON DH, 1978, AM J MED SCI, V275, P53, DOI 10.1097/00000441-197801000-00005; LAWSON DH, 1982, REV INFECT DIS, V4, P429; LINTON AL, 1980, ANN INTERN MED, V93, P735, DOI 10.7326/0003-4819-93-5-735; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MEMBRENO L, 1987, J CLIN ENDOCR METAB, V65, P482, DOI 10.1210/jcem-65-3-482; MURPHY CF, 1989, BRIT MED J, V298, P1181, DOI 10.1136/bmj.298.6681.1181-b; REVERT L, 1988, SEMIN NEPHROL, V8, P82; RICHMOND JM, 1979, LANCET, V1, P493; SCHOENFELD P, 1990, AM J KIDNEY DIS, V16, P14, DOI 10.1016/S0272-6386(12)80780-3; SENEY FD, 1990, AM J KIDNEY DIS, V16, P1; SHOUVAL D, 1978, LANCET, V1, P244; SMITH EJ, 1980, JAMA-J AM MED ASSOC, V244, P360, DOI 10.1001/jama.244.4.360; VAZIRI ND, 1985, J NATL MED ASSOC, V77, P369; VELAZQUEZ H, 1992, Journal of the American Society of Nephrology, V3, P322	25	88	92	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					291	295		10.7326/0003-4819-119-4-199308150-00007	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328737				2022-12-28	WOS:A1993LV52500007
J	MAGUIRE, RB; STRONCEK, DF; CAMPBELL, AC				MAGUIRE, RB; STRONCEK, DF; CAMPBELL, AC			RECURRENT PANCYTOPENIA, COAGULOPATHY, AND RENAL-FAILURE ASSOCIATED WITH MULTIPLE QUININE-DEPENDENT ANTIBODIES	ANNALS OF INTERNAL MEDICINE			English	Note							HEMOLYTIC UREMIC SYNDROME; THROMBOCYTOPENIA		UNIV ILLINOIS, SCH MED, PEORIA, IL 61656 USA; ST FRANCIS MED CTR, PEORIA, IL USA; PROCTOR HOSP, PEORIA, IL USA; UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA; AMER RED CROSS, ST PAUL, MN USA	University of Illinois System; University of Illinois Peoria; University of Minnesota System; University of Minnesota Twin Cities; American Red Cross								BELKIN GA, 1967, ANN INTERN MED, V66, P583, DOI 10.7326/0003-4819-66-3-583; BERNDT MC, 1989, PLATELET IMMUNOBIOLO, P132; CHONG BH, 1983, BLOOD, V62, P1218; GOTTSCHALL JL, 1991, BLOOD, V77, P306; HYLER SE, 1981, PSYCHIAT CLIN N AM, V4, P365; REID DM, 1988, ANN INTERN MED, V108, P206, DOI 10.7326/0003-4819-108-2-206; SALAMA A, 1992, SEMIN HEMATOL, V29, P54; SPEARING RL, 1990, LANCET, V336, P1535, DOI 10.1016/0140-6736(90)93309-D; STRONCEK DF, 1992, BLOOD, V80, P241	9	50	50	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					215	217		10.7326/0003-4819-119-3-199308010-00006	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8323089				2022-12-28	WOS:A1993LU90300006
J	NAUJOKAS, MF; MORIN, M; ANDERSON, MS; PETERSON, M; MILLER, J				NAUJOKAS, MF; MORIN, M; ANDERSON, MS; PETERSON, M; MILLER, J			THE CHONDROITIN SULFATE FORM OF INVARIANT CHAIN CAN ENHANCE STIMULATION OF T-CELL RESPONSES THROUGH INTERACTION WITH CD44	CELL			English	Article							MHC CLASS-II; MAJOR HISTOCOMPATIBILITY COMPLEX; LYMPHOCYTE HOMING RECEPTOR; HLA-DR MOLECULES; PANCREATIC BETA-CELLS; ANTIGEN PRESENTATION; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; B-CELL; SURFACE EXPRESSION	Invariant chain (Ii) is a nonpolymorphic glycoprotein that associates with major histocompatibility complex class II molecules and has been shown to mediate several functions in class II-restricted antigen presentation. A small proportion of Ii is modified by the addition of chondroitin sulfate (Ii-CS), and this form of Ii is associated with class II on the surface of antigen-presenting cells. In this report we show that expression of Ii-CS dramatically enhanced the ability of class II-positive EL4 transfectants to stimulate class II-dependent allogeneic and mitogenic T cell responses. Antibody blocking studies and the ability of CD44 to bind directly to Ii-CS suggest that Ii-CS can function as an accessory molecule during T cell responses through interactions with CD44.	UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637	University of Chicago	NAUJOKAS, MF (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK42857] Funding Source: Medline; NIGMS NIH HHS [GM42071, GM07281] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042071, T32GM007281] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACCOLLA RS, 1985, J IMMUNOL, V134, P3265; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERTOLINO P, 1991, INT IMMUNOL, V3, P435, DOI 10.1093/intimm/3.5.435; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIKOFF EK, 1992, J IMMUNOL, V149, P1; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BUTTERFIELD K, 1989, J EXP MED, V169, P1461, DOI 10.1084/jem.169.4.1461; CONRAD P, 1992, J IMMUNOL, V149, P1833; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DAMLE NK, 1992, J IMMUNOL, V148, P1985; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DENNING SM, 1990, J IMMUNOL, V144, P7; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; FELL HP, 1992, J BIOL CHEM, V267, P15552; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUAGLIARDI L, 1990, NATURE, V345, P172; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; HOLT GD, 1985, J IMMUNOL, V135, P399; HUET S, 1989, J IMMUNOL, V143, P798; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JONES PP, 1979, MOL IMMUNOL, V16, P51, DOI 10.1016/0161-5890(79)90027-0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOCH N, 1982, EUR J IMMUNOL, V12, P909, DOI 10.1002/eji.1830121103; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LIU ZR, 1992, J EXP MED, V175, P1663, DOI 10.1084/jem.175.6.1663; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; LOMBARDI G, 1989, J IMMUNOL, V142, P753; LOSS GE, 1993, J IMMUNOL, V150, P3187; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MILLER J, 1990, J IMMUNOL, V144, P334; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MOST J, 1992, J IMMUNOL, V148, P1635; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; MURAKAMI S, 1991, J IMMUNOL, V146, P1422; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; NORTON SD, 1992, J IMMUNOL, V149, P1556; OZATO K, 1980, J IMMUNOL, V124, P533; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; PETERSON M, 1992, NATURE, V357, P596, DOI 10.1038/357596a0; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; RATH S, 1992, EUR J IMMUNOL, V22, P2121, DOI 10.1002/eji.1830220824; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROSAMOND S, 1988, J IMMUNOL, V139, P1946; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SANT AJ, 1985, J IMMUNOL, V135, P416; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHAIFF WT, 1991, J IMMUNOL, V147, P603; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SIVAK LE, 1987, J IMMUNOL, V138, P1319; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STOCKINGER B, 1989, CELL, V56, P683, DOI 10.1016/0092-8674(89)90590-4; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; WATTS TH, 1984, P NATL ACAD SCI-BIOL, V81, P7564, DOI 10.1073/pnas.81.23.7564; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; YAGI JJ, 1990, J IMMUNOL, V144, P892	89	215	217	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					257	268		10.1016/0092-8674(93)90417-O	http://dx.doi.org/10.1016/0092-8674(93)90417-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343954				2022-12-28	WOS:A1993LP72600007
J	HUGHES, DA; ASHWORTH, A; MARSHALL, CJ				HUGHES, DA; ASHWORTH, A; MARSHALL, CJ			COMPLEMENTATION OF BYR1 IN FISSION YEAST BY MAMMALIAN MAP KINASE KINASE REQUIRES COEXPRESSION OF RAF KINASE	NATURE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; SIGNAL TRANSDUCTION; GENE; ACTIVATION; FUS3; CEREVISIAE; TYROSINE; KSS1	INTRACELLULAR signalling from receptor tyrosine kinases in mammalian cells involves the activation of a signal cascade which includes p21ras and the protein kinases p74raf-1, MAP kinase kinase and MAP kinases1-8. In the yeasts Schizosaccharomyces pombe and Saccharomyces cerevisiae the response to mating pheromones requires the Spk1 and KSS1/FUS3 kinases, which have sequence homology to Vertebrate MAP kinases9-12. The recent cloning of complementary DNAs for mammalian13-15 and frog16 MAP kinase kinases has shown that they are homologous to the S. pombe Byr1 (ref. 17) and S. cerevisiae STE7 (ref. 18) kinases, which have been proposed to function upstream of Spk1 and KSS1/FUS3, respectively19-22. We have investigated whether these apparently similar kinase pathways are functionally conserved between vertebrates and S. pombe. We report here that expression of mammalian MAP kinase kinase alone fails to complement a byr1 mutant of S. pombe. When coexpressed with Raf kinase, however, MAP kinase kinase is activated by phosphorylation and the mating defect of the byr1 mutant is rescued. This suggests that the pathways are functionally homologous and that Raf kinase may directly phosphorylate and activate MAP kinase kinase.			HUGHES, DA (corresponding author), INST CANC RES, CHESTER BEATTY LABS, CELL & MOLEC BIOL SECT, LONDON SW3 6JB, ENGLAND.							ASHWORTH A, 1992, ONCOGENE, V7, P2555; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGEL R, 1971, PLANTA, V98, P89, DOI 10.1007/BF00387025; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, IN PRESS MOL CELL BI; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SEGER R, 1992, J BIOL CHEM, V267, P25628; SMITS AMM, 1992, NATURE, V357, P602; STYRKARSDOTTIR U, 1992, MOL GEN GENET, V235, P122, DOI 10.1007/BF00286189; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	35	61	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 22	1993	364	6435					349	352		10.1038/364349a0	http://dx.doi.org/10.1038/364349a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332194				2022-12-28	WOS:A1993LN57000061
J	OLSEN, RJ; LYNCH, P; COYLE, MB; CUMMINGS, J; BOKETE, T; STAMM, WE				OLSEN, RJ; LYNCH, P; COYLE, MB; CUMMINGS, J; BOKETE, T; STAMM, WE			EXAMINATION GLOVES AS BARRIERS TO HAND CONTAMINATION IN CLINICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYVINYL-CHLORIDE GLOVES; SURGICAL GLOVES; LATEX; PERMEABILITY; VINYL; INFECTION; VIRUS; INTEGRITY; SURGERY; CARE	Objective.-To test the effectiveness of vinyl and latex gloves as barriers to hand contamination with gram-negative organisms and enterococci during routine hospital procedures. Design and Interventions.-We studied 137 procedures during which a health care workers gloved hand contacted a patient's mucous membrane and was thus potentially contaminated with gram-negative rods or enterococci. Quantitative hand cultures were obtained from each health care worker before and after the gloved contact using a modified glove juice method, and the exterior glove surface was also quantitatively cultured after patient contact. Used gloves were then tested for leaks using the American Society for Testing and Materials' watertight test. Setting.-Harborview Medical Center, a 330-bed city-county hospital and level I regional trauma and burn center, is both a teaching facility affiliated with the University of Washington and the major provider of care to indigent and uninsured persons in Seattle-King County, Washington. Patients and Other Participants.-Respiratory therapists performing endotracheal tube care on intubated intensive care unit patients, registered nurses performing digital rectal stimulation for bowel training on patients with spinal cord injury in the rehabilitation ward, and dentists performing routine dental examinations and procedures on healthy outpatients in the dental clinic. Main Outcome Measure and Results.-Eighty-six of the 135 gloves cultured had gram-negative rods or enterococci on the external surface after use and were thus sources of potential hand contamination. Microbial contamination of the health care worker's hands occurred in 11 (13%; 95% confidence interval, 6% to 20%) of these 86 events, and was more frequent with vinyl (10 of 42) than latex (one of 44) gloves (P<.01). After use, glove leaks were also more frequent in vinyl gloves (26 of 61) than with latex gloves (six of 70) (P<.001). Even when leaks were present, gloves prevented hand contamination in 77% of instances and quantitative counts of microorganisms contaminating hands were 2 to 4 logs less than counts on external glove surfaces. Health care workers reported awareness of the presence of glove leaks in only seven (22%) of the 32 events in which leaks were subsequently demonstrated. Conclusions.-Under conditions of routine use, gloves effectively function as a protective barrier even when leaks are present. Latex gloves were less frequently associated with leaks and hand contamination. Since hand contamination occurred after 13% of exposures and cannot be readily identified by health care workers, routine hand washing should be done after each patient contact.	UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT CLIN MICROBIOL, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT INFECT DIS, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT EPIDEMIOL, SEATTLE, WA 98104 USA; NATL HLTH INST, GABORONE, BOTSWANA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle								BERG GA, 1987, BRIT J CLIN PRACT, V41, P903; CONNOR TH, 1984, AM J HOSP PHARM, V41, P676, DOI 10.1093/ajhp/41.4.676; DEGROOTKOSOLCHAROEN J, 1989, AM J INFECT CONTROL, V17, P196, DOI 10.1016/0196-6553(89)90128-4; DIENSTAG JL, 1982, AM J EPIDEMIOL, V115, P26, DOI 10.1093/oxfordjournals.aje.a113277; DODDS RDA, 1990, BRIT J SURG, V77, P219, DOI 10.1002/bjs.1800770228; GERHARDT GG, 1989, ZBL HYG UMWELTMED, V188, P336; JOHNSON S, 1990, AM J MED, V88, P137, DOI 10.1016/0002-9343(90)90462-M; KLEIN BS, 1989, NEW ENGL J MED, V320, P1714, DOI 10.1056/NEJM198906293202603; KLEIN RC, 1990, BIOTECHNIQUES, V9, P196; KORNIEWICZ DM, 1990, J CLIN MICROBIOL, V28, P787, DOI 10.1128/JCM.28.4.787-788.1990; KORNIEWICZ DM, 1989, NURS RES, V38, P144; KOTILAINEN HR, 1989, ARCH INTERN MED, V149, P2749, DOI 10.1001/archinte.149.12.2749; LAIDLAW JL, 1984, AM J HOSP PHARM, V41, P2618, DOI 10.1093/ajhp/41.12.2618; LARSON EL, 1980, J CLIN MICROBIOL, V12, P355, DOI 10.1128/JCM.12.3.355-360.1980; LYNCH P, 1990, AM J INFECT CONTROL, V18, P1, DOI 10.1016/0196-6553(90)90204-6; PUGLIESE G, 1991, UNIVERSAL PRECAUTION, P400; STOIKES ME, 1987, AM J HOSP PHARM, V44, P1341, DOI 10.1093/ajhp/44.6.1341; YANGCO BG, 1989, INFECT CONT HOSP EP, V10, P553, DOI 10.1086/645950; 1977, ANN BOOK ASTM STANDA, P1; 1990, FED REG         1212, V55, P51254; 1987, MMWR MORB MORTAL S25, V36, P1; 1990, M2AA4 NAT COMM CLIN; 1991, FED REG         1206, V56, P64003	23	138	140	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					350	353		10.1001/jama.270.3.350	http://dx.doi.org/10.1001/jama.270.3.350			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8315779				2022-12-28	WOS:A1993LM43500030
J	GREEN, WN; CLAUDIO, T				GREEN, WN; CLAUDIO, T			ACETYLCHOLINE-RECEPTOR ASSEMBLY - SUBUNIT FOLDING AND OLIGOMERIZATION OCCUR SEQUENTIALLY	CELL			English	Article							GATED ION CHANNELS; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; GAMMA-SUBUNIT; TORPEDO-CALIFORNICA; ALPHA-SUBUNIT; PROTEIN; CELLS; TRANSPORT; FIBROBLASTS	The temperature sensitivity of nicotinic acetylcholine receptors (AChRs) from T. californica was used to identify steps in AChR subunit folding and oligomerization. Assembly intermediates were isolated by lowering to an assembly-permissive temperature. The earliest identifiable assembly intermediates, alphabetagamma trimers, form minutes after subunit synthesis. Alphabetagammadelta tetramers are formed slowly by the addition of delta subunits to trimers, and finally a second alpha subunit is added to form alpha2betagammadelta pentamers. Between these oligomerization steps, subunits fold as monitored by alpha-bungarotoxin-binding site formation, appearance of antigenic epitopes, changes in apparent molecular weight, and changes in detergent solubility. Subunit folding requires specific combinations of subunits and correlates in time with subunit additions, suggesting that these subunit folding events contribute to subunit recognition site formation during assembly.	YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA	Yale University					NHLBI NIH HHS [HL38156] Funding Source: Medline; NINDS NIH HHS [NS21714] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021714] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; CLAUDIO T, 1989, J CELL BIOL, V108, P2277, DOI 10.1083/jcb.108.6.2277; CLAUDIO T, 1977, ARCH BIOCHEM BIOPHYS, V181, P484, DOI 10.1016/0003-9861(77)90254-5; CLAUDIO T, 1987, SCIENCE, V238, P1688, DOI 10.1126/science.3686008; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; CONROY WG, 1990, J BIOL CHEM, V265, P21642; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; GARDNER PD, 1990, NUCLEIC ACIDS RES, V18, P6714, DOI 10.1093/nar/18.22.6714; Gething M J, 1990, Semin Cell Biol, V1, P65; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GREEN WN, 1991, NEURON, V7, P659, DOI 10.1016/0896-6273(91)90378-D; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KUROSAKI T, 1987, FEBS LETT, V214, P253, DOI 10.1016/0014-5793(87)80065-0; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; PAULSON HL, 1990, J CELL BIOL, V110, P1705, DOI 10.1083/jcb.110.5.1705; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SINE SM, 1991, J BIOL CHEM, V266, P19369; SMITH MM, 1987, J BIOL CHEM, V262, P4367; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; TZARTOS SJ, 1980, P NATL ACAD SCI-BIOL, V77, P755, DOI 10.1073/pnas.77.2.755; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WAN KK, 1985, BIOCHEMISTRY-US, V24, P1212, DOI 10.1021/bi00326a024; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729	36	128	128	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					57	69		10.1016/0092-8674(93)90294-Z	http://dx.doi.org/10.1016/0092-8674(93)90294-Z			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334706				2022-12-28	WOS:A1993LN62500007
J	WU, DQ; LAROSA, GJ; SIMON, MI				WU, DQ; LAROSA, GJ; SIMON, MI			G-PROTEIN-COUPLED SIGNAL-TRANSDUCTION PATHWAYS FOR INTERLEUKIN-8	SCIENCE			English	Article							ACTIVATING PROTEIN; COMPLEMENTARY-DNA; RECEPTOR; ALPHA; CLONING; FAMILY; CELLS	Interleukin-8 (IL-8) is one of the major mediators of the inflammatory response. The pathways by which IL-8 activates inositide-specific phospholipase C (PLC) were investigated by co-expression of different components of the guanosine triphosphate binding protein (G protein) pathway in COS-7 cells. Two distinct IL-8 receptors reconstituted ligand-dependent activation of endogenous PLC when transfected together with the G protein alpha subunits Galpha14, Galpha15, or Galpha16. However, reconstitution was not observed with cells that overexpressed Galpha(q) or Galpha11. Furthermore, IL-8 receptors interacted with endogenous pertussis toxin-sensitive G proteins or with the recombinant G protein G(i) to release free betagamma subunits that could then specifically activate the beta2 isoform of PLC. These findings suggest that IL-8 acts through signal-transducing pathways that are limited to specific heterotrimeric G proteins and effectors. These may provide suitable targets for the development of anti-inflammatory agents.	CALTECH, DIV BIOL, 147-75, PASADENA, CA 91125 USA; REPLIGEN CORP, DEPT MOLEC BIOL, CAMBRIDGE, MA 02132 USA	California Institute of Technology								AMATRUDA T, UNPUB; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE J, 1992, J BIOL CHEM, V267, P16283; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARK D, 1992, J BIOL CHEM, V267, P16048; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WU D, IN PRESS P NATL ACAD; Wu D., UNPUB; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	35	349	363	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	1993	261	5117					101	103		10.1126/science.8316840	http://dx.doi.org/10.1126/science.8316840			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316840				2022-12-28	WOS:A1993LK43400042
J	NEE, PA; PHILLIPS, BM; BANNISTER, CM				NEE, PA; PHILLIPS, BM; BANNISTER, CM			LESSON OF THE WEEK - EXTRADURAL HEMATOMA IN A CHILD AFTER AN APPARENTLY MILD HEAD-INJURY	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY; FRACTURES; ACCIDENT		BOOTH HALL CHILDRENS HOSP,DEPT NEUROSURG,MANCHESTER M9 2AA,ENGLAND	Royal Manchester Children's Hospital	NEE, PA (corresponding author), BOOTH HALL CHILDRENS HOSP,DEPT PAEDIAT ACCID & EMERGENCY MED,MANCHESTER M9 2AA,ENGLAND.							BALLANTYNE E, 1986, IRCS MED SCI-BIOCHEM, V14, P63; BRIGGS M, 1984, BRIT MED J, V288, P983; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GORMAN DF, 1987, ARCH EMERG MED, V4, P141; JENNETT B, 1977, Lancet, V2, P696; MILLER JD, 1985, LANCET, V1, P1141; MILLER JD, 1968, LANCET, V2, P991; NEE PA, IN PRESS INJURY; STRANG I, 1978, INJURY, V10, P154; THILLAINAYAGAM K, 1987, INJURY, V18, P319, DOI 10.1016/0020-1383(87)90051-9; 1990, MAKING BEST USE DEPT	11	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1665	1666		10.1136/bmj.306.6893.1665	http://dx.doi.org/10.1136/bmj.306.6893.1665			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324439	Bronze, Green Published			2022-12-28	WOS:A1993LJ33700029
J	PELOSI, AJ; APPLEBY, L				PELOSI, AJ; APPLEBY, L			PERSONALITY AND FATAL DISEASES	BRITISH MEDICAL JOURNAL			English	Article							NOVATION BEHAVIOR-THERAPY; CORONARY HEART-DISEASE; PROPHYLACTIC TREATMENT; CANCER; PREDICTOR		UNIV HOSP S MANCHESTER,MANCHESTER M20 8LR,LANCS,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	PELOSI, AJ (corresponding author), HAIRMYRES HOSP,GLASGOW G75 8RG,SCOTLAND.			Pelosi, Anthony/0000-0002-5501-2661				BINIK YM, 1991, BEHAV RES THER, V29, P33, DOI 10.1016/S0005-7967(09)80004-1; Eysenck H.J., 1991, ADULT EPQ R; EYSENCK HJ, 1991, AM J EPIDEMIOL, V133, P429, DOI 10.1093/oxfordjournals.aje.a115907; EYSENCK HJ, 1992, BRIT MED J, V305, P457, DOI 10.1136/bmj.305.6851.457; EYSENCK HJ, 1991, BEHAV RES THER, V29, P17, DOI 10.1016/S0005-7967(09)80003-X; EYSENCK HJ, 1991, PSYCHOL INQ, V2, P297, DOI DOI 10.1207/S15327965PLI0203_21; Eysenck HJ., 1991, PSYCHOL INQ, V2, P221, DOI DOI 10.1207/S15327965P1I0203_1; Fox B. H., 1991, PSYCHOL INQ, V2, P242; FOX BH, 1988, TOPICS HLTH PSYCHOL, P37; GALLACHER JEJ, 1992, PSYCHOLOGIST, P360; GROSSARTHMATICEK R, 1991, BEHAV RES THER, V29, P1; GROSSARTHMATICEK R, 1988, PERS INDIV DIFFER, V9, P479, DOI 10.1016/0191-8869(88)90125-0; GROSSARTHMATICEK R, 1991, BEHAV RES THER, V29, P343, DOI 10.1016/0005-7967(91)90070-J; KISSEN DM, 1962, J PSYCHOSOM RES, V6, P123, DOI 10.1016/0022-3999(62)90062-4; Lee PN., 1991, PSYCHOL INQ, V2, P251; PELOSI AJ, 1992, BRIT MED J, V304, P1295, DOI 10.1136/bmj.304.6837.1295; QUANDERBLAZNIK J, 1991, PERS INDIV DIFFER, V12, P125, DOI 10.1016/0191-8869(91)90095-S; SCHMALE AH, 1971, SOC SCI MED, V5, P95, DOI 10.1016/0037-7856(71)90090-4; SCHMITZ PG, 1992, PERS INDIV DIFFER, V13, P683, DOI 10.1016/0191-8869(92)90239-L; TEMOSHOK L, 1991, PSYCHOL INQUIRY, V2, P277; van der Ploeg HM, 1991, PSYCHOL INQ, V2, P280; 1991, PSYCHOL INQUIRY, V2, P233	22	11	11	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1666	1667		10.1136/bmj.306.6893.1666	http://dx.doi.org/10.1136/bmj.306.6893.1666			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LJ337	8324440	Bronze, Green Published			2022-12-28	WOS:A1993LJ33700030
J	DAVID, J; PRIORWILLEARD, PFS				DAVID, J; PRIORWILLEARD, PFS			RESUSCITATION SKILLS OF MRCP CANDIDATES	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BERKSHIRE HOSP,DEPT MED,READING RG3 1AG,BERKS,ENGLAND	Royal Berkshire Hospital	DAVID, J (corresponding author), BATTLE HOSP,DEPT MED,READING RG3 1AG,BERKS,ENGLAND.							MCINTYRE AS, 1993, J ROY COLL PHYS LOND, V27, P34; THWAITES BC, 1992, J ROY COLL PHYS LOND, V26, P265; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; WYNNE G, 1992, J ROY COLL PHYS LOND, V26, P372; 1987, J R COLL PHYSICIANS, V21, P2	5	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1578	1579		10.1136/bmj.306.6892.1578	http://dx.doi.org/10.1136/bmj.306.6892.1578			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329919	Green Published, Bronze			2022-12-28	WOS:A1993LH12800019
J	KRAPIVINSKY, GB; ACKERMAN, MJ; GORDON, EA; KRAPIVINSKY, LD; CLAPHAM, DE				KRAPIVINSKY, GB; ACKERMAN, MJ; GORDON, EA; KRAPIVINSKY, LD; CLAPHAM, DE			MOLECULAR CHARACTERIZATION OF A SWELLING-INDUCED CHLORIDE CONDUCTANCE REGULATORY PROTEIN, PL(CLN)	CELL			English	Article							CELL-VOLUME REGULATION; RESISTANCE P-GLYCOPROTEIN; EPITHELIAL-CELLS; CYSTIC-FIBROSIS; CL CHANNEL; MDCK CELLS; MEMBRANE; CYTOSKELETON; TRANSPORT; ACTIVATION	Cells maintain control of their volume by the passage of KCl and water across their membranes, but the regulatory proteins are unknown. Expression in Xenopus oocytes of a novel protein, pl(Cln), activated a chloride conductance. We have cloned analogs of pl(Cln), from rat heart and Xenopus ovary. pl(Cln) was identified as an abundant soluble cytosolic protein (similar to 40 kd) that does not immunolocalize with the plasma membrane. pl(Cln) was found in epithelial and cardiac cells, brain, and Xenopus oocytes, forming complexes with soluble actin and other cytosolic proteins. Monoclonal antibodies recognizing pl(Cln) blocked activation of a native hypotonicity-induced chloride conductance (I-Cl.swell) in Xenopus oocytes, suggesting that pin, may link actin-bound cytoskeletal elements to an unidentified volume-sensitive chloride channel. The high degree of sequence conservation and widespread expression of pl(Cln) suggest that it is an important element in cellular volume regulation.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428	NIDDK NIH HHS [NIDDK44025] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044025] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; BILLINGSLEY ML, 1990, METHOD ENZYMOL, V184, P451; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COLMAN A, 1984, PRACTICAL APPROACH S; DOROSHENKO P, 1992, J PHYSIOL-LONDON, V449, P197, DOI 10.1113/jphysiol.1992.sp019082; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FOSKETT JK, 1985, AM J PHYSIOL, V248, pC27, DOI 10.1152/ajpcell.1985.248.1.C27; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; JENNINGS ML, 1990, AM J PHYSIOL, V259, pC960, DOI 10.1152/ajpcell.1990.259.6.C960; KUBO M, 1992, J PHYSIOL-LONDON, V456, P351, DOI 10.1113/jphysiol.1992.sp019340; KUNZELMANN K, 1989, PFLUG ARCH EUR J PHY, V415, P172, DOI 10.1007/BF00370589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RS, 1993, J GEN PHYSIOL, V101, P801, DOI 10.1085/jgp.101.6.801; LEWIS SA, 1990, NEWS PHYSIOL SCI, V5, P112; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MILLS JW, 1985, MOL PHYSIOL, V8, P247; MILLS JW, 1987, CURR TOP MEMBR TRANS, V30, P75; MILLS JW, 1986, AM J PHYSIOL, V250, pC319, DOI 10.1152/ajpcell.1986.250.2.C319; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOSS DJ, 1992, EUR J CELL BIOL, V57, P59; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; SOLC CK, 1991, AM J PHYSL, V262; SOROTA S, 1992, CIRC RES, V70, P679, DOI 10.1161/01.RES.70.4.679; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TSENG GN, 1992, AM J PHYSIOL, V262, pC1056, DOI 10.1152/ajpcell.1992.262.4.C1056; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; YANTORNO RE, 1992, AM J PHYSIOL, V262, pC501, DOI 10.1152/ajpcell.1992.262.2.C501	42	207	217	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					439	448		10.1016/0092-8674(94)90109-0	http://dx.doi.org/10.1016/0092-8674(94)90109-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313467				2022-12-28	WOS:A1994MX20700006
J	IMURA, H; NAKAO, K; SHIMATSU, A; OGAWA, Y; SANDO, T; FUJISAWA, I; YAMABE, H				IMURA, H; NAKAO, K; SHIMATSU, A; OGAWA, Y; SANDO, T; FUJISAWA, I; YAMABE, H			LYMPHOCYTIC INFUNDIBULONEUROHYPOPHYSITIS AS A CAUSE OF CENTRAL DIABETES-INSIPIDUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA-CELL GRANULOMA; POSTERIOR PITUITARY; MR IMAGES; HYPERINTENSE SIGNAL; MAGNETIC-RESONANCE; HYPOPHYSITIS; CHILDREN; HISTIOCYTOSIS; ANTIBODIES; SECRETION	Background. Central diabetes insipidus may be familial, secondary to hypothalamic or pituitary disorders, or idiopathic. Idiopathic central diabetes insipidus is characterized by selective hypofunction of the hypothalamic-neurohypophysial system, but its cause is unknown. Methods. We studied 17 patients with idiopathic diabetes insipidus, in whom the duration of the disorder ranged from 2 months to 20 years. Only four patients had been treated with vasopressin before the study began. All the patients underwent endocrinologic studies and magnetic resonance imaging (MRI) with a 1.5-T superconducting unit, and two patients had biopsies of the neurohypophysis or the pituitary stalk. Results. Nine of the 17 patients had thickening of the pituitary stalk, enlargement of the neurohypophysis, or both and lacked the hyperintense signal of the normal neurohypophysis. In the remaining eight patients, the pituitary stalk and the neurohypophysis were normal, although the hyperintense signal was absent. The abnormalities of thickening and enlargement were seen on MRI only in the patients who had had diabetes insipidus for less than two years, and the abnormalities disappeared during follow-up, suggesting a self-limited process. In addition to vasopressin deficiency, two patients had mild hyperprolactinemia and nine had impaired secretory responses of growth hormone to insulin-induced hypoglycemia. The two biopsies revealed chronic inflammation, with infiltration of lymphocytes (mainly T lymphocytes) and plasma cells. Conclusions. Diabetes insipidus can be caused by lymphocytic infundibuloneurohypophysitis, which can be detected by MRI. The natural course of the disorder is self-limited.	KYOTO UNIV,FAC MED,DEPT RADIOL,KYOTO 60601,JAPAN; KYOTO UNIV HOSP,ANAT PATHOL LAB,KYOTO 606,JAPAN	Kyoto University; Kyoto University	IMURA, H (corresponding author), KYOTO UNIV,FAC MED,DEPT MED,KYOTO 60601,JAPAN.		Shimatsu, Akira/I-3856-2019	Ogawa, Yoshihiro/0000-0002-0834-2836				AOZASA K, 1990, INT J CANCER, V45, P632, DOI 10.1002/ijc.2910450410; ASA SL, 1981, ANN INTERN MED, V95, P166, DOI 10.7326/0003-4819-95-2-166; BAHNSEN U, 1992, EMBO J, V11, P19, DOI 10.1002/j.1460-2075.1992.tb05022.x; CACCIARI E, 1990, ARCH DIS CHILD, V65, P1199, DOI 10.1136/adc.65.11.1199; CANNELLA DM, 1988, J NEUROSURG, V69, P785, DOI 10.3171/jns.1988.69.5.0785; COLOMBO N, 1987, RADIOLOGY, V165, P481, DOI 10.1148/radiology.165.2.3659370; COSMAN F, 1989, MEDICINE, V68, P240, DOI 10.1097/00005792-198907000-00006; CZERNICHOW P, 1985, J PEDIATR-US, V106, P41, DOI 10.1016/S0022-3476(85)80461-3; FUJISAWA I, 1989, J COMPUT ASSIST TOMO, V13, P371, DOI 10.1097/00004728-198905000-00001; FUJISAWA I, 1987, J COMPUT ASSIST TOMO, V11, P221, DOI 10.1097/00004728-198703000-00004; FUJISAWA I, 1987, J COMPUT ASSIST TOMO, V11, P214, DOI 10.1097/00004728-198703000-00003; GOCHMAN GA, 1990, SURG NEUROL, V33, P347, DOI 10.1016/0090-3019(90)90204-3; GREGER NG, 1986, AM J DIS CHILD, V140, P551, DOI 10.1001/archpedi.1986.02140200061028; GUDINCHET F, 1989, AM J ROENTGENOL, V153, P351, DOI 10.2214/ajr.153.2.351; HIGUCHI M, 1992, CLIN ENDOCRINOL TO S, V40, P128; HORTEN BC, 1979, CANCER, V43, P258, DOI 10.1002/1097-0142(197901)43:1<258::AID-CNCR2820430137>3.0.CO;2-9; ITO M, 1991, J CLIN INVEST, V87, P725, DOI 10.1172/JCI115052; JENSEN MD, 1986, ANN INTERN MED, V105, P200, DOI 10.7326/0003-4819-105-2-200; KOJIMA H, 1989, ARCH PATHOL LAB MED, V113, P1399; KUCHARCZYK J, 1989, AM J ROENTGENOL, V152, P153, DOI 10.2214/ajr.152.1.153; MAGHNIE M, 1992, J CLIN ENDOCR METAB, V74, P795, DOI 10.1210/jc.74.4.795; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; MCCUTCHEON IE, 1991, J NEUROSURG, V74, P821, DOI 10.3171/jns.1991.74.5.0821; MOSES AM, 1982, ADV INTERNAL MED, V27, P73; NISHIMURA K, 1986, J COMPUT ASSIST TOMO, V10, P899, DOI 10.1097/00004728-198611000-00001; NUSSBAUM CE, 1991, NEUROSURGERY, V28, P440, DOI 10.1227/00006123-199103000-00019; SAITO T, 1970, J CLIN ENDOCR METAB, V31, P391, DOI 10.1210/jcem-31-4-391; SCHERBAUM WA, 1986, CLIN ENDOCRINOL, V25, P411, DOI 10.1111/j.1365-2265.1986.tb01707.x; SCHERBAUM WA, 1985, J PEDIATR-US, V107, P922, DOI 10.1016/S0022-3476(85)80190-6; SHIMA N, 1990, CANCER-AM CANCER SOC, V66, P1190, DOI 10.1002/1097-0142(19900915)66:6<1190::AID-CNCR2820660619>3.0.CO;2-U; TIEN R, 1991, AM J NEURORADIOL, V12, P533; TIEN RD, 1990, AM J NEURORADIOL, V11, P703; VANNESTE JAL, 1987, SURG NEUROL, V28, P145, DOI 10.1016/0090-3019(87)90089-9; YAMADA T, 1986, EUR J PHARMACOL, V125, P453, DOI 10.1016/0014-2999(86)90802-2; YOULTON R, 1969, PEDIATRICS, V43, P989	35	327	332	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					683	689		10.1056/NEJM199309023291002	http://dx.doi.org/10.1056/NEJM199309023291002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8345854				2022-12-28	WOS:A1993LU58300002
J	DODDS, TA				DODDS, TA			CABOT,RICHARD - MEDICAL REFORMER DURING THE PROGRESSIVE-ERA (1890-1920)	ANNALS OF INTERNAL MEDICINE			English	Article								Richard Cabot's (1868-1939) decision to leave full-time medical work in 1920 to teach social ethics illustrates some of the tensions inherent in twentieth-century medicine's transformation from clinical practice to a biomedical science. Cabot, then one of America's best known physicians, practiced medicine in an era in which science redefined medical practice and thinking. Although a champion of medical science, Cabot's primary concerns were clinical and humanistic. He emphasized the importance of ambulatory medicine, advocated group practice, founded hospital social work, did clinical epidemiologic research, lobbied for preventive medicine, created the Clinical-Pathologic Conference, and wrote extensively on medical ethics. In 1912, despite Cabot's great talents, a top professorship at Harvard Medical School was instead given to David Edsall, a clinician with more extensive basic science training. Cabot's efforts to define the physician's, as well as the health care system's, role in human well-being, however, presaged medicine's current attempts to emphasize the social context of the patient.			DODDS, TA (corresponding author), DEPT VET AFFAIRS MED CTR, WHITE RIVER JCT, VT 05009 USA.							Ackernecht E.H., 1982, SHORT HIST MED; ALTSCHULE MD, 1977, MED HARVARD 1ST 300, P175; AUB JC, 1970, PIONEER MODERN MED; BRIGGS LV, 1927, HIST GENEALOGY CABOT; Burrage Walter L., 1923, HIST MASSACHUSETTS M; CABOR RC, UNPUB RC CABOT PAPER, P71; CABOR RC, RC CABOT PAPERS; Cabot R.C., 1909, SOCIAL SERVICE ART H; Cabot R.C., 1903, AM MED, V5, P344; Cabot RC, 1907, BOSTON MED SURG J, V157, P150, DOI 10.1056/NEJM190708011570504; Cabot RC, 1910, J AMER MED ASSOC, V55, P1343, DOI 10.1001/jama.1910.04330160011005; Cabot RC, 1911, BOSTON MED SURG J, V164, P880, DOI 10.1056/NEJM191106221642503; Cabot RC, 1914, J AMER MED ASSOC, V63, P1461; CABOT RC, 1916, AM MAG, V81, P43; CABOT RC, 1908, RELIG MED PUBLICATIO, V5; CABOT RC, 1908, MCLURE, V31, P472; CABOT RC, 1950, B HIST MED ALLIED SC, V24, P462; CABOT RC, 1907, MARYLAND MED J, V50, P84; CABOT RC, 1911, WISC MED J, V10, P183; CABOT RC, 1901, PHYSICAL DIAGNOSIS; CABOT RC, 1920, BOSTON MED SURG J, V182, P287; CABOT RC, 1897, GUIDE CLIN EXAMINATI; CABOT RC, 1912, CHILD CITY, P41; CABOT RC, 1905, HARVARD ALUMNI B, V1, P32; CABOT RC, 1893, COMMUNICATION   0627; CABOT RC, 1894, BOSTON MED SURG J, V130, P277; CABOT RC, 1893, RC CABOT PAPERS; CABOT RC, 1912, MINOR MED REVOLUTION; CABOT RC, 1911, COMMUNICATION   0217; CABOT RC, 1918, TRAINING REWARDS PHY; CABOT RC, 1923, PHYSICIAN CROWDS OUT; CABOT RC, 1914, COMMUNICATION   0301; CABOT RC, 1915, MOD HOSP, V4; CABOT RC, 1908, ST PAUL MED J; Cabot Richard C., 1936, ART MINISTERING SICK; Cannon WB, 1900, BOSTON MED SURG J, V142, P563, DOI 10.1056/NEJM190005311422203; Cassell EJ, 1984, PLACE HUMANITIES MED; EDSALL DL, 1912, HARVARD MED SCH ARCH, V167, P639; ELIOT CW, 1907, COMMUNICATION   0727; FLEMING D, 1954, WH WELCH RISE MODERN; Flexner A, 1910, FLEXNER REPORT MED E; FLEXNER A, 1930, U AM ENGLISH ENGLISH, P95; HANDLIN O, 1959, BOSTONS IMMIGRANTS, P88; Hays S.P., 1964, PACIFIC NORTHWEAST Q, V55, P157; Hofstadter R, 1963, PROGR MOVEMENT 1900; LOCKE E, 1938, COMMUNICATION   0319; LUBOVE R, 1965, PROFESSIONAL ALTRUIS, P24; LUDMERER KM, 1985, LEARNING HEAL; MEANS JH, 1914, COMMUNICATION   0504; OBRIEN L, 1985, NEW ENGL QUART, V58, P533, DOI 10.2307/365560; ODEGAARD CE, 1986, DEAR DOCTOR PERSONAL, P48; OSLER W, 1911, COMMUNICATION   0108; Reiser S., 1978, MED REIGN TECHNOLOGY; ROGERS WR, 1979, NOURISHING HUMANISTI; ROSEN G, 1971, AM J PUBLIC HEALTH N, V61, P1620, DOI 10.2105/AJPH.61.8.1620; ROSENBERG CE, 1979, B HIST MED, V53, P346; ROSENBERG CE, 1974, J HIST MED ALL SCI, V24, P32; Rosenberg Charles E., 1987, CARE STRANGERS RISE; ROTHSTEIN W, 1972, AM PHYSICIANS 19TH C; Solomon Barbara Miller, 1965, ANCESTORS IMMIGRANTS; Starr P, 1982, SOCIAL TRANSFORMATIO; WARD PS, 1982, HARVARD MED SCH ALUM, V56, P30; Warner J.H., 1986, THERAPEUTIC PERSPECT; WASHBURN FA, 1950, B HIST MED ALLIED SC, V24, P462; WHITE K, 1988, TASK MED; White PD, 1939, NEW ENGL J MED, V220, P1049; WIEBE RH, 1967, SEARCH ORDER 1877-19; WILLIAMS THOMAS FRANKLIN, 1950, BULL HIST MED, V24, P462; [No title captured]	69	13	14	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					417	422		10.7326/0003-4819-119-5-199309010-00011	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338296				2022-12-28	WOS:A1993LZ47600011
J	WANNER, C; RADER, D; BARTENS, W; KRAMER, J; BREWER, HB; SCHOLLMEYER, P; WIELAND, H				WANNER, C; RADER, D; BARTENS, W; KRAMER, J; BREWER, HB; SCHOLLMEYER, P; WIELAND, H			ELEVATED PLASMA LIPOPROTEIN(A) IN PATIENTS WITH THE NEPHROTIC SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						NEPHROTIC SYNDROME; LIPOPROTEIN-(A); CORONARY ARTERIOSCLEROSIS; APOLIPOPROTEIN-A; THROMBOSIS	LP(A) GLYCOPROTEIN PHENOTYPES; CARDIOVASCULAR-DISEASE; SIZE HETEROGENEITY; GLYCEMIC CONTROL; RISK FACTOR; APOLIPOPROTEIN(A); SERUM; ATHEROSCLEROSIS; TRANSPLANTATION; HEMODIALYSIS	Objective: To examine the influence of the nephrotic syndrome on lipoprotein(a) [Lp(a)], a plasma lipoprotein associated with atherosclerotic cardiovascular disease independently of low-density lipoproteins. Factors that modulate plasma Lp(a) concentrations are poorly understood. Patients: A total of 62 patients: 47 with primary kidney disease and 15 with diabetic nephropathy. Measurements: Lipoprotein(a) levels were determined by enzyme-linked immunosorbent assay. Because apo(a) phenotype has a significant effect on Lp(a) levels, apo(a) isoforms were determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Western blotting, and immunoblotting; the data were compared with a healthy control group. Results: Nephrotic patients had significantly higher Lp(a) levels (mean, +/- SE, 69 +/- 10 mg/dL; median, 46 mg/dL, <0.01) compared with 91 healthy controls (mean, 18 +/- 2 mg/dL; median 9 mg/dL). Sixty percent of the patients and 18% of the controls had values greater than 30 mg/dL. Lipoprotein(a) levels correlated significantly with apolipoprotein B, serum cholesterol, and low-density lipoprotein cholesterol but showed no correlation with creatinine, albumin, or proteinuria. Within all apo(a) isoform classes, higher concentrations of Lp(a) were seen in the nephrotic patients compared with controls (P < 0.05). Finally, in nine patients with primary kidney disease and elevated Lp(a) levels, remission of the nephrotic syndrome was induced using immunosuppressive drugs and Lp(a) values decreased dramatically (pretreatment mean, 90 +/- 15 mg/dL versus remission mean, 31 +/- 8 mg/dL). A decrease in Lp(a) levels was also observed when patients with diabetic nephropathy progressed to end-stage renal disease (nephropathy mean, 56 +/- 11 mg/dL versus dialysis mean, 34 +/- 4 10 mg/dL; n = 7). Conclusions. Most patients with the nephrotic syndrome have Lp(a) concentrations that are substantially elevated compared with controls of the same apo(a) isoform. Because Lp(a) concentrations are substantially reduced when remission of the nephrotic syndrome is induced, it is likely that the nephrotic syndrome results directly in elevation of Lp(a) by an as yet unknown mechanism. The high levels of Lp(a) in the nephrotic syndrome could cause glomerular injury as well as increase the risk for atherosclerosis and thrombotic events associated with this disorder.	NHLBI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	WANNER, C (corresponding author), UNIV HOSP FREIBURG, DEPT MED, DIV NEPHROL, HUGSTETTERSTR 55, W-7800 FREIBURG, GERMANY.							ALTMAN DG, 1989, BRIT MED J, P20; APPEL GB, 1985, NEW ENGL J MED, V312, P1544, DOI 10.1056/NEJM198506133122404; BLACK IW, 1992, CLIN CHEM, V38, P353; BOERWINKLE E, 1989, HUM GENET, V82, P73, DOI 10.1007/BF00288277; BRUCKERT E, 1990, JAMA-J AM MED ASSOC, V263, P35, DOI 10.1001/jama.1990.03440010033016; Cameron J, 1988, NEPHROTIC SYNDROME, P849; CAMPBELL MJ, 1989, BRIT MED J, P71; CRESSMAN MD, 1992, CIRCULATION, V86, P475, DOI 10.1161/01.CIR.86.2.475; CURRY RC, 1977, AM J MED, V63, P183, DOI 10.1016/0002-9343(77)90231-5; FLESS GM, 1989, J LIPID RES, V30, P651; FUJITA T, 1992, NEPHRON, V61, P122, DOI 10.1159/000186854; GAUBATZ JW, 1990, J LIPID RES, V31, P603; HAFFNER SM, 1992, METABOLISM, V41, P116, DOI 10.1016/0026-0495(92)90136-X; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JENKINS AJ, 1991, DIABETES, V40, P787, DOI 10.2337/diabetes.40.6.787; KARADI I, 1989, CLIN CHEM, V35, P2121; KNIGHT BL, 1991, ATHEROSCLEROSIS, V87, P227, DOI 10.1016/0021-9150(91)90025-X; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KREMPLER F, 1980, J CLIN INVEST, V65, P1483, DOI 10.1172/JCI109813; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P672, DOI 10.1161/01.ATV.10.5.672; MALLICK NP, 1981, NEPHRON, V27, P54, DOI 10.1159/000182024; MARSH JB, 1960, METABOLISM, V9, P946; MBEWU AD, 1990, ATHEROSCLEROSIS, V85, P1, DOI 10.1016/0021-9150(90)90177-K; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; MOORHEAD JF, 1982, LANCET, V2, P1309; ORDONEZ JD, 1990, KIDNEY INT, V37, P243; PARRA HJ, 1987, CLIN CHEM, V33, P721; RADER DJ, 1993, J CLIN INVEST, V91, P443, DOI 10.1172/JCI116221; SATO H, 1993, KIDNEY INT, V43, P430, DOI 10.1038/ki.1993.63; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; STAPRANS I, 1980, BIOCHIM BIOPHYS ACTA, V617, P514, DOI 10.1016/0005-2760(80)90017-X; THOMAS ME, 1992, NEPHROL DIAL TRANSPL, V7, P597, DOI 10.1093/ndt/7.7.597; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; WASS VJ, 1979, LANCET, V2, P664; WEBB AT, 1992, NEPHROL DIAL TRANSPL, V7, P636; WIELAND H, 1982, CLIN CHEM, V28, P1335	42	151	152	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					263	269		10.7326/0003-4819-119-4-199308150-00002	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328733				2022-12-28	WOS:A1993LV52500002
J	FORREST, S				FORREST, S			GENETIC ALGORITHMS - PRINCIPLES OF NATURAL-SELECTION APPLIED TO COMPUTATION	SCIENCE			English	Article								A genetic algorithm is a form of evolution that occurs on a computer. Genetic algorithms are a search method that can be used for both solving problems and modeling evolutionary systems. With various mapping techniques and an appropriate measure of fitness, a genetic algorithm can be tailored to evolve a solution for many types of problems, including optimization of a function or determination of the proper order of a sequence. Mathematical analysis has begun to explain how genetic algorithms work and how best to use them. Recently, genetic algorithms have been used to model several natural evolutionary systems, including immune systems.			FORREST, S (corresponding author), UNIV NEW MEXICO, DEPT COMP SCI, ALBUQUERQUE, NM 87131 USA.							[Anonymous], 1991, HDB GENETIC ALGORITH; ANTONISSE HJ, 1987, 2ND P INT C GEN ALG, P69; Axelrod R., 1987, GENETIC ALGORITHMS S; AXELROD R, 1986, AM POLIT SCI REV, P80; Back T, 1993, EVOL COMPUT, V1, P1, DOI 10.1162/evco.1993.1.1.1; BEAN JC, IN PRESS J COMPUT; BELEW RK, 1991, 4TH P INT C GEN ALG; BERGMAN A, 1992, PHYSICA D, V56, P57, DOI 10.1016/0167-2789(92)90050-W; Bethke A., 1980, THESIS U MICHIGAN AN; Booker L. B, 1993, FDN GENETIC ALGORITH, V2, P29; BOOKER LB, IN PRESS BASIC PARAD, V1; BOX GEP, 1957, APPLIED STATISTICS, V6, P81; Davidor Y., 1991, WORLD SCI SERIES ROB; DAVIS L, 1987, 2ND P INT C GEN ALG, P252; Davis L., 1991, HDB GENETIC ALGORITH, DOI DOI 10.1.1.87.3586; Dawkins R, 1989, ARTIF LIFE, P201; DeJong K, 1975, THESIS U MICHIGAN AN; FARMER JD, 1986, PHYSICA D, V22, P187, DOI 10.1016/0167-2789(86)90240-X; FOGEL DB, 1990, BIOL CYBERN, V63, P111, DOI 10.1007/BF00203032; Fogel L. J., 1966, ARTIF INTELL; FORREST S, IN PRESS EVOL COMPUT; FORREST S, IN PRESS MACH LEARN; GLOVER DE, 1987, GENETIC ALGORITHMS S, P12; Goldberg D., 1985, P 1 INT C GEN ALG TH, V1, P154, DOI DOI 10.4324/9781315799674; Goldberg D. E., 1991, Complex Systems, V5, P139; Goldberg D. E., 1992, Complex Systems, V6, P333; Goldberg D. E., 1989, Complex Systems, V3, P153; Goldberg D. E., 1989, COMPLEX SYST, V3, P493, DOI DOI 10.1007/978-1-4757-3643-4; GOLDBERG DE, IN PRESS COMMUN ACM; GOLDBERG DE, 1989, GENETIC ALGORITHSM S; Grefenstette J., 1985, PROC 1 INT C GENET A, V160, P160; GREFENSTETTE JJ, 1987, 2ND P INT C GEN ALG; GREFENSTETTE JJ, 1989, 3RD P INT C GEN ALG; GREFENSTETTE JJ, 1985, P INT C GENETIC ALGO; HIGHTOWER R, IN PRESS 2ND EUR C A; HILLIS WD, 1990, PHYSICA D, V42, P228, DOI 10.1016/0167-2789(90)90076-2; Holland J., 1962, J ACM, V3, P297; Holland J.H., 1975, ADAPTATION NATURAL A, DOI DOI 10.7551/MITPRESS/1090.001.0001; HOLLAND JH, IN PRESS INTEGRATIVE; HOLLAND JH, 1988, EVOLUTION LEARNING C; Koza JR, 1992, GENETIC PROGRAMMING; Liepins G. E., 1990, Journal of Experimental and Theoretical Artificial Intelligence, V2, P101, DOI 10.1080/09528139008953717; MANDERICK B, 1991, 4TH P INT C GEN ALG; MUHLENBEIN H, 1988, PARALLEL COMPUT, V7, P65, DOI 10.1016/0167-8191(88)90098-1; PACKARD NH, 1990, COMPLEX SYST, V4; Rechenberg I, 1965, CYBERNETIC SOLUTION, V1122; ROS JP, 1993, FDN GENETIC ALGORITH, V2, P257; SCHAFER CG, 1987, 2ND P INT C GEN ALG, P50; SCHAFER JD, 1989, 3RD P INT C GEN ALGO; SCHAFFER JD, 1989, 3RD P INT C GEN ALG; Schaffer JD, 1985, P 1 INT C GEN ALG TH; SCHRAUDOLPH NN, 1992, MACH LEARN, V9, P9, DOI 10.1007/BF00993252; SIMS K, 1991, COMP GRAPH, V25, P319, DOI 10.1145/127719.122752; SMITH D, 1985, P INT C GENETIC ALGO, P202; Smith R. E., 1992, Complex Systems, V6, P251; SMITH RE, IN PRESS EVOL COMPUT; SYSWERDA G, 1989, 3RD P INT C GEN ALGO; Tanese R., 1989, DISTRIBUTED GENETIC; ULDER NLJ, 1991, LECT NOTES COMPUT SC, V496, P109, DOI 10.1007/BFb0029740; Wilson S. W., 1987, Machine Learning, V2, P199, DOI 10.1023/A:1022655214215; [No title captured]	63	571	599	1	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1993	261	5123					872	878		10.1126/science.8346439	http://dx.doi.org/10.1126/science.8346439			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346439				2022-12-28	WOS:A1993LR89700027
J	BASOGLU, M				BASOGLU, M			PREVENTION OF TORTURE AND CARE OF SURVIVORS - AN INTEGRATED APPROACH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMATIC STRESS DISORDER; VIETNAM COMBAT VETERANS; PRISONERS; WAR; VICTIMS	An analysis of the 1992 Amnesty International report demonstrates the nature and global distribution of reports of human rights violations. Systematic torture was reported in 93 of 204 countries. Reports of torture were more common from regions affected by political unrest, including mass demonstrations, riots, outbreaks of violence, killings, coup attempts, civil war, armed tribal conflict, rebellions, and conflicts with various opposition groups demanding social and political reform. These observations suggest that effective measures against torture require a multilevel analysis of underlying social, political, cultural, and psychological factors. Effective care of survivors of organized violence and torture is an indispensable component of the human rights struggle and needs more scientific attention. An integrated approach involving both preventive efforts and care of survivors can promote the human rights cause.			BASOGLU, M (corresponding author), UNIV LONDON,INST PSYCHIAT,99 DENMARK HILL,LONDON SE5 8AF,ENGLAND.		Basoglu, Metin/A-1394-2008					ABILDGAARD U, 1984, DAN MED BULL, V31, P239; Agger I., 1990, J TRAUMA STRESS, V3, P115, DOI DOI 10.1002/JTS.2490030109; ALLODI F, 1982, CAN J PSYCHIAT, V27, P98, DOI 10.1177/070674378202700203; BARRETT TW, 1988, BEHAV MODIF, V12, P100, DOI 10.1177/01454455880121005; BASOGLU M, 1988, BMJ-BRIT MED J, V297, P1423, DOI 10.1136/bmj.297.6661.1423; Basoglu M., 1992, TORTURE ITS CONSEQUE, P182; Basoglu M., 1992, TORTURE ITS CONSEQUE, P402; BASOGLU M, IN PRESS SCI REFUGE; BASOGLU M, IN PRESS ROLE PSYCHI; Basoglu M., 1992, TORTURE ITS CONSEQUE, P1; BASOGLU M, 1991, J TRAUMA STRESS, V5, P77; BEEBE GW, 1975, AM J EPIDEMIOL, V101, P400, DOI 10.1093/oxfordjournals.aje.a112108; BENYAKAR M, 1978, ISR J PSYCHIAT REL D, V16, P183; BLOCH HS, 1969, AM J PSYCHIAT, V126, P289, DOI 10.1176/ajp.126.3.289; Bustos Enrique, 1992, TORTURE ITS CONSEQUE, P333; CARROLL EM, 1985, J ABNORM PSYCHOL, V94, P329, DOI 10.1037/0021-843X.94.3.329; CIENFUEGOS AJ, 1983, AM J ORTHOPSYCHIAT, V53, P43, DOI 10.1111/j.1939-0025.1983.tb03348.x; CRYER L, 1980, J SEX MARITAL THER, V6, P40, DOI 10.1080/00926238008404244; Dowdall T.L., 1992, TORTURE ITS CONSEQUE, P452; EGENDORF A, 1975, J SOC ISSUES, V31, P111, DOI 10.1111/j.1540-4560.1975.tb01015.x; GIBSON JT, 1990, TORTURE PSYCHOL, P77; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; HAYWOOD CH, 1975, CRISIS INTERVENTION, V6, P43; JONES FD, 1975, J SOC ISSUES, V31, P49; KLUZNIK JC, 1986, AM J PSYCHIAT, V143, P1443; MARKS IM, 1987, FEARS PHOBIAS; MILLER TW, 1989, COMPR PSYCHIAT, V30, P139, DOI 10.1016/0010-440X(89)90066-7; MOLLICA R, 1992, TORTURE CONSEQUENCES, P23; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; MOLLICA RF, 1992, TORTURE ITS CONSEQUE, P253; PARKER MP, 1992, TORTURE ITS CONSEQUE, P72; Peters E., 1985, TORTURE; RASOGLU M, IN PRESS AM J PSYCHI; ROBERTS WR, 1982, J ABNORM PSYCHOL, V91, P444, DOI 10.1037/0021-843X.91.6.444; Saporta Jose A., 1992, TORTURE ITS CONSEQUE, P151; Skylv G., 1992, TORTURE ITS CONSEQUE, Vfirst, P38; SOLKOFF N, 1992, TORTURE ITS CONSEQUE, P136; SOMNIER F, 1992, TORTURE ITS CONSEQUE, P56; SOMNIER FE, 1986, BRIT J PSYCHIAT, V149, P323, DOI 10.1192/bjp.149.3.323; STAUB E, 1990, TORTURE PSYCHOL, P49; SUEDFELD P, 1990, PSYCHOL TORTURE, P1; TENNANT C, 1986, PSYCHOL MED, V16, P833, DOI 10.1017/S0033291700011843; VANWILLIGEN L, 1992, TORTURE ITS CONSEQUE, P277; Vesti Peter, 1992, TORTURE ITS CONSEQUE, P348; 1992, 1992 AMN INT REP; 1992, 2001 AM INT DOC; 1984, TORTURE 80S; 1993, TORTURE, V3, P31	48	32	32	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					606	611		10.1001/jama.270.5.606	http://dx.doi.org/10.1001/jama.270.5.606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331760				2022-12-28	WOS:A1993LP43600026
J	RONCHI, E; TREISMAN, J; DOSTATNI, N; STRUHL, G; DESPLAN, C				RONCHI, E; TREISMAN, J; DOSTATNI, N; STRUHL, G; DESPLAN, C			DOWN-REGULATION OF THE DROSOPHILA MORPHOGEN BICOID BY THE TORSO RECEPTOR-MEDIATED SIGNAL-TRANSDUCTION CASCADE	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; HEAD DEVELOPMENT; TYROSINE KINASE; TRANSCRIPTIONAL ACTIVATOR; ORTHODENTICLE GENE; ANTERIOR PATTERN; TERMINAL ANLAGEN; EMPTY SPIRACLES; GAP GENE; EMBRYO	Anterior body pattern in Drosophila is specified by the graded distribution of the bicoid protein (bcd), which activates subordinate genes in distinct anterior domains. Subsequently, transcription of these target genes is repressed at the anterior pole owing to the activity of the receptor tyrosine kinase torso (tor). We show that both activation by bcd and repression by tor can be reproduced by a minimal promoter containing only bcd-binding sites upstream of a naive transcriptional start site. Repression requires the D-raf kinase and is associated with phosphorylation of bcd protein. Repression does not require either tailless or huckebein, which were previously thought to constitute the sole zygotic output of the tor signaling system. Finally, addition of a heterologous transcriptional activation domain to bcd renders the protein insensitive to tor-mediated repression. We propose that phosphorylation resulting from the activity of the tor signal transduction cascade down-regulates transcriptional activation by the bcd morphogen.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	RONCHI, E (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021, USA.			Desplan, Claude/0000-0002-6914-1413; Treisman, Jessica/0000-0002-7453-107X				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1990, DEVELOPMENT, V110, P621; CHOU TB, 1992, GENETICS, V131, P643; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MELNICK MB, 1993, DEVELOPMENT, V118, P127; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSLEINVOLHARD C, 1991, DEVELOPMENT S1, V13, P1; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; PIGNONI F, 1992, DEVELOPMENT, V115, P239; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1992, CELL, V68, P201; STRECKER TR, 1991, P NATL ACAD SCI USA, V88, P5824, DOI 10.1073/pnas.88.13.5824; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREISMAN J, 1989, CELL, V59, P553; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WALLDORF U, 1992, EMBO J, V11, P2247, DOI 10.1002/j.1460-2075.1992.tb05284.x; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158	45	90	91	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					347	355		10.1016/0092-8674(93)90425-P	http://dx.doi.org/10.1016/0092-8674(93)90425-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343961				2022-12-28	WOS:A1993LP72600015
J	AYANIAN, JZ; KOHLER, BA; ABE, T; EPSTEIN, AM				AYANIAN, JZ; KOHLER, BA; ABE, T; EPSTEIN, AM			THE RELATION BETWEEN HEALTH-INSURANCE COVERAGE AND CLINICAL OUTCOMES AMONG WOMEN WITH BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LATE-STAGE DIAGNOSIS; SOCIOECONOMIC-STATUS; HOSPITAL PATIENTS; ECONOMIC-FACTORS; MARITAL-STATUS; MEDICAL-CARE; SOCIAL-CLASS; SURVIVAL; MAMMOGRAPHY; MORTALITY	Background. Women without private health insurance are less likely than privately insured women to be screened for breast cancer, and their treatment may differ after cancer is diagnosed. In this study we addressed two related questions: Do uninsured patients and those covered by Medicaid have more advanced breast cancer than privately insured patients when the disease is initially diagnosed? And, for each stage of disease, do uninsured patients and patients covered by Medicaid die sooner after breast cancer is diagnosed than privately insured patients? Methods. We studied 4675 women, 35 to 64 years of age, in whom invasive breast cancer was diagnosed from 1985 through 1987, by linking New Jersey State Cancer Registry records to hospital-discharge data. We compared the stage of disease and stage-specific survival among women with private insurance, no insurance, and Medicaid coverage through June 1992. We also estimated the adjusted risk of death for these groups, using proportional-hazards regression analysis to control for age, race, marital status, household income, coexisting diagnoses, and disease stage. Results. Uninsured patients and those covered by Medicaid presented with more advanced disease than did privately insured patients (P<0.001 and P = 0.01, respectively). Survival was worse for uninsured patients and those with Medicaid coverage than for privately insured patients with local disease (P<0.001 for both comparisons) and regional disease (P<0.001 for both comparisons), but not distant metastases. The adjusted risk of death was 49 percent higher (95 percent confidence interval, 20 to 84 percent) for uninsured patients and 40 percent higher (95 percent confidence interval, 4 to 89 percent) for Medicaid patients than for privately insured patients during the 54 to 89 months after diagnosis. Conclusions. The more frequent adverse outcomes of breast cancer among women without private health insurance suggest that such women would benefit from improved access to screening and optimal therapy.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, HLTH SERV & POLICY RES SECT, BOSTON, MA 02115 USA; NEW JERSEY DEPT HLTH, STATE CANC REGISTRY, TRENTON, NJ USA	Harvard University; Brigham & Women's Hospital; New Jersey Department of Health & Senior Services	AYANIAN, JZ (corresponding author), HARVARD UNIV, SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST, PARCEL B, 1ST FL, BOSTON, MA 02115 USA.							ABE T, 1991, MOST FREQIUENT CANCE, V2; ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; BERG JW, 1977, CANCER, V39, P467, DOI 10.1002/1097-0142(197702)39:2<467::AID-CNCR2820390215>3.0.CO;2-B; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BRAVEMAN PA, 1991, JAMA-J AM MED ASSOC, V266, P3300, DOI 10.1001/jama.266.23.3300; BURACK RC, 1989, PUBLIC HEALTH REP, V104, P527; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; COHEN JW, 1989, HEALTH SERV RES, V24, P33; CORNELIUS L, 1991, AHCPR910042 AG HLTH; DAVIS K, 1983, MILBANK FUND Q, V61, P149, DOI 10.2307/3349903; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DUFFY SW, 1991, BRIT J CANCER, V64, P1133, DOI 10.1038/bjc.1991.477; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; GOODWIN JS, 1987, JAMA-J AM MED ASSOC, V258, P3125, DOI 10.1001/jama.258.21.3125; GREENBERG ER, 1988, NEW ENGL J MED, V318, P612, DOI 10.1056/NEJM198803103181006; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HAND R, 1991, JAMA-J AM MED ASSOC, V266, P3429, DOI 10.1001/jama.266.24.3429; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; KLEMI PJ, 1992, BRIT MED J, V304, P467, DOI 10.1136/bmj.304.6825.467; LACEY LP, 1989, PUBLIC HEALTH REP, V104, P536; LIPWORTH L, 1970, J CHRON DIS, V23, P105, DOI 10.1016/0021-9681(70)90069-X; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MCCOY CB, 1991, CANCER S, V67, P808; Moore K G, 1992, Womens Health Issues, V2, P40, DOI 10.1016/S1049-3867(05)80136-7; NEALE AV, 1986, SOC SCI MED, V23, P305, DOI 10.1016/0277-9536(86)90352-7; RIES P, 1989, PHS911250 PUBL HLTH; Romans M C, 1991, Womens Health Issues, V1, P68, DOI 10.1016/S1049-3867(05)80018-0; SHAMBAUGH EM, 1986, NIH862313 PUBL; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; VERNON SW, 1990, SOC SCI MED, V30, P1107, DOI 10.1016/0277-9536(90)90297-6; WAXLERMORRISON N, 1991, SOC SCI MED, V33, P177, DOI 10.1016/0277-9536(91)90178-F; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; Wilensky G, 1982, Health Aff (Millwood), V1, P93, DOI 10.1377/hlthaff.1.4.93; WOOLHANDLER S, 1988, Journal of the American Medical Association, V259, P2872, DOI 10.1001/jama.259.19.2872; YERGAN J, 1988, MED CARE, V26, P1111, DOI 10.1097/00005650-198811000-00009; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; YUDKOWSKY BK, 1990, PEDIATRICS, V85, P567; ZAPKA JG, 1989, AM J PUBLIC HEALTH, V79, P1499, DOI 10.2105/AJPH.79.11.1499; 1991, SAS STAT SOFTWARE PH; 1989, SAS STAT USERS GUIDE; 1988, MANUAL STAGING CANCE; 1991, PHS911232 DHHS PUBL	51	520	525	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					326	331		10.1056/NEJM199307293290507	http://dx.doi.org/10.1056/NEJM199307293290507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8321261				2022-12-28	WOS:A1993LN62100007
J	KLEIN, D; ONO, H; OHUIGIN, C; VINCEK, V; GOLDSCHMIDT, T; KLEIN, J				KLEIN, D; ONO, H; OHUIGIN, C; VINCEK, V; GOLDSCHMIDT, T; KLEIN, J			EXTENSIVE MHC VARIABILITY IN CICHLID FISHES OF LAKE MALAWI	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; EVOLUTION; GENES	LAKE Malawi in East Africa harbours 500-1,000 endemic species of cichlid fishes, all presumably derived by adaptive radiation from a single founding population within the past two million years1-3. The species of this 'flock' differ strikingly in their ecology and behaviour4, moderately in their external morphology1 and very little in their molecular characteristics5,6. Here we describe high sequence variability of class II major histocompatibility complex genes in a sample of species from Lake Malawi. The variability provides a set of molecular markers for studying adaptive radiation and should be useful for estimating the size of the population that founded the species flock.	MAX PLANCK INST BIOL,IMMUNGENET ABT,W-7400 TUBINGEN,GERMANY; LEIDEN UNIV,ZOOL LAB,ECOL MORPHOL RES GRP,2300 RA LEIDEN,NETHERLANDS; YOKOHAMA CITY UNIV,SCH MED,DEPT DERMATOL,KANAZAWA KU,YOKOHAMA 236,JAPAN	Max Planck Society; Leiden University; Leiden University - Excl LUMC; Yokohama City University	KLEIN, D (corresponding author), UNIV MIAMI,DEPT MICROBIOL & IMMUNOL,MIAMI,FL 33101, USA.							Eccles D. H., 1989, MALAWIAN CICHLID FIS; Fryer G, 1972, CICHLID FISHES GREAT; FRYER GEOFFREY, 1959, PROC ZOOL SOC LONDON, V132, P153; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KLEIN J, 1986, CRC CR REV IMMUNOL, V6, P295; KLEIN J, 1986, NATURAL HIST MAJOR H; Kornfield I., 1991, P103; Lewis D., 1986, GUIDE FISHES LAKE MA; MACKAYE KR, 1982, ZOOL J LINN SOC-LOND, V76, P91; ONO H, 1992, P NATL ACAD SCI USA, V89, P11886, DOI 10.1073/pnas.89.24.11886; ONO H, IN PRESS MOL BIOL EV; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ZHU ZF, 1991, MOL BIOL EVOL, V8, P563	14	124	130	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					330	334		10.1038/364330a0	http://dx.doi.org/10.1038/364330a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332189				2022-12-28	WOS:A1993LN57000055
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INTERNATIONAL-CONFERENCE ON HARMONIZING TECHNICAL REQUIREMENTS FOR DRUG APPROVALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1993, FED REG         0512, V58, P28194	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					302	302		10.1001/jama.270.3.302	http://dx.doi.org/10.1001/jama.270.3.302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8315763				2022-12-28	WOS:A1993LM43500006
J	KNIGHT, SJL; FLANNERY, AV; HIRST, MC; CAMPBELL, L; CHRISTODOULOU, Z; PHELPS, SR; POINTON, J; MIDDLETONPRICE, HR; BARNICOAT, A; PEMBREY, ME; HOLLAND, J; OOSTRA, BA; BOBROW, M; DAVIES, KE				KNIGHT, SJL; FLANNERY, AV; HIRST, MC; CAMPBELL, L; CHRISTODOULOU, Z; PHELPS, SR; POINTON, J; MIDDLETONPRICE, HR; BARNICOAT, A; PEMBREY, ME; HOLLAND, J; OOSTRA, BA; BOBROW, M; DAVIES, KE			TRINUCLEOTIDE REPEAT AMPLIFICATION AND HYPERMETHYLATION OF A CPG ISLAND IN FRAXE MENTAL-RETARDATION	CELL			English	Article							FRAGILE-X-SYNDROME; BULBAR MUSCULAR-ATROPHY; MYOTONIC-DYSTROPHY; FMR-1 GENE; DNA; SITES; CHROMOSOME; REGION; INSTABILITY; METHYLATION	We have cloned the fragile site FRAXE and demonstrate that individuals with this fragile site possess amplifications of a GCC repeat adjacent to a CpG island in Xq28 of the human X chromosome. Normal individuals have 6-25 copies of the GCC repeat, whereas mentally retarded, FRAXE-positive individuals have >200 copies and also have methylation at the CpG island. This situation is similar to that seen at the FRAXA locus and is another example in which a trinucleotide repeat expansion is associated with a human genetic disorder. In contrast with the fragile X syndrome, the GCC repeat can expand or contract and is equally unstable when passed through the male or female line. These results also have implications for the understanding of chromosome fragility.	INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS	University of London; University College London; University of London; King's College London; Erasmus University Rotterdam	KNIGHT, SJL (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.			Tinsley, Louise/0000-0002-6893-2096; Knight, Samantha/0000-0002-6047-3462	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CHAKRAVARTI A, 1992, NAT GENET, V1, P237, DOI 10.1038/ng0792-237; DENNIS NR, 1992, AM J MED GENET, V43, P232, DOI 10.1002/ajmg.1320430137; DEVRIES BBA, 1993, EUR J HUM GENET, V1, P72; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLYNN GA, 1993, J MED GENET, V30, P97, DOI 10.1136/jmg.30.2.97; FRYNS JP, 1989, FRAGILE X SYNDROME, P1; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, AM J HUM GENET, V43, P265; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HIRST MC, 1991, NUCLEIC ACIDS RES, V19, P3283, DOI 10.1093/nar/19.12.3283; HIRST MC, 1993, HUM MOL GENET, V2, P197, DOI 10.1093/hmg/2.2.197; HIRST MC, 1991, J MED GENET, V28, P824, DOI 10.1136/jmg.28.12.824; HIRST MC, 1993, IN PRESS J MED GENET; HOLLAND J, 1993, GENOMICS, V15, P297, DOI 10.1006/geno.1993.1060; KEIVITS T, 1990, CYTOGENET CELL GENET, V53, P134; KNIGHT SJL, 1992, AM J MED GENET, V43, P217, DOI 10.1002/ajmg.1320430135; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEHRACH H., 1990, GENOME ANAL, P39; LUBS HA, 1969, AM J HUM GENET, V21, P231; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MIRO R, 1987, HUM GENET, V75, P345, DOI 10.1007/BF00284105; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OUDET C, 1993, AM J HUM GENET, V52, P297; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; POUSTKA A, 1991, P NATL ACAD SCI USA, V88, P8302, DOI 10.1073/pnas.88.19.8302; REYNIERS E, 1993, IN PRESS NATURE GENE; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; ROUSSEAU F, 1991, J MED GENET, V28, P830, DOI 10.1136/jmg.28.12.830; Sambrook J, 1989, MOL CLONING LABORATO; SANZ MM, 1986, AM J MED GENET, V23, P491, DOI 10.1002/ajmg.1320230141; SMEETS DFCM, 1990, CYTOGENET CELL GENET, V53, P8, DOI 10.1159/000132885; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; Sutherland G, 1985, FRAGILE SITES HUMAN; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; SUTHERLAND GR, 1977, SCIENCE, V197, P256; Sutherland Grant R., 1992, Human Molecular Genetics, V1, P111, DOI 10.1093/hmg/1.2.111; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; VOELCKEL MA, 1988, HUM GENET, V80, P375, DOI 10.1007/BF00273654; VOELCKEL MA, 1989, HUM GENET, V81, P353, DOI 10.1007/BF00283690; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WURSTERHILL DH, 1988, CYTOGENET CELL GENET, V49, P278, DOI 10.1159/000132677; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]; 1993, CELL, V72, P971	56	502	515	3	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					127	134		10.1016/0092-8674(93)90300-F	http://dx.doi.org/10.1016/0092-8674(93)90300-F			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334699				2022-12-28	WOS:A1993LN62500013
J	RIDSDALE, L; EVANS, A; JERRETT, W; MANDALIA, S; OSLER, K; VORA, H				RIDSDALE, L; EVANS, A; JERRETT, W; MANDALIA, S; OSLER, K; VORA, H			PATIENTS WITH FATIGUE IN GENERAL-PRACTICE - A PROSPECTIVE-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To describe the characteristics of patients attending their general practitioners and complaining of fatigue or being ''tired all the time.'' Design-Prospective study of cohort aged 16 years and older with follow up at two weeks and by questionnaires at two and six months. Subjects-220 patients (164 women) with mean age 43 years and an age-sex matched comparison group. Settings-Doctors and patients in four practices in Lancashire, Mid Glamorgan, Suffolk, and Surrey. Main outcome measure-General clinical data, results from standard group of laboratory tests, fatigue questionnaire, and 12 item general health questionnaire. Results-Over twice as many patients with fatigue had high scores on the health questionnaire compared with the comparison group (156 (75%) v 69 (34%)). Results of laboratory tests were abnormal and contributed to the diagnosis in 19 patients. 59 out of 102 patients who responded had high fatigue scores six months later. Patients with persistent fatigue were more likely to have a history of anxiety or depression and to have had fatigue for more than three months on entry to the study. Conclusions-Women are particularly at risk of fatigue. The outcome is better if patients have had symptoms for three months or less or there is no history of emotional illness.	UNIV LEEDS, ST JAMES HOSP, DEPT GEN PRACTICE, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; OLD SCH SURG, PONTYCLUN, M GLAM, WALES; THE SURGERY, SUFFOLK IP16 4ES, ENGLAND	Saint James's University Hospital; University of Leeds	RIDSDALE, L (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT GEN PRACTICE, LONDON SE11 6SP, ENGLAND.			Ridsdale, Leone/0000-0002-2234-2859				CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; Hannay D R, 1978, J R Coll Gen Pract, V28, P492; JERRETT WA, 1981, PRACTITIONER, V225, P731; Morrell D C, 1976, J R Coll Gen Pract, V26, P398; MORRELL DC, 1972, J ROY COLL GEN PRACT, V22, P295; RIDSDALE L, 1991, BRIT MED J, V303, P1490, DOI 10.1136/bmj.303.6816.1490; VALDINI A, 1989, FAM PRACT, V6, P286, DOI 10.1093/fampra/6.4.286; VALDINI AF, 1988, J FAM PRACTICE, V26, P33; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940	11	85	85	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1993	307	6896					103	106		10.1136/bmj.307.6896.103	http://dx.doi.org/10.1136/bmj.307.6896.103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343705	Green Published, Bronze			2022-12-28	WOS:A1993LM58500027
J	MOZES, E; KOHN, LD; HAKIM, F; SINGER, DS				MOZES, E; KOHN, LD; HAKIM, F; SINGER, DS			RESISTANCE OF MHC CLASS-I-DEFICIENT MICE TO EXPERIMENTAL SYSTEMIC LUPUS-ERYTHEMATOSUS	SCIENCE			English	Article							T-CELLS; INDUCTION; IDIOTYPE	Experimental systemic lupus erythematosus (SLE) can be induced in mice by immunization with a human monoclonal antibody to DNA that bears a common idiotype (16/6Id). These mice generate antibodies to 16/6Id, antibodies to DNA, and antibodies directed against nuclear antigens. Subsequently, manifestations of SLE develop, including leukopenia, proteinuria, and immune complex deposits in the kidney. In contrast, after immunization with 16/6Id, mice lacking major histocompatibility complex (MHC) class I molecules generated antibodies to 16/6Id but did not generate antibodies to DNA or to nuclear antigen. Furthermore, they did not develop any of the above clinical manifestations. These results reveal an unexpected function of MHC class I in the induction of autoimmune SLE.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								FRICKE H, 1991, IMMUNOLOGY, V73, P421; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; MENDLOVIC S, 1990, IMMUNOLOGY, V69, P228; MENDLOVIC S, 1989, EUR J IMMUNOL, V19, P729, DOI 10.1002/eji.1830190424; MENDLOVIC S, 1988, P NATL ACAD SCI USA, V85, P2260, DOI 10.1073/pnas.85.7.2260; MOZES E, UNPUB; RUIZ P, UNPUB; SHOENFELD Y, 1983, J EXP MED, V158, P718, DOI 10.1084/jem.158.3.718; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; TALAL N, 1977, AUTOIMMUNITY GENETIC; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	13	107	107	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					91	93		10.1126/science.8316860	http://dx.doi.org/10.1126/science.8316860			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316860				2022-12-28	WOS:A1993LK43400038
J	KINLEN, LJ				KINLEN, LJ			CAN PATERNAL PRECONCEPTIONAL RADIATION ACCOUNT FOR THE INCREASE OF LEUKEMIA AND NON-HODGKINS-LYMPHOMA IN SEASCALE	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD LEUKEMIA; WEST CUMBRIA; CHILDREN BORN; FOLLOW; COHORT	Objective-To determine if the excess of leukaemia and non-Hodgkin's lymphoma in Seascale is restricted to those born in the parish and whether it might be explained by the postulated relation with paternal preconceptional radiation. Design-Comparison, separately for those born in the parish and those born elsewhere, of the numbers of these malignancies observed in Seascale with those expected on the basis of reference rates for England and Wales. Details of paternal radiation levels were sought for each case. Setting-The parish of Seascale in west Cumbria. Subjects-Residents of Seascale below age 25 years in the years 1951-91. Main outcome measures-The observed and expected numbers of cases of leukaemia and non-Hodgkin's lymphoma within Seascale among those born there and among those born elsewhere. Also, the levels of any paternal preconceptional radiation associated with each case. Results-A significant excess of leukaemia and non-Hodgkin's lymphoma at ages 0-24 was found in Seascale in those who were born there (ratio of observed to expected cases 8.6 and 20.2 respectively; p<0.01). This also applied to those not born there (7.2 and 16.5; p < 0.01), a group often regarded as not showing an excess. The estimates were then conservatively recalculated so as to overestimate the risks among those born in Seascale and underestimate them among those born elsewhere. On this basis the six cases in those born in Seascale compare with 0.38 expected (15.8; p <0.001), of which two were associated with paternal preconceptional lifetime levels of 100 mSv or greater and three others with levels of 90-99 mSv. Among those born elsewhere, there were five cases (expected 0.74; ratio 6.7, p < 0.01), of which only one was associated with a high level of such radiation. Conclusions-Paternal preconceptional radiation cannot be the sole cause of the excess in Seascale since it will not explain the excess among those born outside Seascale. It follows that, unless two causes are to be postulated, any single cause must be a factor other than paternal preconceptional radiation. On this basis, the association found among those born there, if not partly due to chance, may reflect an indirect relation with the true cause. The recent hypothesis about such paternal radiation has originated in a subgroup of the excess cases that have aroused concern.			KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH,CANC RES CAMPAIGN,EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.							BLACK D, 1984, INVESTIGATION POSSIB; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; DRAPER GJ, 1993, BRIT MED J, V306, P761; EVANS HJ, 1990, NATURE, V345, P16, DOI 10.1038/345016a0; GARDNER MJ, 1990, BRIT MED J, V300, P678, DOI 10.1136/bmj.300.6725.678-a; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; GREAVES MF, 1990, LEUKEMIA, V4, P391; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1990, BRIT MED J, V300, P677, DOI 10.1136/bmj.300.6725.677-a; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; 1988, 2ND COMM MED ASP RAD	17	54	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1718	1721		10.1136/bmj.306.6894.1718	http://dx.doi.org/10.1136/bmj.306.6894.1718			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343627	Bronze, Green Published			2022-12-28	WOS:A1993LK36700018
J	BARNES, PF; BARROWS, SA				BARNES, PF; BARROWS, SA			TUBERCULOSIS IN THE 1990S	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; SHORT-COURSE CHEMOTHERAPY; LINKED-IMMUNOSORBENT-ASSAY; NEGATIVE PULMONARY TUBERCULOSIS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; PREVENTIVE THERAPY; DRUG-RESISTANCE; PATHOGENIC MYCOBACTERIA	Purpose: To summarize major recent developments in tuberculosis and current approaches to its treatment and prevention. Data Identification: Articles published since 1987 that addressed important issues in tuberculosis were identified by searching the MEDLINE database and bibliographies of relevant articles. Study Selection: One hundred one references were selected that were judged by the authors to contain information most relevant to practicing internists. Results: Recent increases in tuberculosis morbidity in the United States are concentrated in racial and ethnic minorities, the foreign-born, and persons with human immunodeficiency virus infection. Amplification of Mycobacterium tuberculosis DNA by polymerase chain reaction allows rapid diagnosis of tuberculosis, and ''DNA fingerprinting'' of individual M. tuberculosis strains allows delineation of patterns of tuberculosis transmission. These techniques are available in research laboratories and are promising clinical tools for the future. Treatment regimens for drug-susceptible tuberculosis yield cure rates of more than 95%. Failure to ensure compliance with antituberculosis medications has resulted in an increasing prevalence of multiple-drug-resistant tuberculosis that responds poorly to therapy. Guidelines for isoniazid chemoprophylaxis have been modified in the past 5 years and are summarized. Conclusion: Control of tuberculosis in the United States will require improved implementation of established techniques to diagnose, treat, and prevent tuberculosis, with renewed emphasis on ensuring compliance with therapy.			BARNES, PF (corresponding author), UNIV SO CALIF, SCH MED, HMR 904, 2025 ZONAL AVE, LOS ANGELES, CA 90033 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027285, R01AI031066, R22AI031066] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31066, AI27285] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALORAINEY IO, 1992, EUR J CLIN MICROBIOL, V11, P58, DOI 10.1007/BF01971274; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Arachi A, 1991, TUBERCLE, V72, P1; BAILEY WC, 1983, AM REV RESPIR DIS, V127, P790; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARNES PF, 1988, CHEST, V94, P316, DOI 10.1378/chest.94.2.316; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BODDINGHAUS B, 1990, J CLIN MICROBIOL, V28, P1751; BRISSONNOEL A, 1991, LANCET, V338, P364, DOI 10.1016/0140-6736(91)90492-8; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUTLER WR, 1988, J CLIN MICROBIOL, V26, P50, DOI 10.1128/JCM.26.1.50-53.1988; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; CHAN SL, 1990, AM REV RESPIR DIS, V142, P385, DOI 10.1164/ajrccm/142.2.385; CIESIELSKI SD, 1991, JAMA-J AM MED ASSOC, V265, P1715, DOI 10.1001/jama.265.13.1715; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; Crawford J T, 1989, Semin Respir Infect, V4, P171; CROWLE AJ, 1988, AM REV RESPIR DIS, V137, P1141, DOI 10.1164/ajrccm/137.5.1141; CUNEO WD, 1989, CLIN CHEST MED, V10, P375; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DANIEL T M, 1992, American Review of Respiratory Disease, V145, pA186; DANIEL TM, 1986, AM REV RESPIR DIS, V134, P662; DAVIDSON PT, 1992, DRUGS, V43, P651, DOI 10.2165/00003495-199243050-00003; DAVIDSON PT, 1987, AM REV RESPIR DIS, V136, P255, DOI 10.1164/ajrccm/136.2.255; DELPORTILLO P, 1991, J CLIN MICROBIOL, V29, P2163, DOI 10.1128/JCM.29.10.2163-2168.1991; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; DUTT AK, 1990, AM REV RESPIR DIS, V141, P1232, DOI 10.1164/ajrccm/141.5_Pt_1.1232; DUTT AK, 1984, AM J MED, V77, P233, DOI 10.1016/0002-9343(84)90697-1; DUTT AK, 1989, AM REV RESPIR DIS, V139, P867, DOI 10.1164/ajrccm/139.4.867; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EISENACH KD, 1990, J INFECT DIS, V161, P977, DOI 10.1093/infdis/161.5.977; EISENACH KD, 1991, AM REV RESPIR DIS, V144, P1160, DOI 10.1164/ajrccm/144.5.1160; ELLARD GA, 1986, AM REV RESPIR DIS, V133, P1076; ELLNER PD, 1988, J CLIN MICROBIOL, V26, P1349, DOI 10.1128/JCM.26.7.1349-1352.1988; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FRENCH GL, 1987, J INFECT DIS, V156, P356, DOI 10.1093/infdis/156.2.356; FRIEDMAN LN, 1987, AM REV RESPIR DIS, V136, P1188, DOI 10.1164/ajrccm/136.5.1188; GIRGIS NI, 1991, PEDIATR INFECT DIS J, V10, P179, DOI 10.1097/00006454-199103000-00002; GIRLING DJ, 1989, AM REV RESPIR DIS, V139, P871; GIRLING DJ, 1988, AM REV RESPIR DIS, V137, P1147; GLASER JB, 1992, J ACQ IMMUN DEF SYND, V5, P430; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GRZYBOWSKI S, 1987, AM REV RESPIR DIS, V135, P1311; HAMADEH MA, 1992, CHEST, V101, P1114, DOI 10.1378/chest.101.4.1114; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P1204, DOI 10.1128/JCM.28.6.1204-1213.1990; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; ISEMAN MD, 1990, AM REV RESPIR DIS, V141, P623, DOI 10.1164/ajrccm/141.3.623; ISEMAN MD, 1989, CLIN CHEST MED, V10, P341; JORDAN TJ, 1991, AM REV RESPIR DIS, V144, P1357, DOI 10.1164/ajrccm/144.6.1357; KANSAL R, 1991, MED MICROBIOL IMMUN, V180, P73, DOI 10.1007/BF00193848; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189, DOI 10.1164/ajrccm/140.5.1189; LEE CH, 1988, CHEST, V94, P1256, DOI 10.1378/chest.94.6.1256; LEYSEN DC, 1989, ANTIMICROB AGENTS CH, V33, P1, DOI 10.1128/AAC.33.1.1; MAZUREK GH, 1991, J CLIN MICROBIOL, V29, P2030, DOI 10.1128/JCM.29.9.2030-2033.1991; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; Murray J F, 1991, Bull Int Union Tuberc Lung Dis, V66, P21; PANG JA, 1989, ANN INTERN MED, V111, P650, DOI 10.7326/0003-4819-111-8-650; PAO CC, 1990, J CLIN MICROBIOL, V28, P1877, DOI 10.1128/JCM.28.9.1877-1880.1990; PEREZSTABLE EJ, 1989, CLIN CHEST MED, V10, P323; PETER G, 1992, PEDIATRICS, V89, P161; RADHAKRISHNAN VV, 1991, J INFECT DIS, V163, P650, DOI 10.1093/infdis/163.3.650; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; RIEDER HL, 1991, CHEST, V100, P678, DOI 10.1378/chest.100.3.678; RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286; SCHEUER PJ, 1974, LANCET, V1, P421; SCHIEFFELBEIN CW, 1988, ARCH INTERN MED, V148, P1843, DOI 10.1001/archinte.148.8.1843; SCHRAUFNAGEL DE, 1990, CHEST, V98, P314, DOI 10.1378/chest.98.2.314; SCHULZER M, 1992, TUBERCLE LUNG DIS, V73, P52, DOI 10.1016/0962-8479(92)90080-4; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SHANKAR P, 1991, LANCET, V337, P5, DOI 10.1016/0140-6736(91)93328-7; SJOBRING U, 1990, J CLIN MICROBIOL, V28, P2200; SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579; SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494, DOI 10.1164/ajrccm/145.2_Pt_1.494; SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; SNIDER DE, 1989, IMPROVING PATIENT CO; STARKE JR, 1990, PEDIATR INFECT DIS J, V9, P785, DOI 10.1097/00006454-199011000-00002; STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304; STRANG JIG, 1987, LANCET, V2, P1418; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; VANDERWERF TS, 1992, MED MICROBIOL IMMUN, V181, P71, DOI 10.1007/BF00189425; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; WATT G, 1988, J INFECT DIS, V158, P681, DOI 10.1093/infdis/158.4.681; YEW WW, 1990, J ANTIMICROB CHEMOTH, V26, P227, DOI 10.1093/jac/26.2.227; 1990, MMWR, V39, P7; 1992, MMWR, V41, P13; 1992, TUBERCLE LUNG DISEAS, V73, P59; 1989, MMWR, V38, P236; 1991, MMWR, V40, P23; 1991, MMWR, V40, P585; [No title captured]; 1992, MMWR, V41, P240; [No title captured]; 1990, MMWR, V39, P369; 1990, MMWR, V39, P1; 1991, MMWR, V40, P21	100	179	182	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					400	410		10.7326/0003-4819-119-5-199309010-00009	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338294				2022-12-28	WOS:A1993LZ47600009
J	BURSTIN, HR; LIPSITZ, SR; UDVARHELYI, S; BRENNAN, TA				BURSTIN, HR; LIPSITZ, SR; UDVARHELYI, S; BRENNAN, TA			THE EFFECT OF HOSPITAL FINANCIAL CHARACTERISTICS ON QUALITY OF CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess the relationship among hospital financial characteristics, patient payer mix, and the incidence of negligent medical injuries. Design.-Retrospective medical record review linked to hospital financial reports. Setting.-Acute care hospitals in New York State in 1984. Population.-Stratified, random sample of 30195 medical records from 51 acute care hospitals. Main Outcome Measures.-Hospital rates of medical injury and substandard care were developed from reviews of 30 195 medical records at 51 acute care hospitals in New York in 1984. Hospital-level variables representing financial status, hospital staffing, and the proportion of self-pay and Medicaid hospital discharges were compiled from a variety of secondary sources. Results.-The likelihood of negligent medical injury was highest in those hospitals with the lowest inpatient operating costs per hospital discharge (odds ratio, 2.8; 95% confidence interval, 1.5 to 5.5). The effect of low inpatient operating costs was marked among hospitals in financial distress, many of which served indigent populations. Conclusions.-Patients admitted to hospitals that are unable to expend sufficient resources on patient care may be at higher risk of substandard care. Further study of the effect of hospital financial status on quality of care appears to be warranted.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	BURSTIN, HR (corresponding author), BRIGHAM & WOMENS HOSP, DIV GEN MED, 75 FRANCIS ST, BOSTON, MA 02115 USA.							BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HOERGER TJ, 1991, J HEALTH ECON, V10, P259, DOI 10.1016/0167-6296(91)90030-Q; KUHN EM, 1991, MED CARE, V29, P1028, DOI 10.1097/00005650-199110000-00008; LAFFEL G, 1992, JAMA-J AM MED ASSOC, V268, P407, DOI 10.1001/jama.268.3.407; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MOREY RC, 1992, MED CARE, V30, P677, DOI 10.1097/00005650-199208000-00002; ROBINSON JC, 1988, JAMA-J AM MED ASSOC, V260, P2676, DOI 10.1001/jama.260.18.2676; SCHRAMM CJ, 1984, EMORY LAW J, V33, P869; SHAH BV, 1981, SESUDAAN STANDARD ER; THORPE KE, 1988, HEALTH SERV RES, V22, P821; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WELSCH GA, 1977, FUNDAMENTALS FINANCI; WILLIAMS D, 1992, MED CARE, V30, P174, DOI 10.1097/00005650-199202000-00008; 1993, 19301 PROSP PAYM ASS; 1985, AM HOSPITAL ASS GUID; 1991, 19104 PROSP PAYM ASS; 1985, HOSPITAL COST REPORT; 1990, AICPA AUDIT ACCOUNTI; 1987, HOSPITAL COST REPORT; 1992, FED REGISTER, V50, P6512; 1992, 19201 PROSP PAYM ASS; 1990, MEDICARES DISPROPORT	25	46	46	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					845	849		10.1001/jama.270.7.845	http://dx.doi.org/10.1001/jama.270.7.845			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340984				2022-12-28	WOS:A1993LR61200030
J	CORDER, EH; SAUNDERS, AM; STRITTMATTER, WJ; SCHMECHEL, DE; GASKELL, PC; SMALL, GW; ROSES, AD; HAINES, JL; PERICAKVANCE, MA				CORDER, EH; SAUNDERS, AM; STRITTMATTER, WJ; SCHMECHEL, DE; GASKELL, PC; SMALL, GW; ROSES, AD; HAINES, JL; PERICAKVANCE, MA			GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES	SCIENCE			English	Article							LINKAGE; LOCUS; CHROMOSOME-14; PROTEIN	The apolipoprotein E type 4 allele (APOE-epsilon4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE-epsilon4 alleles in 42 families with late onset AD. Thus APOE-epsilon4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE-epsilon4 was virtually sufficient to cause AD by age 80.	DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZHEIMERS DIS RES CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZEHEIMERS DIS RES CTR,DEPT NEUROL,DURHAM,NC 27710; DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZEHEIMERS DIS RES CTR,DEPT NEUROBIOL,DURHAM,NC 27710; VET ADM MED CTR,DURHAM,NC 27705; UNIV CALIF LOS ANGELES,CTR HLTH SCI,NEUROPSYCHIAT INST & HOSP,LOS ANGELES,CA 90024; MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129	Duke University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; Harvard University; Massachusetts General Hospital			Zito, Giancarlo/F-9008-2010; Haines, Jonathan/C-3374-2012; Kennedy, Kristen M/B-4699-2008	Haines, Jonathan/0000-0002-4351-4728; Kennedy, Kristen M/0000-0001-5373-9026				CORDER EH, UNPUB; Cox D. R., 1984, ANAL SURVIVAL DATA; FARID NR, 1979, J CLIN INVEST, V63, P108, DOI 10.1172/JCI109263; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GREENBERG DA, 1993, AM J HUM GENET, V52, P135; KOCH GG, 1985, ANAL CATEGORICAL DAT; LANGDON N, 1984, LANCET, V2, P1178; Miller R. G., 1981, SURVIVAL ANAL; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; SAUNDERS AM, IN PRESS NEUROLOGY; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHMECHEL DE, IN PRESS; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, IN PRESS P NATL ACAD; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; 1991, SAS P217 SAS I INC T; 1985, SAS USERS GUIDE STAT; 1988, SAS STAT USERS GUIDE	23	6917	7111	23	682	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					921	923		10.1126/science.8346443	http://dx.doi.org/10.1126/science.8346443			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346443				2022-12-28	WOS:A1993LR89700041
J	LEIZOROVICZ, A; BOISSEL, JP; JULIAN, D; CASTAIGNE, A; HAUGH, MC				LEIZOROVICZ, A; BOISSEL, JP; JULIAN, D; CASTAIGNE, A; HAUGH, MC			PREHOSPITAL THROMBOLYTIC THERAPY IN PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STREPTOKINASE ACTIVATOR COMPLEX; TISSUE PLASMINOGEN-ACTIVATOR; FEASIBILITY; REDUCTION; PROJECT; TRIAL; TIME	Background, The efficacy of thrombolytic therapy for acute myocardial infarction depends partly on how soon after the onset of symptoms it is administered. We therefore studied the efficacy and safety of thrombolytic therapy administered before hospital admission and thrombolytic therapy administered after admission in patients with suspected myocardial infarction. Methods. In a multicenter, double-blind study, patients seen within six hours of the onset of symptoms who had a qualifying 12-lead electrocardiogram were randomly assigned to receive either anistreplase before admission, followed by placebo in the hospital (prehospital group), or placebo before admission, followed by anistreplase in the hospital (hospital group). Prehospital therapy was administered by emergency medical personnel. Results. A total of 2750 patients were randomly assigned to the prehospital group, and 2719 to the hospital group. The patients in the prehospital group received thrombolytic therapy a median of 55 minutes earlier than those in the hospital group. We observed a nonsignificant reduction in overall mortality at 30 days in the prehospital group (9.7 percent vs. 11.1 percent in the hospital group; reduction in risk, 13 percent; 95 percent confidence interval, -1 to 26 percent; P = 0.08). Death from cardiac causes was significantly less frequent in the prehospital group than in the hospital group (8.3 percent vs. 9.8 percent; reduction in risk, 16 percent; 95 percent confidence interval, 0 to 29 percent; P = 0.049). Particular adverse events occurred more frequently in the prehospital group during the period before hospitalization; among these events were ventricular fibrillation (P = 0.02), shock (P<0.001), symptomatic hypotension (P<0.001), and symptomatic bradycardia (P = 0.001). With the exception of symptomatic hypotension, however, the overall incidence of these events was similar for both groups. Conclusions. Prehospital thrombolytic therapy for patients with suspected myocardial infarction is both feasible and safe when administered by well-equipped, well-trained mobile emergency medical staff. Although such therapy appears to reduce mortality from cardiac causes, our data do not definitely establish that it reduces overall mortality.			LEIZOROVICZ, A (corresponding author), EUROPEAN MYOCARDIAL INFARCT PROJECT GRP, UNITE PHARMACOL CLIN, BP 3041, F-69394 LYON 03, FRANCE.							[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; APPLEBAUM D, 1986, AM J EMERG MED, V4, P201, DOI 10.1016/0735-6757(86)90065-3; BARBASH GI, 1990, AM J CARDIOL, V66, P261, DOI 10.1016/0002-9149(90)90832-L; BIPPUS P-H, 1987, European Heart Journal, V8, P103; BOISSEL JP, 1988, EUR J CLIN PHARMACOL, V34, P535, DOI 10.1007/BF00615213; BOISSEL JP, 1988, CONTROL CLIN TRIALS, V9, P285; BOISSEL JP, 1990, THROMBOLYSIS DAWN NE, P96; BOSSAERT L, 1991, EUR HEART J, V12, P965; BOSSAERT LL, 1988, CRIT CARE MED, V16, P823, DOI 10.1097/00003246-198809000-00001; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; FLEISS JL, 1973, STATISTICAL METHODS; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; HOLMBERG S, 1990, AM J CARDIOL, V65, P401; HUNT D, 1992, LANCET, V339, P753; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MACCALLUM AG, 1990, EUR HEART J, V11, P48, DOI 10.1093/eurheartj/11.suppl_F.48; Martin J S, 1990, J Emerg Nurs, V16, P195; MEINERTZ T, 1988, AM J CARDIOL, V62, P347, DOI 10.1016/0002-9149(88)90956-3; O'ROURKE M, 1991, Journal of the American College of Cardiology, V17, p246A; ROTH A, 1990, J AM COLL CARDIOL, V15, P932, DOI 10.1016/0735-1097(90)90219-F; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; WEAVER DW, IN PRESS JAMA; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEISS AT, 1987, CHEST, V92, P124, DOI 10.1378/chest.92.1.124; WILCOX RG, 1988, LANCET, V2, P525	30	350	360	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					383	389						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8326971				2022-12-28	WOS:A1993LQ33900002
J	MCMAHON, HT; USHKARYOV, YA; EDELMANN, L; LINK, E; BINZ, T; NIEMANN, H; JAHN, R; SUDHOF, TC				MCMAHON, HT; USHKARYOV, YA; EDELMANN, L; LINK, E; BINZ, T; NIEMANN, H; JAHN, R; SUDHOF, TC			CELLUBREVIN IS A UBIQUITOUS TETANUS-TOXIN SUBSTRATE HOMOLOGOUS TO A PUTATIVE SYNAPTIC VESICLE FUSION PROTEIN	NATURE			English	Article							MEMBRANE-PROTEIN; SYNAPTOPHYSIN; MICROVESICLES; PC12-CELLS; GENES	TETANUS toxin inhibits neurotransmitter release by selectively blocking fusion of synaptic vesicles1,2. Recently tetanus toxin was shown to proteolytically degrade synaptobrevin II (also named VAMP-2), a synaptic vesicle-specific protein3,4, in vitro and in nerve terminals5,6. As targets of tetanus toxin, synaptobrevins probably function in the exocytotic fusion of synaptic vesicles. Here we describe a new synaptobrevin homologue, cellubrevin, that is present in all cells and tissues tested and demonstrate that it is a membrane trafficking protein of a constitutively recycling pathway. Like synaptobrevin II, cellubrevin is proteolysed by tetanus toxin light chain in vitro and after transfection. Our results suggest that constitutive and regulated vesicular pathways use homologous proteins for membrane trafficking, probably for membrane fusion at the plasma membrane, indicating a greater mechanistic and evolutionary similarity between these pathways than previously thought.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MED GENET,DALLAS,TX 75235; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,DEPT PHARMACOL,NEW HAVEN,CT 06510; FED RES CTR VIRUS DIS ANIM,W-7400 TUBINGEN,GERMANY	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Yale University; Yale University; Yale University			Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Jahn, Reinhard/0000-0003-1542-3498				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGESS TL, 1991, A REV CELL BIOL, V1, P388; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; Huttner W B, 1991, Curr Opin Neurobiol, V1, P388, DOI 10.1016/0959-4388(91)90058-F; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MARSAL J, 1989, P NATL ACAD SCI USA, V86, P372, DOI 10.1073/pnas.86.1.372; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDHOF TC, 1990, J BIOL CHEM, V265, P1988; SUDHOF TC, 1989, NEURON, V2, P1474; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1991, A REV NEUROSCI, V14, P665; [No title captured]	29	430	439	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					346	349		10.1038/364346a0	http://dx.doi.org/10.1038/364346a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332193				2022-12-28	WOS:A1993LN57000060
J	GORE, JM; DALEN, JE				GORE, JM; DALEN, JE			CARDIOVASCULAR-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724	University of Arizona; University of Arizona Health Sciences	GORE, JM (corresponding author), UNIV MASSACHUSETTS,SCH MED,WORCESTER,MA 01605, USA.							DALEN JE, 1992, CHEST S, V102, P3035; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; LAROSA JC, 1992, CIRCULATION, V85, P1229, DOI 10.1161/01.CIR.85.3.1229; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; WEINTRAUB WS, 1993, AM J CARDIOL, V71, P511, DOI 10.1016/0002-9149(93)90504-6; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1993, CIRCULATION, V87, P323; 1993, LANCET, V341, P573; 1989, ARCH INTERN MED, V149, P2650	12	1	1	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					190	192		10.1001/jama.270.2.190	http://dx.doi.org/10.1001/jama.270.2.190			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315725				2022-12-28	WOS:A1993LL36800011
J	GOSTIN, LO				GOSTIN, LO			LAW AND MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GOSTIN, LO (corresponding author), AMER SOC LAW & MED,BOSTON,MA, USA.							GOSTIN LO, 1992, HEALTH AFFAIR, V11, P248, DOI 10.1377/hlthaff.11.3.248; MARSHALL E, 1993, SCIENCE, V259, P588, DOI 10.1126/science.8338515; Pine R N, 1992, Law Med Health Care, V20, P238; 1993, FED REG         0205, V58, P7462	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					225	226		10.1001/jama.270.2.225	http://dx.doi.org/10.1001/jama.270.2.225			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315740				2022-12-28	WOS:A1993LL36800026
J	TRAIL, PA; WILLNER, D; LASCH, SJ; HENDERSON, AJ; HOFSTEAD, S; CASAZZA, AM; FIRESTONE, RA; HELLSTROM, I; HELLSTROM, KE				TRAIL, PA; WILLNER, D; LASCH, SJ; HENDERSON, AJ; HOFSTEAD, S; CASAZZA, AM; FIRESTONE, RA; HELLSTROM, I; HELLSTROM, KE			CURE OF XENOGRAFTED HUMAN CARCINOMAS BY BR96-DOXORUBICIN IMMUNOCONJUGATES	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; LEWIS-A; ANTIGENS; ADRIAMYCIN; INVIVO; CANCER; METHOTREXATE; IMMUNOTOXINS; EXPRESSION; STABILITY	Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The monoclonal antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectivity and is internalized after binding. BR96-DOX induced complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing subcutaneously in athymic mice and cured 70 percent of mice bearing extensive metastases of a human lung carcinoma. Also, BR96-DOX cured 94 percent of athymic rats with subcutaneous human lung carcinoma, even though the rats, like humans and in contrast to mice, expressed the BR96 target antigen in normal tissues.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,WALLINGFORD,CT 06492; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb; Bristol-Myers Squibb	TRAIL, PA (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,PRINCETON,NJ 08543, USA.							ARNON R, 1982, IMMUNOL REV, V62, P5, DOI 10.1111/j.1600-065X.1982.tb00387.x; BLAKEY DC, 1988, MONOCLONAL ANTIBODY, V45, P50; BRASLAWSKY GR, 1990, CANCER RES, V50, P6608; CARTER SK, 1975, J NATL CANCER I, V55, P1265, DOI 10.1093/jnci/55.6.1265; DILLMAN RO, 1988, CANCER RES, V48, P6097; EICHLER HG, 1991, BIOTHERAPY, V3, P11; FELL HP, 1989, P NATL ACAD SCI USA, V86, P8507, DOI 10.1073/pnas.86.21.8507; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; FRIEDMAN PN, 1993, J IMMUNOL, V150, P3054; GARRIGUES J, 1993, AM J PATHOL, V142, P607; GOODMAN GE, 1990, J CLIN ONCOL, V8, P1083, DOI 10.1200/JCO.1990.8.6.1083; HELLSTROM I, 1990, CANCER RES, V50, P2183; HELLSTROM I, UNPUB; Hellstrom K., 1991, BIOL THERAPY CANCER, P35; HURWITZ E, 1992, CANCER IMMUNOL IMMUN, V35, P186, DOI 10.1007/BF01756186; KANEKO T, 1991, BIOCONJUGATE CHEM, V2, P133, DOI 10.1021/bc00009a001; KULKARNI PN, 1981, CANCER RES, V41, P2700; LLOYD KO, 1983, IMMUNOGENETICS, V17, P537, DOI 10.1007/BF00696877; ORNTOFT TF, 1989, INT J CANCER, V43, P774, DOI 10.1002/ijc.2910430505; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PIETERSZ GA, 1992, IMMUNOL REV, V129, P57, DOI 10.1111/j.1600-065X.1992.tb01419.x; POUR PM, 1988, CANCER RES, V48, P5422; SAKAMOTO J, 1989, CANCER RES, V49, P745; SHIH LB, 1988, INT J CANCER, V41, P832, DOI 10.1002/ijc.2910410610; THORPE PE, 1987, CANCER RES, V47, P5924; TRAIL PA, 1992, CANCER RES, V52, P5693; TRAIL PA, UNPUB; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; WAWRZYNCZAK EJ, 1991, BRIT J CANCER, V64, P624, DOI 10.1038/bjc.1991.374; WORRELL NR, 1986, ANTI-CANCER DRUG DES, V1, P179; YANG HM, 1988, P NATL ACAD SCI USA, V85, P1189, DOI 10.1073/pnas.85.4.1189; YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305	32	421	524	4	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					212	215		10.1126/science.8327892	http://dx.doi.org/10.1126/science.8327892			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8327892				2022-12-28	WOS:A1993LL59600041
J	SCHINDELIN, H; MARAHIEL, MA; HEINEMANN, U				SCHINDELIN, H; MARAHIEL, MA; HEINEMANN, U			UNIVERSAL NUCLEIC ACID-BINDING DOMAIN REVEALED BY CRYSTAL-STRUCTURE OF THE BACILLUS-SUBTILIS MAJOR COLD-SHOCK PROTEIN	NATURE			English	Article							ESCHERICHIA-COLI; DNA-BINDING; SECONDARY STRUCTURE; RIBONUCLEOPROTEIN; RESOLUTION; SEQUENCE	THE cold-shock response in both Escherichia coli and Bacillus subtilis is induced by an abrupt downshift in growth temperature. It leads to the increased production of the major cold-shock proteins, CS7.4 and CspB, respectively1-3. CS7.4 is a transcriptional activator of two genes4,5. CS7.4 and CspB share 43 per cent sequence identity with the nucleic acid-binding domain of the eukaryotic gene-regulatory Y-box factors6. This cold-shock domain is conserved from bacteria to man7 and contains the RNA-binding RNP1 sequence motif8. As a prototype of the cold-shock domain, the structure of CspB has been determined here from two crystal forms. In both, CspB is present as an antiparallel five-stranded beta-barrel. Three consecutive beta-strands, the central one containing the RNP1 motif, create a surface rich in aromatic and basic residues that are presumably involved in nucleic acid binding. Preferential binding of CspB to single-stranded DNA is observed in gel retardation experiments.	PHILIPPS UNIV MARBURG,BIOCHEMIE FB CHEM,D-35043 MARBURG,GERMANY	Philipps University Marburg	SCHINDELIN, H (corresponding author), FREE UNIV BERLIN,INST KRISTALLOG,TAKUSTR 6,D-14195 BERLIN,GERMANY.		Schindelin, Hermann/Q-2697-2019; Heinemann, Udo/AAH-4766-2019; Heinemann, Udo/S-3379-2016	Heinemann, Udo/0000-0002-8191-3850; Heinemann, Udo/0000-0002-8191-3850				BRAYER GD, 1983, J MOL BIOL, V169, P565, DOI 10.1016/S0022-2836(83)80065-5; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CRAWFORD DR, 1987, DEVELOPMENT, V101, P741; FOLKERS PJM, 1991, EUR J BIOCHEM, V202, P349, DOI 10.1111/j.1432-1033.1991.tb16382.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MURRAY MT, 1991, J CELL BIOL, V12, P1; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Pope M. T., 1983, HETEROPOLY ISOPOLY O; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHINDELIN H, 1992, PROTEINS, V14, P120, DOI 10.1002/prot.340140113; SCHNUCHEL A, 1993, NATURE, V364; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILLIMSKY G, 1992, J BACTERIOL, V174, P6326, DOI 10.1128/JB.174.20.6326-6335.1992; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WOLFFE AP, 1992, NEW BIOL, V4, P290; 1979, CCP4 SERC DAR LAB CO	30	325	330	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					164	168		10.1038/364164a0	http://dx.doi.org/10.1038/364164a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321288				2022-12-28	WOS:A1993LL36700055
J	FOISNER, R; GERACE, L				FOISNER, R; GERACE, L			INTEGRAL MEMBRANE-PROTEINS OF THE NUCLEAR-ENVELOPE INTERACT WITH LAMINS AND CHROMOSOMES, AND BINDING IS MODULATED BY MITOTIC PHOSPHORYLATION	CELL			English	Article							INTERMEDIATE FILAMENT PROTEINS; PORE COMPLEX; CHROMATIN INVITRO; XENOPUS EGGS; CDC2 KINASE; B-RECEPTOR; MITOSIS; ANTIBODIES; INTERPHASE; FRACTION	Lamina-associated polypeptides (LAPs) 1A, 1B, 1C, and 2 are integral membrane proteins of the nuclear envelope associated with the nuclear lamina. Using in vitro assays, we show that LAPs 1A and 1B specifically bind to both lamins A and C and lamin B1, while LAP 2 associates only with lamin B1. LAP 2 also binds to mitotic chromosomes. The LAPs are phosphorylated during mitosis, and phosphorylation of LAP 2 by mitotic cytosol inhibits its binding to both lamin B1 and chromosomes. During late anaphase, LAP 2 associates with chromosomes prior to assembly of most lamins. Together, these data suggest that LAP 2 may have a key role in initial events of nuclear envelope reassembly, and that both LAP 2 and LAP 1 may be involved in attaching lamins to the nuclear envelope.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Foisner, Roland/AAD-1833-2019	Foisner, Roland/0000-0003-4734-4647				AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BAILER SM, 1991, J CELL BIOL, V114, P389, DOI 10.1083/jcb.114.3.389; BENAVENTE R, 1986, J CELL BIOL, V103, P1847, DOI 10.1083/jcb.103.5.1847; BENAVENTE R, 1989, EUR J CELL BIOL, V50, P209; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANTON D, 1981, CELL, V24, P24, DOI 10.1016/0092-8674(81)90497-9; BURKE B, 1990, EXP CELL RES, V186, P169, DOI 10.1016/0014-4827(90)90223-W; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; Burke B, 1990, CURR OPIN CELL BIOL, V2, P514, DOI 10.1016/0955-0674(90)90136-3; DABAUVALLE MC, 1991, J CELL BIOL, V112, P1073, DOI 10.1083/jcb.112.6.1073; DESSEV G N, 1992, Current Opinion in Cell Biology, V4, P430, DOI 10.1016/0955-0674(92)90008-Z; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; ERLANDSON RA, 1971, J CELL SCI, V8, P353; FOISNER R, 1988, J CELL BIOL, V106, P723, DOI 10.1083/jcb.106.3.723; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; HAREL A, 1989, J CELL SCI, V94, P463; HOGER TH, 1991, EXP CELL RES, V197, P280, DOI 10.1016/0014-4827(91)90434-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; MATSUURA S, 1981, J CELL BIOL, V91, P212, DOI 10.1083/jcb.91.1.212; MEIER J, 1991, J CELL SCI, V98, P271; MURRAY RG, 1965, J CELL BIOL, V26, P601, DOI 10.1083/jcb.26.2.601; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PADAN R, 1990, J BIOL CHEM, V265, P7808; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; POWELL L, 1990, J CELL BIOL, V111, P2225, DOI 10.1083/jcb.111.6.2225; ROBBINS E, 1964, J CELL BIOL, V21, P429, DOI 10.1083/jcb.21.3.429; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SHOEMAN RL, 1990, J BIOL CHEM, V265, P9055; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STICK R, 1988, J CELL BIOL, V107, P397, DOI 10.1083/jcb.107.2.397; ULITZUR N, 1992, J CELL BIOL, V119, P17, DOI 10.1083/jcb.119.1.17; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YUAN J, 1991, J BIOL CHEM, V266, P9211	48	457	467	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1267	1279		10.1016/0092-8674(93)90355-T	http://dx.doi.org/10.1016/0092-8674(93)90355-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324822				2022-12-28	WOS:A1993LL20900004
J	VERA, JC; RIVAS, CI; FISCHBARG, J; GOLDE, DW				VERA, JC; RIVAS, CI; FISCHBARG, J; GOLDE, DW			MAMMALIAN FACILITATIVE HEXOSE TRANSPORTERS MEDIATE THE TRANSPORT OF DEHYDROASCORBIC ACID	NATURE			English	Article							BORDER MEMBRANE-VESICLES; XENOPUS-LAEVIS OOCYTES; L-ASCORBATE TRANSPORT; GLUCOSE-TRANSPORTER; FUNCTIONAL EXPRESSION; LEUKOCYTES; KIDNEY; FIBROBLASTS; DEFICIENCY; INTESTINE	ALTHOUGH vitamin C is critical to human physiology1-5, it is not clear how it is taken up into cells. The kinetics of cell and tissue accumulation of ascorbic acid in vitro indicate that the process is mediated by specific transporters at the cell membrane6. Some experimental observations have linked the transport of ascorbic acid with hexose transport systems in mammalian cells, although no clear information is available regarding the specific role(s) of these transporters, if any, in this process7-16. Here we use the Xenopus laevis oocyte expression system to show that the mammalian facilitative hexose transporters are efficient transporters of the oxidized form of vitamin C (dehydroascorbic acid). Two transport pathways, one with low affinity and one with high affinity for dehydroascorbic acid, were found in oocytes expressing the mammalian transporters, and these oocytes accumulated vitamin C against a concentration gradient when supplied with dehydroascorbic acid. We obtained similar results in experiments using normal human neutrophils. These observations indicate that mammalian facilitative hexose transporters are a physiologically significant pathway for the uptake and accumulation of vitamin C by cells, and suggest a mechanism for the accumulation of ascorbic acid against a concentration gradient.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT OPHTHALMOL,NEW YORK,NY 10032	Columbia University; Columbia University	VERA, JC (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC PHARMACOL & THERAPEUT,1275 YORK AVE,NEW YORK,NY 10021, USA.		Alshali, Rasha A/K-8051-2012					BERGSTEN P, 1990, J BIOL CHEM, V265, P2584; BIANCHI J, 1986, AM J PHYSIOL, V250, pG461, DOI 10.1152/ajpgi.1986.250.4.G461; BIGLEY R, 1983, DIABETES, V32, P545, DOI 10.2337/diabetes.32.6.545; BIGLEY RH, 1974, J EXP MED, V139, P1084, DOI 10.1084/jem.139.5.1084; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; Crandon JH, 1940, NEW ENGL J MED, V223, P353, DOI 10.1056/NEJM194009052231001; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; ENGLARD S, 1986, ANNU REV NUTR, V6, P365, DOI 10.1146/annurev.nu.06.070186.002053; HODGES RE, 1969, AM J CLIN NUTR, V22, P535; HODGES RE, 1971, AM J CLIN NUTR, V24, P432; INGERMANN RL, 1986, AM J PHYSIOL, V250, pC637, DOI 10.1152/ajpcell.1986.250.4.C637; JUNG CY, 1977, J BIOL CHEM, V252, P5456; MCLENNAN S, 1988, DIABETES, V37, P359, DOI 10.2337/diabetes.37.3.359; MOSER U, 1984, INT J VITAM NUTR RES, V54, P47; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; PADH H, 1990, BIOCHEM CELL BIOL, V68, P1166, DOI 10.1139/o90-173; PADH H, 1987, BIOCHIM BIOPHYS ACTA, V901, P283, DOI 10.1016/0005-2736(87)90125-8; RAGHOEBAR M, 1987, LIFE SCI, V40, P499, DOI 10.1016/0024-3205(87)90117-2; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; ROSE RC, 1986, AM J PHYSIOL, V250, pF627, DOI 10.1152/ajprenal.1986.250.4.F627; SILIPRANDI L, 1979, BIOCHIM BIOPHYS ACTA, V552, P129, DOI 10.1016/0005-2736(79)90252-9; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TOGGENBURGER G, 1981, BIOCHIM BIOPHYS ACTA, V646, P433, DOI 10.1016/0005-2736(81)90312-6; VERA JC, 1990, MOL CELL BIOL, V10, P743, DOI 10.1128/MCB.10.2.743; VERA JC, 1989, MOL CELL BIOL, V9, P4187, DOI 10.1128/MCB.9.10.4187; WASKHO P, 1992, J BIOL CHEM, V267, P23568; WEASHKO P, 1989, J BIOL CHEM, V284, P18996; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WILSON JX, 1989, J MEMBRANE BIOL, V111, P83, DOI 10.1007/BF01869211; WINKLER BS, 1987, BIOCHIM BIOPHYS ACTA, V925, P258, DOI 10.1016/0304-4165(87)90190-5; WUNDERLING M, 1986, BIOL CHEM H-S, V367, P1047, DOI 10.1515/bchm3.1986.367.2.1047	31	430	437	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					79	82		10.1038/364079a0	http://dx.doi.org/10.1038/364079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316303				2022-12-28	WOS:A1993LK81800063
J	KARIO, K; MATSUO, T				KARIO, K; MATSUO, T			RELATION BETWEEN SIALIC-ACID CONCENTRATIONS AND THE HEMOSTATIC SYSTEM IN THE ELDERLY	BRITISH MEDICAL JOURNAL			English	Article									HYOGO PREFECTURAL AWAJI HOSP,DEPT INTERNAL MED,SUMOTO,HYOGO 656,JAPAN		KARIO, K (corresponding author), AWAJI HOKUTAN PUBL CLIN,DEPT INTERNAL MED,HOKUTAN,HYOGO 65616,JAPAN.							LINDBERG G, 1991, BRIT MED J, V303, P1306, DOI 10.1136/bmj.303.6813.1306; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; MEADE T W, 1987, Blood Reviews, V1, P2, DOI 10.1016/0268-960X(87)90013-0; SUGAHARA K, 1980, CLIN CHIM ACTA, V108, P493, DOI 10.1016/0009-8981(80)90360-5; WAKABAYASHI I, 1992, BRIT MED J, V305, P562, DOI 10.1136/bmj.305.6853.562	5	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1650	1651		10.1136/bmj.306.6893.1650	http://dx.doi.org/10.1136/bmj.306.6893.1650			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324435	Bronze, Green Published			2022-12-28	WOS:A1993LJ33700022
J	ANDERSON, HV; WILLERSON, JT				ANDERSON, HV; WILLERSON, JT			CURRENT CONCEPTS - THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TISSUE PLASMINOGEN-ACTIVATOR; RANDOMIZED CONTROLLED TRIALS; CORONARY-ARTERY; THROMBIN INHIBITION; DELAYS REOCCLUSION; PROSTAGLANDIN ENDOPEROXIDES; ENHANCES THROMBOLYSIS; CANINE MODEL; THERAPY; HEPARIN		HERMANN HOSP, HOUSTON, TX 77030 USA; ST LUKES EPISCOPAL HOSP, TEXAS HEART INST, HOUSTON, TX 77030 USA	Saint Lukes Episcopal Hospital; Texas Heart Institute	ANDERSON, HV (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT INTERNAL MED, DIV CARDIOL, 6431 FANNIN ST, HOUSTON, TX 77030 USA.							[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1989, NEW ENGL J MED, V320, P618; ARNOUT J, 1992, J AM COLL CARDIOL, V20, P513, DOI 10.1016/0735-1097(92)90001-4; ARONSON DL, 1992, CIRCULATION, V85, P1706, DOI 10.1161/01.CIR.85.5.1706; BECKER RC, 1993, CORONARY ARTERY DIS, V4, P293, DOI 10.1097/00019501-199303000-00010; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; CALIFF RM, 1992, AM J CARDIOL, V69, pA12, DOI 10.1016/0002-9149(92)91168-4; Cannon Christopher P., 1993, Journal of the American College of Cardiology, V21, p136A; COLLEN D, 1991, BLOOD, V78, P3114; COLLER BS, 1992, CORONARY ARTERY DIS, V3, P1016, DOI 10.1097/00019501-199211000-00005; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEBONO DP, 1992, BRIT HEART J, V67, P122; ECKMAN MH, 1992, ANN INTERN MED, V117, P667, DOI 10.7326/0003-4819-117-8-667; EITZMAN DT, 1993, J AM COLL CARDIOL  S, V21, pZ276; FITZGERALD DJ, 1988, J CLIN INVEST, V82, P1708, DOI 10.1172/JCI113784; FITZGERALD DJ, 1989, CIRC RES, V65, P83, DOI 10.1161/01.RES.65.1.83; FLETCHER AP, 1958, T ASSOC AM PHYSICIAN, V71, P287; FORTIN DF, 1990, AM J MED, V88, pN9; FREEMAN MR, 1992, CIRCULATION, V85, P150, DOI 10.1161/01.CIR.85.1.150; GALVANI M, 1993, AM J CARDIOL, V71, P1, DOI 10.1016/0002-9149(93)90700-M; Gil Victor, 1993, Journal of the American College of Cardiology, V21, p300A; GOLD HK, 1988, CIRCULATION, V77, P670, DOI 10.1161/01.CIR.77.3.670; GOLINO P, 1989, CIRCULATION, V79, P911, DOI 10.1161/01.CIR.79.4.911; GOLINO P, 1990, J CLIN INVEST, V86, P1095, DOI 10.1172/JCI114813; GORE JM, 1991, J INVASIVE CARDIOL, V3, pA21; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; GUIDERA SA, 1993, J AM COLL CARDIOL, V21, P1645, DOI 10.1016/0735-1097(93)90381-A; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; HASKEL EJ, 1991, CIRCULATION, V83, P1048, DOI 10.1161/01.CIR.83.3.1048; HIRSH PD, 1981, NEW ENGL J MED, V304, P687; HSIA J, 1992, J AM COLL CARDIOL, V20, P31, DOI 10.1016/0735-1097(92)90133-8; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; HUNT D, 1992, LANCET, V339, P753; JANG IK, 1990, CIRC RES, V67, P1552, DOI 10.1161/01.RES.67.6.1552; KLEIMAN NS, 1992, CIRCULATION, V86, P260; KROON C, 1992, CIRCULATION, V86, P1370, DOI 10.1161/01.CIR.86.5.1370; Lidon Rosa-Maria, 1993, Journal of the American College of Cardiology, V21, p419A; MACMAHON S, 1988, CIRCULATION S2, V78, P98; MATHEY DG, 1988, AM J CARDIOL, V61, P524, DOI 10.1016/0002-9149(88)90758-8; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; Neuhaus Karl-L., 1993, Journal of the American College of Cardiology, V21, p418A; ROUX S, 1992, J AM COLL CARDIOL, V19, P671, DOI 10.1016/S0735-1097(10)80290-6; RUDD MA, 1992, CIRC RES, V70, P829, DOI 10.1161/01.RES.70.4.829; SLOAN MA, 1992, AM J CARDIOL, V69, pA21, DOI 10.1016/0002-9149(92)91169-5; STUMP DC, 1989, CIRCULATION, V80, P1222, DOI 10.1161/01.CIR.80.5.1222; SUTHERLAND JE, 1990, JAMA-J AM MED ASSOC, V264, P3178, DOI 10.1001/jama.264.24.3178; TIEFENBRUNN AJ, 1991, FIBRINOLYSIS, V5, P1, DOI 10.1016/0268-9499(91)90073-D; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1990, LANCET, V336, P71; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; Willerson JT, 1992, TREATMENT HEART DISE, V1, P43; YAO SK, 1992, CIRCULATION, V86, P1993, DOI 10.1161/01.CIR.86.6.1993; YAO SK, 1992, AM J PHYSIOL, V262, pH374, DOI 10.1152/ajpheart.1992.262.2.H374; YAO SK, 1993, CLIN RES, V41, pA228; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1990, CIRCULATION, V82, P117	61	171	177	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					703	709						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8345856				2022-12-28	WOS:A1993LU58300006
J	EVERY, NR; LARSON, EB; LITWIN, PE; MAYNARD, C; FIHN, SD; EISENBERG, MS; HALLSTROM, AP; MARTIN, JS; WEAVER, WD				EVERY, NR; LARSON, EB; LITWIN, PE; MAYNARD, C; FIHN, SD; EISENBERG, MS; HALLSTROM, AP; MARTIN, JS; WEAVER, WD			THE ASSOCIATION BETWEEN ON-SITE CARDIAC-CATHETERIZATION FACILITIES AND THE USE OF CORONARY ANGIOGRAPHY AFTER ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMALL-AREA VARIATIONS; INTERVENTION-REGISTRY; TRIAGE	Background. During the past decade the use of coronary angiography after acute myocardial infarction has substantially increased. Among the possible contributing factors, the increasing availability of cardiac catheterization facilities was the focus of our investigation. Methods. We investigated whether the availability of cardiac catheterization facilities at an admitting hospital was associated with the likelihood that a patient would undergo coronary angiography. After adjusting for age, sex, cardiac history, and cardiac complications during hospitalization, we evaluated this association in 5867 consecutive patients with acute myocardial infarction admitted to 19 Seattle-area hospitals. We also assessed the association between the presence of on-site cardiac catheterization facilities and in-hospital mortality. Results. Patients admitted to hospitals with on-site cardiac catheterization facilities were far more likely to undergo coronary angiography (odds ratio, 3.21; 95 percent confidence interval, 2.81 to 3.67) than patients admitted to hospitals where transfer to another institution would be required to perform cardiac catheterization. Admission to a hospital with on-site facilities was more strongly associated with the use of coronary angiography than any characteristic of the patient. Although our study had limited power to detect differences in mortality, the availability of coronary angiography had no discernible association with in-hospital mortality rates (odds ratio for mortality among patients admitted to hospitals with on-site facilities vs. patients admitted to hospitals without such facilities, 0.88; 95 percent confidence interval, 0.71 to 1.09). Conclusions. In this community-wide study, the availability of on-site cardiac catheterization facilities was associated with a higher likelihood that a patient would undergo coronary angiography. However, admission to hospitals with these facilities did not appear to be associated with lower short-term mortality.	VET AFFAIRS MED CTR, NW HLTH SERV RES & DEV FIELD PROGRAM, SEATTLE, WA USA; UNIV WASHINGTON, DEPT MED CARDIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Maynard, Charles/N-3906-2015; Fihn, Stephan/ABA-1040-2020	Maynard, Charles/0000-0002-1644-7814; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038454] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-38454] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altman DG, 1991, PRACTICAL STAT MED R, P179; [Anonymous], 1991, BMJ, V302, P555; [Anonymous], 1989, NEW ENGL J MED, V320, P618; BENGTSON JR, 1992, J AM COLL CARDIOL, V20, P1482, DOI 10.1016/0735-1097(92)90440-X; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; DEFEYTER PJ, 1982, CIRCULATION, V66, P527, DOI 10.1161/01.CIR.66.3.527; DEWOOD MA, 1989, J AM COLL CARDIOL, V14, P65, DOI 10.1016/0735-1097(89)90055-7; FEILD DJ, 1987, J AM COLL CARDIOL, V10, P935, DOI 10.1016/S0735-1097(87)80294-2; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; Kulick D L, 1990, Cardiovasc Clin, V21, P3; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MITCHELL JB, 1982, REGIONAL VARIATIONS, P103; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; NICOD P, 1991, CIRCULATION, V84, P1004, DOI 10.1161/01.CIR.84.3.1004; ROBINSON JC, 1987, NEW ENGL J MED, V317, P85, DOI 10.1056/NEJM198707093170205; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; SHAIN M, 1959, Mod Hosp, V92, P71; SIMPSON JB, 1985, AM J PUBLIC HEALTH, V75, P1225, DOI 10.2105/AJPH.75.10.1225; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; 1990, SPSS PC PLUS ADV STA; 1992, CONSUM REP, P435; 1991, HOSPITAL STATISTICS, P209	25	203	204	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					546	551		10.1056/NEJM199308193290807	http://dx.doi.org/10.1056/NEJM199308193290807			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8336755				2022-12-28	WOS:A1993LR89200007
J	GALLAGHER, EJ; VISCOLI, CM; HORWITZ, RI				GALLAGHER, EJ; VISCOLI, CM; HORWITZ, RI			THE RELATIONSHIP OF TREATMENT ADHERENCE TO THE RISK OF DEATH AFTER MYOCARDIAL-INFARCTION IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							REGRESSION-MODELS	Objective.-To examine the relationship between adherence to a medical regimen and mortality following a myocardial infarction in women. Design.-Analysis of the female cohort entered into a randomized double-blind multicenter trial. Setting.-National Heart, Lung, and Blood Institute beta-Blocker Heart Attack Trial. Participants.-The 602 women, aged 30 to 69 years, enrolled in the beta-Blocker Heart Attack Trial. Intervention.-Random assignment to propranolol hydrochloride or placebo 5 to 21 days following a myocardial infarction. Measurements.-Adherence for each patient was calculated as the mean of all quarterly adherence estimates during the course of the trial (median follow-up, 26 months). Adherence was classified as good (taking greater-than-or-equal-to 75% of medication) or poor (taking <75% of medication). The end point was death from all causes occurring at any time during the trial, adjusted for treatment category and other clinical and sociodemographic features. Results.-Adherence data were available on 505 women, of whom 32 (6.3%) died. Death occurred in 13.6% of poor adherers compared with 5.6% of good adherers (relative risk, 2.4; 95% confidence interval, 1.1 to 5.6). The effect of adherence on mortality remained undiminished after adjustment for treatment category (propranolol or placebo), age, severity of myocardial infarction, congestive heart failure, smoking history, marital status, educational level, and race (adjusted relative risk of death for poor adherers, 2.5 to 3.0; P less-than-or-equal-to .02). Conclusions.-The independent effect of adherence on mortality following a myocardial infarction in women is clinically substantial, statistically significant, and similar in magnitude to that reported earlier for men.	YALE UNIV,SCH MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PUBL HLTH,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University; Yale University								COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1051, DOI 10.1001/jama.263.8.1051; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1049, DOI 10.1001/jama.263.8.1049; COX DR, 1972, J R STAT SOC B, V34, P187; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P285; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; KRAMR WB, 1979, AM J CARDIOL, V44, P53; RODIN J, 1990, AM PSYCHOL, V45, P1018, DOI 10.1037/0003-066X.45.9.1018; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; 1980, NEW ENGL J MED, V303, P1038; 1982, JAMA-J AM MED ASSOC, V247, P1707; 1989, MMWR MORB MORTAL WKL, V38, P505	13	111	112	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1993	270	6					742	744		10.1001/jama.270.6.742	http://dx.doi.org/10.1001/jama.270.6.742			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ338	8336377				2022-12-28	WOS:A1993LQ33800030
J	DEKARIS, D; SABIONCELLO, A; MAZURAN, R; RABATIC, S; SVOBODABEUSAN, I; RACUNICA, NL; TOMASIC, J				DEKARIS, D; SABIONCELLO, A; MAZURAN, R; RABATIC, S; SVOBODABEUSAN, I; RACUNICA, NL; TOMASIC, J			MULTIPLE CHANGES OF IMMUNOLOGICAL PARAMETERS IN PRISONERS OF WAR - ASSESSMENTS AFTER RELEASE FROM A CAMP IN MANJACA, BOSNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTEIN-CALORIE MALNUTRITION; PITUITARY-ADRENAL AXIS; STRESS; DISORDERS; RESPONSES; DISEASE; SYSTEM; AGE	Objective.-To assess immune reactivity in men just released from a war prisoner camp. Participants.-Random sample of 29 men from a group of 764 liberated detainees in war prisoner camp in Bosnia, 15 matched healthy control subjects, and pre-war historical control subjects. Main Outcome Measures.-Report on immune reactivity parameters, such as lymphocyte immunophenotypes, natural killer cell and phagocyte function, serum cytokines, and hormones. Results.-Compared with control subjects, detainees had significantly lowered red blood cell count, hemogLobin mass concentration, hematocrit, total serum proteins, and albumin level, while the percentage and count of monocytes and nonsegmented neutrophils were increased. Flow cytometry revealed a significant increase in percentage of activated lymphocytes, activated T lymphocytes, Tc/s lymphocytes, B lymphocytes, and total HLA-DR lymphocytes. The absolute counts of activated lymphocytes and activated T lymphocytes were also significantly increased. The percentages of naive Th/i lymphocytes and the ratio of CD4:CD8 lymphocytes were decreased. The in vitro natural killer cell cytotoxic activity and phagocytic functions of ingestion and digestion were significantly depressed. Serum interferon, serum cortisol, and prolactin were also significantly lowered. Serum tumor necrosis factor was increased. Conclusions.-Alterations in the main parameters of the immune system and depression of important immune effector functions may have resulted from the psychological stress, physical deprivation, and malnutrition experienced by these war camp prisoners during their detainment.			DEKARIS, D (corresponding author), UNIV ZAGREB, INST IMMUNOL, ROCKEFELLEROVA 10, 41000 ZAGREB, CROATIA.							AOKI T, 1987, NAT IMMUN CELL GROW, V6, P116; AUSMAN LM, 1989, AM J CLIN NUTR, V50, P19, DOI 10.1093/ajcn/50.1.19; BALLIEUX RE, 1991, J CLIN PERIODONTOL, V18, P427, DOI 10.1111/j.1600-051X.1991.tb02311.x; BENTDAL OH, 1991, CLIN NUTR, V10, P167, DOI 10.1016/0261-5614(91)90053-F; BORCIC D, 1992, CROATIAN MED J S, V2, P93; CERAMI A, 1992, CLIN IMMUNOL IMMUNOP, V62, pS3, DOI 10.1016/0090-1229(92)90035-M; CHANDRA RK, 1992, J NUTR, V122, P597, DOI 10.1093/jn/122.suppl_3.597; CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087, DOI 10.1093/ajcn/53.5.1087; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; DEKARIS D, 1992, M EUROPEAN GROUP IMM, P110; DEKARIS D, IN PRESS WIEN MED WO; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DEZAN D, 1992, CROATIAN MED J S, V2, P97; GEARING AJH, 1987, LYMPHOKINES INTERFER, P291; HANSEN MB, 1990, J IMMUNOL METHODS, V127, P241, DOI 10.1016/0022-1759(90)90074-6; HARBUZ MS, 1992, J ENDOCRINOL, V134, P327, DOI 10.1677/joe.0.1340327; HOMODELARCHE F, 1991, J STEROID BIOCHEM, V40, P616; KHANSARI DN, 1990, IMMUNOL TODAY, V11, P170, DOI 10.1016/0167-5699(90)90069-L; Kiecolt-Glaser JK, 1991, PSYCHONEUROIMMUNOLOG, P849; LAW DK, 1973, ANN INTERN MED, V79, P545, DOI 10.7326/0003-4819-79-4-545; LEVY SM, 1991, NAT IMMUN CELL GROW, V10, P289; MALOZOWSKI S, 1990, CLIN ENDOCRINOL, V32, P461, DOI 10.1111/j.1365-2265.1990.tb00886.x; MATTHEWS N, 1987, LYMPHOKINES INTERFER, P221; MAZOWIECKI T, 1992, COMMUNICATION, P18; NOVOTNY Z, 1992, CROATIAN MED J S, V2, P90; OLEARY A, 1990, PSYCHOL BULL, V108, P363, DOI 10.1037/0033-2909.108.3.363; PETERSON PK, 1991, REV INFECT DIS, V13, P710; POLLOCK RE, 1991, ARCH SURG-CHICAGO, V126, P338; RABATIC S, 1988, MECH AGEING DEV, V45, P223, DOI 10.1016/0047-6374(88)90004-8; REDMOND HP, 1991, SURGERY, V110, P311; REICHERT T, 1991, CLIN IMMUNOL IMMUNOP, V60, P190, DOI 10.1016/0090-1229(91)90063-G; SAKSELA E, 1979, IMMUNOL REV, V44, P71, DOI 10.1111/j.1600-065X.1979.tb00268.x; Serban G, 1991, Methods Achiev Exp Pathol, V15, P200; THEODORSSONNORHEIM E, 1986, COMPUT METH PROG BIO, V23, P57, DOI 10.1016/0169-2607(86)90081-7; WAAGE A, 1992, IMMUNOL REV, V127, P221, DOI 10.1111/j.1600-065X.1992.tb01416.x; WEIGENT DA, 1987, IMMUNOL REV, V100, P79, DOI 10.1111/j.1600-065X.1987.tb00528.x; XIE QW, 1991, NEUROENDOCRINOLOGY, V53, P52, DOI 10.1159/000125796; YANG KD, 1991, J PEDIATR-US, V119, P343, DOI 10.1016/S0022-3476(05)82044-X	38	69	70	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					595	599		10.1001/jama.270.5.595	http://dx.doi.org/10.1001/jama.270.5.595			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331758				2022-12-28	WOS:A1993LP43600024
J	LEE, LE; FONSECA, V; BRETT, KM; SANCHEZ, J; MULLEN, RC; QUENEMOEN, LE; GROSECLOSE, SL; HOPKINS, RS				LEE, LE; FONSECA, V; BRETT, KM; SANCHEZ, J; MULLEN, RC; QUENEMOEN, LE; GROSECLOSE, SL; HOPKINS, RS			ACTIVE MORBIDITY SURVEILLANCE AFTER HURRICANE-ANDREW - FLORIDA, 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FLOOD	Objective.-To describe the health status of and to detect disease outbreaks in the population affected by Hurricane Andrew in south Dade County, Florida. Design.-The Florida Department of Health and Rehabilitative Services and the US Army conducted active surveillance for gastrointestinal illness, respiratory illness, injury, and other index conditions by monitoring civilian and service member visits to care sites (civilian and military free care sites and hospital emergency departments) from August 30 (1 week after the hurricane's landfall) through September 30,1992. Setting.-South Dade County, Florida. Main Outcome Measures.-Proportional morbidity: the number of daily visits for each index condition divided by the total number of visits, expressed as a percentage. Morbidity rate: the total number of daily visits by service members divided by the total number of service members, expressed as a percentage. Results.-Six index conditions accounted for 41.3% of visits to civilian free care sites: diarrhea (4.7%), cough (4.7%), other infection (9.6%), rash (5.4%), animal bite (1.2%), and injury (15.7%). At military free care sites, five index conditions accounted for 75.7% of civilian visits: injury (23.7%), dermatologic illness (12.4%), respiratory illness (9.9%), gastrointestinal illness (5.3%), and other medical conditions (24.4%). Two index conditions accounted for 54.1 % of service member visits: injury (36.2%) and dermatologic illness (17.9%). During the 5 weeks after the hurricane, proportional morbidity from injury decreased; proportional morbidity from respiratory illness increased; and proportional morbidity from diarrhea was stable. No infectious disease outbreaks occurred. Conclusions.-Injuries were an important source of morbidity throughout the surveillance period, especially among service members. Enteric and respiratory agents did not cause disease outbreaks, despite alarming rumors to the contrary.	CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV ANAL,OFF ANAL & EPIDEMIOL,ATLANTA,GA 30333; FLORIDA DEPT HLTH & REHABIL SERV,OFF DIS CONTROL & AIDS PREVENT,EPIDEMIOL PROGRAM,TALLAHASSEE,FL; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV ENVIRONM HAZARDS & HLTH EFFECTS,ATLANTA,GA 30333; WALTER REED ARMY INST RES,DIV PREVENT MED,WASHINGTON,DC 20307	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Florida Department of Health; Centers for Disease Control & Prevention - USA; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	LEE, LE (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV FIELD EPIDEMIOL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333, USA.		fonseca, vincent/AAD-5865-2019					[Anonymous], 1990, MMWR MORB MORTAL WKL, V39, P41; DIETZ VJ, 1990, DISASTERS, V14, P164, DOI 10.1111/j.1467-7717.1990.tb01057.x; WOODRUFF BA, 1990, DISASTERS, V14, P151, DOI 10.1111/j.1467-7717.1990.tb01056.x; 1979, WHO CHRON, V33, P214; 1992, UNPUB HURRICANE ANDR; 1992, MMWR CDC SURVEILL SU, V41, P9; 1992, HURRICANE ANDREW IMP; 1993, PRELIMINARY REPORT H; 1992, MMWR MORB MORTAL WKL, V41, P685	9	43	43	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					591	594		10.1001/jama.270.5.591	http://dx.doi.org/10.1001/jama.270.5.591			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331757				2022-12-28	WOS:A1993LP43600023
J	CHANSON, P; WEINTRAUB, BD; HARRIS, AG				CHANSON, P; WEINTRAUB, BD; HARRIS, AG			OCTREOTIDE THERAPY FOR THYROID-STIMULATING HORMONE-SECRETING PITUITARY-ADENOMAS - A FOLLOW-UP OF 52 PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Review							ACTING SOMATOSTATIN ANALOG; SMS 201-995; INAPPROPRIATE SECRETION; GROWTH-HORMONE; THYROTROPIN; SMS-201-995; TSH; IMPROVEMENT; INHIBITION; RECEPTORS	Objective: To evaluate the efficacy of octreotide in the treatment of pituitar Data Sources. Combination of review and original data. Review data included information supplied by Sandoz Pharmaceuticals from patient case report forms and information from abstracts and articles published in the French or English language between 1987 and 1991. Original data included follow-up data on 15 of 37 previously reported cases and data on 15 new cases provided by 11 investigators. Study Selection: Fifty-two cases from 24 medical centers in nine countries reported between 1987 and 1991. Data Extraction: Chief clinical characteristics of the patients; dose and duration of octreotide treatment; serum TSH, thyroid hormone, and free alpha-subunit levels before and during treatment; serial anatomic evaluation of the pituitary gland by either computed tomographic scanning or magnetic resonance imaging; and side effects. Data Synthesis: After the first octreotide dose (50 to 100 mug), TSH levels decreased in all but 2 patients (mean decrease for the whole group, 55.8% +/- 27%). Levels of alpha-subunit decreased in 15 of the 19 patients who had alpha-subunit assessments (mean decrease, 37.5% +/- 24%). Reduction of TSH levels after short-term treatment (50 or 100 mug two or three times daily) was observed in 30 of 33 patients (mean decrease, 74.1%). Thyroid hormone levels were reduced in all patients and returned to normal in 73%. Despite an initial response to therapy, thyroid hormone levels continued to rise (''true escape'') in 2 patients receiving short-term therapy and in 3 patients receiving long-term therapy. Partial shrinkage of the adenoma occurred in 11 patients. Conclusions: Octreotide is an effective treatment for TSH-secreting adenomas. Thyroid-stimulating hormone levels almost always decreased, and thyroid hormone levels reverted to normal in about three quarters of patients. Partial tumor shrinkage was observed in one third of patients receiving long-term octreotide treatment.	NIH, BETHESDA, MD 20892 USA; CEDARS SINAI MED CTR, LOS ANGELES, CA 90048 USA	National Institutes of Health (NIH) - USA; Cedars Sinai Medical Center	CHANSON, P (corresponding author), HOP LARIBOISIERE, DEPT INTERNAL MED & ENDOCRINOL, 2 RUE AMBROISE PARE, F-75475 PARIS 10, FRANCE.		Chanson, Philippe/F-8511-2013	Chanson, Philippe/0000-0001-5096-5722; Harris, Alan/0000-0002-6618-2092				ASAI J, 1988, 8TH INT C END; BECKERS A, 1988, Revue Medicale de Liege, V43, P396; BECKERS A, 1991, J CLIN ENDOCR METAB, V72, P477, DOI 10.1210/jcem-72-2-477; BECKPECCOZ P, 1988, HORM RES, V29, P121, DOI 10.1159/000180986; BECKPECCOZ P, 1989, J CLIN ENDOCR METAB, V68, P208, DOI 10.1210/jcem-68-1-208; BELDENT V, 1988, ANN ENDOCRINOL-PARIS, V50, P282; BERTHERAT J, 1992, J CLIN ENDOCR METAB, V75, P540, DOI 10.1210/jc.75.2.540; BRENNERGATI L, 1985, PITUITARY GLAND, P467; BUCHFELDER M, 1990, ACTA ENDOCR-COP   S1, V122, P140; CHANSON P, 1987, PRESSE MED, V16, P1644; CHAPMAN C, 1989, J ENDOCRINOL S, V12, P137; COMI RJ, 1987, NEW ENGL J MED, V317, P12, DOI 10.1056/NEJM198707023170103; FRANCAVILLA TL, 1991, NEUROSURGERY, V28, P826, DOI 10.1227/00006123-199106000-00007; FRANCIA G, 1989, J ENDOCRINOL INVE S1, V12, P42; GESUNDHEIT N, 1989, ANN INTERN MED, V111, P827, DOI 10.7326/0003-4819-111-10-827; GIRELLI ME, 1989, J ENDOCRINOL INVE S1, V12, P37; GUILLAUSSEAU PJ, 1987, NEW ENGL J MED, V317, P53; HIRASAWA R, 1991, ACTA MED OKAYAMA, V45, P107; HOUDENT C, 1989, ANN ENDOCRINOL-PARIS, V50, P227; LEVY A, 1989, J NEUROENDOCRINOL, V1, P321, DOI 10.1111/j.1365-2826.1989.tb00123.x; LINQUETTE M, 1989, B ACAD NAT MED PARIS, V173, P217; MALARKEY WB, 1989, NEUROENDOCRINOLOGY, V49, P267, DOI 10.1159/000125127; MCCUTCHEON IE, 1990, J NEUROSURG, V73, P674, DOI 10.3171/jns.1990.73.5.0674; MONTINI M, 1988, ADV PITUITARY ADENOM, V69, P429; MUHR C, 1990, J ENDOCRINOL INVE S2, V13, pS79; POLAK M, 1991, ACTA ENDOCRINOL-COP, V124, P479, DOI 10.1530/acta.0.1240479; RESCHINI E, 1976, J CLIN ENDOCR METAB, V43, P924, DOI 10.1210/jcem-43-4-924; ROGER P, 1988, 8TH INT C END; SASSOLAS G, 1988, HORM RES, V29, P124, DOI 10.1159/000180987; SHAKER JL, 1991, 73RD M END SOC, P1138; SILER TM, 1974, J CLIN ENDOCR METAB, V38, P742, DOI 10.1210/jcem-38-5-742; SMALLRIDGE RC, 1987, ENDOCRIN METAB CLIN, V16, P765, DOI 10.1016/S0889-8529(18)30473-0; VANCE ML, 1991, ARCH INTERN MED, P8; VUILLERMET P, 1991, ANN ENDOCRINOL-PARIS, V532, P36; WARNET A, 1991, ACTA ENDOCRINOL-COP, V124, P487, DOI 10.1530/acta.0.1240487; WEEKE J, 1975, J CLIN ENDOCR METAB, V41, P168, DOI 10.1210/jcem-41-1-168; WEINTRAUB BD, 1981, ANN INTERN MED, V95, P339, DOI 10.7326/0003-4819-95-3-339; WEMEAU JL, 1988, J CLIN ENDOCR METAB, V66, P636, DOI 10.1210/jcem-66-3-636	38	162	168	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					236	240		10.7326/0003-4819-119-3-199308010-00010	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8323093				2022-12-28	WOS:A1993LU90300010
J	ZHENG, LB; COLLINS, FH; KUMAR, V; KAFATOS, FC				ZHENG, LB; COLLINS, FH; KUMAR, V; KAFATOS, FC			A DETAILED GENETIC-MAP FOR THE X-CHROMOSOME OF THE MALARIA VECTOR, ANOPHELES-GAMBIAE	SCIENCE			English	Article							ESTERASE LOCUS; DNA; POLYMORPHISMS; COMPLEX; REPEAT	Anopheles gambiae, the primary vector of human malaria in Africa, is responsible for approximately a million deaths per year, mostly of children. Despite its significance in disease transmission, this mosquito has not been studied extensively by genetic or molecular techniques. To facilitate studies on this vector, a genetic map has been developed that covers the X chromosome at an average resolution of 2 centimorgans. This map has been integrated with the chromosome banding pattern and used to localize a recessive, sex-linked mutation (white eye) to within 1 centimorgan of flanking markers.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138; FORTH,INST MOLEC BIOL & BIOTECHNOL,GR-71110 IRAKLION,GREECE; UNIV CRETE,DEPT BIOL,GR-71110 IRAKLION,GREECE; CTR DIS CONTROL,MALARIA BRANCH F12,ATLANTA,GA 30333	Harvard University; Foundation for Research & Technology - Hellas (FORTH); University of Crete; Centers for Disease Control & Prevention - USA								BAKER RH, 1961, AM ZOOL, V1, P435; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BESANSKY NJ, COMMUNICATION; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1; CURTIS CF, 1976, R SOC TROP MED HYG, V70, P281; GREEN CA, 1980, GENETICA, V51, P187, DOI 10.1007/BF00121610; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; KITZMILLER JB, 1967, GENETICS INSECT VECT, P3; LITT M, 1989, AM J HUM GENET, V44, P397; MASON GF, 1967, GENET RES, V10, P205, DOI 10.1017/S001667230001096X; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; ROMANS P, 1991, J MED ENTOMOL, V28, P147, DOI 10.1093/jmedent/28.1.147; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEVERSON DW, IN PRESS J HERED; VERNICK KD, 1989, AM J TROP MED HYG, V40, P593, DOI 10.4269/ajtmh.1989.40.593; WEBER JL, 1989, AM J HUM GENET, V44, P388; ZHENG LB, 1991, P NATL ACAD SCI USA, V88, P11187, DOI 10.1073/pnas.88.24.11187	19	83	88	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					605	608		10.1126/science.8342025	http://dx.doi.org/10.1126/science.8342025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342025				2022-12-28	WOS:A1993LP72800038
J	OSENSAND, A; CATSICAS, M; STAPLE, JK; JONES, KA; AYALA, G; KNOWLES, J; GRENNINGLOH, G; CATSICAS, S				OSENSAND, A; CATSICAS, M; STAPLE, JK; JONES, KA; AYALA, G; KNOWLES, J; GRENNINGLOH, G; CATSICAS, S			INHIBITION OF AXONAL GROWTH BY SNAP-25 ANTISENSE OLIGONUCLEOTIDES IN-VITRO AND IN-VIVO	NATURE			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; RAT-BRAIN; EXPRESSION; TERMINALS; RETINA; CELLS	AXONAL elongation and the transformation of growth cones to synaptic terminals are major steps of brain development and the molecular mechanisms involved form the basis of the correct wiring of the nervous system. The same mechanisms may also contribute to the remodelling of nerve terminals that occurs in the adult brain, as a morphological substrate to memory and learning1. We have investigated the function of the nerve terminal protein SNAP-25 (ref. 2) during development. We report here that SNAP-25 is expressed in axonal growth cones during late stages of elongation and that selective inhibition of SNAP-25 expression prevents neurite elongation by rat cortical neurons and PC-12 cells in vitro and by amacrine cells of the developing chick retina in vivo. These results demonstrate that SNAP-25 plays a key role in axonal growth. They also suggest that high levels of SNAP-25 expression in specific areas of the adult brain2 may contribute to nerve terminal plasticity.	GLAXO INST MOLEC BIOL SA,14 CHEMIN AULX,CASE POSTALE 674,CH-1228 PLAN LES OUATES,SWITZERLAND; INST ANAT,CH-1005 LAUSANNE,SWITZERLAND	GlaxoSmithKline			Ayala, Gustavo/ABC-6625-2020					ALVAREZBOLADO G, 1991, ABSTR SOC NEUROSCI, V17, P215; BARK C, 1991, ABSTR SOC NEUROSCI, V17, P531; BAUGHMAN RW, 1991, CULTURING NERVE CELL, P227; CATSICAS S, 1991, P NATL ACAD SCI USA, V88, P785, DOI 10.1073/pnas.88.3.785; CATSICAS S, 1992, J NEUROSCI RES, V33, P1, DOI 10.1002/jnr.490330102; CATSICAS S, 1987, J COMP NEUROL, V262, P512, DOI 10.1002/cne.902620405; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; ELLIS JH, 1991, CELL TISSUE RES, V264, P197, DOI 10.1007/BF00313956; GEDDES JW, 1990, NEUROSCIENCE, V38, P515, DOI 10.1016/0306-4522(90)90047-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HESS DT, 1992, J NEUROSCI, V12, P4634; HESS EJ, 1992, J NEUROSCI, V12, P2865; LOEWY A, 1991, J NEUROSCI, V11, P3412; MASLIAH E, 1990, J HISTOCHEM CYTOCHEM, V38, P837, DOI 10.1177/38.6.2110586; OYLER GA, 1991, P NATL ACAD SCI USA, V88, P5247, DOI 10.1073/pnas.88.12.5247; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; OYLER GA, 1992, DEV BRAIN RES, V65, P133, DOI 10.1016/0165-3806(92)90172-S; PFENNINGER KH, 1991, GROWTH CONE, P111; SANNA PP, 1991, DEV BRAIN RES, V59, P104, DOI 10.1016/0165-3806(91)90035-H; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; WALLACE SW, 1991, LONG TERM POTENTIATI, P189	23	362	377	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					445	448		10.1038/364445a0	http://dx.doi.org/10.1038/364445a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332215				2022-12-28	WOS:A1993LP64000055
J	STEEL, MA; LOCKHART, PJ; PENNY, D				STEEL, MA; LOCKHART, PJ; PENNY, D			CONFIDENCE IN EVOLUTIONARY TREES FROM BIOLOGICAL SEQUENCE DATA	NATURE			English	Article							INFLUENZA-VIRUSES; GENOME; ORIGINS; GENES	THE reliable construction of evolutionary trees from nucleotide sequences often depends on randomization tests such as the boot-strap1 and PTP (cladistic permutation tail probability) tests2-6. The genomes of bacteria7, viruses8, animals7,9,10 and plants11, however, vary widely in their nucleotide frequencies. Where genomes have independently acquired similar G+C base compositions, signals in the data arise that cause methods of evolutionary tree reconstruction to estimate the wrong tree by grouping together sequences with similar G+C content12-14. Under these conditions randomization tests can lead to both the rejection of the correct evolutionary hypothesis and acceptance of an incorrect hypothesis (such as with the contradictory inferences from the photosynthetic rbcS and rbcL sequences14). We have proposed one approach to testing for the G+C content problem15. Here we present a formalization of this method, a frequency-dependent significance test, which has general application.	MASSEY UNIV,MOLEC GENET UNIT,PALMERSTON NORTH,NEW ZEALAND	Massey University	STEEL, MA (corresponding author), MASSEY UNIV,DEPT MATH,PALMERSTON NORTH,NEW ZEALAND.		Lockhart, Peter J/E-6624-2011; Penny, David/E-9410-2011	Steel, Mike/0000-0001-7015-4644				ARCHIE JW, 1989, SYST ZOOL, V38, P239, DOI 10.2307/2992285; BERNARDI G, 1986, J MOL EVOL, V24, P1, DOI 10.1007/BF02099946; CROZIER RH, 1993, GENETICS, V133, P97; FAITH DP, 1991, CLADISTICS, V7, P1, DOI 10.1111/j.1096-0031.1991.tb00020.x; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; HASEGAWA M, 1993, NATURE, V361, P23, DOI 10.1038/361023b0; HENDERSON IM, 1987, NATURE, V326, P22, DOI 10.1038/326022a0; HENDERSON IM, 1989, J THEOR BIOL, V140, P289, DOI 10.1016/S0022-5193(89)80087-6; JUKES TH, 1986, J MOL EVOL, V24, P39, DOI 10.1007/BF02099949; KEESE P, 1989, VIROLOGY, V172, P536, DOI 10.1016/0042-6822(89)90196-7; Lockhart P., 1992, RES PHOTOSYNTHESIS, V3, P499; LOCKHART PJ, 1992, J MOL EVOL, V34, P153; LOCKHART PJ, 1992, FEBS LETT, V301, P127, DOI 10.1016/0014-5793(92)81231-A; LOCKHART PJ, IN PRESS PHOTOSYN RE; OLIVER JL, 1990, NUCLEIC ACIDS RES, V18, P65, DOI 10.1093/nar/18.1.65; PENNY D, 1990, Australian Systematic Botany, V3, P21, DOI 10.1071/SB9900021; SACCONE C, 1989, J MOL EVOL, V29, P407, DOI 10.1007/BF02602910; STEEL MA, 1992, J CLASSIF, V9, P71, DOI 10.1007/BF02618469	18	150	152	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					440	442		10.1038/364440a0	http://dx.doi.org/10.1038/364440a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332213				2022-12-28	WOS:A1993LP64000053
J	SIMONDS, RJ; OXTOBY, MJ; CALDWELL, MB; GWINN, ML; ROGERS, MF				SIMONDS, RJ; OXTOBY, MJ; CALDWELL, MB; GWINN, ML; ROGERS, MF			PNEUMOCYSTIS-CARINII PNEUMONIA AMONG UNITED-STATES CHILDREN WITH PERINATALLY ACQUIRED HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-SYNDROME; SURVIVAL; HYPOGAMMAGLOBULINEMIA; CHEMOPROPHYLAXIS; PREVALENCE; PATTERNS; SAMPLES; AIDS	Objective.-To describe epidemiologic characteristics of Pneumocystis carinii pneumonia (PCP) among children with perinatally acquired human immunodeficiency virus (HIV) infection to guide prevention efforts. Design.-National acquired immunodeficiency syndrome (AIDS) surveillance of children aged 0 through 12 years, a multisite surveillance study of HIV infection in children aged 0 through 12 years, and the national HIV serosurvey of childbearing women. Setting.-Surveillance conducted by state and local health departments and reported to the Centers for Disease Control and Prevention 1982 through 1992. Results.-Pneumocystis carinii pneumonia was reported in 1374 (37%) of 3665 perinatally acquired AIDS cases. Over half of these cases occurred between 3 and 6 months of age. In 183 (64%) of 275 PCP cases reported in the special surveillance study, PCP was the first or only AIDS-defining condition diagnosed, and in 44% of cases, the child had not been evaluated for HIV infection before diagnosis of PCP. The estimated median survival after diagnosis of PCP was 19 months. Conclusions.-Pneumocystis carinii pneumonia is a common and serious opportunistic infection that affects young children with HIV infection. Effective efforts to prevent PCP in this population will require identification as early as possible of children who may be infected with HIV.			SIMONDS, RJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,1600 CLIFTON RD,MAILSTOP E-45,ATLANTA,GA 30333, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BERNSTEIN LJ, 1989, AM J DIS CHILD, V143, P775, DOI 10.1001/archpedi.1989.02150190025013; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BRESLOW N, 1970, BIOMETRIKA, V57, P579, DOI 10.2307/2334776; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; BURKE BA, 1973, MEDICINE, V52, P23, DOI 10.1097/00005792-197301000-00002; Centers for Disease Control (CDC), 1987, MMWR Morb Mortal Wkly Rep, V36, P509; CHUSID MJ, 1967, PEDIATRICS, V62, P1031; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; Dutz W, 1976, Natl Cancer Inst Monogr, V43, P31; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GAJDUSEK DC, 1957, PEDIATRICS, V19, P543; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HARDY AM, 1984, J INFECT DIS, V149, P143, DOI 10.1093/infdis/149.2.143; HOOVER DR, 1991, AM REV RESPIR DIS, V144, P756, DOI 10.1164/ajrccm/144.4.756; HSU H, 1990, 30TH ANN M INT C ANT; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1984, J INFECT DIS, V150, P305, DOI 10.1093/infdis/150.2.305-a; HUGHES WT, 1974, AM J DIS CHILD, V128, P44, DOI 10.1001/archpedi.1974.02110260046008; HUGHES WT, 1973, J PEDIATR-US, V82, P404, DOI 10.1016/S0022-3476(73)80113-1; LEGGIADRO RJ, 1981, J PEDIATR-US, V99, P96, DOI 10.1016/S0022-3476(81)80967-5; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MILLER RF, 1992, LANCET, V339, P747, DOI 10.1016/0140-6736(92)90650-R; OXTOBY MJ, 1991, PEDIATRIC AIDS CHALL, P3; RAO CP, 1983, J PEDIATR-US, V103, P410, DOI 10.1016/S0022-3476(83)80415-6; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; SAULSBURY FT, 1979, J PEDIATR-US, V95, P559, DOI 10.1016/S0022-3476(79)80766-0; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SINGER C, 1975, ANN INTERN MED, V82, P772, DOI 10.7326/0003-4819-82-6-722; THOMAS P, 1992, PEDIATR INFECT DIS J, V11, P34, DOI 10.1097/00006454-199201000-00009; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; 1991, MMWR MORB MORTAL WKL, V40, P1; 1987, MMWR MORB MORTAL WKL, V36, P225; 1992, PEDIATRICS, V89, P791; 1993, HIV AIDS SURVEIL FEB, P1; 1990, LIFE TABLES SURVIVOR; 1987, MMWR MORB MORTAL WKL, V36, pS1; 1991, HIV SCREENING PREGNA, P33; 1982, MMWR MORB MORTAL WKL, V31, P507; 1991, LANCET, V337, P253; 1982, MMWR MORB MORTAL WKL, V31, P513	41	111	112	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					470	473		10.1001/jama.270.4.470	http://dx.doi.org/10.1001/jama.270.4.470			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320786				2022-12-28	WOS:A1993LN42600026
J	ZHOU, YX; BAKER, CL				ZHOU, YX; BAKER, CL			A PROCESSING STREAM IN MAMMALIAN VISUAL-CORTEX NEURONS FOR NON-FOURIER RESPONSES	SCIENCE			English	Article							CATS STRIATE CORTEX; SPATIAL-FREQUENCY; COMPLEX CELLS; GRATINGS; PATTERNS; SYSTEM; DISCRIMINATION; THRESHOLDS; HYPOTHESIS; STIMULI	Mammalian striate and circumstriate cortical neurons have long been understood as coding spatially localized retinal luminance variations, providing a basis for computing motion, stereopsis, and contours from the retinal image. However, such perceptual attributes do not always correspond to the retinal luminance variations in natural vision. Recordings from area 17 and 18 neurons of the cat revealed a specialized nonlinear processing stream that responds to stimulus attributes that have no corresponding luminance variations. This nonlinear stream acts in parallel to the conventional luminance processing of single cortical neurons. The two streams were consistent in their preference for orientation and direction of motion but distinct in processing spatial variations of the stimulus attributes.	MCGILL UNIV,DEPT OPHTHALMOL,MCGILL VIS RES UNIT,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT PSYCHOL,MONTREAL H3A 1B1,QUEBEC,CANADA	McGill University; McGill University			Baker, Curtis/A-8794-2011					ALBRECHT DG, 1980, SCIENCE, V207, P88, DOI 10.1126/science.6765993; ALBRECHT DG, 1981, J PHYSIOL-LONDON, V319, P497, DOI 10.1113/jphysiol.1981.sp013922; ALBRIGHT TD, 1992, SCIENCE, V255, P1141, DOI 10.1126/science.1546317; BAKER CL, 1990, VISUAL NEUROSCI, V4, P101, DOI 10.1017/S0952523800002273; BLAKE R, 1974, VISION RES, V14, P1211, DOI 10.1016/0042-6989(74)90218-1; BOULTON JC, IN PRESS VISION RES; BURTON GJ, 1973, VISION RES, V13, P1211, DOI 10.1016/0042-6989(73)90198-3; CAMPBELL FW, 1968, J PHYSIOL-LONDON, V197, P551, DOI 10.1113/jphysiol.1968.sp008574; CHEN B, 1993, VISION RES, V33, P413, DOI 10.1016/0042-6989(93)90095-E; CHUBB C, 1988, J OPT SOC AM A, V5, P1986, DOI 10.1364/JOSAA.5.001986; DERRINGTON AM, 1987, VISION RES, V27, P1377, DOI 10.1016/0042-6989(87)90214-8; DERRINGTON AM, 1985, VISION RES, V25, P1869, DOI 10.1016/0042-6989(85)90010-0; GROSOF DH, 1992, INVEST OPHTH VIS SCI, V33, P1257; HENNING GB, 1975, VISION RES, V15, P887, DOI 10.1016/0042-6989(75)90228-X; HESS RF, 1992, VISION RES, V32, P1085, DOI 10.1016/0042-6989(92)90009-8; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P79, DOI 10.1113/jphysiol.1978.sp012489; NACHMIAS J, 1989, VISION RES, V29, P137, DOI 10.1016/0042-6989(89)90180-6; PETERHANS E, 1991, TRENDS NEUROSCI, V14, P112, DOI 10.1016/0166-2236(91)90072-3; POLLEN DA, 1988, VISION RES, V28, P25, DOI 10.1016/0042-6989(88)90004-1; REDIES C, 1986, EXP BRAIN RES, V61, P469; Robson J. G., 1980, VISUAL CODING ADAPTA, P177; SHAPLEY R, 1985, ANNU REV NEUROSCI, V8, P547, DOI 10.1146/annurev.ne.08.030185.002555; SKOTTUN BC, 1991, VISION RES, V31, P1079, DOI 10.1016/0042-6989(91)90033-2; SPITZER H, 1988, PROG NEUROBIOL, V31, P285, DOI 10.1016/0301-0082(88)90016-0; TOET A, 1988, VISION RES, V28, P133, DOI 10.1016/S0042-6989(88)80013-0; TURANO K, 1989, VISION RES, V29, P207, DOI 10.1016/0042-6989(89)90125-9; WILSON HR, 1991, J OPT SOC AM A, V8, P229, DOI 10.1364/JOSAA.8.000229; 1989, 1989 P IEEE WORKSH V, P126	30	184	186	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					98	101		10.1126/science.8316862	http://dx.doi.org/10.1126/science.8316862			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316862				2022-12-28	WOS:A1993LK43400041
J	WAWER, MJ; SEWANKAMBO, NK; BERKLEY, S; SERWADDA, D; MUSGRAVE, SD; GRAY, RH; MUSAGARA, M; STALLINGS, RY; KONDELULE, JK				WAWER, MJ; SEWANKAMBO, NK; BERKLEY, S; SERWADDA, D; MUSGRAVE, SD; GRAY, RH; MUSAGARA, M; STALLINGS, RY; KONDELULE, JK			INCIDENCE OF HIV-1 INFECTION IN A RURAL REGION OF UGANDA	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; DISTRICT	Objective-To determine the incidence of infection with HIV-1 and the risk factors associated with seroconversion in three geographical strata of a rural Ugandan district. Design-Serological, sociodemographic, and behavioural surveys of everyone aged 13 or more in 21 randomly selected communities at baseline and one year later. Setting-Rural population of Rakai district, southwestern Uganda, residing in main road trading centres, secondary trading villages, and agricultural villages. Subjects-In 1989, 1292 adults provided a blood sample and interview data; one year later, 778 survivors (77%) who had been seronegative at baseline provided follow up data. Main outcome measures-Incidence of HIV infection in relation to individual characteristics and risk factors, including place of residence. Results-Incidence of HIV infection in all adults was 2.1/100 person years of observation (SE 0.5 (95% confidence interval 1.1 to 3.1)); in people aged 15-39 the incidence was 3.2/100 person years. Incidence was highest in men and women aged 20-24 (9.2/100 person years (3.9) and 6.8/100 person years (2-9) respectively). Risk factors significantly associated with seroconversion were age 24 and under and two or more sexual partners. Between the surveys the proportion of all respondents reporting high risk behaviour (two or more partners) significantly increased from 8.9% to 12.3%. Conclusions-Despite preventive programmes and substantial knowledge about AIDS the incidence of HIV infection remains high in this rural population. Prevention aimed at vulnerable rural communities is urgently needed to contain the HIV epidemic.	MAKERERE UNIV,DEPT MED,KAMPALA,UGANDA; MAKERERE UNIV,INST PUBL HLTH,KAMPALA,UGANDA; ROCKEFELLER FDN,DIV HLTH SCI,NEW YORK,NY 10036; UGANDA VIRUS RES INST,RAKAI PROJECT,COLUMBIA UNIV OFF,ENTEBBE,UGANDA; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT POPULAT DYNAM,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21218	Makerere University; Makerere University; Uganda Virus Research Institute; Johns Hopkins University; Johns Hopkins University	WAWER, MJ (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,CTR POPULAT & FAMILY HLTH,60 HAVEN AVE,NEW YORK,NY 10032, USA.			Sewankambo, Nelson/0000-0001-9362-053X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029314] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI29314] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN S, 1991, JAMA-J AM MED ASSOC, V266, P1657; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; ORUBULOYE IO, 1991, STUD FAMILY PLANN, V22, P61, DOI 10.2307/1966777; SERWADDA D, 1992, AIDS, V6, P983, DOI 10.1097/00002030-199209000-00012; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303; 1991, WORLD DEV REPORT; 1987, RELEASE 6 04	8	84	85	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					171	173		10.1136/bmj.308.6922.171	http://dx.doi.org/10.1136/bmj.308.6922.171			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MR974	8312767	Green Published			2022-12-28	WOS:A1994MR97400018
J	WENGER, NS; SHPINER, RB				WENGER, NS; SHPINER, RB			AN ANALYSIS OF MORNING REPORT - IMPLICATIONS FOR INTERNAL-MEDICINE EDUCATION	ANNALS OF INTERNAL MEDICINE			English	Article							AUTOPSY	Objective: To compare the initial diagnosis of cases presented at morning report with the final morning report diagnosis reached at discharge from the Medicine service and the diagnosis as evaluated 6 months after discharge. Design: Prospective cohort study of morning report cases. Setting: A university internal medicine residency program. Measurements: Proportion of morning report cases in which the initial morning report diagnosis differed from the final morning report diagnosis at discharge or, in cases where a firm diagnosis was not reached at discharge, the proportion for which a diagnosis was established by 6 months after discharge. Main Results: In 24% of cases, a firm morning report diagnosis was not available at discharge. For 61% of these, a diagnosis could be established by 6-month follow-up: for 36% the diagnosis differed from the final morning report diagnosis; and for 25% it was the same. Among cases where a firm final diagnosis was reached during morning report, the initial morning report diagnosis differed for 17%. Conclusions: Most patients discharged without a firm diagnosis have one established by 6 months later-often with surprising results. Postdischarge follow-up information could enhance the educational value of inpatient cases.			WENGER, NS (corresponding author), UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT MED, DIV GEN INTERNAL MED & HLTH SERV RES, LOS ANGELES, CA 90024 USA.							DANS PE, 1989, MEDICAL COST-CONTAINMENT CRISIS, P271; DEGROOT LJ, 1979, NEW ENGL J MED, V301, P1285, DOI 10.1056/NEJM197912063012311; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; JOHNSON HA, 1991, JAMA-J AM MED ASSOC, V265, P2229, DOI 10.1001/jama.265.17.2229; KASSIRER JP, 1983, NEW ENGL J MED, V309, P921, DOI 10.1056/NEJM198310133091511; LEVEY GS, 1992, ANN INTERN MED, V116, P1046, DOI 10.7326/0003-4819-116-12-1046; MCPHEE SJ, 1986, AM J MED, V80, P665, DOI 10.1016/0002-9343(86)90822-3; PARRINO TA, 1986, JAMA-J AM MED ASSOC, V256, P730; ROBERTS WC, 1978, NEW ENGL J MED, V299, P332, DOI 10.1056/NEJM197808172990704; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SHANKEL SW, 1986, JAMA-J AM MED ASSOC, V256, P725, DOI 10.1001/jama.256.6.725; WHEELER PS, 1982, RADIOLOGY, V145, P227, DOI 10.1148/radiology.145.1.7122886; [No title captured]	13	26	26	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					395	399		10.7326/0003-4819-119-5-199309010-00008	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338293				2022-12-28	WOS:A1993LZ47600008
J	KIEBLER, M; KEIL, P; SCHNEIDER, H; VANDERKLEI, IJ; PFANNER, N; NEUPERT, W				KIEBLER, M; KEIL, P; SCHNEIDER, H; VANDERKLEI, IJ; PFANNER, N; NEUPERT, W			THE MITOCHONDRIAL RECEPTOR COMPLEX - A CENTRAL ROLE OF MOM22 IN MEDIATING PREPROTEIN TRANSFER FROM RECEPTORS TO THE GENERAL INSERTION PORE	CELL			English	Article							OUTER-MEMBRANE PROTEIN; ADP-ATP CARRIER; ENDOPLASMIC-RETICULUM MEMBRANE; PRECURSOR PROTEINS; DNA-POLYMERASE; POSTTRANSLATIONAL TRANSFER; NUCLEOSIDE TRIPHOSPHATES; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; ESCHERICHIA-COLI	The receptor complex in the mitochondrial outer membrane, which consists of at least seven different proteins, is responsible for the recognition and translocation of cytosolically synthesized preproteins. Two of its subunits, MOM19 and MOM72, function as surface receptors for preproteins. Four other subunits (MOM38, MOM30, MOM8, and MOM7) have been suggested to constitute the general insertion pore (GIP). Here we report on the structure and function of MOM22. MOM22 is anchored in the outer membrane by a single transmembrane segment. The highly negatively charged N-terminal domain is exposed to the cytosol and the C-terminal domain to the intermembrane space. MOM22 appears to be a central component of the receptor complex, required for the transfer of preproteins from the receptors to the GIP. We speculate that the negatively charged domain of MOM22 is involved in the transfer of positively charged signal sequences of preproteins.	UNIV FREIBURG, INST BIOCHEM, D-79104 FREIBURG, GERMANY	University of Freiburg	KIEBLER, M (corresponding author), UNIV MUNICH, INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY.		van der Klei, Ida J/D-1919-2012; Pfanner, Nikolaus/AAV-7878-2021	Kiebler, Michael/0000-0002-8850-6297; Van der Klei, Ida J./0000-0001-7165-9679				ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKER K, 1992, J BIOL CHEM, V267, P5637; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; KEEGSTRA K, 1992, CELL ORGANELLES, P353; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAGE MG, 1981, METHOD ENZYMOL, V73, P142; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; PFANNER N, 1990, J BIOL CHEM, V265, P16324; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZIMMERMANN R, 1980, EUR J BIOCHEM, V109, P217, DOI 10.1111/j.1432-1033.1980.tb04787.x	55	166	167	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 13	1993	74	3					483	492		10.1016/0092-8674(93)80050-O	http://dx.doi.org/10.1016/0092-8674(93)80050-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348615	Green Published			2022-12-28	WOS:A1993LT73900010
J	MELENDEZ, JC; MCCRANK, E				MELENDEZ, JC; MCCRANK, E			ANXIETY-RELATED REACTIONS ASSOCIATED WITH MAGNETIC-RESONANCE-IMAGING EXAMINATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PATIENT TOLERANCE; CLAUSTROPHOBIA; MRI	Objective.-To review the epidemiology of anxiety-related reactions during magnetic resonance imaging (MRI) examinations, the feasibility of identifying patients at risk, and the management strategies that have been applied. Data Sources.-Published original articles were retrieved using computerized MEDLINE searches encompassing 1980 through April 1993. Further references were obtained from the primary sources. Study Selection and Data Extraction.-All studies obtained through the data search were chosen for review. All data relevant to anxiety-related reactions were analyzed. Data Synthesis.-Anxiety-related reactions occur in approximately 4% to 30% of patients undergoing MRI, ranging from apprehension to severe reactions that interfere with the performance of the test. Criteria for diagnosis or categorization of the reactions and identification of patients at risk are scanty. Several management strategies have been proposed, including patient education, drug therapy, and cognitive-behavioral intervention. Conclusions.-While a more precise characterization of the nature and incidence of anxiety-related reactions during MRI examinations and better methods of recognizing patients at risk are desirable, a strategy for general and individual prophylaxis, identification of patients at risk, and individual patient management can be developed on the basis of current knowledge.	UNIV WESTERN ONTARIO,DEPT PSYCHIAT,ANXIETY DISORDERS UNIT,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario)								AVRAHAMI E, 1990, AM J NEURORADIOL, V11, P833; AXEL L, 1989, AM J ROENTGENOL, V152, P653, DOI 10.2214/ajr.152.3.653-a; BRENNAN SC, 1988, LANCET, V1, P512; DANTENDORFER K, 1991, LANCET, V338, P761, DOI 10.1016/0140-6736(91)91486-E; EDELMAN DR, 1993, NEW ENGL J MED, V328, P708; FISHBAIN DA, 1988, AM J PSYCHIAT, V145, P1038; FLAHERTY JA, 1989, NEW ENGL J MED, V320, P467; FRIDAY PJ, 1990, AM J CLIN HYPN, V33, P80, DOI 10.1080/00029157.1990.10402908; Granet R B, 1990, N J Med, V87, P479; HRICAK H, 1984, RADIOLOGY, V152, P819, DOI 10.1148/radiology.152.3.6463267; KILBORN LC, 1990, J BEHAV MED, V13, P339; KLEIN DS, 1991, AM J ROENTGENOL, V156, P633, DOI 10.2214/ajr.156.3.1899765; KLONOFF EA, 1986, J BEHAV THER EXP PSY, V17, P189, DOI 10.1016/0005-7916(86)90026-1; MIYAMOTO AT, 1988, AM J ROENTGENOL, V151, P1060, DOI 10.2214/ajr.151.5.1060; PHELPS LA, 1990, AM FAM PHYSICIAN, V42, P930; QUIRK ME, 1989, RADIOLOGY, V170, P463, DOI 10.1148/radiology.170.2.2911670; QUIRK ME, 1989, RADIOLOGY, V173, P759, DOI 10.1148/radiology.173.3.2682775; SLIFER KJ, 1991, AM J ROENTGENOL, V156, P403, DOI 10.2214/ajr.156.2.1898824; THORP D, 1990, CLIN RADIOL, V41, P276, DOI 10.1016/S0009-9260(05)81665-4; WEINREB JC, 1984, AM J ROENTGENOL, V143, P1285, DOI 10.2214/ajr.143.6.1285	20	165	167	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1993	270	6					745	747		10.1001/jama.270.6.745	http://dx.doi.org/10.1001/jama.270.6.745			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LQ338	8336378				2022-12-28	WOS:A1993LQ33800031
J	JOHNSON, JT; FERRETTI, GA; NETHERY, WJ; VALDEZ, IH; FOX, PC; NG, D; MUSCOPLAT, CC; GALLAGHER, SC				JOHNSON, JT; FERRETTI, GA; NETHERY, WJ; VALDEZ, IH; FOX, PC; NG, D; MUSCOPLAT, CC; GALLAGHER, SC			ORAL PILOCARPINE FOR POSTIRRADIATION XEROSTOMIA IN PATIENTS WITH HEAD AND NECK-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTAINING ARTIFICIAL SALIVA; BLIND CROSSOVER TRIAL; SUBSTITUTES; MUCINS	Background and Methods. We evaluated pilocarpine hydrochloride for the treatment of radiation-induced xerostomia, a common complication of irradiation of the head and neck. A prospective, randomized, double-blind, placebo-controlled trial was undertaken to test the safety and efficacy of pilocarpine, particularly in reversing the decrease in the production of saliva and other manifestations of xerostomia. Patients received either placebo or pilocarpine (5 mg or 10 mg orally three times a day) for 12 weeks and were evaluated at base line and every 4 weeks. Results. We studied 207 patients who had each received greater-than-or-equal-to 4000 cGy of radiation to the head and neck. In the patients receiving the 5-mg dose of pilocarpine, oral dryness improved in 44 percent, as compared with 25 percent of the patients receiving placebo (P = 0.027). There was overall improvement in 54 percent of the 5-mg group as compared with 25 percent of the placebo group (P = 0.003), and 31 percent of the 5-mg group had improved comfort of the mouth and tongue, as compared with 10 percent of the placebo group (P = 0.002). Speaking ability improved in 33 percent of the 5-mg group as compared with 18 percent of the placebo group (P = 0.037). Saliva production was improved, but it did not correlate with symptomatic relief. There were comparable improvements in the group receiving the 10-mg dose. The primary adverse effect was sweating, in addition to other minor cholinergic effects. Six and 29 percent of the patients in the 5-mg and 10-mg groups, respectively, withdrew from the study because of adverse effects. There were no serious adverse effects related to pilocarpine. Conclusions. Pilocarpine improved saliva production and relieved symptoms of xerostomia after irradiation for cancer of the head and neck, with minor side effects that were predominantly limited to sweating.	UNIV KENTUCKY, LEXINGTON, KY 40506 USA; LOMA LINDA UNIV, LOMA LINDA, CA 92350 USA; NIDR, CLIN INVEST & PATIENT CARE BRANCH, BETHESDA, MD 20892 USA; PHARMACO DYNAM RES, AUSTIN, TX USA; MGI PHARMA, MINNEAPOLIS, MN USA	University of Kentucky; Loma Linda University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	JOHNSON, JT (corresponding author), UNIV PITTSBURGH, SCH MED, DEPT OTOLARYNGOL, 203 LOTHROP ST, SUITE 500, PITTSBURGH, PA 15261 USA.							AMERONGEN AVN, 1984, BIOCHIM BIOPHYS ACTA, V798, P103; Baum B J, 1985, Spec Care Dentist, V5, P274, DOI 10.1111/j.1754-4505.1985.tb00593.x; DENNY PC, 1987, J DENT RES, V66, P1011, DOI 10.1177/00220345870660050301; DREIZEN S, 1977, J DENT RES, V56, P99, DOI 10.1177/00220345770560022101; DUXBURY AJ, 1989, BRIT DENT J, V166, P115, DOI 10.1038/sj.bdj.4806731; FOX PC, 1991, ARCH INTERN MED, V151, P1149, DOI 10.1001/archinte.151.6.1149; FOX PC, 1985, J AM DENT ASSOC, V110, P519, DOI 10.14219/jada.archive.1985.0384; FRANK RM, 1965, J AM DENT ASSOC, V70, P868, DOI 10.14219/jada.archive.1965.0220; GALLAGHER JT, 1986, BIOCHIM BIOPHYS ACTA, V886, P243, DOI 10.1016/0167-4889(86)90142-4; GREENSPAN D, 1987, CANCER, V59, P1123, DOI 10.1002/1097-0142(19870315)59:6<1123::AID-CNCR2820590614>3.0.CO;2-X; KOMABAYASHI T, 1983, JPN J PHYSIOL, V33, P921, DOI 10.2170/jjphysiol.33.921; Mandel I D, 1971, Pharmacol Ther Dent, V1, P71; MANDEL ID, 1967, J ORAL THER PHARMACO, V4, P192; MASON DK, 1967, ODENT MAG ORAL TOPIC, V84, P235; MILNE RW, 1973, VOX SANG, V25, P298, DOI 10.1111/j.1423-0410.1973.tb04377.x; S-GRAVENMADE E J, 1974, International Journal of Oral Surgery, V3, P435; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; TABAK LA, 1982, J ORAL PATHOL MED, V11, P1, DOI 10.1111/j.1600-0714.1982.tb00138.x; TAYLOR P, 1990, P122; VISCH LL, 1986, INT J ORAL MAX SURG, V15, P395, DOI 10.1016/S0300-9785(86)80027-8; VISSINK A, 1987, GERODONTOLOGY, V6, P95, DOI 10.1111/j.1741-2358.1987.tb00283.x; VISSINK A, 1986, J DENT RES, V65, P1121, DOI 10.1177/00220345860650090301; YANAURA S, 1982, JPN J PHARMACOL, V32, P29, DOI 10.1254/jjp.32.29	23	329	341	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					390	395		10.1056/NEJM199308053290603	http://dx.doi.org/10.1056/NEJM199308053290603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8326972				2022-12-28	WOS:A1993LQ33900003
J	TASHIRO, K; TADA, H; HEILKER, R; SHIROZU, M; NAKANO, T; HONJO, T				TASHIRO, K; TADA, H; HEILKER, R; SHIROZU, M; NAKANO, T; HONJO, T			SIGNAL SEQUENCE TRAP - A CLONING STRATEGY FOR SECRETED PROTEINS AND TYPE-I MEMBRANE-PROTEINS	SCIENCE			English	Article							STROMAL CELL CLONE; MOLECULAR-CLONING; DIFFERENTIATION; CDNA; EXPRESSION; RECEPTOR; GROWTH; IDENTIFICATION; CULTURE; INVITRO	A method was developed to clone, without the use of specific functional assays, complementary DNAs (cDNAs) that carry specific amino-terminal signal sequences, such as those encoding intercellular signal-transducing molecules and receptors. The vector used in this system directed the cell surface expression of interleukin-2 receptor fusion proteins when inserts with signal sequences were cloned in-frame with the correct orientation. An expression cDNA library was constructed from a bone marrow stromal cell line, which contained 5' portion-enriched cDNAs (the average size was 400 base pairs). Two cDNAs that encoded putative cytokine molecules, stromal cell-derived factor-1alpha (SDF-1alpha) and SDF-1beta, which belong to the intercrine-macrophage inflammatory protein superfamily, were cloned.	KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Honjo, Tasuku/N-4470-2016					BROXMEYER HE, 1990, BLOOD, V76, P1110; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; IKEDA T, 1991, J BONE MINER RES, V6, P1013; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KATAMINE S, 1984, NATURE, V309, P369, DOI 10.1038/309369a0; Kinashi T, 1989, INT IMMUNOL, V1, P11, DOI 10.1093/intimm/1.1.11; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE KH, 1991, J EXP MED, V173, P1257, DOI 10.1084/jem.173.5.1257; MORITA M, 1991, BLOOD, V77, P1766; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RALPH P, 1973, J IMMUNOL, V110, P1470; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SHIROZU M, UNPUB; Sideras P, 1989, Int Immunol, V1, P631, DOI 10.1093/intimm/1.6.631; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TASHIRO K, 1991, IMMUNOL LETT, V28, P147, DOI 10.1016/0165-2478(91)90113-O; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068	31	629	754	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					600	603		10.1126/science.8342023	http://dx.doi.org/10.1126/science.8342023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342023				2022-12-28	WOS:A1993LP72800036
J	GREENBLATT, J; NODWELL, JR; MASON, SW				GREENBLATT, J; NODWELL, JR; MASON, SW			TRANSCRIPTIONAL ANTITERMINATION	NATURE			English	Review							HIV-1 TAT PROTEIN; RNA POLYMERASE-II; HUMAN-IMMUNODEFICIENCY-VIRUS; NUSA GENE PROTEIN; ESCHERICHIA-COLI; PHAGE-LAMBDA; BACTERIOPHAGE-LAMBDA; ANTI-TERMINATION; ELONGATION COMPLEXES; N-PROTEIN	Antiterminator proteins control gene expression by recognizing control signals near the promoter and preventing transcriptional termination which would otherwise occur at sites that may be a long way downstream. The N protein of bacteriophage lambda recognizes a sequence in the nascent RNA, and modifies RNA polymerase by catalysing the formation of a stable ribonucleo-protein complex on its surface, whereas the lambda Q protein recognizes a sequence in the DNA. These mechanisms of antitermination in lambda provide models for analysing antitermination in viruses such as HIV-1 and in eukaryotic genes.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto	GREENBLATT, J (corresponding author), UNIV TORONTO,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA.			Mason, Stephen/0000-0002-6662-9624				ALBRECHTSEN B, 1990, J MOL BIOL, V213, P123, DOI 10.1016/S0022-2836(05)80125-1; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; DESAI K, 1991, P NATL ACAD SCI USA, V88, P8875, DOI 10.1073/pnas.88.20.8875; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FRANKLIN NC, 1985, J MOL BIOL, V181, P85, DOI 10.1016/0022-2836(85)90326-2; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GREENBLATT J, 1984, CAN J BIOCHEM CELL B, V62, P79, DOI 10.1139/o84-012; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LI J, 1992, J BIOL CHEM, V267, P6012; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; LOZERON HA, 1977, J MOL BIOL, V109, P359, DOI 10.1016/S0022-2836(77)80039-9; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MASON SW, 1992, J BIOL CHEM, V267, P19418; MORGAN EA, 1986, J BACTERIOL, V168, P1; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; OLSEN ER, 1984, J MOL BIOL, V180, P1053; PUGH BF, 1992, J BIOL CHEM, V267, P679; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; SPENCER CA, 1990, ONCOGENE, V5, P777; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SULLIVAN SL, 1992, J BACTERIOL, V174, P1339, DOI 10.1128/jb.174.4.1339-1344.1992; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; WARREN F, 1984, P NATL ACAD SCI-BIOL, V81, P3612, DOI 10.1073/pnas.81.12.3612; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WHALEN W, 1988, P NATL ACAD SCI USA, V85, P2494, DOI 10.1073/pnas.85.8.2494; WHALEN W A, 1990, New Biologist, V2, P975; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	68	219	221	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					401	406		10.1038/364401a0	http://dx.doi.org/10.1038/364401a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332211				2022-12-28	WOS:A1993LP64000043
J	HELLINGER, FJ				HELLINGER, FJ			THE LIFETIME COST OF TREATING A PERSON WITH HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE COSTS; AIDS; EXPERIENCE; FORECASTS	Objective.-To estimate the cost (total charges for services) of medical care for persons with human immunodeficiency virus (HIV) from the time of infection until death. Design and Setting.-Data from the AIDS (acquired immunodeficiency syndrome) Cost and Service Utilization Survey were used. Patients.-Data from interviews conducted during the spring and early summer of 1992 with 1164 respondents with HIV were analyzed. The respondents were recruited at 26 sites (hospitals, clinics, and physicians' offices) in 10 cities. Billing data from a survey of providers also were used. Outcome Measures.-Estimates of the mean occupancy time in each of four disease stages were obtained from the San Francisco Men's Health Study. These estimates were multiplied by the monthly cost in each stage and summed to derive a synthetic estimate of the lifetime medical care costs of treating a person with HIV. Results.-It is estimated herein that the lifetime cost of treating a person with HIV from the time of infection until death is approximately $119 000. The estimated cost of care from HIV infection until the development of AIDS is $50 000, while the estimated cost from Al DS development until death is approximately $69 000. These estimates define upper bounds because they assume persons receive treatment continuously from the moment of infection until death. Conclusions.-This study found that the cost of treating a person with AIDS, which has risen rapidly in the past, has fallen as a result of a reduction in the use of inpatient hospital services.			HELLINGER, FJ (corresponding author), US PHS,AGCY HLTH CARE POLICY & RES,CTR GEN HLTH SERV EXTRAMURAL RES,ROCKVILLE,MD 20852, USA.							ANDRULIS DP, 1987, JAMA-J AM MED ASSOC, V258, P1343; ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BARTLETT JG, 1992, 1992 1993 RECOMMENDA; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P1; BENNETT CL, 1991, J ACQ IMMUN DEF SYND, V4, P197; EISENHANDLER J, 1992, AIDS UPDATE; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SATTEN GA, 1992, 8TH INT C AIDS AMST; SCITOVSKY AA, 1989, MILBANK Q, V67, P318, DOI 10.2307/3350143; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; 1992, DISTRICT COLUMBIA CO; 1992, AIDS NEW YORK STATE; 1990, AIDS NEW YORK STATE	18	241	243	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					474	478		10.1001/jama.270.4.474	http://dx.doi.org/10.1001/jama.270.4.474			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN426	8320787				2022-12-28	WOS:A1993LN42600027
J	TOPOL, EJ; LEYA, F; PINKERTON, CA; WHITLOW, PL; HOFLING, B; SIMONTON, CA; MASDEN, RR; SERRUYS, PW; LEON, MB; WILLIAMS, DO; KING, SB; MARK, DB; ISNER, JM; HOLMES, DR; ELLIS, SG; LEE, KL; KEELER, GP; BERDAN, LG; HINOHARA, T; CALIFF, RM				TOPOL, EJ; LEYA, F; PINKERTON, CA; WHITLOW, PL; HOFLING, B; SIMONTON, CA; MASDEN, RR; SERRUYS, PW; LEON, MB; WILLIAMS, DO; KING, SB; MARK, DB; ISNER, JM; HOLMES, DR; ELLIS, SG; LEE, KL; KEELER, GP; BERDAN, LG; HINOHARA, T; CALIFF, RM			A COMPARISON OF DIRECTIONAL ATHERECTOMY WITH CORONARY ANGIOPLASTY IN PATIENTS WITH CORONARY-ARTERY DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; RESTENOSIS	Background. Directional coronary atherectomy is a new technique of coronary revascularization by which atherosclerotic plaque is excised and retrieved from target lesions. With respect to the rate of restenosis and clinical outcomes, it is not known how this procedure compares with balloon angioplasty, which relies on dilation of the plaque and vessel wall. We compared the rate of restenosis after angioplasty with that after atherectomy. Methods. At 35 sites in the United States and Europe, 1012 patients were randomly assigned to either atherectomy (512 patients) or angioplasty (500 patients). The patients underwent coronary angiography at base line and again after six months; the paired angiograms were quantitatively assessed at one laboratory by investigators unaware of the treatment assignments. Results. Stenosis was reduced to 50 percent or less more often with atherectomy than with angioplasty (89 percent vs. 80 percent, P<0.001), and there was a greater immediate increase in vessel caliber (1.05 vs. 0.86 mm, P<0.001). This was accompanied by a higher rate of early complications (11 percent vs. 5 percent, P<0.001) and higher in-hospital costs ($11,904 vs. $10,637; P = 0.006). At six months, the rate of restenosis was 50 percent for atherectomy and 57 percent for angioplasty (P = 0.06). However, the probability of death or myocardial infarction within six months was higher in the atherectomy group (8.6 percent vs. 4.6 percent, P = 0.007). Conclusions. Removing coronary artery plaque with atherectomy led to a larger luminal diameter and a small reduction in angiographic restenosis, the latter being confined largely to the proximal left anterior descending coronary artery. However, atherectomy led to a higher rate of early complications, increased cost, and no apparent clinical benefit after six months of follow-up.	UNIV MUNICH,KLINIKUM GROSSHADERN,W-8000 MUNICH 70,GERMANY; LOYOLA MED CTR,CHICAGO,IL; ST VINCENTS HOSP,INDIANAPOLIS,IN; CAROLINAS MED CTR,CHARLOTTE,NC; JEWISH HOSP,LOUISVILLE,KY; ERASMUS UNIV ROTTERDAM,3000 DR ROTTERDAM,NETHERLANDS; WASHINGTON CARDIOL CTR,WASHINGTON,DC; RHODE ISL HOSP,PROVIDENCE,RI 02902; EMORY UNIV HOSP,ATLANTA,GA 30322; DUKE UNIV,MED CTR,DURHAM,NC 27710; ST ELIZABETHS HOSP BOSTON,BOSTON,MA; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; SEQUOIA HOSP,REDWOOD CITY,CA	University of Munich; Loyola University Chicago; Carolinas Medical Center; Erasmus University Rotterdam; Lifespan Health Rhode Island; Rhode Island Hospital; Emory University; Duke University; Mayo Clinic	TOPOL, EJ (corresponding author), CLEVELAND CLIN FDN,DEPT CARDIOL,DESK F25,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Mark, Daniel/0000-0001-6340-8087				BAUTERS C, 1993, EUR HEART J, V14, P235, DOI 10.1093/eurheartj/14.2.235; ELLIS S, 1990, TXB INTERVENTIONAL C, P199; FAXON D, 1992, Journal of the American College of Cardiology, V19, p258A; FISHMAN RF, 1992, J AM COLL CARDIOL, V20, P1101, DOI 10.1016/0735-1097(92)90365-T; FRID DJ, 1990, CIRCULATION, V82, P427; Frid DJ, 1990, TXB INTERVENTIONAL C, P363; HINOHARA T, 1992, J AM COLL CARDIOL, V20, P623, DOI 10.1016/0735-1097(92)90017-H; KUNTZ RE, 1992, J AM COLL CARDIOL, V19, P1493, DOI 10.1016/0735-1097(92)90609-Q; KUNTZ RE, 1992, CIRCULATION, V86, P1394, DOI 10.1161/01.CIR.86.5.1394; KUNTZ RE, 1992, CIRCULATION, V86, P1827, DOI 10.1161/01.CIR.86.6.1827; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; MANCINI GBJ, 1987, CIRCULATION, V75, P452, DOI 10.1161/01.CIR.75.2.452; MANCINI GBJ, 1987, CIRCULATION, V75, P1199; MARK DB, 1993, THROMBOLYSIS ADJUNCT, P471; MATTHEWS DE, 1988, USING UNDERSTANDING; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; PEPINE CJ, 1990, CIRCULATION, V81, P1753, DOI 10.1161/01.CIR.81.6.1753; POPMA JJ, 1993, AM J CARDIOL, V71, P552, DOI 10.1016/0002-9149(93)90510-J; POPMA JJ, 1991, CIRCULATION, V84, P1426, DOI 10.1161/01.CIR.84.3.1426; POPMA JJ, 1992, J AM COLL CARDIOL, V19, P1372, DOI 10.1016/0735-1097(92)90590-J; RENSING BJ, 1992, J AM COLL CARDIOL, V19, P939, DOI 10.1016/0735-1097(92)90274-Q; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; TOPOL EJ, 1993, CIRCULATION, V87, P1489, DOI 10.1161/01.CIR.87.5.1489; UMANS V, 1992, EUR HEART J, V13, P918, DOI 10.1093/oxfordjournals.eurheartj.a060293; UMANS VA, 1993, J AM COLL CARDIOL, V21, P1382, DOI 10.1016/0735-1097(93)90313-P; 1992, CIRCULATION, V86, P100	28	562	576	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					221	227		10.1056/NEJM199307223290401	http://dx.doi.org/10.1056/NEJM199307223290401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM682	8316266	Green Submitted			2022-12-28	WOS:A1993LM68200001
J	TIAN, M; MANIATIS, T				TIAN, M; MANIATIS, T			A SPLICING ENHANCER COMPLEX CONTROLS ALTERNATIVE SPLICING OF DOUBLESEX PREMESSENGER RNA	CELL			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; SITE SELECTION; DROSOPHILA-MELANOGASTER; BINDING PROTEINS; CONSERVED FAMILY; SEXUAL-DIFFERENTIATION; MAMMALIAN SPLICEOSOME; EXON SEQUENCES; 70K PROTEIN; FACTOR SC35	Female-specific splicing of Drosophila doublesex (dsx) pre-mRNA is regulated by the products of the transformer (tra) and transformer 2 (tra2) genes. In this paper we show that Tra and Tra2 act by recruiting general splicing factors to a regulatory element located downstream of a female-specific 3' splice site. Remarkably, Tra, Tra2, and members of the serine/arginine-rich (SR) family of general splicing factors are sufficient to commit dsx pre-mRNA to female-specific splicing, and individual SR proteins differ significantly in their ability to participate in commitment complex formation. Characterization of the proteins associated with affinity purified complex formed on dsx pre-mRNA reveals the presence of Tra, Tra2, SR proteins, and additional unidentified components. We conclude that Tra, Tra2, and SR proteins are essential components of a splicing enhancer complex.			TIAN, M (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.							ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANZIULIS RJ, 1989, GENE DEV, P431; BARDWELL VJ, 1990, NUCLEIC ACIDS RES, V18, P6587, DOI 10.1093/nar/18.22.6587; BENNETT M, 1992, MOL CELL BIOL, V12, P3165, DOI 10.1128/MCB.12.7.3165; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAMER A, 1988, GENE DEV, V2, P1155, DOI 10.1101/gad.2.9.1155; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; NOTHIGER R, 1987, GENET RES, V50, P113, DOI 10.1017/S001667230002351X; REED R, 1988, CELL, V53, P949, DOI 10.1016/S0092-8674(88)90489-8; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; Rio Donald C., 1992, Gene Expression, V2, P1; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	56	313	321	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					105	114		10.1016/0092-8674(93)90298-5	http://dx.doi.org/10.1016/0092-8674(93)90298-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334698				2022-12-28	WOS:A1993LN62500011
J	ALSHEHRI, A; STANLEY, I; THOMAS, P				ALSHEHRI, A; STANLEY, I; THOMAS, P			DEVELOPING ORGANIZATIONAL VISION IN GENERAL-PRACTICE	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Vision is a fashionable but ill defined term in management circles. Nevertheless, it embodies a significant concept related to guiding an organisation from present realities, through opportunities and hazards, to a viable future. Until recently a typical general practice could assume a stable external environment, but now it is caught up in the uncertainties stemming from the NHS reforms. For such a practice to undertake effective strategic planning it will have to develop a vision connecting the present with aspirations for the future. While vision is usually considered to be an individual talent, it is possible to develop a collective organisational vision within a general practice, and the small size of general practices makes this relatively easy. The vision needs to be broad; it needs to be continuous; and its capacity to predict the future needs to be monitored.	UNIV LIVERPOOL, DEPT GEN PRACTICE, POB 147, LIVERPOOL L69 3BX, ENGLAND	University of Liverpool								MCCORMICK J, 1990, BUSINESS MOUTH, V135, P66; SPIEGAL N, 1992, BRIT MED J, V304, P231, DOI 10.1136/bmj.304.6821.231; Stephens G G, 1975, J Fam Pract, V2, P423; 1991, INTEGRATING PRIMARY; HOLY BIBLE, P5	5	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1993	307	6896					101	103		10.1136/bmj.307.6896.101	http://dx.doi.org/10.1136/bmj.307.6896.101			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343704	Green Published, Bronze			2022-12-28	WOS:A1993LM58500026
J	HAMMOND, SA; BOLLINGER, RC; TOBERY, TW; SILICIANO, RF				HAMMOND, SA; BOLLINGER, RC; TOBERY, TW; SILICIANO, RF			TRANSPORTER-INDEPENDENT PROCESSING OF HIV-1 ENVELOPE PROTEIN FOR RECOGNITION BY CD8+ T-CELLS	NATURE			English	Article							TOXIC LYMPHOCYTES-T; MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II REGION; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; SIGNAL SEQUENCE; VIRUS; MHC; EXPRESSION; GENE	CD8+ cytolytic T lymphocytes (CTL) identify virally infected cells by recognizing processed viral antigen in association with class I major histocompatibility complex (MHC) molecules on infected cells1-4. Processing begins in the cytosol5-7 with the generation of peptides, possibly by a protease complex with MHC-encoded subunits, known as the proteasome8-11. Transport of the resulting cytosolic peptides into the endoplasmic reticulum for association with class I molecules is essential and probably involves a heterodimer of the MHC-encoded proteins, Tap-1 and Tap-2(12-17). The site of processing of viral envelope proteins is uncertain. These proteins are not present in the cytosol because of cotranslational translocation into the endoplasmic reticulum. We show here that the HIV-1 envelope (env) protein is processed in infected cells by a novel Tap-1/Tap-2-independent pathway that seems to be localized to the endoplasmic reticulum.			HAMMOND, SA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205, USA.			Bollinger, Robert/0000-0002-6798-6834				ALDRICH CJ, 1992, J IMMUNOL, V149, P3773; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; CALLAHAN KC, IN PRESS J IMMUN; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOODING LR, 1983, J IMMUNOL, V131, P2580; HAFFAR OK, 1990, J VIROL, V64, P3100, DOI 10.1128/JVI.64.6.3100-3103.1990; HAMMOND SA, 1992, J EXP MED, V176, P1531, DOI 10.1084/jem.176.6.1531; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; OHLEN C, 1990, J IMMUNOL, V145, P52; ORENTAS RJ, 1990, SCIENCE, V248, P1234, DOI 10.1126/science.2190315; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; OTTEN GR, 1992, J IMMUNOL, V148, P3723; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; POLYDEFKIS M, 1990, J EXP MED, V171, P875, DOI 10.1084/jem.171.3.875; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBINNENDIJK RS, 1992, J EXP MED, V176, P119, DOI 10.1084/jem.176.1.119; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WILSTROM L, 1991, J CELL BIOL, V113, P997; YEWDELL JW, 1988, SCIENCE, V239, P637, DOI 10.1126/science.3257585	50	97	97	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					158	161		10.1038/364158a0	http://dx.doi.org/10.1038/364158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321286				2022-12-28	WOS:A1993LL36700053
J	SHULTZ, LD; SCHWEITZER, PA; RAJAN, TV; YI, TL; IHLE, JN; MATTHEWS, RJ; THOMAS, ML; BEIER, DR				SHULTZ, LD; SCHWEITZER, PA; RAJAN, TV; YI, TL; IHLE, JN; MATTHEWS, RJ; THOMAS, ML; BEIER, DR			MUTATIONS AT THE MURINE MOTH-EATEN LOCUS ARE WITHIN THE HEMATOPOIETIC-CELL PROTEIN-TYROSINE-PHOSPHATASE (HCPH) GENE	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW CELLS; EATEN MUTANT MICE; VIABLE MOTHEATEN; MOTH-EATEN; B-CELLS; DEFECTIVE LYMPHOPOIESIS; IMMUNODEFICIENT MUTANT; GROWTH-FACTOR; MOUSE	Mice homozygous for the recessive allelic mutation motheaten (me) or viable motheaten (me(v)) on chromosome 6 develop severe defects in hematopoiesis. In this paper we present the findings that the me and me(v) mutations are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. High resolution mapping localized me to an area tightly linked to Hcph on chromosome 6. Abnormalities of the Hcph protein product were demonstrated by Western blot analysis and by activity assays in both me/me and me(v)/me(v) mice. Molecular analysis of the Hcph cDNA identified abnormal transcripts in both mutants. DNA sequence analyses of cDNA and genomic clones revealed that both the me and me(v) mutations are point mutations that result in aberrant splicing of the Hcph transcript. These findings provide the first available animal models for a specific protein-tyrosine phosphatase deficiency, thus facilitating determination of the precise role of this signaling molecule in hematopoiesis.	UNIV CONNECTICUT, CTR HLTH, DEPT PATHOL, FARMINGTON, CT 06030 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA	University of Connecticut; St Jude Children's Research Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Harvard University; Brigham & Women's Hospital; Harvard Medical School	SHULTZ, LD (corresponding author), JACKSON LAB, BAR HARBOR, ME 04609 USA.				NATIONAL CANCER INSTITUTE [R01CA020408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI030389, R01AI030389] Funding Source: NIH RePORTER; NCI NIH HHS [CA20408] Funding Source: Medline; NIAID NIH HHS [AI2773, AI30389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG JA, 1985, IMMUNOL TODAY, V6, P121, DOI 10.1016/0167-5699(85)90076-3; BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; BLOM J, 1976, ACTA PATH MICRO IM A, V84, P335; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CAHILLY LA, 1985, CYTOGENET CELL GENET, V39, P140, DOI 10.1159/000132123; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL AJ, 1987, BLOOD, V70, P1962; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1981, IMMUNOGENETICS, V12, P601, DOI 10.1007/BF01561700; DAVIDSON WF, 1979, J IMMUNOL, V122, P884; DIETRICH W, 1992, GENETICS, V131, P423; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FREITAS AA, 1990, EUR J IMMUNOL, V20, P1033, DOI 10.1002/eji.1830200513; GEBBERS JO, 1976, PATHOL EUR, V11, P271; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HAYASHI SI, 1988, J IMMUNOL, V140, P2139; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; KASTURI KN, 1990, J IMMUNOL, V145, P2304; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOLBER DL, 1991, EUR J IMMUNOL, V21, P721, DOI 10.1002/eji.1830210327; KOMSCHLIES KL, 1987, J EXP MED, V166, P1162, DOI 10.1084/jem.166.4.1162; KOO GC, 1991, J IMMUNOL, V147, P1194; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P1679; MEDLOCK ES, 1987, J IMMUNOL, V138, P3590; MILLER DR, 1966, PEDIATRICS, V38, P986; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MORRIS DL, 1993, J IMMUNOL, V150, pA262; PAINTER CJ, 1988, J EXP MED, V167, P1137, DOI 10.1084/jem.167.3.1137; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PLUTZKY J, 1992, GENOMICS, V13, P869, DOI 10.1016/0888-7543(92)90172-O; PROCHAZKA M, 1992, P NATL ACAD SCI USA, V89, P3290, DOI 10.1073/pnas.89.8.3290; QUIMBY FW, 1989, IMMUNODEFICIENT RODE; RAIMONDI SC, 1986, BLOOD, V68, P69; RAIMONDI SC, 1991, BLOOD, V77, P2016; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; SCHWEITZER PA, 1991, J CELL BIOL, V114, P35, DOI 10.1083/jcb.114.1.35; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Shultz L D, 1991, Semin Immunol, V3, P397; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1983, EXP HEMATOL, V11, P667; SHULTZ LD, 1976, J IMMUNOL, V116, P936; SHULTZ LD, 1987, AM J PATHOL, V127, P38; SHULTZ LD, 1991, AM J ANAT, V191, P303, DOI 10.1002/aja.1001910310; SHULTZ LD, 1988, CURR TOP MICROBIOL, V137, P216; SIDMAN CL, 1978, J IMMUNOL, V121, P2392; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SPIVAK JL, 1992, EXP HEMATOL, V20, P500; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VANZANT G, 1989, EXP HEMATOL, V17, P81; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI T, 1993, MOL CELL BIOL, V13, P3550; YI TL, 1992, GENOMICS, V14, P793, DOI 10.1016/S0888-7543(05)80189-2; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1991, BLOOD, V78, P2222; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; 1993, GENOMIC DATABASE MIC	68	665	691	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 2	1993	73	7					1445	1454		10.1016/0092-8674(93)90369-2	http://dx.doi.org/10.1016/0092-8674(93)90369-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324828	Bronze			2022-12-28	WOS:A1993LL20900018
J	HOWARD, RJ; LILLIS, C; TUCK, SM				HOWARD, RJ; LILLIS, C; TUCK, SM			CONTRACEPTIVES, COUNSELING, AND PREGNANCY IN WOMEN WITH SICKLE-CELL DISEASE	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS	Sickle cell disease is listed in the manufacturers' data sheets in the United Kingdom as a contraindication to the use of most combined contraceptive pills; the result is confused advice on family planning to a group of women who are at substantial risk from both planned and unplanned pregnancy. A study in north London on the use of contraceptives by women with sickle cell disease indicates that the use of combined oral contraceptives is common. Although medical staff usually advised against pregnancy, such advice was almost always ignored. Over half of the women surveyed had some knowledge about antenatal diagnosis. Family planning advice should be an integral part of the care of women with sickle cell disease. In the absence of specific data to the contrary all methods of contraception may be considered, although with appropriate caution.			HOWARD, RJ (corresponding author), UNIV LONDON,ROYAL FREE HOSP,DEPT OBSTET & GYNAECOL,LONDON NW3 2QG,ENGLAND.							ANIONWU EN, 1987, J MED GENET, V25, P769; CHARACHE S, 1985, CLIN HAEMATOL, V14, P729; DECEULAER K, 1982, LANCET, V2, P229; EVANS DK, 1984, BR J FAM PLANN, V10, P80; FLEISSIG A, 1991, BRIT MED J, V302, P147, DOI 10.1136/bmj.302.6769.147; FOSTER HW, 1981, SOUTHERN MED J, V74, P543, DOI 10.1097/00007611-198105000-00009; FREIE HMP, 1983, ACTA OBSTET GYN SCAN, V62, P211, DOI 10.3109/00016348309155794; Greenwald J G, 1971, Conn Med, V35, P231; HARGUS EP, 1977, AM J OBSTET GYNECOL, V129, P697, DOI 10.1016/0002-9378(77)90656-1; HAYNES RL, 1967, JAMA-J AM MED ASSOC, V200, P186; LOUDEN N, 1991, HDB FAMILY PLANNING; LOUKOPOULOS D, 1990, ANN NY ACAD SCI, V612, P226; LUTCHER CL, 1986, CLIN RES, V34, pA217; MORRISON J C, 1979, Clinical Obstetrics and Gynecology, V22, P819, DOI 10.1097/00003081-197912000-00005; PERKINS RP, 1971, NEW ENGL J MED, V285, P296; PETROU M, 1990, ANN NY ACAD SCI, V612, P251; ROWLEY PT, 1991, AM J HUM GENET, V48, P439; SAMUELSREID JH, 1984, J NATL MED ASSOC, V76, P879; SERGEANT GR, 1983, BMJ, V287, P628; SMITH T, 1990, BRIT MED J, V300, P1154, DOI 10.1136/bmj.300.6733.1154; TUCK SM, 1983, BRIT J OBSTET GYNAEC, V90, P112, DOI 10.1111/j.1471-0528.1983.tb08893.x	21	29	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1735	1737		10.1136/bmj.306.6894.1735	http://dx.doi.org/10.1136/bmj.306.6894.1735			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343632	Bronze, Green Published			2022-12-28	WOS:A1993LK36700026
J	BEKKER, H; MODELL, M; DENNISS, G; SILVER, A; MATHEW, C; BOBROW, M; MARTEAU, T				BEKKER, H; MODELL, M; DENNISS, G; SILVER, A; MATHEW, C; BOBROW, M; MARTEAU, T			UPTAKE OF CYSTIC-FIBROSIS TESTING IN PRIMARY-CARE - SUPPLY PUSH OR DEMAND PULL	BRITISH MEDICAL JOURNAL			English	Article							GENE; IDENTIFICATION; MUTATIONS	Objective-To determine the acceptability and feasibility of screening for carriers of cystic fibrosis in a primary care setting. Design-Follow up study over 15 months of patients offered carrier testing by mouthwash. Setting-A general practice in inner London. Subjects-5529 patients aged 18-45 invited by various methods and combinations of methods (letter, booklet, personal approach) for testing. Main outcome measures-Uptake of screening, anxiety, and knowledge of test. Results-957 (17%) invitees were screened over the 15 months. 28 carriers and no carrier couples were detected. Uptake rates were 12% (59/502 patients) among patients invited by letter and tested by appointment; 9% (47/496) among patients invited by letter, with leaflet, and tested by appointment; 4% (128/2953) among patients invited by letter six weeks before the end of the study and tested by appointment; 17% (81/471) among patients offered passive opportunistic testing; 70% (453/649) among patients offered active opportunistic testing; and 25% (22/88) among patients offered active opportunistic testing by appointment. A short term rise in anxiety among those given a positive test result had dissipated by three months. At three months about one fifth and one third of those given positive and negative results respectively did not understand their results correctly. Conclusion-These results suggest that the strongest variable in determining uptake of screening is the active approach by a health professional offering immediate testing. It remains to be resolved whether the high uptake rates achieved by active recruitment indicate a supply push for this new test rather than a demand from the population.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, WELLCOME PSYCHOL & GENET RES GRP, GUYS CAMPUS, LONDON SE1 9RT, ENGLAND; UCL, WHITTINGTON HOSP, UNIV COLL & MIDDLESEX SCH MED, DEPT PRIMARY HLTH CARE, LONDON N19 5NF, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, DIV MED & MOLEC GENET, PAEDIAT RES UNIT, LONDON SE1 9RT, ENGLAND	University of London; King's College London; University of London; University College London; University of London; King's College London			Bekker, Hilary L/A-9183-2010; Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838; Bekker, Hilary/0000-0003-1978-5795; Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHEADLE J, 1992, J MED GENET, V29, P642, DOI 10.1136/jmg.29.9.642; FERRIE RM, 1992, AM J HUM GENET, V51, P251; FLINTER FA, 1992, LANCET, V339, P1539, DOI 10.1016/0140-6736(92)91304-Q; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LENCH N, 1988, LANCET, V1, P1356; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; MATHEW CG, 1989, LANCET, V2, P1346; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; NG ISL, 1991, HUM GENET, V87, P613; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; SUPER M, 1992, LANCET, V340, P490, DOI 10.1016/0140-6736(92)91816-Q; TENKATE LP, 1990, PRENATAL DIAG, V10, P275, DOI 10.1002/pd.1970100413; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WATSON E, 1991, BRIT MED J, V393, P504; WATSON EK, 1992, LANCET, V340, P217, DOI 10.1016/0140-6736(92)90477-K; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; WILLIAMSON R, 1989, PRENAT DIAGN, V98, P727; 1989, PRENATAL DIAGNOSIS G	21	132	132	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1584	1586		10.1136/bmj.306.6892.1584	http://dx.doi.org/10.1136/bmj.306.6892.1584			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329922	Green Published, Bronze			2022-12-28	WOS:A1993LH12800022
J	DOYAL, L; WILSHER, D				DOYAL, L; WILSHER, D			WITHHOLDING CARDIOPULMONARY-RESUSCITATION - PROPOSALS FOR FORMAL GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article							DECISIONS; SURVIVAL; ORDERS; ETHICS; DNR	Working with members of the Royal London Trust and its medical council, Len Doyal and Daniel Wilsher have composed a set of guidelines governing the making of decisions to withhold resuscitation from patients. The guidelines describe the procedures that should be followed when giving orders for non-resuscitation and the clinical, legal, and moral criteria that should be satisfied before such orders arc issued. The authors hope that these guidelines will be of help to those responsible for the creation of hospitals' policies for non-resuscitation.	ST BARTHOLOMEWS HOSP,COLL MED,JOINT DEPT HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London	DOYAL, L (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,JOINT DEPT HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND.							AARONS EJ, 1991, BRIT MED J, V303, P1504, DOI 10.1136/bmj.303.6816.1504; [Anonymous], 1989, ALL ER, V2, P782; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; DOYAL LT, IN PRESS SURGERY NEW; EVANS TR, 1990, ABS RESUSCITATION, P66; GEORGE AL, 1989, AM J MED, V87, P28; Great Britain. England. Court of Appeal Civil Division, 1990, All Engl Law Rep, V[1990] 3, P930; HOLMBERG S, 1992, RESUSCITATION, V24, P239, DOI 10.1016/0300-9572(92)90184-E; KENNEDY I, 1990, MED LAW TEST MATERIA, P936; LOEWY EH, 1991, J MED ETHICS, V17, P156, DOI 10.1136/jme.17.3.156; Re T, 1992, WLR, V3, P782; SAUNDERS J, 1992, J ROY COLL PHYS LOND, V26, P254; SCHADE SG, 1989, J MED ETHICS, V15, P186, DOI 10.1136/jme.15.4.186; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; WALKER RM, 1991, JAMA-J AM MED ASSOC, V266, P2407, DOI 10.1001/jama.266.17.2407; 1993, BMLR, V9, P20; 1983, DECIDING FOREGO LIFE, P231; 1993, DECISIONS RELATING C; 1991, 1990 1991 HLTH SERV, P12; 1991, PLCMO9122 DEP HLTH	21	64	64	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1593	1596		10.1136/bmj.306.6892.1593	http://dx.doi.org/10.1136/bmj.306.6892.1593			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329925	Green Published, Bronze			2022-12-28	WOS:A1993LH12800025
J	THERIOT, JA; ROSENBLATT, J; PORTNOY, DA; GOLDSCHMIDTCLERMONT, PJ; MITCHISON, TJ				THERIOT, JA; ROSENBLATT, J; PORTNOY, DA; GOLDSCHMIDTCLERMONT, PJ; MITCHISON, TJ			INVOLVEMENT OF PROFILIN IN THE ACTIN-BASED MOTILITY OF L-MONOCYTOGENES IN CELLS AND IN CELL-FREE-EXTRACTS	CELL			English	Article							HEAVY-CHAIN GENE; LISTERIA-MONOCYTOGENES; DICTYOSTELIUM-DISCOIDEUM; FILAMENT NUCLEATION; CYCLIN SYNTHESIS; POLYMERIZATION; MOVEMENT; PROTEIN; SPREAD; END	Within hours of Listeria monocytogenes infection, host cell actin filaments form a dense cloud around the intracytoplasmic bacteria and then rearrange to form a polarized comet tail that is associated with moving bacteria. We have devised a cell-free extract system capable of faithfully reconstituting L. monocytogenes motility, and we have used this system to demonstrate that profilin, a host actin monomer-binding protein, is necessary for bacterial actin-based motility. We find that extracts from which profilin has been depleted do not support comet tail formation or bacterial motility. In extracts and host cells, profilin is localized to the back half of the surface of motile L. monocytogenes, the site of actin filament assembly in the tail. This association is not observed with L. monocytogenes mutants that do not express the ActA protein, a bacterial gene product necessary for motility and virulence. Profilin also fails to bind L. monocytogenes grown outside of host cytoplasm, suggesting that at least one other host cell factor is required for this association.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104; JOHNS HOPKINS UNIV,SCH MED,DEPT CARDIOL,BALTIMORE,MD 21205	University of California System; University of California San Francisco; University of Pennsylvania; Johns Hopkins University	THERIOT, JA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143, USA.		Theriot, Julie/HHN-2034-2022; Rosenblatt, Jody/AAD-4260-2019	Rosenblatt, Jody/0000-0001-9460-5868; Theriot, Julie/0000-0002-2334-2535	NIAID NIH HHS [R37 AI036929] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036929] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BRUNDAGE RA, 1993, P NATL ACAD SCI USA, V90, P11890, DOI 10.1073/pnas.90.24.11890; BUSS F, 1992, CELL MOTIL CYTOSKEL, V22, P51, DOI 10.1002/cm.970220106; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CHAKRABORTY T, 1992, J BACTERIOL, V174, P568, DOI 10.1128/jb.174.2.568-574.1992; CONDEELIS JS, 1977, J CELL BIOL, V74, P901, DOI 10.1083/jcb.74.3.901; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; EDAMATSU M, 1992, J BIOCHEM-TOKYO, V112, P637, DOI 10.1093/oxfordjournals.jbchem.a123952; FINKEL T, 1994, IN PRESS P NATL ACAD; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KANE RE, 1980, J CELL BIOL, V86, P803, DOI 10.1083/jcb.86.3.803; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KOCKS C, 1993, J CELL SCI, V105, P699; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LEIMEISTERWACHTER M, 1989, INFECT IMMUN, V57, P2350; MENGAUD J, 1991, MOL MICROBIOL, V5, P2273, DOI 10.1111/j.1365-2958.1991.tb02158.x; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NIEBUHR K, 1993, INFECT IMMUN, V61, P2793, DOI 10.1128/IAI.61.7.2793-2802.1993; OSTER GF, 1987, J CELL SCI S, V8, P35; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; POLLARD TD, 1976, J CELL BIOL, V68, P579, DOI 10.1083/jcb.68.3.579; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Theriot Julie A., 1992, Trends in Cell Biology, V2, P219, DOI 10.1016/0962-8924(92)90298-2; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; TILNEY LG, 1992, J CELL BIOL, V118, P83, DOI 10.1083/jcb.118.1.83; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; VAZQUEZBOLAND JA, 1992, INFECT IMMUN, V60, P219, DOI 10.1128/IAI.60.1.219-230.1992	55	240	243	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					505	517		10.1016/0092-8674(94)90114-7	http://dx.doi.org/10.1016/0092-8674(94)90114-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313471				2022-12-28	WOS:A1994MX20700011
J	ALDRICH, FD				ALDRICH, FD			RADIATION FROM DIGITAL CLOCKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter																		GAUGER JR, 1985, IEEE T POWER AP SYST, V104, P2436, DOI 10.1109/TPAS.1985.318988; 1989, BONNEVILLE POWER ADM	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					879	879						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340991				2022-12-28	WOS:A1993LR61200038
J	ALDERMAN, MH				ALDERMAN, MH			BLOOD-PRESSURE MANAGEMENT - INDIVIDUALIZED TREATMENT BASED ON ABSOLUTE RISK AND THE POTENTIAL FOR BENEFIT	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; FRAMINGHAM; STROKE; REDUCTION; PROFILE; HYPERTENSION; MORTALITY; EPIDEMIOLOGY	Clinical practice often conflicts with epidemiologic evidence in the management of blood pressure. Anti-hypertensive therapy is generally prescribed if blood pressure exceeds some arbitrary level, thus committing many persons with minimal cardiovascular risk to long-term drug therapy. By contrast, below that level, regardless of cardiovascular risk, blood pressure reduction is rarely sought. Epidemiologic data, however, consistently show a continuous, positive, linear relationship of the height of both systolic and diastolic blood pressure with the incidence of stroke and heart attack. No threshold level distinguishes those who will have a cardiovascular event from those who will not. In fact, most heart attacks and many strokes occur among persons with ''normal'' blood pressures. Observational experience suggests that benefit could be obtained from universal blood pressure reduction of even a few millimeters of mercury. This public health strategy can be augmented by identifying those individuals, at every level of blood pressure, whose risk for cardiovascular disease justifies the cost of pharmacologic intervention. Antihypertensive drug therapy will be most efficient and effective if directed at those who, by virtue of their constellation of risk factors or evidence of preclinical vascular disease, are likely to have a heart attack or stroke. The resulting redirection of clinical resources will spare many hypertensive persons whose absolute risk for a cardiovascular event is small, from life-long treatment. At the same time, other persons, currently classified as normotensive, will become candidates for blood pressure reduction because their cardiovascular risk is high.			ALDERMAN, MH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, 1300 MORRIS PK, BRONX, NY 10461 USA.							ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALDERMAN MH, 1981, HYPERTENSION, V3, P192, DOI 10.1161/01.HYP.3.2.192; ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; ALDERMAN MH, 1990, J CLIN EPIDEMIOL, V43, P195, DOI 10.1016/0895-4356(90)90185-R; ALDERMAN MH, 1982, CARDIOLOGY, V1; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1970, JAMA, V213, P1143; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; DUSTAN HP, 1958, CIRCULATION, V18, P644, DOI 10.1161/01.CIR.18.4.644; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; GORDON T, 1971, FRAMINGHAM STUDY EPI; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HORAN MJ, 1989, HYPERTENSION S1, V13, P164; KANNEL WB, 1976, AM J CARDIOL, V37, P269, DOI 10.1016/0002-9149(76)90323-4; KANNEL WB, 1970, J AMER MED ASSOC, V214, P301, DOI 10.1001/jama.214.2.301; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KANNEL WB, 1992, AM HEART J, V123, P264, DOI 10.1016/0002-8703(92)90789-X; Kannel WB, 1975, EPIDEMIOLOGY CONTROL, P553; KANNEL WB, 1990, HYPERTENSION PATHOPH, P101; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KOTTKE TE, 1988, J CLIN EPIDEMIOL, V41, P1083, DOI 10.1016/0895-4356(88)90078-9; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MADHAVAN S, 1981, ARCH INTERN MED, V141, P1583, DOI 10.1001/archinte.141.12.1583; MARMOT MG, 1986, LANCET, V1, P897; OLIVER MF, 1982, NEW ENGL J MED, V306, P297, DOI 10.1056/NEJM198202043060511; PEART WS, 1988, BRIT MED J, V296, P1565; PICKERING G, 1978, AM J MED, V65, P561, DOI 10.1016/0002-9343(78)90839-2; PIGUOLI P, 1986, CIRCULATION, V74, P1399; RAFTERY EB, 1990, INT J CARDIOL, V28, P143, DOI 10.1016/0167-5273(90)90054-9; RANDALL T, 1992, BRIT MED J, V305, P227, DOI 10.1136/bmj.305.6847.227; STAMLER J, 1978, FUTURE DIRECTIONS HL; STOKES J, 1987, CIRCULATION, V75, P65; THOMPSON SG, 1985, HDB HYPERTENSION, V6, P331; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; YUDKIN JS, 1988, LANCET, V2, P530; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	44	115	116	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					329	335		10.7326/0003-4819-119-4-199308150-00013	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328743				2022-12-28	WOS:A1993LV52500013
J	BOWERMAN, B; DRAPER, BW; MELLO, CC; PRIESS, JR				BOWERMAN, B; DRAPER, BW; MELLO, CC; PRIESS, JR			THE MATERNAL GENE SKN-1 ENCODES A PROTEIN THAT IS DISTRIBUTED UNEQUALLY IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; CELLULAR INTERACTIONS; ESCHERICHIA-COLI; LOCALIZATION; LINEAGES; REVERSAL; GLP-1; GUT	The autonomous or cell-intrinsic developmental properties of early embryonic blastomeres in nematodes are thought to result from the action of maternally provided determinants. After the first cleavage of the C. elegans embryo, only the posterior blastomere, P1, has a cell-intrinsic ability to produce pharyngeal cells. The product of the maternal gene skn-1 is required for P1 to produce pharyngeal cells. We show here that the Skn-1 protein is nuclear localized and that P1 appears to accumulate markedly higher levels of Skn-1 protein than its sister, the AB blastomere. We have examined the distribution of Skn-1 protein in embryos from mothers with maternal-effect mutations in the genes mex-1, par-1, and pie-1. These results suggest that mex-1(+) and par-1(+) activities are required for the unequal distribution of the Skn-1 protein and that pie-1(+) activity may function to regulate the activity of Skn-1 protein in the descendants of the posterior blastomere P1.	FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle				Draper, Bruce W/0000-0002-4397-7749				ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; Ausubel FM, 1988, MOL REPROD DEV; Boveri T., 1910, FESTSCHRIFT R HERTWI, VIII, P133; Boveri Th., 1899, Festschrift C von Kupffer, P383; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; BRENNER S, 1974, GENETICS, V77, P71; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KONAPKA JB, 1984, J VIROL, V51, P223; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; Sambrook J, 1989, MOL CLONING LABORATO; SCHIERENBERG E, 1985, COLD SPRING HARB SYM, V50, P59, DOI 10.1101/SQB.1985.050.01.010; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; Stevens NM, 1909, ARCH ENTWICKLUNG ORG, V27, P622, DOI 10.1007/BF02161872; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0	33	208	214	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					443	452		10.1016/0092-8674(93)80046-H	http://dx.doi.org/10.1016/0092-8674(93)80046-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348611				2022-12-28	WOS:A1993LT73900006
J	SCHAPIRA, RM; SCHAPIRA, MM; FUNAHASHI, A; MCAULIFFE, TL; VARKEY, B				SCHAPIRA, RM; SCHAPIRA, MM; FUNAHASHI, A; MCAULIFFE, TL; VARKEY, B			THE VALUE OF THE FORCED EXPIRATORY TIME IN THE PHYSICAL DIAGNOSIS OF OBSTRUCTIVE AIRWAYS DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIKELIHOOD RATIOS; HISTORY	Objective.-To evaluate the test characteristics-of the forced expiratory time (FET) in the diagnosis of obstructive airways disease. Design.-A cross-sectional diagnostic test study. The FET of 400 subjects was measured by a physician examiner and was compared with the criterion standard of spirometry. In a second sample of 100 subjects, the FET was measured by pairs of physician examiners to evaluate interexaminer agreement. Setting.-A pulmonary function test laboratory at a tertiary care hospital that receives referrals for preoperative evaluations, acute and chronic pulmonary disease, and occupational lung disease. Subjects.-A consecutive sample of patients who were referred to the pulmonary function laboratory from primary care internists, pulmonary physicians, and surgeons. Interventions.-None. Main Outcome Measures.-The sensitivity and specificity of the FET in the diagnosis of obstructive airways disease at cutoff values ranging from 2 to 14 seconds. A receiver operating characteristic curve was used to evaluate the diagnostic performance of the FET. Likelihood ratio lines were determined using a logistic regression model adjusting for the subjects age. Interexaminer agreement was evaluated with a kappa statistic. Results.-Using the FET maneuver with a cutoff value of 6 seconds will correctly diagnose the greatest number of subjects with obstructive airways disease. The FET maneuver is more discriminating for subjects 60 years or older compared with younger subjects. The positive likelihood ratio for a subject aged 60 years or older with an FET of 4 to 6 seconds is 0.42 (95% confidence interval [CI], 0.24 to 0.73); of 6 to 8 seconds, 2.19 (95% CI, 1.02 to 4.80); and of greater than 8 seconds, 4.08 (95% CI, 2.54 to 6.79). The kappa statistic for interexaminer agreement is 0.70. Conclusions.-The FET demonstrates moderately good performance as a diagnostic test for obstructive airways disease. The value of the test will depend on the pretest probability of disease and the clinical circumstances in which it is used.	MED COLL WISCONSIN,DEPT INTERNAL MED,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DIV GEN INTERNAL MED,MILWAUKEE,WI 53226; CLEMENT J ZABLOCKI VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,MILWAUKEE,WI 53295; MED COLL WISCONSIN,DIV PULM & CRIT CARE MED,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	SCHAPIRA, RM (corresponding author), CLEMENT J ZABLOCKI VET AFFAIRS MED CTR,PULM & CRIT CARE MED SECT,111-E,5000 W NATL AVE,MILWAUKEE,WI 53295, USA.							ALBERT A, 1982, CLIN CHEM, V28, P1113; BADGETT RG, 1993, AM J MED, V94, P188, DOI 10.1016/0002-9343(93)90182-O; BARKUN AN, 1991, AM J MED, V91, P512, DOI 10.1016/0002-9343(91)90188-4; BATES B, 1991, GUIDE PHYSICAL EXAMI, P231; BURROWS B, 1992, MERCK MANUAL DIAGNOS, P646; CAMPBELL EJ, 1969, THORAX, V24, P1, DOI 10.1136/thx.24.1.1; CENTOR RM, 1992, MED DECIS MAKING, V12, P229, DOI 10.1177/0272989X9201200309; CHERNIAK RM, 1972, RESPIRATION HLTH DIS, P217; CHERNIAK RM, 1972, RESPIRATION HLTH DIS, P303; FITZGERALD FT, 1990, WESTERN J MED, V152, P377; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; GEORGOPOULOS D, 1991, CHRONIC OBSTRUCTIVE, P357; GODFREY S, 1969, THORAX, V24, P4, DOI 10.1136/thx.24.1.4; GODFREY S, 1970, THORAX, V25, P285, DOI 10.1136/thx.25.3.285; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOLLEMAN DR, 1993, J GEN INTERN MED, V8, P63, DOI 10.1007/BF02599985; HONIG E, 1990, CLIN METHODS, P193; KERN DG, 1991, CHEST, V100, P636, DOI 10.1378/chest.100.3.636; LAL S, 1964, BRIT MED J, V1, P814, DOI 10.1136/bmj.1.5386.814; MACDONALD JB, 1975, THORAX, V30, P554, DOI 10.1136/thx.30.5.554; MORRIS JF, 1973, AM REV RESPIR DIS, V108, P1000; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; PETERSON MC, 1992, WESTERN J MED, V156, P163; PETTY TL, 1988, HOSP PRACT, V23, P39; PETTY TL, 1989, TXB INTERNAL MED, P1884; Pingleton Susan K., 1993, P565; ROSENBLATT G, 1962, NEW ENGL J MED, V267, P432, DOI 10.1056/NEJM196208302670903; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2683; SMITH JG, 1992, CURRENT DIAGNOSIS, V8, P343; SNIDER GL, 1988, TXB RESPIRATORY MED, P1069; TISI GM, 1980, PULMONARY PHYSL CLIN, P145; TISI GM, 1980, PULMONARY PHYSL CLIN, P53; TSI GM, 1980, PULMONARY PHYSL CLIN, P29; TSI GM, 1980, PULMONARY PHYSL CLIN, P131; WEG JG, 1989, CLIN DIAGNOSIS PHYSL, P197; WEINMANN GG, 1988, PRINCIPLES PRACTICE, P202; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WILLIAMS JW, 1992, JAMA-J AM MED ASSOC, V267, P2645, DOI 10.1001/jama.267.19.2645; [No title captured]; 1991, AM REV RESPIR DIS, V144, P1202	42	31	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1993	270	6					731	736		10.1001/jama.270.6.731	http://dx.doi.org/10.1001/jama.270.6.731			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ338	8336375				2022-12-28	WOS:A1993LQ33800028
J	HOOPER, RR				HOOPER, RR			UNITED-STATES HOSPITAL SHIPS - A PROPOSAL FOR THEIR USE IN HUMANITARIAN MISSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											HOOPER, RR (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PREVENT MED & BIOMETR,BETHESDA,MD 20814, USA.							CABLE J, 1986, US NAVAL I P, V112, P37; MORROW RC, 1970, J AMER MED ASSOC, V211, P257; OCHSNER MG, 1992, J TRAUMA, V32, P501, DOI 10.1097/00005373-199204000-00015; PERRONE J, 1992, AM MED NEWS     1019, P7; RAYMOND C, 1989, JAMA-J AM MED ASSOC, V261, P2795; 1973, NAVAL HIST F SERIE 2, V18; 1987, ASIA PACIFIC DEF FAL, V12, P42	7	6	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					621	623		10.1001/jama.270.5.621	http://dx.doi.org/10.1001/jama.270.5.621			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331763				2022-12-28	WOS:A1993LP43600029
J	HALL, K; COLE, DG; YEH, Y; SCHOLEY, JM; BASKIN, RJ				HALL, K; COLE, DG; YEH, Y; SCHOLEY, JM; BASKIN, RJ			FORCE-VELOCITY RELATIONSHIPS IN KINESIN-DRIVEN MOTILITY	NATURE			English	Article							CENTRIFUGE MICROSCOPE; MOVEMENT; MOLECULES; INVITRO	KINESIN is a microtubule-based motor protein that uses energy released from Mg-ATP hydrolysis to generate force for the movement of intracellular membranes towards the fast-growing (plus) ends of microtubule tracks in cells1. Kinesin-driven microtubule movement can be visualized and quantified using light microscope motility assays2-5 but our understanding of how kinesin generates force and motion is incomplete6. Here we report the use of a centrifuge microscope7,8 to obtain force-velocity curves for kinesin-driven motility and to estimate that the maximal isometric force generated per kinesin is 0.12+/-0.03 pN per molecule.	UNIV CALIF DAVIS, MOLEC & CELLULAR BIOL SECT, BIOPHYS GRAD GRP, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, DEPT APPL SCI, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis								BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BUSTER D, 1991, J CELL SCI, P109; COHN SA, 1989, J BIOL CHEM, V264, P4290; DASILVA LB, 1992, SCIENCE, V258, P269, DOI 10.1126/science.1411525; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P637, DOI 10.1016/0009-2509(67)80047-2; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; KAMIMURA S, 1992, J CELL BIOL, V118, P865, DOI 10.1083/jcb.118.4.865; KAMITSUBO E, 1989, PROTOPLASMA, V152, P148, DOI 10.1007/BF01323074; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; OIWA K, 1990, P NATL ACAD SCI USA, V87, P7893, DOI 10.1073/pnas.87.20.7893; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; VALE RD, 1993, SCIENCE, V260, P169, DOI 10.1126/science.8469971; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	18	24	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1993	364	6436					457	459		10.1038/364457a0	http://dx.doi.org/10.1038/364457a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332217				2022-12-28	WOS:A1993LP64000059
J	LUFT, HS; ROMANO, PS				LUFT, HS; ROMANO, PS			CHANCE, CONTINUITY, AND CHANGE IN HOSPITAL MORTALITY-RATES - CORONARY-ARTERY BYPASS GRAFT PATIENTS IN CALIFORNIA HOSPITALS, 1983 TO 1989	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; RISK-FACTORS; SURGERY; VOLUME; QUALITY; CARE	Objective.-To assess whether risk-adjusted mortality rates for hospitals reflect primarily chance variation. Design.-Observation over time. Setting.-All 115 California hospitals with five or more coronary artery bypass graft (CABG) patients in any year 1983 to 1989. Patients.-All CABG patients aged 18 years and older excluding those with other open heart procedures and percutaneous transluminal coronary angioplasty on the day of CABG surgery (n=132 750). Outcome Measure.-Inpatient mortality adjusted for age, gender, chronic comorbidities, timing of surgery, and presence of additional procedures. Methods.-Data were derived from routinely collected hospital discharge abstracts. Observed and expected semiannual mortality rates were examined for each hospital to identify consistent patterns over time. Using the quartile of patients with the highest predicted risk (average mortality, 10%), high- and low-outlier hospitals were identified from 2 consecutive years of pooled data and outcomes 2 years later were examined. Each hospital-year observation was also examined individually to identify outliers and to assess differences for observed and expected death rates, patient volume, and other characteristics. Results.-Some hospitals showed consistently lower-than-expected inpatient mortality. Some hospitals had periods of significantly higher-than-expected mortality followed by a correction. High-outlier hospitals that were selected based on 2 years of data had mortality rates 2 years later that averaged 31% above expected, while low-outlier hospitals had rates 2 years later that averaged 28% below expected. On a contemporaneous basis, high outliers had proportionately more transfers to other acute care hospitals and longer postoperative stays among survivors. Conclusions.-Risk-adjusted outcomes for CABG patients derived from administrative data exhibit substantial patterns of consistency. Such patterns cannot be detected for low-risk patients but are evident for the top quartile of patients stratified by risk. Even with reporting lags and changes in hospital outcomes over time, a policy of channeling high-risk patients away from high-outlier hospitals and toward low-outlier hospitals could lower the overall risk-adjusted mortality rate by 54%.	UNIV CALIF DAVIS, DIV GEN MED, DAVIS, CA 95616 USA	University of California System; University of California Davis	LUFT, HS (corresponding author), UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA.		Romano, Patrick S/N-4225-2014	Romano, Patrick S/0000-0001-6749-3979	AHRQ HHS [HS06216, HS06503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BOWEN OR, 1987, 00744 US DEP HLTH HU; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JOHNS L, 1992, HEALTH AFFAIR, V11, P266, DOI 10.1377/hlthaff.11.1.266; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; KRITCHEVSKY SB, 1991, JAMA-J AM MED ASSOC, V266, P1817, DOI 10.1001/jama.266.13.1817; LUFT HS, 1990, HOSPITAL VOLUME PHYS; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PARK R E, 1990, Journal of the American Medical Association, V264, P484, DOI 10.1001/jama.264.4.484; PHIBBS CS, 1992, IMPROVING FIT LOGIST; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; 1990, HE5488 PENNS HLTH CA	16	80	80	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					331	337		10.1001/jama.270.3.331	http://dx.doi.org/10.1001/jama.270.3.331			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8315777				2022-12-28	WOS:A1993LM43500027
J	BERRY, ZS; LYNN, J				BERRY, ZS; LYNN, J			HOSPICE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; PAIN		DARTMOUTH COLL,HITCHCOCK MED CTR,HANOVER,NH 03756	Dartmouth College	BERRY, ZS (corresponding author), GEORGE WASHINGTON UNIV,WASHINGTON,DC 20052, USA.							[Anonymous], 1992, J Clin Oncol, V10, P1976; Bonica JJ, 1953, MANAGEMENT PAIN; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BURCHMAN SL, 1992, PRACTICAL MANAGEMENT; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; Fields HE, 1991, CORE CURRICULUM PROF; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; LYNN J, 1983, HASTINGS CENT REP, V13, P17, DOI 10.2307/3560572; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; PORTER J, 1980, NEW ENGL J MED, V302, P123; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; SAUNDERS CM, 1981, THERAPY PAIN; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; TWYCROSS RG, 1974, INT J CLIN PHARM TH, V9, P184; TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304-3959(82)90137-3; 1990, CANCER PAIN RELIEF P	17	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					221	223		10.1001/jama.270.2.221	http://dx.doi.org/10.1001/jama.270.2.221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315738				2022-12-28	WOS:A1993LL36800024
J	MILLER, AC; HARVEY, JE				MILLER, AC; HARVEY, JE			GUIDELINES FOR THE MANAGEMENT OF SPONTANEOUS PNEUMOTHORAX	BRITISH MEDICAL JOURNAL			English	Article								Simple flow diagrams, with explanatory notes, have been devised to assist in the immediate and subsequent management of patients presenting to casualty departments with spontaneous pneumothorax. They cover decision making about which patients require admission; whether a drainage procedure is necessary; if so, the appropriate method, including technical details; inpatient treatment; referral of inpatients to a respiratory specialist; and follow up arrangements. The guidelines, designed for incorporation into casualty and ward handbooks, have already proved valuable in several district general hospitals, and can be used as a basis for audit.	SOUTHMEAD GEN HOSP,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital	MILLER, AC (corresponding author), MAYDAY HOSP,CROYDON CR7 7YE,ENGLAND.							ARCHER GJ, 1985, BRIT J DIS CHEST, V79, P177, DOI 10.1016/0007-0971(85)90028-2; HARVEY JE, 1993, THORAX, V48, P430; RAJA OG, 1981, BRIT J DIS CHEST, V75, P207, DOI 10.1016/0007-0971(81)90055-3; STRADLING P, 1966, THORAX, V21, P145, DOI 10.1136/thx.21.2.145	4	109	116	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					114	116		10.1136/bmj.307.6896.114	http://dx.doi.org/10.1136/bmj.307.6896.114			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343708	Green Published, Bronze			2022-12-28	WOS:A1993LM58500032
J	TAUSSIG, R; INIGUEZLLUHI, JA; GILMAN, AG				TAUSSIG, R; INIGUEZLLUHI, JA; GILMAN, AG			INHIBITION OF ADENYLYL-CYCLASE BY G(I-ALPHA)	SCIENCE			English	Article							BINDING REGULATORY COMPONENT; G-PROTEIN SUBUNITS; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; BETA-GAMMA; ALPHA; EXPRESSION; PURIFICATION; MEMBRANES; RECEPTOR	Evidence suggests that both alpha and betagamma subunits of heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins) inhibit adenylyl cyclase. Although type I adenylyl cyclase is inhibited directly by exogenous betagamma, inhibition of adenylyl cyclase by G(ialpha) has not been convincingly demonstrated in vitro. Concentration-dependent inhibition of adenylyl cyclases by purified G(ialpha) subunits is described. Activated G(ialpha) but not G(oalpha) was effective, and myristoylation of G(ialpha) was required. The characteristics of the inhibitory effect were dependent on the type of adenylyl cyclase and the nature of the activator of the enzyme. The concentrations of G(ialpha) required to inhibit adenylyl cyclase were substantially higher than those normally thought to be relevant physiologically. However, analysis indicates that these concentrations may be relevant and reasonable.			TAUSSIG, R (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, CELL, V70, P41; BIRNBAUMER L, 1987, TRENDS PHARMACOL SCI, V8, P209, DOI 10.1016/0165-6147(87)90064-2; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P9695, DOI 10.1073/pnas.89.20.9695; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JAKOBS KH, 1979, N-S ARCH PHARMACOL, V310, P113, DOI 10.1007/BF00500275; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATADA T, 1984, J BIOL CHEM, V259, P3568; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MAY DC, 1985, J BIOL CHEM, V260, P5829; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUNTZ KH, 1992, CIRCULATION, V86, P764; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STERNWEIS PC, 1990, TRENDS NEUROSCI, V13, P122, DOI 10.1016/0166-2236(90)90002-R; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, UNPUB; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	31	330	338	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					218	221		10.1126/science.8327893	http://dx.doi.org/10.1126/science.8327893			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8327893				2022-12-28	WOS:A1993LL59600043
J	LEYSER, HMO; LINCOLN, CA; TIMPTE, C; LAMMER, D; TURNER, J; ESTELLE, M				LEYSER, HMO; LINCOLN, CA; TIMPTE, C; LAMMER, D; TURNER, J; ESTELLE, M			ARABIDOPSIS AUXIN-RESISTANCE GENE-AXR1 ENCODES A PROTEIN RELATED TO UBIQUITIN-ACTIVATING ENZYME-E1	NATURE			English	Article							THALIANA; SEQUENCE; GENE; TRANSFORMATION; EXPRESSION; MUTANTS; CLONING; LINKAGE	THE plant hormone auxin has a central role in many aspects of plant growth and development1,2. By screening for mutants of Arabidopsis that are resistant to exogenous auxin, we have identified several genes that are required for normal auxin response3. One of these genes, AXR1, is defined by recessive mutations that confer auxin resistance to the roots, rosettes and inflorescences of mutant plants4-6. In addition, axr1 mutants display a variety of morphological defects that are consistent with a reduction in auxin sensitivity5. Here we isolate the AXR1 gene using a map-based approach and report that AXR1 encodes a new protein with significant sequence similarity to the ubiquitin-activating enzyme E1. The AXR1 protein is highly diverged from previously characterized E1 enzymes, however, and lacks a key cysteine residue that is essential for E1 activity7. AXR1 may therefore define a new class of enzymes in the ubiquitin pathway or it may have a novel function in cellular regulation which is unrelated to ubiquitin conjugation.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington			Estelle, Mark/ABD-6742-2021; Leyser, Ottoline/AAC-5577-2019	Leyser, Ottoline/0000-0003-2161-3829				CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; Davies P. J., 1988, PLANT HORMONES THEIR, P1; DELLAPORTA SL, 1983, PLANT MOL BIOL REP, V1, P181; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESTELLE M, 1992, BIOESSAYS, V14, P439, DOI 10.1002/bies.950140703; ESTELLE MA, 1987, MOL GEN GENET, V206, P200, DOI 10.1007/BF00333575; EVANS ML, 1984, ENCY PLANT PHYSL, V10, P23; FINLEY K, 1991, REV CELL BIOL, V7, P25; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; LINCOLN C, 1991, IOWA ACAD SCI, V98, P68; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MORI S, 1992, J BIOL CHEM, V267, P6429; NAIRN CJ, 1988, GENE, V65, P247, DOI 10.1016/0378-1119(88)90461-1; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Sambrook J, 1989, MOL CLONING LABORATO; SUITER KA, 1983, J HERED, V74, P203, DOI 10.1093/oxfordjournals.jhered.a109766; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501	25	406	434	2	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					161	164		10.1038/364161a0	http://dx.doi.org/10.1038/364161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321287				2022-12-28	WOS:A1993LL36700054
J	BOSCH, X; PEDROL, E; CASADO, X; URBANOMARQUEZ, A				BOSCH, X; PEDROL, E; CASADO, X; URBANOMARQUEZ, A			JOSAMYCIN-INDUCED PEDAL EDEMA	BRITISH MEDICAL JOURNAL			English	Letter											BOSCH, X (corresponding author), HOSP CLIN BARCELONA,DISPENSARI URGENCIES,E-08036 BARCELONA,SPAIN.							DUKES MNG, 1986, MEYLERS SIDE EFFECTS; MENSA J, 1989, MED CLIN-BARCELONA, V92, P285; PRIVITERA G, 1984, INT J CLIN PHARM RES, V4, P201; QUINN X, 1986, J ANTIMICROB CHEMOTH, V18, P747; STRAUSBAUGH LJ, 1976, ANTIMICROB AGENTS CH, V10, P450, DOI 10.1128/AAC.10.3.450; WENZEL RP, 1976, ANTIMICROB AGENTS CH, V10, P899, DOI 10.1128/AAC.10.6.899; WESTERMAN EL, 1976, ANTIMICROB AGENTS CH, V9, P988, DOI 10.1128/AAC.9.6.988	7	0	0	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					26	26		10.1136/bmj.307.6895.26-a	http://dx.doi.org/10.1136/bmj.307.6895.26-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343666	Green Published			2022-12-28	WOS:A1993LL36900024
J	RAYMENT, I; RYPNIEWSKI, WR; SCHMIDTBASE, K; SMITH, R; TOMCHICK, DR; BENNING, MM; WINKELMANN, DA; WESENBERG, G; HOLDEN, HM				RAYMENT, I; RYPNIEWSKI, WR; SCHMIDTBASE, K; SMITH, R; TOMCHICK, DR; BENNING, MM; WINKELMANN, DA; WESENBERG, G; HOLDEN, HM			3-DIMENSIONAL STRUCTURE OF MYOSIN SUBFRAGMENT-1 - A MOLECULAR MOTOR	SCIENCE			English	Article							SKELETAL-MUSCLE MYOSIN; LIGHT-CHAINS; HEAVY-CHAIN; NUCLEOTIDE BINDING; 2.8-A RESOLUTION; TROPONIN-C; ACTIN; ATP; SITE; CONTRACTION	Directed movement is a characteristic of many living organisms and occurs as a result of the transformation of chemical energy into mechanical energy. Myosin is one of three families of molecular motors that are responsible for cellular motility. The three-dimensional structure of the head portion of myosin, or subfragment-1, which contains both the actin and nucleotide binding sites, is described. This structure of a molecular motor was determined by single crystal x-ray diffraction. The data provide a structural framework for understanding the molecular basis of motility.	UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53705; ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854	University of Wisconsin System; University of Wisconsin Madison; Rutgers State University New Brunswick; Rutgers State University Medical Center	RAYMENT, I (corresponding author), UNIV WISCONSIN,DEPT BIOCHEM,1710 UNIV AVE,MADISON,WI 53705, USA.		Tomchick, Diana/HGV-2018-2022; rayment, ivan/A-2720-2008; Rypniewski, Wojciech/W-5330-2018	rayment, ivan/0000-0001-9279-7835; Tomchick, Diana/0000-0002-7529-4643; Rypniewski, Wojciech/0000-0002-6097-5518				ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; BURKE M, 1977, BIOCHEMISTRY-US, V16, P5559, DOI 10.1021/bi00644a026; CITI S, 1987, BIOESSAYS, V7, P155, DOI 10.1002/bies.950070404; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; CREMO CR, 1989, J BIOL CHEM, V264, P6608; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; GEEVES MA, 1991, BIOCHEM J, V274, P1; GOODY RS, 1977, EUR J BIOCHEM, V78, P317, DOI 10.1111/j.1432-1033.1977.tb11742.x; GRAMMER J, 1991, Biophysical Journal, V59, p226A; GRATZER WB, 1969, J BIOL CHEM, V244, P22; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HOLDEN HM, 1991, ARCH BIOCHEM BIOPHYS, V291, P187, DOI 10.1016/0003-9861(91)90122-Y; HUSTON EE, 1988, BIOCHEMISTRY-US, V27, P8945, DOI 10.1021/bi00425a011; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LOWEY S, 1969, J MOL BIOL, V42, P1, DOI 10.1016/0022-2836(69)90483-5; LOWEY S, 1986, MYOLOGY, V19, P563; LYMM RW, 1971, BIOCHEMISTRY-US, V10, P4617; MAHMOOD R, 1989, BIOCHEMISTRY-US, V28, P3989, DOI 10.1021/bi00435a054; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MARGOSSIAN SS, 1981, BIOCHEMISTRY-US, V20, P2151, DOI 10.1021/bi00511a012; MATSUDA G, 1983, ADV BIOPHYS, V16, P185; MATSUDA G, 1977, FEBS LETT, V84, P53, DOI 10.1016/0014-5793(77)81055-7; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MORNET D, 1981, BIOCHEMISTRY-US, V20, P2110, DOI 10.1021/bi00511a007; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NABESHIMA YI, 1984, NATURE, V308, P333, DOI 10.1038/308333a0; OKAMOTO Y, 1985, P NATL ACAD SCI USA, V82, P1575, DOI 10.1073/pnas.82.6.1575; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1984, P NATL ACAD SCI-BIOL, V81, P4378; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE RH, 1971, J BIOL CHEM, V246, P831; ROSSMANN MG, 1960, ACTA CRYSTALLOGR, V13, P221, DOI 10.1107/S0365110X60000510; ROSSMANN MG, 1985, METHOD ENZYMOL, V114, P237; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RYPNIEWSKI WR, IN PRESS BIOCH; SELLERS JS, 1991, CURR OPIN CELL BIOL, V1, P98; SILBERSTEIN L, 1981, J MOL BIOL, V148, P153, DOI 10.1016/0022-2836(81)90510-6; SLEEP JA, 1981, J MUSCLE RES CELL M, V2, P373, DOI 10.1007/BF00711966; SMITH RE, UNPUB, P54011; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P4800, DOI 10.1021/bi00262a043; SZILAGYI L, 1979, BIOCHEM BIOPH RES CO, V87, P936, DOI 10.1016/0006-291X(79)92047-3; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR B, V39, P913; TESI C, 1988, FEBS LETT, V236, P256, DOI 10.1016/0014-5793(88)80326-0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WEEDS AG, 1971, J MOL BIOL, V61, P701, DOI 10.1016/0022-2836(71)90074-X; WELLS JA, 1982, METHOD ENZYMOL, V85, P93; WHITE H, IN PRESS BIOCH; WINKELMANN DA, 1985, J MOL BIOL, V181, P487, DOI 10.1016/0022-2836(85)90422-X; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701; YAMAMOTO K, 1991, J MOL BIOL, V217, P229, DOI 10.1016/0022-2836(91)90535-E; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044	74	1907	1934	5	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					50	58		10.1126/science.8316857	http://dx.doi.org/10.1126/science.8316857			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316857				2022-12-28	WOS:A1993LK43400028
J	MORTONJONES, T; PRINGLE, M				MORTONJONES, T; PRINGLE, M			EXPLAINING VARIATIONS IN PRESCRIBING COSTS ACROSS ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objective-To derive a predictive model for national prescribing behaviour in terms of basic morbidity and demographic factors. Design-24 demographic, morbidity, and practice factors were entered into a multiple regression analysis to determine the net ingredient cost per patient. Setting-The 90 family health service authorities in England for 1989. Results-For net ingredient cost per patient only two demographic factors (numbers of pensioners and the mobility of the registered population measured by list inflation) and two morbidity related factors (standardised mortality ratios and numbers of prepayment certificates issued) significantly contributed to a multiple regression model. This model explained 81% of the variation in net ingredient cost per registered patient between family health services authorities. The model also enabled a weighting factor of 4.6 (95% confidence interval 3.2 to 6.7) to be derived for the net ingredient cost for elderly patients (compared with the existing prescribing unit factor of 3). Conclusions-The model shows that variations in prescribing costs essentially reflect demand. It also suggests that the current prescribing unit value of 3 for patients aged 65 or more underestimates the extra costs of prescribing for elderly patients.			MORTONJONES, T (corresponding author), QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; BRENNAN ME, 1980, J EPIDEMIOL COMMUN H, V34, P134, DOI 10.1136/jech.34.2.134; EDWARDS C, 1991, INT J PHARM PRACTICE, V1, P73; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; GILLEGHAN JD, 1991, 54 ROYAL COLL GEN PR; HARRIS CM, 1984, RCGP24 OCC PAP; HARRIS CM, 1986, BR J GEN PRACT, V36, P148; HARRIS CM, 1990, ANAL PRESCRIBING GEN; HARRIS JF, 1990, SOMAT CELL MOLEC GEN, V16, P39, DOI 10.1007/BF01650478; Marinker M, 1973, J R Coll Gen Pract, V23 Suppl 2, P26; MAYS N, 1992, J EPIDEMIOL COMMUN H, V46, P38, DOI 10.1136/jech.46.1.38; MAYS N, 1989, J EPIDEMIOL COMMUN H, V43, P191, DOI 10.1136/jech.43.2.191; MORTONJONES AJ, 1993, BRIT MED J, V306, P1244; MORTONJONES AJ, IN PRESS BR J GEN PR; Taylor R J, 1977, J R Coll Gen Pract, V27, P79; TAYLOR RJ, 1991, BRIT J GEN PRACT, V41, P244; VIRJI A, 1991, FAM PRACT, V8, P314, DOI 10.1093/fampra/8.4.314; 1991, ANN REPORT 1 APRIL 1, P9; 1991, NHLTH SERVICES INDIC; 1991, REGIONAL TRENDS, V26	21	35	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1731	1734		10.1136/bmj.306.6894.1731	http://dx.doi.org/10.1136/bmj.306.6894.1731			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343631	Green Published, Bronze			2022-12-28	WOS:A1993LK36700024
